ID AAPK2_HUMAN Reviewed; 552 AA. AC P54646; Q9H1E8; Q9UD43; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 16-APR-2002, sequence version 2. DT 28-JAN-2026, entry version 231. DE RecName: Full=5'-AMP-activated protein kinase catalytic subunit alpha-2; DE Short=AMPK subunit alpha-2; DE EC=2.7.11.1 {ECO:0000269|PubMed:28552616, ECO:0000269|PubMed:32029622, ECO:0000269|PubMed:36732624, ECO:0000269|PubMed:37079666}; DE AltName: Full=Acetyl-CoA carboxylase kinase; DE Short=ACACA kinase; DE AltName: Full=Hydroxymethylglutaryl-CoA reductase kinase; DE Short=HMGCR kinase; DE EC=2.7.11.31 {ECO:0000250|UniProtKB:Q09137}; GN Name=PRKAA2 {ECO:0000312|HGNC:HGNC:9377}; Synonyms=AMPK, AMPK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION. RC TISSUE=Heart; RX PubMed=7959015; DOI=10.1016/0378-1119(94)90174-0; RA Aguan K., Scott J., See C.G., Sarkar N.H.; RT "Characterization and chromosomal localization of the human homologue of a RT rat AMP-activated protein kinase-encoding gene: a major regulator of lipid RT metabolism in mammals."; RL Gene 149:345-350(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Skeletal muscle; RX PubMed=7988703; DOI=10.1016/0014-5793(94)01247-4; RA Beri R.K., Marley A.E., See C.G., Sopwith W.F., Aguan K., Carling D., RA Scott J., Carey F.; RT "Molecular cloning, expression and chromosomal localisation of human AMP- RT activated protein kinase."; RL FEBS Lett. 356:117-121(1994). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP FUNCTION. RX PubMed=11554766; DOI=10.1006/bbrc.2001.5627; RA Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H.; RT "Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated RT protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D- RT ribofuranoside, in a human hepatocellular carcinoma cell line."; RL Biochem. Biophys. Res. Commun. 287:562-567(2001). RN [6] RP FUNCTION IN PHOSPHORYLATION OF EP300. RX PubMed=11518699; DOI=10.1074/jbc.c100316200; RA Yang W., Hong Y.H., Shen X.Q., Frankowski C., Camp H.S., Leff T.; RT "Regulation of transcription by AMP-activated protein kinase: RT phosphorylation of p300 blocks its interaction with nuclear receptors."; RL J. Biol. Chem. 276:38341-38344(2001). RN [7] RP ACTIVITY REGULATION. RX PubMed=11602624; DOI=10.1172/jci13505; RA Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., RA Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F., Goodyear L.J., RA Moller D.E.; RT "Role of AMP-activated protein kinase in mechanism of metformin action."; RL J. Clin. Invest. 108:1167-1174(2001). RN [8] RP FUNCTION IN PHOSPHORYLATION OF CFTR. RX PubMed=12519745; DOI=10.1152/ajpcell.00227.2002; RA Hallows K.R., Kobinger G.P., Wilson J.M., Witters L.A., Foskett J.K.; RT "Physiological modulation of CFTR activity by AMP-activated protein kinase RT in polarized T84 cells."; RL Am. J. Physiol. 284:C1297-C1308(2003). RN [9] RP FUNCTION IN PHOSPHORYLATION OF TSC2. RX PubMed=14651849; DOI=10.1016/s0092-8674(03)00929-2; RA Inoki K., Zhu T., Guan K.L.; RT "TSC2 mediates cellular energy response to control cell growth and RT survival."; RL Cell 115:577-590(2003). RN [10] RP PHOSPHORYLATION AT THR-172, AND ACTIVITY REGULATION. RX PubMed=15980064; DOI=10.1074/jbc.m503824200; RA Hurley R.L., Anderson K.A., Franzone J.M., Kemp B.E., Means A.R., RA Witters L.A.; RT "The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated RT protein kinase kinases."; RL J. Biol. Chem. 280:29060-29066(2005). RN [11] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=15866171; DOI=10.1016/j.molcel.2005.03.027; RA Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., RA Thompson C.B.; RT "AMP-activated protein kinase induces a p53-dependent metabolic RT checkpoint."; RL Mol. Cell 18:283-293(2005). RN [12] RP FUNCTION IN PHOSPHORYLATION OF FOXO3. RX PubMed=17711846; DOI=10.1074/jbc.m705325200; RA Greer E.L., Oskoui P.R., Banko M.R., Maniar J.M., Gygi M.P., Gygi S.P., RA Brunet A.; RT "The energy sensor AMP-activated protein kinase directly regulates the RT mammalian FOXO3 transcription factor."; RL J. Biol. Chem. 282:30107-30119(2007). RN [13] RP FUNCTION IN CELL POLARITY. RX PubMed=17486097; DOI=10.1038/nature05828; RA Lee J.H., Koh H., Kim M., Kim Y., Lee S.Y., Karess R.E., Lee S.H., RA Shong M., Kim J.M., Kim J., Chung J.; RT "Energy-dependent regulation of cell structure by AMP-activated protein RT kinase."; RL Nature 447:1017-1020(2007). RN [14] RP FUNCTION IN PHOSPHORYLATION OF HDAC5. RX PubMed=18184930; DOI=10.2337/db07-0843; RA McGee S.L., van Denderen B.J., Howlett K.F., Mollica J., Schertzer J.D., RA Kemp B.E., Hargreaves M.; RT "AMP-activated protein kinase regulates GLUT4 transcription by RT phosphorylating histone deacetylase 5."; RL Diabetes 57:860-867(2008). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [18] RP FUNCTION IN PHOSPHORYLATION OF KLC1. RX PubMed=20074060; DOI=10.1042/bst0380205; RA McDonald A., Fogarty S., Leclerc I., Hill E.V., Hardie D.G., Rutter G.A.; RT "Cell-wide analysis of secretory granule dynamics in three dimensions in RT living pancreatic beta-cells: evidence against a role for AMPK-dependent RT phosphorylation of KLC1 at Ser517/Ser520 in glucose-stimulated insulin RT granule movement."; RL Biochem. Soc. Trans. 38:205-208(2010). RN [19] RP FUNCTION. RX PubMed=20160076; DOI=10.1073/pnas.0913860107; RA Alexander A., Cai S.L., Kim J., Nanez A., Sahin M., MacLean K.H., Inoki K., RA Guan K.L., Shen J., Person M.D., Kusewitt D., Mills G.B., Kastan M.B., RA Walker C.L.; RT "ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to RT ROS."; RL Proc. Natl. Acad. Sci. U.S.A. 107:4153-4158(2010). RN [20] RP PHOSPHORYLATION BY ULK1. RX PubMed=21460634; DOI=10.4161/auto.7.7.15451; RA Loffler A.S., Alers S., Dieterle A.M., Keppeler H., Franz-Wachtel M., RA Kundu M., Campbell D.G., Wesselborg S., Alessi D.R., Stork B.; RT "Ulk1-mediated phosphorylation of AMPK constitutes a negative regulatory RT feedback loop."; RL Autophagy 7:696-706(2011). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [22] RP FUNCTION IN PHOSPHORYLATION OF ULK1. RX PubMed=21205641; DOI=10.1126/science.1196371; RA Egan D.F., Shackelford D.B., Mihaylova M.M., Gelino S., Kohnz R.A., RA Mair W., Vasquez D.S., Joshi A., Gwinn D.M., Taylor R., Asara J.M., RA Fitzpatrick J., Dillin A., Viollet B., Kundu M., Hansen M., Shaw R.J.; RT "Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects RT energy sensing to mitophagy."; RL Science 331:456-461(2011). RN [23] RP REVIEW ON FUNCTION. RX PubMed=17307971; DOI=10.1161/01.res.0000256090.42690.05; RA Towler M.C., Hardie D.G.; RT "AMP-activated protein kinase in metabolic control and insulin signaling."; RL Circ. Res. 100:328-341(2007). RN [24] RP REVIEW ON FUNCTION. RX PubMed=17712357; DOI=10.1038/nrm2249; RA Hardie D.G.; RT "AMP-activated/SNF1 protein kinases: conserved guardians of cellular RT energy."; RL Nat. Rev. Mol. Cell Biol. 8:774-785(2007). RN [25] RP ACTIVITY REGULATION BY SALICYLATE. RX PubMed=22517326; DOI=10.1126/science.1215327; RA Hawley S.A., Fullerton M.D., Ross F.A., Schertzer J.D., Chevtzoff C., RA Walker K.J., Peggie M.W., Zibrova D., Green K.A., Mustard K.J., Kemp B.E., RA Sakamoto K., Steinberg G.R., Hardie D.G.; RT "The ancient drug salicylate directly activates AMP-activated protein RT kinase."; RL Science 336:918-922(2012). RN [26] RP DEPHOSPHORYLATION AT THR-172. RX PubMed=23088624; DOI=10.1042/bj20121201; RA Chida T., Ando M., Matsuki T., Masu Y., Nagaura Y., Takano-Yamamoto T., RA Tamura S., Kobayashi T.; RT "N-Myristoylation is essential for protein phosphatases PPM1A and PPM1B to RT dephosphorylate their physiological substrates in cells."; RL Biochem. J. 449:741-749(2013). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [28] RP PHOSPHORYLATION AT THR-172. RX PubMed=24767988; DOI=10.1016/j.celrep.2014.03.065; RA Lanning N.J., Looyenga B.D., Kauffman A.L., Niemi N.M., Sudderth J., RA DeBerardinis R.J., MacKeigan J.P.; RT "A mitochondrial RNAi screen defines cellular bioenergetic determinants and RT identifies an adenylate kinase as a key regulator of ATP levels."; RL Cell Rep. 7:907-917(2014). RN [29] RP FUNCTION, AND SUBUNIT. RX PubMed=25687571; DOI=10.1074/mcp.m114.047159; RA Boutchueng-Djidjou M., Collard-Simard G., Fortier S., Hebert S.S., RA Kelly I., Landry C.R., Faure R.L.; RT "The last enzyme of the de novo purine synthesis pathway 5-aminoimidazole- RT 4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) RT plays a central role in insulin signaling and the Golgi/endosomes protein RT network."; RL Mol. Cell. Proteomics 14:1079-1092(2015). RN [30] RP FUNCTION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT THR-172, INTERACTION WITH RP ACSS2, AND MUTAGENESIS OF THR-172. RX PubMed=28552616; DOI=10.1016/j.molcel.2017.04.026; RA Li X., Yu W., Qian X., Xia Y., Zheng Y., Lee J.H., Li W., Lyu J., Rao G., RA Zhang X., Qian C.N., Rozen S.G., Jiang T., Lu Z.; RT "Nucleus-Translocated ACSS2 Promotes Gene Transcription for Lysosomal RT Biogenesis and Autophagy."; RL Mol. Cell 66:684-697(2017). RN [31] RP FUNCTION. RX PubMed=28561066; DOI=10.1038/ncomms15637; RA Bakula D., Mueller A.J., Zuleger T., Takacs Z., Franz-Wachtel M., RA Thost A.K., Brigger D., Tschan M.P., Frickey T., Robenek H., Macek B., RA Proikas-Cezanne T.; RT "WIPI3 and WIPI4 beta-propellers are scaffolds for LKB1-AMPK-TSC signalling RT circuits in the control of autophagy."; RL Nat. Commun. 8:15637-15637(2017). RN [32] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=32029622; DOI=10.1126/science.aay0542; RA Zhao P., Sun X., Chaggan C., Liao Z., In Wong K., He F., Singh S., RA Loomba R., Karin M., Witztum J.L., Saltiel A.R.; RT "An AMPK-caspase-6 axis controls liver damage in nonalcoholic RT steatohepatitis."; RL Science 367:652-660(2020). RN [33] RP FUNCTION. RX PubMed=34077757; DOI=10.1016/j.molcel.2021.05.005; RA Liu R., Lee J.H., Li J., Yu R., Tan L., Xia Y., Zheng Y., Bian X.L., RA Lorenzi P.L., Chen Q., Lu Z.; RT "Choline kinase alpha 2 acts as a protein kinase to promote lipolysis of RT lipid droplets."; RL Mol. Cell 81:2722-2735(2021). RN [34] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=36732624; DOI=10.1038/s42255-022-00732-4; RA Dai X., Jiang C., Jiang Q., Fang L., Yu H., Guo J., Yan P., Chi F., RA Zhang T., Inuzuka H., Asara J.M., Wang P., Guo J., Wei W.; RT "AMPK-dependent phosphorylation of the GATOR2 component WDR24 suppresses RT glucose-mediated mTORC1 activation."; RL Nat. Metab. 5:265-276(2023). RN [35] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=37079666; DOI=10.1126/science.abj5559; RA Malik N., Ferreira B.I., Hollstein P.E., Curtis S.D., Trefts E., RA Weiser Novak S., Yu J., Gilson R., Hellberg K., Fang L., Sheridan A., RA Hah N., Shadel G.S., Manor U., Shaw R.J.; RT "Induction of lysosomal and mitochondrial biogenesis by AMPK RT phosphorylation of FNIP1."; RL Science 380:eabj5559-eabj5559(2023). RN [36] RP FUNCTION, INTERACTION WITH ARF6, AND MUTAGENESIS OF LYS-45 AND THR-172. RX PubMed=36017701; DOI=10.1242/jcs.259609; RA Chen K.J., Hsu J.W., Lee F.S.; RT "AMPK promotes Arf6 activation in a kinase-independent manner upon glucose RT starvation."; RL J. Cell Sci. 135:0-0(2022). RN [37] RP FUNCTION. RX PubMed=36367943; DOI=10.1126/sciadv.abo7956; RA Tilokani L., Russell F.M., Hamilton S., Virga D.M., Segawa M., Paupe V., RA Gruszczyk A.V., Protasoni M., Tabara L.C., Johnson M., Anand H., RA Murphy M.P., Hardie D.G., Polleux F., Prudent J.; RT "AMPK-dependent phosphorylation of MTFR1L regulates mitochondrial RT morphology."; RL Sci. Adv. 8:eabo7956-eabo7956(2022). RN [38] RP X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 6-279. RX PubMed=20124709; DOI=10.1107/s1744309109052543; RA Littler D.R., Walker J.R., Davis T., Wybenga-Groot L.E., Finerty P.J. Jr., RA Newman E., Mackenzie F., Dhe-Paganon S.; RT "A conserved mechanism of autoinhibition for the AMPK kinase domain: ATP- RT binding site and catalytic loop refolding as a means of regulation."; RL Acta Crystallogr. F 66:143-151(2010). RN [39] RP X-RAY CRYSTALLOGRAPHY (2.08 ANGSTROMS) OF 6-279 OF MUTANT THR-172 IN RP COMPLEX WITH COMPOUND C, ACTIVITY REGULATION, AND MUTAGENESIS OF THR-172. RX PubMed=21543851; DOI=10.1107/s0907444911010201; RA Handa N., Takagi T., Saijo S., Kishishita S., Takaya D., Toyama M., RA Terada T., Shirouzu M., Suzuki A., Lee S., Yamauchi T., Okada-Iwabu M., RA Iwabu M., Kadowaki T., Minokoshi Y., Yokoyama S.; RT "Structural basis for compound C inhibition of the human AMP-activated RT protein kinase alpha2 subunit kinase domain."; RL Acta Crystallogr. D 67:480-487(2011). RN [40] RP VARIANTS [LARGE SCALE ANALYSIS] THR-371 AND GLY-523. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [41] RP VARIANTS [LARGE SCALE ANALYSIS] THR-371 AND GLN-407. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Catalytic subunit of AMP-activated protein kinase (AMPK), an CC energy sensor protein kinase that plays a key role in regulating CC cellular energy metabolism (PubMed:17307971, PubMed:17712357). In CC response to reduction of intracellular ATP levels, AMPK activates CC energy-producing pathways and inhibits energy-consuming processes: CC inhibits protein, carbohydrate and lipid biosynthesis, as well as cell CC growth and proliferation (PubMed:17307971, PubMed:17712357). AMPK acts CC via direct phosphorylation of metabolic enzymes, and by longer-term CC effects via phosphorylation of transcription regulators CC (PubMed:17307971, PubMed:17712357). Regulates lipid synthesis by CC phosphorylating and inactivating lipid metabolic enzymes such as ACACA, CC ACACB, GYS1, HMGCR and LIPE; regulates fatty acid and cholesterol CC synthesis by phosphorylating acetyl-CoA carboxylase (ACACA and ACACB) CC and hormone-sensitive lipase (LIPE) enzymes, respectively CC (PubMed:7959015). Promotes lipolysis of lipid droplets by mediating CC phosphorylation of isoform 1 of CHKA (CHKalpha2) (PubMed:34077757). CC Regulates insulin-signaling and glycolysis by phosphorylating IRS1, CC PFKFB2 and PFKFB3 (By similarity). Involved in insulin receptor/INSR CC internalization (PubMed:25687571). AMPK stimulates glucose uptake in CC muscle by increasing the translocation of the glucose transporter CC SLC2A4/GLUT4 to the plasma membrane, possibly by mediating CC phosphorylation of TBC1D4/AS160 (By similarity). Regulates CC transcription and chromatin structure by phosphorylating transcription CC regulators involved in energy metabolism such as CRTC2/TORC2, FOXO3, CC histone H2B, HDAC5, MEF2C, MLXIPL/ChREBP, EP300, HNF4A, p53/TP53, CC SREBF1, SREBF2 and PPARGC1A (PubMed:11518699, PubMed:11554766, CC PubMed:15866171, PubMed:17711846, PubMed:18184930). Acts as a key CC regulator of glucose homeostasis in liver by phosphorylating CC CRTC2/TORC2, leading to CRTC2/TORC2 sequestration in the cytoplasm (By CC similarity). In response to stress, phosphorylates 'Ser-36' of histone CC H2B (H2BS36ph), leading to promote transcription (By similarity). Acts CC as a key regulator of cell growth and proliferation by phosphorylating CC FNIP1, TSC2, RPTOR, WDR24 and ATG1/ULK1: in response to nutrient CC limitation, negatively regulates the mTORC1 complex by phosphorylating CC RPTOR component of the mTORC1 complex and by phosphorylating and CC activating TSC2 (PubMed:14651849, PubMed:20160076, PubMed:21205641). CC Also phosphorylates and inhibits GATOR2 subunit WDR24 in response to CC nutrient limitation, leading to suppress glucose-mediated mTORC1 CC activation (PubMed:36732624). In response to energetic stress, CC phosphorylates FNIP1, inactivating the non-canonical mTORC1 signaling, CC thereby promoting nuclear translocation of TFEB and TFE3, and inducing CC transcription of lysosomal or autophagy genes (PubMed:37079666). In CC response to nutrient limitation, promotes autophagy by phosphorylating CC and activating ATG1/ULK1 (PubMed:21205641). In that process, it also CC activates WDR45/WIPI4 (PubMed:28561066). Phosphorylates CASP6, thereby CC preventing its autoprocessing and subsequent activation CC (PubMed:32029622). AMPK also acts as a regulator of circadian rhythm by CC mediating phosphorylation of CRY1, leading to destabilize it (By CC similarity). May regulate the Wnt signaling pathway by phosphorylating CC CTNNB1, leading to stabilize it (By similarity). Also acts as a CC regulator of cellular polarity by remodeling the actin cytoskeleton; CC probably by indirectly activating myosin (PubMed:17486097). Also CC phosphorylates CFTR, EEF2K, KLC1, NOS3 and SLC12A1 (PubMed:12519745, CC PubMed:20074060). Plays an important role in the differential CC regulation of pro-autophagy (composed of PIK3C3, BECN1, PIK3R4 and CC UVRAG or ATG14) and non-autophagy (composed of PIK3C3, BECN1 and CC PIK3R4) complexes, in response to glucose starvation (By similarity). CC Can inhibit the non-autophagy complex by phosphorylating PIK3C3 and can CC activate the pro-autophagy complex by phosphorylating BECN1 (By CC similarity). Upon glucose starvation, promotes ARF6 activation in a CC kinase-independent manner leading to cell migration (PubMed:36017701). CC Upon glucose deprivation mediates the phosphorylation of ACSS2 at 'Ser- CC 659', which exposes the nuclear localization signal of ACSS2, required CC for its interaction with KPNA1 and nuclear translocation CC (PubMed:28552616). Upon stress, regulates mitochondrial fragmentation CC through phosphorylation of MTFR1L (PubMed:36367943). CC {ECO:0000250|UniProtKB:Q09137, ECO:0000250|UniProtKB:Q8BRK8, CC ECO:0000269|PubMed:11518699, ECO:0000269|PubMed:11554766, CC ECO:0000269|PubMed:12519745, ECO:0000269|PubMed:14651849, CC ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:17486097, CC ECO:0000269|PubMed:17711846, ECO:0000269|PubMed:18184930, CC ECO:0000269|PubMed:20074060, ECO:0000269|PubMed:20160076, CC ECO:0000269|PubMed:21205641, ECO:0000269|PubMed:25687571, CC ECO:0000269|PubMed:28552616, ECO:0000269|PubMed:28561066, CC ECO:0000269|PubMed:32029622, ECO:0000269|PubMed:34077757, CC ECO:0000269|PubMed:36017701, ECO:0000269|PubMed:36367943, CC ECO:0000269|PubMed:36732624, ECO:0000269|PubMed:37079666, CC ECO:0000269|PubMed:7959015, ECO:0000303|PubMed:17307971, CC ECO:0000303|PubMed:17712357}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:28552616, ECO:0000269|PubMed:32029622, CC ECO:0000269|PubMed:36732624, ECO:0000269|PubMed:37079666}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:Q09137}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[acetyl-CoA carboxylase] + ATP = O-phospho-L-seryl- CC [acetyl-CoA carboxylase] + ADP + H(+); Xref=Rhea:RHEA:20333, CC Rhea:RHEA-COMP:13722, Rhea:RHEA-COMP:13723, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, CC ChEBI:CHEBI:456216; Evidence={ECO:0000250|UniProtKB:Q09137}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[3-hydroxy-3-methylglutaryl-coenzyme A reductase] + CC ATP = O-phospho-L-seryl-[3-hydroxy-3-methylglutaryl-coenzyme A CC reductase] + ADP + H(+); Xref=Rhea:RHEA:23172, Rhea:RHEA-COMP:13692, CC Rhea:RHEA-COMP:13693, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; CC EC=2.7.11.31; Evidence={ECO:0000250|UniProtKB:Q09137}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000305}; CC -!- ACTIVITY REGULATION: Activated by phosphorylation on Thr-172 CC (PubMed:15980064). Binding of AMP to non-catalytic gamma subunit CC (PRKAG1, PRKAG2 or PRKAG3) results in allosteric activation, inducing CC phosphorylation on Thr-172 (PubMed:15980064). AMP-binding to gamma CC subunit also sustains activity by preventing dephosphorylation of Thr- CC 172 (PubMed:15980064). ADP also stimulates Thr-172 phosphorylation, CC without stimulating already phosphorylated AMPK (PubMed:15980064). ATP CC promotes dephosphorylation of Thr-172, rendering the enzyme inactive CC (PubMed:15980064). Under physiological conditions AMPK mainly exists in CC its inactive form in complex with ATP, which is much more abundant than CC AMP. AMPK is activated by antihyperglycemic drug metformin, a drug CC prescribed to patients with type 2 diabetes: in vivo, metformin seems CC to mainly inhibit liver gluconeogenesis. However, metformin can be used CC to activate AMPK in muscle and other cells in culture or ex vivo CC (PubMed:11602624). Selectively inhibited by compound C (6-[4-(2- CC Piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-pyyrazolo[1,5-a] CC pyrimidine. Activated by resveratrol, a natural polyphenol present in CC red wine, and S17834, a synthetic polyphenol. Salicylate/aspirin CC directly activates kinase activity, primarily by inhibiting Thr-172 CC dephosphorylation. {ECO:0000269|PubMed:11602624, CC ECO:0000269|PubMed:15980064, ECO:0000269|PubMed:21543851, CC ECO:0000269|PubMed:22517326}. CC -!- SUBUNIT: AMPK is a heterotrimer of an alpha catalytic subunit (PRKAA1 CC or PRKAA2), a beta (PRKAB1 or PRKAB2) and a gamma non-catalytic CC subunits (PRKAG1, PRKAG2 or PRKAG3) (PubMed:21543851). Interacts with CC FNIP1 and FNIP2. Associates with internalized insulin receptor/INSR CC complexes on Golgi/endosomal membranes; PRKAA2/AMPK2 together with ATIC CC and HACD3/PTPLAD1 is proposed to be part of a signaling network CC regulating INSR autophosphorylation and endocytosis (PubMed:25687571). CC Interacts with ARF6 (PubMed:36017701). The phosphorylated form at Thr- CC 172 mediated by CamKK2 interacts with ACSS2 (PubMed:28552616). CC {ECO:0000269|PubMed:21543851, ECO:0000269|PubMed:25687571, CC ECO:0000269|PubMed:28552616, ECO:0000269|PubMed:36017701}. CC -!- INTERACTION: CC P54646; Q8IZP0-5: ABI1; NbExp=3; IntAct=EBI-1383852, EBI-11743294; CC P54646; Q9NYB9: ABI2; NbExp=5; IntAct=EBI-1383852, EBI-743598; CC P54646; Q9NYB9-2: ABI2; NbExp=3; IntAct=EBI-1383852, EBI-11096309; CC P54646; Q13155: AIMP2; NbExp=3; IntAct=EBI-1383852, EBI-745226; CC P54646; Q9ULX6: AKAP8L; NbExp=3; IntAct=EBI-1383852, EBI-357530; CC P54646; P31749: AKT1; NbExp=3; IntAct=EBI-1383852, EBI-296087; CC P54646; A2BDD9: AMOT; NbExp=3; IntAct=EBI-1383852, EBI-17286414; CC P54646; Q9Y2J4: AMOTL2; NbExp=3; IntAct=EBI-1383852, EBI-746752; CC P54646; Q9NYG5-2: ANAPC11; NbExp=3; IntAct=EBI-1383852, EBI-12224467; CC P54646; Q92624: APPBP2; NbExp=3; IntAct=EBI-1383852, EBI-743771; CC P54646; Q96B67: ARRDC3; NbExp=3; IntAct=EBI-1383852, EBI-2875665; CC P54646; Q5T686: AVPI1; NbExp=3; IntAct=EBI-1383852, EBI-8640233; CC P54646; Q9P1Z2: CALCOCO1; NbExp=3; IntAct=EBI-1383852, EBI-749920; CC P54646; Q13137: CALCOCO2; NbExp=3; IntAct=EBI-1383852, EBI-739580; CC P54646; P0C7W6: CCDC172; NbExp=3; IntAct=EBI-1383852, EBI-2548868; CC P54646; Q9NPC3: CCNB1IP1; NbExp=4; IntAct=EBI-1383852, EBI-745269; CC P54646; Q00587-2: CDC42EP1; NbExp=3; IntAct=EBI-1383852, EBI-11027409; CC P54646; Q01850: CDR2; NbExp=3; IntAct=EBI-1383852, EBI-1181367; CC P54646; O14627: CDX4; NbExp=3; IntAct=EBI-1383852, EBI-10181162; CC P54646; Q8N684-3: CPSF7; NbExp=3; IntAct=EBI-1383852, EBI-11523759; CC P54646; O75638-2: CTAG2; NbExp=3; IntAct=EBI-1383852, EBI-12265122; CC P54646; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-1383852, EBI-3867333; CC P54646; Q9NQM4: DNAAF6; NbExp=3; IntAct=EBI-1383852, EBI-10239299; CC P54646; P50570: DNM2; NbExp=3; IntAct=EBI-1383852, EBI-346547; CC P54646; Q92997: DVL3; NbExp=3; IntAct=EBI-1383852, EBI-739789; CC P54646; Q9Y6C2-2: EMILIN1; NbExp=3; IntAct=EBI-1383852, EBI-11748557; CC P54646; O95208-2: EPN2; NbExp=3; IntAct=EBI-1383852, EBI-12135243; CC P54646; Q53EP0-3: FNDC3B; NbExp=3; IntAct=EBI-1383852, EBI-10242151; CC P54646; Q6FG41: FOS; NbExp=3; IntAct=EBI-1383852, EBI-10198738; CC P54646; O75420: GIGYF1; NbExp=3; IntAct=EBI-1383852, EBI-947774; CC P54646; P08151: GLI1; NbExp=3; IntAct=EBI-1383852, EBI-308084; CC P54646; Q08379: GOLGA2; NbExp=3; IntAct=EBI-1383852, EBI-618309; CC P54646; Q9NYA3: GOLGA6A; NbExp=3; IntAct=EBI-1383852, EBI-11163335; CC P54646; O75791: GRAP2; NbExp=3; IntAct=EBI-1383852, EBI-740418; CC P54646; P28799: GRN; NbExp=3; IntAct=EBI-1383852, EBI-747754; CC P54646; Q6NT76: HMBOX1; NbExp=3; IntAct=EBI-1383852, EBI-2549423; CC P54646; Q8IX15-3: HOMEZ; NbExp=3; IntAct=EBI-1383852, EBI-10172004; CC P54646; Q13422-7: IKZF1; NbExp=3; IntAct=EBI-1383852, EBI-11522367; CC P54646; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-1383852, EBI-747204; CC P54646; Q719H9: KCTD1; NbExp=3; IntAct=EBI-1383852, EBI-9027502; CC P54646; Q7L273: KCTD9; NbExp=3; IntAct=EBI-1383852, EBI-4397613; CC P54646; Q86T90: KIAA1328; NbExp=3; IntAct=EBI-1383852, EBI-3437878; CC P54646; Q96L93-6: KIF16B; NbExp=3; IntAct=EBI-1383852, EBI-10988217; CC P54646; Q5T7B8-2: KIF24; NbExp=3; IntAct=EBI-1383852, EBI-10213781; CC P54646; Q9BVG8: KIFC3; NbExp=4; IntAct=EBI-1383852, EBI-2125614; CC P54646; P08779: KRT16; NbExp=3; IntAct=EBI-1383852, EBI-356410; CC P54646; Q15323: KRT31; NbExp=3; IntAct=EBI-1383852, EBI-948001; CC P54646; Q8IUG1: KRTAP1-3; NbExp=3; IntAct=EBI-1383852, EBI-11749135; CC P54646; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-1383852, EBI-10172052; CC P54646; Q96JM7: L3MBTL3; NbExp=3; IntAct=EBI-1383852, EBI-2686809; CC P54646; Q96JM7-2: L3MBTL3; NbExp=3; IntAct=EBI-1383852, EBI-11985629; CC P54646; P80188: LCN2; NbExp=3; IntAct=EBI-1383852, EBI-11911016; CC P54646; Q9BRK4: LZTS2; NbExp=3; IntAct=EBI-1383852, EBI-741037; CC P54646; Q13064: MKRN3; NbExp=3; IntAct=EBI-1383852, EBI-2340269; CC P54646; Q6PF18: MORN3; NbExp=3; IntAct=EBI-1383852, EBI-9675802; CC P54646; Q9Y605: MRFAP1; NbExp=3; IntAct=EBI-1383852, EBI-995714; CC P54646; Q5JR59-3: MTUS2; NbExp=4; IntAct=EBI-1383852, EBI-11522433; CC P54646; P12524-2: MYCL; NbExp=3; IntAct=EBI-1383852, EBI-18936665; CC P54646; Q15742: NAB2; NbExp=3; IntAct=EBI-1383852, EBI-8641936; CC P54646; Q7Z6G3-2: NECAB2; NbExp=3; IntAct=EBI-1383852, EBI-10172876; CC P54646; Q15233-2: NONO; NbExp=3; IntAct=EBI-1383852, EBI-10203843; CC P54646; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-1383852, EBI-945833; CC P54646; Q96F24: NRBF2; NbExp=3; IntAct=EBI-1383852, EBI-2362014; CC P54646; Q86Y26: NUTM1; NbExp=3; IntAct=EBI-1383852, EBI-10178410; CC P54646; Q494U1-3: PLEKHN1; NbExp=3; IntAct=EBI-1383852, EBI-12014286; CC P54646; Q9NQX0: PRDM6; NbExp=3; IntAct=EBI-1383852, EBI-11320284; CC P54646; Q9Y478: PRKAB1; NbExp=10; IntAct=EBI-1383852, EBI-719769; CC P54646; O43741: PRKAB2; NbExp=18; IntAct=EBI-1383852, EBI-1053424; CC P54646; P54619: PRKAG1; NbExp=14; IntAct=EBI-1383852, EBI-1181439; CC P54646; P31321: PRKAR1B; NbExp=3; IntAct=EBI-1383852, EBI-2805516; CC P54646; P41219: PRPH; NbExp=3; IntAct=EBI-1383852, EBI-752074; CC P54646; Q86YV0: RASAL3; NbExp=3; IntAct=EBI-1383852, EBI-3437896; CC P54646; Q93062: RBPMS; NbExp=3; IntAct=EBI-1383852, EBI-740322; CC P54646; Q04864-2: REL; NbExp=4; IntAct=EBI-1383852, EBI-10829018; CC P54646; Q8HWS3: RFX6; NbExp=3; IntAct=EBI-1383852, EBI-746118; CC P54646; Q9Y3C5: RNF11; NbExp=3; IntAct=EBI-1383852, EBI-396669; CC P54646; Q7Z5V6-2: SAXO4; NbExp=3; IntAct=EBI-1383852, EBI-12000762; CC P54646; Q9UJW9: SERTAD3; NbExp=3; IntAct=EBI-1383852, EBI-748621; CC P54646; Q15477: SKIC2; NbExp=3; IntAct=EBI-1383852, EBI-373226; CC P54646; Q9H6Q3: SLA2; NbExp=3; IntAct=EBI-1383852, EBI-1222854; CC P54646; Q5JUK2: SOHLH1; NbExp=3; IntAct=EBI-1383852, EBI-12288855; CC P54646; O43609: SPRY1; NbExp=3; IntAct=EBI-1383852, EBI-3866665; CC P54646; Q6ZMT1: STAC2; NbExp=3; IntAct=EBI-1383852, EBI-948802; CC P54646; Q15831: STK11; NbExp=3; IntAct=EBI-1383852, EBI-306838; CC P54646; P15884: TCF4; NbExp=3; IntAct=EBI-1383852, EBI-533224; CC P54646; Q96CG3: TIFA; NbExp=3; IntAct=EBI-1383852, EBI-740711; CC P54646; Q08117: TLE5; NbExp=3; IntAct=EBI-1383852, EBI-717810; CC P54646; Q08117-2: TLE5; NbExp=3; IntAct=EBI-1383852, EBI-11741437; CC P54646; Q15645: TRIP13; NbExp=3; IntAct=EBI-1383852, EBI-358993; CC P54646; Q15654: TRIP6; NbExp=3; IntAct=EBI-1383852, EBI-742327; CC P54646; Q9Y3Q8: TSC22D4; NbExp=3; IntAct=EBI-1383852, EBI-739485; CC P54646; O75385: ULK1; NbExp=2; IntAct=EBI-1383852, EBI-908831; CC P54646; Q9Y6N9-4: USH1C; NbExp=3; IntAct=EBI-1383852, EBI-11523636; CC P54646; Q495M9: USH1G; NbExp=3; IntAct=EBI-1383852, EBI-8601749; CC P54646; Q8N6Y0: USHBP1; NbExp=3; IntAct=EBI-1383852, EBI-739895; CC P54646; Q9UK41-2: VPS28; NbExp=3; IntAct=EBI-1383852, EBI-12146727; CC P54646; Q9H9H4: VPS37B; NbExp=3; IntAct=EBI-1383852, EBI-4400866; CC P54646; Q8N1B4: VPS52; NbExp=3; IntAct=EBI-1383852, EBI-2799833; CC P54646; O76024: WFS1; NbExp=3; IntAct=EBI-1383852, EBI-720609; CC P54646; O00308: WWP2; NbExp=3; IntAct=EBI-1383852, EBI-743923; CC P54646; P62258: YWHAE; NbExp=2; IntAct=EBI-1383852, EBI-356498; CC P54646; Q96BR9: ZBTB8A; NbExp=3; IntAct=EBI-1383852, EBI-742740; CC P54646; Q9H0C1: ZMYND12; NbExp=3; IntAct=EBI-1383852, EBI-12030590; CC P54646; Q9UDV6: ZNF212; NbExp=3; IntAct=EBI-1383852, EBI-1640204; CC P54646; Q8NF99: ZNF397; NbExp=3; IntAct=EBI-1383852, EBI-10213894; CC P54646; Q3MJ62: ZSCAN23; NbExp=3; IntAct=EBI-1383852, EBI-5667532; CC P54646; Q9WTK7: Stk11; Xeno; NbExp=2; IntAct=EBI-1383852, EBI-8627450; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q8BRK8}. Nucleus CC {ECO:0000269|PubMed:15866171}. Note=In response to stress, recruited by CC p53/TP53 to specific promoters. {ECO:0000269|PubMed:15866171}. CC -!- DOMAIN: The AIS (autoinhibitory sequence) region shows some sequence CC similarity with the ubiquitin-associated domains and represses kinase CC activity. {ECO:0000250|UniProtKB:Q13131}. CC -!- PTM: Ubiquitinated. {ECO:0000250|UniProtKB:Q8BRK8}. CC -!- PTM: Phosphorylated at Thr-172 by STK11/LKB1 in complex with STE20- CC related adapter-alpha (STRADA) pseudo kinase and CAB39. Also CC phosphorylated at Thr-172 by CAMKK2; triggered by a rise in CC intracellular calcium ions, without detectable changes in the AMP/ATP CC ratio. CAMKK1 can also phosphorylate Thr-172, but at much lower level. CC Dephosphorylated by protein phosphatase 2A and 2C (PP2A and PP2C). CC Phosphorylated by ULK1; leading to negatively regulate AMPK activity CC and suggesting the existence of a regulatory feedback loop between ULK1 CC and AMPK. Dephosphorylated by PPM1A and PPM1B at Thr-172 (mediated by CC STK11/LKB1). {ECO:0000269|PubMed:15980064, CC ECO:0000269|PubMed:21460634}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. SNF1 subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U06454; AAA64745.1; -; mRNA. DR EMBL; AL035705; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC069680; AAH69680.1; -; mRNA. DR EMBL; BC069740; AAH69740.1; -; mRNA. DR EMBL; BC069823; AAH69823.1; -; mRNA. DR CCDS; CCDS605.1; -. DR PIR; S51025; S51025. DR RefSeq; NP_006243.2; NM_006252.3. DR PDB; 2H6D; X-ray; 1.85 A; A=6-279. DR PDB; 2LTU; NMR; -; A=282-339. DR PDB; 2YZA; X-ray; 3.02 A; A=6-279. DR PDB; 3AQV; X-ray; 2.08 A; A=6-279. DR PDB; 4CFE; X-ray; 3.02 A; A/C=1-552. DR PDB; 4CFF; X-ray; 3.92 A; A/C=1-552. DR PDB; 4ZHX; X-ray; 2.99 A; A/C=2-552. DR PDB; 5EZV; X-ray; 2.99 A; A/C=2-347, A/C=397-552. DR PDB; 5ISO; X-ray; 2.63 A; A/C=1-552. DR PDB; 6B1U; X-ray; 2.77 A; A/C=2-552. DR PDB; 6B2E; X-ray; 3.80 A; A=2-552. DR PDB; 6BX6; X-ray; 2.90 A; A=6-279. DR PDB; 7MYJ; X-ray; 2.95 A; A/C=2-552. DR PDB; 8BIK; X-ray; 2.50 A; A/D=1-552. DR PDB; 9IC2; X-ray; 2.50 A; A=6-280. DR PDBsum; 2H6D; -. DR PDBsum; 2LTU; -. DR PDBsum; 2YZA; -. DR PDBsum; 3AQV; -. DR PDBsum; 4CFE; -. DR PDBsum; 4CFF; -. DR PDBsum; 4ZHX; -. DR PDBsum; 5EZV; -. DR PDBsum; 5ISO; -. DR PDBsum; 6B1U; -. DR PDBsum; 6B2E; -. DR PDBsum; 6BX6; -. DR PDBsum; 7MYJ; -. DR PDBsum; 8BIK; -. DR PDBsum; 9IC2; -. DR AlphaFoldDB; P54646; -. DR BMRB; P54646; -. DR SMR; P54646; -. DR BioGRID; 111550; 239. DR ComplexPortal; CPX-5787; AMPK complex, alpha2-beta1-gamma1 variant. DR ComplexPortal; CPX-5790; AMPK complex, alpha2-beta2-gamma1 variant. DR ComplexPortal; CPX-5840; AMPK complex, alpha2-beta2-gamma3 variant. DR ComplexPortal; CPX-5843; AMPK complex, alpha2-beta1-gamma3 variant. DR ComplexPortal; CPX-5844; AMPK complex, alpha2-beta1-gamma2 variant. DR ComplexPortal; CPX-5845; AMPK complex, alpha2-beta2-gamma2 variant. DR CORUM; P54646; -. DR DIP; DIP-39796N; -. DR FunCoup; P54646; 2136. DR IntAct; P54646; 181. DR MINT; P54646; -. DR STRING; 9606.ENSP00000360290; -. DR BindingDB; P54646; -. DR ChEMBL; CHEMBL2116; -. DR DrugBank; DB00945; Acetylsalicylic acid. DR DrugBank; DB00131; Adenosine phosphate. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB00273; Topiramate. DR DrugCentral; P54646; -. DR TCDB; 8.A.104.1.1; the 5'-amp-activated protein kinase (ampk) family. DR GlyConnect; 985; 2 N-Linked glycans (1 site). DR GlyCosmos; P54646; 1 site, 3 glycans. DR GlyGen; P54646; 2 sites, 3 N-linked glycans (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P54646; -. DR PhosphoSitePlus; P54646; -. DR BioMuta; PRKAA2; -. DR DMDM; 20178276; -. DR jPOST; P54646; -. DR MassIVE; P54646; -. DR PaxDb; 9606-ENSP00000360290; -. DR PeptideAtlas; P54646; -. DR ProteomicsDB; 56689; -. DR Pumba; P54646; -. DR Antibodypedia; 3399; 836 antibodies from 45 providers. DR DNASU; 5563; -. DR Ensembl; ENST00000371244.9; ENSP00000360290.4; ENSG00000162409.13. DR GeneID; 5563; -. DR KEGG; hsa:5563; -. DR MANE-Select; ENST00000371244.9; ENSP00000360290.4; NM_006252.4; NP_006243.2. DR UCSC; uc001cyk.5; human. DR AGR; HGNC:9377; -. DR CIViC; 5563; 1 evidence item across 1 molecular profile. DR ClinPGx; PA33745; -. DR CTD; 5563; -. DR DisGeNET; 5563; -. DR GeneCards; PRKAA2; -. DR HGNC; HGNC:9377; PRKAA2. DR HPA; ENSG00000162409; Tissue enhanced (heart muscle, skeletal muscle, tongue). DR MIM; 600497; gene. DR OpenTargets; ENSG00000162409; -. DR VEuPathDB; HostDB:ENSG00000162409; -. DR eggNOG; KOG0583; Eukaryota. DR GeneTree; ENSGT00940000156945; -. DR HOGENOM; CLU_000288_59_3_1; -. DR InParanoid; P54646; -. DR OrthoDB; 193931at2759; -. DR PAN-GO; P54646; 4 GO annotations based on evolutionary models. DR PhylomeDB; P54646; -. DR BRENDA; 2.7.11.1; 2681. DR BRENDA; 2.7.11.31; 2681. DR PathwayCommons; P54646; -. DR Reactome; R-HSA-1445148; Translocation of SLC2A4 (GLUT4) to the plasma membrane. DR Reactome; R-HSA-1632852; Macroautophagy. DR Reactome; R-HSA-163680; AMPK inhibits chREBP transcriptional activation activity. DR Reactome; R-HSA-200425; Carnitine shuttle. DR Reactome; R-HSA-2151209; Activation of PPARGC1A (PGC-1alpha) by phosphorylation. DR Reactome; R-HSA-380972; Energy dependent regulation of mTOR by LKB1-AMPK. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-9613354; Lipophagy. DR Reactome; R-HSA-9619483; Activation of AMPK downstream of NMDARs. DR Reactome; R-HSA-9759194; Nuclear events mediated by NFE2L2. DR SignaLink; P54646; -. DR SIGNOR; P54646; -. DR Agora; ENSG00000162409; -. DR BioGRID-ORCS; 5563; 16 hits in 1188 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; PRKAA2; human. DR EvolutionaryTrace; P54646; -. DR GeneWiki; PRKAA2; -. DR GenomeRNAi; 5563; -. DR Pharos; P54646; Tchem. DR PRO; PR:P54646; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P54646; protein. DR Bgee; ENSG00000162409; Expressed in skeletal muscle tissue of rectus abdominis and 181 other cell types or tissues. DR ExpressionAtlas; P54646; baseline and differential. DR GO; GO:0030424; C:axon; ISS:ARUK-UCL. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0010494; C:cytoplasmic stress granule; ISS:ARUK-UCL. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030425; C:dendrite; ISS:ARUK-UCL. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0043025; C:neuronal cell body; ISS:ARUK-UCL. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0031588; C:nucleotide-activated protein kinase complex; IPI:ComplexPortal. DR GO; GO:0005634; C:nucleus; IDA:ComplexPortal. DR GO; GO:0047322; F:[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity; IEA:UniProtKB-EC. DR GO; GO:0004679; F:AMP-activated protein kinase activity; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003682; F:chromatin binding; ISS:UniProtKB. DR GO; GO:0140823; F:histone H2BS36 kinase activity; ISS:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:MGI. DR GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW. DR GO; GO:0071277; P:cellular response to calcium ion; ISS:ARUK-UCL. DR GO; GO:0042149; P:cellular response to glucose starvation; IDA:UniProtKB. DR GO; GO:0071333; P:cellular response to glucose stimulus; ISS:ARUK-UCL. DR GO; GO:0031669; P:cellular response to nutrient levels; IDA:ComplexPortal. DR GO; GO:0034599; P:cellular response to oxidative stress; ISS:ARUK-UCL. DR GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEA:Ensembl. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0006695; P:cholesterol biosynthetic process; IEA:UniProtKB-KW. DR GO; GO:0097009; P:energy homeostasis; ISS:UniProtKB. DR GO; GO:0006633; P:fatty acid biosynthetic process; IEA:UniProtKB-KW. DR GO; GO:0055089; P:fatty acid homeostasis; ISS:UniProtKB. DR GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB. DR GO; GO:0008610; P:lipid biosynthetic process; ISS:UniProtKB. DR GO; GO:1905691; P:lipid droplet disassembly; IDA:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB. DR GO; GO:0010629; P:negative regulation of gene expression; ISS:ARUK-UCL. DR GO; GO:1903944; P:negative regulation of hepatocyte apoptotic process; IDA:UniProt. DR GO; GO:0032007; P:negative regulation of TOR signaling; ISS:UniProtKB. DR GO; GO:1904262; P:negative regulation of TORC1 signaling; IDA:UniProtKB. DR GO; GO:1904428; P:negative regulation of tubulin deacetylation; IEA:Ensembl. DR GO; GO:0010508; P:positive regulation of autophagy; ISS:UniProtKB. DR GO; GO:0045821; P:positive regulation of glycolytic process; ISS:UniProtKB. DR GO; GO:0016239; P:positive regulation of macroautophagy; TAS:ParkinsonsUK-UCL. DR GO; GO:1903829; P:positive regulation of protein localization; ISS:ARUK-UCL. DR GO; GO:1990044; P:protein localization to lipid droplet; IDA:UniProtKB. DR GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB. DR GO; GO:0016241; P:regulation of macroautophagy; ISS:UniProtKB. DR GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; ISS:ARUK-UCL. DR GO; GO:0062028; P:regulation of stress granule assembly; IEA:Ensembl. DR GO; GO:0014850; P:response to muscle activity; IEA:Ensembl. DR GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW. DR CDD; cd12200; AMPKA2_C; 1. DR CDD; cd14079; STKc_AMPK_alpha; 1. DR CDD; cd14404; UBA_AID_AAPK2; 1. DR FunFam; 1.10.510.10:FF:000079; Non-specific serine/threonine protein kinase; 1. DR FunFam; 1.10.8.10:FF:000014; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:000136; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.310.80:FF:000003; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.30.310.80; Kinase associated domain 1, KA1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00661; -. DR InterPro; IPR032270; AMPK_C. DR InterPro; IPR039148; AMPKA2_C. DR InterPro; IPR028375; KA1/Ssp2_C. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR049020; PRKAA1/2_AID. DR InterPro; IPR028783; PRKAA2. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24346:SF104; 5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2; 1. DR PANTHER; PTHR24346; MAP/MICROTUBULE AFFINITY-REGULATING KINASE; 1. DR Pfam; PF16579; AdenylateSensor; 1. DR Pfam; PF21147; AMPK_alpha_AID; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF103243; KA1-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Autophagy; Biological rhythms; KW Cholesterol biosynthesis; Cholesterol metabolism; Chromatin regulator; KW Cytoplasm; Fatty acid biosynthesis; Fatty acid metabolism; Kinase; KW Lipid biosynthesis; Lipid metabolism; Magnesium; Metal-binding; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Steroid biosynthesis; KW Steroid metabolism; Sterol biosynthesis; Sterol metabolism; Transcription; KW Transcription regulation; Transferase; Ubl conjugation; KW Wnt signaling pathway. FT CHAIN 1..552 FT /note="5'-AMP-activated protein kinase catalytic subunit FT alpha-2" FT /id="PRO_0000085594" FT DOMAIN 16..268 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 291..376 FT /note="AIS" FT /evidence="ECO:0000250|UniProtKB:Q13131" FT REGION 477..521 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 480..490 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 501..510 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 511..521 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 139 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 22..30 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 45 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 172 FT /note="Phosphothreonine; by LKB1 and CaMKK2" FT /evidence="ECO:0000269|PubMed:15980064, FT ECO:0000269|PubMed:24767988, ECO:0000269|PubMed:28552616" FT MOD_RES 258 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q09137" FT MOD_RES 377 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163" FT MOD_RES 491 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q09137" FT VARIANT 371 FT /note="P -> T (in breast cancer samples; infiltrating FT ductal carcinoma; somatic mutation)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17344846" FT /id="VAR_035623" FT VARIANT 407 FT /note="R -> Q (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040355" FT VARIANT 523 FT /note="S -> G (in a breast cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035624" FT MUTAGEN 45 FT /note="K->R: Complete loss of kinase activity." FT /evidence="ECO:0000305|PubMed:36017701" FT MUTAGEN 172 FT /note="T->A: Loss of ARF6 activation. Loss of interaction FT with ACSS2." FT /evidence="ECO:0000269|PubMed:28552616, FT ECO:0000269|PubMed:36017701" FT MUTAGEN 172 FT /note="T->D: Phosphomimetic mutant." FT /evidence="ECO:0000269|PubMed:21543851" FT CONFLICT 180 FT /note="A -> T (in Ref. 1; AAA64745)" FT /evidence="ECO:0000305" FT CONFLICT 271 FT /note="D -> G (in Ref. 1; AAA64745)" FT /evidence="ECO:0000305" FT CONFLICT 403..404 FT /note="HL -> RQ (in Ref. 1; AAA64745)" FT /evidence="ECO:0000305" FT STRAND 16..24 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 26..35 FT /evidence="ECO:0007829|PDB:2H6D" FT TURN 36..38 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 41..48 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 49..54 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 58..69 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 79..84 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 86..94 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 101..108 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 113..133 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 142..144 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 145..147 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 153..155 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 160..162 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 177..179 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 183..185 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 192..209 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 219..228 FT /evidence="ECO:0007829|PDB:2H6D" FT STRAND 235..237 FT /evidence="ECO:0007829|PDB:6BX6" FT HELIX 239..248 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 253..255 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 259..264 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 266..269 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 274..276 FT /evidence="ECO:0007829|PDB:2H6D" FT HELIX 283..286 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 290..299 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 304..312 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 319..335 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 338..341 FT /evidence="ECO:0007829|PDB:8BIK" FT STRAND 403..408 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 412..425 FT /evidence="ECO:0007829|PDB:8BIK" FT STRAND 429..434 FT /evidence="ECO:0007829|PDB:8BIK" FT STRAND 437..443 FT /evidence="ECO:0007829|PDB:8BIK" FT TURN 445..447 FT /evidence="ECO:0007829|PDB:8BIK" FT STRAND 450..461 FT /evidence="ECO:0007829|PDB:8BIK" FT STRAND 464..471 FT /evidence="ECO:0007829|PDB:8BIK" FT HELIX 535..549 FT /evidence="ECO:0007829|PDB:8BIK" SQ SEQUENCE 552 AA; 62320 MW; C46AAFC1D5104975 CRC64; MAEKQKHDGR VKIGHYVLGD TLGVGTFGKV KIGEHQLTGH KVAVKILNRQ KIRSLDVVGK IKREIQNLKL FRHPHIIKLY QVISTPTDFF MVMEYVSGGE LFDYICKHGR VEEMEARRLF QQILSAVDYC HRHMVVHRDL KPENVLLDAH MNAKIADFGL SNMMSDGEFL RTSCGSPNYA APEVISGRLY AGPEVDIWSC GVILYALLCG TLPFDDEHVP TLFKKIRGGV FYIPEYLNRS VATLLMHMLQ VDPLKRATIK DIREHEWFKQ DLPSYLFPED PSYDANVIDD EAVKEVCEKF ECTESEVMNS LYSGDPQDQL AVAYHLIIDN RRIMNQASEF YLASSPPSGS FMDDSAMHIP PGLKPHPERM PPLIADSPKA RCPLDALNTT KPKSLAVKKA KWHLGIRSQS KPYDIMAEVY RAMKQLDFEW KVVNAYHLRV RRKNPVTGNY VKMSLQLYLV DNRSYLLDFK SIDDEVVEQR SGSSTPQRSC SAAGLHRPRS SFDSTTAESH SLSGSLTGSL TGSTLSSVSP RLGSHTMDFF EMCASLITTL AR // ID AKT1_HUMAN Reviewed; 480 AA. AC P31749; B2RAM5; B7Z5R1; Q9BWB6; DT 01-JUL-1993, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-2005, sequence version 2. DT 28-JAN-2026, entry version 272. DE RecName: Full=RAC-alpha serine/threonine-protein kinase; DE EC=2.7.11.1 {ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:15861136, ECO:0000269|PubMed:29343641, ECO:0000269|PubMed:32322062, ECO:0000269|PubMed:33594058}; DE AltName: Full=Protein kinase B; DE Short=PKB; DE AltName: Full=Protein kinase B alpha; DE Short=PKB alpha; DE AltName: Full=Proto-oncogene c-Akt; DE AltName: Full=RAC-PK-alpha; GN Name=AKT1 {ECO:0000312|HGNC:HGNC:391}; Synonyms=PKB, RAC; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CATALYTIC ACTIVITY. RX PubMed=1851997; DOI=10.1073/pnas.88.10.4171; RA Jones P.F., Jakubowicz T., Pitossi F.J., Maurer F., Hemmings B.A.; RT "Molecular cloning and identification of a serine/threonine protein kinase RT of the second-messenger subfamily."; RL Proc. Natl. Acad. Sci. U.S.A. 88:4171-4175(1991). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=11508278; DOI=10.1007/s001250100577; RA Matsubara A., Wasson J.C., Donelan S.S., Welling C.M., Glaser B., RA Permutt M.A.; RT "Isolation and characterization of the human AKT1 gene, identification of RT 13 single nucleotide polymorphisms (SNPs), and their lack of association RT with Type II diabetes."; RL Diabetologia 44:910-913(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Adrenal gland; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=19054851; DOI=10.1038/nmeth.1273; RA Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., RA Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., RA Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B., RA Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., RA Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., RA Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., RA Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., RA Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., RA Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., RA Nomura N.; RT "Human protein factory for converting the transcriptome into an in vitro- RT expressed proteome."; RL Nat. Methods 5:1011-1017(2008). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12508121; DOI=10.1038/nature01348; RA Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C., RA Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A., RA Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H., RA Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T., RA Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B., RA Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D., RA Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R., RA Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S., RA Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C., RA Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S., RA Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., RA Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., RA Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M., RA Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V., RA Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J., RA Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F., RA Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F., RA Waterston R., Hood L., Weissenbach J.; RT "The DNA sequence and analysis of human chromosome 14."; RL Nature 421:601-607(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Muscle, and Ovary; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 63-480 (ISOFORM 1), FUNCTION, CATALYTIC RP ACTIVITY, AND TISSUE SPECIFICITY. RC TISSUE=Foreskin; RX PubMed=1718748; DOI=10.1111/j.1432-1033.1991.tb16305.x; RA Coffer P.J., Woodgett J.R.; RT "Molecular cloning and characterisation of a novel putative protein-serine RT kinase related to the cAMP-dependent and protein kinase C families."; RL Eur. J. Biochem. 201:475-481(1991). RN [8] RP ERRATUM OF PUBMED:1718748, AND SEQUENCE REVISION. RX PubMed=1533586; RA Coffer P.J., Woodgett J.R.; RL Eur. J. Biochem. 205:1217-1218(1992). RN [9] RP FUNCTION IN PHOSPHORYLATION OF CREB1. RX PubMed=9829964; DOI=10.1074/jbc.273.49.32377; RA Du K., Montminy M.; RT "CREB is a regulatory target for the protein kinase Akt/PKB."; RL J. Biol. Chem. 273:32377-32379(1998). RN [10] RP ACTIVITY REGULATION, AND PHOSPHORYLATION AT SER-473. RX PubMed=9736715; DOI=10.1073/pnas.95.19.11211; RA Delcommenne M., Tan C., Gray V., Rue L., Woodgett J.R., Dedhar S.; RT "Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase RT kinase 3 and protein kinase B/AKT by the integrin-linked kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 95:11211-11216(1998). RN [11] RP MUTAGENESIS OF THR-308 AND SER-473, AND PHOSPHORYLATION AT THR-308 AND RP SER-473. RX PubMed=8978681; DOI=10.1002/j.1460-2075.1996.tb01045.x; RA Alessi D.R., Andjelkovic M., Caudwell F.B., Cron P., Morrice N., Cohen P., RA Hemmings B.A.; RT "Mechanism of activation of protein kinase B by insulin and IGF-1."; RL EMBO J. 15:6541-6551(1996). RN [12] RP FUNCTION, ACTIVITY REGULATION, AND PHOSPHORYLATION AT THR-308 BY PDPK1. RX PubMed=9512493; DOI=10.1042/bj3310299; RA Walker K.S., Deak M., Paterson A., Hudson K., Cohen P., Alessi D.R.; RT "Activation of protein kinase B beta and gamma isoforms by insulin in vivo RT and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison RT with protein kinase B alpha."; RL Biochem. J. 331:299-308(1998). RN [13] RP FUNCTION IN PHOSPHORYLATION OF FOXO1. RX PubMed=10358075; DOI=10.1074/jbc.274.24.17179; RA Rena G., Guo S., Cichy S.C., Unterman T.G., Cohen P.; RT "Phosphorylation of the transcription factor forkhead family member FKHR by RT protein kinase B."; RL J. Biol. Chem. 274:17179-17183(1999). RN [14] RP FUNCTION IN PHOSPHORYLATION OF RAF1, AND INTERACTION WITH RAF1. RX PubMed=10576742; DOI=10.1126/science.286.5445.1741; RA Zimmermann S., Moelling K.; RT "Phosphorylation and regulation of Raf by Akt (protein kinase B)."; RL Science 286:1741-1744(1999). RN [15] RP FUNCTION IN PHOSPHORYLATION OF BAD, AND INTERACTION WITH BAD AND PKN2. RX PubMed=10926925; DOI=10.1074/jbc.m001753200; RA Koh H., Lee K.H., Kim D., Kim S., Kim J.W., Chung J.; RT "Inhibition of Akt and its anti-apoptotic activities by tumor necrosis RT factor-induced protein kinase C-related kinase 2 (PRK2) cleavage."; RL J. Biol. Chem. 275:34451-34458(2000). RN [16] RP INTERACTION WITH MTCP1; TCL1A AND TCL1B. RX PubMed=10983986; DOI=10.1016/s1097-2765(00)00039-3; RA Laine J., Kuenstle G., Obata T., Sha M., Noguchi M.; RT "The protooncogene TCL1 is an Akt kinase coactivator."; RL Mol. Cell 6:395-407(2000). RN [17] RP INTERACTION WITH TCL1A. RX PubMed=10716693; DOI=10.1073/pnas.97.7.3028; RA Pekarsky Y., Koval A., Hallas C., Bichi R., Tresini M., Malstrom S., RA Russo G., Tsichlis P., Croce C.M.; RT "Tcl1 enhances Akt kinase activity and mediates its nuclear RT translocation."; RL Proc. Natl. Acad. Sci. U.S.A. 97:3028-3033(2000). RN [18] RP FUNCTION IN PHOSPHORYLATION OF MAP3K5, AND INTERACTION WITH MAP3K5. RX PubMed=11154276; DOI=10.1128/mcb.21.3.893-901.2001; RA Kim A.H., Khursigara G., Sun X., Franke T.F., Chao M.V.; RT "Akt phosphorylates and negatively regulates apoptosis signal-regulating RT kinase 1."; RL Mol. Cell. Biol. 21:893-901(2001). RN [19] RP INTERACTION WITH THEM4, AND SUBCELLULAR LOCATION. RX PubMed=11598301; DOI=10.1126/science.1062030; RA Maira S.-M., Galetic I., Brazil D.P., Kaech S., Ingley E., Thelen M., RA Hemmings B.A.; RT "Carboxyl-terminal modulator protein (CTMP), a negative regulator of RT PKB/Akt and v-Akt at the plasma membrane."; RL Science 294:374-380(2001). RN [20] RP FUNCTION IN PHOSPHORYLATION OF TBC1D4. RX PubMed=11994271; DOI=10.1074/jbc.c200198200; RA Kane S., Sano H., Liu S.C.H., Asara J.M., Lane W.S., Garner C.C., RA Lienhard G.E.; RT "A method to identify serine kinase substrates. Akt phosphorylates a novel RT adipocyte protein with a Rab GTPase-activating protein (GAP) domain."; RL J. Biol. Chem. 277:22115-22118(2002). RN [21] RP INTERACTION WITH CDKN1B, AND FUNCTION. RX PubMed=12042314; DOI=10.1074/jbc.m203668200; RA Fujita N., Sato S., Katayama K., Tsuruo T.; RT "Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and RT cytoplasmic localization."; RL J. Biol. Chem. 277:28706-28713(2002). RN [22] RP PHOSPHORYLATION AT TYR-474, AND MUTAGENESIS OF TYR-474. RX PubMed=12149249; DOI=10.1074/jbc.m203387200; RA Conus N.M., Hannan K.M., Cristiano B.E., Hemmings B.A., Pearson R.B.; RT "Direct identification of tyrosine 474 as a regulatory phosphorylation site RT for the Akt protein kinase."; RL J. Biol. Chem. 277:38021-38028(2002). RN [23] RP FUNCTION IN PHOSPHORYLATION OF TSC2. RX PubMed=12150915; DOI=10.1016/s1097-2765(02)00568-3; RA Manning B.D., Tee A.R., Logsdon M.N., Blenis J., Cantley L.C.; RT "Identification of the tuberous sclerosis complex-2 tumor suppressor gene RT product tuberin as a target of the phosphoinositide 3-kinase/akt pathway."; RL Mol. Cell 10:151-162(2002). RN [24] RP INTERACTION WITH TCL1A. RX PubMed=11839817; DOI=10.1128/mcb.22.5.1513-1525.2002; RA Kuenstle G., Laine J., Pierron G., Kagami S., Nakajima H., Hoh F., RA Roumestand C., Stern M.H., Noguchi M.; RT "Identification of Akt association and oligomerization domains of the Akt RT kinase coactivator TCL1."; RL Mol. Cell. Biol. 22:1513-1525(2002). RN [25] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-179. RX PubMed=12172553; DOI=10.1038/ncb839; RA Inoki K., Li Y., Zhu T., Wu J., Guan K.L.; RT "TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR RT signalling."; RL Nat. Cell Biol. 4:648-657(2002). RN [26] RP INTERACTION WITH CDKN1B, FUNCTION, AND MUTAGENESIS OF THR-308 AND SER-473. RX PubMed=12244301; DOI=10.1038/nm759; RA Shin I., Yakes F.M., Rojo F., Shin N.-Y., Bakin A.V., Baselga J., RA Arteaga C.L.; RT "PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at RT threonine 157 and modulation of its cellular localization."; RL Nat. Med. 8:1145-1152(2002). RN [27] RP FUNCTION IN PARTICIPATION IN KIT SIGNALING. RX PubMed=12878163; DOI=10.1016/s0014-4827(03)00206-4; RA Lennartsson J., Wernstedt C., Engstrom U., Hellman U., Ronnstrand L.; RT "Identification of Tyr900 in the kinase domain of c-Kit as a Src-dependent RT phosphorylation site mediating interaction with c-Crk."; RL Exp. Cell Res. 288:110-118(2003). RN [28] RP INTERACTION WITH AGAP2, AND PHOSPHORYLATION AT SER-473. RX PubMed=14761976; DOI=10.1074/jbc.m312175200; RA Ahn J.-Y., Rong R., Kroll T.G., Van Meir E.G., Snyder S.H., Ye K.; RT "PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt RT activity and mediates cellular invasion."; RL J. Biol. Chem. 279:16441-16451(2004). RN [29] RP PHOSPHORYLATION AT SER-473. RX PubMed=15047712; DOI=10.1074/jbc.m314192200; RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RT "LGI1, a putative tumor metastasis suppressor gene, controls in vitro RT invasiveness and expression of matrix metalloproteinases in glioma cells RT through the ERK1/2 pathway."; RL J. Biol. Chem. 279:23151-23157(2004). RN [30] RP ERRATUM OF PUBMED:15047712. RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RL J. Biol. Chem. 282:2752-2752(2007). RN [31] RP PHOSPHORYLATION AT SER-473. RX PubMed=15262962; DOI=10.1074/jbc.m406731200; RA Feng J., Park J., Cron P., Hess D., Hemmings B.A.; RT "Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA- RT dependent protein kinase."; RL J. Biol. Chem. 279:41189-41196(2004). RN [32] RP INTERACTION WITH AKTIP. RX PubMed=14749367; DOI=10.1128/mcb.24.4.1493-1504.2004; RA Remy I., Michnick S.W.; RT "Regulation of apoptosis by the Ft1 protein, a new modulator of protein RT kinase B/Akt."; RL Mol. Cell. Biol. 24:1493-1504(2004). RN [33] RP INTERACTION WITH AGAP2. RX PubMed=15118108; DOI=10.1073/pnas.0400921101; RA Ahn J.-Y., Hu Y., Kroll T.G., Allard P., Ye K.; RT "PIKE-A is amplified in human cancers and prevents apoptosis by up- RT regulating Akt."; RL Proc. Natl. Acad. Sci. U.S.A. 101:6993-6998(2004). RN [34] RP PHOSPHORYLATION AT SER-473 IN RESPONSE TO FLT3 SIGNALING. RX PubMed=16266983; DOI=10.1158/0008-5472.can-05-0422; RA Brandts C.H., Sargin B., Rode M., Biermann C., Lindtner B., Schwable J., RA Buerger H., Muller-Tidow C., Choudhary C., McMahon M., Berdel W.E., RA Serve H.; RT "Constitutive activation of Akt by Flt3 internal tandem duplications is RT necessary for increased survival, proliferation, and myeloid RT transformation."; RL Cancer Res. 65:9643-9650(2005). RN [35] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH CCDC88A. RX PubMed=16139227; DOI=10.1016/j.devcel.2005.08.001; RA Enomoto A., Murakami H., Asai N., Morone N., Watanabe T., Kawai K., RA Murakumo Y., Usukura J., Kaibuchi K., Takahashi M.; RT "Akt/PKB regulates actin organization and cell motility via Girdin/APE."; RL Dev. Cell 9:389-402(2005). RN [36] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15861136; DOI=10.1038/sj.emboj.7600648; RA Cartlidge R.A., Knebel A., Peggie M., Alexandrov A., Phizicky E.M., RA Cohen P.; RT "The tRNA methylase METTL1 is phosphorylated and inactivated by PKB and RSK RT in vitro and in cells."; RL EMBO J. 24:1696-1705(2005). RN [37] RP PHOSPHORYLATION AT THR-308, AND PHOSPHORYLATION AT SER-473 BY MTOR. RX PubMed=15718470; DOI=10.1126/science.1106148; RA Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M.; RT "Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex."; RL Science 307:1098-1101(2005). RN [38] RP PHOSPHORYLATION AT SER-473. RX PubMed=17013611; DOI=10.1007/s00401-006-0128-y; RA Schick V., Majores M., Engels G., Spitoni S., Koch A., Elger C.E., RA Simon M., Knobbe C., Bluemcke I., Becker A.J.; RT "Activation of Akt independent of PTEN and CTMP tumor-suppressor gene RT mutations in epilepsy-associated Taylor-type focal cortical dysplasias."; RL Acta Neuropathol. 112:715-725(2006). RN [39] RP INTERACTION WITH WDFY2, AND SUBCELLULAR LOCATION. RX PubMed=16792529; DOI=10.1042/bj20060511; RA Fritzius T., Burkard G., Haas E., Heinrich J., Schweneker M., Bosse M., RA Zimmermann S., Frey A.D., Caelers A., Bachmann A.S., Moelling K.; RT "A WD-FYVE protein binds to the kinases Akt and PKCzeta/lambda."; RL Biochem. J. 399:9-20(2006). RN [40] RP FUNCTION, AND INTERACTION WITH RARA. RX PubMed=16417524; DOI=10.1042/bj20051794; RA Srinivas H., Xia D., Moore N.L., Uray I.P., Kim H., Ma L., Weigel N.L., RA Brown P.H., Kurie J.M.; RT "Akt phosphorylates and suppresses the transactivation of retinoic acid RT receptor alpha."; RL Biochem. J. 395:653-662(2006). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-129, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [42] RP BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=16540465; DOI=10.1074/jbc.m601384200; RA Zhang X., Zhang S., Yamane H., Wahl R., Ali A., Lofgren J.A., Kendall R.L.; RT "Kinetic mechanism of AKT/PKB enzyme family."; RL J. Biol. Chem. 281:13949-13956(2006). RN [43] RP FUNCTION IN PHOSPHORYLATION OF CDKN1A. RX PubMed=16982699; DOI=10.1128/mcb.00201-06; RA Heron-Milhavet L., Franckhauser C., Rana V., Berthenet C., Fisher D., RA Hemmings B.A., Fernandez A., Lamb N.J.; RT "Only Akt1 is required for proliferation, while Akt2 promotes cell cycle RT exit through p21 binding."; RL Mol. Cell. Biol. 26:8267-8280(2006). RN [44] RP INTERACTION WITH STK4/MST1, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=17932490; DOI=10.1038/sj.emboj.7601872; RA Cinar B., Fang P.K., Lutchman M., Di Vizio D., Adam R.M., Pavlova N., RA Rubin M.A., Yelick P.C., Freeman M.R.; RT "The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct RT inhibitors of Akt1."; RL EMBO J. 26:4523-4534(2007). RN [45] RP FUNCTION, AND INTERACTION WITH STK4/MST1. RX PubMed=17726016; DOI=10.1074/jbc.m704542200; RA Jang S.W., Yang S.J., Srinivasan S., Ye K.; RT "Akt phosphorylates MstI and prevents its proteolytic activation, blocking RT FOXO3 phosphorylation and nuclear translocation."; RL J. Biol. Chem. 282:30836-30844(2007). RN [46] RP FUNCTION IN PHOSPHORYLATION OF PROHIBITIN. RX PubMed=18507042; RA Han E.K., Mcgonigal T., Butler C., Giranda V.L., Luo Y.; RT "Characterization of Akt overexpression in MiaPaCa-2 cells: prohibitin is RT an Akt substrate both in vitro and in cells."; RL Anticancer Res. 28:957-963(2008). RN [47] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-124; SER-126 AND SER-129, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [48] RP UBIQUITINATION BY TTC3. RX PubMed=20059950; DOI=10.1016/j.devcel.2009.09.007; RA Suizu F., Hiramuki Y., Okumura F., Matsuda M., Okumura A.J., Hirata N., RA Narita M., Kohno T., Yokota J., Bohgaki M., Obuse C., Hatakeyama S., RA Obata T., Noguchi M.; RT "The E3 ligase TTC3 facilitates ubiquitination and degradation of RT phosphorylated Akt."; RL Dev. Cell 17:800-810(2009). RN [49] RP FUNCTION IN PHOSPHORYLATION OF SRPK2, AND INTERACTION WITH SRPK2. RX PubMed=19592491; DOI=10.1074/jbc.m109.026237; RA Jang S.W., Liu X., Fu H., Rees H., Yepes M., Levey A., Ye K.; RT "Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell cycle RT and cell death in neurons."; RL J. Biol. Chem. 284:24512-24525(2009). RN [50] RP FUNCTION. RX PubMed=19934221; DOI=10.1242/jcs.053728; RA Bristow J.M., Sellers M.H., Majumdar D., Anderson B., Hu L., Webb D.J.; RT "The Rho-family GEF Asef2 activates Rac to modulate adhesion and actin RT dynamics and thereby regulate cell migration."; RL J. Cell Sci. 122:4535-4546(2009). RN [51] RP UBIQUITINATION, INTERACTION WITH TRAF6, MUTAGENESIS OF LYS-8 AND LYS-14, RP AND CHARACTERIZATION OF VARIANT BREAST CANCER LYS-17. RX PubMed=19713527; DOI=10.1126/science.1175065; RA Yang W.-L., Wang J., Chan C.-H., Lee S.-W., Campos A.D., Lamothe B., RA Hur L., Grabiner B.C., Lin X., Darnay B.G., Lin H.-K.; RT "The E3 ligase TRAF6 regulates Akt ubiquitination and activation."; RL Science 325:1134-1138(2009). RN [52] RP FUNCTION, AND INTERACTION WITH STK3/MST2. RX PubMed=20086174; DOI=10.1158/0008-5472.can-09-3147; RA Romano D., Matallanas D., Weitsman G., Preisinger C., Ng T., Kolch W.; RT "Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, RT Raf-1, and Akt."; RL Cancer Res. 70:1195-1203(2010). RN [53] RP RETRACTED PAPER. RX PubMed=19940129; DOI=10.1074/jbc.m109.059675; RA Yuan Z., Kim D., Shu S., Wu J., Guo J., Xiao L., Kaneko S., Coppola D., RA Cheng J.Q.; RT "Phosphoinositide 3-kinase/Akt inhibits MST1-mediated pro-apoptotic RT signaling through phosphorylation of threonine 120."; RL J. Biol. Chem. 285:3815-3824(2010). RN [54] RP RETRACTION NOTICE OF PUBMED:19940129. RX PubMed=27825096; DOI=10.1074/jbc.a109.059675; RA Yuan Z., Kim D., Shu S., Wu J., Guo J., Xiao L., Kaneko S., Coppola D., RA Cheng J.Q.; RL J. Biol. Chem. 291:22858-22858(2016). RN [55] RP FUNCTION, AND INTERACTION WITH CLK2. RX PubMed=20682768; DOI=10.1074/jbc.m110.122044; RA Nam S.Y., Seo H.H., Park H.S., An S., Kim J.Y., Yang K.H., Kim C.S., RA Jeong M., Jin Y.W.; RT "Phosphorylation of CLK2 at serine 34 and threonine 127 by AKT controls RT cell survival after ionizing radiation."; RL J. Biol. Chem. 285:31157-31163(2010). RN [56] RP FUNCTION IN PHOSPHORYLATION OF PALLD. RX PubMed=20471940; DOI=10.1016/j.molcel.2010.02.031; RA Chin Y.R., Toker A.; RT "The actin-bundling protein palladin is an Akt1-specific substrate that RT regulates breast cancer cell migration."; RL Mol. Cell 38:333-344(2010). RN [57] RP RETRACTED PAPER. RX PubMed=20231902; DOI=10.1371/journal.pone.0009616; RA Kim D., Shu S., Coppola M.D., Kaneko S., Yuan Z.Q., Cheng J.Q.; RT "Regulation of proapoptotic mammalian ste20-like kinase MST2 by the IGF1- RT Akt pathway."; RL PLoS ONE 5:E9616-E9616(2010). RN [58] RP CAUTION, AND RETRACTION NOTICE OF PUBMED:20231902. RX PubMed=37490513; DOI=10.1371/journal.pone.0289329; RG PLOS ONE Editors; RT "Retraction: Regulation of Proapoptotic Mammalian ste20-Like Kinase MST2 by RT the IGF1-Akt Pathway."; RL PLoS ONE 18:e0289329-e0289329(2023). RN [59] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-176; THR-308 AND RP SER-473, MUTAGENESIS OF TYR-176, INTERACTION WITH TNK2, AND TISSUE RP SPECIFICITY. RX PubMed=20333297; DOI=10.1371/journal.pone.0009646; RA Mahajan K., Coppola D., Challa S., Fang B., Chen Y.A., Zhu W., Lopez A.S., RA Koomen J., Engelman R.W., Rivera C., Muraoka-Cook R.S., Cheng J.Q., RA Schoenbrunn E., Sebti S.M., Earp H.S., Mahajan N.P.; RT "Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its RT activation."; RL PLoS ONE 5:E9646-E9646(2010). RN [60] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [61] RP INTERACTION WITH TRIM13, AND UBIQUITINATION. RX PubMed=21333377; DOI=10.1016/j.ejcb.2010.12.001; RA Joo H.M., Kim J.Y., Jeong J.B., Seong K.M., Nam S.Y., Yang K.H., Kim C.S., RA Kim H.S., Jeong M., An S., Jin Y.W.; RT "Ret finger protein 2 enhances ionizing radiation-induced apoptosis via RT degradation of AKT and MDM2."; RL Eur. J. Cell Biol. 90:420-431(2011). RN [62] RP INTERACTION WITH PPP2R5B, AND DEPHOSPHORYLATION. RX PubMed=21329884; DOI=10.1016/j.molcel.2011.02.007; RA Rodgers J.T., Vogel R.O., Puigserver P.; RT "Clk2 and B56-beta mediate insulin-regulated assembly of the PP2A RT phosphatase holoenzyme complex on Akt."; RL Mol. Cell 41:471-479(2011). RN [63] RP INTERACTION WITH FAM168A. RX PubMed=23251525; DOI=10.1371/journal.pone.0051413; RA Peng B., Gu Y., Xiong Y., Zheng G., He Z.; RT "Microarray-assisted pathway analysis identifies MT1X & NFkappaB as RT mediators of TCRP1-associated resistance to cisplatin in oral squamous cell RT carcinoma."; RL PLoS ONE 7:E51413-E51413(2012). RN [64] RP PROTEOLYTIC CLEAVAGE. RX PubMed=23152800; DOI=10.1371/journal.pone.0048770; RA Sen T., Sen N., Noordhuis M.G., Ravi R., Wu T.C., Ha P.K., Sidransky D., RA Hoque M.O.; RT "OGDHL is a modifier of AKT-dependent signaling and NF-kappaB function."; RL PLoS ONE 7:e48770-e48770(2012). RN [65] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-129, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [66] RP INTERACTION WITH FAM83B. RX PubMed=23676467; DOI=10.18632/oncotarget.1027; RA Cipriano R., Miskimen K.L., Bryson B.L., Foy C.R., Bartel C.A., RA Jackson M.W.; RT "FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to RT promote epithelial cell transformation and resistance to targeted RT therapies."; RL Oncotarget 4:729-738(2013). RN [67] RP REVIEW ON ROLE IN KIT SIGNALING. RX PubMed=15526160; DOI=10.1007/s00018-004-4189-6; RA Ronnstrand L.; RT "Signal transduction via the stem cell factor receptor/c-Kit."; RL Cell. Mol. Life Sci. 61:2535-2548(2004). RN [68] RP REVIEW ON FUNCTION. RX PubMed=11882383; DOI=10.1016/s0898-6568(01)00271-6; RA Nicholson K.M., Anderson N.G.; RT "The protein kinase B/Akt signalling pathway in human malignancy."; RL Cell. Signal. 14:381-395(2002). RN [69] RP PHOSPHORYLATION AT SER-473. RX PubMed=20978158; DOI=10.1158/1535-7163.mct-10-0730; RA Kunoh T., Noda T., Koseki K., Sekigawa M., Takagi M., Shin-ya K., RA Goshima N., Iemura S., Natsume T., Wada S., Mukai Y., Ohta S., Sasaki R., RA Mizukami T.; RT "A novel human dynactin-associated protein, dynAP, promotes activation of RT Akt, and ergosterol-related compounds induce dynAP-dependent apoptosis of RT human cancer cells."; RL Mol. Cancer Ther. 9:2934-2942(2010). RN [70] RP REVIEW ON FUNCTION. RX PubMed=21620960; DOI=10.1016/j.cellsig.2011.05.004; RA Hers I., Vincent E.E., Tavare J.M.; RT "Akt signalling in health and disease."; RL Cell. Signal. 23:1515-1527(2011). RN [71] RP REVIEW ON FUNCTION. RX PubMed=21432781; DOI=10.14670/hh-26.651; RA Heron-Milhavet L., Khouya N., Fernandez A., Lamb N.J.; RT "Akt1 and Akt2: differentiating the aktion."; RL Histol. Histopathol. 26:651-662(2011). RN [72] RP PHOSPHORYLATION AT THR-308 AND SER-473. RX PubMed=21464307; DOI=10.1073/pnas.1016132108; RA Xie X., Zhang D., Zhao B., Lu M.K., You M., Condorelli G., Wang C.Y., RA Guan K.L.; RT "IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct RT phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 108:6474-6479(2011). RN [73] RP INTERACTION WITH SIRT1, ACETYLATION AT LYS-14 AND LYS-20, DEACETYLATION AT RP LYS-14 AND LYS-20, AND MUTAGENESIS OF LYS-14; GLU-17 AND LYS-20. RX PubMed=21775285; DOI=10.1126/scisignal.2001465; RA Sundaresan N.R., Pillai V.B., Wolfgeher D., Samant S., Vasudevan P., RA Parekh V., Raghuraman H., Cunningham J.M., Gupta M., Gupta M.P.; RT "The deacetylase SIRT1 promotes membrane localization and activation of Akt RT and PDK1 during tumorigenesis and cardiac hypertrophy."; RL Sci. Signal. 4:RA46-RA46(2011). RN [74] RP UBIQUITINATION AT LYS-284. RX PubMed=22410793; DOI=10.1038/cr.2012.38; RA Bae S., Kim S.Y., Jung J.H., Yoon Y., Cha H.J., Lee H., Kim K., Kim J., RA An I.S., Kim J., Um H.D., Park I.C., Lee S.J., Nam S.Y., Jin Y.W., RA Lee J.H., An S.; RT "Akt is negatively regulated by the MULAN E3 ligase."; RL Cell Res. 22:873-885(2012). RN [75] RP GLYCOSYLATION AT SER-126; SER-129; THR-305 AND THR-312, SUBCELLULAR RP LOCATION, INTERACTION WITH PDPK1, AND MUTAGENESIS OF THR-305 AND THR-312. RX PubMed=22629392; DOI=10.1371/journal.pone.0037427; RA Wang S., Huang X., Sun D., Xin X., Pan Q., Peng S., Liang Z., Luo C., RA Yang Y., Jiang H., Huang M., Chai W., Ding J., Geng M.; RT "Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates RT Akt signaling."; RL PLoS ONE 7:E37427-E37427(2012). RN [76] RP PHOSPHORYLATION AT SER-473, AND DEPHOSPHORYLATION BY CPPED1. RX PubMed=23799035; DOI=10.1371/journal.pone.0065679; RA Zhuo D.X., Zhang X.W., Jin B., Zhang Z., Xie B.S., Wu C.L., Gong K., RA Mao Z.B.; RT "CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell RT apoptosis, and suppresses tumor growth of bladder cancer by directly RT dephosphorylating Akt at Ser473 site."; RL PLoS ONE 8:E65679-E65679(2013). RN [77] RP FUNCTION. RX PubMed=23431171; DOI=10.1073/pnas.1300490110; RA Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I., Prives C.; RT "MOZ increases p53 acetylation and premature senescence through its complex RT formation with PML."; RL Proc. Natl. Acad. Sci. U.S.A. 110:3895-3900(2013). RN [78] RP INTERACTION WITH SYAP1. RX PubMed=23300339; DOI=10.1126/scisignal.2003295; RA Yao Y., Suraokar M., Darnay B.G., Hollier B.G., Shaiken T.E., Asano T., RA Chen C.H., Chang B.H., Lu Y., Mills G.B., Sarbassov D., Mani S.A., RA Abbruzzese J.L., Reddy S.A.; RT "BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress RT expression of FoxC2 and stimulate adipocyte differentiation."; RL Sci. Signal. 6:RA2-RA2(2013). RN [79] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-448 AND THR-450, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [80] RP PHOSPHORYLATION AT SER-477 AND THR-479, AND MUTAGENESIS OF 76-ARG--LEU-78 RP AND 273-ARG--LEU-275. RX PubMed=24670654; DOI=10.1038/nature13079; RA Liu P., Begley M., Michowski W., Inuzuka H., Ginzberg M., Gao D., Tsou P., RA Gan W., Papa A., Kim B.M., Wan L., Singh A., Zhai B., Yuan M., Wang Z., RA Gygi S.P., Lee T.H., Lu K.P., Toker A., Pandolfi P.P., Asara J.M., RA Kirschner M.W., Sicinski P., Cantley L., Wei W.; RT "Cell-cycle-regulated activation of Akt kinase by phosphorylation at its RT carboxyl terminus."; RL Nature 508:541-545(2014). RN [81] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=26440888; DOI=10.1016/j.celrep.2015.09.007; RA Seo G.J., Yang A., Tan B., Kim S., Liang Q., Choi Y., Yuan W., Feng P., RA Park H.S., Jung J.U.; RT "Akt kinase-mediated checkpoint of cGAS DNA sensing pathway."; RL Cell Rep. 13:440-449(2015). RN [82] RP INTERACTION WITH KIF14. RX PubMed=24784001; DOI=10.1016/j.neo.2014.03.008; RA Singel S.M., Cornelius C., Zaganjor E., Batten K., Sarode V.R., RA Buckley D.L., Peng Y., John G.B., Li H.C., Sadeghi N., Wright W.E., Lum L., RA Corson T.W., Shay J.W.; RT "KIF14 promotes AKT phosphorylation and contributes to chemoresistance in RT triple-negative breast cancer."; RL Neoplasia 16:247-256(2014). RN [83] RP PHOSPHORYLATION AT SER-473, DEPHOSPHORYLATION, AND INTERACTION WITH PHLPP1 RP AND FKBP5. RX PubMed=28147277; DOI=10.1016/j.celrep.2017.01.009; RA Yu J., Qin B., Wu F., Qin S., Nowsheen S., Shan S., Zayas J., Pei H., RA Lou Z., Wang L.; RT "Regulation of serine-threonine kinase Akt activation by NAD+-dependent RT deacetylase SIRT7."; RL Cell Rep. 18:1229-1240(2017). RN [84] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=29343641; DOI=10.1073/pnas.1705954115; RA Choppara S., Malonia S.K., Sankaran G., Green M.R., Santra M.K.; RT "Degradation of FBXO31 by APC/C is regulated by AKT- and ATM-mediated RT phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 115:998-1003(2018). RN [85] RP FUNCTION. RX PubMed=30504268; DOI=10.15252/embj.201899435; RA Marchi S., Corricelli M., Branchini A., Vitto V.A.M., Missiroli S., RA Morciano G., Perrone M., Ferrarese M., Giorgi C., Pinotti M., Galluzzi L., RA Kroemer G., Pinton P.; RT "Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca2+ levels RT and tumor growth."; RL EMBO J. 38:0-0(2019). RN [86] RP FUNCTION. RX PubMed=31204173; DOI=10.1016/j.devcel.2019.05.022; RA Walia V., Cuenca A., Vetter M., Insinna C., Perera S., Lu Q., Ritt D.A., RA Semler E., Specht S., Stauffer J., Morrison D.K., Lorentzen E., RA Westlake C.J.; RT "Akt Regulates a Rab11-Effector Switch Required for Ciliogenesis."; RL Dev. Cell 50:229-246(2019). RN [87] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=31548394; DOI=10.1073/pnas.1904774116; RA Padi S.K.R., Singh N., Bearss J.J., Olive V., Song J.H., Cardo-Vila M., RA Kraft A.S., Okumura K.; RT "Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases RT inhibition of mTORC1 and promotes tumor growth."; RL Proc. Natl. Acad. Sci. U.S.A. 116:20505-20510(2019). RN [88] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=32322062; DOI=10.1038/s41586-020-2183-2; RA Xu D., Wang Z., Xia Y., Shao F., Xia W., Wei Y., Li X., Qian X., Lee J.H., RA Du L., Zheng Y., Lv G., Leu J.S., Wang H., Xing D., Liang T., Hung M.C., RA Lu Z.; RT "The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis."; RL Nature 580:530-535(2020). RN [89] RP INTERACTION WITH TMEM175, AND FUNCTION. RX PubMed=32228865; DOI=10.7554/elife.53430; RA Oh S., Paknejad N., Hite R.K.; RT "Gating and selectivity mechanisms for the lysosomal K+ channel TMEM175."; RL Elife 9:0-0(2020). RN [90] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-179. RX PubMed=33594058; DOI=10.1038/s41467-021-21206-3; RA Li T., Wang X., Ju E., da Silva S.R., Chen L., Zhang X., Wei S., Gao S.J.; RT "RNF167 activates mTORC1 and promotes tumorigenesis by targeting CASTOR1 RT for ubiquitination and degradation."; RL Nat. Commun. 12:1055-1055(2021). RN [91] RP INTERACTION WITH SLC9D1, PHOSPHORYLATION AT THR-308 AND SER-473, AND RP SUBCELLULAR LOCATION. RX PubMed=40285646; DOI=10.1002/advs.202504187; RA Li X., Han M., Zhu H., Pan Y., Su C., Liu Y., Liao Z., Zhang B., Chen X.; RT "m6A-Mediated TMCO3 Promotes Hepatocellular Carcinoma Progression by RT Facilitating the Membrane Translocation and Activation of AKT."; RL Adv. Sci. 12:e2504187-e2504187(2025). RN [92] RP X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1-123, FUNCTION, INTERACTION WITH RP PTDINS(3,4,5)P3 AND PTDINS(3,4)P2, MUTAGENESIS OF LYS-14; ARG-25 AND RP ARG-86, AND CHARACTERIZATION OF VARIANT CWS6 CYS-25. RX PubMed=12176338; DOI=10.1016/s0960-9822(02)00972-7; RA Thomas C.C., Deak M., Alessi D.R., van Aalten D.M.; RT "High-resolution structure of the pleckstrin homology domain of protein RT kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate."; RL Curr. Biol. 12:1256-1262(2002). RN [93] RP X-RAY CRYSTALLOGRAPHY (0.98 ANGSTROMS) OF 1-121, FUNCTION, AND INTERACTION RP WITH PTDINS(1,3,4,5)P4. RX PubMed=12964941; DOI=10.1042/bj20031229; RA Milburn C.C., Deak M., Kelly S.M., Price N.C., Alessi D.R., RA Van Aalten D.M.; RT "Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin RT homology domain of protein kinase B induces a conformational change."; RL Biochem. J. 375:531-538(2003). RN [94] {ECO:0007744|PDB:3CQU, ECO:0007744|PDB:3CQW} RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 144-480, PHOSPHORYLATION AT RP THR-308, AND ACTIVITY REGULATION. RX PubMed=18456494; DOI=10.1016/j.bmcl.2008.04.034; RA Lippa B., Pan G., Corbett M., Li C., Kauffman G.S., Pandit J., Robinson S., RA Wei L., Kozina E., Marr E.S., Borzillo G., Knauth E., Barbacci-Tobin E.G., RA Vincent P., Troutman M., Baker D., Rajamohan F., Kakar S., Clark T., RA Morris J.; RT "Synthesis and structure based optimization of novel Akt inhibitors."; RL Bioorg. Med. Chem. Lett. 18:3359-3363(2008). RN [95] {ECO:0007744|PDB:3OCB} RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 144-480, AND ACTIVITY REGULATION. RX PubMed=20810279; DOI=10.1016/j.bmcl.2010.08.053; RA Blake J.F., Kallan N.C., Xiao D., Xu R., Bencsik J.R., Skelton N.J., RA Spencer K.L., Mitchell I.S., Woessner R.D., Gloor S.L., Risom T., RA Gross S.D., Martinson M., Morales T.H., Vigers G.P., Brandhuber B.J.; RT "Discovery of pyrrolopyrimidine inhibitors of Akt."; RL Bioorg. Med. Chem. Lett. 20:5607-5612(2010). RN [96] {ECO:0007744|PDB:3MV5, ECO:0007744|PDB:3MVH} RP X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 144-480, PHOSPHORYLATION AT RP THR-308, AND ACTIVITY REGULATION. RX PubMed=20481595; DOI=10.1021/jm1003842; RA Freeman-Cook K.D., Autry C., Borzillo G., Gordon D., Barbacci-Tobin E., RA Bernardo V., Briere D., Clark T., Corbett M., Jakubczak J., Kakar S., RA Knauth E., Lippa B., Luzzio M.J., Mansour M., Martinelli G., Marx M., RA Nelson K., Pandit J., Rajamohan F., Robinson S., Subramanyam C., Wei L., RA Wythes M., Morris J.; RT "Design of selective, ATP-competitive inhibitors of Akt."; RL J. Med. Chem. 53:4615-4622(2010). RN [97] {ECO:0007744|PDB:3O96} RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 2-443, AND DISULFIDE BOND. RX PubMed=20886116; DOI=10.1371/journal.pone.0012913; RA Wu W.I., Voegtli W.C., Sturgis H.L., Dizon F.P., Vigers G.P., RA Brandhuber B.J.; RT "Crystal structure of human AKT1 with an allosteric inhibitor reveals a new RT mode of kinase inhibition."; RL PLoS ONE 5:E12913-E12913(2010). RN [98] {ECO:0007744|PDB:3QKK, ECO:0007744|PDB:3QKL} RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 144-480, AND ACTIVITY REGULATION. RX PubMed=21392984; DOI=10.1016/j.bmcl.2011.02.073; RA Kallan N.C., Spencer K.L., Blake J.F., Xu R., Heizer J., Bencsik J.R., RA Mitchell I.S., Gloor S.L., Martinson M., Risom T., Gross S.D., RA Morales T.H., Wu W.I., Vigers G.P., Brandhuber B.J., Skelton N.J.; RT "Discovery and SAR of spirochromane Akt inhibitors."; RL Bioorg. Med. Chem. Lett. 21:2410-2414(2011). RN [99] RP VARIANT BREAST CANCER LYS-17, AND CHARACTERIZATION OF VARIANT BREAST CANCER RP LYS-17. RX PubMed=17611497; DOI=10.1038/nature05933; RA Carpten J.D., Faber A.L., Horn C., Donoho G.P., Briggs S.L., Robbins C.M., RA Hostetter G., Boguslawski S., Moses T.Y., Savage S., Uhlik M., Lin A., RA Du J., Qian Y.-W., Zeckner D.J., Tucker-Kellogg G., Touchman J., Patel K., RA Mousses S., Bittner M., Schevitz R., Lai M.-H.T., Blanchard K.L., RA Thomas J.E.; RT "A transforming mutation in the pleckstrin homology domain of AKT1 in RT cancer."; RL Nature 448:439-444(2007). RN [100] RP CHARACTERIZATION OF VARIANT PROTEUSS LYS-17. RX PubMed=18954143; DOI=10.1021/bi801683k; RA Landgraf K.E., Pilling C., Falke J.J.; RT "Molecular mechanism of an oncogenic mutation that alters membrane RT targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH RT domain."; RL Biochemistry 47:12260-12269(2008). RN [101] RP VARIANT PROTEUSS LYS-17. RX PubMed=21793738; DOI=10.1056/nejmoa1104017; RA Lindhurst M.J., Sapp J.C., Teer J.K., Johnston J.J., Finn E.M., Peters K., RA Turner J., Cannons J.L., Bick D., Blakemore L., Blumhorst C., Brockmann K., RA Calder P., Cherman N., Deardorff M.A., Everman D.B., Golas G., RA Greenstein R.M., Kato B.M., Keppler-Noreuil K.M., Kuznetsov S.A., RA Miyamoto R.T., Newman K., Ng D., O'Brien K., Rothenberg S., RA Schwartzentruber D.J., Singhal V., Tirabosco R., Upton J., Wientroub S., RA Zackai E.H., Hoag K., Whitewood-Neal T., Robey P.G., Schwartzberg P.L., RA Darling T.N., Tosi L.L., Mullikin J.C., Biesecker L.G.; RT "A mosaic activating mutation in AKT1 associated with the Proteus RT syndrome."; RL N. Engl. J. Med. 365:611-619(2011). RN [102] RP VARIANTS CWS6 CYS-25 AND PRO-435. RX PubMed=23246288; DOI=10.1016/j.ajhg.2012.10.021; RA Orloff M.S., He X., Peterson C., Chen F., Chen J.L., Mester J.L., Eng C.; RT "Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes."; RL Am. J. Hum. Genet. 92:76-80(2013). CC -!- FUNCTION: AKT1 is one of 3 closely related serine/threonine-protein CC kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate CC many processes including metabolism, proliferation, cell survival, CC growth and angiogenesis (PubMed:11882383, PubMed:15526160, CC PubMed:15861136, PubMed:21432781, PubMed:21620960, PubMed:31204173). CC This is mediated through serine and/or threonine phosphorylation of a CC range of downstream substrates (PubMed:11882383, PubMed:15526160, CC PubMed:21432781, PubMed:21620960, PubMed:29343641, PubMed:31204173). CC Over 100 substrate candidates have been reported so far, but for most CC of them, no isoform specificity has been reported (PubMed:11882383, CC PubMed:15526160, PubMed:21432781, PubMed:21620960). AKT is responsible CC of the regulation of glucose uptake by mediating insulin-induced CC translocation of the SLC2A4/GLUT4 glucose transporter to the cell CC surface (By similarity). Phosphorylation of PTPN1 at 'Ser-50' CC negatively modulates its phosphatase activity preventing CC dephosphorylation of the insulin receptor and the attenuation of CC insulin signaling (By similarity). Phosphorylation of TBC1D4 triggers CC the binding of this effector to inhibitory 14-3-3 proteins, which is CC required for insulin-stimulated glucose transport (PubMed:11994271). CC AKT also regulates the storage of glucose in the form of glycogen by CC phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in CC inhibition of its kinase activity (By similarity). Phosphorylation of CC GSK3 isoforms by AKT is also thought to be one mechanism by which cell CC proliferation is driven (By similarity). AKT also regulates cell CC survival via the phosphorylation of MAP3K5 (apoptosis signal-related CC kinase) (PubMed:11154276). Phosphorylation of 'Ser-83' decreases MAP3K5 CC kinase activity stimulated by oxidative stress and thereby prevents CC apoptosis (PubMed:11154276). AKT mediates insulin-stimulated protein CC synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby CC activating the mTORC1 signaling pathway, and leading to both CC phosphorylation of 4E-BP1 and in activation of RPS6KB1 CC (PubMed:12150915, PubMed:12172553). Also regulates the mTORC1 signaling CC pathway by catalyzing phosphorylation of CASTOR1 and DEPDC5 CC (PubMed:31548394, PubMed:33594058). AKT plays a role as key modulator CC of the AKT-mTOR signaling pathway controlling the tempo of the process CC of newborn neurons integration during adult neurogenesis, including CC correct neuron positioning, dendritic development and synapse formation CC (By similarity). Part of a positive feedback loop of mTORC2 signaling CC by mediating phosphorylation of MAPKAP1/SIN1, promoting mTORC2 CC activation (By similarity). AKT is involved in the phosphorylation of CC members of the FOXO factors (Forkhead family of transcription factors), CC leading to binding of 14-3-3 proteins and cytoplasmic localization CC (PubMed:10358075). In particular, FOXO1 is phosphorylated at 'Thr-24', CC 'Ser-256' and 'Ser-319' (PubMed:10358075). FOXO3 and FOXO4 are CC phosphorylated on equivalent sites (PubMed:10358075). AKT has an CC important role in the regulation of NF-kappa-B-dependent gene CC transcription and positively regulates the activity of CREB1 (cyclic CC AMP (cAMP)-response element binding protein) (PubMed:9829964). The CC phosphorylation of CREB1 induces the binding of accessory proteins that CC are necessary for the transcription of pro-survival genes such as BCL2 CC and MCL1 (PubMed:9829964). AKT phosphorylates 'Ser-454' on ATP citrate CC lyase (ACLY), thereby potentially regulating ACLY activity and fatty CC acid synthesis (By similarity). Activates the 3B isoform of cyclic CC nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', CC resulting in reduced cyclic AMP levels and inhibition of lipolysis (By CC similarity). Phosphorylates PIKFYVE on 'Ser-318', which results in CC increased PI(3)P-5 activity (By similarity). The Rho GTPase-activating CC protein DLC1 is another substrate and its phosphorylation is implicated CC in the regulation cell proliferation and cell growth (By similarity). CC Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate CC the effects of various growth factors such as platelet-derived growth CC factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like CC growth factor 1 (IGF1) (PubMed:12176338, PubMed:12964941). AKT mediates CC the antiapoptotic effects of IGF1 (By similarity). Essential for the CC SPATA13-mediated regulation of cell migration and adhesion assembly and CC disassembly (PubMed:19934221). May be involved in the regulation of the CC placental development (By similarity). Phosphorylates STK4/MST1 at CC 'Thr-120' and 'Thr-387' leading to inhibition of its: kinase activity, CC nuclear translocation, autophosphorylation and ability to phosphorylate CC FOXO3 (PubMed:17726016). Phosphorylates STK3/MST2 at 'Thr-117' and CC 'Thr-384' leading to inhibition of its: cleavage, kinase activity, CC autophosphorylation at Thr-180, binding to RASSF1 and nuclear CC translocation (PubMed:20086174). Phosphorylates SRPK2 and enhances its CC kinase activity towards SRSF2 and ACIN1 and promotes its nuclear CC translocation (PubMed:19592491). Phosphorylates RAF1 at 'Ser-259' and CC negatively regulates its activity (PubMed:10576742). Phosphorylation of CC BAD stimulates its pro-apoptotic activity (PubMed:10926925). CC Phosphorylates KAT6A at 'Thr-369' and this phosphorylation inhibits the CC interaction of KAT6A with PML and negatively regulates its acetylation CC activity towards p53/TP53 (PubMed:23431171). Phosphorylates palladin CC (PALLD), modulating cytoskeletal organization and cell motility CC (PubMed:20471940). Phosphorylates prohibitin (PHB), playing an CC important role in cell metabolism and proliferation (PubMed:18507042). CC Phosphorylates CDKN1A, for which phosphorylation at 'Thr-145' induces CC its release from CDK2 and cytoplasmic relocalization (PubMed:16982699). CC These recent findings indicate that the AKT1 isoform has a more CC specific role in cell motility and proliferation (PubMed:16139227). CC Phosphorylates CLK2 thereby controlling cell survival to ionizing CC radiation (PubMed:20682768). Phosphorylates PCK1 at 'Ser-90', reducing CC the binding affinity of PCK1 to oxaloacetate and changing PCK1 into an CC atypical protein kinase activity using GTP as donor (PubMed:32322062). CC Also acts as an activator of TMEM175 potassium channel activity in CC response to growth factors: forms the lysoK(GF) complex together with CC TMEM175 and acts by promoting TMEM175 channel activation, independently CC of its protein kinase activity (PubMed:32228865). Acts as a regulator CC of mitochondrial calcium uptake by mediating phosphorylation of MICU1 CC in the mitochondrial intermembrane space, impairing MICU1 maturation CC (PubMed:30504268). Acts as an inhibitor of tRNA methylation by CC mediating phosphorylation of the N-terminus of METTL1, thereby CC inhibiting METTL1 methyltransferase activity (PubMed:15861136). In CC response to LPAR1 receptor pathway activation, phosphorylates CC Rabin8/RAB3IP which alters its activity and phosphorylates WDR44 which CC induces WDR44 binding to Rab11, thereby switching Rab11 vesicular CC function from preciliary trafficking to endocytic recycling CC (PubMed:31204173). {ECO:0000250|UniProtKB:P31750, CC ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:10358075, CC ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10926925, CC ECO:0000269|PubMed:11154276, ECO:0000269|PubMed:11994271, CC ECO:0000269|PubMed:12150915, ECO:0000269|PubMed:12172553, CC ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:12964941, CC ECO:0000269|PubMed:15861136, ECO:0000269|PubMed:16139227, CC ECO:0000269|PubMed:16982699, ECO:0000269|PubMed:17726016, CC ECO:0000269|PubMed:18507042, ECO:0000269|PubMed:19592491, CC ECO:0000269|PubMed:19934221, ECO:0000269|PubMed:20086174, CC ECO:0000269|PubMed:20471940, ECO:0000269|PubMed:20682768, CC ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:30504268, CC ECO:0000269|PubMed:31204173, ECO:0000269|PubMed:31548394, CC ECO:0000269|PubMed:32228865, ECO:0000269|PubMed:32322062, CC ECO:0000269|PubMed:33594058, ECO:0000269|PubMed:9829964, CC ECO:0000303|PubMed:11882383, ECO:0000303|PubMed:15526160, CC ECO:0000303|PubMed:21432781, ECO:0000303|PubMed:21620960}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:15861136, CC ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:1718748, CC ECO:0000269|PubMed:1851997, ECO:0000269|PubMed:26440888, CC ECO:0000269|PubMed:29343641, ECO:0000269|PubMed:31548394, CC ECO:0000269|PubMed:32322062, ECO:0000269|PubMed:33594058}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:16139227, CC ECO:0000269|PubMed:1718748, ECO:0000269|PubMed:1851997}; CC -!- ACTIVITY REGULATION: Three specific sites, one in the kinase domain CC (Thr-308) and the two other ones in the C-terminal regulatory region CC (Ser-473 and Tyr-474), need to be phosphorylated for its full CC activation (PubMed:15262962, PubMed:20481595, PubMed:21392984, CC PubMed:9512493, PubMed:9736715). Inhibited by pyrrolopyrimidine CC inhibitors like aniline triazole and spiroindoline (PubMed:18456494, CC PubMed:20810279). {ECO:0000269|PubMed:15262962, CC ECO:0000269|PubMed:18456494, ECO:0000269|PubMed:20481595, CC ECO:0000269|PubMed:20810279, ECO:0000269|PubMed:21392984, CC ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715, CC ECO:0000305|PubMed:20810279}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=52.8 uM for ATP (for purified and in vitro activated AKT1) CC {ECO:0000269|PubMed:16540465}; CC KM=0.5 uM for peptide substrate (for purified and in vitro activated CC AKT1) {ECO:0000269|PubMed:16540465}; CC KM=143.3 uM for ATP (for recombinant myristoylated AKT1 expressed and CC immunoprecipitated from Rat-1 cells) {ECO:0000269|PubMed:16540465}; CC KM=2.9 uM for peptide substrate (for recombinant myristoylated AKT1 CC expressed and immunoprecipitated from Rat-1 cells) CC {ECO:0000269|PubMed:16540465}; CC -!- SUBUNIT: Interacts with BTBD10 (By similarity). Interacts with KCTD20 CC (By similarity). Interacts (via the C-terminus) with CCDC88A (via its CC C-terminus). Interacts with GRB10; the interaction leads to GRB10 CC phosphorylation thus promoting YWHAE-binding (By similarity). Interacts CC with AGAP2 (isoform 2/PIKE-A); the interaction occurs in the presence CC of guanine nucleotides. Interacts with AKTIP. Interacts (via PH domain) CC with MTCP1, TCL1A and TCL1B. Interacts with CDKN1B; the interaction CC phosphorylates CDKN1B promoting 14-3-3 binding and cell-cycle CC progression. Interacts with MAP3K5 and TRAF6. Interacts with BAD, CC PPP2R5B, STK3 and STK4. Interacts (via PH domain) with SIRT1. Interacts CC with SRPK2 in a phosphorylation-dependent manner. Interacts with RAF1. CC Interacts with TRIM13; the interaction ubiquitinates AKT1 leading to CC its proteasomal degradation. Interacts with TNK2 and CLK2. Interacts CC (via the C-terminus) with THEM4 (via its C-terminus). Interacts with CC and phosphorylated by PDPK1. Interacts with PA2G4 (By similarity). CC Interacts with KIF14; the interaction is detected in the plasma CC membrane upon INS stimulation and promotes AKT1 phosphorylation CC (PubMed:24784001). Interacts with FAM83B; activates the PI3K/AKT CC signaling cascade (PubMed:23676467). Interacts with WDFY2 (via WD CC repeats 1-3) (PubMed:16792529). Forms a complex with WDFY2 and FOXO1 CC (By similarity). Interacts with FAM168A (PubMed:23251525). Interacts CC with SYAP1 (via phosphorylated form and BSD domain); this interaction CC is enhanced in a mTORC2-mediated manner in response to epidermal growth CC factor (EGF) stimulation and activates AKT1 (PubMed:23300339). CC Interacts with PKHM3 (By similarity). Interacts with FKBP5/FKBP51; CC promoting interaction between Akt/AKT1 and PHLPP1, thereby enhancing CC dephosphorylation and subsequent activation of Akt/AKT1 CC (PubMed:28147277). Interacts with TMEM175; leading to formation of the CC lysoK(GF) complex (PubMed:32228865). Acts as a negative regulator of CC the cGAS-STING pathway by mediating phosphorylation of CGAS during CC mitosis, leading to its inhibition (PubMed:26440888). Interacts with CC SLC9D1 (when phosphorylated); the interaction facilitates the membrane CC translocation and activation of AKT1 (PubMed:40285646). CC {ECO:0000250|UniProtKB:P31750, ECO:0000250|UniProtKB:P47196, CC ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10716693, CC ECO:0000269|PubMed:10926925, ECO:0000269|PubMed:10983986, CC ECO:0000269|PubMed:11154276, ECO:0000269|PubMed:11598301, CC ECO:0000269|PubMed:11839817, ECO:0000269|PubMed:12042314, CC ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:12244301, CC ECO:0000269|PubMed:12964941, ECO:0000269|PubMed:14749367, CC ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15118108, CC ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:16417524, CC ECO:0000269|PubMed:16792529, ECO:0000269|PubMed:17726016, CC ECO:0000269|PubMed:17932490, ECO:0000269|PubMed:19592491, CC ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:20086174, CC ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20682768, CC ECO:0000269|PubMed:21329884, ECO:0000269|PubMed:21333377, CC ECO:0000269|PubMed:21775285, ECO:0000269|PubMed:22629392, CC ECO:0000269|PubMed:23251525, ECO:0000269|PubMed:23300339, CC ECO:0000269|PubMed:23676467, ECO:0000269|PubMed:24784001, CC ECO:0000269|PubMed:26440888, ECO:0000269|PubMed:28147277, CC ECO:0000269|PubMed:32228865, ECO:0000269|PubMed:40285646}. CC -!- INTERACTION: CC P31749; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-296087, EBI-10173507; CC P31749; P31749: AKT1; NbExp=4; IntAct=EBI-296087, EBI-296087; CC P31749; P31751: AKT2; NbExp=3; IntAct=EBI-296087, EBI-296058; CC P31749; Q86V81: ALYREF; NbExp=5; IntAct=EBI-296087, EBI-347640; CC P31749; P32121: ARRB2; NbExp=5; IntAct=EBI-296087, EBI-714559; CC P31749; Q8IXJ9: ASXL1; NbExp=3; IntAct=EBI-296087, EBI-1646500; CC P31749; Q13315: ATM; NbExp=5; IntAct=EBI-296087, EBI-495465; CC P31749; P54253: ATXN1; NbExp=6; IntAct=EBI-296087, EBI-930964; CC P31749; Q99728: BARD1; NbExp=3; IntAct=EBI-296087, EBI-473181; CC P31749; O95999: BCL10; NbExp=5; IntAct=EBI-296087, EBI-958922; CC P31749; Q6W2J9: BCOR; NbExp=3; IntAct=EBI-296087, EBI-950027; CC P31749; P15056: BRAF; NbExp=4; IntAct=EBI-296087, EBI-365980; CC P31749; Q9H0C5: BTBD1; NbExp=3; IntAct=EBI-296087, EBI-935503; CC P31749; P62324: BTG1; NbExp=4; IntAct=EBI-296087, EBI-742279; CC P31749; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-296087, EBI-1383687; CC P31749; P20248: CCNA2; NbExp=2; IntAct=EBI-296087, EBI-457097; CC P31749; P30281: CCND3; NbExp=3; IntAct=EBI-296087, EBI-375013; CC P31749; Q16543: CDC37; NbExp=5; IntAct=EBI-296087, EBI-295634; CC P31749; P46527: CDKN1B; NbExp=4; IntAct=EBI-296087, EBI-519280; CC P31749; Q8TAP6: CEP76; NbExp=4; IntAct=EBI-296087, EBI-742887; CC P31749; Q92793: CREBBP; NbExp=3; IntAct=EBI-296087, EBI-81215; CC P31749; Q15438: CYTH1; NbExp=3; IntAct=EBI-296087, EBI-997830; CC P31749; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-296087, EBI-742054; CC P31749; P26358: DNMT1; NbExp=6; IntAct=EBI-296087, EBI-719459; CC P31749; P00533: EGFR; NbExp=4; IntAct=EBI-296087, EBI-297353; CC P31749; Q9UJM3: ERRFI1; NbExp=3; IntAct=EBI-296087, EBI-2941912; CC P31749; Q15910: EZH2; NbExp=3; IntAct=EBI-296087, EBI-530054; CC P31749; Q1W6H9: FAM110C; NbExp=2; IntAct=EBI-296087, EBI-3942563; CC P31749; Q00597: FANCC; NbExp=4; IntAct=EBI-296087, EBI-81625; CC P31749; Q9HB96: FANCE; NbExp=4; IntAct=EBI-296087, EBI-396803; CC P31749; Q969H0: FBXW7; NbExp=5; IntAct=EBI-296087, EBI-359574; CC P31749; Q12778: FOXO1; NbExp=2; IntAct=EBI-296087, EBI-1108782; CC P31749; O43524: FOXO3; NbExp=4; IntAct=EBI-296087, EBI-1644164; CC P31749; P06241: FYN; NbExp=3; IntAct=EBI-296087, EBI-515315; CC P31749; P22466: GAL; NbExp=3; IntAct=EBI-296087, EBI-6624768; CC P31749; P49841: GSK3B; NbExp=5; IntAct=EBI-296087, EBI-373586; CC P31749; P68431: H3C12; NbExp=4; IntAct=EBI-296087, EBI-79722; CC P31749; Q96LI6-3: HSFY2; NbExp=3; IntAct=EBI-296087, EBI-25830912; CC P31749; P08238: HSP90AB1; NbExp=3; IntAct=EBI-296087, EBI-352572; CC P31749; P42858: HTT; NbExp=3; IntAct=EBI-296087, EBI-466029; CC P31749; P08476: INHBA; NbExp=3; IntAct=EBI-296087, EBI-8077140; CC P31749; Q8WZ60: KLHL6; NbExp=3; IntAct=EBI-296087, EBI-6426464; CC P31749; Q5S007: LRRK2; NbExp=6; IntAct=EBI-296087, EBI-5323863; CC P31749; Q99683: MAP3K5; NbExp=2; IntAct=EBI-296087, EBI-476263; CC P31749; O15264: MAPK13; NbExp=4; IntAct=EBI-296087, EBI-2116951; CC P31749; Q8TD08: MAPK15; NbExp=3; IntAct=EBI-296087, EBI-1383794; CC P31749; Q9BPZ7: MAPKAP1; NbExp=3; IntAct=EBI-296087, EBI-749938; CC P31749; P10636: MAPT; NbExp=2; IntAct=EBI-296087, EBI-366182; CC P31749; Q07820: MCL1; NbExp=3; IntAct=EBI-296087, EBI-1003422; CC P31749; Q00987: MDM2; NbExp=6; IntAct=EBI-296087, EBI-389668; CC P31749; Q14696: MESD; NbExp=3; IntAct=EBI-296087, EBI-6165891; CC P31749; P42345: MTOR; NbExp=6; IntAct=EBI-296087, EBI-359260; CC P31749; P04198: MYCN; NbExp=3; IntAct=EBI-296087, EBI-878369; CC P31749; P25963: NFKBIA; NbExp=3; IntAct=EBI-296087, EBI-307386; CC P31749; Q9BZQ8: NIBAN1; NbExp=2; IntAct=EBI-296087, EBI-6916466; CC P31749; P04150: NR3C1; NbExp=5; IntAct=EBI-296087, EBI-493507; CC P31749; O15530: PDPK1; NbExp=5; IntAct=EBI-296087, EBI-717097; CC P31749; Q96S96: PEBP4; NbExp=2; IntAct=EBI-296087, EBI-8563667; CC P31749; P19174: PLCG1; NbExp=9; IntAct=EBI-296087, EBI-79387; CC P31749; Q03181: PPARD; NbExp=3; IntAct=EBI-296087, EBI-6426768; CC P31749; O60437: PPL; NbExp=2; IntAct=EBI-296087, EBI-368321; CC P31749; P62136: PPP1CA; NbExp=4; IntAct=EBI-296087, EBI-357253; CC P31749; P67775: PPP2CA; NbExp=4; IntAct=EBI-296087, EBI-712311; CC P31749; P30153: PPP2R1A; NbExp=3; IntAct=EBI-296087, EBI-302388; CC P31749; P54646: PRKAA2; NbExp=3; IntAct=EBI-296087, EBI-1383852; CC P31749; P17612: PRKACA; NbExp=3; IntAct=EBI-296087, EBI-476586; CC P31749; Q05513: PRKCZ; NbExp=2; IntAct=EBI-296087, EBI-295351; CC P31749; Q8WUY3: PRUNE2; NbExp=3; IntAct=EBI-296087, EBI-743880; CC P31749; Q06124: PTPN11; NbExp=3; IntAct=EBI-296087, EBI-297779; CC P31749; P04049: RAF1; NbExp=3; IntAct=EBI-296087, EBI-365996; CC P31749; P10276: RARA; NbExp=3; IntAct=EBI-296087, EBI-413374; CC P31749; Q9NS23: RASSF1; NbExp=3; IntAct=EBI-296087, EBI-367363; CC P31749; Q6R327: RICTOR; NbExp=3; IntAct=EBI-296087, EBI-1387196; CC P31749; P15880: RPS2; NbExp=3; IntAct=EBI-296087, EBI-443446; CC P31749; P23443: RPS6KB1; NbExp=3; IntAct=EBI-296087, EBI-1775921; CC P31749; Q15047: SETDB1; NbExp=10; IntAct=EBI-296087, EBI-79691; CC P31749; Q96EB6: SIRT1; NbExp=5; IntAct=EBI-296087, EBI-1802965; CC P31749; Q13309: SKP2; NbExp=4; IntAct=EBI-296087, EBI-456291; CC P31749; Q13485: SMAD4; NbExp=6; IntAct=EBI-296087, EBI-347263; CC P31749; Q8N3U4: STAG2; NbExp=3; IntAct=EBI-296087, EBI-1057252; CC P31749; Q14849: STARD3; NbExp=3; IntAct=EBI-296087, EBI-9819324; CC P31749; Q13043: STK4; NbExp=13; IntAct=EBI-296087, EBI-367376; CC P31749; Q9UNE7-1: STUB1; NbExp=5; IntAct=EBI-296087, EBI-15687717; CC P31749; P56279: TCL1A; NbExp=8; IntAct=EBI-296087, EBI-749995; CC P31749; Q9NYB0: TERF2IP; NbExp=2; IntAct=EBI-296087, EBI-750109; CC P31749; Q5T1C6: THEM4; NbExp=4; IntAct=EBI-296087, EBI-7684443; CC P31749; Q92547: TOPBP1; NbExp=2; IntAct=EBI-296087, EBI-308302; CC P31749; P53804: TTC3; NbExp=4; IntAct=EBI-296087, EBI-2681313; CC P31749; P10599: TXN; NbExp=3; IntAct=EBI-296087, EBI-594644; CC P31749; P08670: VIM; NbExp=29; IntAct=EBI-296087, EBI-353844; CC P31749; Q6GPH4: XAF1; NbExp=4; IntAct=EBI-296087, EBI-2815120; CC P31749; P17028: ZNF24; NbExp=3; IntAct=EBI-296087, EBI-707773; CC P31749; P29067: Arrb2; Xeno; NbExp=2; IntAct=EBI-296087, EBI-1636616; CC P31749; P06762: Hmox1; Xeno; NbExp=2; IntAct=EBI-296087, EBI-7410266; CC P31749; Q83730: m005R; Xeno; NbExp=3; IntAct=EBI-296087, EBI-6859930; CC P31749; P03165: X; Xeno; NbExp=3; IntAct=EBI-296087, EBI-7683985; CC P31749-1; Q15118-1: PDK1; NbExp=2; IntAct=EBI-12562306, EBI-12562315; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P31750}. Nucleus CC {ECO:0000269|PubMed:20333297}. Cell membrane CC {ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:40285646}. CC Mitochondrion intermembrane space {ECO:0000250|UniProtKB:P31750}. CC Note=Nucleus after activation by integrin-linked protein kinase 1 CC (ILK1). Nuclear translocation is enhanced by interaction with TCL1A. CC Phosphorylation on Tyr-176 by TNK2 results in its localization to the CC cell membrane where it is targeted for further phosphorylations on Thr- CC 308 and Ser-473 leading to its activation and the activated form CC translocates to the nucleus. Colocalizes with WDFY2 in intracellular CC vesicles (PubMed:16792529). Also localizes to mitochondrial CC intermembrane space in response to rapamycin treatment (By similarity). CC {ECO:0000250|UniProtKB:P31750, ECO:0000269|PubMed:16792529}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P31749-1; Sequence=Displayed; CC Name=2; CC IsoId=P31749-2; Sequence=VSP_056180; CC -!- TISSUE SPECIFICITY: Expressed in prostate cancer and levels increase CC from the normal to the malignant state (at protein level). Expressed in CC all human cell types so far analyzed. The Tyr-176 phosphorylated form CC shows a significant increase in expression in breast cancers during the CC progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma CC in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node CC metastatic (LNMM) stages. {ECO:0000269|PubMed:1718748, CC ECO:0000269|PubMed:17932490, ECO:0000269|PubMed:20333297}. CC -!- DOMAIN: Binding of the PH domain to phosphatidylinositol 3,4,5- CC trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3-kinase CC alpha (PIK3CA) activity results in its targeting to the plasma membrane CC (PubMed:12176338, PubMed:12964941). PI(3,4,5)P3 is also required for CC phosphorylation at Thr-308 and subsequent activation (By similarity). CC The PH domain mediates interaction with TNK2 and Tyr-176 is also CC essential for this interaction (PubMed:20333297). CC {ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:12176338, CC ECO:0000269|PubMed:12964941, ECO:0000269|PubMed:20333297}. CC -!- DOMAIN: The AGC-kinase C-terminal mediates interaction with THEM4. CC {ECO:0000269|PubMed:11598301}. CC -!- PTM: O-GlcNAcylation at Thr-305 and Thr-312 inhibits activating CC phosphorylation at Thr-308 via disrupting the interaction between AKT1 CC and PDPK1. O-GlcNAcylation at Ser-473 also probably interferes with CC phosphorylation at this site. {ECO:0000269|PubMed:14761976, CC ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:16266983, ECO:0000269|PubMed:17013611, CC ECO:0000269|PubMed:18456494, ECO:0000269|PubMed:20333297, CC ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:20978158, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:23799035, CC ECO:0000269|PubMed:8978681, ECO:0000269|PubMed:9512493, CC ECO:0000269|PubMed:9736715}. CC -!- PTM: Phosphorylation on Thr-308, Ser-473 and Tyr-474 is required for CC full activity (PubMed:12149249, PubMed:15047712, PubMed:15262962, CC PubMed:16266983, PubMed:18456494, PubMed:20481595, PubMed:20978158, CC PubMed:8978681, PubMed:9512493, PubMed:9736715). Phosphorylation of the CC activation loop at Thr-308 by PDPK1/PDK1 is a prerequisite for full CC activation (PubMed:9512493). Phosphorylation by mTORC2 in response to CC growth factors plays a key role in AKT1 activation: mTORC2 CC phosphorylates different sites depending on the context, such as Thr- CC 450, Ser-473, Ser-477 or Thr-479, thereby facilitating subsequent CC phosphorylation of the activation loop by PDPK1/PDK1 (PubMed:15718470, CC PubMed:24670654). Phosphorylation at Ser-473 by mTORC2 promotes CC ubiquitination and degradation by the proteasome (By similarity). Also CC phosphorylated at Ser-477 and Thr-479 by CDK2, facilitating subsequent CC phosphorylation of the activation loop by PDPK1/PDK1 (PubMed:24670654). CC Activated TNK2 phosphorylates it on Tyr-176 resulting in its binding to CC the anionic plasma membrane phospholipid PA (PubMed:20333297). This CC phosphorylated form localizes to the cell membrane, where it is CC targeted by PDPK1 and PDPK2 for further phosphorylations on Thr-308 and CC Ser-473 leading to its activation (PubMed:20333297). Phosphorylated at CC Thr-308 and Ser-473 by IKBKE and TBK1 (PubMed:21464307). Ser-473 CC phosphorylation is enhanced by interaction with AGAP2 isoform 2 (PIKE- CC A) (PubMed:14761976). Ser-473 phosphorylation is enhanced in focal CC cortical dysplasias with Taylor-type balloon cells (PubMed:17013611). CC Ser-473 phosphorylation is enhanced by signaling through activated FLT3 CC (PubMed:16266983). Ser-473 is dephosphorylated by PHLPP CC (PubMed:28147277). Dephosphorylated at Thr-308 and Ser-473 by PP2A CC phosphatase (PubMed:21329884). The phosphorylated form of PPP2R5B is CC required for bridging AKT1 with PP2A phosphatase (PubMed:21329884). CC Ser-473 is dephosphorylated by CPPED1, leading to termination of CC signaling (PubMed:23799035). AIM2 acts as an inhibitor of AKT1 by CC inhibiting phosphorylation Ser-473: AIM2 acts both by inhibiting the CC activity of PRKDC/DNA-PK kinase and promoting dephosphorylation by PP2A CC phosphatase (By similarity). {ECO:0000250|UniProtKB:P31750, CC ECO:0000269|PubMed:12149249, ECO:0000269|PubMed:14761976, CC ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15262962, CC ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983, CC ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494, CC ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595, CC ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21329884, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:23799035, CC ECO:0000269|PubMed:24670654, ECO:0000269|PubMed:28147277, CC ECO:0000269|PubMed:8978681, ECO:0000269|PubMed:9512493, CC ECO:0000269|PubMed:9736715}. CC -!- PTM: Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked CC polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1 ubiquitination CC is critical for phosphorylation and activation (PubMed:19713527). When CC ubiquitinated, it translocates to the plasma membrane, where it becomes CC phosphorylated (PubMed:20059950). When fully phosphorylated and CC translocated into the nucleus, undergoes 'Lys-48'-polyubiquitination CC catalyzed by TTC3, leading to its degradation by the proteasome CC (PubMed:20059950). Also ubiquitinated by TRIM13 leading to its CC proteasomal degradation (PubMed:21333377). Phosphorylated, undergoes CC 'Lys-48'-linked polyubiquitination preferentially at Lys-284 catalyzed CC by MUL1, leading to its proteasomal degradation (PubMed:22410793). CC Ubiquitinated via 'Lys-48'-linked polyubiquitination by ZNRF1, leading CC to its degradation by the proteasome (By similarity). CC {ECO:0000250|UniProtKB:P31750, ECO:0000269|PubMed:19713527, CC ECO:0000269|PubMed:20059950, ECO:0000269|PubMed:21333377, CC ECO:0000269|PubMed:22410793}. CC -!- PTM: Acetylated on Lys-14 and Lys-20 by the histone acetyltransferases CC EP300 and KAT2B. Acetylation results in reduced phosphorylation and CC inhibition of activity. Deacetylated at Lys-14 and Lys-20 by SIRT1. CC SIRT1-mediated deacetylation relieves the inhibition. CC {ECO:0000269|PubMed:21775285}. CC -!- PTM: Cleavage by caspase-3/CASP3 (By similarity). Cleaved at the CC caspase-3 consensus site Asp-462 during apoptosis, resulting in down- CC regulation of the AKT signaling pathway and decreased cell survival CC (PubMed:23152800). {ECO:0000250|UniProtKB:P31750, CC ECO:0000269|PubMed:23152800}. CC -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy CC originating from breast epithelial tissue. Breast neoplasms can be CC distinguished by their histologic pattern. Invasive ductal carcinoma is CC by far the most common type. Breast cancer is etiologically and CC genetically heterogeneous. Important genetic factors have been CC indicated by familial occurrence and bilateral involvement. Mutations CC at more than one locus can be involved in different families or even in CC the same case. {ECO:0000269|PubMed:17611497}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. Note=The gene represented in this entry may be CC involved in disease pathogenesis. CC -!- DISEASE: Note=Genetic variations in AKT1 may play a role in CC susceptibility to ovarian cancer. CC -!- DISEASE: Proteus syndrome (PROTEUSS) [MIM:176920]: A highly variable, CC severe disorder of asymmetric and disproportionate overgrowth of body CC parts, connective tissue nevi, epidermal nevi, dysregulated adipose CC tissue, and vascular malformations. Many features of Proteus syndrome CC overlap with other overgrowth syndromes. {ECO:0000269|PubMed:18954143, CC ECO:0000269|PubMed:21793738}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cowden syndrome 6 (CWS6) [MIM:615109]: A form of Cowden CC syndrome, a hamartomatous polyposis syndrome with age-related CC penetrance. Cowden syndrome is characterized by hamartomatous lesions CC affecting derivatives of ectodermal, mesodermal and endodermal layers, CC macrocephaly, facial trichilemmomas (benign tumors of the hair follicle CC infundibulum), acral keratoses, papillomatous papules, and elevated CC risk for development of several types of malignancy, particularly CC breast carcinoma in women and thyroid carcinoma in both men and women. CC Colon cancer and renal cell carcinoma have also been reported. CC Hamartomas can be found in virtually every organ, but most commonly in CC the skin, gastrointestinal tract, breast and thyroid. CC {ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:23246288}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. RAC subfamily. {ECO:0000305}. CC -!- CAUTION: PUBMED:20231902 has been retracted because there was evidence CC of data fabrication and/or falsification in multiple figure panels. CC {ECO:0000305|PubMed:20231902, ECO:0000305|PubMed:37490513}. CC -!- CAUTION: PUBMED:19940129 has been retracted because the same data were CC used to represent different experimental conditions. CC {ECO:0000305|PubMed:19940129, ECO:0000305|PubMed:27825096}. CC -!- CAUTION: In light of strong homologies in the primary amino acid CC sequence, the 3 AKT kinases were long surmised to play redundant and CC overlapping roles. More recent studies has brought into question the CC redundancy within AKT kinase isoforms and instead pointed to isoform CC specific functions in different cellular events and diseases. AKT1 is CC more specifically involved in cellular survival pathways, by inhibiting CC apoptotic processes; whereas AKT2 is more specific for the insulin CC receptor signaling pathway. Moreover, while AKT1 and AKT2 are often CC implicated in many aspects of cellular transformation, the 2 isoforms CC act in a complementary opposing manner. The role of AKT3 is less clear, CC though it appears to be predominantly expressed in brain. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/355/AKT1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M63167; AAA36539.1; -; mRNA. DR EMBL; AF283830; AAL55732.1; -; Genomic_DNA. DR EMBL; AF283819; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283820; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283821; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283822; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283823; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283824; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283825; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283826; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283827; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283828; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283829; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AK299310; BAH12997.1; -; mRNA. DR EMBL; AK314256; BAG36922.1; -; mRNA. DR EMBL; AB451242; BAG70056.1; -; mRNA. DR EMBL; AB451367; BAG70181.1; -; mRNA. DR EMBL; AL583722; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL590327; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC000479; AAH00479.1; -; mRNA. DR EMBL; BC084538; AAH84538.1; -; mRNA. DR EMBL; X61037; CAA43372.1; -; mRNA. DR CCDS; CCDS9994.1; -. [P31749-1] DR PIR; A39360; A39360. DR RefSeq; NP_001014431.1; NM_001014431.2. [P31749-1] DR RefSeq; NP_001014432.1; NM_001014432.2. [P31749-1] DR RefSeq; NP_001369359.1; NM_001382430.1. [P31749-1] DR RefSeq; NP_001369360.1; NM_001382431.1. [P31749-1] DR RefSeq; NP_001369361.1; NM_001382432.1. [P31749-1] DR RefSeq; NP_001369362.1; NM_001382433.1. [P31749-1] DR RefSeq; NP_005154.2; NM_005163.2. [P31749-1] DR RefSeq; XP_047287025.1; XM_047431069.1. [P31749-1] DR RefSeq; XP_047287026.1; XM_047431070.1. [P31749-1] DR RefSeq; XP_047287027.1; XM_047431071.1. [P31749-1] DR RefSeq; XP_047287028.1; XM_047431072.1. [P31749-1] DR RefSeq; XP_047287029.1; XM_047431073.1. [P31749-1] DR RefSeq; XP_047287030.1; XM_047431074.1. [P31749-1] DR RefSeq; XP_047287031.1; XM_047431075.1. [P31749-1] DR RefSeq; XP_054231528.1; XM_054375553.1. [P31749-1] DR RefSeq; XP_054231529.1; XM_054375554.1. [P31749-1] DR RefSeq; XP_054231530.1; XM_054375555.1. [P31749-1] DR RefSeq; XP_054231531.1; XM_054375556.1. [P31749-1] DR RefSeq; XP_054231532.1; XM_054375557.1. [P31749-1] DR RefSeq; XP_054231533.1; XM_054375558.1. [P31749-1] DR PDB; 1H10; X-ray; 1.40 A; A=1-123. DR PDB; 1UNP; X-ray; 1.65 A; A=1-121. DR PDB; 1UNQ; X-ray; 0.98 A; A=1-123. DR PDB; 1UNR; X-ray; 1.25 A; A=1-123. DR PDB; 2UVM; X-ray; 1.94 A; A=1-123. DR PDB; 2UZR; X-ray; 1.94 A; A=1-123. DR PDB; 2UZS; X-ray; 2.46 A; A=1-123. DR PDB; 3CQU; X-ray; 2.20 A; A=144-480. DR PDB; 3CQW; X-ray; 2.00 A; A=144-480. DR PDB; 3MV5; X-ray; 2.47 A; A=144-480. DR PDB; 3MVH; X-ray; 2.01 A; A=144-480. DR PDB; 3O96; X-ray; 2.70 A; A=2-443. DR PDB; 3OCB; X-ray; 2.70 A; A/B=144-480. DR PDB; 3OW4; X-ray; 2.60 A; A/B=144-480. DR PDB; 3QKK; X-ray; 2.30 A; A=144-480. DR PDB; 3QKL; X-ray; 1.90 A; A=144-480. DR PDB; 3QKM; X-ray; 2.20 A; A=144-480. DR PDB; 4EJN; X-ray; 2.19 A; A=2-446. DR PDB; 4EKK; X-ray; 2.80 A; A/B=144-480. DR PDB; 4EKL; X-ray; 2.00 A; A=144-480. DR PDB; 4GV1; X-ray; 1.49 A; A=144-480. DR PDB; 5KCV; X-ray; 2.70 A; A=2-446. DR PDB; 6BUU; X-ray; 2.40 A; A/B=144-480. DR PDB; 6CCY; X-ray; 2.18 A; A=144-466. DR PDB; 6HHF; X-ray; 2.90 A; A=2-446. DR PDB; 6HHG; X-ray; 2.30 A; A=2-446. DR PDB; 6HHH; X-ray; 2.70 A; A=2-446. DR PDB; 6HHI; X-ray; 2.70 A; A=2-446. DR PDB; 6HHJ; X-ray; 2.30 A; A=2-446. DR PDB; 6NPZ; X-ray; 2.12 A; A/B=123-480, A/B=144-480. DR PDB; 6S9W; X-ray; 2.30 A; A=2-446. DR PDB; 6S9X; X-ray; 2.60 A; A=2-446. DR PDB; 7APJ; X-ray; 2.05 A; A=1-119, A=136-445. DR PDB; 7MYX; X-ray; 1.39 A; A=1-121. DR PDB; 7NH4; X-ray; 2.30 A; A=2-446. DR PDB; 7NH5; X-ray; 1.90 A; A=2-446. DR PDB; 8JOW; X-ray; 1.40 A; B/D=466-477. DR PDB; 8UVY; X-ray; 2.11 A; A=2-446. DR PDB; 8UW2; X-ray; 2.20 A; A=2-446. DR PDB; 8UW7; X-ray; 1.97 A; A=2-446. DR PDB; 8UW9; X-ray; 1.90 A; A=2-446. DR PDB; 8ZPU; X-ray; 2.80 A; C/D=466-477. DR PDBsum; 1H10; -. DR PDBsum; 1UNP; -. DR PDBsum; 1UNQ; -. DR PDBsum; 1UNR; -. DR PDBsum; 2UVM; -. DR PDBsum; 2UZR; -. DR PDBsum; 2UZS; -. DR PDBsum; 3CQU; -. DR PDBsum; 3CQW; -. DR PDBsum; 3MV5; -. DR PDBsum; 3MVH; -. DR PDBsum; 3O96; -. DR PDBsum; 3OCB; -. DR PDBsum; 3OW4; -. DR PDBsum; 3QKK; -. DR PDBsum; 3QKL; -. DR PDBsum; 3QKM; -. DR PDBsum; 4EJN; -. DR PDBsum; 4EKK; -. DR PDBsum; 4EKL; -. DR PDBsum; 4GV1; -. DR PDBsum; 5KCV; -. DR PDBsum; 6BUU; -. DR PDBsum; 6CCY; -. DR PDBsum; 6HHF; -. DR PDBsum; 6HHG; -. DR PDBsum; 6HHH; -. DR PDBsum; 6HHI; -. DR PDBsum; 6HHJ; -. DR PDBsum; 6NPZ; -. DR PDBsum; 6S9W; -. DR PDBsum; 6S9X; -. DR PDBsum; 7APJ; -. DR PDBsum; 7MYX; -. DR PDBsum; 7NH4; -. DR PDBsum; 7NH5; -. DR PDBsum; 8JOW; -. DR PDBsum; 8UVY; -. DR PDBsum; 8UW2; -. DR PDBsum; 8UW7; -. DR PDBsum; 8UW9; -. DR PDBsum; 8ZPU; -. DR AlphaFoldDB; P31749; -. DR SMR; P31749; -. DR BioGRID; 106710; 600. DR CORUM; P31749; -. DR DIP; DIP-24269N; -. DR ELM; P31749; -. DR FunCoup; P31749; 3098. DR IntAct; P31749; 602. DR MINT; P31749; -. DR STRING; 9606.ENSP00000451828; -. DR BindingDB; P31749; -. DR ChEMBL; CHEMBL4282; -. DR DrugBank; DB08073; (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE. DR DrugBank; DB07585; 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine. DR DrugBank; DB08568; A-674563. DR DrugBank; DB11648; Afuresertib. DR DrugBank; DB05971; Archexin. DR DrugBank; DB01169; Arsenic trioxide. DR DrugBank; DB00171; ATP. DR DrugBank; DB03777; Bisindolylmaleimide I. DR DrugBank; DB15399; BMS-754807. DR DrugBank; DB05424; Canertinib. DR DrugBank; DB12218; Capivasertib. DR DrugBank; DB12429; CI-1040. DR DrugBank; DB12795; CMX-2043. DR DrugBank; DB06486; Enzastaurin. DR DrugBank; DB01645; Genistein. DR DrugBank; DB01863; Inositol 1,3,4,5-Tetrakisphosphate. DR DrugBank; DB11743; Ipatasertib. DR DrugBank; DB15431; M-2698. DR DrugBank; DB14982; Miransertib. DR DrugBank; DB07584; N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine. DR DrugBank; DB06641; Perifosine. DR DrugBank; DB02709; Resveratrol. DR DrugBank; DB04462; Tetrabromo-2-Benzotriazole. DR DrugCentral; P31749; -. DR GuidetoPHARMACOLOGY; 1479; -. DR TCDB; 8.A.104.1.10; the 5'-amp-activated protein kinase (ampk) family. DR GlyCosmos; P31749; 6 sites, 1 glycan. DR GlyGen; P31749; 7 sites, 1 O-linked glycan (6 sites). DR iPTMnet; P31749; -. DR MetOSite; P31749; -. DR PhosphoSitePlus; P31749; -. DR BioMuta; AKT1; -. DR DMDM; 60391226; -. DR CPTAC; CPTAC-3162; -. DR CPTAC; CPTAC-3163; -. DR CPTAC; CPTAC-3164; -. DR CPTAC; CPTAC-3165; -. DR CPTAC; CPTAC-3166; -. DR CPTAC; CPTAC-3167; -. DR CPTAC; CPTAC-5758; -. DR CPTAC; CPTAC-5759; -. DR CPTAC; CPTAC-5805; -. DR CPTAC; CPTAC-5806; -. DR CPTAC; CPTAC-5807; -. DR CPTAC; CPTAC-5808; -. DR CPTAC; CPTAC-783; -. DR CPTAC; CPTAC-784; -. DR CPTAC; non-CPTAC-5328; -. DR CPTAC; non-CPTAC-5329; -. DR CPTAC; non-CPTAC-5332; -. DR CPTAC; non-CPTAC-5527; -. DR CPTAC; non-CPTAC-5528; -. DR CPTAC; non-CPTAC-5719; -. DR CPTAC; non-CPTAC-5720; -. DR jPOST; P31749; -. DR MassIVE; P31749; -. DR PaxDb; 9606-ENSP00000451828; -. DR PeptideAtlas; P31749; -. DR ProteomicsDB; 54800; -. [P31749-1] DR ProteomicsDB; 6712; -. DR Pumba; P31749; -. DR ABCD; P31749; 12 sequenced antibodies. DR Antibodypedia; 135; 5291 antibodies from 58 providers. DR CPTC; P31749; 6 antibodies. DR DNASU; 207; -. DR Ensembl; ENST00000349310.7; ENSP00000270202.4; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000402615.6; ENSP00000385326.2; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000407796.7; ENSP00000384293.2; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000554581.5; ENSP00000451828.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000554848.5; ENSP00000451166.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000555528.5; ENSP00000450688.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000649815.2; ENSP00000497822.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000683722.1; ENSP00000507879.1; ENSG00000142208.20. [P31749-1] DR GeneID; 207; -. DR KEGG; hsa:207; -. DR MANE-Select; ENST00000649815.2; ENSP00000497822.1; NM_001382430.1; NP_001369359.1. DR UCSC; uc001ypk.4; human. [P31749-1] DR AGR; HGNC:391; -. DR CIViC; 207; 18 evidence items across 19 molecular profiles. DR ClinPGx; PA24684; -. DR CTD; 207; -. DR DisGeNET; 207; -. DR GeneCards; AKT1; -. DR GeneReviews; AKT1; -. DR HGNC; HGNC:391; AKT1. DR HPA; ENSG00000142208; Low tissue specificity. DR MalaCards; AKT1; -. DR MIM; 114480; phenotype. DR MIM; 114500; phenotype. DR MIM; 164730; gene. DR MIM; 176920; phenotype. DR MIM; 615109; phenotype. DR OpenTargets; ENSG00000142208; -. DR Orphanet; 201; Cowden syndrome. DR Orphanet; 2495; Meningioma. DR Orphanet; 744; Proteus syndrome. DR VEuPathDB; HostDB:ENSG00000142208; -. DR eggNOG; KOG0690; Eukaryota. DR GeneTree; ENSGT00940000158752; -. DR HOGENOM; CLU_000288_11_0_1; -. DR InParanoid; P31749; -. DR OMA; MDMEIYL; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; P31749; 3 GO annotations based on evolutionary models. DR PhylomeDB; P31749; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P31749; -. DR Reactome; R-HSA-111447; Activation of BAD and translocation to mitochondria. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling. DR Reactome; R-HSA-1445148; Translocation of SLC2A4 (GLUT4) to the plasma membrane. DR Reactome; R-HSA-1474151; Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation. DR Reactome; R-HSA-165159; MTOR signalling. DR Reactome; R-HSA-198323; AKT phosphorylates targets in the cytosol. DR Reactome; R-HSA-198693; AKT phosphorylates targets in the nucleus. DR Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network. DR Reactome; R-HSA-203615; eNOS activation. DR Reactome; R-HSA-211163; AKT-mediated inactivation of FOXO1A. DR Reactome; R-HSA-354192; Integrin signaling. DR Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex. DR Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling. DR Reactome; R-HSA-389513; Co-inhibition by CTLA4. DR Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma. DR Reactome; R-HSA-450385; Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA. DR Reactome; R-HSA-450604; KSRP (KHSRP) binds and destabilizes mRNA. DR Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation. DR Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-69202; Cyclin E associated events during G1/S transition. DR Reactome; R-HSA-69656; Cyclin A:Cdk2-associated events at S phase entry. DR Reactome; R-HSA-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1. DR Reactome; R-HSA-8876198; RAB GEFs exchange GTP for GDP on RABs. DR Reactome; R-HSA-8941332; RUNX2 regulates genes involved in cell migration. DR Reactome; R-HSA-8948751; Regulation of PTEN stability and activity. DR Reactome; R-HSA-9009391; Extra-nuclear estrogen signaling. DR Reactome; R-HSA-9604323; Negative regulation of NOTCH4 signaling. DR Reactome; R-HSA-9607240; FLT3 Signaling. DR Reactome; R-HSA-9614399; Regulation of localization of FOXO transcription factors. DR Reactome; R-HSA-9634638; Estrogen-dependent nuclear events downstream of ESR-membrane signaling. DR Reactome; R-HSA-9755511; KEAP1-NFE2L2 pathway. DR Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways. DR Reactome; R-HSA-9841251; Mitochondrial unfolded protein response (UPRmt). DR Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells. DR Reactome; R-HSA-9856532; Mechanical load activates signaling by PIEZO1 and integrins in osteocytes. DR SABIO-RK; P31749; -. DR SignaLink; P31749; -. DR SIGNOR; P31749; -. DR Agora; ENSG00000142208; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 207; 54 hits in 1212 CRISPR screens. DR ChiTaRS; AKT1; human. DR EvolutionaryTrace; P31749; -. DR GeneWiki; AKT1; -. DR GenomeRNAi; 207; -. DR Pharos; P31749; Tchem. DR PRO; PR:P31749; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; P31749; protein. DR Bgee; ENSG00000142208; Expressed in stromal cell of endometrium and 189 other cell types or tissues. DR ExpressionAtlas; P31749; baseline and differential. DR GO; GO:0005938; C:cell cortex; NAS:BHF-UCL. DR GO; GO:0005911; C:cell-cell junction; IEA:Ensembl. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0030027; C:lamellipodium; NAS:BHF-UCL. DR GO; GO:0016020; C:membrane; IDA:UniProt. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:HPA. DR GO; GO:0005758; C:mitochondrial intermembrane space; ISS:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0033011; C:perinuclear theca; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098794; C:postsynapse; IEA:GOC. DR GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0120238; C:sperm glycocalyx; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0005819; C:spindle; IEA:Ensembl. DR GO; GO:0031982; C:vesicle; IDA:UniProtKB. DR GO; GO:0071889; F:14-3-3 protein binding; IPI:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0005516; F:calmodulin binding; IDA:UniProtKB. DR GO; GO:0019899; F:enzyme binding; ISS:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0016301; F:kinase activity; IDA:MGI. DR GO; GO:0019900; F:kinase binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0030235; F:nitric-oxide synthase regulator activity; IMP:BHF-UCL. DR GO; GO:0005547; F:phosphatidylinositol-3,4,5-trisphosphate binding; IDA:UniProtKB. DR GO; GO:0043325; F:phosphatidylinositol-3,4-bisphosphate binding; IDA:UniProtKB. DR GO; GO:0099104; F:potassium channel activator activity; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IEA:Ensembl. DR GO; GO:0106310; F:protein serine kinase activity; TAS:Reactome. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0030291; F:protein serine/threonine kinase inhibitor activity; ISS:BHF-UCL. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:BHF-UCL. DR GO; GO:1904841; F:TORC2 complex binding; IDA:ParkinsonsUK-UCL. DR GO; GO:0006924; P:activation-induced cell death of T cells; IMP:MGI. DR GO; GO:0043276; P:anoikis; NAS:ParkinsonsUK-UCL. DR GO; GO:0008637; P:apoptotic mitochondrial changes; IEA:Ensembl. DR GO; GO:0048266; P:behavioral response to pain; IEA:Ensembl. DR GO; GO:0160213; P:beta-arrestin-dependent dopamine receptor signaling pathway; NAS:ParkinsonsUK-UCL. DR GO; GO:0030154; P:cell differentiation; TAS:UniProtKB. DR GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; IMP:BHF-UCL. DR GO; GO:0008283; P:cell population proliferation; TAS:UniProtKB. DR GO; GO:0036294; P:cellular response to decreased oxygen levels; IEA:Ensembl. DR GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IDA:UniProtKB. DR GO; GO:0097011; P:cellular response to granulocyte macrophage colony-stimulating factor stimulus; IEA:Ensembl. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:UniProtKB. DR GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IMP:UniProtKB. DR GO; GO:0140052; P:cellular response to oxidised low-density lipoprotein particle stimulus; IMP:BHF-UCL. DR GO; GO:1901653; P:cellular response to peptide; IEA:Ensembl. DR GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEA:Ensembl. DR GO; GO:0072752; P:cellular response to rapamycin; ISS:UniProt. DR GO; GO:0033554; P:cellular response to stress; TAS:Reactome. DR GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl. DR GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IEA:Ensembl. DR GO; GO:0002430; P:complement receptor mediated signaling pathway; IDA:BHF-UCL. DR GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0072655; P:establishment of protein localization to mitochondrion; IMP:ParkinsonsUK-UCL. DR GO; GO:0060079; P:excitatory postsynaptic potential; NAS:ParkinsonsUK-UCL. DR GO; GO:0097194; P:execution phase of apoptosis; IEA:Ensembl. DR GO; GO:0010761; P:fibroblast migration; NAS:BHF-UCL. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:ProtInc. DR GO; GO:0010467; P:gene expression; IEA:Ensembl. DR GO; GO:0042593; P:glucose homeostasis; IEA:Ensembl. DR GO; GO:0006006; P:glucose metabolic process; IEA:UniProtKB-KW. DR GO; GO:0005978; P:glycogen biosynthetic process; IEA:UniProtKB-KW. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0008286; P:insulin receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0035655; P:interleukin-18-mediated signaling pathway; IDA:BHF-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IDA:MGI. DR GO; GO:0060716; P:labyrinthine layer blood vessel development; IEA:Ensembl. DR GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0072656; P:maintenance of protein location in mitochondrion; IMP:ParkinsonsUK-UCL. DR GO; GO:0022605; P:mammalian oogenesis stage; IEA:Ensembl. DR GO; GO:0060644; P:mammary gland epithelial cell differentiation; TAS:UniProtKB. DR GO; GO:0001893; P:maternal placenta development; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0010507; P:negative regulation of autophagy; IMP:BHF-UCL. DR GO; GO:0160049; P:negative regulation of cGAS/STING signaling pathway; IDA:UniProt. DR GO; GO:1902018; P:negative regulation of cilium assembly; IDA:UniProtKB. DR GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; TAS:BHF-UCL. DR GO; GO:0031999; P:negative regulation of fatty acid beta-oxidation; IMP:BHF-UCL. DR GO; GO:1903384; P:negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway; IMP:ParkinsonsUK-UCL. DR GO; GO:1903038; P:negative regulation of leukocyte cell-cell adhesion; IMP:BHF-UCL. DR GO; GO:0010748; P:negative regulation of long-chain fatty acid import across plasma membrane; IMP:BHF-UCL. DR GO; GO:2000402; P:negative regulation of lymphocyte migration; IMP:BHF-UCL. DR GO; GO:0016242; P:negative regulation of macroautophagy; NAS:ParkinsonsUK-UCL. DR GO; GO:0045746; P:negative regulation of Notch signaling pathway; TAS:Reactome. DR GO; GO:1902176; P:negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; NAS:BHF-UCL. DR GO; GO:1903898; P:negative regulation of PERK-mediated unfolded protein response; ISS:UniProt. DR GO; GO:0150033; P:negative regulation of protein localization to lysosome; IDA:UniProtKB. DR GO; GO:1903318; P:negative regulation of protein maturation; ISS:UniProt. DR GO; GO:0031397; P:negative regulation of protein ubiquitination; IMP:ARUK-UCL. DR GO; GO:0045861; P:negative regulation of proteolysis; IMP:BHF-UCL. DR GO; GO:0090201; P:negative regulation of release of cytochrome c from mitochondria; ISS:UniProtKB. DR GO; GO:0006809; P:nitric oxide biosynthetic process; TAS:ProtInc. DR GO; GO:0046209; P:nitric oxide metabolic process; TAS:Reactome. DR GO; GO:0001649; P:osteoblast differentiation; IDA:UniProt. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:0032287; P:peripheral nervous system myelin maintenance; IEA:Ensembl. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:BHF-UCL. DR GO; GO:0016310; P:phosphorylation; IDA:UniProtKB. DR GO; GO:1905786; P:positive regulation of anaphase-promoting complex-dependent catabolic process; IDA:UniProt. DR GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:DFLAT. DR GO; GO:0030307; P:positive regulation of cell growth; IDA:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProt. DR GO; GO:0046326; P:positive regulation of D-glucose import; IMP:BHF-UCL. DR GO; GO:0032079; P:positive regulation of endodeoxyribonuclease activity; IDA:UniProtKB. DR GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:BHF-UCL. DR GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB. DR GO; GO:0045600; P:positive regulation of fat cell differentiation; IMP:BHF-UCL. DR GO; GO:0010763; P:positive regulation of fibroblast migration; IEA:Ensembl. DR GO; GO:1900087; P:positive regulation of G1/S transition of mitotic cell cycle; IMP:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0010907; P:positive regulation of glucose metabolic process; IMP:BHF-UCL. DR GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IMP:BHF-UCL. DR GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IDA:UniProtKB. DR GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:BHF-UCL. DR GO; GO:0046622; P:positive regulation of organ growth; IEA:Ensembl. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IDA:UniProt. DR GO; GO:2000010; P:positive regulation of protein localization to cell surface; IEA:Ensembl. DR GO; GO:1905552; P:positive regulation of protein localization to endoplasmic reticulum; IDA:UniProt. DR GO; GO:1900182; P:positive regulation of protein localization to nucleus; IMP:UniProtKB. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IMP:BHF-UCL. DR GO; GO:0051247; P:positive regulation of protein metabolic process; ISS:BHF-UCL. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IDA:BHF-UCL. DR GO; GO:0010765; P:positive regulation of sodium ion transport; IEA:Ensembl. DR GO; GO:1904263; P:positive regulation of TORC1 signaling; IDA:UniProtKB. DR GO; GO:1904515; P:positive regulation of TORC2 signaling; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB. DR GO; GO:0006606; P:protein import into nucleus; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0016567; P:protein ubiquitination; IEA:Ensembl. DR GO; GO:0042981; P:regulation of apoptotic process; ISS:UniProtKB. DR GO; GO:0030334; P:regulation of cell migration; IMP:UniProtKB. DR GO; GO:0005979; P:regulation of glycogen biosynthetic process; IMP:BHF-UCL. DR GO; GO:0043488; P:regulation of mRNA stability; TAS:Reactome. DR GO; GO:0031641; P:regulation of myelination; IEA:Ensembl. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0099175; P:regulation of postsynapse organization; IEA:Ensembl. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0006417; P:regulation of translation; IEA:UniProtKB-KW. DR GO; GO:0110002; P:regulation of tRNA methylation; IDA:UniProt. DR GO; GO:2000074; P:regulation of type B pancreatic cell development; TAS:Reactome. DR GO; GO:0034405; P:response to fluid shear stress; IMP:BHF-UCL. DR GO; GO:0032094; P:response to food; IEA:Ensembl. DR GO; GO:0070848; P:response to growth factor; IDA:UniProtKB. DR GO; GO:0060416; P:response to growth hormone; ISS:AgBase. DR GO; GO:0009408; P:response to heat; TAS:ProtInc. DR GO; GO:1990418; P:response to insulin-like growth factor stimulus; ISS:AgBase. DR GO; GO:0006979; P:response to oxidative stress; ISS:ParkinsonsUK-UCL. DR GO; GO:0070141; P:response to UV-A; IDA:BHF-UCL. DR GO; GO:0007165; P:signal transduction; TAS:UniProtKB. DR GO; GO:0003376; P:sphingosine-1-phosphate receptor signaling pathway; IMP:BHF-UCL. DR GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl. DR GO; GO:0031295; P:T cell costimulation; TAS:Reactome. DR GO; GO:0031929; P:TOR signaling; NAS:ParkinsonsUK-UCL. DR GO; GO:0097700; P:vascular endothelial cell response to laminar fluid shear stress; TAS:Reactome. DR CDD; cd01241; PH_PKB; 1. DR CDD; cd05594; STKc_PKB_alpha; 1. DR DisProt; DP03300; -. DR FunFam; 1.10.510.10:FF:000033; Non-specific serine/threonine protein kinase; 1. DR FunFam; 2.30.29.30:FF:000027; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:000838; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00412; -. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR034676; Akt1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR001849; PH_domain. DR InterPro; IPR039026; PH_PKB. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00169; PH; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR SMART; SM00233; PH; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50003; PH_DOMAIN; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Carbohydrate metabolism; Cell membrane; Cytoplasm; Developmental protein; KW Disease variant; Disulfide bond; Glucose metabolism; Glycogen biosynthesis; KW Glycogen metabolism; Glycoprotein; Isopeptide bond; Kinase; Membrane; KW Mitochondrion; Neurogenesis; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Sugar transport; Transferase; KW Translation regulation; Transport; Ubl conjugation. FT CHAIN 1..480 FT /note="RAC-alpha serine/threonine-protein kinase" FT /id="PRO_0000085605" FT DOMAIN 5..108 FT /note="PH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT DOMAIN 150..408 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 409..480 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 113..138 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 450..480 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 274 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 14..19 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 23..25 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 53 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 86 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 156..164 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 179 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 462 FT /note="Cleavage; by caspase-3" FT /evidence="ECO:0000250|UniProtKB:P31750" FT MOD_RES 14 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:21775285" FT MOD_RES 20 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:21775285" FT MOD_RES 124 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 126 FT /note="Phosphoserine; alternate" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 129 FT /note="Phosphoserine; alternate" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 176 FT /note="Phosphotyrosine; by TNK2" FT /evidence="ECO:0000269|PubMed:20333297" FT MOD_RES 308 FT /note="Phosphothreonine; by IKKE, PDPK1 and TBK1" FT /evidence="ECO:0000269|PubMed:15718470, FT ECO:0000269|PubMed:18456494, ECO:0000269|PubMed:20333297, FT ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:21464307, FT ECO:0000269|PubMed:40285646, ECO:0000269|PubMed:8978681, FT ECO:0000269|PubMed:9512493" FT MOD_RES 448 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 450 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 473 FT /note="Phosphoserine; by IKKE, MTOR, PRKDC and TBK1; FT alternate" FT /evidence="ECO:0000269|PubMed:14761976, FT ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15262962, FT ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983, FT ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:20333297, FT ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307, FT ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:40285646, FT ECO:0000269|PubMed:8978681, ECO:0000269|PubMed:9736715" FT MOD_RES 474 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:12149249" FT MOD_RES 477 FT /note="Phosphoserine; by CDK2 and MTOR" FT /evidence="ECO:0000269|PubMed:24670654" FT MOD_RES 479 FT /note="Phosphothreonine; by CDK2 and MTOR" FT /evidence="ECO:0000269|PubMed:24670654" FT CARBOHYD 126 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 129 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 305 FT /note="O-linked (GlcNAc) threonine" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 312 FT /note="O-linked (GlcNAc) threonine" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 473 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000250|UniProtKB:P31750" FT DISULFID 60..77 FT /evidence="ECO:0000269|PubMed:20886116" FT DISULFID 296..310 FT /evidence="ECO:0000250|UniProtKB:P31751" FT CROSSLNK 284 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:22410793" FT VAR_SEQ 1..62 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_056180" FT VARIANT 17 FT /note="E -> K (in PROTEUSS and breast cancer; also detected FT in colorectal and ovarian cancer; somatic mutation; results FT in increased phosphorylation at T-308 and higher basal FT ubiquitination; the mutant protein is more efficiently FT recruited to the plasma membrane; alters FT phosphatidylinositiol phosphates lipid specificity of the FT AKT1 PH domain; dbSNP:rs121434592)" FT /evidence="ECO:0000269|PubMed:17611497, FT ECO:0000269|PubMed:18954143, ECO:0000269|PubMed:19713527, FT ECO:0000269|PubMed:21793738" FT /id="VAR_055422" FT VARIANT 25 FT /note="R -> C (in CWS6; impairs interaction with FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2; dbSNP:rs397514644)" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:23246288" FT /id="VAR_069791" FT VARIANT 167 FT /note="V -> A (in dbSNP:rs11555433)" FT /id="VAR_051617" FT VARIANT 435 FT /note="T -> P (in CWS6; dbSNP:rs397514645)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069792" FT MUTAGEN 8 FT /note="K->R: Substantial reduction of ubiquitination, FT phosphorylation at T-308 and S-473, AKT activation as well FT as IGF1-induced membrane recruitment. Decrease in FT ubiquitination and phosphorylation at T-308 as well as FT impaired association with the membrane; when associated FT with K-17." FT /evidence="ECO:0000269|PubMed:19713527" FT MUTAGEN 14 FT /note="K->A: Impairs interaction with PtdIns(3,4,5)P3 and FT PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285" FT MUTAGEN 14 FT /note="K->Q: Substantial reduction of phosphorylation at T- FT 308 and S-473, loss of AKT activation, and loss of binding FT to PIP3 as well as IGF1-induced membrane recruitment." FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285" FT MUTAGEN 14 FT /note="K->R: Substantial reduction of ubiquitination, FT phosphorylation at T-308 and S-473, AKT activation, loss of FT binding to PIP3 as well as IGF1-induced membrane FT recruitment." FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285" FT MUTAGEN 17 FT /note="E->K: Loss of membrane localization; when associated FT with Q-20." FT /evidence="ECO:0000269|PubMed:21775285" FT MUTAGEN 20 FT /note="K->Q: Substantial reduction of phosphorylation at T- FT 308 and S-473, reduced AKT activation, and reduced binding FT to PIP3 as well as IGF1-induced membrane recruitment. Loss FT of membrane localization; when associated with K-17." FT /evidence="ECO:0000269|PubMed:21775285" FT MUTAGEN 20 FT /note="K->R: Slight increase of phosphorylation at T-308 FT and S-473." FT /evidence="ECO:0000269|PubMed:21775285" FT MUTAGEN 25 FT /note="R->A: Impairs interaction with PtdIns(3,4,5)P3 and FT PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:12176338" FT MUTAGEN 76..78 FT /note="RCL->ACA: Abolished binding to cyclin-A, preventing FT phosphorylation by CDK2." FT /evidence="ECO:0000269|PubMed:24670654" FT MUTAGEN 86 FT /note="R->A: Impairs interaction with PtdIns(3,4,5)P3 and FT PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:12176338" FT MUTAGEN 176 FT /note="Y->F: Significant loss of interaction with TNK2. FT Loss of membrane localization. Significant reduction in FT phosphorylation on Ser-473." FT /evidence="ECO:0000269|PubMed:20333297" FT MUTAGEN 179 FT /note="K->M: Abolished serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:12172553, FT ECO:0000269|PubMed:33594058" FT MUTAGEN 273..275 FT /note="RDL->ADA: Abolished binding to cyclin-A, preventing FT phosphorylation by CDK2." FT /evidence="ECO:0000269|PubMed:24670654" FT MUTAGEN 305 FT /note="T->A: Reduces O-GlcNAc levels; Reduces O-GlcNAc FT levels even more; when associated with A-312." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 305 FT /note="T->Y: Abolishes phosphorylation at Thr-308." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 308 FT /note="T->D: 5-fold activation and 18-fold activation; when FT associated with D-473." FT /evidence="ECO:0000269|PubMed:12244301, FT ECO:0000269|PubMed:8978681" FT MUTAGEN 312 FT /note="T->A: Reduces O-GlcNAc levels; Reduces O-GlcNAc FT levels even more; when associated with A-305." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 312 FT /note="T->Y: Abolishes phosphorylation at Thr-308." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 473 FT /note="S->D: 7-fold activation and 25-fold activation; when FT associated with D-308." FT /evidence="ECO:0000269|PubMed:12244301, FT ECO:0000269|PubMed:8978681" FT MUTAGEN 474 FT /note="Y->F: 55% inhibition of activation." FT /evidence="ECO:0000269|PubMed:12149249" FT CONFLICT 173..174 FT /note="GR -> A (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 202 FT /note="L -> Q (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 212 FT /note="A -> R (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 246 FT /note="S -> A (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 409 FT /note="A -> T (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 476 FT /note="A -> P (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 478 FT /note="G -> A (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 478 FT /note="G -> S (in Ref. 1; AAA36539, 2; AAL55732, 3; FT BAG36922 and 4; BAG70056/BAG70181)" FT /evidence="ECO:0000305" FT HELIX 2..4 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 6..15 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 17..19 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 22..30 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 33..40 FT /evidence="ECO:0007829|PDB:1UNQ" FT HELIX 42..44 FT /evidence="ECO:0007829|PDB:7APJ" FT HELIX 45..48 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 52..56 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 61..65 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 67..69 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 72..79 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 82..89 FT /evidence="ECO:0007829|PDB:1UNQ" FT HELIX 93..115 FT /evidence="ECO:0007829|PDB:1UNQ" FT HELIX 147..149 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 150..158 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 160..169 FT /evidence="ECO:0007829|PDB:4GV1" FT TURN 170..172 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 175..182 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 183..188 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 192..204 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 213..218 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 220..227 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 235..242 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 247..268 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 277..279 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 280..282 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 284..286 FT /evidence="ECO:0007829|PDB:4EJN" FT STRAND 288..290 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 309..311 FT /evidence="ECO:0007829|PDB:3MVH" FT HELIX 313..315 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 318..322 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 330..344 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 354..363 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 374..383 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 388..390 FT /evidence="ECO:0007829|PDB:4GV1" FT TURN 396..398 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 399..403 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 406..408 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 413..417 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 430..433 FT /evidence="ECO:0007829|PDB:3MVH" FT TURN 436..438 FT /evidence="ECO:0007829|PDB:7NH5" FT HELIX 440..443 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 464..466 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 473..475 FT /evidence="ECO:0007829|PDB:4GV1" SQ SEQUENCE 480 AA; 55686 MW; 6EAFF4F8AD436714 CRC64; MSDVAIVKEG WLHKRGEYIK TWRPRYFLLK NDGTFIGYKE RPQDVDQREA PLNNFSVAQC QLMKTERPRP NTFIIRCLQW TTVIERTFHV ETPEEREEWT TAIQTVADGL KKQEEEEMDF RSGSPSDNSG AEEMEVSLAK PKHRVTMNEF EYLKLLGKGT FGKVILVKEK ATGRYYAMKI LKKEVIVAKD EVAHTLTENR VLQNSRHPFL TALKYSFQTH DRLCFVMEYA NGGELFFHLS RERVFSEDRA RFYGAEIVSA LDYLHSEKNV VYRDLKLENL MLDKDGHIKI TDFGLCKEGI KDGATMKTFC GTPEYLAPEV LEDNDYGRAV DWWGLGVVMY EMMCGRLPFY NQDHEKLFEL ILMEEIRFPR TLGPEAKSLL SGLLKKDPKQ RLGGGSEDAK EIMQHRFFAG IVWQHVYEKK LSPPFKPQVT SETDTRYFDE EFTAQMITIT PPDQDDSMEC VDSERRPHFP QFSYSASGTA // ID CADH1_HUMAN Reviewed; 882 AA. AC P12830; A8K1U7; Q13799; Q14216; Q15855; Q16194; Q4PJ14; Q9UII8; DT 01-OCT-1989, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-1993, sequence version 3. DT 28-JAN-2026, entry version 271. DE RecName: Full=Cadherin-1 {ECO:0000312|HGNC:HGNC:1748}; DE AltName: Full=CAM 120/80; DE AltName: Full=Epithelial cadherin {ECO:0000305}; DE Short=E-cadherin {ECO:0000312|HGNC:HGNC:1748}; DE AltName: Full=Uvomorulin {ECO:0000303|PubMed:8459805}; DE AltName: CD_antigen=CD324; DE Contains: DE RecName: Full=E-Cad/CTF1; DE Contains: DE RecName: Full=E-Cad/CTF2; DE Contains: DE RecName: Full=E-Cad/CTF3; DE Flags: Precursor; GN Name=CDH1 {ECO:0000312|HGNC:HGNC:1748}; GN Synonyms=CDHE, UVO {ECO:0000312|HGNC:HGNC:1748}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Pancreas; RX PubMed=8459805; DOI=10.1007/bf00996219; RA Bussemakers M.J.G., Mees S.G.M., van Bokhoven A., Debruyne F.M.J., RA Schalken J.A.; RT "Molecular cloning and characterization of the human E-cadherin cDNA."; RL Mol. Biol. Rep. 17:123-128(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT 274-GLY--PRO-277 DEL. RX PubMed=8127895; DOI=10.1073/pnas.91.5.1858; RA Oda T., Kanai Y., Oyama T., Yoshiura K., Shimoyama Y., Birchmeier W., RA Sugimura T., Hirohashi S.; RT "E-cadherin gene mutations in human gastric carcinoma cell lines."; RL Proc. Natl. Acad. Sci. U.S.A. 91:1858-1862(1994). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Liver; RX PubMed=8185635; DOI=10.1006/bbrc.1994.1656; RA Rimm D.L., Morrow J.S.; RT "Molecular cloning of human E-cadherin suggests a novel subdivision of the RT cadherin superfamily."; RL Biochem. Biophys. Res. Commun. 200:1754-1761(1994). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 586-591, RP PROTEOLYTIC PROCESSING, AND SUBCELLULAR LOCATION. RC TISSUE=Epidermal carcinoma; RX PubMed=10597309; DOI=10.1038/sj.onc.1203191; RA Ito K., Okamoto I., Araki N., Kawano Y., Nakao M., Fujiyama S., Tomita K., RA Mimori T., Saya H.; RT "Calcium influx triggers the sequential proteolysis of extracellular and RT cytoplasmic domains of E-cadherin, leading to loss of beta-catenin from RT cell-cell contacts."; RL Oncogene 18:7080-7090(1999). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Shibamoto S., Fukudome Y., Yanagihara K.; RT "Mutant E-cadherin."; RL Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Hippocampus, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-478; THR-617; MET-832 RP AND LYS-880. RG NIEHS SNPs program; RL Submitted (JUN-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15616553; DOI=10.1038/nature03187; RA Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G., RA Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E., RA Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M., RA Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C., RA Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M., RA Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M., RA Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D., RA Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., RA Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., RA Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., RA Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., RA Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J., RA Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D., RA Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S., RA Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A., RA Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M., RA Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H., RA Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A., RA Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J., RA DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J., RA Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., RA Myers R.M., Rubin E.M., Pennacchio L.A.; RT "The sequence and analysis of duplication-rich human chromosome 16."; RL Nature 432:988-994(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16. RX PubMed=8093045; DOI=10.1006/bbrc.1994.2321; RA Bussemakers M.J.G., Giroldi L.A., van Bokhoven A., Schalken J.A.; RT "Transcriptional regulation of the human E-cadherin gene in human prostate RT cancer cell lines: characterization of the human E-cadherin gene RT promoter."; RL Biochem. Biophys. Res. Commun. 203:1284-1290(1994). RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16. RC TISSUE=Placenta; RX PubMed=7543680; DOI=10.1073/pnas.92.16.7416; RA Yoshiura K., Kanai Y., Ochiai A., Shimoyama Y., Sugimura T., Hirohashi S.; RT "Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in RT human carcinomas."; RL Proc. Natl. Acad. Sci. U.S.A. 92:7416-7419(1995). RN [12] RP INTERACTION WITH CTNNB1 AND PKP2. RX PubMed=11790773; DOI=10.1074/jbc.m108765200; RA Chen X., Bonne S., Hatzfeld M., van Roy F., Green K.J.; RT "Protein binding and functional characterization of plakophilin 2. Evidence RT for its diverse roles in desmosomes and beta -catenin signaling."; RL J. Biol. Chem. 277:10512-10522(2002). RN [13] RP INTERACTION WITH PIP5K1C. RX PubMed=17261850; DOI=10.1083/jcb.200606023; RA Ling K., Bairstow S.F., Carbonara C., Turbin D.A., Huntsman D.G., RA Anderson R.A.; RT "Type I gamma phosphatidylinositol phosphate kinase modulates adherens RT junction and E-cadherin trafficking via a direct interaction with mu 1B RT adaptin."; RL J. Cell Biol. 176:343-353(2007). RN [14] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 56-882. RC TISSUE=Placenta; RX PubMed=7601454; DOI=10.1016/0888-7543(95)80212-5; RA Berx G., Staes K., van Hengel J., Molemans F., Bussemakers M.J.G., RA van Bokhoven A., van Roy F.; RT "Cloning and characterization of the human invasion suppressor gene E- RT cadherin (CDH1)."; RL Genomics 26:281-289(1995). RN [15] RP PROTEIN SEQUENCE OF 155-174, AND FUNCTION AS L.MONOCYTOGENES RECEPTOR RP (MICROBIAL INFECTION). RX PubMed=8601315; DOI=10.1016/s0092-8674(00)81070-3; RA Mengaud J., Ohayon H., Gounon P., Mege R.M., Cossart P.; RT "E-cadherin is the receptor for internalin, a surface protein required for RT entry of L. monocytogenes into epithelial cells."; RL Cell 84:923-932(1996). RN [16] RP NUCLEOTIDE SEQUENCE [MRNA] OF 172-311 (ISOFORM 1/2), AND TISSUE RP SPECIFICITY. RC TISSUE=Liver; RX PubMed=3263290; DOI=10.1111/j.1432-0436.1988.tb00593.x; RA Mansouri A., Spurr N., Goodfellow P.N., Kemler R.; RT "Characterization and chromosomal localization of the gene encoding the RT human cell adhesion molecule uvomorulin."; RL Differentiation 38:67-71(1988). RN [17] RP NUCLEOTIDE SEQUENCE [MRNA] OF 265-392 (ISOFORM 1). RC TISSUE=Liver; RA Frixen U.H.; RL Submitted (MAR-1990) to the EMBL/GenBank/DDBJ databases. RN [18] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 337-476, AND VARIANTS ALA-370 AND RP ASP-473. RX PubMed=8033105; RA Becker K.-F., Atkinson M.J., Reich U., Becker I., Nekarda H., Siewert J.R., RA Hoefler H.; RT "E-cadherin gene mutations provide clues to diffuse type gastric RT carcinomas."; RL Cancer Res. 54:3845-3852(1994). RN [19] RP PROTEIN SEQUENCE OF 701-714 AND 732-742, PROTEOLYTIC PROCESSING BY RP GAMMA-SECRETASE/PS1 AND A MEMBRANE-BOUND METALLOPROTEINASE, AND MUTAGENESIS RP OF 759-GLY--GLY-761. RX PubMed=11953314; DOI=10.1093/emboj/21.8.1948; RA Marambaud P., Shioi J., Serban G., Georgakopoulos A., Sarner S., Nagy V., RA Baki L., Wen P., Efthimiopoulos S., Shao Z., Wisniewski T., Robakis N.K.; RT "A presenilin-1/gamma-secretase cleavage releases the E-cadherin RT intracellular domain and regulates disassembly of adherens junctions."; RL EMBO J. 21:1948-1956(2002). RN [20] RP PARTIAL PROTEIN SEQUENCE, AND PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION). RX PubMed=23532847; DOI=10.1074/jbc.m113.459875; RA Sumitomo T., Nakata M., Higashino M., Terao Y., Kawabata S.; RT "Group A streptococcal cysteine protease cleaves epithelial junctions and RT contributes to bacterial translocation."; RL J. Biol. Chem. 288:13317-13324(2013). RN [21] RP DOMAIN CATENIN-BINDING. RX PubMed=2349235; DOI=10.1073/pnas.87.11.4246; RA Ozawa M., Ringwald M., Kemler R.; RT "Uvomorulin-catenin complex formation is regulated by a specific domain in RT the cytoplasmic region of the cell adhesion molecule."; RL Proc. Natl. Acad. Sci. U.S.A. 87:4246-4250(1990). RN [22] RP IDENTIFICATION IN AN E-CADHERIN/CATENIN ADHESION COMPLEX. RX PubMed=7982500; DOI=10.1016/0014-5793(94)01205-9; RA Butz S., Kemler R.; RT "Distinct cadherin-catenin complexes in Ca(2+)-dependent cell-cell RT adhesion."; RL FEBS Lett. 355:195-200(1994). RN [23] RP FUNCTION AS L.MONOCYTOGENES RECEPTOR (MICROBIAL INFECTION), AND MUTAGENESIS RP OF PRO-170. RX PubMed=10406800; DOI=10.1093/emboj/18.14.3956; RA Lecuit M., Dramsi S., Gottardi C., Fedor-Chaiken M., Gumbiner B., RA Cossart P.; RT "A single amino acid in E-cadherin responsible for host specificity towards RT the human pathogen Listeria monocytogenes."; RL EMBO J. 18:3956-3963(1999). RN [24] RP PROTEOLYTIC PROCESSING. RX PubMed=11076937; DOI=10.1074/jbc.m006102200; RA Steinhusen U., Weiske J., Badock V., Tauber R., Bommert K., Huber O.; RT "Cleavage and shedding of E-cadherin after induction of apoptosis."; RL J. Biol. Chem. 276:4972-4980(2001). RN [25] RP INTERACTION WITH PSEN1. RX PubMed=11226248; DOI=10.1073/pnas.041603398; RA Baki L., Marambaud P., Efthimiopoulos S., Georgakopoulos A., Wen P., RA Cui W., Shioi J., Koo E., Ozawa M., Friedrich V.L., Robakis N.K.; RT "Presenilin-1 binds cytoplasmic epithelial cadherin, inhibits cadherin/p120 RT association, and regulates stability and function of the cadherin/catenin RT adhesion complex."; RL Proc. Natl. Acad. Sci. U.S.A. 98:2381-2386(2001). RN [26] RP INTERCHAIN DISULFIDE BOND. RX PubMed=11856755; DOI=10.1074/jbc.m200916200; RA Makagiansar I.T., Nguyen P.D., Ikesue A., Kuczera K., Dentler W., RA Urbauer J.L., Galeva N., Alterman M., Siahaan T.J.; RT "Disulfide bond formation promotes the cis- and trans-dimerization of the RT E-cadherin-derived first repeat."; RL J. Biol. Chem. 277:16002-16010(2002). RN [27] RP FUNCTION. RX PubMed=11976333; DOI=10.1074/jbc.m201984200; RA Meigs T.E., Fedor-Chaiken M., Kaplan D.D., Brackenbury R., Casey P.J.; RT "Galpha12 and Galpha13 negatively regulate the adhesive functions of RT cadherin."; RL J. Biol. Chem. 277:24594-24600(2002). RN [28] RP INTERACTION WITH DLGAP5, AND SUBCELLULAR LOCATION. RX PubMed=14699157; DOI=10.1074/jbc.m309843200; RA Laprise P., Viel A., Rivard N.; RT "Human homolog of disc-large is required for adherens junction assembly and RT differentiation of human intestinal epithelial cells."; RL J. Biol. Chem. 279:10157-10166(2004). RN [29] RP INTERACTION WITH AJAP1. RC TISSUE=Brain; RX PubMed=14595118; DOI=10.1091/mbc.e03-05-0281; RA Bharti S., Handrow-Metzmacher H., Zickenheiner S., Zeitvogel A., RA Baumann R., Starzinski-Powitz A.; RT "Novel membrane protein shrew-1 targets to cadherin-mediated junctions in RT polarized epithelial cells."; RL Mol. Biol. Cell 15:397-406(2004). RN [30] RP INTERACTION WITH CTNND1. RX PubMed=15240885; DOI=10.1073/pnas.0401366101; RA Krakstad B.F., Ardawatia V.V., Aragay A.M.; RT "A role for Galpha12/Galpha13 in p120ctn regulation."; RL Proc. Natl. Acad. Sci. U.S.A. 101:10314-10319(2004). RN [31] RP INTERACTION WITH PSEN1 AND CTNNB1, AND MUTAGENESIS OF 759-GLY--GLY-761. RX PubMed=16126725; DOI=10.1074/jbc.m507503200; RA Serban G., Kouchi Z., Baki L., Georgakopoulos A., Litterst C.M., Shioi J., RA Robakis N.K.; RT "Cadherins mediate both the association between PS1 and beta-catenin and RT the effects of PS1 on beta-catenin stability."; RL J. Biol. Chem. 280:36007-36012(2005). RN [32] RP SUBCELLULAR LOCATION. RX PubMed=15689490; DOI=10.1091/mbc.e04-10-0867; RA Lock J.G., Stow J.L.; RT "Rab11 in recycling endosomes regulates the sorting and basolateral RT transport of E-cadherin."; RL Mol. Biol. Cell 16:1744-1755(2005). RN [33] RP FUNCTION OF E-CAD/CTF2. RX PubMed=16417575; DOI=10.1111/j.1471-4159.2005.03616.x; RA Agiostratidou G., Muros R.M., Shioi J., Marambaud P., Robakis N.K.; RT "The cytoplasmic sequence of E-cadherin promotes non-amyloidogenic RT degradation of A beta precursors."; RL J. Neurochem. 96:1182-1188(2006). RN [34] RP INDUCTION. RX PubMed=17893710; DOI=10.1038/cr.2007.79; RA Meng Y.G., Han W.-D., Zhao Y.-L., Huang K., Si Y.-L., Wu Z.-Q., Mu Y.-M.; RT "Induction of the LRP16 gene by estrogen promotes the invasive growth of RT Ishikawa human endometrial cancer cells through the downregulation of E- RT cadherin."; RL Cell Res. 17:869-880(2007). RN [35] RP INVOLVEMENT IN LBC. RX PubMed=17660459; DOI=10.1136/jmg.2007.051268; RA Masciari S., Larsson N., Senz J., Boyd N., Kaurah P., Kandel M.J., RA Harris L.N., Pinheiro H.C., Troussard A., Miron P., Tung N., Oliveira C., RA Collins L., Schnitt S., Garber J.E., Huntsman D.; RT "Germline E-cadherin mutations in familial lobular breast cancer."; RL J. Med. Genet. 44:726-731(2007). RN [36] RP SUBCELLULAR LOCATION. RX PubMed=18343367; DOI=10.1016/j.yexcr.2008.01.031; RA Kanno M., Isa Y., Aoyama Y., Yamamoto Y., Nagai M., Ozawa M., Kitajima Y.; RT "P120-catenin is a novel desmoglein 3 interacting partner: identification RT of the p120-catenin association site of desmoglein 3."; RL Exp. Cell Res. 314:1683-1692(2008). RN [37] RP GLYCOSYLATION AT ASN-558; ASN-570; ASN-622 AND ASN-637, AND MUTAGENESIS OF RP ASN-637. RX PubMed=18491227; DOI=10.1007/s10719-008-9133-9; RA Zhou F., Su J., Fu L., Yang Y., Zhang L., Wang L., Zhao H., Zhang D., RA Li Z., Zha X.; RT "Unglycosylation at Asn-633 made extracellular domain of E-cadherin folded RT incorrectly and arrested in endoplasmic reticulum, then sequentially RT degraded by ERAD."; RL Glycoconj. J. 25:727-740(2008). RN [38] RP INTERACTION WITH LIMA1. RX PubMed=18093941; DOI=10.1073/pnas.0710504105; RA Abe K., Takeichi M.; RT "EPLIN mediates linkage of the cadherin catenin complex to F-actin and RT stabilizes the circumferential actin belt."; RL Proc. Natl. Acad. Sci. U.S.A. 105:13-19(2008). RN [39] RP REVIEW ON CADHERINS. RX PubMed=20066110; DOI=10.1101/cshperspect.a003053; RA Shapiro L., Weis W.I.; RT "Structure and biochemistry of cadherins and catenins."; RL Cold Spring Harb. Perspect. Biol. 1:A3053-A3053(2009). RN [40] RP SUBCELLULAR LOCATION, AND GLYCOSYLATION. RX PubMed=19403558; DOI=10.1093/hmg/ddp194; RA Pinho S.S., Reis C.A., Paredes J., Magalhaes A.M., Ferreira A.C., RA Figueiredo J., Xiaogang W., Carneiro F., Gaertner F., Seruca R.; RT "The role of N-acetylglucosaminyltransferase III and V in the post- RT transcriptional modifications of E-cadherin."; RL Hum. Mol. Genet. 18:2599-2608(2009). RN [41] RP INTERACTION WITH TBC1D2. RX PubMed=20116244; DOI=10.1016/j.cub.2009.12.053; RA Frasa M.A., Maximiano F.C., Smolarczyk K., Francis R.E., Betson M.E., RA Lozano E., Goldenring J., Seabra M.C., Rak A., Ahmadian M.R., Braga V.M.; RT "Armus is a Rac1 effector that inactivates Rab7 and regulates E-cadherin RT degradation."; RL Curr. Biol. 20:198-208(2010). RN [42] RP SUBCELLULAR LOCATION, AND INTERACTION WITH DDR1. RX PubMed=20432435; DOI=10.1002/jcp.22134; RA Eswaramoorthy R., Wang C.K., Chen W.C., Tang M.J., Ho M.L., Hwang C.C., RA Wang H.M., Wang C.Z.; RT "DDR1 regulates the stabilization of cell surface E-cadherin and E- RT cadherin-mediated cell aggregation."; RL J. Cell. Physiol. 224:387-397(2010). RN [43] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [44] RP SUBCELLULAR LOCATION. RX PubMed=20859650; DOI=10.1007/s00018-010-0531-3; RA Gosavi P., Kundu S.T., Khapare N., Sehgal L., Karkhanis M.S., Dalal S.N.; RT "E-cadherin and plakoglobin recruit plakophilin3 to the cell border to RT initiate desmosome assembly."; RL Cell. Mol. Life Sci. 68:1439-1454(2011). RN [45] RP UBIQUITINATION BY CBLL1. RX PubMed=21283129; DOI=10.1038/cr.2011.17; RA Zhou W.J., Geng Z.H., Chi S., Zhang W., Niu X.F., Lan S.J., Ma L., Yang X., RA Wang L.J., Ding Y.Q., Geng J.G.; RT "Slit-Robo signaling induces malignant transformation through Hakai- RT mediated E-cadherin degradation during colorectal epithelial cell RT carcinogenesis."; RL Cell Res. 21:609-626(2011). RN [46] RP UBIQUITINATION BY A SKP2-CONTAINING SCF COMPLEX, AND PHOSPHORYLATION BY RP CSNK1A1. RX PubMed=22770219; DOI=10.1016/j.cell.2012.05.038; RA Inuzuka H., Gao D., Finley L.W., Yang W., Wan L., Fukushima H., Chin Y.R., RA Zhai B., Shaik S., Lau A.W., Wang Z., Gygi S.P., Nakayama K., RA Teruya-Feldstein J., Toker A., Haigis M.C., Pandolfi P.P., Wei W.; RT "Acetylation-dependent regulation of Skp2 function."; RL Cell 150:179-193(2012). RN [47] RP PHOSPHORYLATION AT TYR-753; TYR-754 AND TYR-755, AND MUTAGENESIS OF RP TYR-754. RX PubMed=22252131; DOI=10.1038/emboj.2011.496; RA Mukherjee M., Chow S.Y., Yusoff P., Seetharaman J., Ng C., Sinniah S., RA Koh X.W., Asgar N.F., Li D., Yim D., Jackson R.A., Yew J., Qian J., Iyu A., RA Lim Y.P., Zhou X., Sze S.K., Guy G.R., Sivaraman J.; RT "Structure of a novel phosphotyrosine-binding domain in Hakai that targets RT E-cadherin."; RL EMBO J. 31:1308-1319(2012). RN [48] RP INTERACTION WITH DSG3, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=22294297; DOI=10.1002/path.3982; RA Tsang S.M., Brown L., Lin K., Liu L., Piper K., O'Toole E.A., Grose R., RA Hart I.R., Garrod D.R., Fortune F., Wan H.; RT "Non-junctional human desmoglein 3 acts as an upstream regulator of Src in RT E-cadherin adhesion, a pathway possibly involved in the pathogenesis of RT pemphigus vulgaris."; RL J. Pathol. 227:81-93(2012). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-770 AND SER-793, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [50] RP IDENTIFICATION IN A COMPLEX WITH PKP3 AND RAP1A, INTERACTION WITH PKP3 AND RP RAP1A, AND SUBCELLULAR LOCATION. RX PubMed=25208567; DOI=10.1091/mbc.e14-05-0968; RA Todorovic V., Koetsier J.L., Godsel L.M., Green K.J.; RT "Plakophilin 3 mediates Rap1-dependent desmosome assembly and adherens RT junction maturation."; RL Mol. Biol. Cell 25:3749-3764(2014). RN [51] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=27760340; DOI=10.1016/j.immuni.2016.09.014; RA Cronan M.R., Beerman R.W., Rosenberg A.F., Saelens J.W., Johnson M.G., RA Oehlers S.H., Sisk D.M., Jurcic Smith K.L., Medvitz N.A., Miller S.E., RA Trinh L.A., Fraser S.E., Madden J.F., Turner J., Stout J.E., Lee S., RA Tobin D.M.; RT "Macrophage Epithelial Reprogramming Underlies Mycobacterial Granuloma RT Formation and Promotes Infection."; RL Immunity 45:861-876(2016). RN [52] RP SUBCELLULAR LOCATION. RX PubMed=28169360; DOI=10.1038/srep42125; RA Liu J., Li J., Li P., Wang Y., Liang Z., Jiang Y., Li J., Feng C., Wang R., RA Chen H., Zhou C., Zhang J., Yang J., Liu P.; RT "Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo RT signaling pathway."; RL Sci. Rep. 7:42125-42125(2017). RN [53] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LEU-175. RX PubMed=29999492; DOI=10.7554/elife.37629; RA Shafraz O., Ruebsam M., Stahley S.N., Caldara A.L., Kowalczyk A.P., RA Niessen C.M., Sivasankar S.; RT "E-cadherin binds to desmoglein to facilitate desmosome assembly."; RL Elife 7:0-0(2018). RN [54] RP INTERACTION WITH SPEF1. RX PubMed=31473225; DOI=10.1053/j.gastro.2019.08.031; RA Tapia R., Perez-Yepez E.A., Carlino M.J., Karandikar U.C., Kralicek S.E., RA Estes M.K., Hecht G.A.; RT "Sperm Flagellar 1 Binds Actin in Intestinal Epithelial Cells and RT Contributes to Formation of Filopodia and Lamellipodia."; RL Gastroenterology 157:1544-1555(2019). RN [55] RP INDUCTION. RX PubMed=31835537; DOI=10.3390/ijms20246221; RA Uttagomol J., Ahmad U.S., Rehman A., Huang Y., Laly A.C., Kang A., RA Soetaert J., Chance R., Teh M.T., Connelly J.T., Wan H.; RT "Evidence for the Desmosomal Cadherin Desmoglein-3 in Regulating YAP and RT Phospho-YAP in Keratinocyte Responses to Mechanical Forces."; RL Int. J. Mol. Sci. 20:0-0(2019). RN [56] RP SUBCELLULAR LOCATION. RX PubMed=33596089; DOI=10.1091/mbc.e20-12-0775; RA Raya-Sandino A., Luissint A.C., Kusters D.H.M., Narayanan V., Flemming S., RA Garcia-Hernandez V., Godsel L.M., Green K.J., Hagen S.J., Conway D.E., RA Parkos C.A., Nusrat A.; RT "Regulation of intestinal epithelial intercellular adhesion and barrier RT function by desmosomal cadherin desmocollin-2."; RL Mol. Biol. Cell 32:753-768(2021). RN [57] RP SUBCELLULAR LOCATION. RX PubMed=36309486; DOI=10.1038/s41419-022-05326-2; RA Myo Min K.K., Rojas-Canales D., Penko D., DeNichilo M., Cockshell M.P., RA Ffrench C.B., Thompson E.J., Asplund O., Drogemuller C.J., Prasad R.B., RA Groop L., Grey S.T., Thomas H.E., Loudovaris T., Kay T.W., Mahoney M.G., RA Jessup C.F., Coates P.T., Bonder C.S.; RT "Desmoglein-2 is important for islet function and beta-cell survival."; RL Cell Death Dis. 13:911-911(2022). RN [58] {ECO:0007744|PDB:1O6S} RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 156-255 IN COMPLEX WITH RP L.MONOCYTOGENES INLA, FUNCTION (MICROBIAL INFECTION), SUBUNIT (MICROBIAL RP INFECTION), AND MUTAGENESIS OF TRP-156 AND PRO-170. RX PubMed=12526809; DOI=10.1016/s0092-8674(02)01136-4; RA Schubert W.-D., Urbanke C., Ziehm T., Beier V., Machner M.P., Domann E., RA Wehland J., Chakraborty T., Heinz D.W.; RT "Structure of internalin, a major invasion protein of Listeria RT monocytogenes, in complex with its human receptor E-cadherin."; RL Cell 111:825-836(2002). RN [59] RP REVIEW ON VARIANTS. RX PubMed=9744472; RX DOI=10.1002/(sici)1098-1004(1998)12:4<226::aid-humu2>3.0.co;2-d; RA Berx G., Becker K.-F., Hoefler H., van Roy F.; RT "Mutations of the human E-cadherin (CDH1) gene."; RL Hum. Mutat. 12:226-237(1998). RN [60] {ECO:0007744|PDB:2OMV, ECO:0007744|PDB:2OMY} RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 156-255 IN COMPLEX WITH RP L.MONOCYTOGENES INLA, FUNCTION (MICROBIAL INFECTION), AND SUBUNIT RP (MICROBIAL INFECTION). RX PubMed=17540170; DOI=10.1016/j.cell.2007.03.049; RA Wollert T., Pasche B., Rochon M., Deppenmeier S., van den Heuvel J., RA Gruber A.D., Heinz D.W., Lengeling A., Schubert W.D.; RT "Extending the host range of Listeria monocytogenes by rational protein RT design."; RL Cell 129:891-902(2007). RN [61] {ECO:0007744|PDB:2OMU, ECO:0007744|PDB:2OMZ} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 156-255 IN COMPLEX WITH RP L.MONOCYTOGENES INLA, AND SUBUNIT (MICROBIAL INFECTION). RX PubMed=17715295; DOI=10.1073/pnas.0702199104; RA Wollert T., Heinz D.W., Schubert W.D.; RT "Thermodynamically reengineering the listerial invasion complex InlA/E- RT cadherin."; RL Proc. Natl. Acad. Sci. U.S.A. 104:13960-13965(2007). RN [62] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 155-367, AND CALCIUM-BINDING RP SITES. RX PubMed=17850815; DOI=10.1016/j.jmb.2007.08.011; RA Parisini E., Higgins J.M., Liu J.H., Brenner M.B., Wang J.H.; RT "The crystal structure of human E-cadherin domains 1 and 2, and comparison RT with other cadherins in the context of adhesion mechanism."; RL J. Mol. Biol. 373:401-411(2007). RN [63] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 155-253 IN COMPLEX WITH KLRG1. RX PubMed=19604491; DOI=10.1016/j.immuni.2009.04.019; RA Li Y., Hofmann M., Wang Q., Teng L., Chlewicki L.K., Pircher H., RA Mariuzza R.A.; RT "Structure of natural killer cell receptor KLRG1 bound to E-cadherin RT reveals basis for MHC-independent missing self recognition."; RL Immunity 31:35-46(2009). RN [64] RP VARIANT LOBULAR BREAST CARCINOMA SER-315. RX PubMed=7961105; DOI=10.1111/j.1349-7006.1994.tb02902.x; RA Kanai Y., Oda T., Tsuda H., Ochiai A., Hirohashi S.; RT "Point mutation of the E-cadherin gene in invasive lobular carcinoma of the RT breast."; RL Jpn. J. Cancer Res. 85:1035-1039(1994). RN [65] RP VARIANTS THR-617 AND VAL-711, AND VARIANT OVARIAN CANCER GLY-838. RX PubMed=8075649; DOI=10.1038/ng0594-98; RA Risinger J.I., Berchuck A., Kohler M.F., Boyd J.; RT "Mutations of the E-cadherin gene in human gynecologic cancers."; RL Nat. Genet. 7:98-102(1994). RN [66] RP VARIANT PRO-193. RX PubMed=8797891; DOI=10.1111/j.1349-7006.1996.tb02109.x; RA Muta H., Noguchi M., Kanai Y., Ochiai A., Nawata H., Hirohashi S.; RT "E-cadherin gene mutations in signet ring cell carcinoma of the stomach."; RL Jpn. J. Cancer Res. 87:843-848(1996). RN [67] RP VARIANTS ASP-400 DEL AND 418-ASP--PHE-423 DEL. RX PubMed=9045944; DOI=10.1111/j.1349-7006.1996.tb03125.x; RA Tamura G., Sakata K., Nishizuka S., Maesawa C., Suzuki Y., Iwaya T., RA Terashima M., Saito K., Satodate R.; RT "Inactivation of the E-cadherin gene in primary gastric carcinomas and RT gastric carcinoma cell lines."; RL Jpn. J. Cancer Res. 87:1153-1159(1996). RN [68] RP VARIANT THYROID CANCER THR-592. RX PubMed=8985087; RX DOI=10.1002/(sici)1097-0215(19970106)70:1<32::aid-ijc5>3.0.co;2-7; RA Soares P., Berx G., van Roy F., Sobrinho-Simoes M.; RT "E-cadherin gene alterations are rare events in thyroid tumors."; RL Int. J. Cancer 70:32-38(1997). RN [69] RP VARIANT DGLBC ASP-336, AND VARIANT ILE-470. RX PubMed=9537325; DOI=10.1038/32918; RA Guilford P.J., Hopkins J.B.W., Harraway J., McLeod M., McLeod N., RA Harawira P., Taite H., Scoular R., Miller A., Reeve A.E.; RT "E-cadherin germline mutations in familial gastric cancer."; RL Nature 392:402-405(1998). RN [70] RP VARIANTS DGLBC GLY-244 AND ALA-487. RX PubMed=10319582; DOI=10.1007/s100380050137; RA Yoon K.-A., Ku J.-L., Yang H.-K., Kim W.H., Park S.Y., Park J.-G.; RT "Germline mutations of E-cadherin gene in Korean familial gastric cancer RT patients."; RL J. Hum. Genet. 44:177-180(1999). RN [71] RP VARIANT ALA-340. RX PubMed=10896919; DOI=10.1136/gut.47.2.262; RA Kim H.C., Wheeler J.M.D., Kim J.C., Ilyas M., Beck N.E., Kim B.S., RA Park K.C., Bodmer W.F.; RT "The E-cadherin gene (CDH1) variants T340A and L599V in gastric and RT colorectal cancer patients in Korea."; RL Gut 47:262-267(2000). RN [72] RP VARIANT ALA-270. RX PubMed=11705864; RA Ikonen T., Matikainen M., Mononen N., Hyytinen E.R., Helin H.J., RA Tommola S., Tammela T.L., Pukkala E., Schleutker J., Kallioniemi O.-P., RA Koivisto P.A.; RT "Association of E-cadherin germ-line alterations with prostate cancer."; RL Clin. Cancer Res. 7:3465-3471(2001). RN [73] RP VARIANT THR-592. RX PubMed=11562785; DOI=10.3892/ijmm.8.4.439; RA Salahshor S., Hou H., Diep C.B., Loukola A., Zhang H., Liu T., Chen J., RA Iselius L., Rubio C., Lothe R.A., Aaltonen L., Sun X.F., Lindmark G., RA Lindblom A.; RT "A germline E-cadherin mutation in a family with gastric and colon RT cancer."; RL Int. J. Mol. Med. 8:439-443(2001). RN [74] RP VARIANT ALA-340. RX PubMed=11968083; DOI=10.1002/humu.10068; RA Oliveira C., Bordin M.C., Grehan N., Huntsman D., Suriano G., Machado J.C., RA Kiviluoto T., Aaltonen L., Jackson C.E., Seruca R., Caldas C.; RT "Screening E-cadherin in gastric cancer families reveals germline mutations RT only in hereditary diffuse gastric cancer kindred."; RL Hum. Mutat. 19:510-517(2002). RN [75] RP VARIANT DGLBC MET-832. RX PubMed=12216071; DOI=10.1002/ijc.10633; RA Yabuta T., Shinmura K., Tani M., Yamaguchi S., Yoshimura K., Katai H., RA Nakajima T., Mochiki E., Tsujinaka T., Takami M., Hirose K., Yamaguchi A., RA Takenoshita S., Yokota J.; RT "E-cadherin gene variants in gastric cancer families whose probands are RT diagnosed with diffuse gastric cancer."; RL Int. J. Cancer 101:434-441(2002). RN [76] RP VARIANTS THR-617 AND VAL-634, AND CHARACTERIZATION OF VARIANTS ALA-340; RP THR-617 AND VAL-634. RX PubMed=12588804; DOI=10.1093/hmg/ddg048; RA Suriano G., Oliveira C., Ferreira P., Machado J.C., Bordin M.C., RA De Wever O., Bruyneel E.A., Moguilevsky N., Grehan N., Porter T.R., RA Richards F.M., Hruban R.H., Roviello F., Huntsman D., Mareel M., RA Carneiro F., Caldas C., Seruca R.; RT "Identification of CDH1 germline missense mutations associated with RT functional inactivation of the E-cadherin protein in young gastric cancer RT probands."; RL Hum. Mol. Genet. 12:575-582(2003). RN [77] RP VARIANTS ILE-282 AND ASN-777. RX PubMed=17224074; DOI=10.1186/bcr1637; RA Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A., Presswalla S., RA Kaaresen R., Strausberg R.L., Gerhard D.S., Kristensen V., Perou C.M., RA Boerresen-Dale A.-L.; RT "Somatic sequence alterations in twenty-one genes selected by expression RT profile analysis of breast carcinomas."; RL Breast Cancer Res. 9:R5-R5(2007). RN [78] RP INVOLVEMENT IN BCDS1, VARIANTS BCDS1 TYR-254; VAL-257 AND VAL-454 DEL, RP CHARACTERIZATION OF VARIANTS BCDS1 TYR-254; VAL-257 AND VAL-454 DEL, AND RP SUBCELLULAR LOCATION. RX PubMed=28301459; DOI=10.1038/gim.2017.11; RA Ghoumid J., Stichelbout M., Jourdain A.S., Frenois F., Lejeune-Dumoulin S., RA Alex-Cordier M.P., Lebrun M., Guerreschi P., Duquennoy-Martinot V., RA Vinchon M., Ferri J., Jung M., Vicaire S., Vanlerberghe C., Escande F., RA Petit F., Manouvrier-Hanu S.; RT "Blepharocheilodontic syndrome is a CDH1 pathway-related disorder due to RT mutations in CDH1 and CTNND1."; RL Genet. Med. 19:1013-1021(2017). CC -!- FUNCTION: Cadherins are calcium-dependent cell adhesion proteins CC (PubMed:11976333). They preferentially interact with themselves in a CC homophilic manner in connecting cells; cadherins may thus contribute to CC the sorting of heterogeneous cell types. CDH1 is involved in mechanisms CC regulating cell-cell adhesions, mobility and proliferation of CC epithelial cells (PubMed:11976333). Promotes organization of radial CC actin fiber structure and cellular response to contractile forces, via CC its interaction with AMOTL2 which facilitates anchoring of radial actin CC fibers to CDH1 junction complexes at the cell membrane (By similarity). CC Plays a role in the early stages of desmosome cell-cell junction CC formation via facilitating the recruitment of DSG2 and DSP to desmosome CC plaques (PubMed:29999492). Has a potent invasive suppressor role. It is CC a ligand for integrin alpha-E/beta-7. {ECO:0000250|UniProtKB:F1PAA9, CC ECO:0000269|PubMed:11976333, ECO:0000269|PubMed:16417575, CC ECO:0000269|PubMed:29999492}. CC -!- FUNCTION: E-Cad/CTF2 promotes non-amyloidogenic degradation of Abeta CC precursors. Has a strong inhibitory effect on APP C99 and C83 CC production. {ECO:0000269|PubMed:16417575}. CC -!- FUNCTION: (Microbial infection) Serves as a receptor for Listeria CC monocytogenes; internalin A (InlA) binds to this protein and promotes CC uptake of the bacteria. {ECO:0000269|PubMed:10406800, CC ECO:0000269|PubMed:17540170, ECO:0000269|PubMed:8601315}. CC -!- SUBUNIT: Homodimer; disulfide-linked (PubMed:11856755). Component of an CC E-cadherin/ catenin adhesion complex composed of at least E- CC cadherin/CDH1, beta-catenin/CTNNB1 or gamma-catenin/JUP, and CC potentially alpha-catenin/CTNNA1; the complex is located to adherens CC junctions (PubMed:16126725, PubMed:7982500). Found in a complex CC composed of CDH1, RAP1A and PKP3; PKP3 acts as a scaffold protein CC within the complex, the complex is required for CDH1 localization to CC mature desmosome cell junctions (PubMed:25208567). Interacts with the CC TRPV4 and CTNNB1 complex (By similarity). Interacts with CTNND1 CC (PubMed:15240885). The stable association of CTNNA1 is controversial as CC CTNNA1 was shown not to bind to F-actin when assembled in the complex CC (By similarity). Alternatively, the CTNNA1-containing complex may be CC linked to F-actin by other proteins such as LIMA1 (By similarity). CC Interaction with PSEN1, cleaves CDH1 resulting in the disassociation of CC cadherin-based adherens junctions (CAJs) (PubMed:11226248, CC PubMed:16126725). Interacts with AJAP1 and DLGAP5 (PubMed:14595118, CC PubMed:14699157). Interacts with TBC1D2 (PubMed:20116244). Interacts CC with LIMA1 (PubMed:18093941). Interacts with CAV1. Interacts with CC PIP5K1C (PubMed:17261850). Interacts with RAB8B (By similarity). CC Interacts with RAPGEF2 (By similarity). Interacts with DDR1; this CC stabilizes CDH1 at the cell surface and inhibits its internalization CC (PubMed:20432435). Interacts with KLRG1 (PubMed:19604491). Forms a CC ternary complex composed of ADAM10, CADH1 and EPHA4; within the CC complex, CADH1 is cleaved by ADAM10 which disrupts adherens junctions CC (By similarity). Interacts with SPEF1 (PubMed:31473225). Interacts with CC CTNNB1 and PKP2 (PubMed:11790773). Interacts with AMOTL2; the CC interaction may facilitate binding of radial actin fibers to cell CC junction complexes (By similarity). Interacts with DSG3; the CC interaction is required for CDH1 localization to developing adherens CC junctions (PubMed:22294297). {ECO:0000250, CC ECO:0000250|UniProtKB:F1PAA9, ECO:0000250|UniProtKB:P09803, CC ECO:0000250|UniProtKB:Q9R0T4, ECO:0000269|PubMed:11226248, CC ECO:0000269|PubMed:11790773, ECO:0000269|PubMed:11856755, CC ECO:0000269|PubMed:12526809, ECO:0000269|PubMed:14595118, CC ECO:0000269|PubMed:14699157, ECO:0000269|PubMed:15240885, CC ECO:0000269|PubMed:16126725, ECO:0000269|PubMed:17261850, CC ECO:0000269|PubMed:18093941, ECO:0000269|PubMed:19604491, CC ECO:0000269|PubMed:20116244, ECO:0000269|PubMed:20432435, CC ECO:0000269|PubMed:22294297, ECO:0000269|PubMed:25208567, CC ECO:0000269|PubMed:31473225, ECO:0000269|PubMed:7982500}. CC -!- SUBUNIT: (Microbial infection) Interacts with L.monocytogenes InlA CC (PubMed:12526809, PubMed:17540170, PubMed:17715295). The formation of CC the complex between InlA and cadherin-1 is calcium-dependent CC (PubMed:12526809). {ECO:0000269|PubMed:12526809, CC ECO:0000269|PubMed:17540170, ECO:0000269|PubMed:17715295}. CC -!- INTERACTION: CC P12830; O94983-5: CAMTA2; NbExp=3; IntAct=EBI-727477, EBI-10176008; CC P12830; P30260: CDC27; NbExp=2; IntAct=EBI-727477, EBI-994813; CC P12830; P12830: CDH1; NbExp=8; IntAct=EBI-727477, EBI-727477; CC P12830; Q6UXH1-2: CRELD2; NbExp=3; IntAct=EBI-727477, EBI-21670927; CC P12830; P35221: CTNNA1; NbExp=8; IntAct=EBI-727477, EBI-701918; CC P12830; P35222: CTNNB1; NbExp=23; IntAct=EBI-727477, EBI-491549; CC P12830; O60716: CTNND1; NbExp=9; IntAct=EBI-727477, EBI-701927; CC P12830; P49184: DNASE1L1; NbExp=3; IntAct=EBI-727477, EBI-20894690; CC P12830; Q9H8V3: ECT2; NbExp=3; IntAct=EBI-727477, EBI-1054039; CC P12830; P00533: EGFR; NbExp=4; IntAct=EBI-727477, EBI-297353; CC P12830; P16422: EPCAM; NbExp=3; IntAct=EBI-727477, EBI-1171184; CC P12830; P11362: FGFR1; NbExp=3; IntAct=EBI-727477, EBI-1028277; CC P12830; Q7Z6Z7-2: HUWE1; NbExp=3; IntAct=EBI-727477, EBI-10975491; CC P12830; Q9UHB6: LIMA1; NbExp=2; IntAct=EBI-727477, EBI-351479; CC P12830; P43356: MAGEA2B; NbExp=3; IntAct=EBI-727477, EBI-5650739; CC P12830; Q7Z434: MAVS; NbExp=3; IntAct=EBI-727477, EBI-995373; CC P12830; P08581: MET; NbExp=2; IntAct=EBI-727477, EBI-1039152; CC P12830; Q8NCR3: MFI; NbExp=3; IntAct=EBI-727477, EBI-744790; CC P12830; Q8TB02: MGC39372; NbExp=3; IntAct=EBI-727477, EBI-25834188; CC P12830; Q9NPC7: MYNN; NbExp=3; IntAct=EBI-727477, EBI-3446748; CC P12830; Q9HC98-4: NEK6; NbExp=3; IntAct=EBI-727477, EBI-11750983; CC P12830; Q8N323: NXPE1; NbExp=3; IntAct=EBI-727477, EBI-25834085; CC P12830; Q8N2W9: PIAS4; NbExp=3; IntAct=EBI-727477, EBI-473160; CC P12830; Q8NBT0: POC1A; NbExp=3; IntAct=EBI-727477, EBI-2557132; CC P12830; P62136: PPP1CA; NbExp=2; IntAct=EBI-727477, EBI-357253; CC P12830; Q96QH2: PRAM1; NbExp=3; IntAct=EBI-727477, EBI-2860740; CC P12830; P17612: PRKACA; NbExp=3; IntAct=EBI-727477, EBI-476586; CC P12830; Q15139: PRKD1; NbExp=7; IntAct=EBI-727477, EBI-1181072; CC P12830; Q9Y617: PSAT1; NbExp=3; IntAct=EBI-727477, EBI-709652; CC P12830; P49768: PSEN1; NbExp=2; IntAct=EBI-727477, EBI-297277; CC P12830; P50454: SERPINH1; NbExp=3; IntAct=EBI-727477, EBI-350723; CC P12830; Q02978: SLC25A11; NbExp=3; IntAct=EBI-727477, EBI-359174; CC P12830; P12931: SRC; NbExp=2; IntAct=EBI-727477, EBI-621482; CC P12830; P48775: TDO2; NbExp=3; IntAct=EBI-727477, EBI-743494; CC P12830; P37173: TGFBR2; NbExp=3; IntAct=EBI-727477, EBI-296151; CC P12830; Q9BT49: THAP7; NbExp=3; IntAct=EBI-727477, EBI-741350; CC P12830; Q68CZ2: TNS3; NbExp=2; IntAct=EBI-727477, EBI-1220488; CC P12830; Q9ULW0: TPX2; NbExp=3; IntAct=EBI-727477, EBI-1037322; CC P12830; Q96EF9: ZHX1-C8orf76; NbExp=3; IntAct=EBI-727477, EBI-25830993; CC P12830; Q9BQ29; NbExp=3; IntAct=EBI-727477, EBI-22013570; CC P12830; A0A0S2C3P2: cagA; Xeno; NbExp=3; IntAct=EBI-727477, EBI-55025805; CC P12830; Q9JIY2: Cbll1; Xeno; NbExp=21; IntAct=EBI-727477, EBI-7644904; CC P12830; P0DJM0: inlA; Xeno; NbExp=3; IntAct=EBI-727477, EBI-1035388; CC -!- SUBCELLULAR LOCATION: Cell junction, adherens junction CC {ECO:0000269|PubMed:18343367, ECO:0000269|PubMed:22294297, CC ECO:0000269|PubMed:27760340, ECO:0000269|PubMed:28169360}. Cell CC membrane {ECO:0000269|PubMed:19403558, ECO:0000269|PubMed:20859650, CC ECO:0000269|PubMed:28301459, ECO:0000269|PubMed:36309486}; Single-pass CC type I membrane protein. Endosome {ECO:0000269|PubMed:15689490}. Golgi CC apparatus, trans-Golgi network {ECO:0000269|PubMed:15689490}. Cytoplasm CC {ECO:0000269|PubMed:22294297}. Cell junction, desmosome CC {ECO:0000269|PubMed:25208567, ECO:0000269|PubMed:29999492, CC ECO:0000269|PubMed:33596089}. Note=Colocalizes with DLGAP5 at sites of CC cell-cell contact in intestinal epithelial cells. Anchored to actin CC microfilaments through association with alpha-, beta- and gamma- CC catenin. Sequential proteolysis induced by apoptosis or calcium influx, CC results in translocation from sites of cell-cell contact to the CC cytoplasm. Colocalizes with RAB11A endosomes during its transport from CC the Golgi apparatus to the plasma membrane. Recruited to desmosomes at CC the initial assembly phase and also accumulates progressively at mature CC desmosome cell-cell junctions (PubMed:25208567, PubMed:29999492). CC Localizes to cell-cell contacts as keratinocyte differentiation CC progresses (By similarity). {ECO:0000250|UniProtKB:P09803, CC ECO:0000269|PubMed:25208567, ECO:0000269|PubMed:29999492}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P12830-1; Sequence=Displayed; CC Name=2; CC IsoId=P12830-2; Sequence=VSP_055586; CC -!- TISSUE SPECIFICITY: Expressed in granuloma macrophages (at protein CC level) (PubMed:27760340). Expressed in the skin (at protein level) CC (PubMed:22294297). Expressed in the liver (PubMed:3263290). CC {ECO:0000269|PubMed:22294297, ECO:0000269|PubMed:27760340, CC ECO:0000269|PubMed:3263290}. CC -!- INDUCTION: Induced in the hours following cyclic mechanical strain in CC keratinocytes (PubMed:31835537). Expression is repressed by MACROD1 CC (PubMed:17893710). {ECO:0000269|PubMed:17893710, CC ECO:0000269|PubMed:31835537}. CC -!- DOMAIN: Three calcium ions are usually bound at the interface of each CC cadherin domain and strengthen the connections, imparting a strong CC curvature to the full-length ectodomain. {ECO:0000269|PubMed:2349235}. CC -!- PTM: During apoptosis or with calcium influx, cleaved by a membrane- CC bound metalloproteinase (ADAM10), PS1/gamma-secretase and caspase-3 CC (PubMed:10597309, PubMed:11076937, PubMed:11953314). Processing by the CC metalloproteinase, induced by calcium influx, causes disruption of CC cell-cell adhesion and the subsequent release of beta-catenin into the CC cytoplasm (PubMed:10597309). The residual membrane-tethered cleavage CC product is rapidly degraded via an intracellular proteolytic pathway CC (PubMed:10597309). Cleavage by caspase-3 releases the cytoplasmic tail CC resulting in disintegration of the actin microfilament system CC (PubMed:11076937). The gamma-secretase-mediated cleavage promotes CC disassembly of adherens junctions (PubMed:11953314). During development CC of the cochlear organ of Corti, cleavage by ADAM10 at adherens CC junctions promotes pillar cell separation (By similarity). CC {ECO:0000250|UniProtKB:P09803, ECO:0000269|PubMed:10597309, CC ECO:0000269|PubMed:11076937, ECO:0000269|PubMed:11953314}. CC -!- PTM: N-glycosylation at Asn-637 is essential for expression, folding CC and trafficking. Addition of bisecting N-acetylglucosamine by MGAT3 CC modulates its cell membrane location (PubMed:19403558). CC {ECO:0000269|PubMed:18491227, ECO:0000269|PubMed:19403558}. CC -!- PTM: Ubiquitinated by a SCF complex containing SKP2, which requires CC prior phosphorylation by CK1/CSNK1A1. Ubiquitinated by CBLL1/HAKAI, CC requires prior phosphorylation at Tyr-754. CC {ECO:0000269|PubMed:21283129, ECO:0000269|PubMed:22252131, CC ECO:0000269|PubMed:22770219}. CC -!- PTM: O-glycosylated. O-manosylated by TMTC1, TMTC2, TMTC3 or TMTC4. CC Thr-285 and Thr-509 are O-mannosylated by TMTC2 or TMTC4 but not TMTC1 CC or TMTC3. {ECO:0000250|UniProtKB:P09803}. CC -!- PTM: (Microbial infection) Cleaved by S.pyogenes SpeB protease; leading CC to its degradation (PubMed:23532847). Degradation by SpeB promotes CC bacterial translocation across the host epithelial barrier CC (PubMed:23532847). {ECO:0000269|PubMed:23532847}. CC -!- DISEASE: Diffuse gastric and lobular breast cancer syndrome (DGLBC) CC [MIM:137215]: A cancer predisposition syndrome with increased CC susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a CC malignant disease characterized by poorly differentiated infiltrating CC lesions resulting in thickening of the stomach. Malignant tumors start CC in the stomach, can spread to the esophagus or the small intestine, and CC can extend through the stomach wall to nearby lymph nodes and organs. CC It also can metastasize to other parts of the body. In addition to CC gastric cancer, most female mutation carriers develop lobular carcinoma CC of the breast. {ECO:0000269|PubMed:10319582, CC ECO:0000269|PubMed:12216071, ECO:0000269|PubMed:9537325}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. Heterozygous CDH1 germline mutations are CC responsible for familial cases of diffuse gastric cancer. Somatic CC mutations has also been found in patients with sporadic diffuse gastric CC cancer and lobular breast cancer. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. Note=Disease susceptibility is associated with CC variants affecting the gene represented in this entry. CC -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer CC defines malignancies originating from ovarian tissue. Although many CC histologic types of ovarian tumors have been described, epithelial CC ovarian carcinoma is the most common form. Ovarian cancers are often CC asymptomatic and the recognized signs and symptoms, even of late-stage CC disease, are vague. Consequently, most patients are diagnosed with CC advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast CC cancer that begins in the milk-producing glands (lobules) of the CC breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in CC this entry may be involved in disease pathogenesis. CC -!- DISEASE: Blepharocheilodontic syndrome 1 (BCDS1) [MIM:119580]: A form CC of blepharocheilodontic syndrome, a rare autosomal dominant disorder. CC It is characterized by lower eyelid ectropion, upper eyelid CC distichiasis, euryblepharon, bilateral cleft lip and palate, and CC features of ectodermal dysplasia, including hair anomalies, conical CC teeth and tooth agenesis. An additional rare manifestation is CC imperforate anus. There is considerable phenotypic variability among CC affected individuals. {ECO:0000269|PubMed:28301459}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- MISCELLANEOUS: May play a role in blister formation in Pemphigus CC vulgaris patients, expression is lost at sites of cell-cell contact CC between the basal and suprabasal layers in blisters and immediately CC adjacent to blisters. {ECO:0000269|PubMed:22294297}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA61259.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/166/CDH1"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=E-cadherin entry; CC URL="https://en.wikipedia.org/wiki/E-cadherin"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Z13009; CAA78353.1; -; mRNA. DR EMBL; Z18923; CAA79356.1; -; mRNA. DR EMBL; L08599; AAA61259.1; ALT_FRAME; mRNA. DR EMBL; AB025105; BAA88956.1; -; mRNA. DR EMBL; AK290012; BAF82701.1; -; mRNA. DR EMBL; AK312551; BAG35448.1; -; mRNA. DR EMBL; DQ090940; AAY68225.1; -; Genomic_DNA. DR EMBL; AC099314; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471092; EAW83243.1; -; Genomic_DNA. DR EMBL; CH471092; EAW83244.1; -; Genomic_DNA. DR EMBL; L34545; AAA21764.1; -; Genomic_DNA. DR EMBL; D49685; BAA08537.1; -; Genomic_DNA. DR EMBL; Z35402; CAA84586.1; -; Genomic_DNA. DR EMBL; Z35403; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35404; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35405; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35406; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35407; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35408; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35409; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35410; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35411; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35412; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35413; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35414; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35415; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; X12790; CAA31279.1; -; mRNA. DR EMBL; X52279; CAA36522.1; -; mRNA. DR EMBL; S72492; AAD14108.1; -; Genomic_DNA. DR EMBL; S72397; AAD14108.1; JOINED; Genomic_DNA. DR EMBL; S72491; AAD14108.1; JOINED; Genomic_DNA. DR CCDS; CCDS10869.1; -. [P12830-1] DR CCDS; CCDS82005.1; -. [P12830-2] DR PIR; S37654; IJHUCE. DR RefSeq; NP_001304113.1; NM_001317184.2. [P12830-2] DR RefSeq; NP_001304114.1; NM_001317185.1. DR RefSeq; NP_001304115.1; NM_001317186.1. DR RefSeq; NP_004351.1; NM_004360.5. [P12830-1] DR PDB; 1O6S; X-ray; 1.80 A; B=156-255. DR PDB; 2O72; X-ray; 2.00 A; A=155-367. DR PDB; 2OMT; X-ray; 2.00 A; B=156-255. DR PDB; 2OMU; X-ray; 1.80 A; B=156-255. DR PDB; 2OMV; X-ray; 1.90 A; B=156-255. DR PDB; 2OMX; X-ray; 1.70 A; B=156-258. DR PDB; 2OMY; X-ray; 1.70 A; B=156-254. DR PDB; 2OMZ; X-ray; 1.60 A; B=156-254. DR PDB; 3FF7; X-ray; 1.80 A; A/B=155-253. DR PDB; 3FF8; X-ray; 2.00 A; A/B=155-254. DR PDB; 3L6X; X-ray; 2.40 A; B=756-773. DR PDB; 3L6Y; X-ray; 3.00 A; B/D/F=756-773. DR PDB; 4ZT1; X-ray; 1.92 A; A/B=157-367. DR PDB; 4ZTE; X-ray; 2.13 A; A/B=157-367. DR PDB; 6CXY; X-ray; 2.20 A; C=155-371. DR PDB; 6OLE; EM; 3.10 A; y=693-730. DR PDB; 6OLF; EM; 3.90 A; y=693-730. DR PDB; 6OLG; EM; 3.40 A; A=693-730. DR PDB; 6VEL; X-ray; 2.65 A; C=155-371. DR PDB; 7STZ; X-ray; 2.95 A; C/D=155-698. DR PDB; 8H62; X-ray; 1.91 A; B=155-367. DR PDBsum; 1O6S; -. DR PDBsum; 2O72; -. DR PDBsum; 2OMT; -. DR PDBsum; 2OMU; -. DR PDBsum; 2OMV; -. DR PDBsum; 2OMX; -. DR PDBsum; 2OMY; -. DR PDBsum; 2OMZ; -. DR PDBsum; 3FF7; -. DR PDBsum; 3FF8; -. DR PDBsum; 3L6X; -. DR PDBsum; 3L6Y; -. DR PDBsum; 4ZT1; -. DR PDBsum; 4ZTE; -. DR PDBsum; 6CXY; -. DR PDBsum; 6OLE; -. DR PDBsum; 6OLF; -. DR PDBsum; 6OLG; -. DR PDBsum; 6VEL; -. DR PDBsum; 7STZ; -. DR PDBsum; 8H62; -. DR AlphaFoldDB; P12830; -. DR EMDB; EMD-25883; -. DR EMDB; EMD-25884; -. DR EMDB; EMD-25886; -. DR EMDB; EMD-25892; -. DR SMR; P12830; -. DR BioGRID; 107434; 777. DR CORUM; P12830; -. DR DIP; DIP-477N; -. DR ELM; P12830; -. DR FunCoup; P12830; 811. DR IntAct; P12830; 146. DR MINT; P12830; -. DR STRING; 9606.ENSP00000261769; -. DR BindingDB; P12830; -. DR ChEMBL; CHEMBL2321609; -. DR TCDB; 8.A.204.1.1; the cadhesin (cdh) family. DR UniLectin; P12830; -. DR GlyCosmos; P12830; 13 sites, No reported glycans. DR GlyGen; P12830; 16 sites, 2 O-linked glycans (3 sites). DR iPTMnet; P12830; -. DR PhosphoSitePlus; P12830; -. DR SwissPalm; P12830; -. DR BioMuta; CDH1; -. DR DMDM; 399166; -. DR CPTAC; CPTAC-1599; -. DR CPTAC; CPTAC-5772; -. DR CPTAC; CPTAC-5773; -. DR CPTAC; non-CPTAC-5366; -. DR CPTAC; non-CPTAC-5367; -. DR CPTAC; non-CPTAC-5370; -. DR CPTAC; non-CPTAC-5541; -. DR CPTAC; non-CPTAC-5542; -. DR jPOST; P12830; -. DR MassIVE; P12830; -. DR PaxDb; 9606-ENSP00000261769; -. DR PeptideAtlas; P12830; -. DR ProteomicsDB; 52879; -. [P12830-1] DR ProteomicsDB; 84533; -. DR Pumba; P12830; -. DR TopDownProteomics; P12830-2; -. [P12830-2] DR ABCD; P12830; 29 sequenced antibodies. DR Antibodypedia; 1347; 3254 antibodies from 63 providers. DR CPTC; P12830; 4 antibodies. DR DNASU; 999; -. DR Ensembl; ENST00000261769.10; ENSP00000261769.4; ENSG00000039068.21. [P12830-1] DR Ensembl; ENST00000422392.6; ENSP00000414946.2; ENSG00000039068.21. [P12830-2] DR GeneID; 999; -. DR KEGG; hsa:999; -. DR MANE-Select; ENST00000261769.10; ENSP00000261769.4; NM_004360.5; NP_004351.1. DR UCSC; uc002ewg.2; human. [P12830-1] DR AGR; HGNC:1748; -. DR CIViC; 999; 4 evidence items across 4 molecular profiles. DR ClinPGx; PA26282; -. DR CTD; 999; -. DR DisGeNET; 999; -. DR GeneCards; CDH1; -. DR GeneReviews; CDH1; -. DR HGNC; HGNC:1748; CDH1. DR HPA; ENSG00000039068; Tissue enhanced (parathyroid). DR MalaCards; CDH1; -. DR MIM; 119580; phenotype. DR MIM; 137215; phenotype. DR MIM; 167000; phenotype. DR MIM; 192090; gene. DR MIM; 608089; phenotype. DR OpenTargets; ENSG00000039068; -. DR Orphanet; 1997; Blepharo-cheilo-odontic syndrome. DR Orphanet; 199306; Cleft lip/palate. DR Orphanet; 1331; Familial prostate cancer. DR Orphanet; 227535; Hereditary breast cancer. DR Orphanet; 26106; Hereditary diffuse gastric cancer. DR VEuPathDB; HostDB:ENSG00000039068; -. DR eggNOG; KOG3594; Eukaryota. DR GeneTree; ENSGT00940000157175; -. DR HOGENOM; CLU_005284_2_1_1; -. DR InParanoid; P12830; -. DR OrthoDB; 6079678at2759; -. DR PAN-GO; P12830; 8 GO annotations based on evolutionary models. DR PhylomeDB; P12830; -. DR PathwayCommons; P12830; -. DR Reactome; R-HSA-1474228; Degradation of the extracellular matrix. DR Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell. DR Reactome; R-HSA-216083; Integrin cell surface interactions. DR Reactome; R-HSA-351906; Apoptotic cleavage of cell adhesion proteins. DR Reactome; R-HSA-418990; Adherens junctions interactions. DR Reactome; R-HSA-5626467; RHO GTPases activate IQGAPs. DR Reactome; R-HSA-8876493; InlA-mediated entry of Listeria monocytogenes into host cells. DR Reactome; R-HSA-9764561; Regulation of CDH1 Function. DR Reactome; R-HSA-9764562; Regulation of CDH1 mRNA translation by microRNAs. DR Reactome; R-HSA-9766229; Degradation of CDH1. DR Reactome; R-HSA-9768727; Regulation of CDH1 posttranslational processing and trafficking to plasma membrane. DR Reactome; R-HSA-9823730; Formation of definitive endoderm. DR Reactome; R-HSA-9856649; Transcriptional and post-translational regulation of MITF-M expression and activity. DR Reactome; R-HSA-9926550; Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition. DR Reactome; R-HSA-9927432; Developmental Lineage of Mammary Gland Myoepithelial Cells. DR Reactome; R-HSA-9938206; Developmental Lineage of Mammary Stem Cells. DR SignaLink; P12830; -. DR SIGNOR; P12830; -. DR Agora; ENSG00000039068; -. DR BioGRID-ORCS; 999; 47 hits in 1173 CRISPR screens. DR ChiTaRS; CDH1; human. DR EvolutionaryTrace; P12830; -. DR GeneWiki; CDH1_(gene); -. DR GenomeRNAi; 999; -. DR Pharos; P12830; Tbio. DR PRO; PR:P12830; -. DR Proteomes; UP000005640; Chromosome 16. DR RNAct; P12830; protein. DR Bgee; ENSG00000039068; Expressed in jejunal mucosa and 158 other cell types or tissues. DR ExpressionAtlas; P12830; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IDA:BHF-UCL. DR GO; GO:0005912; C:adherens junction; IDA:UniProtKB. DR GO; GO:0043296; C:apical junction complex; IDA:UniProtKB. DR GO; GO:0016342; C:catenin complex; IDA:BHF-UCL. DR GO; GO:0030054; C:cell junction; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB. DR GO; GO:0030057; C:desmosome; IDA:UniProtKB. DR GO; GO:0031901; C:early endosome membrane; TAS:Reactome. DR GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome. DR GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0016600; C:flotillin complex; IDA:UniProtKB. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005796; C:Golgi lumen; TAS:Reactome. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0030027; C:lamellipodium; IDA:UniProtKB. DR GO; GO:0016328; C:lateral plasma membrane; IDA:BHF-UCL. DR GO; GO:0005765; C:lysosomal membrane; TAS:Reactome. DR GO; GO:0016020; C:membrane; IDA:BHF-UCL. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098794; C:postsynapse; IEA:Ensembl. DR GO; GO:0005802; C:trans-Golgi network; IMP:BHF-UCL. DR GO; GO:0030506; F:ankyrin binding; IPI:BHF-UCL. DR GO; GO:0008013; F:beta-catenin binding; IDA:BHF-UCL. DR GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL. DR GO; GO:0005509; F:calcium ion binding; IEA:InterPro. DR GO; GO:0098631; F:cell adhesion mediator activity; IDA:UniProt. DR GO; GO:0050839; F:cell adhesion molecule binding; IPI:UniProtKB. DR GO; GO:0045295; F:gamma-catenin binding; IPI:BHF-UCL. DR GO; GO:0032794; F:GTPase activating protein binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:1990782; F:protein tyrosine kinase binding; IEA:Ensembl. DR GO; GO:0034332; P:adherens junction organization; IMP:UniProtKB. DR GO; GO:0016339; P:calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules; IBA:GO_Central. DR GO; GO:0016477; P:cell migration; IBA:GO_Central. DR GO; GO:0000902; P:cell morphogenesis; IBA:GO_Central. DR GO; GO:0098609; P:cell-cell adhesion; IDA:BHF-UCL. DR GO; GO:0044331; P:cell-cell adhesion mediated by cadherin; IDA:BHF-UCL. DR GO; GO:0007043; P:cell-cell junction assembly; IBA:GO_Central. DR GO; GO:0071681; P:cellular response to indole-3-methanol; IDA:UniProtKB. DR GO; GO:0071285; P:cellular response to lithium ion; IDA:UniProtKB. DR GO; GO:0002159; P:desmosome assembly; IMP:UniProtKB. DR GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; NAS:UniProtKB. DR GO; GO:0030517; P:negative regulation of axon extension; IEA:Ensembl. DR GO; GO:0030336; P:negative regulation of cell migration; IMP:ARUK-UCL. DR GO; GO:0022408; P:negative regulation of cell-cell adhesion; IMP:UniProtKB. DR GO; GO:0031175; P:neuron projection development; IEA:Ensembl. DR GO; GO:0021983; P:pituitary gland development; IEA:Ensembl. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:BHF-UCL. DR GO; GO:0042307; P:positive regulation of protein import into nucleus; IDA:BHF-UCL. DR GO; GO:1903829; P:positive regulation of protein localization; IMP:UniProtKB. DR GO; GO:0072659; P:protein localization to plasma membrane; IDA:BHF-UCL. DR GO; GO:0010468; P:regulation of gene expression; IMP:UniProtKB. DR GO; GO:0099576; P:regulation of protein catabolic process at postsynapse, modulating synaptic transmission; IEA:Ensembl. DR GO; GO:0140459; P:response to Gram-positive bacterium; IEA:Ensembl. DR GO; GO:0071503; P:response to heparin; IEA:Ensembl. DR GO; GO:0009636; P:response to toxic substance; IEA:Ensembl. DR GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0007416; P:synapse assembly; IBA:GO_Central. DR CDD; cd00031; CA_like; 1. DR CDD; cd11304; Cadherin_repeat; 3. DR FunFam; 2.60.40.60:FF:000011; Cadherin 1; 1. DR FunFam; 2.60.40.60:FF:000191; Cadherin 1; 1. DR FunFam; 2.60.40.60:FF:000019; Cadherin 2; 1. DR FunFam; 2.60.40.60:FF:000022; Cadherin 2; 1. DR FunFam; 2.60.40.60:FF:000027; Cadherin 2; 1. DR FunFam; 4.10.900.10:FF:000001; Cadherin 2; 1. DR FunFam; 2.60.40.60:FF:000031; Cadherin 3; 1. DR Gene3D; 2.60.40.60; Cadherins; 6. DR Gene3D; 4.10.900.10; TCF3-CBD (Catenin binding domain); 1. DR InterPro; IPR039808; Cadherin. DR InterPro; IPR002126; Cadherin-like_dom. DR InterPro; IPR015919; Cadherin-like_sf. DR InterPro; IPR020894; Cadherin_CS. DR InterPro; IPR014868; Cadherin_pro_dom. DR InterPro; IPR000233; Cadherin_Y-type_LIR. DR InterPro; IPR027397; Catenin-bd_sf. DR PANTHER; PTHR24027:SF319; CADHERIN-1; 1. DR PANTHER; PTHR24027; CADHERIN-23; 1. DR Pfam; PF01049; CADH_Y-type_LIR; 1. DR Pfam; PF00028; Cadherin; 5. DR Pfam; PF08758; Cadherin_pro; 1. DR PRINTS; PR00205; CADHERIN. DR SMART; SM00112; CA; 4. DR SMART; SM01055; Cadherin_pro; 1. DR SUPFAM; SSF49313; Cadherin-like; 6. DR PROSITE; PS00232; CADHERIN_1; 3. DR PROSITE; PS50268; CADHERIN_2; 5. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Calcium; Cell adhesion; Cell junction; KW Cell membrane; Cleavage on pair of basic residues; Cytoplasm; KW Direct protein sequencing; Disease variant; Disulfide bond; KW Ectodermal dysplasia; Endosome; Glycoprotein; Golgi apparatus; Membrane; KW Metal-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Signal; Transmembrane; Transmembrane helix; KW Ubl conjugation. FT SIGNAL 1..22 FT /evidence="ECO:0000255" FT PROPEP 23..154 FT /evidence="ECO:0000255" FT /id="PRO_0000003715" FT CHAIN 155..882 FT /note="Cadherin-1" FT /id="PRO_0000003716" FT CHAIN 701..882 FT /note="E-Cad/CTF1" FT /id="PRO_0000236067" FT CHAIN 732..882 FT /note="E-Cad/CTF2" FT /id="PRO_0000236068" FT CHAIN 751..882 FT /note="E-Cad/CTF3" FT /id="PRO_0000236069" FT TOPO_DOM 155..709 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 710..730 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 731..882 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 155..262 FT /note="Cadherin 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 263..375 FT /note="Cadherin 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 376..486 FT /note="Cadherin 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 487..593 FT /note="Cadherin 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 594..697 FT /note="Cadherin 5" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT REGION 747..767 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 758..769 FT /note="Required for binding CTNND1 and PSEN1" FT REGION 811..882 FT /note="Required for binding alpha, beta and gamma catenins" FT COMPBIAS 755..767 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 257 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT BINDING 257 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT BINDING 288 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT SITE 364..365 FT /note="Cleavage; by S.pyogenes SpeB" FT /evidence="ECO:0000269|PubMed:23532847" FT SITE 700..701 FT /note="Cleavage; by a metalloproteinase" FT SITE 731..732 FT /note="Cleavage; by gamma-secretase/PS1" FT SITE 750..751 FT /note="Cleavage; by caspase-3" FT MOD_RES 753 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:22252131" FT MOD_RES 754 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:22252131" FT MOD_RES 755 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:22252131" FT MOD_RES 770 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 793 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 838 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT MOD_RES 840 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT MOD_RES 846 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 280 FT /note="O-linked (Man...) serine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 285 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 358 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 470 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 472 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 509 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 558 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18491227" FT CARBOHYD 570 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18491227" FT CARBOHYD 576 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 578 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 580 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 622 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18491227" FT CARBOHYD 637 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18491227" FT DISULFID 163 FT /note="Interchain" FT VAR_SEQ 380..440 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.5" FT /id="VSP_055586" FT VARIANT 72 FT /note="D -> N (in dbSNP:rs35606263)" FT /id="VAR_048500" FT VARIANT 123 FT /note="H -> Y (in a gastric cancer sample; FT dbSNP:rs1555514482)" FT /evidence="ECO:0000269|PubMed:9744472" FT /id="VAR_001306" FT VARIANT 193 FT /note="T -> P (in a diffuse gastric cancer sample; FT dbSNP:rs1597891014)" FT /evidence="ECO:0000269|PubMed:8797891" FT /id="VAR_001307" FT VARIANT 244 FT /note="D -> G (in DGLBC; likely benign; FT dbSNP:rs1064794231)" FT /evidence="ECO:0000269|PubMed:10319582" FT /id="VAR_008712" FT VARIANT 254 FT /note="D -> Y (in BCDS1; abolishes protein abundance; loss FT of cell membrane localization; dbSNP:rs1555515445)" FT /evidence="ECO:0000269|PubMed:28301459" FT /id="VAR_079392" FT VARIANT 257 FT /note="D -> V (in BCDS1; slightly decreases protein FT abundance; loss of cell membrane localization; FT dbSNP:rs1555515446)" FT /evidence="ECO:0000269|PubMed:28301459" FT /id="VAR_079393" FT VARIANT 270 FT /note="S -> A (in dbSNP:rs587776399)" FT /evidence="ECO:0000269|PubMed:11705864" FT /id="VAR_013970" FT VARIANT 274..277 FT /note="Missing (found in gastric carcinoma cell lines)" FT /evidence="ECO:0000269|PubMed:8127895" FT /id="VAR_001308" FT VARIANT 282 FT /note="M -> I (in a breast cancer sample; somatic mutation; FT dbSNP:rs200932258)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033026" FT VARIANT 315 FT /note="N -> S (in lobular breast carcinoma)" FT /evidence="ECO:0000269|PubMed:7961105" FT /id="VAR_001309" FT VARIANT 336 FT /note="E -> D (in DGLBC; likely pathogenic; FT dbSNP:rs267606712)" FT /evidence="ECO:0000269|PubMed:9537325" FT /id="VAR_001310" FT VARIANT 340 FT /note="T -> A (found in gastric and colorectal cancer FT samples; cells exhibited decreased aggregation increased FT invasiveness and non-uniform migration in vitro compared to FT cells transfected with wild-type sequence; FT dbSNP:rs116093741)" FT /evidence="ECO:0000269|PubMed:10896919, FT ECO:0000269|PubMed:11968083, ECO:0000269|PubMed:12588804" FT /id="VAR_013971" FT VARIANT 370 FT /note="D -> A (in a diffuse gastric cancer sample; FT dbSNP:rs2152132676)" FT /evidence="ECO:0000269|PubMed:8033105" FT /id="VAR_001311" FT VARIANT 393 FT /note="I -> N (in dbSNP:rs34466743)" FT /id="VAR_048501" FT VARIANT 400 FT /note="Missing (in a gastric carcinoma sample; loss of FT heterozygosity)" FT /evidence="ECO:0000269|PubMed:9045944" FT /id="VAR_001312" FT VARIANT 418..423 FT /note="Missing (in a gastric carcinoma sample)" FT /evidence="ECO:0000269|PubMed:9045944" FT /id="VAR_001313" FT VARIANT 454 FT /note="Missing (in BCDS1; decreases protein abundance; loss FT of cell membrane localization)" FT /evidence="ECO:0000269|PubMed:28301459" FT /id="VAR_079394" FT VARIANT 463 FT /note="E -> Q (in a gastric carcinoma sample; FT dbSNP:rs1960961009)" FT /evidence="ECO:0000269|PubMed:9744472" FT /id="VAR_001314" FT VARIANT 470 FT /note="T -> I (in dbSNP:rs370864592)" FT /evidence="ECO:0000269|PubMed:9537325" FT /id="VAR_001315" FT VARIANT 473 FT /note="V -> D (in a diffuse gastric cancer sample; FT dbSNP:rs2152134881)" FT /evidence="ECO:0000269|PubMed:8033105" FT /id="VAR_001317" FT VARIANT 473 FT /note="V -> I (in dbSNP:rs36087757)" FT /id="VAR_048502" FT VARIANT 478 FT /note="L -> P (in dbSNP:rs35520415)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_023357" FT VARIANT 487 FT /note="V -> A (in DGLBC; dbSNP:rs1960965342)" FT /evidence="ECO:0000269|PubMed:10319582" FT /id="VAR_008713" FT VARIANT 592 FT /note="A -> T (in dbSNP:rs35187787)" FT /evidence="ECO:0000269|PubMed:11562785, FT ECO:0000269|PubMed:8985087" FT /id="VAR_001318" FT VARIANT 598 FT /note="R -> Q (in a gastric cancer sample; FT dbSNP:rs780759537)" FT /evidence="ECO:0000269|PubMed:9744472" FT /id="VAR_001319" FT VARIANT 617 FT /note="A -> T (detected in an endometrial cancer sample; FT loss of heterozygosity; cells exhibited an intermediate FT phenotype concerning aggregation invasiveness and migration FT in vitro compared to cells transfected with wild-type FT sequence; dbSNP:rs33935154)" FT /evidence="ECO:0000269|PubMed:12588804, FT ECO:0000269|PubMed:8075649, ECO:0000269|Ref.7" FT /id="VAR_001320" FT VARIANT 630 FT /note="L -> V (in dbSNP:rs2276331)" FT /id="VAR_021868" FT VARIANT 634 FT /note="A -> V (found in a gastric cancer sample; cells FT exhibited decreased aggregation increased invasiveness and FT non-uniform migration in vitro compared to cells FT transfected with wild-type sequence; dbSNP:rs121964878)" FT /evidence="ECO:0000269|PubMed:12588804" FT /id="VAR_055431" FT VARIANT 695 FT /note="C -> R (in dbSNP:rs9282655)" FT /id="VAR_021869" FT VARIANT 711 FT /note="L -> V (detected in an endometrial cancer sample; FT dbSNP:rs121964871)" FT /evidence="ECO:0000269|PubMed:8075649" FT /id="VAR_001321" FT VARIANT 777 FT /note="D -> N (in dbSNP:rs372989292)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033027" FT VARIANT 832 FT /note="V -> M (in DGLBC; benign; dbSNP:rs35572355)" FT /evidence="ECO:0000269|PubMed:12216071, ECO:0000269|Ref.7" FT /id="VAR_023358" FT VARIANT 838 FT /note="S -> G (in an ovarian carcinoma sample; somatic FT mutation; loss of heterozygosity; dbSNP:rs121964872)" FT /evidence="ECO:0000269|PubMed:8075649" FT /id="VAR_001322" FT VARIANT 880 FT /note="E -> K (in dbSNP:rs34507583)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_023359" FT MUTAGEN 156 FT /note="W->A,S: No longer binds L.monocytogenes InlA." FT /evidence="ECO:0000269|PubMed:12526809" FT MUTAGEN 156 FT /note="W->D: Protein is partially unfolded, no longer binds FT L.monocytogenes InlA." FT /evidence="ECO:0000269|PubMed:12526809" FT MUTAGEN 170 FT /note="P->A,E,V: No longer binds L.monocytogenes InlA." FT /evidence="ECO:0000269|PubMed:12526809" FT MUTAGEN 170 FT /note="P->E: No longer adheres to L.monocytogenes InlA FT coated beads, nor do cells take up InlA coated beads." FT /evidence="ECO:0000269|PubMed:10406800" FT MUTAGEN 175 FT /note="L->D: Reduces localization to desmosome cell-cell FT junctions. Also reduces the localization of DSG2 and DSP to FT desmosome cell-cell junctions." FT /evidence="ECO:0000269|PubMed:29999492" FT MUTAGEN 637 FT /note="N->Q: CDH1 becomes a substrate for ERAD and is FT retro-translocated from ER to cytoplasm." FT /evidence="ECO:0000269|PubMed:18491227" FT MUTAGEN 754 FT /note="Y->F: Abolishes binding to CBLL1." FT /evidence="ECO:0000269|PubMed:22252131" FT MUTAGEN 759..761 FT /note="GGG->AAA: Binds to CTNNB1 but abolishes interaction FT of CTNNB1 with PSEN1. Abolishes gamma-secretase cleavage." FT /evidence="ECO:0000269|PubMed:11953314, FT ECO:0000269|PubMed:16126725" FT CONFLICT 10 FT /note="A -> G (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 29 FT /note="H -> L (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 47 FT /note="E -> R (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 70..71 FT /note="SL -> P (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 483 FT /note="A -> G (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 530 FT /note="A -> R (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 543 FT /note="S -> F (in Ref. 2; CAA79356)" FT /evidence="ECO:0000305" FT CONFLICT 615 FT /note="I -> H (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 634..636 FT /note="ASA -> RVP (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 868 FT /note="R -> P (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 882 FT /note="D -> H (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT STRAND 163..166 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 169..177 FT /evidence="ECO:0007829|PDB:2OMZ" FT HELIX 181..184 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 189..195 FT /evidence="ECO:0007829|PDB:2OMZ" FT TURN 196..198 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 199..201 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 204..207 FT /evidence="ECO:0007829|PDB:2OMZ" FT TURN 209..211 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 213..216 FT /evidence="ECO:0007829|PDB:2OMZ" FT TURN 222..224 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 227..235 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 241..243 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 246..253 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 261..263 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 265..272 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 280..283 FT /evidence="ECO:0007829|PDB:8H62" FT TURN 292..294 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 301..309 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 316..319 FT /evidence="ECO:0007829|PDB:8H62" FT TURN 321..323 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 325..328 FT /evidence="ECO:0007829|PDB:8H62" FT TURN 335..337 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 340..348 FT /evidence="ECO:0007829|PDB:8H62" FT HELIX 350..352 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 356..366 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 374..384 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 394..396 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 407..409 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 410..417 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 423..428 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 429..432 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 433..440 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 444..446 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 448..460 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 470..477 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 485..498 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 504..507 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 522..527 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 533..535 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 537..539 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 541..544 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 553..555 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 557..568 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 571..573 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 576..586 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 594..596 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 599..607 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 610..615 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 622..625 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 627..633 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 635..637 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 638..644 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 648..656 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 660..673 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 675..691 FT /evidence="ECO:0007829|PDB:7STZ" FT HELIX 769..771 FT /evidence="ECO:0007829|PDB:3L6X" SQ SEQUENCE 882 AA; 97456 MW; E427118043A13C67 CRC64; MGPWSRSLSA LLLLLQVSSW LCQEPEPCHP GFDAESYTFT VPRRHLERGR VLGRVNFEDC TGRQRTAYFS LDTRFKVGTD GVITVKRPLR FHNPQIHFLV YAWDSTYRKF STKVTLNTVG HHHRPPPHQA SVSGIQAELL TFPNSSPGLR RQKRDWVIPP ISCPENEKGP FPKNLVQIKS NKDKEGKVFY SITGQGADTP PVGVFIIERE TGWLKVTEPL DRERIATYTL FSHAVSSNGN AVEDPMEILI TVTDQNDNKP EFTQEVFKGS VMEGALPGTS VMEVTATDAD DDVNTYNAAI AYTILSQDPE LPDKNMFTIN RNTGVISVVT TGLDRESFPT YTLVVQAADL QGEGLSTTAT AVITVTDTND NPPIFNPTTY KGQVPENEAN VVITTLKVTD ADAPNTPAWE AVYTILNDDG GQFVVTTNPV NNDGILKTAK GLDFEAKQQY ILHVAVTNVV PFEVSLTTST ATVTVDVLDV NEAPIFVPPE KRVEVSEDFG VGQEITSYTA QEPDTFMEQK ITYRIWRDTA NWLEINPDTG AISTRAELDR EDFEHVKNST YTALIIATDN GSPVATGTGT LLLILSDVND NAPIPEPRTI FFCERNPKPQ VINIIDADLP PNTSPFTAEL THGASANWTI QYNDPTQESI ILKPKMALEV GDYKINLKLM DNQNKDQVTT LEVSVCDCEG AAGVCRKAQP VEAGLQIPAI LGILGGILAL LILILLLLLF LRRRAVVKEP LLPPEDDTRD NVYYYDEEGG GEEDQDFDLS QLHRGLDARP EVTRNDVAPT LMSVPRYLPR PANPDEIGNF IDENLKAADT DPTAPPYDSL LVFDYEGSGS EAASLSSLNS SESDKDQDYD YLNEWGNRFK KLADMYGGGE DD // ID CAMKV_HUMAN Reviewed; 501 AA. AC Q8NCB2; A6NFD4; Q6FIB8; Q8NBS8; Q8NC85; Q8NDU4; Q8WTT8; Q9BQC9; Q9H0Q5; DT 19-SEP-2006, integrated into UniProtKB/Swiss-Prot. DT 19-SEP-2006, sequence version 2. DT 28-JAN-2026, entry version 178. DE RecName: Full=CaM kinase-like vesicle-associated protein; GN Name=CAMKV; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Retinoblastoma, and Teratocarcinoma; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RX PubMed=11230166; DOI=10.1101/gr.gr1547r; RA Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S., RA Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J., RA Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W., RA Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B., RA Klein M., Poustka A.; RT "Towards a catalog of human genes and proteins: sequencing and analysis of RT 500 novel complete protein coding human cDNAs."; RL Genome Res. 11:422-435(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT CYS-491. RC TISSUE=Brain, and Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP VARIANTS [LARGE SCALE ANALYSIS] TRP-40; SER-60; TRP-274; ASP-279 AND RP LEU-472. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Does not appear to have detectable kinase activity. CC -!- COFACTOR: CC Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Evidence={ECO:0000250}; CC -!- SUBUNIT: Interacts with calmodulin, in the presence of calcium. CC {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Peripheral membrane CC protein {ECO:0000250}. Cytoplasmic vesicle membrane {ECO:0000250}; CC Peripheral membrane protein {ECO:0000250}. Note=Predominantly observed CC in association with the plasma membrane of soma and in neurites, both CC axons and dendrites. May be associated with vesicular structures (By CC similarity). {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q8NCB2-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8NCB2-2; Sequence=VSP_020600; CC Name=3; CC IsoId=Q8NCB2-3; Sequence=VSP_020601; CC -!- DOMAIN: The protein kinase domain is predicted to be catalytically CC inactive. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK074856; BAC11248.1; -; mRNA. DR EMBL; AK074899; BAC11278.1; -; mRNA. DR EMBL; AK075294; BAC11528.1; -; mRNA. DR EMBL; AL136697; CAB66632.1; -; mRNA. DR EMBL; CR533508; CAG38539.1; -; mRNA. DR EMBL; AL833943; CAD38798.2; -; Transcribed_RNA. DR EMBL; AC105935; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471055; EAW65027.1; -; Genomic_DNA. DR EMBL; BC000497; AAH00497.1; -; mRNA. DR EMBL; BC001921; AAH01921.1; -; mRNA. DR EMBL; BC005828; AAH05828.1; -; mRNA. DR EMBL; BC017363; AAH17363.1; -; mRNA. DR EMBL; BC019256; AAH19256.1; -; mRNA. DR CCDS; CCDS33762.1; -. [Q8NCB2-1] DR CCDS; CCDS82776.1; -. [Q8NCB2-3] DR RefSeq; NP_001307076.1; NM_001320147.2. [Q8NCB2-3] DR RefSeq; NP_076951.2; NM_024046.5. [Q8NCB2-1] DR AlphaFoldDB; Q8NCB2; -. DR SMR; Q8NCB2; -. DR BioGRID; 122482; 114. DR FunCoup; Q8NCB2; 552. DR IntAct; Q8NCB2; 138. DR MINT; Q8NCB2; -. DR STRING; 9606.ENSP00000419195; -. DR GlyCosmos; Q8NCB2; 4 sites, 1 glycan. DR GlyGen; Q8NCB2; 6 sites, 1 O-linked glycan (5 sites). DR iPTMnet; Q8NCB2; -. DR PhosphoSitePlus; Q8NCB2; -. DR SwissPalm; Q8NCB2; -. DR BioMuta; CAMKV; -. DR DMDM; 115311319; -. DR jPOST; Q8NCB2; -. DR MassIVE; Q8NCB2; -. DR PaxDb; 9606-ENSP00000419195; -. DR PeptideAtlas; Q8NCB2; -. DR ProteomicsDB; 72868; -. [Q8NCB2-1] DR ProteomicsDB; 72869; -. [Q8NCB2-2] DR ProteomicsDB; 72870; -. [Q8NCB2-3] DR Pumba; Q8NCB2; -. DR Antibodypedia; 2091; 210 antibodies from 29 providers. DR DNASU; 79012; -. DR Ensembl; ENST00000296471.11; ENSP00000296471.6; ENSG00000164076.18. [Q8NCB2-2] DR Ensembl; ENST00000477224.6; ENSP00000419195.1; ENSG00000164076.18. [Q8NCB2-1] DR Ensembl; ENST00000488336.5; ENSP00000418809.1; ENSG00000164076.18. [Q8NCB2-3] DR Ensembl; ENST00000620470.4; ENSP00000484045.1; ENSG00000164076.18. [Q8NCB2-2] DR GeneID; 79012; -. DR KEGG; hsa:79012; -. DR MANE-Select; ENST00000477224.6; ENSP00000419195.1; NM_024046.5; NP_076951.2. DR UCSC; uc003cxt.2; human. [Q8NCB2-1] DR AGR; HGNC:28788; -. DR ClinPGx; PA142672205; -. DR CTD; 79012; -. DR DisGeNET; 79012; -. DR GeneCards; CAMKV; -. DR HGNC; HGNC:28788; CAMKV. DR HPA; ENSG00000164076; Tissue enriched (brain). DR MIM; 614993; gene. DR OpenTargets; ENSG00000164076; -. DR VEuPathDB; HostDB:ENSG00000164076; -. DR eggNOG; KOG0032; Eukaryota. DR GeneTree; ENSGT00940000156468; -. DR InParanoid; Q8NCB2; -. DR OMA; GPATCNG; -. DR OrthoDB; 40902at2759; -. DR PAN-GO; Q8NCB2; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q8NCB2; -. DR PathwayCommons; Q8NCB2; -. DR SignaLink; Q8NCB2; -. DR Agora; ENSG00000164076; -. DR BioGRID-ORCS; 79012; 19 hits in 1183 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; CAMKV; human. DR GenomeRNAi; 79012; -. DR Pharos; Q8NCB2; Tbio. DR PRO; PR:Q8NCB2; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q8NCB2; protein. DR Bgee; ENSG00000164076; Expressed in cortical plate and 100 other cell types or tissues. DR ExpressionAtlas; Q8NCB2; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell. DR GO; GO:0045202; C:synapse; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:InterPro. DR GO; GO:0004683; F:calcium/calmodulin-dependent protein kinase activity; IBA:GO_Central. DR GO; GO:0005516; F:calmodulin binding; IBA:GO_Central. DR GO; GO:0050804; P:modulation of chemical synaptic transmission; IEA:Ensembl. DR GO; GO:0099159; P:regulation of modification of postsynaptic structure; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR CDD; cd14088; STKc_CaMK_like; 1. DR FunFam; 1.10.510.10:FF:000188; CaM kinase-like vesicle-associated, like; 1. DR FunFam; 3.30.200.20:FF:000155; CaM kinase-like vesicle-associated, like; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR PANTHER; PTHR24347; SERINE/THREONINE-PROTEIN KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW Alternative splicing; Calmodulin-binding; Cell membrane; KW Cytoplasmic vesicle; Membrane; Phosphoprotein; Proteomics identification; KW Reference proteome. FT CHAIN 1..501 FT /note="CaM kinase-like vesicle-associated protein" FT /id="PRO_0000250094" FT DOMAIN 24..286 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 327..501 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 331..365 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 387..428 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 438..451 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 435 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q63092" FT MOD_RES 459 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q3UHL1" FT VAR_SEQ 188..215 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11230166, ECO:0000303|Ref.3" FT /id="VSP_020600" FT VAR_SEQ 352..382 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_020601" FT VARIANT 40 FT /note="R -> W (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1407808379)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041337" FT VARIANT 60 FT /note="G -> S (in an ovarian serous carcinoma sample; FT somatic mutation; dbSNP:rs2082026503)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041338" FT VARIANT 274 FT /note="R -> W (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041339" FT VARIANT 279 FT /note="E -> D (in dbSNP:rs56071455)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041340" FT VARIANT 472 FT /note="P -> L (in dbSNP:rs56307047)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041341" FT VARIANT 491 FT /note="Y -> C (in dbSNP:rs17849325)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_027539" FT CONFLICT 22 FT /note="D -> G (in Ref. 3; CAG38539)" FT /evidence="ECO:0000305" FT CONFLICT 64 FT /note="R -> Q (in Ref. 1; BAC11528)" FT /evidence="ECO:0000305" FT CONFLICT 285 FT /note="W -> S (in Ref. 1; BAC11248)" FT /evidence="ECO:0000305" SQ SEQUENCE 501 AA; 54354 MW; 1D6DBF8ABA0D1D70 CRC64; MPFGCVTLGD KKNYNQPSEV TDRYDLGQVI KTEEFCEIFR AKDKTTGKLH TCKKFQKRDG RKVRKAAKNE IGILKMVKHP NILQLVDVFV TRKEYFIFLE LATGREVFDW ILDQGYYSER DTSNVVRQVL EAVAYLHSLK IVHRNLKLEN LVYYNRLKNS KIVISDFHLA KLENGLIKEP CGTPEYLAPE VVGRQRYGRP VDCWAIGVIM YILLSGNPPF YEEVEEDDYE NHDKNLFRKI LAGDYEFDSP YWDDISQAAK DLVTRLMEVE QDQRITAEEA ISHEWISGNA ASDKNIKDGV CAQIEKNFAR AKWKKAVRVT TLMKRLRAPE QSSTAAAQSA SATDTATPGA AGGATAAAAS GATSAPEGDA ARAAKSDNVA PADRSATPAT DGSATPATDG SVTPATDGSI TPATDGSVTP ATDRSATPAT DGRATPATEE STVPTTQSSA MLATKAAATP EPAMAQPDST APEGATGQAP PSSKGEEAAG YAQESQREEA S // ID CEAM6_HUMAN Reviewed; 344 AA. AC P40199; Q13774; Q14920; Q53XP7; DT 01-FEB-1995, integrated into UniProtKB/Swiss-Prot. DT 23-FEB-2022, sequence version 4. DT 28-JAN-2026, entry version 202. DE RecName: Full=Cell adhesion molecule CEACAM6 {ECO:0000305}; DE AltName: Full=Carcinoembryonic antigen-related cell adhesion molecule 6; DE Short=CEA cell adhesion molecule 6 {ECO:0000312|HGNC:HGNC:1818}; DE AltName: Full=Non-specific crossreacting antigen {ECO:0000303|PubMed:3220478}; DE AltName: Full=Normal cross-reacting antigen; DE AltName: CD_antigen=CD66c; DE Flags: Precursor; GN Name=CEACAM6 {ECO:0000312|HGNC:HGNC:1818}; GN Synonyms=NCA {ECO:0000303|PubMed:3220478}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT GLY-239. RX PubMed=3220478; DOI=10.1016/0888-7543(88)90160-7; RA Barnett T., Goebel S.J., Nothdurft M.A., Elting J.J.; RT "Carcinoembryonic antigen family: characterization of cDNAs coding for NCA RT and CEA and suggestion of nonrandom sequence variation in their conserved RT loop-domains."; RL Genomics 3:59-66(1988). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Lung carcinoma; RX PubMed=3337731; DOI=10.1016/0006-291x(88)90490-1; RA Tawaragi Y., Oikawa S., Matsuoka Y., Kosaki G., Nakazato H.; RT "Primary structure of nonspecific crossreacting antigen (NCA), a member of RT carcinoembryonic antigen (CEA) gene family, deduced from cDNA sequence."; RL Biochem. Biophys. Res. Commun. 150:89-96(1988). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT GLY-239. RX PubMed=2830274; DOI=10.1016/s0021-9258(18)69055-6; RA Neumaier M., Zimmermann W., Shively L., Hinoda Y., Riggs A.D., RA Shively J.E.; RT "Characterization of a cDNA clone for the nonspecific cross-reacting RT antigen (NCA) and a comparison of NCA and carcinoembryonic antigen."; RL J. Biol. Chem. 263:3202-3207(1988). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP PROTEIN SEQUENCE OF 35-49. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [10] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=2803308; DOI=10.1016/0006-291x(89)91679-3; RA Oikawa S., Inuzuka C., Kuroki M., Matsuoka Y., Kosaki G., Nakazato H.; RT "Cell adhesion activity of non-specific cross-reacting antigen (NCA) and RT carcinoembryonic antigen (CEA) expressed on CHO cell surface: homophilic RT and heterophilic adhesion."; RL Biochem. Biophys. Res. Commun. 164:39-45(1989). RN [11] RP SUBCELLULAR LOCATION, AND GPI-ANCHOR. RX PubMed=2317824; RA Hefta L.J., Schrewe H., Thompson J.A., Oikawa S., Nakazato H., RA Shively J.E.; RT "Expression of complementary DNA and genomic clones for carcinoembryonic RT antigen and nonspecific cross-reacting antigen in Chinese hamster ovary and RT mouse fibroblast cells and characterization of the membrane-expressed RT products."; RL Cancer Res. 50:2397-2403(1990). RN [12] RP FUNCTION, AND DOMAIN. RX PubMed=2022629; DOI=10.1016/s0021-9258(18)92930-3; RA Oikawa S., Inuzuka C., Kuroki M., Arakawa F., Matsuoka Y., Kosaki G., RA Nakazato H.; RT "A specific heterotypic cell adhesion activity between members of RT carcinoembryonic antigen family, W272 and NCA, is mediated by N-domains."; RL J. Biol. Chem. 266:7995-8001(1991). RN [13] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=1378450; DOI=10.1083/jcb.118.2.457; RA Kuijpers T.W., Hoogerwerf M., van der Laan L.J., Nagel G., RA van der Schoot C.E., Grunert F., Roos D.; RT "CD66 nonspecific cross-reacting antigens are involved in neutrophil RT adherence to cytokine-activated endothelial cells."; RL J. Cell Biol. 118:457-466(1992). RN [14] RP FUNCTION, SUBCELLULAR LOCATION, AND DOMAIN. RX PubMed=8776764; DOI=10.1006/prep.1996.0065; RA Yamanaka T., Kuroki M., Kinugasa T., Matsuo Y., Matsuoka Y.; RT "Preparation and characterization of two human carcinoembryonic antigen RT family proteins of neutrophils, CD66b and c, in silkworm larvae."; RL Protein Expr. Purif. 7:438-446(1996). RN [15] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=10436421; DOI=10.1159/000030075; RA Fraengsmyr L., Baranov V., Hammarstroem S.; RT "Four carcinoembryonic antigen subfamily members, CEA, NCA, BGP and CGM2, RT selectively expressed in the normal human colonic epithelium, are integral RT components of the fuzzy coat."; RL Tumor Biol. 20:277-292(1999). RN [16] RP FUNCTION. RX PubMed=10910050; RA Ordonez C., Screaton R.A., Ilantzis C., Stanners C.P.; RT "Human carcinoembryonic antigen functions as a general inhibitor of RT anoikis."; RL Cancer Res. 60:3419-3424(2000). RN [17] RP FUNCTION, DOMAIN, AND MUTAGENESIS OF ALA-55; ASN-61; ARG-62; ILE-63; SER-66 RP AND LEU-78. RX PubMed=11590190; RA Kuroki M., Abe H., Imakiirei T., Liao S., Uchida H., Yamauchi Y., RA Oikawa S., Kuroki M.; RT "Identification and comparison of residues critical for cell-adhesion RT activities of two neutrophil CD66 antigens, CEACAM6 and CEACAM8."; RL J. Leukoc. Biol. 70:543-550(2001). RN [18] RP RETRACTED PAPER. RX PubMed=14724575; DOI=10.1038/sj.onc.1207036; RA Duxbury M.S., Ito H., Zinner M.J., Ashley S.W., Whang E.E.; RT "CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic RT ability of pancreatic adenocarcinoma cells."; RL Oncogene 23:465-473(2004). RN [19] RP RETRACTION NOTICE OF PUBMED:14724575. RX PubMed=36765147; DOI=10.1038/s41388-023-02625-6; RA Duxbury M.S., Ito H., Zinner M.J., Ashley S.W., Whang E.E.; RT "Retraction Note: CEACAM6 gene silencing impairs anoikis resistance and in RT vivo metastatic ability of pancreatic adenocarcinoma cells."; RL Oncogene 42:939-939(2023). RN [20] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=16204051; DOI=10.1158/0008-5472.can-05-0420; RA Blumenthal R.D., Hansen H.J., Goldenberg D.M.; RT "Inhibition of adhesion, invasion, and metastasis by antibodies targeting RT CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen)."; RL Cancer Res. 65:8809-8817(2005). RN [21] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-197. RC TISSUE=Saliva; RX PubMed=16740002; DOI=10.1021/pr050492k; RA Ramachandran P., Boontheung P., Xie Y., Sondej M., Wong D.T., Loo J.A.; RT "Identification of N-linked glycoproteins in human saliva by glycoprotein RT capture and mass spectrometry."; RL J. Proteome Res. 5:1493-1503(2006). RN [22] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-224. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [23] {ECO:0007744|PDB:4WHC} RP X-RAY CRYSTALLOGRAPHY (2.71 ANGSTROMS) OF 34-141 OF HOMODIMER. RA Prive G.G., Kirouac K.N.; RT "Human CEACAM6 N-domain."; RL Submitted (SEP-2014) to the PDB data bank. RN [24] {ECO:0007744|PDB:4WTZ} RP X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 34-141 IN COMPLEX WITH CEACAM8. RA Kirouac K.N., Prive G.G.; RT "Human CEACAM6-CEACAM8 N-domain heterodimer complex."; RL Submitted (OCT-2014) to the PDB data bank. RN [25] {ECO:0007744|PDB:4Y8A, ECO:0007744|PDB:4YIQ} RP X-RAY CRYSTALLOGRAPHY (1.83 ANGSTROMS) OF 34-141 OF HOMODIMER AND IN RP COMPLEX WITH CEACAM8, SUBUNIT, GLYCOSYLATION, AND MUTAGENESIS OF ILE-38; RP LEU-53; GLN-123 AND LEU-129. RX PubMed=26483485; DOI=10.1073/pnas.1509511112; RA Bonsor D.A., Gunther S., Beadenkopf R., Beckett D., Sundberg E.J.; RT "Diverse oligomeric states of CEACAM IgV domains."; RL Proc. Natl. Acad. Sci. U.S.A. 112:13561-13566(2015). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=18318008; DOI=10.1002/pmic.200700884; RA Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D., RA Zou H., Gu J.; RT "Large-scale phosphoproteome analysis of human liver tissue by enrichment RT and fractionation of phosphopeptides with strong anion exchange RT chromatography."; RL Proteomics 8:1346-1361(2008). CC -!- FUNCTION: Cell surface glycoprotein that plays a role in cell adhesion CC and tumor progression (PubMed:10910050, PubMed:11590190, CC PubMed:1378450, PubMed:16204051, PubMed:2022629, PubMed:2803308, CC PubMed:8776764). Intercellular adhesion occurs in a calcium- and CC fibronectin-independent manner (PubMed:16204051, PubMed:2022629). CC Mediates homophilic and heterophilic cell adhesion with other CC carcinoembryonic antigen-related cell adhesion molecules, such as CC CEACAM5 and CEACAM8 (PubMed:11590190, PubMed:16204051, PubMed:2022629, CC PubMed:2803308, PubMed:8776764). Heterophilic interaction with CEACAM8 CC occurs in activated neutrophils (PubMed:8776764). Plays a role in CC neutrophil adhesion to cytokine-activated endothelial cells CC (PubMed:1378450). Plays a role in cell migration and cell adhesion to CC endothelial cells (PubMed:16204051). {ECO:0000269|PubMed:10910050, CC ECO:0000269|PubMed:11590190, ECO:0000269|PubMed:1378450, CC ECO:0000269|PubMed:16204051, ECO:0000269|PubMed:2022629, CC ECO:0000269|PubMed:2803308, ECO:0000269|PubMed:8776764}. CC -!- SUBUNIT: Homodimer; homodimerizes via its Ig-like V-type domain. CC Heterodimer with CEACAM8; heterodimerizes via its Ig-like V-type CC domain. {ECO:0000269|PubMed:26483485}. CC -!- INTERACTION: CC P40199; Q86U10: ASPG; NbExp=3; IntAct=EBI-4314501, EBI-19946665; CC P40199; Q16568: CARTPT; NbExp=3; IntAct=EBI-4314501, EBI-4314526; CC P40199; P13688: CEACAM1; NbExp=3; IntAct=EBI-4314501, EBI-4314481; CC P40199; P40199: CEACAM6; NbExp=7; IntAct=EBI-4314501, EBI-4314501; CC P40199; P31997: CEACAM8; NbExp=8; IntAct=EBI-4314501, EBI-4314540; CC P40199; Q99828: CIB1; NbExp=3; IntAct=EBI-4314501, EBI-372594; CC P40199; P33240: CSTF2; NbExp=3; IntAct=EBI-4314501, EBI-711360; CC P40199; Q86VI1: EXOC3L1; NbExp=3; IntAct=EBI-4314501, EBI-2813180; CC P40199; O75593: FOXH1; NbExp=3; IntAct=EBI-4314501, EBI-1759806; CC P40199; O75603: GCM2; NbExp=3; IntAct=EBI-4314501, EBI-10188645; CC P40199; O95872: GPANK1; NbExp=3; IntAct=EBI-4314501, EBI-751540; CC P40199; O14964: HGS; NbExp=3; IntAct=EBI-4314501, EBI-740220; CC P40199; Q9UM19: HPCAL4; NbExp=3; IntAct=EBI-4314501, EBI-744820; CC P40199; Q63ZY3: KANK2; NbExp=3; IntAct=EBI-4314501, EBI-2556193; CC P40199; Q4VC12: MSS51; NbExp=5; IntAct=EBI-4314501, EBI-11599933; CC P40199; Q9NP98: MYOZ1; NbExp=3; IntAct=EBI-4314501, EBI-744402; CC P40199; P78337: PITX1; NbExp=3; IntAct=EBI-4314501, EBI-748265; CC P40199; Q96HA1-2: POM121; NbExp=3; IntAct=EBI-4314501, EBI-11956563; CC P40199; Q2TAL8: QRICH1; NbExp=3; IntAct=EBI-4314501, EBI-2798044; CC P40199; Q9BQY4: RHOXF2; NbExp=3; IntAct=EBI-4314501, EBI-372094; CC P40199; Q92529: SHC3; NbExp=3; IntAct=EBI-4314501, EBI-79084; CC P40199; Q96GM5: SMARCD1; NbExp=3; IntAct=EBI-4314501, EBI-358489; CC P40199; O43711: TLX3; NbExp=3; IntAct=EBI-4314501, EBI-3939165; CC P40199; P22105-1: TNXB; NbExp=3; IntAct=EBI-4314501, EBI-20753895; CC P40199; Q9UHD9: UBQLN2; NbExp=5; IntAct=EBI-4314501, EBI-947187; CC P40199; O95231: VENTX; NbExp=3; IntAct=EBI-4314501, EBI-10191303; CC P40199; Q14119: VEZF1; NbExp=3; IntAct=EBI-4314501, EBI-11980193; CC P40199; Q9NZC7-5: WWOX; NbExp=3; IntAct=EBI-4314501, EBI-12040603; CC P40199; Q96E35: ZMYND19; NbExp=3; IntAct=EBI-4314501, EBI-746595; CC P40199; P36508: ZNF76; NbExp=3; IntAct=EBI-4314501, EBI-7254550; CC -!- SUBCELLULAR LOCATION: Cell membrane; Lipid-anchor, GPI-anchor CC {ECO:0000269|PubMed:2317824}. Apical cell membrane CC {ECO:0000269|PubMed:10436421}. Cell surface CC {ECO:0000269|PubMed:1378450, ECO:0000269|PubMed:16204051, CC ECO:0000269|PubMed:2317824, ECO:0000269|PubMed:8776764, CC ECO:0000305|PubMed:2803308}. Note=Localized to the apical glycocalyx CC surface. {ECO:0000269|PubMed:10436421}. CC -!- TISSUE SPECIFICITY: Expressed in neutrophils (PubMed:1378450). CC Expressed in columnar epithelial and goblet cells of the colon CC (PubMed:10436421). Expressed in numerous tumor cell lines (at protein CC level) (PubMed:16204051). {ECO:0000269|PubMed:10436421, CC ECO:0000269|PubMed:1378450, ECO:0000269|PubMed:16204051}. CC -!- DOMAIN: The extracellular N-terminus Ig-like V-type domain is necessary CC for homophilic and heterophilic intercellular adhesion. CC {ECO:0000269|PubMed:11590190, ECO:0000269|PubMed:2022629, CC ECO:0000269|PubMed:8776764}. CC -!- PTM: Glycosylated. {ECO:0000269|PubMed:26483485}. CC -!- SIMILARITY: Belongs to the immunoglobulin superfamily. CEA family. CC {ECO:0000305}. CC -!- CAUTION: Described to function in anoikis resistance and to be up- CC regulated in anoikis-resistant pancreatic adenocarcinoma cells in an CC article that was finally retracted. {ECO:0000269|PubMed:14724575, CC ECO:0000269|PubMed:36765147}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M29541; AAA59915.1; -; mRNA. DR EMBL; M18728; AAA59907.1; -; mRNA. DR EMBL; M18216; AAA51739.1; -; mRNA. DR EMBL; BT009774; AAP88776.1; -; mRNA. DR EMBL; AK312542; BAG35441.1; -; mRNA. DR EMBL; AC011513; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471126; EAW57061.1; -; Genomic_DNA. DR EMBL; BC005008; AAH05008.1; -; mRNA. DR CCDS; CCDS12585.1; -. DR RefSeq; NP_002474.4; NM_002483.6. DR PDB; 4WHC; X-ray; 2.71 A; A/B=34-141. DR PDB; 4WTZ; X-ray; 2.52 A; A/B/C/D/E/F=34-141. DR PDB; 4Y8A; X-ray; 1.83 A; A/B=34-141. DR PDB; 4YIQ; X-ray; 1.85 A; B/D=34-141. DR PDBsum; 4WHC; -. DR PDBsum; 4WTZ; -. DR PDBsum; 4Y8A; -. DR PDBsum; 4YIQ; -. DR AlphaFoldDB; P40199; -. DR SMR; P40199; -. DR BioGRID; 110760; 260. DR FunCoup; P40199; 11. DR IntAct; P40199; 31. DR STRING; 9606.ENSP00000199764; -. DR GlyCosmos; P40199; 12 sites, No reported glycans. DR GlyGen; P40199; 17 sites, 7 N-linked glycans (3 sites), 3 N-linked;o-linked glycans (3 sites), 1 O-linked glycan (2 sites). DR iPTMnet; P40199; -. DR PhosphoSitePlus; P40199; -. DR BioMuta; CEACAM6; -. DR DMDM; 296439410; -. DR jPOST; P40199; -. DR MassIVE; P40199; -. DR PaxDb; 9606-ENSP00000199764; -. DR PeptideAtlas; P40199; -. DR ProteomicsDB; 55345; -. DR ABCD; P40199; 5 sequenced antibodies. DR Antibodypedia; 3642; 624 antibodies from 37 providers. DR DNASU; 4680; -. DR Ensembl; ENST00000199764.7; ENSP00000199764.6; ENSG00000086548.10. DR GeneID; 4680; -. DR KEGG; hsa:4680; -. DR MANE-Select; ENST00000199764.7; ENSP00000199764.6; NM_002483.7; NP_002474.4. DR UCSC; uc032hyc.2; human. DR AGR; HGNC:1818; -. DR ClinPGx; PA26362; -. DR CTD; 4680; -. DR DisGeNET; 4680; -. DR GeneCards; CEACAM6; -. DR HGNC; HGNC:1818; CEACAM6. DR HPA; ENSG00000086548; Tissue enhanced (bone marrow, esophagus, intestine, lung, salivary gland). DR MalaCards; CEACAM6; -. DR MIM; 163980; gene. DR OpenTargets; ENSG00000086548; -. DR Orphanet; 586; Cystic fibrosis. DR VEuPathDB; HostDB:ENSG00000086548; -. DR eggNOG; ENOG502RXPD; Eukaryota. DR GeneTree; ENSGT01100000263479; -. DR HOGENOM; CLU_024555_2_0_1; -. DR InParanoid; P40199; -. DR OMA; FTCEPEV; -. DR OrthoDB; 6159398at2759; -. DR PAN-GO; P40199; 2 GO annotations based on evolutionary models. DR PhylomeDB; P40199; -. DR PathwayCommons; P40199; -. DR Reactome; R-HSA-1566977; Fibronectin matrix formation. DR Reactome; R-HSA-202733; Cell surface interactions at the vascular wall. DR Reactome; R-HSA-6798695; Neutrophil degranulation. DR SignaLink; P40199; -. DR Agora; ENSG00000086548; -. DR BioGRID-ORCS; 4680; 70 hits in 1136 CRISPR screens. DR ChiTaRS; CEACAM6; human. DR EvolutionaryTrace; P40199; -. DR GeneWiki; CEACAM6; -. DR GenomeRNAi; 4680; -. DR Pharos; P40199; Tbio. DR PRO; PR:P40199; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; P40199; protein. DR Bgee; ENSG00000086548; Expressed in pancreatic ductal cell and 152 other cell types or tissues. DR ExpressionAtlas; P40199; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB. DR GO; GO:0035577; C:azurophil granule membrane; TAS:Reactome. DR GO; GO:0009986; C:cell surface; IDA:UniProtKB. DR GO; GO:0005615; C:extracellular space; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; TAS:Reactome. DR GO; GO:0098552; C:side of membrane; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IDA:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0007157; P:heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules; IMP:UniProtKB. DR GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; IMP:UniProtKB. DR GO; GO:2000811; P:negative regulation of anoikis; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:BHF-UCL. DR GO; GO:1904906; P:positive regulation of endothelial cell-matrix adhesion via fibronectin; IMP:UniProtKB. DR GO; GO:0034116; P:positive regulation of heterotypic cell-cell adhesion; IMP:UniProtKB. DR CDD; cd20948; IgC2_CEACAM5-like; 1. DR CDD; cd05740; IgI_hCEACAM_2_4_6_like; 1. DR CDD; cd05774; IgV_CEACAM_D1; 1. DR FunFam; 2.60.40.10:FF:000340; Carcinoembryonic antigen-related cell adhesion molecule 1; 1. DR FunFam; 2.60.40.10:FF:000517; Carcinoembryonic antigen-related cell adhesion molecule 1; 1. DR FunFam; 2.60.40.10:FF:000244; carcinoembryonic antigen-related cell adhesion molecule 16; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 3. DR InterPro; IPR050831; CEA_cell_adhesion. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR013106; Ig_V-set. DR PANTHER; PTHR44427:SF1; CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE 1; 1. DR PANTHER; PTHR44427; CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE 19; 1. DR Pfam; PF13895; Ig_2; 1. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF07686; V-set; 1. DR SMART; SM00409; IG; 3. DR SMART; SM00408; IGc2; 2. DR SUPFAM; SSF48726; Immunoglobulin; 3. DR PROSITE; PS50835; IG_LIKE; 2. PE 1: Evidence at protein level; KW 3D-structure; Apoptosis; Cell adhesion; Cell membrane; KW Direct protein sequencing; Disulfide bond; Glycoprotein; GPI-anchor; KW Immunoglobulin domain; Lipoprotein; Membrane; Oncogene; KW Proteomics identification; Reference proteome; Repeat; Signal. FT SIGNAL 1..34 FT /evidence="ECO:0000269|PubMed:15340161" FT CHAIN 35..320 FT /note="Cell adhesion molecule CEACAM6" FT /id="PRO_0000014568" FT PROPEP 321..344 FT /note="Removed in mature form" FT /evidence="ECO:0000250" FT /id="PRO_0000014569" FT DOMAIN 35..142 FT /note="Ig-like V-type" FT /evidence="ECO:0000250|UniProtKB:P31997" FT DOMAIN 145..232 FT /note="Ig-like C2-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DOMAIN 240..314 FT /note="Ig-like C2-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT LIPID 320 FT /note="GPI-anchor amidated glycine" FT /evidence="ECO:0000250|UniProtKB:P31997" FT CARBOHYD 104 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00498" FT CARBOHYD 111 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00498" FT CARBOHYD 115 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00498" FT CARBOHYD 152 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00498" FT CARBOHYD 173 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00498" FT CARBOHYD 197 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00498, FT ECO:0000269|PubMed:16740002" FT CARBOHYD 224 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00498, FT ECO:0000269|PubMed:19159218" FT CARBOHYD 256 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00498" FT CARBOHYD 274 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00498" FT CARBOHYD 288 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00498" FT CARBOHYD 292 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00498" FT CARBOHYD 309 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00498" FT DISULFID 167..215 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 259..299 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VARIANT 239 FT /note="V -> G (in dbSNP:rs11548735)" FT /evidence="ECO:0000269|PubMed:2830274, FT ECO:0000269|PubMed:3220478" FT /id="VAR_034680" FT MUTAGEN 38 FT /note="I->A: Loss of homodimerization and FT heterodimerization with CEACAM8." FT /evidence="ECO:0000269|PubMed:26483485" FT MUTAGEN 53 FT /note="L->A: No effect on homodimerization. Reduces FT heterodimerization with CEACAM8." FT /evidence="ECO:0000269|PubMed:26483485" FT MUTAGEN 55 FT /note="A->V: No effect on homophilic and heterophilic cell FT adhesion." FT /evidence="ECO:0000269|PubMed:11590190" FT MUTAGEN 61 FT /note="N->H: Inhibits homophilic and heterophilic cell FT adhesion." FT /evidence="ECO:0000269|PubMed:11590190" FT MUTAGEN 62 FT /note="R->L: No effect on homophilic cell adhesion. Reduces FT heterophilic cell adhesion." FT /evidence="ECO:0000269|PubMed:11590190" FT MUTAGEN 63 FT /note="I->F: No effect on homophilic cell adhesion. FT Inhibits heterophilic cell adhesion." FT /evidence="ECO:0000269|PubMed:11590190" FT MUTAGEN 66 FT /note="S->N: Inhibits homophilic cell adhesion. Reduces FT heterophilic cell adhesion." FT /evidence="ECO:0000269|PubMed:11590190" FT MUTAGEN 78 FT /note="L->Q: Inhibits homophilic cell adhesion. No effect FT on heterophilic cell adhesion." FT /evidence="ECO:0000269|PubMed:11590190" FT MUTAGEN 123 FT /note="Q->A: No effect on homodimerization. Reduces FT heterodimerization with CEACAM8." FT /evidence="ECO:0000269|PubMed:26483485" FT MUTAGEN 129 FT /note="L->A: Reduces homodimerization. Loss of FT heterodimerization with CEACAM8." FT /evidence="ECO:0000269|PubMed:26483485" FT CONFLICT 138 FT /note="F -> L (in Ref. 1; AAA59915)" FT /evidence="ECO:0000305" FT STRAND 37..45 FT /evidence="ECO:0007829|PDB:4Y8A" FT STRAND 51..57 FT /evidence="ECO:0007829|PDB:4Y8A" FT STRAND 62..72 FT /evidence="ECO:0007829|PDB:4Y8A" FT HELIX 75..77 FT /evidence="ECO:0007829|PDB:4Y8A" FT STRAND 78..83 FT /evidence="ECO:0007829|PDB:4Y8A" FT TURN 84..87 FT /evidence="ECO:0007829|PDB:4Y8A" FT STRAND 88..91 FT /evidence="ECO:0007829|PDB:4Y8A" FT STRAND 99..101 FT /evidence="ECO:0007829|PDB:4Y8A" FT STRAND 107..109 FT /evidence="ECO:0007829|PDB:4Y8A" FT HELIX 114..116 FT /evidence="ECO:0007829|PDB:4Y8A" FT STRAND 118..126 FT /evidence="ECO:0007829|PDB:4Y8A" FT STRAND 132..140 FT /evidence="ECO:0007829|PDB:4Y8A" SQ SEQUENCE 344 AA; 37237 MW; 4322C5D6E25849F5 CRC64; MGPPSAPPCR LHVPWKEVLL TASLLTFWNP PTTAKLTIES TPFNVAEGKE VLLLAHNLPQ NRIGYSWYKG ERVDGNSLIV GYVIGTQQAT PGPAYSGRET IYPNASLLIQ NVTQNDTGFY TLQVIKSDLV NEEATGQFHV YPELPKPSIS SNNSNPVEDK DAVAFTCEPE VQNTTYLWWV NGQSLPVSPR LQLSNGNMTL TLLSVKRNDA GSYECEIQNP ASANRSDPVT LNVLYGPDVP TISPSKANYR PGENLNLSCH AASNPPAQYS WFINGTFQQS TQELFIPNIT VNNSGSYMCQ AHNSATGLNR TTVTMITVSG SAPVLSAVAT VGITIGVLAR VALI // ID CEMIP_HUMAN Reviewed; 1361 AA. AC Q8WUJ3; Q6L9J5; Q9H1K5; Q9NPN9; Q9ULM1; DT 13-APR-2004, integrated into UniProtKB/Swiss-Prot. DT 13-APR-2004, sequence version 2. DT 28-JAN-2026, entry version 168. DE RecName: Full=Cell migration-inducing and hyaluronan-binding protein; DE EC=3.2.1.35 {ECO:0000269|PubMed:23509262, ECO:0000269|PubMed:24269685}; DE AltName: Full=Hyaluronan binding protein involved in hyaluronan depolymerization {ECO:0000303|PubMed:23509262}; DE Flags: Precursor; GN Name=CEMIP {ECO:0000312|HGNC:HGNC:29213}; GN Synonyms=HYBID {ECO:0000303|PubMed:23509262}, KIAA1199; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], VARIANTS CYS-187; HIS-187 AND TYR-783, AND RP VARIANTS ARG-783; ILE-1109 AND ALA-1169. RX PubMed=14577002; DOI=10.1007/s10038-003-0079-2; RA Abe S., Usami S., Nakamura Y.; RT "Mutations in the gene encoding KIAA1199 protein, an inner-ear protein RT expressed in Deiters' cells and the fibrocytes, as the cause of RT nonsyndromic hearing loss."; RL J. Hum. Genet. 48:564-570(2003). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=16157444; DOI=10.1016/j.canlet.2005.07.028; RA Michishita E., Garces G., Barrett J.C., Horikawa I.; RT "Upregulation of the KIAA1199 gene is associated with cellular mortality."; RL Cancer Lett. 239:71-77(2006). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 349-1361 (ISOFORM 1), AND TISSUE RP SPECIFICITY. RC TISSUE=Brain; RX PubMed=10574462; DOI=10.1093/dnares/6.5.337; RA Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XV. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 6:337-345(1999). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 558-1361. RG The European IMAGE consortium; RL Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 862-1361. RX PubMed=11247670; DOI=10.1006/geno.2000.6466; RA Wines M.E., Lee L., Katari M.S., Zhang L., DeRossi C., Shi Y., Perkins S., RA Feldman M., McCombie W.R., Holdener B.C.; RT "Identification of mesoderm development (mesd) candidate genes by RT comparative mapping and genome sequence analysis."; RL Genomics 72:88-98(2001). RN [8] RP TISSUE SPECIFICITY. RX PubMed=12471561; DOI=10.1086/345398; RA Abe S., Katagiri T., Saito-Hisaminato A., Usami S., Inoue Y., Tsunoda T., RA Nakamura Y.; RT "Identification of CRYM as a candidate responsible for nonsyndromic RT deafness, through cDNA microarray analysis of human cochlear and vestibular RT tissues."; RL Am. J. Hum. Genet. 72:73-82(2003). RN [9] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=19434458; DOI=10.1245/s10434-009-0469-6; RA Matsuzaki S., Tanaka F., Mimori K., Tahara K., Inoue H., Mori M.; RT "Clinicopathologic significance of KIAA1199 overexpression in human gastric RT cancer."; RL Ann. Surg. Oncol. 16:2042-2051(2009). RN [10] RP PROBABLE FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=21772334; DOI=10.1038/bjc.2011.268; RA Birkenkamp-Demtroder K., Maghnouj A., Mansilla F., Thorsen K., RA Andersen C.L., Oster B., Hahn S., Orntoft T.F.; RT "Repression of KIAA1199 attenuates Wnt-signalling and decreases the RT proliferation of colon cancer cells."; RL Br. J. Cancer 105:552-561(2011). RN [11] RP TISSUE SPECIFICITY, AND INDUCTION. RX PubMed=22970280; DOI=10.1371/journal.pone.0044661; RA Kuscu C., Evensen N., Kim D., Hu Y.J., Zucker S., Cao J.; RT "Transcriptional and epigenetic regulation of KIAA1199 gene expression in RT human breast cancer."; RL PLoS ONE 7:E44661-E44661(2012). RN [12] RP FUNCTION IN CANCER, INTERACTION WITH HSPA5, SUBCELLULAR LOCATION, AND RP TISSUE SPECIFICITY. RX PubMed=23990668; DOI=10.1093/jnci/djt224; RA Evensen N.A., Kuscu C., Nguyen H.L., Zarrabi K., Dufour A., Kadam P., RA Hu Y.J., Pulkoski-Gross A., Bahou W.F., Zucker S., Cao J.; RT "Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in RT cancer cell migration."; RL J. Natl. Cancer Inst. 105:1402-1416(2013). RN [13] RP INTERACTION WITH EPHA2 AND ITPR3, GLYCOSYLATION, SUBCELLULAR LOCATION, AND RP TISSUE SPECIFICITY. RX PubMed=23936024; DOI=10.1371/journal.pone.0069473; RA Tiwari A., Schneider M., Fiorino A., Haider R., Okoniewski M.J., RA Roschitzki B., Uzozie A., Menigatti M., Jiricny J., Marra G.; RT "Early insights into the function of KIAA1199, a markedly overexpressed RT protein in human colorectal tumors."; RL PLoS ONE 8:E69473-E69473(2013). RN [14] RP FUNCTION IN HYALURONIC ACID DEGRADATION, CATALYTIC ACTIVITY, ACTIVITY RP REGULATION, HYALURONIC ACID-BINDING, INTERACTION WITH CLATHRIN, SUBCELLULAR RP LOCATION, INDUCTION, AND CHARACTERIZATION OF VARIANTS CYS-187; HIS-187; RP ARG-783 AND ILE-1109. RX PubMed=23509262; DOI=10.1073/pnas.1215432110; RA Yoshida H., Nagaoka A., Kusaka-Kikushima A., Tobiishi M., Kawabata K., RA Sayo T., Sakai S., Sugiyama Y., Enomoto H., Okada Y., Inoue S.; RT "KIAA1199, a deafness gene of unknown function, is a new hyaluronan binding RT protein involved in hyaluronan depolymerization."; RL Proc. Natl. Acad. Sci. U.S.A. 110:5612-5617(2013). RN [15] RP FUNCTION IN HYALURONIC ACID DEGRADATION, CATALYTIC ACTIVITY, GLYCOSYLATION, RP SUBCELLULAR LOCATION, PROTEOLYTIC PROCESSING, AND SIGNAL SEQUENCE CLEAVAGE RP SITE. RX PubMed=24269685; DOI=10.1016/j.febslet.2013.11.017; RA Yoshida H., Nagaoka A., Nakamura S., Tobiishi M., Sugiyama Y., Inoue S.; RT "N-Terminal signal sequence is required for cellular trafficking and RT hyaluronan-depolymerization of KIAA1199."; RL FEBS Lett. 588:111-116(2014). CC -!- FUNCTION: Mediates depolymerization of hyaluronic acid (HA) via the CC cell membrane-associated clathrin-coated pit endocytic pathway. Binds CC to hyaluronic acid. Hydrolyzes high molecular weight hyaluronic acid to CC produce an intermediate-sized product, a process that may occur through CC rapid vesicle endocytosis and recycling without intracytoplasmic CC accumulation or digestion in lysosomes. Involved in hyaluronan CC catabolism in the dermis of the skin and arthritic synovium. Positively CC regulates epithelial-mesenchymal transition (EMT), and hence tumor cell CC growth, invasion and cancer dissemination. In collaboration with CC HSPA5/BIP, promotes cancer cell migration in a calcium and PKC- CC dependent manner. May be involved in hearing. CC {ECO:0000269|PubMed:23509262, ECO:0000269|PubMed:23990668, CC ECO:0000269|PubMed:24269685}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D- CC glucosamine and D-glucuronate residues in hyaluronate.; EC=3.2.1.35; CC Evidence={ECO:0000269|PubMed:23509262, ECO:0000269|PubMed:24269685}; CC -!- ACTIVITY REGULATION: Activity is up-regulated by histamine. CC {ECO:0000269|PubMed:23509262}. CC -!- SUBUNIT: Interacts with EPHA2 and ITPR3. Interacts with HSPA5/BIP; the CC interaction induces calcium leakage from the endoplasmic reticulum and CC cell migration. Interacts with clathrin heavy chain/CLTC. CC {ECO:0000269|PubMed:23509262, ECO:0000269|PubMed:23936024, CC ECO:0000269|PubMed:23990668}. CC -!- INTERACTION: CC Q8WUJ3; P53621: COPA; NbExp=2; IntAct=EBI-310606, EBI-356273; CC Q8WUJ3; Q93100: PHKB; NbExp=2; IntAct=EBI-310606, EBI-740559; CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Endoplasmic reticulum. Cell CC membrane. Membrane, clathrin-coated pit. Secreted. Note=Retained in the CC endoplasmic reticulum (ER) in a HSPA5/BIP-dependent manner. Colocalized CC with clathrin heavy chain/CLTC in clathrin-coated vesicles. Strongly CC detected in the cytoplasm of breast carcinoma cells, whereas poorly CC detected in adjacent normal epithelial cells, stromal cells, or benign CC breast tissues. Localized in the nucleus and cytoplasm of colon CC adenocarcinomas. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q8WUJ3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8WUJ3-2; Sequence=VSP_009814, VSP_009815; CC -!- TISSUE SPECIFICITY: Expressed in dermal and in synovial fibroblasts. CC Strongly expressed in gastric cancers compared with the paired normal CC tissues. Strongly expressed in both ductal carcinoma and invasive CC breast cancer cells compared with benign epithelial cells (at protein CC level). Strongly expressed in brain, placenta, prostate, breast, lung CC and testis. Expressed in fibroblasts, epithelial cells and cancer CC cells. In ear, it is specifically expressed in inner ear. Expressed in CC cochlea and vestibule tissues. Strongly expressed in gastric cancers CC compared with the paired normal tissues. Strongly expressed in colon CC adenocarcinomas compared with normal colonic mucosas. Strongly CC expressed in breast cancer as compared to normal breast tissue. CC {ECO:0000269|PubMed:10574462, ECO:0000269|PubMed:12471561, CC ECO:0000269|PubMed:16157444, ECO:0000269|PubMed:19434458, CC ECO:0000269|PubMed:21772334, ECO:0000269|PubMed:22970280, CC ECO:0000269|PubMed:23936024, ECO:0000269|PubMed:23990668}. CC -!- INDUCTION: Up-regulated by histamine. Up-regulated by the adapter CC protein complex 1 (AP-1) and NF-kappaB/RELA. Down-regulated by CC transforming growth factor TGFB1. {ECO:0000269|PubMed:22970280, CC ECO:0000269|PubMed:23509262}. CC -!- DOMAIN: The signal sequence is essential in mediating its proper CC translocation, hyaluronic acid (HA) degradation activity and secretion. CC -!- PTM: N-glycosylated; glycosylation is not necessary for HA-binding. CC {ECO:0000269|PubMed:23936024, ECO:0000269|PubMed:24269685}. CC -!- SIMILARITY: Belongs to the CEMIP family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB103330; BAD02451.1; -; mRNA. DR EMBL; CH471136; EAW99111.1; -; Genomic_DNA. DR EMBL; BC020256; AAH20256.1; -; mRNA. DR EMBL; AB033025; BAA86513.1; -; mRNA. DR EMBL; AL359061; CAB94391.1; -; mRNA. DR EMBL; AY007811; AAG41059.1; -; mRNA. DR CCDS; CCDS10315.1; -. [Q8WUJ3-1] DR RefSeq; NP_001280227.1; NM_001293298.2. [Q8WUJ3-1] DR RefSeq; NP_001280233.1; NM_001293304.2. [Q8WUJ3-1] DR RefSeq; NP_061159.1; NM_018689.3. [Q8WUJ3-1] DR RefSeq; XP_047288856.1; XM_047432900.1. [Q8WUJ3-1] DR RefSeq; XP_054234488.1; XM_054378513.1. [Q8WUJ3-1] DR AlphaFoldDB; Q8WUJ3; -. DR SMR; Q8WUJ3; -. DR BioGRID; 121452; 96. DR FunCoup; Q8WUJ3; 405. DR IntAct; Q8WUJ3; 15. DR MINT; Q8WUJ3; -. DR STRING; 9606.ENSP00000378177; -. DR CarbonylDB; Q8WUJ3; -. DR GlyCosmos; Q8WUJ3; 7 sites, No reported glycans. DR GlyGen; Q8WUJ3; 8 sites, 3 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; Q8WUJ3; -. DR PhosphoSitePlus; Q8WUJ3; -. DR BioMuta; CEMIP; -. DR DMDM; 46396475; -. DR jPOST; Q8WUJ3; -. DR MassIVE; Q8WUJ3; -. DR PaxDb; 9606-ENSP00000378177; -. DR PeptideAtlas; Q8WUJ3; -. DR ProteomicsDB; 74690; -. [Q8WUJ3-1] DR ProteomicsDB; 74691; -. [Q8WUJ3-2] DR Antibodypedia; 27890; 248 antibodies from 26 providers. DR DNASU; 57214; -. DR Ensembl; ENST00000220244.7; ENSP00000220244.3; ENSG00000103888.18. [Q8WUJ3-1] DR Ensembl; ENST00000356249.9; ENSP00000348583.5; ENSG00000103888.18. [Q8WUJ3-1] DR Ensembl; ENST00000394685.8; ENSP00000378177.3; ENSG00000103888.18. [Q8WUJ3-1] DR GeneID; 57214; -. DR KEGG; hsa:57214; -. DR MANE-Select; ENST00000394685.8; ENSP00000378177.3; NM_001293298.2; NP_001280227.1. DR UCSC; uc002bfw.2; human. [Q8WUJ3-1] DR AGR; HGNC:29213; -. DR ClinPGx; PA134967531; -. DR CTD; 57214; -. DR DisGeNET; 57214; -. DR GeneCards; CEMIP; -. DR HGNC; HGNC:29213; CEMIP. DR HPA; ENSG00000103888; Tissue enhanced (endometrium). DR MIM; 608366; gene. DR OpenTargets; ENSG00000103888; -. DR VEuPathDB; HostDB:ENSG00000103888; -. DR eggNOG; ENOG502QT0K; Eukaryota. DR GeneTree; ENSGT00940000153636; -. DR HOGENOM; CLU_005606_1_0_1; -. DR InParanoid; Q8WUJ3; -. DR OMA; YGRADED; -. DR OrthoDB; 120976at2759; -. DR PAN-GO; Q8WUJ3; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q8WUJ3; -. DR PathwayCommons; Q8WUJ3; -. DR Reactome; R-HSA-2160916; Hyaluronan degradation. DR SignaLink; Q8WUJ3; -. DR Agora; ENSG00000103888; -. DR BioGRID-ORCS; 57214; 16 hits in 1143 CRISPR screens. DR ChiTaRS; CEMIP; human. DR GeneWiki; KIAA1199; -. DR GenomeRNAi; 57214; -. DR Pharos; Q8WUJ3; Tbio. DR PRO; PR:Q8WUJ3; -. DR Proteomes; UP000005640; Chromosome 15. DR RNAct; Q8WUJ3; protein. DR Bgee; ENSG00000103888; Expressed in choroid plexus epithelium and 132 other cell types or tissues. DR ExpressionAtlas; Q8WUJ3; baseline and differential. DR GO; GO:0045334; C:clathrin-coated endocytic vesicle; IDA:UniProtKB. DR GO; GO:0005905; C:clathrin-coated pit; IEA:UniProtKB-SubCell. DR GO; GO:0030665; C:clathrin-coated vesicle membrane; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0001650; C:fibrillar center; IDA:HPA. DR GO; GO:0031965; C:nuclear membrane; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW. DR GO; GO:0032050; F:clathrin heavy chain binding; IDA:UniProtKB. DR GO; GO:0046923; F:ER retention sequence binding; IDA:UniProtKB. DR GO; GO:0005540; F:hyaluronic acid binding; IDA:UniProtKB. DR GO; GO:0004415; F:hyalurononglucosaminidase activity; IMP:UniProtKB. DR GO; GO:0030214; P:hyaluronan catabolic process; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB. DR GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:1900020; P:positive regulation of protein kinase C activity; IDA:UniProtKB. DR GO; GO:0090314; P:positive regulation of protein targeting to membrane; IDA:UniProtKB. DR GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IDA:UniProtKB. DR GO; GO:0007605; P:sensory perception of sound; IMP:UniProtKB. DR CDD; cd13941; PANDER_like_KIAA1199; 1. DR CDD; cd13938; PANDER_like_TMEM2; 1. DR InterPro; IPR052252; CEMIP/CEMIP2. DR InterPro; IPR055401; CEMIP_beta-hel_dom. DR InterPro; IPR055400; CEMIP_X. DR InterPro; IPR019316; G8_domain. DR InterPro; IPR039477; ILEI/PANDER_dom. DR InterPro; IPR011050; Pectin_lyase_fold/virulence. DR InterPro; IPR039473; TMEM2_PANDER-like. DR InterPro; IPR025155; WxxW_domain. DR PANTHER; PTHR15535:SF15; CELL MIGRATION-INDUCING AND HYALURONAN-BINDING PROTEIN; 1. DR PANTHER; PTHR15535; TRANSMEMBRANE PROTEIN 2-RELATED; 1. DR Pfam; PF24606; CEMIP_beta-hel; 1. DR Pfam; PF24605; CEMIP_X; 1. DR Pfam; PF10162; G8; 1. DR Pfam; PF15711; ILEI; 2. DR Pfam; PF13330; Mucin2_WxxW; 2. DR SMART; SM01225; G8; 1. DR SUPFAM; SSF51126; Pectin lyase-like; 1. DR PROSITE; PS51484; G8; 1. DR PROSITE; PS52031; GG_LECTIN; 2. PE 1: Evidence at protein level; KW Alternative splicing; Cell membrane; Coated pit; Cytoplasm; KW Endoplasmic reticulum; Glycoprotein; Glycosidase; Hyaluronic acid; KW Hydrolase; Lectin; Membrane; Nucleus; Proteomics identification; KW Reference proteome; Repeat; Secreted; Signal. FT SIGNAL 1..30 FT /evidence="ECO:0000269|PubMed:24269685" FT CHAIN 31..1361 FT /note="Cell migration-inducing and hyaluronan-binding FT protein" FT /id="PRO_0000021538" FT DOMAIN 44..166 FT /note="G8" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00817" FT DOMAIN 176..317 FT /note="GG-type lectin 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01375" FT REPEAT 572..594 FT /note="PbH1 1" FT REPEAT 595..617 FT /note="PbH1 2" FT REPEAT 719..741 FT /note="PbH1 3" FT REPEAT 798..819 FT /note="PbH1 4" FT DOMAIN 1227..1361 FT /note="GG-type lectin 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01375" FT REGION 295..591 FT /note="Necessary for its endoplasmic reticulum (ER) FT retention and interaction with HSPA5" FT /evidence="ECO:0000269|PubMed:23990668" FT CARBOHYD 119 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 165 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 312 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 370 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 420 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 889 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 921 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 978..992 FT /note="NWLVRHPDCINVPDW -> KWHSLASKAASGPSG (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_009814" FT VAR_SEQ 993..1361 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_009815" FT VARIANT 187 FT /note="R -> C (in a family with non-syndromic hearing loss; FT reduces hyaluronic acid degradation activity; FT dbSNP:rs368854657)" FT /evidence="ECO:0000269|PubMed:14577002, FT ECO:0000269|PubMed:23509262" FT /id="VAR_018165" FT VARIANT 187 FT /note="R -> H (in two unrelated families with non-syndromic FT hearing loss; reduces hyaluronic acid (HA) degradation FT activity; dbSNP:rs144446375)" FT /evidence="ECO:0000269|PubMed:14577002, FT ECO:0000269|PubMed:23509262" FT /id="VAR_018166" FT VARIANT 783 FT /note="H -> R (does not inhibit hyaluronic acid degradation FT activity; dbSNP:rs12441101)" FT /evidence="ECO:0000269|PubMed:14577002, FT ECO:0000269|PubMed:23509262" FT /id="VAR_018167" FT VARIANT 783 FT /note="H -> Y (in a sporadic case of non-syndromic hearing FT loss; dbSNP:rs996035812)" FT /evidence="ECO:0000269|PubMed:14577002" FT /id="VAR_018168" FT VARIANT 1109 FT /note="V -> I (does not inhibit hyaluronic acid degradation FT activity; dbSNP:rs751807711)" FT /evidence="ECO:0000269|PubMed:14577002, FT ECO:0000269|PubMed:23509262" FT /id="VAR_018169" FT VARIANT 1169 FT /note="P -> A (in dbSNP:rs16972583)" FT /evidence="ECO:0000269|PubMed:14577002" FT /id="VAR_018170" FT CONFLICT 558..564 FT /note="HFHLAGD -> TRPPTRP (in Ref. 6; CAB94391)" FT /evidence="ECO:0000305" FT CONFLICT 862 FT /note="H -> T (in Ref. 7; AAG41059)" FT /evidence="ECO:0000305" SQ SEQUENCE 1361 AA; 152998 MW; 40CDFFB84F99516C CRC64; MGAAGRQDFL FKAMLTISWL TLTCFPGATS TVAAGCPDQS PELQPWNPGH DQDHHVHIGQ GKTLLLTSSA TVYSIHISEG GKLVIKDHDE PIVLRTRHIL IDNGGELHAG SALCPFQGNF TIILYGRADE GIQPDPYYGL KYIGVGKGGA LELHGQKKLS WTFLNKTLHP GGMAEGGYFF ERSWGHRGVI VHVIDPKSGT VIHSDRFDTY RSKKESERLV QYLNAVPDGR ILSVAVNDEG SRNLDDMARK AMTKLGSKHF LHLGFRHPWS FLTVKGNPSS SVEDHIEYHG HRGSAAARVF KLFQTEHGEY FNVSLSSEWV QDVEWTEWFD HDKVSQTKGG EKISDLWKAH PGKICNRPID IQATTMDGVN LSTEVVYKKG QDYRFACYDR GRACRSYRVR FLCGKPVRPK LTVTIDTNVN STILNLEDNV QSWKPGDTLV IASTDYSMYQ AEEFQVLPCR SCAPNQVKVA GKPMYLHIGE EIDGVDMRAE VGLLSRNIIV MGEMEDKCYP YRNHICNFFD FDTFGGHIKF ALGFKAAHLE GTELKHMGQQ LVGQYPIHFH LAGDVDERGG YDPPTYIRDL SIHHTFSRCV TVHGSNGLLI KDVVGYNSLG HCFFTEDGPE ERNTFDHCLG LLVKSGTLLP SDRDSKMCKM ITEDSYPGYI PKPRQDCNAV STFWMANPNN NLINCAAAGS EETGFWFIFH HVPTGPSVGM YSPGYSEHIP LGKFYNNRAH SNYRAGMIID NGVKTTEASA KDKRPFLSII SARYSPHQDA DPLKPREPAI IRHFIAYKNQ DHGAWLRGGD VWLDSCRFAD NGIGLTLASG GTFPYDDGSK QEIKNSLFVG ESGNVGTEMM DNRIWGPGGL DHSGRTLPIG QNFPIRGIQL YDGPINIQNC TFRKFVALEG RHTSALAFRL NNAWQSCPHN NVTGIAFEDV PITSRVFFGE PGPWFNQLDM DGDKTSVFHD VDGSVSEYPG SYLTKNDNWL VRHPDCINVP DWRGAICSGC YAQMYIQAYK TSNLRMKIIK NDFPSHPLYL EGALTRSTHY QQYQPVVTLQ KGYTIHWDQT APAELAIWLI NFNKGDWIRV GLCYPRGTTF SILSDVHNRL LKQTSKTGVF VRTLQMDKVE QSYPGRSHYY WDEDSGLLFL KLKAQNEREK FAFCSMKGCE RIKIKALIPK NAGVSDCTAT AYPKFTERAV VDVPMPKKLF GSQLKTKDHF LEVKMESSKQ HFFHLWNDFA YIEVDGKKYP SSEDGIQVVV IDGNQGRVVS HTSFRNSILQ GIPWQLFNYV ATIPDNSIVL MASKGRYVSR GPWTRVLEKL GADRGLKLKE QMAFVGFKGS FRPIWVTLDT EDHKAKIFQV VPIPVVKKKK L // ID CPNE3_HUMAN Reviewed; 537 AA. AC O75131; A8KA47; Q8IYA1; DT 01-DEC-2000, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1998, sequence version 1. DT 28-JAN-2026, entry version 200. DE RecName: Full=Copine-3 {ECO:0000305}; DE AltName: Full=Copine III {ECO:0000303|PubMed:11041869, ECO:0000312|HGNC:HGNC:2316}; GN Name=CPNE3 {ECO:0000312|HGNC:HGNC:2316}; GN Synonyms=CPN3, KIAA0636 {ECO:0000303|PubMed:9734811}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, TISSUE SPECIFICITY, RP AND PHOSPHORYLATION. RX PubMed=11041869; DOI=10.1021/bi001250v; RA Caudell E.G., Caudell J.J., Tang C.-H., Yu T.-K., Frederick M.J., RA Grimm E.A.; RT "Characterization of human copine III as a phosphoprotein with associated RT kinase activity."; RL Biochemistry 39:13034-13043(2000). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=9734811; DOI=10.1093/dnares/5.3.169; RA Ishikawa K., Nagase T., Suyama M., Miyajima N., Tanaka A., Kotani H., RA Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. X. The RT complete sequences of 100 new cDNA clones from brain which can code for RT large proteins in vitro."; RL DNA Res. 5:169-176(1998). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT MET-412. RC TISSUE=Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain, and Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP SUBUNIT, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MASS SPECTROMETRY. RX PubMed=12949241; DOI=10.1189/jlb.0203083; RA Cowland J.B., Carter D., Bjerregaard M.D., Johnsen A.H., Borregaard N., RA Lollike K.; RT "Tissue expression of copines and isolation of copines I and III from the RT cytosol of human neutrophils."; RL J. Leukoc. Biol. 74:379-388(2003). RN [6] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [7] RP SUBCELLULAR LOCATION. RX PubMed=21087455; DOI=10.1111/j.1742-4658.2010.07935.x; RA Perestenko P.V., Pooler A.M., Noorbakhshnia M., Gray A., Bauccio C., RA Jeffrey McIlhinney R.A.; RT "Copines-1, -2, -3, -6 and -7 show different calcium-dependent RT intracellular membrane translocation and targeting."; RL FEBS J. 277:5174-5189(2010). RN [8] RP FUNCTION, INTERACTION WITH ERBB2; RACK1 AND SHC1, SUBCELLULAR LOCATION, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=20010870; DOI=10.1038/onc.2009.456; RA Heinrich C., Keller C., Boulay A., Vecchi M., Bianchi M., Sack R., RA Lienhard S., Duss S., Hofsteenge J., Hynes N.E.; RT "Copine-III interacts with ErbB2 and promotes tumor cell migration."; RL Oncogene 29:1598-1610(2010). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14 AND SER-243, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14 AND SER-197, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). CC -!- FUNCTION: Calcium-dependent phospholipid-binding protein that plays a CC role in ERBB2-mediated tumor cell migration in response to growth CC factor heregulin stimulation (PubMed:20010870). CC {ECO:0000269|PubMed:20010870}. CC -!- COFACTOR: CC Name=Ca(2+); Xref=ChEBI:CHEBI:29108; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU00041}; CC -!- SUBUNIT: Monomer (PubMed:12949241). Interacts with ERBB2 CC (preferentially with the tyrosine phosphorylated form); this CC interaction occurs at the cell membrane and is increased in a growth CC factor heregulin-dependent manner (PubMed:20010870). Interacts with CC SHC1; this interaction may mediate the binding of CPNE3 with ERBB2 CC (PubMed:20010870). Interacts with RACK1 (PubMed:20010870). CC {ECO:0000269|PubMed:12949241, ECO:0000269|PubMed:20010870}. CC -!- INTERACTION: CC O75131; Q9BSI4: TINF2; NbExp=2; IntAct=EBI-718988, EBI-717399; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20010870, CC ECO:0000269|PubMed:21087455}. Cytoplasm {ECO:0000269|PubMed:12949241, CC ECO:0000269|PubMed:20010870, ECO:0000269|PubMed:21087455}. Cell CC membrane {ECO:0000269|PubMed:20010870, ECO:0000269|PubMed:21087455}. CC Cell junction {ECO:0000269|PubMed:20010870}. Cell junction, focal CC adhesion {ECO:0000269|PubMed:20010870}. Note=Associates to the membrane CC in a calcium-dependent manner (PubMed:20010870). Translocates to the CC cell membrane and the nucleus in a calcium- or growth factor heregulin- CC dependent manner (PubMed:20010870, PubMed:21087455). Colocalizes with CC the tyrosine phosphorylated ERBB2 form at cell membrane and focal CC adhesions in a calcium- or growth factor heregulin-dependent manner CC (PubMed:20010870). {ECO:0000269|PubMed:20010870, CC ECO:0000269|PubMed:21087455}. CC -!- TISSUE SPECIFICITY: Expressed in breast and weakly in prostate and CC ovarian tissues (PubMed:20010870). Expressed in neutrophils (at protein CC level) (PubMed:12949241). Widely expressed (PubMed:11041869). Expressed CC in the brain. Expressed in neutrophil precursors from the bone marrow CC and peripheral blood (PubMed:12949241). Expressed in primary breast CC tumors and ovarian endometrioid adenocarcinoma (PubMed:20010870). CC {ECO:0000269|PubMed:11041869, ECO:0000269|PubMed:12949241, CC ECO:0000269|PubMed:20010870}. CC -!- PTM: Phosphorylated on serine and threonine residues (PubMed:11041869). CC {ECO:0000269|PubMed:11041869}. CC -!- SIMILARITY: Belongs to the copine family. {ECO:0000305}. CC -!- CAUTION: Was reported to have a protein kinase activity. CC {ECO:0000305|PubMed:11041869}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA31611.2; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF077226; AAD46074.2; -; mRNA. DR EMBL; AB014536; BAA31611.2; ALT_INIT; mRNA. DR EMBL; AK292912; BAF85601.1; -; mRNA. DR EMBL; BC036242; AAH36242.1; -; mRNA. DR EMBL; BC066597; AAH66597.1; -; mRNA. DR CCDS; CCDS6243.1; -. DR RefSeq; NP_003900.1; NM_003909.5. DR RefSeq; XP_005251150.1; XM_005251093.5. DR RefSeq; XP_016869434.1; XM_017013945.3. DR RefSeq; XP_024303090.1; XM_024447322.2. DR RefSeq; XP_047278349.1; XM_047422393.1. DR RefSeq; XP_047278350.1; XM_047422394.1. DR RefSeq; XP_047278351.1; XM_047422395.1. DR RefSeq; XP_054217423.1; XM_054361448.1. DR RefSeq; XP_054217424.1; XM_054361449.1. DR RefSeq; XP_054217425.1; XM_054361450.1. DR RefSeq; XP_054217426.1; XM_054361451.1. DR RefSeq; XP_054217427.1; XM_054361452.1. DR RefSeq; XP_054217428.1; XM_054361453.1. DR AlphaFoldDB; O75131; -. DR SMR; O75131; -. DR BioGRID; 114412; 124. DR FunCoup; O75131; 1341. DR IntAct; O75131; 51. DR MINT; O75131; -. DR STRING; 9606.ENSP00000477590; -. DR TCDB; 8.A.210.1.2; the plasma membrane repair (pmr) family. DR GlyCosmos; O75131; 1 site, 1 glycan. DR GlyGen; O75131; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; O75131; -. DR MetOSite; O75131; -. DR PhosphoSitePlus; O75131; -. DR SwissPalm; O75131; -. DR BioMuta; CPNE3; -. DR jPOST; O75131; -. DR MassIVE; O75131; -. DR PaxDb; 9606-ENSP00000477590; -. DR PeptideAtlas; O75131; -. DR ProteomicsDB; 49793; -. DR Pumba; O75131; -. DR Antibodypedia; 25495; 163 antibodies from 29 providers. DR DNASU; 8895; -. DR Ensembl; ENST00000517490.6; ENSP00000477590.1; ENSG00000085719.14. DR GeneID; 8895; -. DR KEGG; hsa:8895; -. DR MANE-Select; ENST00000517490.6; ENSP00000477590.1; NM_003909.5; NP_003900.1. DR UCSC; uc033bsf.1; human. DR AGR; HGNC:2316; -. DR ClinPGx; PA26833; -. DR CTD; 8895; -. DR DisGeNET; 8895; -. DR GeneCards; CPNE3; -. DR HGNC; HGNC:2316; CPNE3. DR HPA; ENSG00000085719; Low tissue specificity. DR MIM; 604207; gene. DR OpenTargets; ENSG00000085719; -. DR VEuPathDB; HostDB:ENSG00000085719; -. DR eggNOG; KOG1327; Eukaryota. DR GeneTree; ENSGT00940000154968; -. DR HOGENOM; CLU_020452_3_2_1; -. DR InParanoid; O75131; -. DR OMA; EMAAQCV; -. DR OrthoDB; 5855668at2759; -. DR PAN-GO; O75131; 5 GO annotations based on evolutionary models. DR PhylomeDB; O75131; -. DR PathwayCommons; O75131; -. DR Reactome; R-HSA-1483206; Glycerophospholipid biosynthesis. DR Reactome; R-HSA-6798695; Neutrophil degranulation. DR SignaLink; O75131; -. DR Agora; ENSG00000085719; -. DR BioGRID-ORCS; 8895; 9 hits in 1158 CRISPR screens. DR ChiTaRS; CPNE3; human. DR GenomeRNAi; 8895; -. DR Pharos; O75131; Tbio. DR PRO; PR:O75131; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; O75131; protein. DR Bgee; ENSG00000085719; Expressed in tongue squamous epithelium and 211 other cell types or tissues. DR ExpressionAtlas; O75131; baseline and differential. DR GO; GO:0035577; C:azurophil granule membrane; TAS:Reactome. DR GO; GO:0030054; C:cell junction; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005925; C:focal adhesion; IDA:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:HPA. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0005544; F:calcium-dependent phospholipid binding; IDA:UniProtKB. DR GO; GO:0048306; F:calcium-dependent protein binding; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0005543; F:phospholipid binding; TAS:Reactome. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:UniProtKB. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0071277; P:cellular response to calcium ion; IDA:UniProtKB. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:UniProtKB. DR GO; GO:0038128; P:ERBB2 signaling pathway; IDA:UniProtKB. DR GO; GO:0046474; P:glycerophospholipid biosynthetic process; TAS:Reactome. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB. DR CDD; cd04048; C2A_Copine; 1. DR CDD; cd04047; C2B_Copine; 1. DR CDD; cd01459; vWA_copine_like; 1. DR FunFam; 2.60.40.150:FF:000042; Copine 3; 1. DR FunFam; 2.60.40.150:FF:000099; Copine 3; 1. DR Gene3D; 2.60.40.150; C2 domain; 2. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR037768; C2B_Copine. DR InterPro; IPR045052; Copine. DR InterPro; IPR010734; Copine_C. DR InterPro; IPR002035; VWF_A. DR InterPro; IPR036465; vWFA_dom_sf. DR PANTHER; PTHR10857; COPINE; 1. DR PANTHER; PTHR10857:SF22; COPINE-3; 1. DR Pfam; PF00168; C2; 2. DR Pfam; PF07002; Copine; 1. DR SMART; SM00239; C2; 2. DR SMART; SM00327; VWA; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 2. DR SUPFAM; SSF53300; vWA-like; 1. DR PROSITE; PS50004; C2; 2. PE 1: Evidence at protein level; KW Calcium; Cell junction; Cell membrane; Cytoplasm; KW Direct protein sequencing; Membrane; Metal-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat. FT CHAIN 1..537 FT /note="Copine-3" FT /id="PRO_0000144838" FT DOMAIN 1..115 FT /note="C2 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 124..247 FT /note="C2 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 291..513 FT /note="VWFA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00219" FT BINDING 22 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 22 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 28 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 81 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 81 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 83 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 83 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 93 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 154 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 154 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 160 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 216 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 216 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 218 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 218 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 224 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT MOD_RES 14 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 197 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 243 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VARIANT 252 FT /note="E -> D (in dbSNP:rs41333046)" FT /id="VAR_048848" FT VARIANT 412 FT /note="T -> M (in dbSNP:rs2304789)" FT /evidence="ECO:0000269|PubMed:14702039" FT /id="VAR_024424" FT CONFLICT 394 FT /note="P -> Q (in Ref. 4; AAH36242)" FT /evidence="ECO:0000305" FT CONFLICT 419 FT /note="Q -> R (in Ref. 4; AAH36242)" FT /evidence="ECO:0000305" FT CONFLICT 475 FT /note="R -> H (in Ref. 4; AAH36242)" FT /evidence="ECO:0000305" SQ SEQUENCE 537 AA; 60131 MW; 91F2C5EAD611B842 CRC64; MAAQCVTKVA LNVSCANLLD KDIGSKSDPL CVLFLNTSGQ QWYEVERTER IKNCLNPQFS KTFIIDYYFE VVQKLKFGVY DIDNKTIELS DDDFLGECEC TLGQIVSSKK LTRPLVMKTG RPAGKGSITI SAEEIKDNRV VLFEMEARKL DNKDLFGKSD PYLEFHKQTS DGNWLMVHRT EVVKNNLNPV WRPFKISLNS LCYGDMDKTI KVECYDYDND GSHDLIGTFQ TTMTKLKEAS RSSPVEFECI NEKKRQKKKS YKNSGVISVK QCEITVECTF LDYIMGGCQL NFTVGVDFTG SNGDPRSPDS LHYISPNGVN EYLTALWSVG LVIQDYDADK MFPAFGFGAQ IPPQWQVSHE FPMNFNPSNP YCNGIQGIVE AYRSCLPQIK LYGPTNFSPI INHVARFAAA ATQQQTASQY FVLLIITDGV ITDLDETRQA IVNASRLPMS IIIVGVGGAD FSAMEFLDGD GGSLRSPLGE VAIRDIVQFV PFRQFQNAPK EALAQCVLAE IPQQVVGYFN TYKLLPPKNP ATKQQKQ // ID DCLK1_HUMAN Reviewed; 740 AA. AC O15075; B7Z3E9; Q5VZY8; Q5VZZ0; Q5VZZ1; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 30-MAY-2000, sequence version 2. DT 28-JAN-2026, entry version 221. DE RecName: Full=Serine/threonine-protein kinase DCLK1; DE EC=2.7.11.1; DE AltName: Full=Doublecortin domain-containing protein 3A; DE AltName: Full=Doublecortin-like and CAM kinase-like 1; DE AltName: Full=Doublecortin-like kinase 1; GN Name=DCLK1; Synonyms=DCAMKL1, DCDC3A, KIAA0369; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 4). RX PubMed=9747029; DOI=10.1007/s100380050063; RA Omori Y., Suzuki M., Ozaki K., Harada Y., Nakamura Y., Takahashi E., RA Fujiwara T.; RT "Expression and chromosomal localization of KIAA0369, a putative kinase RT structurally related to Doublecortin."; RL J. Hum. Genet. 43:169-177(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Fetal brain; RX PubMed=10036192; DOI=10.1006/geno.1998.5718; RA Sossey-Alaoui K., Srivastava A.K.; RT "DCAMKL1, a brain-specific transmembrane protein on 13q12.3 that is similar RT to doublecortin (DCX)."; RL Genomics 56:121-126(1999). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=9205841; DOI=10.1093/dnares/4.2.141; RA Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N., RA Tanaka A., Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. VII. The RT complete sequences of 100 new cDNA clones from brain which can code for RT large proteins in vitro."; RL DNA Res. 4:141-150(1997). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Hippocampus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057823; DOI=10.1038/nature02379; RA Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L., RA Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S., RA Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P., RA Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L., RA Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P., RA Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P., RA Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C., RA Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P., RA Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L., RA Frankish A.G., Frankland J., French L., Garner P., Garnett J., RA Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M., RA Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D., RA Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D., RA Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., RA Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S., RA Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S., RA Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R., RA Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W., RA Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P., RA Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L., RA Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R., RA Rogers J., Ross M.T.; RT "The DNA sequence and analysis of human chromosome 13."; RL Nature 428:522-528(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (FEB-2008) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP TISSUE SPECIFICITY. RX PubMed=10051403; DOI=10.1006/geno.1998.5673; RA Matsumoto N., Pilz D.T., Ledbetter D.H.; RT "Genomic structure, chromosomal mapping, and expression pattern of human RT DCAMKL1 (KIAA0369), a homologue of DCX (XLIS)."; RL Genomics 56:179-183(1999). RN [9] RP INDUCTION, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=16548883; DOI=10.1111/j.1462-5822.2005.00644.x; RA Leong W.F., Chow V.T.; RT "Transcriptomic and proteomic analyses of rhabdomyosarcoma cells reveal RT differential cellular gene expression in response to enterovirus 71 RT infection."; RL Cell. Microbiol. 8:565-580(2006). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-352, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [11] RP STRUCTURE BY NMR OF 51-156. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the N-terminal DCX domain of human doublecortin-like RT kinase."; RL Submitted (NOV-2003) to the PDB data bank. RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-29; MET-46; GLN-93; PHE-291 AND RP HIS-292. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Probable kinase that may be involved in a calcium-signaling CC pathway controlling neuronal migration in the developing brain. May CC also participate in functions of the mature nervous system. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- INTERACTION: CC O15075; Q96M94: KLHL15; NbExp=2; IntAct=EBI-2684263, EBI-2510129; CC O15075-2; Q9UJX2: CDC23; NbExp=3; IntAct=EBI-12324841, EBI-396137; CC O15075-2; Q5JST6: EFHC2; NbExp=3; IntAct=EBI-12324841, EBI-2349927; CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Comment=Additional isoforms seem to exist. Type A (AS and AL) and CC type B (BS and BL) isoforms differ respectively by the presence or CC absence of the doublecortin domain. An alternative splicing occurring CC in 3' of the mRNA produces the long (L) instead of the short (S) CC isoforms.; CC Name=2; Synonyms=AL; CC IsoId=O15075-1; Sequence=Displayed; CC Name=1; Synonyms=AS; CC IsoId=O15075-2; Sequence=VSP_004907; CC Name=3; Synonyms=BS; CC IsoId=O15075-3; Sequence=VSP_004905, VSP_004906, VSP_004907; CC Name=4; Synonyms=BL; CC IsoId=O15075-4; Sequence=VSP_004905, VSP_004906; CC -!- TISSUE SPECIFICITY: In fetal tissues, highly expressed in brain, CC detectable in lung and liver, but not in kidney. In adult tissues, CC expressed ubiquitously in the brain, detectable in the heart, liver, CC spleen, thymus, prostate, testis, ovary, small intestine and colon. The CC type A isoforms seem to be expressed predominantly in fetal brain CC whereas type B isoforms are expressed abundantly in both fetal and CC adult brain. {ECO:0000269|PubMed:10051403}. CC -!- INDUCTION: Up-regulated in response to enterovirus 71 (EV71) infection CC (at protein level). {ECO:0000269|PubMed:16548883}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. CaMK subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA20824.2; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB002367; BAA20824.2; ALT_INIT; mRNA. DR EMBL; AL157760; CAH70167.1; -; Genomic_DNA. DR EMBL; AL157694; CAH70167.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAH70167.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAH70167.1; JOINED; Genomic_DNA. DR EMBL; AL157760; CAH70170.1; -; Genomic_DNA. DR EMBL; AK295777; BAH12185.1; -; mRNA. DR EMBL; AL157760; CAH70168.1; -; Genomic_DNA. DR EMBL; AL157694; CAH70168.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAH70168.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAH70168.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAH70261.1; -; Genomic_DNA. DR EMBL; AL157694; CAH70261.1; JOINED; Genomic_DNA. DR EMBL; AL157760; CAH70261.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAH70261.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAH70262.1; -; Genomic_DNA. DR EMBL; AL157694; CAH70262.1; JOINED; Genomic_DNA. DR EMBL; AL157760; CAH70262.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAH70262.1; JOINED; Genomic_DNA. DR EMBL; AL157694; CAH70656.1; -; Genomic_DNA. DR EMBL; AL157760; CAH70656.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAH70656.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAH70656.1; JOINED; Genomic_DNA. DR EMBL; AL157694; CAH70657.1; -; Genomic_DNA. DR EMBL; AL157760; CAH70657.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAH70657.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAH70657.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAI15720.1; -; Genomic_DNA. DR EMBL; AL157694; CAI15720.1; JOINED; Genomic_DNA. DR EMBL; AL157760; CAI15720.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAI15720.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAI15721.1; -; Genomic_DNA. DR EMBL; AL157694; CAI15721.1; JOINED; Genomic_DNA. DR EMBL; AL157760; CAI15721.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAI15721.1; JOINED; Genomic_DNA. DR EMBL; CH471075; EAX08550.1; -; Genomic_DNA. DR EMBL; CH471075; EAX08551.1; -; Genomic_DNA. DR EMBL; BC152456; AAI52457.1; -; mRNA. DR CCDS; CCDS55895.1; -. [O15075-4] DR CCDS; CCDS73561.1; -. [O15075-3] DR CCDS; CCDS81762.1; -. [O15075-1] DR CCDS; CCDS9354.1; -. [O15075-2] DR RefSeq; NP_001182344.1; NM_001195415.2. [O15075-3] DR RefSeq; NP_001182345.1; NM_001195416.2. [O15075-4] DR RefSeq; NP_001317000.1; NM_001330071.2. [O15075-1] DR RefSeq; NP_001317001.1; NM_001330072.2. [O15075-1] DR RefSeq; NP_004725.1; NM_004734.5. [O15075-2] DR PDB; 1MFW; X-ray; 1.60 A; A=49-154. DR PDB; 1MG4; X-ray; 1.50 A; A=49-154. DR PDB; 1UF0; NMR; -; A=54-156. DR PDB; 5JZJ; X-ray; 1.71 A; A/B=372-649. DR PDB; 5JZN; X-ray; 2.85 A; A/B=372-649. DR PDB; 6KYQ; X-ray; 2.14 A; A/B=379-704. DR PDB; 6KYR; X-ray; 2.21 A; A/B=379-704. DR PDB; 7F3G; X-ray; 2.10 A; A/B=372-649. DR PDB; 7KX6; X-ray; 2.50 A; A/B=372-649. DR PDB; 7KX8; X-ray; 3.10 A; A/B=372-686. DR PDB; 7KXW; X-ray; 3.00 A; A/B=372-649. DR PDBsum; 1MFW; -. DR PDBsum; 1MG4; -. DR PDBsum; 1UF0; -. DR PDBsum; 5JZJ; -. DR PDBsum; 5JZN; -. DR PDBsum; 6KYQ; -. DR PDBsum; 6KYR; -. DR PDBsum; 7F3G; -. DR PDBsum; 7KX6; -. DR PDBsum; 7KX8; -. DR PDBsum; 7KXW; -. DR AlphaFoldDB; O15075; -. DR SMR; O15075; -. DR BioGRID; 114635; 123. DR FunCoup; O15075; 1256. DR IntAct; O15075; 121. DR MINT; O15075; -. DR STRING; 9606.ENSP00000353846; -. DR BindingDB; O15075; -. DR ChEMBL; CHEMBL5683; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; O15075; -. DR GuidetoPHARMACOLOGY; 2005; -. DR CarbonylDB; O15075; -. DR GlyGen; O15075; 1 site, 1 N-linked glycan (1 site). DR iPTMnet; O15075; -. DR PhosphoSitePlus; O15075; -. DR SwissPalm; O15075; -. DR BioMuta; DCLK1; -. DR jPOST; O15075; -. DR MassIVE; O15075; -. DR PaxDb; 9606-ENSP00000255448; -. DR PeptideAtlas; O15075; -. DR ProteomicsDB; 48428; -. [O15075-1] DR ProteomicsDB; 48429; -. [O15075-2] DR ProteomicsDB; 48430; -. [O15075-3] DR ProteomicsDB; 48431; -. [O15075-4] DR Pumba; O15075; -. DR Antibodypedia; 23046; 446 antibodies from 40 providers. DR DNASU; 9201; -. DR Ensembl; ENST00000255448.8; ENSP00000255448.4; ENSG00000133083.16. [O15075-2] DR Ensembl; ENST00000360631.8; ENSP00000353846.3; ENSG00000133083.16. [O15075-1] DR Ensembl; ENST00000379893.5; ENSP00000369223.1; ENSG00000133083.16. [O15075-4] DR Ensembl; ENST00000615680.5; ENSP00000484452.1; ENSG00000133083.16. [O15075-3] DR GeneID; 9201; -. DR KEGG; hsa:9201; -. DR MANE-Select; ENST00000360631.8; ENSP00000353846.3; NM_001330071.2; NP_001317000.1. DR UCSC; uc001uve.4; human. [O15075-1] DR AGR; HGNC:2700; -. DR ClinPGx; PA162383325; -. DR CTD; 9201; -. DR DisGeNET; 9201; -. DR GeneCards; DCLK1; -. DR HGNC; HGNC:2700; DCLK1. DR HPA; ENSG00000133083; Tissue enhanced (brain). DR MIM; 604742; gene. DR OpenTargets; ENSG00000133083; -. DR VEuPathDB; HostDB:ENSG00000133083; -. DR eggNOG; KOG0032; Eukaryota. DR eggNOG; KOG3757; Eukaryota. DR GeneTree; ENSGT00940000154956; -. DR HOGENOM; CLU_000288_63_0_1; -. DR InParanoid; O15075; -. DR OMA; CWEFEGS; -. DR OrthoDB; 1738954at2759; -. DR PAN-GO; O15075; 1 GO annotation based on evolutionary models. DR PhylomeDB; O15075; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; O15075; -. DR SignaLink; O15075; -. DR SIGNOR; O15075; -. DR Agora; ENSG00000133083; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 9201; 13 hits in 1181 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; DCLK1; human. DR EvolutionaryTrace; O15075; -. DR GeneWiki; DCLK1; -. DR GenomeRNAi; 9201; -. DR Pharos; O15075; Tchem. DR PRO; PR:O15075; -. DR Proteomes; UP000005640; Chromosome 13. DR RNAct; O15075; protein. DR Bgee; ENSG00000133083; Expressed in endothelial cell and 188 other cell types or tissues. DR ExpressionAtlas; O15075; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; TAS:ProtInc. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0048675; P:axon extension; IBA:GO_Central. DR GO; GO:0007417; P:central nervous system development; TAS:ProtInc. DR GO; GO:0016197; P:endosomal transport; NAS:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro. DR GO; GO:0007399; P:nervous system development; TAS:ProtInc. DR GO; GO:0034504; P:protein localization to nucleus; IBA:GO_Central. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0009615; P:response to virus; IEP:UniProtKB. DR CDD; cd17140; DCX1_DCLK1; 1. DR CDD; cd17069; DCX2; 1. DR CDD; cd14183; STKc_DCKL1; 1. DR FunFam; 3.10.20.230:FF:000003; Neuronal migration protein doublecortin; 1. DR FunFam; 1.10.510.10:FF:000066; Serine/threonine-protein kinase DCLK1 isoform 2; 1. DR FunFam; 3.30.200.20:FF:000057; Serine/threonine-protein kinase DCLK1 isoform 2; 1. DR FunFam; 3.10.20.230:FF:000001; serine/threonine-protein kinase DCLK1 isoform X1; 1. DR Gene3D; 3.10.20.230; Doublecortin domain; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003533; Doublecortin_dom. DR InterPro; IPR036572; Doublecortin_dom_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24347; SERINE/THREONINE-PROTEIN KINASE; 1. DR Pfam; PF03607; DCX; 2. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00537; DCX; 2. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF89837; Doublecortin (DC); 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50309; DC; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Developmental protein; KW Differentiation; Kinase; Neurogenesis; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..740 FT /note="Serine/threonine-protein kinase DCLK1" FT /id="PRO_0000085919" FT DOMAIN 57..143 FT /note="Doublecortin 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00072" FT DOMAIN 186..269 FT /note="Doublecortin 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00072" FT DOMAIN 390..647 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 287..378 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 697..740 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 297..313 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 347..362 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 366..377 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 697..707 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 511 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 396..404 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 419 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 32 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 36 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 46 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 305 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 307 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 330 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 332 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 334 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 337 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 347 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 352 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 353 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O08875" FT MOD_RES 355 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 364 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 376 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 520 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 726 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 735 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 738 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT VAR_SEQ 1..307 FT /note="Missing (in isoform 3 and isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:9747029" FT /id="VSP_004905" FT VAR_SEQ 308..313 FT /note="PASTSS -> MLELIE (in isoform 3 and isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:9747029" FT /id="VSP_004906" FT VAR_SEQ 687..740 FT /note="TTALDKERQVFRRRRNQDVRSRYKAQPAPPELNSESEDYSPSSSETVRSPNS FT PF -> LDHGFTIKRSGSLDYYQQPGMYWIRPPLLIRRGRFSDEDATRM (in FT isoform 1 and isoform 3)" FT /evidence="ECO:0000303|PubMed:10036192, FT ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:9205841, ECO:0000303|PubMed:9747029" FT /id="VSP_004907" FT VARIANT 29 FT /note="G -> C (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045673" FT VARIANT 46 FT /note="T -> M (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045674" FT VARIANT 93 FT /note="R -> Q (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1366698690)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045675" FT VARIANT 291 FT /note="S -> F (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045676" FT VARIANT 292 FT /note="R -> H (in dbSNP:rs56185003)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045677" FT HELIX 53..55 FT /evidence="ECO:0007829|PDB:1MFW" FT STRAND 56..63 FT /evidence="ECO:0007829|PDB:1MG4" FT STRAND 72..76 FT /evidence="ECO:0007829|PDB:1MG4" FT TURN 78..80 FT /evidence="ECO:0007829|PDB:1MG4" FT HELIX 84..95 FT /evidence="ECO:0007829|PDB:1MG4" FT STRAND 98..101 FT /evidence="ECO:0007829|PDB:1MG4" FT STRAND 107..110 FT /evidence="ECO:0007829|PDB:1MG4" FT HELIX 120..122 FT /evidence="ECO:0007829|PDB:1MG4" FT STRAND 128..135 FT /evidence="ECO:0007829|PDB:1MG4" FT TURN 142..145 FT /evidence="ECO:0007829|PDB:1MG4" FT HELIX 148..151 FT /evidence="ECO:0007829|PDB:1MG4" FT HELIX 384..389 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 390..398 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 400..409 FT /evidence="ECO:0007829|PDB:5JZJ" FT TURN 410..412 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 415..422 FT /evidence="ECO:0007829|PDB:5JZJ" FT TURN 423..425 FT /evidence="ECO:0007829|PDB:6KYQ" FT STRAND 427..429 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 436..440 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 451..456 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 458..466 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 473..480 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 485..504 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 514..516 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 517..521 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 523..525 FT /evidence="ECO:0007829|PDB:7KX6" FT STRAND 527..531 FT /evidence="ECO:0007829|PDB:5JZJ" FT TURN 551..553 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 556..560 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 568..582 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 596..603 FT /evidence="ECO:0007829|PDB:5JZJ" FT TURN 610..615 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 618..627 FT /evidence="ECO:0007829|PDB:5JZJ" FT TURN 632..634 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 638..643 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 645..647 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 662..668 FT /evidence="ECO:0007829|PDB:6KYQ" FT TURN 678..682 FT /evidence="ECO:0007829|PDB:6KYQ" FT HELIX 683..686 FT /evidence="ECO:0007829|PDB:6KYQ" FT HELIX 689..691 FT /evidence="ECO:0007829|PDB:6KYQ" SQ SEQUENCE 740 AA; 82224 MW; D7B6D855099A315C CRC64; MSFGRDMELE HFDERDKAQR YSRGSRVNGL PSPTHSAHCS FYRTRTLQTL SSEKKAKKVR FYRNGDRYFK GIVYAISPDR FRSFEALLAD LTRTLSDNVN LPQGVRTIYT IDGLKKISSL DQLVEGESYV CGSIEPFKKL EYTKNVNPNW SVNVKTTSAS RAVSSLATAK GSPSEVRENK DFIRPKLVTI IRSGVKPRKA VRILLNKKTA HSFEQVLTDI TDAIKLDSGV VKRLYTLDGK QVMCLQDFFG DDDIFIACGP EKFRYQDDFL LDESECRVVK STSYTKIASS SRRSTTKSPG PSRRSKSPAS TSSVNGTPGS QLSTPRSGKS PSPSPTSPGS LRKQRSSQHG GSSTSLASTK VCSSMDENDG PGEEVSEEGF QIPATITERY KVGRTIGDGN FAVVKECVER STAREYALKI IKKSKCRGKE HMIQNEVSIL RRVKHPNIVL LIEEMDVPTE LYLVMELVKG GDLFDAITST NKYTERDASG MLYNLASAIK YLHSLNIVHR DIKPENLLVY EHQDGSKSLK LGDFGLATIV DGPLYTVCGT PTYVAPEIIA ETGYGLKVDI WAAGVITYIL LCGFPPFRGS GDDQEVLFDQ ILMGQVDFPS PYWDNVSDSA KELITMMLLV DVDQRFSAVQ VLEHPWVNDD GLPENEHQLS VAGKIKKHFN TGPKPNSTAA GVSVIATTAL DKERQVFRRR RNQDVRSRYK AQPAPPELNS ESEDYSPSSS ETVRSPNSPF // ID ECT2_HUMAN Reviewed; 914 AA. AC Q9H8V3; Q0MT80; Q2M269; Q6U836; Q9NSV8; Q9NVW9; DT 26-SEP-2001, integrated into UniProtKB/Swiss-Prot. DT 16-NOV-2011, sequence version 4. DT 28-JAN-2026, entry version 195. DE RecName: Full=Protein ECT2; DE AltName: Full=Epithelial cell-transforming sequence 2 oncogene; GN Name=ECT2 {ECO:0000312|HGNC:HGNC:3155}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, PHOSPHORYLATION, AND RP SUBCELLULAR LOCATION. RX PubMed=10579713; DOI=10.1083/jcb.147.5.921; RA Tatsumoto T., Xie X., Blumenthal R., Okamoto I., Miki T.; RT "Human ECT2 is an exchange factor for Rho GTPases, phosphorylated in G2/M RT phases, and involved in cytokinesis."; RL J. Cell Biol. 147:921-928(1999). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RX PubMed=14587037; DOI=10.1002/jcb.10688; RA Saito S., Tatsumoto T., Lorenzi M.V., Chedid M., Kapoor V., Sakata H., RA Rubin J.S., Miki T.; RT "Rho exchange factor ECT2 is induced by growth factors and regulates RT cytokinesis through the N-terminal cell cycle regulator-related domains."; RL J. Cell. Biochem. 90:819-836(2003). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH PKP4, AND RP SUBCELLULAR LOCATION. RX PubMed=17115030; DOI=10.1038/ncb1504; RA Wolf A., Keil R., Gotzl O., Mun A., Schwarze K., Lederer M., RA Huttelmaier S., Hatzfeld M.; RT "The armadillo protein p0071 regulates Rho signalling during cytokinesis."; RL Nat. Cell Biol. 8:1432-1440(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Teratocarcinoma, and Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 662-914 (ISOFORM 3). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [8] RP FUNCTION, HOMODIMERIZATION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP 379-ARG--ARG-381; 402-ARG--ARG-404 AND 596-PRO--ARG-599. RX PubMed=14645260; DOI=10.1074/jbc.m306725200; RA Saito S., Liu X.F., Kamijo K., Raziuddin R., Tatsumoto T., Okamoto I., RA Chen X., Lee C.C., Lorenzi M.V., Ohara N., Miki T.; RT "Deregulation and mislocalization of the cytokinesis regulator ECT2 RT activate the Rho signaling pathways leading to malignant transformation."; RL J. Biol. Chem. 279:7169-7179(2004). RN [9] RP FUNCTION, INTERACTION WITH PARD3; PARD6A; PARD6B AND PRKCQ, INDUCTION, AND RP SUBCELLULAR LOCATION. RX PubMed=15254234; DOI=10.1128/mcb.24.15.6665-6675.2004; RA Liu X.F., Ishida H., Raziuddin R., Miki T.; RT "Nucleotide exchange factor ECT2 interacts with the polarity protein RT complex Par6/Par3/protein kinase Czeta (PKCzeta) and regulates PKCzeta RT activity."; RL Mol. Cell. Biol. 24:6665-6675(2004). RN [10] RP FUNCTION, HOMODIMERIZATION, HOMOOLIGOMERIZATION, AND MUTAGENESIS OF RP TRP-336. RX PubMed=15545273; DOI=10.1074/jbc.m409298200; RA Kim J.E., Billadeau D.D., Chen J.; RT "The tandem BRCT domains of Ect2 are required for both negative and RT positive regulation of Ect2 in cytokinesis."; RL J. Biol. Chem. 280:5733-5739(2005). RN [11] RP FUNCTION. RX PubMed=15642749; DOI=10.1083/jcb.200408085; RA Oceguera-Yanez F., Kimura K., Yasuda S., Higashida C., Kitamura T., RA Hiraoka Y., Haraguchi T., Narumiya S.; RT "Ect2 and MgcRacGAP regulate the activation and function of Cdc42 in RT mitosis."; RL J. Cell Biol. 168:221-232(2005). RN [12] RP FUNCTION, INTERACTION WITH RACGAP1, MUTAGENESIS OF THR-373, AND SUBCELLULAR RP LOCATION. RX PubMed=16103226; DOI=10.1083/jcb.200501097; RA Yuce O., Piekny A., Glotzer M.; RT "An ECT2-centralspindlin complex regulates the localization and function of RT RhoA."; RL J. Cell Biol. 170:571-582(2005). RN [13] RP INTERACTION WITH RACGAP1. RX PubMed=16129829; DOI=10.1073/pnas.0504145102; RA Zhao W.-M., Fang G.; RT "MgcRacGAP controls the assembly of the contractile ring and the initiation RT of cytokinesis."; RL Proc. Natl. Acad. Sci. U.S.A. 102:13158-13163(2005). RN [14] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=16495035; DOI=10.1016/j.cellsig.2006.01.007; RA Liu X.F., Ohno S., Miki T.; RT "Nucleotide exchange factor ECT2 regulates epithelial cell polarity."; RL Cell. Signal. 18:1604-1615(2006). RN [15] RP INTERACTION WITH NEDD9, AND SUBCELLULAR LOCATION. RX PubMed=16394104; DOI=10.1091/mbc.e05-03-0237; RA Dadke D., Jarnik M., Pugacheva E.N., Singh M.K., Golemis E.A.; RT "Deregulation of HEF1 impairs M-phase progression by disrupting the RhoA RT activation cycle."; RL Mol. Biol. Cell 17:1204-1217(2006). RN [16] RP FUNCTION, IDENTIFICATION IN THE CENTRALSPINDLIN COMPLEX, INTERACTION WITH RP KIF23 AND RACGAP1, AND SUBCELLULAR LOCATION. RX PubMed=16236794; DOI=10.1091/mbc.e05-06-0569; RA Kamijo K., Ohara N., Abe M., Uchimura T., Hosoya H., Lee J.S., Miki T.; RT "Dissecting the role of Rho-mediated signaling in contractile ring RT formation."; RL Mol. Biol. Cell 17:43-55(2006). RN [17] RP FUNCTION, HOMODIMERIZATION, PHOSPHORYLATION AT THR-373, AND MUTAGENESIS OF RP THR-373. RX PubMed=16170345; DOI=10.1038/sj.onc.1209078; RA Hara T., Abe M., Inoue H., Yu L.R., Veenstra T.D., Kang Y.H., Lee K.S., RA Miki T.; RT "Cytokinesis regulator ECT2 changes its conformation through RT phosphorylation at Thr-341 in G2/M phase."; RL Oncogene 25:566-578(2006). RN [18] RP PHOSPHORYLATION AT THR-444, INTERACTION WITH PLK1, AND MUTAGENESIS OF RP THR-444 AND THR-846. RX PubMed=16247472; DOI=10.1038/sj.onc.1209124; RA Niiya F., Tatsumoto T., Lee K.S., Miki T.; RT "Phosphorylation of the cytokinesis regulator ECT2 at G2/M phase stimulates RT association of the mitotic kinase Plk1 and accumulation of GTP-bound RT RhoA."; RL Oncogene 25:827-837(2006). RN [19] RP INTERACTION WITH RAB11FIP3. RX PubMed=18511905; DOI=10.1038/emboj.2008.112; RA Simon G.C., Schonteich E., Wu C.C., Piekny A., Ekiert D., Yu X., RA Gould G.W., Glotzer M., Prekeris R.; RT "Sequential Cyk-4 binding to ECT2 and FIP3 regulates cleavage furrow RT ingression and abscission during cytokinesis."; RL EMBO J. 27:1791-1803(2008). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-367; SER-370; THR-373; RP SER-376; SER-842 AND THR-846, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [22] RP FUNCTION. RX PubMed=19129481; DOI=10.1091/mbc.e08-01-0001; RA Asiedu M., Wu D., Matsumura F., Wei Q.; RT "Centrosome/spindle pole-associated protein regulates cytokinesis via RT promoting the recruitment of MyoGEF to the central spindle."; RL Mol. Biol. Cell 20:1428-1440(2009). RN [23] RP FUNCTION, INTERACTION WITH PARD6A AND PRKCI, SUBCELLULAR LOCATION, AND RP TISSUE SPECIFICITY. RX PubMed=19617897; DOI=10.1038/onc.2009.217; RA Justilien V., Fields A.P.; RT "Ect2 links the PKCiota-Par6alpha complex to Rac1 activation and cellular RT transformation."; RL Oncogene 28:3597-3607(2009). RN [24] RP FUNCTION, INTERACTION WITH KIF23 AND RACGAP1, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF THR-184 AND LYS-226. RX PubMed=19468300; DOI=10.1371/journal.pbio.1000110; RA Wolfe B.A., Takaki T., Petronczki M., Glotzer M.; RT "Polo-like kinase 1 directs assembly of the HsCyk-4 RhoGAP/Ect2 RhoGEF RT complex to initiate cleavage furrow formation."; RL PLoS Biol. 7:E1000110-E1000110(2009). RN [25] RP INTERACTION WITH RACGAP1. RX PubMed=19468302; DOI=10.1371/journal.pbio.1000111; RA Burkard M.E., Maciejowski J., Rodriguez-Bravo V., Repka M., Lowery D.M., RA Clauser K.R., Zhang C., Shokat K.M., Carr S.A., Yaffe M.B., RA Jallepalli P.V.; RT "Plk1 self-organization and priming phosphorylation of HsCYK-4 at the RT spindle midzone regulate the onset of division in human cells."; RL PLoS Biol. 7:E1000111-E1000111(2009). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-359, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [28] RP FUNCTION, PHOSPHORYLATION AT THR-359, MUTAGENESIS OF THR-359, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=21189248; DOI=10.1074/jbc.m110.196113; RA Justilien V., Jameison L., Der C.J., Rossman K.L., Fields A.P.; RT "Oncogenic activity of Ect2 is regulated through protein kinase C iota- RT mediated phosphorylation."; RL J. Biol. Chem. 286:8149-8157(2011). RN [29] RP FUNCTION, AND INDUCTION. RX PubMed=21373644; DOI=10.1371/journal.pone.0017108; RA Srougi M.C., Burridge K.; RT "The nuclear guanine nucleotide exchange factors Ect2 and Net1 regulate RT RhoB-mediated cell death after DNA damage."; RL PLoS ONE 6:E17108-E17108(2011). RN [30] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-359, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [31] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-359; SER-367; SER-716; RP SER-861 AND SER-866, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [33] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-611, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [34] RP X-RAY CRYSTALLOGRAPHY (1.48 ANGSTROMS) OF 268-361. RG Structural genomics consortium (SGC); RT "Crystal structure of the second BRCT domain of epithelial cell RT transforming 2 (ECT2)."; RL Submitted (JAN-2010) to the PDB data bank. RN [35] {ECO:0007744|PDB:4N40} RP X-RAY CRYSTALLOGRAPHY (3.11 ANGSTROMS) OF 45-356, FUNCTION, ACTIVITY RP REGULATION, INTERACTION WITH RACGAP1, AND MUTAGENESIS OF THR-184 AND RP LYS-226. RX PubMed=25068414; DOI=10.1016/j.febslet.2014.07.019; RA Zou Y., Shao Z., Peng J., Li F., Gong D., Wang C., Zuo X., Zhang Z., Wu J., RA Shi Y., Gong Q.; RT "Crystal structure of triple-BRCT-domain of ECT2 and insights into the RT binding characteristics to CYK-4."; RL FEBS Lett. 588:2911-2920(2014). RN [36] {ECO:0007744|PDB:6L30} RP X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 173-865, FUNCTION, ACTIVITY RP REGULATION, INTERACTION WITH RHOA, DOMAIN, IDENTIFICATION BY MASS RP SPECTROMETRY, AND MUTAGENESIS OF TRP-338; ARG-488; ARG-570; ALA-573; RP ARG-586; PRO-601; PHE-652; TYR-656; ARG-670; PRO-734 AND CYS-796. RX PubMed=31888991; DOI=10.1073/pnas.1913054117; RA Chen M., Pan H., Sun L., Shi P., Zhang Y., Li L., Huang Y., Chen J., RA Jiang P., Fang X., Wu C., Chen Z.; RT "Structure and regulation of human epithelial cell transforming 2 RT protein."; RL Proc. Natl. Acad. Sci. U.S.A. 117:1027-1035(2020). RN [37] RP VARIANT [LARGE SCALE ANALYSIS] PRO-833. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). CC -!- FUNCTION: Guanine nucleotide exchange factor (GEF) that catalyzes the CC exchange of GDP for GTP. Promotes guanine nucleotide exchange on the CC Rho family members of small GTPases, like RHOA, RHOC, RAC1 and CDC42. CC Required for signal transduction pathways involved in the regulation of CC cytokinesis. Component of the centralspindlin complex that serves as a CC microtubule-dependent and Rho-mediated signaling required for the CC myosin contractile ring formation during the cell cycle cytokinesis. CC Regulates the translocation of RHOA from the central spindle to the CC equatorial region. Plays a role in the control of mitotic spindle CC assembly; regulates the activation of CDC42 in metaphase for the CC process of spindle fibers attachment to kinetochores before chromosome CC congression. Involved in the regulation of epithelial cell polarity; CC participates in the formation of epithelial tight junctions in a CC polarity complex PARD3-PARD6-protein kinase PRKCQ-dependent manner. CC Plays a role in the regulation of neurite outgrowth. Inhibits CC phenobarbital (PB)-induced NR1I3 nuclear translocation. Stimulates the CC activity of RAC1 through its association with the oncogenic PARD6A- CC PRKCI complex in cancer cells, thereby acting to coordinately drive CC tumor cell proliferation and invasion. Also stimulates genotoxic CC stress-induced RHOB activity in breast cancer cells leading to their CC cell death. {ECO:0000269|PubMed:10579713, ECO:0000269|PubMed:14645260, CC ECO:0000269|PubMed:15254234, ECO:0000269|PubMed:15545273, CC ECO:0000269|PubMed:15642749, ECO:0000269|PubMed:16103226, CC ECO:0000269|PubMed:16170345, ECO:0000269|PubMed:16236794, CC ECO:0000269|PubMed:16495035, ECO:0000269|PubMed:19129481, CC ECO:0000269|PubMed:19468300, ECO:0000269|PubMed:19617897, CC ECO:0000269|PubMed:21189248, ECO:0000269|PubMed:21373644, CC ECO:0000269|PubMed:25068414, ECO:0000269|PubMed:31888991}. CC -!- ACTIVITY REGULATION: Autoinhibited by the C-terminal PH domain which CC folds back and binds to the surface of the DH domain, blocking binding CC of RHOA to the catalytic center of the DH domain (PubMed:31888991). The CC 2nd BRCT domain is also involved in inhibition, probably by helping to CC impede RHOA binding (PubMed:31888991). Allosterically activated by CC binding of activated GTP-bound RHOA to the PH domain which stimulates CC the release of PH inhibition and promotes the binding of substrate RHOA CC to the catalytic center (PubMed:31888991). Binding of phosphorylated CC RACGAP1 to the N-terminal BRCT domain-containing region also releases CC autoinhibition (PubMed:25068414). {ECO:0000269|PubMed:25068414, CC ECO:0000269|PubMed:31888991}. CC -!- SUBUNIT: Homodimer (PubMed:14645260, PubMed:15545273, PubMed:16170345). CC Homooligomer (PubMed:15545273). Found in the centralspindlin complex CC (PubMed:16236794). Interacts with NR1I3 (By similarity). Interacts CC (Thr-359 phosphorylated form) with PARD6A; the interaction is observed CC in cancer cells (PubMed:15254234, PubMed:19617897). Interacts (Thr-359 CC phosphorylated form) with PRKCI; the interaction is observed in cancer CC cells (PubMed:19617897). Interacts with PKP4; the interaction is CC observed at the midbody (PubMed:22814378). Interacts with RACGAP1/CYK4; CC the interaction is direct, occurs in a microtubule-dependent manner, CC occurs at anaphase and during cytokinesis, is inhibited in metaphase by CC phosphorylation of ECT2 on Thr-373 and is stimulated in early anaphase CC by dephosphorylation of ECT2 probably on Thr-373 through CDK1 activity CC (PubMed:16103226, PubMed:16129829, PubMed:16236794, PubMed:19468300, CC PubMed:19468302, PubMed:25068414). Interacts with PLK1; the interaction CC is stimulated upon its phosphorylation on Thr-444 (PubMed:16247472). CC Interacts with RHOA; the interaction results in allosteric activation CC of ECT2 (PubMed:31888991). Interacts with KIF23, PARD3, PARD6B and CC PRKCQ (PubMed:15254234, PubMed:16236794). Interacts with NEDD9/HEF1 CC (PubMed:16394104). {ECO:0000250|UniProtKB:Q07139, CC ECO:0000269|PubMed:14645260, ECO:0000269|PubMed:15254234, CC ECO:0000269|PubMed:15545273, ECO:0000269|PubMed:16103226, CC ECO:0000269|PubMed:16129829, ECO:0000269|PubMed:16170345, CC ECO:0000269|PubMed:16236794, ECO:0000269|PubMed:16247472, CC ECO:0000269|PubMed:16394104, ECO:0000269|PubMed:19468300, CC ECO:0000269|PubMed:19468302, ECO:0000269|PubMed:19617897, CC ECO:0000269|PubMed:22814378, ECO:0000269|PubMed:25068414, CC ECO:0000269|PubMed:31888991}. CC -!- INTERACTION: CC Q9H8V3; P12830: CDH1; NbExp=3; IntAct=EBI-1054039, EBI-727477; CC Q9H8V3; P35221: CTNNA1; NbExp=3; IntAct=EBI-1054039, EBI-701918; CC Q9H8V3; Q02241: KIF23; NbExp=2; IntAct=EBI-1054039, EBI-306852; CC Q9H8V3; P16333: NCK1; NbExp=3; IntAct=EBI-1054039, EBI-389883; CC Q9H8V3; O00444: PLK4; NbExp=3; IntAct=EBI-1054039, EBI-746202; CC Q9H8V3; Q9H0H5: RACGAP1; NbExp=15; IntAct=EBI-1054039, EBI-717233; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10579713, CC ECO:0000269|PubMed:14645260, ECO:0000269|PubMed:15254234, CC ECO:0000269|PubMed:16103226, ECO:0000269|PubMed:16495035, CC ECO:0000269|PubMed:19617897}. Cytoplasm {ECO:0000269|PubMed:10579713, CC ECO:0000269|PubMed:16236794, ECO:0000269|PubMed:16394104}. Cytoplasm, CC cytoskeleton, spindle {ECO:0000269|PubMed:10579713, CC ECO:0000269|PubMed:16103226, ECO:0000269|PubMed:16236794, CC ECO:0000269|PubMed:17115030, ECO:0000269|PubMed:19468300}. Cleavage CC furrow {ECO:0000269|PubMed:10579713}. Midbody CC {ECO:0000269|PubMed:15254234, ECO:0000269|PubMed:16394104, CC ECO:0000269|PubMed:17115030}. Cell junction CC {ECO:0000269|PubMed:15254234, ECO:0000269|PubMed:16495035}. Cell CC junction, tight junction {ECO:0000269|PubMed:15254234}. Cytoplasm, CC cytoskeleton, microtubule organizing center, centrosome CC {ECO:0000269|PubMed:17115030}. Note=Sequestered within the nucleus CC during interphase (PubMed:10579713). Dispersed throughout the cytoplasm CC upon breakdown of the nuclear envelope during mitosis CC (PubMed:10579713). Colocalizes with the centralspindlin complex to the CC mitotic spindles during anaphase/metaphase, the cleavage furrow during CC telophase and at the midbody at the end of cytokinesis CC (PubMed:10579713). Colocalized with RhoA at the midbody CC (PubMed:10579713). Its subcellular localization to tight junction is CC increased by calcium (PubMed:15254234). {ECO:0000269|PubMed:10579713, CC ECO:0000269|PubMed:15254234}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=Q9H8V3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9H8V3-2; Sequence=VSP_041976, VSP_041977; CC Name=3; CC IsoId=Q9H8V3-3; Sequence=VSP_041978; CC Name=4; CC IsoId=Q9H8V3-4; Sequence=VSP_041977; CC -!- TISSUE SPECIFICITY: Expressed in lung epithelial cells (at protein CC level). Expressed in squamous cell carcinoma, primary non-small cell CC lung cancer tumors and lung adenocarcinoma. CC {ECO:0000269|PubMed:19617897}. CC -!- INDUCTION: Up-regulated by calcium in cells forming cell-cell contact CC sites. Up-regulated by DNA damaging agents like H(2)O(2) or ionizing CC radiation (IR). {ECO:0000269|PubMed:15254234, CC ECO:0000269|PubMed:21373644}. CC -!- DOMAIN: The BRCT domains 1 and 2 are required for intramolecular CC interaction, but not for intermolecular oligomerization CC (PubMed:15545273). The BRCT domains negatively inhibit its GEF activity CC in interphase cells (PubMed:15545273, PubMed:31888991). The same BRCT CC domains may act as a positive regulatory motif for the completion of CC cytokinesis after the breakdown of nuclear membrane during mitosis CC (PubMed:15545273). {ECO:0000269|PubMed:15545273, CC ECO:0000269|PubMed:31888991}. CC -!- PTM: Phosphorylated by PLK1 in vitro. Hyperphosphorylated during the G2 CC phase of the cell cycle. Phosphorylation at Thr-373 occurs during the CC G2/M phase, relieves its auto-inhibition status and stimulates its GEF CC activity. Phosphorylation at Thr-444 in G2/M phase is required for CC subsequent binding with PLK1 and Rho exchange activation. CC Dephosphorylated at the time of cytokinesis. Phosphorylation at Thr-359 CC is required for its transformation activity in cancer cells. CC {ECO:0000269|PubMed:10579713, ECO:0000269|PubMed:16170345, CC ECO:0000269|PubMed:16247472, ECO:0000269|PubMed:21189248}. CC -!- MISCELLANEOUS: [Isoform 3]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA91624.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40400/ECT2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY376439; AAQ83675.1; -; mRNA. DR EMBL; DQ847274; ABH10140.1; -; mRNA. DR EMBL; AK001323; BAA91624.1; ALT_INIT; mRNA. DR EMBL; AK023267; BAB14498.1; -; mRNA. DR EMBL; AK314581; BAG37157.1; -; mRNA. DR EMBL; AC108667; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC112086; AAI12087.1; -; mRNA. DR EMBL; AL137710; CAB70886.1; -; mRNA. DR CCDS; CCDS3220.1; -. [Q9H8V3-4] DR CCDS; CCDS58860.1; -. [Q9H8V3-1] DR CCDS; CCDS87168.1; -. [Q9H8V3-2] DR RefSeq; NP_001245244.1; NM_001258315.2. [Q9H8V3-1] DR RefSeq; NP_001245245.1; NM_001258316.2. [Q9H8V3-4] DR RefSeq; NP_001336023.1; NM_001349094.2. [Q9H8V3-3] DR RefSeq; NP_001336024.1; NM_001349095.2. [Q9H8V3-3] DR RefSeq; NP_001336025.1; NM_001349096.2. [Q9H8V3-3] DR RefSeq; NP_001336027.1; NM_001349098.2. [Q9H8V3-1] DR RefSeq; NP_001336028.1; NM_001349099.2. [Q9H8V3-1] DR RefSeq; NP_001336029.1; NM_001349100.2. [Q9H8V3-1] DR RefSeq; NP_001336031.1; NM_001349102.2. [Q9H8V3-2] DR RefSeq; NP_060568.3; NM_018098.5. [Q9H8V3-4] DR RefSeq; XP_047303563.1; XM_047447607.1. [Q9H8V3-3] DR RefSeq; XP_047303564.1; XM_047447608.1. [Q9H8V3-3] DR RefSeq; XP_047303565.1; XM_047447609.1. [Q9H8V3-3] DR RefSeq; XP_047303573.1; XM_047447617.1. [Q9H8V3-1] DR RefSeq; XP_047303574.1; XM_047447618.1. [Q9H8V3-1] DR RefSeq; XP_047303583.1; XM_047447627.1. [Q9H8V3-4] DR RefSeq; XP_047303584.1; XM_047447628.1. [Q9H8V3-4] DR RefSeq; XP_047303585.1; XM_047447629.1. [Q9H8V3-4] DR RefSeq; XP_047303586.1; XM_047447630.1. [Q9H8V3-4] DR RefSeq; XP_054201507.1; XM_054345532.1. [Q9H8V3-3] DR RefSeq; XP_054201508.1; XM_054345533.1. [Q9H8V3-3] DR RefSeq; XP_054201509.1; XM_054345534.1. [Q9H8V3-3] DR RefSeq; XP_054201517.1; XM_054345542.1. [Q9H8V3-1] DR RefSeq; XP_054201518.1; XM_054345543.1. [Q9H8V3-1] DR RefSeq; XP_054201528.1; XM_054345553.1. [Q9H8V3-4] DR RefSeq; XP_054201529.1; XM_054345554.1. [Q9H8V3-4] DR RefSeq; XP_054201530.1; XM_054345555.1. [Q9H8V3-4] DR RefSeq; XP_054201531.1; XM_054345556.1. [Q9H8V3-4] DR PDB; 3L46; X-ray; 1.48 A; A/B=268-361. DR PDB; 4N40; X-ray; 3.11 A; A=45-356. DR PDB; 6L30; X-ray; 2.80 A; A=173-865. DR PDBsum; 3L46; -. DR PDBsum; 4N40; -. DR PDBsum; 6L30; -. DR AlphaFoldDB; Q9H8V3; -. DR SMR; Q9H8V3; -. DR BioGRID; 108223; 896. DR CORUM; Q9H8V3; -. DR DIP; DIP-47496N; -. DR FunCoup; Q9H8V3; 1534. DR IntAct; Q9H8V3; 46. DR MINT; Q9H8V3; -. DR STRING; 9606.ENSP00000376457; -. DR GlyGen; Q9H8V3; 6 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (5 sites). DR iPTMnet; Q9H8V3; -. DR MetOSite; Q9H8V3; -. DR PhosphoSitePlus; Q9H8V3; -. DR SwissPalm; Q9H8V3; -. DR BioMuta; ECT2; -. DR DMDM; 357529579; -. DR jPOST; Q9H8V3; -. DR MassIVE; Q9H8V3; -. DR PaxDb; 9606-ENSP00000376457; -. DR PeptideAtlas; Q9H8V3; -. DR ProteomicsDB; 81243; -. [Q9H8V3-1] DR ProteomicsDB; 81244; -. [Q9H8V3-2] DR ProteomicsDB; 81245; -. [Q9H8V3-3] DR Pumba; Q9H8V3; -. DR Antibodypedia; 33733; 365 antibodies from 31 providers. DR DNASU; 1894; -. DR Ensembl; ENST00000232458.9; ENSP00000232458.5; ENSG00000114346.15. [Q9H8V3-4] DR Ensembl; ENST00000392692.8; ENSP00000376457.3; ENSG00000114346.15. [Q9H8V3-1] DR Ensembl; ENST00000417960.5; ENSP00000415876.1; ENSG00000114346.15. [Q9H8V3-2] DR Ensembl; ENST00000441497.6; ENSP00000412259.2; ENSG00000114346.15. [Q9H8V3-4] DR Ensembl; ENST00000540509.5; ENSP00000443160.2; ENSG00000114346.15. [Q9H8V3-4] DR GeneID; 1894; -. DR KEGG; hsa:1894; -. DR MANE-Select; ENST00000392692.8; ENSP00000376457.3; NM_001258315.2; NP_001245244.1. DR UCSC; uc003fih.4; human. [Q9H8V3-1] DR AGR; HGNC:3155; -. DR ClinPGx; PA27600; -. DR CTD; 1894; -. DR DisGeNET; 1894; -. DR GeneCards; ECT2; -. DR HGNC; HGNC:3155; ECT2. DR HPA; ENSG00000114346; Low tissue specificity. DR MIM; 600586; gene. DR OpenTargets; ENSG00000114346; -. DR VEuPathDB; HostDB:ENSG00000114346; -. DR eggNOG; KOG3524; Eukaryota. DR GeneTree; ENSGT00940000156299; -. DR HOGENOM; CLU_008187_0_0_1; -. DR InParanoid; Q9H8V3; -. DR OMA; PIYDVHK; -. DR OrthoDB; 9997817at2759; -. DR PAN-GO; Q9H8V3; 5 GO annotations based on evolutionary models. DR PathwayCommons; Q9H8V3; -. DR Reactome; R-HSA-193648; NRAGE signals death through JNK. DR Reactome; R-HSA-416482; G alpha (12/13) signalling events. DR Reactome; R-HSA-8980692; RHOA GTPase cycle. DR Reactome; R-HSA-9013026; RHOB GTPase cycle. DR Reactome; R-HSA-9013148; CDC42 GTPase cycle. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR SignaLink; Q9H8V3; -. DR SIGNOR; Q9H8V3; -. DR Agora; ENSG00000114346; -. DR BioGRID-ORCS; 1894; 654 hits in 1167 CRISPR screens. DR ChiTaRS; ECT2; human. DR EvolutionaryTrace; Q9H8V3; -. DR GeneWiki; ECT2; -. DR GenomeRNAi; 1894; -. DR Pharos; Q9H8V3; Tbio. DR PRO; PR:Q9H8V3; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q9H8V3; protein. DR Bgee; ENSG00000114346; Expressed in secondary oocyte and 166 other cell types or tissues. DR ExpressionAtlas; Q9H8V3; baseline and differential. DR GO; GO:0005923; C:bicellular tight junction; IDA:UniProtKB. DR GO; GO:0005938; C:cell cortex; IBA:GO_Central. DR GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB. DR GO; GO:0097149; C:centralspindlin complex; IDA:UniProtKB. DR GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell. DR GO; GO:0032154; C:cleavage furrow; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0072686; C:mitotic spindle; IDA:UniProtKB. DR GO; GO:0016604; C:nuclear body; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005096; F:GTPase activator activity; IMP:UniProtKB. DR GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0031267; F:small GTPase binding; IEA:Ensembl. DR GO; GO:0090630; P:activation of GTPase activity; IDA:UniProtKB. DR GO; GO:0032147; P:activation of protein kinase activity; IDA:UniProtKB. DR GO; GO:0070830; P:bicellular tight junction assembly; IMP:UniProtKB. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0000902; P:cell morphogenesis; IEA:Ensembl. DR GO; GO:0071277; P:cellular response to calcium ion; IDA:UniProtKB. DR GO; GO:0070301; P:cellular response to hydrogen peroxide; IDA:UniProtKB. DR GO; GO:0071479; P:cellular response to ionizing radiation; IDA:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro. DR GO; GO:0000281; P:mitotic cytokinesis; IMP:UniProtKB. DR GO; GO:0007399; P:nervous system development; IBA:GO_Central. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; HMP:UniProtKB. DR GO; GO:0032467; P:positive regulation of cytokinesis; IDA:UniProtKB. DR GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB. DR GO; GO:1903438; P:positive regulation of mitotic cytokinetic process; IMP:UniProt. DR GO; GO:0045666; P:positive regulation of neuron differentiation; ISS:UniProtKB. DR GO; GO:0042307; P:positive regulation of protein import into nucleus; ISS:UniProtKB. DR GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB. DR GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW. DR GO; GO:0051988; P:regulation of attachment of spindle microtubules to kinetochore; IMP:UniProtKB. DR GO; GO:2000431; P:regulation of cytokinesis, actomyosin contractile ring assembly; IEA:InterPro. DR GO; GO:0045859; P:regulation of protein kinase activity; IDA:UniProtKB. DR GO; GO:0051056; P:regulation of small GTPase mediated signal transduction; TAS:Reactome. DR CDD; cd17733; BRCT_Ect2_rpt1; 1. DR CDD; cd17732; BRCT_Ect2_rpt2; 1. DR CDD; cd01229; PH_Ect2; 1. DR CDD; cd00160; RhoGEF; 1. DR FunFam; 3.40.50.10190:FF:000058; Epithelial cell transforming 2; 1. DR FunFam; 1.20.900.10:FF:000022; protein ECT2 isoform X1; 1. DR FunFam; 3.40.50.10190:FF:000015; protein ECT2 isoform X1; 1. DR FunFam; 2.30.29.30:FF:000162; protein ECT2 isoform X2; 1. DR FunFam; 3.40.50.10190:FF:000016; protein ECT2 isoform X3; 1. DR Gene3D; 3.40.50.10190; BRCT domain; 3. DR Gene3D; 1.20.900.10; Dbl homology (DH) domain; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR InterPro; IPR001357; BRCT_dom. DR InterPro; IPR036420; BRCT_dom_sf. DR InterPro; IPR035899; DBL_dom_sf. DR InterPro; IPR000219; DH_dom. DR InterPro; IPR026817; Ect2. DR InterPro; IPR049396; ECT2_BRCT0. DR InterPro; IPR049395; ECT2_PH. DR InterPro; IPR001331; GDS_CDC24_CS. DR InterPro; IPR011993; PH-like_dom_sf. DR PANTHER; PTHR16777; PROTEIN ECT2; 1. DR PANTHER; PTHR16777:SF2; PROTEIN ECT2; 1. DR Pfam; PF00533; BRCT; 1. DR Pfam; PF21243; ECT2_BRCT0; 1. DR Pfam; PF21242; ECT2_PH; 1. DR Pfam; PF12738; PTCB-BRCT; 1. DR Pfam; PF00621; RhoGEF; 1. DR SMART; SM00292; BRCT; 2. DR SMART; SM00325; RhoGEF; 1. DR SUPFAM; SSF52113; BRCT domain; 2. DR SUPFAM; SSF48065; DBL homology domain (DH-domain); 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR PROSITE; PS50172; BRCT; 2. DR PROSITE; PS00741; DH_1; 1. DR PROSITE; PS50010; DH_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cell cycle; Cell division; KW Cell junction; Cytoplasm; Cytoskeleton; Differentiation; KW Guanine-nucleotide releasing factor; Isopeptide bond; Neurogenesis; KW Nucleus; Oncogene; Phosphoprotein; Protein transport; KW Proteomics identification; Reference proteome; Repeat; Tight junction; KW Transport; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..914 FT /note="Protein ECT2" FT /id="PRO_0000080938" FT DOMAIN 171..260 FT /note="BRCT 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00033" FT DOMAIN 266..354 FT /note="BRCT 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00033" FT DOMAIN 452..641 FT /note="DH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00062" FT DOMAIN 675..794 FT /note="PH" FT REGION 388..449 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 857..884 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 378..382 FT /note="Nuclear localization signal" FT MOTIF 401..405 FT /note="Nuclear localization signal" FT COMPBIAS 418..429 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 432..449 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 359 FT /note="Phosphothreonine; by PKC/PRKCI" FT /evidence="ECO:0000269|PubMed:21189248, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 367 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 370 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 373 FT /note="Phosphothreonine; by CDK1" FT /evidence="ECO:0000269|PubMed:16170345, FT ECO:0007744|PubMed:18669648" FT MOD_RES 376 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 444 FT /note="Phosphothreonine; by CDK1" FT /evidence="ECO:0000269|PubMed:16247472" FT MOD_RES 716 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 842 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 846 FT /note="Phosphothreonine; by CDK1" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 861 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 866 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 611 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 44 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10579713, FT ECO:0000303|PubMed:14587037, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_041976" FT VAR_SEQ 71..101 FT /note="Missing (in isoform 2 and isoform 4)" FT /evidence="ECO:0000303|PubMed:10579713, FT ECO:0000303|PubMed:14587037, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_041977" FT VAR_SEQ 886..914 FT /note="GIPSPSLVSLPSFFERRSHTLSRSTTHLI -> ITHSVSTSNVIGFTKHVYV FT QRLNSTGGRSQYSWFQSVRHSAFRASFSEILEGNTDFSNFKKVLSKSSLTFVKN (in FT isoform 3)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_041978" FT VARIANT 15 FT /note="S -> T (in dbSNP:rs34703432)" FT /id="VAR_047064" FT VARIANT 833 FT /note="T -> P (in a breast cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035975" FT MUTAGEN 184 FT /note="T->A: Inhibits interaction with RACGAP1. Abolishes FT targeting to the central spindle." FT /evidence="ECO:0000269|PubMed:19468300, FT ECO:0000269|PubMed:25068414" FT MUTAGEN 226 FT /note="K->A: Inhibits interaction with RACGAP1. Abolishes FT targeting to the central spindle." FT /evidence="ECO:0000269|PubMed:19468300, FT ECO:0000269|PubMed:25068414" FT MUTAGEN 336 FT /note="W->R: Inhibits homodimerization. Increases binding FT with RhoA and GEF activity." FT /evidence="ECO:0000269|PubMed:15545273" FT MUTAGEN 338 FT /note="W->A: 2-fold increase in GEF activity." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 359 FT /note="T->A: Inhibits its phosphorylation and anchorage- FT independent growth and invasion in cancer cells. Does not FT inhibit its GEF activity." FT /evidence="ECO:0000269|PubMed:21189248" FT MUTAGEN 373 FT /note="T->A: Does not inhibit its Rho exchange activity. FT Increases interaction with RACGAP1. Does not inhibit FT anchorage-independent growth and invasion in cancer cells." FT /evidence="ECO:0000269|PubMed:16103226, FT ECO:0000269|PubMed:16170345" FT MUTAGEN 373 FT /note="T->D: Does not inhibit subcellular localization or FT homodimerization. Enhances its Rho exchange activity." FT /evidence="ECO:0000269|PubMed:16103226, FT ECO:0000269|PubMed:16170345" FT MUTAGEN 379..381 FT /note="KRR->AAA: Shows both nuclear and cytoplasmic FT localization and activates its transforming activity." FT /evidence="ECO:0000269|PubMed:14645260" FT MUTAGEN 402..404 FT /note="RKR->AKA: Shows both nuclear and cytoplasmic FT localization and activates its transforming activity." FT /evidence="ECO:0000269|PubMed:14645260" FT MUTAGEN 444 FT /note="T->A: Diminishes its phosphorylation status. Reduces FT its interaction with PLK1 and Rho exchange activity. Does FT not change its subcellular localization. Does not inhibit FT anchorage-independent growth and invasion in cancer cells." FT /evidence="ECO:0000269|PubMed:16247472" FT MUTAGEN 444 FT /note="T->D: Does not reduce its interaction with PLK1, FT change its subcellular localization and Rho exchange FT activity." FT /evidence="ECO:0000269|PubMed:16247472" FT MUTAGEN 488 FT /note="R->C: Partially releases inhibition." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 570 FT /note="R->D: 2-fold increase in GEF activity." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 573 FT /note="A->D: 2-fold increase in GEF activity." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 586 FT /note="R->Q: Complete loss of GEF activity and failure to FT support cytokinesis." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 596..599 FT /note="PVQR->AAAA: Inhibits activation of the transforming FT activity." FT /evidence="ECO:0000269|PubMed:14645260" FT MUTAGEN 601 FT /note="P->S: Complete loss of GEF activity and failure to FT support cytokinesis." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 652 FT /note="F->A: No effect on GEF activity but severely FT decreases ECT2 activation by RHOA. Localizes correctly but FT fails to rescue the cytokinesis defect caused by knockdown FT of endogenous ECT2 in contrast to the wild-type protein FT which rescues this defect." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 656 FT /note="Y->A: No effect on GEF activity but severely FT decreases ECT2 activation by RHOA. Fails to rescue the FT cytokinesis defect caused by knockdown of endogenous ECT2 FT in contrast to the wild-type protein which rescues this FT defect." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 670 FT /note="R->Q: Marked increase in GEF activity and rescues FT the cytokinesis defect caused by depletion of endogenous FT ECT2. When expressed in a cancer cell line, causes faster FT cell proliferation than the wild-type protein." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 734 FT /note="P->D: More than 10-fold increase in GEF activity. FT Overexpression causes noticeable changes in interphase cell FT morphology such as cell rounding and formation of stress FT fibers, suggesting ectopic RhoA activation." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 796 FT /note="C->K: More than 10-fold increase in GEF activity. FT Overexpression causes noticeable changes in interphase cell FT morphology such as cell rounding and formation of stress FT fibers, suggesting ectopic RHOA activation." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 846 FT /note="T->A: Diminishes its phosphorylation status." FT /evidence="ECO:0000269|PubMed:16247472" FT CONFLICT 66 FT /note="I -> T (in Ref. 5; BAB14498)" FT /evidence="ECO:0000305" FT CONFLICT 276 FT /note="L -> F (in Ref. 5; BAB14498)" FT /evidence="ECO:0000305" FT CONFLICT 393 FT /note="E -> D (in Ref. 5; BAB14498)" FT /evidence="ECO:0000305" FT STRAND 51..56 FT /evidence="ECO:0007829|PDB:4N40" FT HELIX 57..59 FT /evidence="ECO:0007829|PDB:4N40" FT HELIX 63..70 FT /evidence="ECO:0007829|PDB:4N40" FT STRAND 107..112 FT /evidence="ECO:0007829|PDB:4N40" FT HELIX 115..119 FT /evidence="ECO:0007829|PDB:4N40" FT STRAND 124..129 FT /evidence="ECO:0007829|PDB:4N40" FT HELIX 136..143 FT /evidence="ECO:0007829|PDB:4N40" FT STRAND 147..149 FT /evidence="ECO:0007829|PDB:4N40" FT HELIX 151..159 FT /evidence="ECO:0007829|PDB:4N40" FT TURN 173..178 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 180..184 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 189..201 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 215..224 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 225..233 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 241..249 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 260..263 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 264..266 FT /evidence="ECO:0007829|PDB:6L30" FT TURN 270..273 FT /evidence="ECO:0007829|PDB:3L46" FT STRAND 278..280 FT /evidence="ECO:0007829|PDB:3L46" FT HELIX 283..295 FT /evidence="ECO:0007829|PDB:3L46" FT STRAND 309..313 FT /evidence="ECO:0007829|PDB:3L46" FT TURN 315..317 FT /evidence="ECO:0007829|PDB:3L46" FT STRAND 318..320 FT /evidence="ECO:0007829|PDB:3L46" FT STRAND 330..333 FT /evidence="ECO:0007829|PDB:3L46" FT HELIX 334..343 FT /evidence="ECO:0007829|PDB:3L46" FT HELIX 349..351 FT /evidence="ECO:0007829|PDB:3L46" FT HELIX 453..477 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 479..483 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 495..502 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 505..522 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 532..552 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 554..567 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 569..579 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 582..584 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 589..611 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 622..634 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 635..637 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 642..657 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 664..667 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 672..687 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 691..697 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 700..706 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 726..734 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 735..737 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 738..744 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 748..758 FT /evidence="ECO:0007829|PDB:6L30" FT TURN 761..763 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 767..773 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 780..795 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 803..807 FT /evidence="ECO:0007829|PDB:6L30" SQ SEQUENCE 914 AA; 103505 MW; F40FC4F982FB8C78 CRC64; MAENSVLTST TGRTSLADSS IFDSKVTEIS KENLLIGSTS YVEEEMPQIE TRVILVQEAG KQEELIKALK TIKIMEVPVI KIKESCPGKS DEKLIKSVIN MDIKVGFVKM ESVEEFEGLD SPEFENVFVV TDFQDSVFND LYKADCRVIG PPVVLNCSQK GEPLPFSCRP LYCTSMMNLV LCFTGFRKKE ELVRLVTLVH HMGGVIRKDF NSKVTHLVAN CTQGEKFRVA VSLGTPIMKP EWIYKAWERR NEQDFYAAVD DFRNEFKVPP FQDCILSFLG FSDEEKTNME EMTEMQGGKY LPLGDERCTH LVVEENIVKD LPFEPSKKLY VVKQEWFWGS IQMDARAGET MYLYEKANTP ELKKSVSMLS LNTPNSNRKR RRLKETLAQL SRETDVSPFP PRKRPSAEHS LSIGSLLDIS NTPESSINYG DTPKSCTKSS KSSTPVPSKQ SARWQVAKEL YQTESNYVNI LATIIQLFQV PLEEEGQRGG PILAPEEIKT IFGSIPDIFD VHTKIKDDLE DLIVNWDESK SIGDIFLKYS KDLVKTYPPF VNFFEMSKET IIKCEKQKPR FHAFLKINQA KPECGRQSLV ELLIRPVQRL PSVALLLNDL KKHTADENPD KSTLEKAIGS LKEVMTHINE DKRKTEAQKQ IFDVVYEVDG CPANLLSSHR SLVQRVETIS LGEHPCDRGE QVTLFLFNDC LEIARKRHKV IGTFRSPHGQ TRPPASLKHI HLMPLSQIKK VLDIRETEDC HNAFALLVRP PTEQANVLLS FQMTSDELPK ENWLKMLCRH VANTICKADA ENLIYTADPE SFEVNTKDMD STLSRASRAI KKTSKKVTRA FSFSKTPKRA LRRALMTSHG SVEGRSPSSN DKHVMSRLSS TSSLAGIPSP SLVSLPSFFE RRSHTLSRST THLI // ID EF2K_HUMAN Reviewed; 725 AA. AC O00418; Q8N588; DT 15-JUL-1998, integrated into UniProtKB/Swiss-Prot. DT 28-JUL-2009, sequence version 2. DT 28-JAN-2026, entry version 216. DE RecName: Full=Eukaryotic elongation factor 2 kinase; DE Short=eEF-2 kinase; DE Short=eEF-2K; DE EC=2.7.11.20 {ECO:0000269|PubMed:11015200, ECO:0000269|PubMed:9144159}; DE AltName: Full=Calcium/calmodulin-dependent eukaryotic elongation factor 2 kinase; GN Name=EEF2K; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, AND VARIANT RP ARG-361. RC TISSUE=Glial tumor; RX PubMed=9144159; DOI=10.1073/pnas.94.10.4884; RA Ryazanov A.G., Ward M.D., Mendola C.E., Pavur K.S., Dorovkov M.V., RA Wiedmann M., Erdjument-Bromage H., Tempst P., Parmer T.G., Prostko C.R., RA Germino F.J., Hait W.N.; RT "Identification of a new class of protein kinases represented by eukaryotic RT elongation factor-2 kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 94:4884-4889(1997). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15616553; DOI=10.1038/nature03187; RA Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G., RA Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E., RA Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M., RA Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C., RA Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M., RA Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M., RA Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D., RA Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., RA Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., RA Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., RA Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., RA Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J., RA Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D., RA Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S., RA Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A., RA Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M., RA Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H., RA Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A., RA Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J., RA DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J., RA Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., RA Myers R.M., Rubin E.M., Pennacchio L.A.; RT "The sequence and analysis of duplication-rich human chromosome 16."; RL Nature 432:988-994(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-23 AND ARG-361. RC TISSUE=Lymph; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP CATALYTIC ACTIVITY, IDENTIFICATION OF THE CALMODULIN-BINDING REGION, RP AUTOPHOSPHORYLATION, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=11015200; DOI=10.1021/bi0007270; RA Pavur K.S., Petrov A.N., Ryazanov A.G.; RT "Mapping the functional domains of elongation factor-2 kinase."; RL Biochemistry 39:12216-12224(2000). RN [5] RP PHOSPHORYLATION AT SER-359. RX PubMed=11500363; DOI=10.1093/emboj/20.16.4360; RA Knebel A., Morrice N., Cohen P.; RT "A novel method to identify protein kinase substrates: eEF2 kinase is RT phosphorylated and inhibited by SAPK4/p38delta."; RL EMBO J. 20:4360-4369(2001). RN [6] RP PHOSPHORYLATION AT SER-366 BY RPS6KA1 AND RPS6KB1, AND MUTAGENESIS OF RP SER-366. RX PubMed=11500364; DOI=10.1093/emboj/20.16.4370; RA Wang X., Li W., Williams M., Terada N., Alessi D.R., Proud C.G.; RT "Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase."; RL EMBO J. 20:4370-4379(2001). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=15144186; DOI=10.1021/ac035352d; RA Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M., RA Peters E.C.; RT "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from RT human T cells using immobilized metal affinity chromatography and tandem RT mass spectrometry."; RL Anal. Chem. 76:2763-2772(2004). RN [8] RP FUNCTION, AND PHOSPHORYLATION AT SER-398. RX PubMed=14709557; DOI=10.1074/jbc.m309773200; RA Browne G.J., Finn S.G., Proud C.G.; RT "Stimulation of the AMP-activated protein kinase leads to activation of RT eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel RT site, serine 398."; RL J. Biol. Chem. 279:12220-12231(2004). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18 AND SER-474, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18 AND SER-445, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [11] RP PHOSPHORYLATION AT SER-359. RX PubMed=18337751; DOI=10.1038/emboj.2008.39; RA Smith E.M., Proud C.G.; RT "cdc2-cyclin B regulates eEF2 kinase activity in a cell cycle- and amino RT acid-dependent manner."; RL EMBO J. 27:1005-1016(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-348; SER-470; SER-474 AND RP SER-477, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18; THR-348; SER-445; SER-470 RP AND SER-474, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [17] RP PHOSPHORYLATION AT SER-78. RX PubMed=21112387; DOI=10.1016/j.cellsig.2010.11.011; RA Perraud A.L., Zhao X., Ryazanov A.G., Schmitz C.; RT "The channel-kinase TRPM7 regulates phosphorylation of the translational RT factor eEF2 via eEF2-k."; RL Cell. Signal. 23:586-593(2011). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18 AND SER-470, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [19] RP PHOSPHORYLATION AT SER-61; SER-66; SER-78; THR-348; THR-353; SER-366; RP SER-445; SER-474 AND SER-491, AND MUTAGENESIS OF SER-78; THR-348 AND RP SER-366. RX PubMed=22216903; DOI=10.1042/bj20111530; RA Pyr Dit Ruys S., Wang X., Smith E.M., Herinckx G., Hussain N., Rider M.H., RA Vertommen D., Proud C.G.; RT "Identification of autophosphorylation sites in eukaryotic elongation RT factor-2 kinase."; RL Biochem. J. 442:681-692(2012). RN [20] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18; SER-70; SER-72; SER-74; RP SER-78; SER-243; THR-348; THR-353; SER-435; SER-445; SER-470; SER-474; RP SER-477 AND SER-491, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27; THR-348; SER-445 AND RP SER-474, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [23] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-23; ALA-75; MET-291; TRP-433 AND RP HIS-609. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Threonine kinase that regulates protein synthesis by CC controlling the rate of peptide chain elongation. Upon activation by a CC variety of upstream kinases including AMPK or TRPM7, phosphorylates the CC elongation factor EEF2 at a single site, renders it unable to bind CC ribosomes and thus inactive. In turn, the rate of protein synthesis is CC reduced. {ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:9144159}. CC -!- CATALYTIC ACTIVITY: CC Reaction=[translation elongation factor 2] + ATP = [translation CC elongation factor 2]-phosphate + ADP + H(+); Xref=Rhea:RHEA:21436, CC Rhea:RHEA-COMP:11268, Rhea:RHEA-COMP:11269, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:43176, ChEBI:CHEBI:68546, CC ChEBI:CHEBI:456216; EC=2.7.11.20; CC Evidence={ECO:0000269|PubMed:11015200, ECO:0000269|PubMed:9144159}; CC -!- ACTIVITY REGULATION: Undergoes calcium/calmodulin-dependent CC intramolecular autophosphorylation, and this results in it becoming CC partially calcium/calmodulin-independent. CC {ECO:0000250|UniProtKB:P70531}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=1.2 uM for EEF2 {ECO:0000269|PubMed:11015200}; CC Vmax=4 nmol/min/mg enzyme {ECO:0000269|PubMed:11015200}; CC -!- SUBUNIT: Monomer or homodimer (Probable). Interacts with CC Calmodulin/CALM1; this interaction is strictly required for CC phosphorylation activity (PubMed:11015200). CC {ECO:0000269|PubMed:11015200, ECO:0000305}. CC -!- PTM: Autophosphorylated at multiple residues, Thr-348 being the major CC site. Phosphorylated by AMP-activated protein kinase AMPK at Ser-398 CC leading to EEF2K activation and protein synthesis inhibition. CC Phosphorylated by TRPM7 at Ser-78 resulting in improved protein CC stability, higher EE2F phosphorylated and subsequently reduced rate of CC protein synthesis. Phosphorylation by other kinases such as CDK1 and CC MAPK13 at Ser-359 or RPS6KA1 and RPS6KB1 at Ser-366 instead decrease CC EEF2K activity and promote protein synthesis. CC {ECO:0000269|PubMed:11015200, ECO:0000269|PubMed:11500363, CC ECO:0000269|PubMed:11500364, ECO:0000269|PubMed:14709557, CC ECO:0000269|PubMed:18337751, ECO:0000269|PubMed:21112387, CC ECO:0000269|PubMed:22216903}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Alpha-type CC protein kinase family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U93850; AAB58270.1; -; mRNA. DR EMBL; AC009034; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC032665; AAH32665.1; -; mRNA. DR CCDS; CCDS10604.1; -. DR RefSeq; NP_037434.2; NM_013302.5. DR PDB; 5J8H; NMR; -; B=74-100. DR PDB; 5KS5; NMR; -; A=627-725. DR PDB; 6NX4; NMR; -; A=562-725. DR PDB; 7SHQ; X-ray; 2.34 A; A=70-358, A=490-725. DR PDB; 8FNY; X-ray; 2.22 A; A/C=70-358, A/C=490-725. DR PDB; 8FO6; X-ray; 2.55 A; A=70-358, A=490-725. DR PDB; 8GM4; X-ray; 2.12 A; A=70-358, A=490-725. DR PDB; 8GM5; X-ray; 2.12 A; A=70-358, A=490-725. DR PDBsum; 5J8H; -. DR PDBsum; 5KS5; -. DR PDBsum; 6NX4; -. DR PDBsum; 7SHQ; -. DR PDBsum; 8FNY; -. DR PDBsum; 8FO6; -. DR PDBsum; 8GM4; -. DR PDBsum; 8GM5; -. DR AlphaFoldDB; O00418; -. DR SMR; O00418; -. DR BioGRID; 118953; 62. DR BioGRID; 3193665; 1. DR ELM; O00418; -. DR FunCoup; O00418; 1312. DR IntAct; O00418; 27. DR MINT; O00418; -. DR STRING; 9606.ENSP00000263026; -. DR BindingDB; O00418; -. DR ChEMBL; CHEMBL5026; -. DR DrugBank; DB01259; Lapatinib. DR GuidetoPHARMACOLOGY; 2014; -. DR GlyGen; O00418; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O00418; -. DR MetOSite; O00418; -. DR PhosphoSitePlus; O00418; -. DR BioMuta; EEF2K; -. DR jPOST; O00418; -. DR MassIVE; O00418; -. DR PaxDb; 9606-ENSP00000263026; -. DR PeptideAtlas; O00418; -. DR ProteomicsDB; 47876; -. DR Pumba; O00418; -. DR Antibodypedia; 25835; 476 antibodies from 35 providers. DR DNASU; 29904; -. DR Ensembl; ENST00000263026.10; ENSP00000263026.5; ENSG00000103319.13. DR GeneID; 29904; -. DR KEGG; hsa:29904; -. DR MANE-Select; ENST00000263026.10; ENSP00000263026.5; NM_013302.5; NP_037434.2. DR UCSC; uc002dki.4; human. DR AGR; HGNC:24615; -. DR ClinPGx; PA134992891; -. DR CTD; 29904; -. DR DisGeNET; 29904; -. DR GeneCards; EEF2K; -. DR HGNC; HGNC:24615; EEF2K. DR HPA; ENSG00000103319; Tissue enhanced (skin). DR MIM; 606968; gene. DR OpenTargets; ENSG00000103319; -. DR VEuPathDB; HostDB:ENSG00000103319; -. DR eggNOG; ENOG502QVA3; Eukaryota. DR GeneTree; ENSGT00940000157839; -. DR HOGENOM; CLU_382143_0_0_1; -. DR InParanoid; O00418; -. DR OMA; CLQMEAK; -. DR OrthoDB; 301415at2759; -. DR PAN-GO; O00418; 1 GO annotation based on evolutionary models. DR PhylomeDB; O00418; -. DR BRENDA; 2.7.11.20; 2681. DR PathwayCommons; O00418; -. DR Reactome; R-HSA-166208; mTORC1-mediated signalling. DR SignaLink; O00418; -. DR SIGNOR; O00418; -. DR Agora; ENSG00000103319; -. DR BioGRID-ORCS; 29904; 10 hits in 1191 CRISPR screens. DR ChiTaRS; EEF2K; human. DR GeneWiki; EEF2K; -. DR Pharos; O00418; Tchem. DR PRO; PR:O00418; -. DR Proteomes; UP000005640; Chromosome 16. DR RNAct; O00418; protein. DR Bgee; ENSG00000103319; Expressed in skin of leg and 103 other cell types or tissues. DR ExpressionAtlas; O00418; baseline and differential. DR GO; GO:0005737; C:cytoplasm; TAS:ProtInc. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0043197; C:dendritic spine; IEA:Ensembl. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0014069; C:postsynaptic density; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IEA:InterPro. DR GO; GO:0005516; F:calmodulin binding; IDA:UniProtKB. DR GO; GO:0004686; F:elongation factor-2 kinase activity; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0008135; F:translation factor activity, RNA binding; TAS:ProtInc. DR GO; GO:0071454; P:cellular response to anoxia; IEA:Ensembl. DR GO; GO:1990416; P:cellular response to brain-derived neurotrophic factor stimulus; IEA:Ensembl. DR GO; GO:0071277; P:cellular response to calcium ion; IEA:Ensembl. DR GO; GO:0071320; P:cellular response to cAMP; IEA:Ensembl. DR GO; GO:0032869; P:cellular response to insulin stimulus; IEA:Ensembl. DR GO; GO:0031037; P:myosin II filament disassembly; IBA:GO_Central. DR GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl. DR GO; GO:0061003; P:positive regulation of dendritic spine morphogenesis; IEA:Ensembl. DR GO; GO:0045807; P:positive regulation of endocytosis; IEA:Ensembl. DR GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0140245; P:regulation of translation at postsynapse; IEA:Ensembl. DR GO; GO:0002931; P:response to ischemia; IEA:Ensembl. DR GO; GO:1990637; P:response to prolactin; IEA:Ensembl. DR GO; GO:0006414; P:translational elongation; TAS:ProtInc. DR CDD; cd16967; Alpha_kinase_eEF2K; 1. DR DisProt; DP04157; -. DR FunFam; 1.25.40.10:FF:000229; Eukaryotic elongation factor 2 kinase; 1. DR FunFam; 3.20.200.10:FF:000002; Eukaryotic elongation factor 2 kinase; 1. DR FunFam; 3.30.200.20:FF:000230; Eukaryotic elongation factor 2 kinase; 1. DR FunFam; 3.30.200.20:FF:000336; Eukaryotic elongation factor 2 kinase; 1. DR Gene3D; 3.20.200.10; MHCK/EF2 kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.25.40.10; Tetratricopeptide repeat domain; 1. DR InterPro; IPR004166; a-kinase_dom. DR InterPro; IPR051852; Alpha-type_PK. DR InterPro; IPR017400; eEF-2K. DR InterPro; IPR047588; eEF2K_a_kinase_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR011990; TPR-like_helical_dom_sf. DR PANTHER; PTHR45992:SF2; EUKARYOTIC ELONGATION FACTOR 2 KINASE; 1. DR PANTHER; PTHR45992; EUKARYOTIC ELONGATION FACTOR 2 KINASE-RELATED; 1. DR Pfam; PF02816; Alpha_kinase; 1. DR PIRSF; PIRSF038139; Elongation_factor_2_kinase; 1. DR SMART; SM00811; Alpha_kinase; 1. DR SUPFAM; SSF81901; HCP-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51158; ALPHA_KINASE; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ATP-binding; Calcium; Calmodulin-binding; KW Kinase; Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22223895" FT CHAIN 2..725 FT /note="Eukaryotic elongation factor 2 kinase" FT /id="PRO_0000086936" FT DOMAIN 116..326 FT /note="Alpha-type protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00501" FT REGION 1..38 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 81..94 FT /note="Calmodulin-binding" FT /evidence="ECO:0000269|PubMed:11015200" FT REGION 352..405 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 423..477 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..12 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 27..36 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 363..377 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 386..404 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 423..436 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 445..469 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 296..302 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22223895" FT MOD_RES 18 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:15144186, FT ECO:0007744|PubMed:16964243, ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 27 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 61 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:22216903" FT MOD_RES 66 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:22216903" FT MOD_RES 70 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 71 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O08796" FT MOD_RES 72 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 74 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 78 FT /note="Phosphoserine; by autocatalysis and TRPM7" FT /evidence="ECO:0000269|PubMed:21112387, FT ECO:0000269|PubMed:22216903, ECO:0007744|PubMed:23186163" FT MOD_RES 243 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 348 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:22216903, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 353 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:22216903, FT ECO:0007744|PubMed:23186163" FT MOD_RES 359 FT /note="Phosphoserine; by MAPK13 and CDK1" FT /evidence="ECO:0000269|PubMed:11500363, FT ECO:0000269|PubMed:18337751" FT MOD_RES 366 FT /note="Phosphoserine; by autocatalysis, RPS6KA1 and FT RPS6KB1" FT /evidence="ECO:0000269|PubMed:11500364, FT ECO:0000269|PubMed:22216903" FT MOD_RES 392 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O08796" FT MOD_RES 398 FT /note="Phosphoserine; by AMPK" FT /evidence="ECO:0000269|PubMed:14709557" FT MOD_RES 435 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 445 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:22216903, FT ECO:0007744|PubMed:16964243, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 470 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 474 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:22216903, FT ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 477 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 491 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:22216903, FT ECO:0007744|PubMed:23186163" FT MOD_RES 500 FT /note="Phosphoserine; by PKA" FT /evidence="ECO:0000250|UniProtKB:P70531" FT VARIANT 23 FT /note="H -> R (in dbSNP:rs9935059)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:17344846" FT /id="VAR_033915" FT VARIANT 75 FT /note="P -> A (in dbSNP:rs17841292)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_033916" FT VARIANT 291 FT /note="T -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs147978363)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041534" FT VARIANT 361 FT /note="Q -> R (in dbSNP:rs4783453)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:9144159" FT /id="VAR_058405" FT VARIANT 433 FT /note="R -> W (in dbSNP:rs56137739)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041535" FT VARIANT 609 FT /note="D -> H" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041536" FT MUTAGEN 78 FT /note="S->A: Decreased kinase activity." FT /evidence="ECO:0000269|PubMed:22216903" FT MUTAGEN 348 FT /note="T->A: Decreased kinase activity." FT /evidence="ECO:0000269|PubMed:22216903" FT MUTAGEN 366 FT /note="S->A: Abrogates phosphorylation by RPS6KB1." FT /evidence="ECO:0000269|PubMed:11500364, FT ECO:0000269|PubMed:22216903" FT MUTAGEN 366 FT /note="S->A: Decreased kinase activity." FT /evidence="ECO:0000269|PubMed:11500364, FT ECO:0000269|PubMed:22216903" FT STRAND 78..80 FT /evidence="ECO:0007829|PDB:5J8H" FT HELIX 82..94 FT /evidence="ECO:0007829|PDB:8GM4" FT HELIX 100..102 FT /evidence="ECO:0007829|PDB:8GM4" FT HELIX 104..106 FT /evidence="ECO:0007829|PDB:8GM4" FT STRAND 110..118 FT /evidence="ECO:0007829|PDB:8GM4" FT TURN 119..122 FT /evidence="ECO:0007829|PDB:8GM4" FT STRAND 123..133 FT /evidence="ECO:0007829|PDB:8GM4" FT STRAND 138..140 FT /evidence="ECO:0007829|PDB:8GM4" FT STRAND 142..151 FT /evidence="ECO:0007829|PDB:8GM4" FT STRAND 154..158 FT /evidence="ECO:0007829|PDB:8GM4" FT HELIX 161..163 FT /evidence="ECO:0007829|PDB:8GM4" FT STRAND 165..174 FT /evidence="ECO:0007829|PDB:8GM4" FT HELIX 178..199 FT /evidence="ECO:0007829|PDB:8GM4" FT STRAND 213..216 FT /evidence="ECO:0007829|PDB:8GM4" FT STRAND 218..220 FT /evidence="ECO:0007829|PDB:7SHQ" FT STRAND 225..230 FT /evidence="ECO:0007829|PDB:8GM4" FT STRAND 236..238 FT /evidence="ECO:0007829|PDB:8GM4" FT STRAND 242..244 FT /evidence="ECO:0007829|PDB:8GM4" FT STRAND 248..250 FT /evidence="ECO:0007829|PDB:7SHQ" FT HELIX 253..265 FT /evidence="ECO:0007829|PDB:8GM4" FT TURN 266..268 FT /evidence="ECO:0007829|PDB:8GM4" FT STRAND 269..273 FT /evidence="ECO:0007829|PDB:8GM4" FT STRAND 276..278 FT /evidence="ECO:0007829|PDB:8GM4" FT STRAND 286..291 FT /evidence="ECO:0007829|PDB:8GM4" FT HELIX 296..298 FT /evidence="ECO:0007829|PDB:8FO6" FT HELIX 302..311 FT /evidence="ECO:0007829|PDB:8GM4" FT HELIX 316..320 FT /evidence="ECO:0007829|PDB:8GM4" FT HELIX 330..337 FT /evidence="ECO:0007829|PDB:8GM4" FT HELIX 340..344 FT /evidence="ECO:0007829|PDB:8FNY" FT HELIX 502..508 FT /evidence="ECO:0007829|PDB:8GM5" FT HELIX 517..536 FT /evidence="ECO:0007829|PDB:8GM4" FT TURN 537..539 FT /evidence="ECO:0007829|PDB:8GM4" FT HELIX 548..560 FT /evidence="ECO:0007829|PDB:8GM4" FT HELIX 564..574 FT /evidence="ECO:0007829|PDB:8GM4" FT TURN 581..584 FT /evidence="ECO:0007829|PDB:8GM4" FT HELIX 591..606 FT /evidence="ECO:0007829|PDB:8GM4" FT HELIX 610..622 FT /evidence="ECO:0007829|PDB:8GM4" FT TURN 624..626 FT /evidence="ECO:0007829|PDB:6NX4" FT HELIX 634..645 FT /evidence="ECO:0007829|PDB:8GM4" FT STRAND 649..653 FT /evidence="ECO:0007829|PDB:6NX4" FT HELIX 664..677 FT /evidence="ECO:0007829|PDB:8GM4" FT STRAND 680..682 FT /evidence="ECO:0007829|PDB:6NX4" FT HELIX 686..702 FT /evidence="ECO:0007829|PDB:8GM4" FT HELIX 706..720 FT /evidence="ECO:0007829|PDB:8GM4" SQ SEQUENCE 725 AA; 82144 MW; 9D2900E50EFF12DA CRC64; MADEDLIFRL EGVDGGQSPR AGHDGDSDGD SDDEEGYFIC PITDDPSSNQ NVNSKVNKYY SNLTKSERYS SSGSPANSFH FKEAWKHAIQ KAKHMPDPWA EFHLEDIATE RATRHRYNAV TGEWLDDEVL IKMASQPFGR GAMRECFRTK KLSNFLHAQQ WKGASNYVAK RYIEPVDRDV YFEDVRLQME AKLWGEEYNR HKPPKQVDIM QMCIIELKDR PGKPLFHLEH YIEGKYIKYN SNSGFVRDDN IRLTPQAFSH FTFERSGHQL IVVDIQGVGD LYTDPQIHTE TGTDFGDGNL GVRGMALFFY SHACNRICES MGLAPFDLSP RERDAVNQNT KLLQSAKTIL RGTEEKCGSP QVRTLSGSRP PLLRPLSENS GDENMSDVTF DSLPSSPSSA TPHSQKLDHL HWPVFSDLDN MASRDHDHLD NHRESENSGD SGYPSEKRGE LDDPEPREHG HSYSNRKYES DEDSLGSSGR VCVEKWNLLN SSRLHLPRAS AVALEVQRLN ALDLEKKIGK SILGKVHLAM VRYHEGGRFC EKGEEWDQES AVFHLEHAAN LGELEAIVGL GLMYSQLPHH ILADVSLKET EENKTKGFDY LLKAAEAGDR QSMILVARAF DSGQNLSPDR CQDWLEALHW YNTALEMTDC DEGGEYDGMQ DEPRYMMLAR EAEMLFTGGY GLEKDPQRSG DLYTQAAEAA MEAMKGRLAN QYYQKAEEAW AQMEE // ID GPER1_HUMAN Reviewed; 375 AA. AC Q99527; A8K6C5; B5BUJ1; O00143; O43494; Q13631; Q6FHL1; Q96F42; Q99981; DT 15-JUL-1998, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1997, sequence version 1. DT 28-JAN-2026, entry version 209. DE RecName: Full=G-protein coupled estrogen receptor 1 {ECO:0000305}; DE AltName: Full=Chemoattractant receptor-like 2; DE AltName: Full=Flow-induced endothelial G-protein coupled receptor 1; DE Short=FEG-1; DE AltName: Full=G protein-coupled estrogen receptor 1; DE AltName: Full=G-protein coupled receptor 30 {ECO:0000303|PubMed:17379646, ECO:0000303|PubMed:18566127}; DE AltName: Full=GPCR-Br; DE AltName: Full=IL8-related receptor DRY12; DE AltName: Full=Lymphocyte-derived G-protein coupled receptor; DE Short=LYGPR; DE AltName: Full=Membrane estrogen receptor; DE Short=mER; GN Name=GPER1 {ECO:0000312|HGNC:HGNC:4485}; GN Synonyms=CEPR, CMKRL2, DRY12, GPER, GPR30 {ECO:0000303|PubMed:17379646, GN ECO:0000303|PubMed:18566127}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=8920907; DOI=10.1006/bbrc.1996.1654; RA Owman C.S.O., Blay P., Nilsson C., Lolait S.J.; RT "Cloning of human cDNA encoding a novel heptahelix receptor expressed in RT Burkitt's lymphoma and widely distributed in brain and peripheral RT tissues."; RL Biochem. Biophys. Res. Commun. 228:285-292(1996). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9070864; DOI=10.1006/bbrc.1997.6161; RA Feng Y., Gregor P.; RT "Cloning of a novel member of the G protein-coupled receptor family related RT to peptide receptors."; RL Biochem. Biophys. Res. Commun. 231:651-654(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9398636; DOI=10.1006/bbrc.1997.7734; RA Takada Y., Kato C., Kondo S., Korenaga R., Ando J.; RT "Cloning of cDNAs encoding G protein-coupled receptor expressed in human RT endothelial cells exposed to fluid shear stress."; RL Biochem. Biophys. Res. Commun. 240:737-741(1997). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9141481; DOI=10.1016/s0014-5793(97)00278-0; RA Kvingedal A.M., Smeland E.B.; RT "A novel putative G-protein-coupled receptor expressed in lung, heart and RT lymphoid tissue."; RL FEBS Lett. 407:59-62(1997). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9367686; DOI=10.1006/geno.1997.4972; RA Carmeci C., Thompson D.A., Ring H.Z., Francke U., Weigel R.J.; RT "Identification of a gene (GPR30) with homology to the G-protein-coupled RT receptor superfamily associated with estrogen receptor expression in breast RT cancer."; RL Genomics 45:607-617(1997). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9479505; DOI=10.1006/geno.1998.5095; RA O'Dowd B.F., Nguyen T., Marchese A., Cheng R., Lynch K.R., Heng H.H.Q., RA Kolakowski L.F. Jr., George S.R.; RT "Discovery of three novel G-protein-coupled receptor genes."; RL Genomics 47:310-313(1998). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Liver; RA McCoy R.L., Perlmutter D.H.; RT "Cloning of novel IL8-related receptors from human hepatic tissue."; RL Submitted (JUN-1996) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LEU-16. RX PubMed=19054851; DOI=10.1038/nmeth.1273; RA Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., RA Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., RA Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B., RA Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., RA Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., RA Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., RA Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., RA Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., RA Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., RA Nomura N.; RT "Human protein factory for converting the transcriptome into an in vitro- RT expressed proteome."; RL Nat. Methods 5:1011-1017(2008). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LEU-16. RC TISSUE=Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [14] RP FUNCTION. RX PubMed=11043579; DOI=10.1210/mend.14.10.0532; RA Filardo E.J., Quinn J.A., Bland K.I., Frackelton A.R. Jr.; RT "Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein- RT coupled receptor homolog, GPR30, and occurs via trans-activation of the RT epidermal growth factor receptor through release of HB-EGF."; RL Mol. Endocrinol. 14:1649-1660(2000). RN [15] RP INDUCTION. RX PubMed=12027886; DOI=10.1046/j.1432-1033.2002.02912.x; RA Ahola T.M., Purmonen S., Pennanen P., Zhuang Y.H., Tuohimaa P., Ylikomi T.; RT "Progestin upregulates G-protein-coupled receptor 30 in breast cancer RT cells."; RL Eur. J. Biochem. 269:2485-2490(2002). RN [16] RP FUNCTION, ESTROGEN-BINDING, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBCELLULAR RP LOCATION. RX PubMed=15539556; DOI=10.1210/en.2004-1064; RA Thomas P., Pang Y., Filardo E.J., Dong J.; RT "Identity of an estrogen membrane receptor coupled to a G protein in human RT breast cancer cells."; RL Endocrinology 146:624-632(2005). RN [17] RP FUNCTION, ESTROGEN-BINDING, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBCELLULAR RP LOCATION. RX PubMed=15705806; DOI=10.1126/science.1106943; RA Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., Prossnitz E.R.; RT "A transmembrane intracellular estrogen receptor mediates rapid cell RT signaling."; RL Science 307:1625-1630(2005). RN [18] RP ABSENCE OF ESTROGEN-BINDING, AND SUBCELLULAR LOCATION. RX PubMed=16645038; DOI=10.1210/me.2005-0525; RA Pedram A., Razandi M., Levin E.R.; RT "Nature of functional estrogen receptors at the plasma membrane."; RL Mol. Endocrinol. 20:1996-2009(2006). RN [19] RP SUBCELLULAR LOCATION. RX PubMed=17379646; DOI=10.1210/en.2006-1605; RA Filardo E., Quinn J., Pang Y., Graeber C., Shaw S., Dong J., Thomas P.; RT "Activation of the novel estrogen receptor G protein-coupled receptor 30 RT (GPR30) at the plasma membrane."; RL Endocrinology 148:3236-3245(2007). RN [20] RP ABSENCE OF ESTROGEN-BINDING, AND SUBCELLULAR LOCATION. RX PubMed=18566127; DOI=10.1210/en.2008-0269; RA Otto C., Rohde-Schulz B., Schwarz G., Fuchs I., Klewer M., Brittain D., RA Langer G., Bader B., Prelle K., Nubbemeyer R., Fritzemeier K.H.; RT "G protein-coupled receptor 30 localizes to the endoplasmic reticulum and RT is not activated by estradiol."; RL Endocrinology 149:4846-4856(2008). RN [21] RP FUNCTION. RX PubMed=19179659; DOI=10.1161/circresaha.108.190892; RA Haas E., Bhattacharya I., Brailoiu E., Damjanovic M., Brailoiu G.C., RA Gao X., Mueller-Guerre L., Marjon N.A., Gut A., Minotti R., Meyer M.R., RA Amann K., Ammann E., Perez-Dominguez A., Genoni M., Clegg D.J., Dun N.J., RA Resta T.C., Prossnitz E.R., Barton M.; RT "Regulatory role of G protein-coupled estrogen receptor for vascular RT function and obesity."; RL Circ. Res. 104:288-291(2009). RN [22] RP FUNCTION. RX PubMed=19342448; DOI=10.1210/me.2008-0262; RA Quinn J.A., Graeber C.T., Frackelton A.R. Jr., Kim M., Schwarzbauer J.E., RA Filardo E.J.; RT "Coordinate regulation of estrogen-mediated fibronectin matrix assembly and RT epidermal growth factor receptor transactivation by the G protein-coupled RT receptor, GPR30."; RL Mol. Endocrinol. 23:1052-1064(2009). RN [23] RP INTERACTION WITH EGFR AND ESR1, AND INDUCTION. RX PubMed=19749156; DOI=10.1210/me.2009-0120; RA Vivacqua A., Lappano R., De Marco P., Sisci D., Aquila S., De Amicis F., RA Fuqua S.A., Ando S., Maggiolini M.; RT "G protein-coupled receptor 30 expression is up-regulated by EGF and TGF RT alpha in estrogen receptor alpha-positive cancer cells."; RL Mol. Endocrinol. 23:1815-1826(2009). RN [24] RP FUNCTION, INTERACTION WITH EGFR, ASSOCIATION WITH CHROMATIN, SUBCELLULAR RP LOCATION, AND TISSUE SPECIFICITY. RX PubMed=20551055; DOI=10.1158/0008-5472.can-10-0408; RA Madeo A., Maggiolini M.; RT "Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol- RT induced gene expression and migration in breast cancer-associated RT fibroblasts."; RL Cancer Res. 70:6036-6046(2010). RN [25] RP FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=20203690; DOI=10.1038/cdd.2010.20; RA Chan Q.K., Lam H.M., Ng C.F., Lee A.Y., Chan E.S., Ng H.K., Ho S.M., RA Lau K.M.; RT "Activation of GPR30 inhibits the growth of prostate cancer cells through RT sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, RT and induction of G(2) cell-cycle arrest."; RL Cell Death Differ. 17:1511-1523(2010). RN [26] RP ESTROGEN-BINDING, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=19931550; DOI=10.1016/j.steroids.2009.11.005; RA Thomas P., Alyea R., Pang Y., Peyton C., Dong J., Berg A.H.; RT "Conserved estrogen binding and signaling functions of the G protein- RT coupled estrogen receptor 1 (GPER) in mammals and fish."; RL Steroids 75:595-602(2010). RN [27] RP FUNCTION, SUBCELLULAR LOCATION, GLYCOSYLATION, AND TISSUE SPECIFICITY. RX PubMed=21427217; DOI=10.1210/en.2010-0979; RA Maiti K., Paul J.W., Read M., Chan E.C., Riley S.C., Nahar P., Smith R.; RT "G-1-activated membrane estrogen receptors mediate increased contractility RT of the human myometrium."; RL Endocrinology 152:2448-2455(2011). RN [28] RP ALDOSTERONE-BINDING, AND FUNCTION. RX PubMed=21242460; DOI=10.1161/hypertensionaha.110.161653; RA Gros R., Ding Q., Sklar L.A., Prossnitz E.E., Arterburn J.B., RA Chorazyczewski J., Feldman R.D.; RT "GPR30 expression is required for the mineralocorticoid receptor- RT independent rapid vascular effects of aldosterone."; RL Hypertension 57:442-451(2011). RN [29] RP SUBCELLULAR LOCATION, AND UBIQUITINATION. RX PubMed=21540189; DOI=10.1074/jbc.m111.224071; RA Cheng S.B., Quinn J.A., Graeber C.T., Filardo E.J.; RT "Down-modulation of the G-protein-coupled estrogen receptor, GPER, from the RT cell surface occurs via a trans-Golgi-proteasome pathway."; RL J. Biol. Chem. 286:22441-22455(2011). RN [30] RP FUNCTION, INTERACTION WITH KRT7 AND KRT8, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=21149639; DOI=10.1124/mol.110.069500; RA Sanden C., Broselid S., Cornmark L., Andersson K., Daszkiewicz-Nilsson J., RA Martensson U.E., Olde B., Leeb-Lundberg L.M.; RT "G protein-coupled estrogen receptor 1/G protein-coupled receptor 30 RT localizes in the plasma membrane and traffics intracellularly on RT cytokeratin intermediate filaments."; RL Mol. Pharmacol. 79:400-410(2011). RN [31] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=21354433; DOI=10.1016/j.steroids.2011.02.018; RA Cheng S.B., Graeber C.T., Quinn J.A., Filardo E.J.; RT "Retrograde transport of the transmembrane estrogen receptor, G-protein- RT coupled-receptor-30 (GPR30/GPER) from the plasma membrane towards the RT nucleus."; RL Steroids 76:892-896(2011). RN [32] RP FUNCTION. RX PubMed=23135268; DOI=10.1074/jbc.m112.417303; RA Santolla M.F., Lappano R., De Marco P., Pupo M., Vivacqua A., Sisci D., RA Abonante S., Iacopetta D., Cappello A.R., Dolce V., Maggiolini M.; RT "G protein-coupled estrogen receptor mediates the up-regulation of fatty RT acid synthase induced by 17beta-estradiol in cancer cells and cancer- RT associated fibroblasts."; RL J. Biol. Chem. 287:43234-43245(2012). RN [33] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=23285008; DOI=10.1371/journal.pone.0052357; RA Chakrabarti S., Davidge S.T.; RT "G-protein coupled receptor 30 (GPR30): a novel regulator of endothelial RT inflammation."; RL PLoS ONE 7:E52357-E52357(2012). RN [34] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [35] RP ALDOSTERONE-BINDING, AND FUNCTION. RX PubMed=23283935; DOI=10.1152/ajpcell.00203.2012; RA Gros R., Ding Q., Liu B., Chorazyczewski J., Feldman R.D.; RT "Aldosterone mediates its rapid effects in vascular endothelial cells RT through GPER activation."; RL Am. J. Physiol. 304:C532-C540(2013). RN [36] RP FUNCTION, INTERACTION WITH RAMP3, AND SUBCELLULAR LOCATION. RX PubMed=23674134; DOI=10.1530/jme-13-0021; RA Lenhart P.M., Broselid S., Barrick C.J., Leeb-Lundberg L.M., Caron K.M.; RT "G-protein-coupled receptor 30 interacts with receptor activity-modifying RT protein 3 and confers sex-dependent cardioprotection."; RL J. Mol. Endocrinol. 51:191-202(2013). RN [37] RP REVIEW. RX PubMed=22521564; DOI=10.1016/j.steroids.2012.04.001; RA Barton M.; RT "Position paper: The membrane estrogen receptor GPER--Clues and RT questions."; RL Steroids 77:935-942(2012). RN [38] RP REVIEW. RX PubMed=22495674; DOI=10.1210/en.2012-1061; RA Filardo E.J., Thomas P.; RT "Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism RT of action and role in female reproductive cancer, renal and vascular RT physiology."; RL Endocrinology 153:2953-2962(2012). CC -!- FUNCTION: G-protein coupled estrogen receptor that binds to 17-beta- CC estradiol (E2) with high affinity, leading to rapid and transient CC activation of numerous intracellular signaling pathways. Stimulates CC cAMP production, calcium mobilization and tyrosine kinase Src inducing CC the release of heparin-bound epidermal growth factor (HB-EGF) and CC subsequent transactivation of the epidermal growth factor receptor CC (EGFR), activating downstream signaling pathways such as PI3K/Akt and CC ERK/MAPK. Mediates pleiotropic functions among others in the CC cardiovascular, endocrine, reproductive, immune and central nervous CC systems. Has a role in cardioprotection by reducing cardiac hypertrophy CC and perivascular fibrosis in a RAMP3-dependent manner. Regulates CC arterial blood pressure by stimulating vasodilation and reducing CC vascular smooth muscle and microvascular endothelial cell CC proliferation. Plays a role in blood glucose homeostasis contributing CC to the insulin secretion response by pancreatic beta cells. Triggers CC mitochondrial apoptosis during pachytene spermatocyte differentiation. CC Stimulates uterine epithelial cell proliferation. Enhances uterine CC contractility in response to oxytocin. Contributes to thymic atrophy by CC inducing apoptosis. Attenuates TNF-mediated endothelial expression of CC leukocyte adhesion molecules. Promotes neuritogenesis in developing CC hippocampal neurons. Plays a role in acute neuroprotection against CC NMDA-induced excitotoxic neuronal death. Increases firing activity and CC intracellular calcium oscillations in luteinizing hormone-releasing CC hormone (LHRH) neurons. Inhibits early osteoblast proliferation at CC growth plate during skeletal development. Inhibits mature adipocyte CC differentiation and lipid accumulation. Involved in the recruitment of CC beta-arrestin 2 ARRB2 at the plasma membrane in epithelial cells. Also CC functions as a receptor for aldosterone mediating rapid regulation of CC vascular contractibility through the PI3K/ERK signaling pathway. CC Involved in cancer progression regulation. Stimulates cancer-associated CC fibroblast (CAF) proliferation by a rapid genomic response through the CC EGFR/ERK transduction pathway. Associated with EGFR, may act as a CC transcription factor activating growth regulatory genes (c-fos, cyclin CC D1). Promotes integrin alpha-5/beta-1 and fibronectin (FN) matrix CC assembly in breast cancer cells. {ECO:0000269|PubMed:11043579, CC ECO:0000269|PubMed:15539556, ECO:0000269|PubMed:15705806, CC ECO:0000269|PubMed:19179659, ECO:0000269|PubMed:19342448, CC ECO:0000269|PubMed:20203690, ECO:0000269|PubMed:20551055, CC ECO:0000269|PubMed:21149639, ECO:0000269|PubMed:21242460, CC ECO:0000269|PubMed:21427217, ECO:0000269|PubMed:23135268, CC ECO:0000269|PubMed:23283935, ECO:0000269|PubMed:23285008, CC ECO:0000269|PubMed:23674134}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC Note=Binds 17-beta-estradiol (E2) in plasma membranes with high CC affinity (Kd is 3.3 nM) and displays rapid kinetics of association CC and dissociation. {ECO:0000269|PubMed:15539556, CC ECO:0000269|PubMed:15705806, ECO:0000269|PubMed:19931550}; CC -!- SUBUNIT: Homodimer (Probable). Heterodimer; heterodimerizes with other CC G-protein-coupled receptor (GPCRs) like CRHR1, HTR1A and PAQR8. CC Interacts (via C-terminus tail motif) with DLG4 (via N-terminus tandem CC pair of PDZ domains); the interaction is direct and induces the CC increase of GPER1 protein levels residing at the plasma membrane CC surface in a estradiol-independent manner (By similarity). Interacts CC with RAMP3; the interaction confers proper subcellular localization and CC function in cardioprotection. Interacts with KRT7 and KRT8. Interacts CC with EGFR; the interaction increases after agonist-induced stimulation CC in cancer-associated fibroblasts (CAF). Interacts with EGFR and ESR1. CC {ECO:0000250, ECO:0000269|PubMed:19749156, ECO:0000269|PubMed:20551055, CC ECO:0000269|PubMed:21149639, ECO:0000269|PubMed:23674134, ECO:0000305}. CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}. Cytoplasm, CC perinuclear region. Cytoplasm, cytoskeleton. Cell membrane; Multi-pass CC membrane protein. Basolateral cell membrane; Multi-pass membrane CC protein. Cytoplasmic vesicle membrane; Multi-pass membrane protein. CC Early endosome. Recycling endosome. Golgi apparatus membrane CC {ECO:0000250}; Multi-pass membrane protein {ECO:0000250}. Golgi CC apparatus, trans-Golgi network. Endoplasmic reticulum membrane CC {ECO:0000269|PubMed:18566127}; Multi-pass membrane protein. Cell CC projection, dendrite {ECO:0000250}. Cell projection, dendritic spine CC membrane {ECO:0000250}; Multi-pass membrane protein {ECO:0000250}. Cell CC projection, axon {ECO:0000250}. Postsynaptic density {ECO:0000250}. CC Mitochondrion membrane {ECO:0000250}; Multi-pass membrane protein CC {ECO:0000250}. Note=Colocalized with BSN to the active zone of CC presynaptic density. Colocalized with DLG4/PSD95 and neurabin-2 PPP1R9B CC in neuronal synaptosomes (By similarity). Endocytosed in a agonist- and CC arrestin-independent manner. Colocalized with RAMP3 and clathrin-coated CC pits at the plasma membrane. Colocalized with transferrin receptor at CC the plasma membrane and perinuclear region. Accumulated and colocalized CC with RAB11 proteins in recycling endosomes and trans-Golgi network CC (TGN), but does neither recycle back to the cell surface nor traffics CC to late endosome or lysosome. Colocalized with calnexin in the CC endoplasmic reticulum. Traffics to intracellular sites via cytokeratin CC intermediate filaments like KRT7 and KRT8 after constitutive CC endocytosis in epithelial cells. Colocalized with EGFR in the nucleus CC of agonist-induced cancer-associated fibroblasts (CAF). {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Expressed in placenta, endothelial and epithelial CC cells, non laboring and laboring term myometrium, fibroblasts and CC cancer-associated fibroblasts (CAF), prostate cancer cells and invasive CC adenocarcinoma (at protein level). Ubiquitously expressed, but is most CC abundant in placenta. In brain regions, expressed as a 2.8 kb CC transcript in basal forebrain, frontal cortex, thalamus, hippocampus, CC caudate and putamen. {ECO:0000269|PubMed:20203690, CC ECO:0000269|PubMed:20551055, ECO:0000269|PubMed:21149639, CC ECO:0000269|PubMed:21354433, ECO:0000269|PubMed:21427217, CC ECO:0000269|PubMed:23285008}. CC -!- INDUCTION: Up-regulated by EGF and TGF-alpha in endometrial, ovarian CC and breast tumor cells. Up-regulated by progestin and by phorbol 12- CC myristate 13-acetate (PMA) in breast cancer cell lines. CC {ECO:0000269|PubMed:12027886, ECO:0000269|PubMed:19749156}. CC -!- PTM: Ubiquitinated; ubiquitination occurs at the plasma membrane and CC leads to proteasome-mediated degradation. CC {ECO:0000269|PubMed:21540189}. CC -!- PTM: Glycosylated. {ECO:0000269|PubMed:21427217}. CC -!- MISCELLANEOUS: Does not bind estradiol according to PubMed:18566127 and CC PubMed:16645038. CC -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family. CC {ECO:0000255|PROSITE-ProRule:PRU00521}. CC -!- CAUTION: Data is conflicting regarding whether it fulfills the criteria CC of a membrane-bound estrogen receptor (PubMed:15705806, CC PubMed:17379646). Other reports suggest that it is not CC (PubMed:16645038, PubMed:18566127). {ECO:0000305|PubMed:15705806, CC ECO:0000305|PubMed:16645038, ECO:0000305|PubMed:17379646, CC ECO:0000305|PubMed:18566127}. CC -!- CAUTION: Data is conflicting regarding whether it is localized either CC at the cell membrane (PM) (PubMed:15539556, PubMed:21149639, CC PubMed:21354433, PubMed:21427217, PubMed:21540189, PubMed:23674134). CC Other reports suggest that it localizes at the endoplasmic reticulum CC (ER) (PubMed:15705806, PubMed:18566127). {ECO:0000305|PubMed:15539556, CC ECO:0000305|PubMed:15705806, ECO:0000305|PubMed:18566127, CC ECO:0000305|PubMed:21149639, ECO:0000305|PubMed:21354433, CC ECO:0000305|PubMed:21427217, ECO:0000305|PubMed:21540189, CC ECO:0000305|PubMed:23674134}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/44344/GPER"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Y08162; CAA69354.1; -; mRNA. DR EMBL; U77827; AAC51173.1; -; Genomic_DNA. DR EMBL; AF015257; AAC51904.1; -; mRNA. DR EMBL; X98510; CAA67133.1; -; mRNA. DR EMBL; U63917; AAB88017.1; -; mRNA. DR EMBL; AF027956; AAC52027.1; -; Genomic_DNA. DR EMBL; U58828; AAB02736.1; -; mRNA. DR EMBL; CR541741; CAG46541.1; -; mRNA. DR EMBL; AK291590; BAF84279.1; -; mRNA. DR EMBL; AB451427; BAG70241.1; -; mRNA. DR EMBL; CH236953; EAL23938.1; -; Genomic_DNA. DR EMBL; CH471144; EAW87194.1; -; Genomic_DNA. DR EMBL; BC011634; AAH11634.1; -; mRNA. DR CCDS; CCDS5322.1; -. DR PIR; G02670; G02670. DR PIR; JC5069; JC5069. DR RefSeq; NP_001035055.1; NM_001039966.2. DR RefSeq; NP_001091671.1; NM_001098201.3. DR RefSeq; NP_001496.1; NM_001505.3. DR PDB; 8XOF; EM; 2.60 A; R=1-375. DR PDB; 8XOG; EM; 2.90 A; R=1-375. DR PDB; 8XOH; EM; 3.20 A; R=1-375. DR PDB; 8XOI; EM; 3.20 A; R=1-375. DR PDB; 8XOJ; EM; 3.10 A; R=1-375. DR PDBsum; 8XOF; -. DR PDBsum; 8XOG; -. DR PDBsum; 8XOH; -. DR PDBsum; 8XOI; -. DR PDBsum; 8XOJ; -. DR AlphaFoldDB; Q99527; -. DR EMDB; EMD-38527; -. DR EMDB; EMD-38528; -. DR EMDB; EMD-38529; -. DR EMDB; EMD-38530; -. DR EMDB; EMD-38531; -. DR SMR; Q99527; -. DR BioGRID; 109110; 4. DR CORUM; Q99527; -. DR FunCoup; Q99527; 533. DR IntAct; Q99527; 1. DR STRING; 9606.ENSP00000380281; -. DR BindingDB; Q99527; -. DR ChEMBL; CHEMBL5872; -. DR DrugBank; DB00783; Estradiol. DR DrugBank; DB13952; Estradiol acetate. DR DrugBank; DB13953; Estradiol benzoate. DR DrugBank; DB13954; Estradiol cypionate. DR DrugBank; DB13955; Estradiol dienanthate. DR DrugBank; DB13956; Estradiol valerate. DR DrugBank; DB01645; Genistein. DR DrugBank; DB18091; LNS-8801. DR DrugBank; DB05939; MK-0354. DR DrugCentral; Q99527; -. DR GuidetoPHARMACOLOGY; 221; -. DR TCDB; 9.A.14.13.19; the g-protein-coupled receptor (gpcr) family. DR GlyCosmos; Q99527; 3 sites, No reported glycans. DR GlyGen; Q99527; 3 sites. DR iPTMnet; Q99527; -. DR PhosphoSitePlus; Q99527; -. DR BioMuta; GPER1; -. DR DMDM; 3023539; -. DR MassIVE; Q99527; -. DR PaxDb; 9606-ENSP00000380281; -. DR PeptideAtlas; Q99527; -. DR Antibodypedia; 10887; 427 antibodies from 34 providers. DR DNASU; 2852; -. DR Ensembl; ENST00000297469.3; ENSP00000297469.3; ENSG00000164850.17. DR Ensembl; ENST00000397088.4; ENSP00000380277.3; ENSG00000164850.17. DR Ensembl; ENST00000397092.5; ENSP00000380281.1; ENSG00000164850.17. DR Ensembl; ENST00000401670.1; ENSP00000385151.1; ENSG00000164850.17. DR GeneID; 2852; -. DR KEGG; hsa:2852; -. DR MANE-Select; ENST00000397088.4; ENSP00000380277.3; NM_001098201.3; NP_001091671.1. DR UCSC; uc003sjz.1; human. DR AGR; HGNC:4485; -. DR ClinPGx; PA28873; -. DR CTD; 2852; -. DR DisGeNET; 2852; -. DR GeneCards; GPER1; -. DR HGNC; HGNC:4485; GPER1. DR HPA; ENSG00000164850; Tissue enhanced (stomach). DR MIM; 601805; gene. DR OpenTargets; ENSG00000164850; -. DR VEuPathDB; HostDB:ENSG00000164850; -. DR eggNOG; ENOG502QU56; Eukaryota. DR GeneTree; ENSGT00940000154307; -. DR HOGENOM; CLU_009579_8_3_1; -. DR InParanoid; Q99527; -. DR OMA; FRTKQHA; -. DR OrthoDB; 5957382at2759; -. DR PAN-GO; Q99527; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q99527; -. DR PathwayCommons; Q99527; -. DR Reactome; R-HSA-375276; Peptide ligand-binding receptors. DR Reactome; R-HSA-418594; G alpha (i) signalling events. DR Reactome; R-HSA-9634597; GPER1 signaling. DR SignaLink; Q99527; -. DR SIGNOR; Q99527; -. DR Agora; ENSG00000164850; -. DR BioGRID-ORCS; 2852; 13 hits in 1132 CRISPR screens. DR GeneWiki; GPR30; -. DR GenomeRNAi; 2852; -. DR Pharos; Q99527; Tchem. DR PRO; PR:Q99527; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; Q99527; protein. DR Bgee; ENSG00000164850; Expressed in body of stomach and 131 other cell types or tissues. DR ExpressionAtlas; Q99527; baseline and differential. DR GO; GO:0030424; C:axon; ISS:UniProtKB. DR GO; GO:0043679; C:axon terminus; ISS:UniProtKB. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030425; C:dendrite; ISS:UniProtKB. DR GO; GO:0043198; C:dendritic shaft; ISS:UniProtKB. DR GO; GO:0044327; C:dendritic spine head; ISS:UniProtKB. DR GO; GO:0032591; C:dendritic spine membrane; ISS:UniProtKB. DR GO; GO:0005769; C:early endosome; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell. DR GO; GO:0098686; C:hippocampal mossy fiber to CA3 synapse; IEA:Ensembl. DR GO; GO:0045095; C:keratin filament; IDA:UniProtKB. DR GO; GO:0031966; C:mitochondrial membrane; ISS:UniProtKB. DR GO; GO:0005635; C:nuclear envelope; IDA:UniProtKB. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0014069; C:postsynaptic density; ISS:UniProtKB. DR GO; GO:0048786; C:presynaptic active zone; ISS:UniProtKB. DR GO; GO:0042734; C:presynaptic membrane; ISS:UniProtKB. DR GO; GO:0055037; C:recycling endosome; IDA:UniProtKB. DR GO; GO:0005802; C:trans-Golgi network; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0038054; F:G protein-coupled estrogen receptor activity; ISS:UniProtKB. DR GO; GO:0004930; F:G protein-coupled receptor activity; TAS:ProtInc. DR GO; GO:0030284; F:nuclear estrogen receptor activity; IDA:UniProtKB. DR GO; GO:0005496; F:steroid binding; IDA:UniProtKB. DR GO; GO:1990239; F:steroid hormone binding; IDA:UniProtKB. DR GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0030263; P:apoptotic chromosome condensation; ISS:UniProtKB. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0071392; P:cellular response to estradiol stimulus; IDA:UniProtKB. DR GO; GO:0071333; P:cellular response to glucose stimulus; ISS:UniProtKB. DR GO; GO:0071389; P:cellular response to mineralocorticoid stimulus; ISS:UniProtKB. DR GO; GO:0071375; P:cellular response to peptide hormone stimulus; IDA:UniProtKB. DR GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IMP:AgBase. DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW. DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW. DR GO; GO:0010948; P:negative regulation of cell cycle process; IMP:AgBase. DR GO; GO:0008285; P:negative regulation of cell population proliferation; ISS:UniProtKB. DR GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IMP:AgBase. DR GO; GO:0045599; P:negative regulation of fat cell differentiation; ISS:UniProtKB. DR GO; GO:0010629; P:negative regulation of gene expression; IMP:AgBase. DR GO; GO:0050728; P:negative regulation of inflammatory response; IDA:UniProtKB. DR GO; GO:0002695; P:negative regulation of leukocyte activation; IDA:UniProtKB. DR GO; GO:0051055; P:negative regulation of lipid biosynthetic process; ISS:UniProtKB. DR GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:AgBase. DR GO; GO:1904706; P:negative regulation of vascular associated smooth muscle cell proliferation; IMP:AgBase. DR GO; GO:0007399; P:nervous system development; IEA:UniProtKB-KW. DR GO; GO:0019228; P:neuronal action potential; ISS:UniProtKB. DR GO; GO:0030264; P:nuclear fragmentation involved in apoptotic nuclear change; ISS:UniProtKB. DR GO; GO:0030518; P:nuclear receptor-mediated steroid hormone signaling pathway; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; ISS:UniProtKB. DR GO; GO:2000724; P:positive regulation of cardiac vascular smooth muscle cell differentiation; IMP:AgBase. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; ISS:UniProtKB. DR GO; GO:2000353; P:positive regulation of endothelial cell apoptotic process; ISS:UniProtKB. DR GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB. DR GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; ISS:UniProtKB. DR GO; GO:0045745; P:positive regulation of G protein-coupled receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:AgBase. DR GO; GO:0032962; P:positive regulation of inositol trisphosphate biosynthetic process; IDA:UniProtKB. DR GO; GO:0032024; P:positive regulation of insulin secretion; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB. DR GO; GO:0050769; P:positive regulation of neurogenesis; ISS:UniProtKB. DR GO; GO:0001956; P:positive regulation of neurotransmitter secretion; ISS:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProtKB. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IDA:UniProtKB. DR GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB. DR GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; ISS:UniProtKB. DR GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IDA:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0070474; P:positive regulation of uterine smooth muscle contraction; IDA:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; ISS:UniProtKB. DR GO; GO:0051480; P:regulation of cytosolic calcium ion concentration; ISS:UniProtKB. DR GO; GO:0043401; P:steroid hormone receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0042311; P:vasodilation; ISS:UniProtKB. DR CDD; cd14989; 7tmA_GPER1; 1. DR FunFam; 1.20.1070.10:FF:000093; G-protein coupled estrogen receptor 1; 1. DR Gene3D; 1.20.1070.10; Rhodopsin 7-helix transmembrane proteins; 1. DR InterPro; IPR000276; GPCR_Rhodpsn. DR InterPro; IPR017452; GPCR_Rhodpsn_7TM. DR InterPro; IPR047143; GPER1-like. DR PANTHER; PTHR24226:SF2; G-PROTEIN COUPLED ESTROGEN RECEPTOR 1; 1. DR PANTHER; PTHR24226; G-PROTEIN COUPLED RECEPTOR 182 AND ESTROGEN RECEPTOR 1; 1. DR Pfam; PF00001; 7tm_1; 1. DR PRINTS; PR00237; GPCRRHODOPSN. DR SUPFAM; SSF81321; Family A G protein-coupled receptor-like; 1. DR PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1. DR PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Apoptosis; Cell cycle; Cell membrane; KW Cell projection; Cytoplasm; Cytoplasmic vesicle; Cytoskeleton; KW Differentiation; Disulfide bond; Endoplasmic reticulum; Endosome; KW G-protein coupled receptor; Glycoprotein; Golgi apparatus; Immunity; KW Inflammatory response; Innate immunity; Membrane; Mitochondrion; KW Neurogenesis; Nucleus; Postsynaptic cell membrane; KW Proteomics identification; Receptor; Reference proteome; Synapse; KW Transducer; Transmembrane; Transmembrane helix; Ubl conjugation. FT CHAIN 1..375 FT /note="G-protein coupled estrogen receptor 1" FT /id="PRO_0000069310" FT TOPO_DOM 1..62 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 63..84 FT /note="Helical; Name=1" FT /evidence="ECO:0000255" FT TOPO_DOM 85..96 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 97..120 FT /note="Helical; Name=2" FT /evidence="ECO:0000255" FT TOPO_DOM 121..132 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 133..153 FT /note="Helical; Name=3" FT /evidence="ECO:0000255" FT TOPO_DOM 154..175 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 176..194 FT /note="Helical; Name=4" FT /evidence="ECO:0000255" FT TOPO_DOM 195..220 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 221..236 FT /note="Helical; Name=5" FT /evidence="ECO:0000255" FT TOPO_DOM 237..259 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 260..280 FT /note="Helical; Name=6" FT /evidence="ECO:0000255" FT TOPO_DOM 281..306 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 307..327 FT /note="Helical; Name=7" FT /evidence="ECO:0000255" FT TOPO_DOM 328..375 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:22814378" FT CARBOHYD 25 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 32 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 44 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 130..207 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00521" FT VARIANT 16 FT /note="P -> L (in dbSNP:rs11544331)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:19054851" FT /id="VAR_033319" FT CONFLICT 20..21 FT /note="QP -> HA (in Ref. 6; AAC52027)" FT /evidence="ECO:0000305" FT CONFLICT 32..49 FT /note="Missing (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 104 FT /note="A -> G (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 140..146 FT /note="NMYSSVF -> QHVQAASS (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 179 FT /note="G -> A (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 184 FT /note="A -> S (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 312 FT /note="A -> T (in Ref. 2; AAC51173)" FT /evidence="ECO:0000305" FT CONFLICT 320 FT /note="N -> T (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 355 FT /note="A -> V (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 358 FT /note="A -> V (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT HELIX 53..86 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 88..90 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 93..115 FT /evidence="ECO:0007829|PDB:8XOG" FT TURN 116..118 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 121..124 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 127..160 FT /evidence="ECO:0007829|PDB:8XOG" FT STRAND 161..164 FT /evidence="ECO:0007829|PDB:8XOG" FT TURN 166..168 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 171..199 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 212..222 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 224..245 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 255..284 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 303..324 FT /evidence="ECO:0007829|PDB:8XOG" FT TURN 325..327 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 329..341 FT /evidence="ECO:0007829|PDB:8XOG" SQ SEQUENCE 375 AA; 42248 MW; 0A54EED8A698F075 CRC64; MDVTSQARGV GLEMYPGTAQ PAAPNTTSPE LNLSHPLLGT ALANGTGELS EHQQYVIGLF LSCLYTIFLF PIGFVGNILI LVVNISFREK MTIPDLYFIN LAVADLILVA DSLIEVFNLH ERYYDIAVLC TFMSLFLQVN MYSSVFFLTW MSFDRYIALA RAMRCSLFRT KHHARLSCGL IWMASVSATL VPFTAVHLQH TDEACFCFAD VREVQWLEVT LGFIVPFAII GLCYSLIVRV LVRAHRHRGL RPRRQKALRM ILAVVLVFFV CWLPENVFIS VHLLQRTQPG AAPCKQSFRH AHPLTGHIVN LAAFSNSCLN PLIYSFLGET FRDKLRLYIE QKTNLPALNR FCHAALKAVI PDSTEQSDVR FSSAV // ID GUC2F_HUMAN Reviewed; 1108 AA. AC P51841; Q9UJF1; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 02-NOV-2010, sequence version 2. DT 28-JAN-2026, entry version 220. DE RecName: Full=Retinal guanylyl cyclase 2; DE Short=RETGC-2 {ECO:0000303|PubMed:7777544}; DE EC=4.6.1.2 {ECO:0000269|PubMed:7777544}; DE AltName: Full=Guanylate cyclase 2F, retinal {ECO:0000312|HGNC:HGNC:4691}; DE AltName: Full=Guanylate cyclase F; DE Short=GC-F; DE AltName: Full=Rod outer segment membrane guanylate cyclase 2; DE Short=ROS-GC2; DE Flags: Precursor; GN Name=GUCY2F; Synonyms=GUC2F, RETGC2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], VARIANT GLN-296, TISSUE SPECIFICITY, ACTIVITY RP REGULATION, AND CATALYTIC ACTIVITY. RC TISSUE=Retina; RX PubMed=7777544; DOI=10.1073/pnas.92.12.5535; RA Lowe D.G., Dizhoor A.M., Liu K., Gu Q., Spencer M., Laura R., Lu L., RA Hurley J.B.; RT "Cloning and expression of a second photoreceptor-specific membrane retina RT guanylyl cyclase (RetGC), RetGC-2."; RL Proc. Natl. Acad. Sci. U.S.A. 92:5535-5539(1995). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [3] RP VARIANT [LARGE SCALE ANALYSIS] PRO-10. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [4] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-40; ASN-160; TRP-230; PRO-284; GLN-305; RP CYS-308; HIS-380; ARG-434; ASP-568; GLN-628; LEU-677; LYS-794; VAL-1010; RP ARG-1052 AND ASP-1055. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [5] RP VARIANT ASP-872. RX PubMed=23033978; DOI=10.1056/nejmoa1206524; RA de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G., RA Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C., RA del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G., RA Veltman J.A., Vissers L.E.; RT "Diagnostic exome sequencing in persons with severe intellectual RT disability."; RL N. Engl. J. Med. 367:1921-1929(2012). RN [6] RP ACTIVITY REGULATION. RX PubMed=29515371; DOI=10.3389/fnmol.2018.00052; RA Wimberg H., Janssen-Bienhold U., Koch K.W.; RT "Control of the Nucleotide Cycle in Photoreceptor Cell Extracts by Retinal RT Degeneration Protein 3."; RL Front. Mol. Neurosci. 11:52-52(2018). CC -!- FUNCTION: Responsible for the synthesis of cyclic GMP (cGMP) in rods CC and cones of photoreceptors (PubMed:7777544). Plays an essential role CC in phototransduction, by mediating cGMP replenishment (By similarity). CC May also participate in the trafficking of membrane-associated proteins CC to the photoreceptor outer segment membrane (By similarity). CC {ECO:0000250|UniProtKB:Q5SDA5, ECO:0000269|PubMed:7777544}. CC -!- CATALYTIC ACTIVITY: CC Reaction=GTP = 3',5'-cyclic GMP + diphosphate; Xref=Rhea:RHEA:13665, CC ChEBI:CHEBI:33019, ChEBI:CHEBI:37565, ChEBI:CHEBI:57746; EC=4.6.1.2; CC Evidence={ECO:0000269|PubMed:7777544}; CC -!- ACTIVITY REGULATION: Activated by GUCA1B when free calcium ions CC concentration is low, and inhibited by GUCA1B when free calcium ions CC concentration is high (PubMed:15772651). Inhibited by RD3 CC (PubMed:29515371). {ECO:0000269|PubMed:15772651, CC ECO:0000269|PubMed:29515371}. CC -!- SUBUNIT: Homodimer (By similarity). Interacts with RD3; promotes the CC exit of GUCY2F from the endoplasmic reticulum and its trafficking to CC the photoreceptor outer segments (By similarity). CC {ECO:0000250|UniProtKB:P51842, ECO:0000250|UniProtKB:Q5SDA5}. CC -!- SUBCELLULAR LOCATION: Photoreceptor outer segment membrane CC {ECO:0000250|UniProtKB:O02740}; Single-pass type I membrane protein CC {ECO:0000255}. CC -!- TISSUE SPECIFICITY: Retina. Localized exclusively in the outer nuclear CC layer and inner segments of the rod and cone photoreceptor cells. CC {ECO:0000269|PubMed:7777544}. CC -!- DOMAIN: The protein kinase domain is predicted to be catalytically CC inactive. CC -!- PTM: There are 9 conserved cysteine residues in sensory guanylate CC cyclases, 6 in the extracellular domain, which may be involved in CC intra- or interchain disulfide bonds. CC -!- SIMILARITY: Belongs to the adenylyl cyclase class-4/guanylyl cyclase CC family. {ECO:0000255|PROSITE-ProRule:PRU00099}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L37378; AAA74451.1; -; mRNA. DR EMBL; AL031387; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS14545.1; -. DR PIR; I59385; I59385. DR RefSeq; NP_001513.2; NM_001522.3. DR AlphaFoldDB; P51841; -. DR SMR; P51841; -. DR BioGRID; 109241; 6. DR FunCoup; P51841; 179. DR IntAct; P51841; 6. DR MINT; P51841; -. DR STRING; 9606.ENSP00000218006; -. DR iPTMnet; P51841; -. DR PhosphoSitePlus; P51841; -. DR BioMuta; GUCY2F; -. DR DMDM; 311033391; -. DR jPOST; P51841; -. DR MassIVE; P51841; -. DR PaxDb; 9606-ENSP00000218006; -. DR PeptideAtlas; P51841; -. DR ProteomicsDB; 56431; -. DR Antibodypedia; 29460; 108 antibodies from 18 providers. DR DNASU; 2986; -. DR Ensembl; ENST00000218006.3; ENSP00000218006.2; ENSG00000101890.5. DR GeneID; 2986; -. DR KEGG; hsa:2986; -. DR MANE-Select; ENST00000218006.3; ENSP00000218006.2; NM_001522.3; NP_001513.2. DR UCSC; uc065aqx.1; human. DR AGR; HGNC:4691; -. DR ClinPGx; PA29071; -. DR CTD; 2986; -. DR DisGeNET; 2986; -. DR GeneCards; GUCY2F; -. DR HGNC; HGNC:4691; GUCY2F. DR HPA; ENSG00000101890; Tissue enriched (retina). DR MIM; 300041; gene. DR OpenTargets; ENSG00000101890; -. DR VEuPathDB; HostDB:ENSG00000101890; -. DR eggNOG; KOG1023; Eukaryota. DR GeneTree; ENSGT00940000162146; -. DR HOGENOM; CLU_001072_1_0_1; -. DR InParanoid; P51841; -. DR OMA; QDSQSMR; -. DR OrthoDB; 1890790at2759; -. DR PAN-GO; P51841; 5 GO annotations based on evolutionary models. DR PhylomeDB; P51841; -. DR BRENDA; 4.6.1.2; 2681. DR PathwayCommons; P51841; -. DR Reactome; R-HSA-2514859; Inactivation, recovery and regulation of the phototransduction cascade. DR SignaLink; P51841; -. DR BioGRID-ORCS; 2986; 10 hits in 794 CRISPR screens. DR ChiTaRS; GUCY2F; human. DR GenomeRNAi; 2986; -. DR Pharos; P51841; Tbio. DR PRO; PR:P51841; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; P51841; protein. DR Bgee; ENSG00000101890; Expressed in male germ line stem cell (sensu Vertebrata) in testis and 14 other cell types or tissues. DR GO; GO:0005640; C:nuclear outer membrane; TAS:ProtInc. DR GO; GO:0097381; C:photoreceptor disc membrane; TAS:Reactome. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0120200; C:rod photoreceptor outer segment; ISS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:InterPro. DR GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW. DR GO; GO:0004383; F:guanylate cyclase activity; IBA:GO_Central. DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl. DR GO; GO:0001653; F:peptide receptor activity; IBA:GO_Central. DR GO; GO:0004672; F:protein kinase activity; IEA:InterPro. DR GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl. DR GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc. DR GO; GO:0006182; P:cGMP biosynthetic process; IBA:GO_Central. DR GO; GO:0019934; P:cGMP-mediated signaling; IEA:Ensembl. DR GO; GO:0050908; P:detection of light stimulus involved in visual perception; IEA:Ensembl. DR GO; GO:0007168; P:receptor guanylyl cyclase signaling pathway; IBA:GO_Central. DR GO; GO:0022400; P:regulation of opsin-mediated signaling pathway; TAS:Reactome. DR GO; GO:0007601; P:visual perception; TAS:ProtInc. DR CDD; cd07302; CHD; 1. DR CDD; cd06371; PBP1_sensory_GC_DEF-like; 1. DR FunFam; 1.10.510.10:FF:000404; Guanylate cyclase; 1. DR FunFam; 3.30.70.1230:FF:000013; Guanylate cyclase; 1. DR FunFam; 3.40.50.2300:FF:000114; Guanylate cyclase; 1. DR Gene3D; 3.40.50.2300; -; 2. DR Gene3D; 3.30.70.1230; Nucleotide cyclase; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR001054; A/G_cyclase. DR InterPro; IPR018297; A/G_cyclase_CS. DR InterPro; IPR001828; ANF_lig-bd_rcpt. DR InterPro; IPR050401; Cyclic_nucleotide_synthase. DR InterPro; IPR011645; HNOB_dom_associated. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR029787; Nucleotide_cyclase. DR InterPro; IPR028082; Peripla_BP_I. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR PANTHER; PTHR11920; GUANYLYL CYCLASE; 1. DR PANTHER; PTHR11920:SF349; RETINAL GUANYLYL CYCLASE 2; 1. DR Pfam; PF01094; ANF_receptor; 1. DR Pfam; PF00211; Guanylate_cyc; 1. DR Pfam; PF07701; HNOBA; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00044; CYCc; 1. DR SUPFAM; SSF55073; Nucleotide cyclase; 1. DR SUPFAM; SSF53822; Periplasmic binding protein-like I; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00452; GUANYLATE_CYCLASE_1; 1. DR PROSITE; PS50125; GUANYLATE_CYCLASE_2; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW Cell projection; cGMP biosynthesis; Disulfide bond; GTP-binding; Lyase; KW Membrane; Nucleotide-binding; Proteomics identification; KW Reference proteome; Sensory transduction; Signal; Transmembrane; KW Transmembrane helix; Vision. FT SIGNAL 1..50 FT /evidence="ECO:0000255" FT CHAIN 51..1108 FT /note="Retinal guanylyl cyclase 2" FT /id="PRO_0000012386" FT TOPO_DOM 51..467 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 468..490 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 491..1108 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 532..812 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 884..1014 FT /note="Guanylate cyclase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00099" FT DISULFID 104..132 FT /evidence="ECO:0000250" FT DISULFID 452 FT /note="Interchain" FT /evidence="ECO:0000250" FT DISULFID 460 FT /note="Interchain" FT /evidence="ECO:0000250" FT VARIANT 10 FT /note="R -> P (in a breast cancer sample; somatic mutation; FT dbSNP:rs755991142)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036419" FT VARIANT 40 FT /note="S -> C (in dbSNP:rs34228145)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042233" FT VARIANT 160 FT /note="I -> N (in dbSNP:rs33971675)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042234" FT VARIANT 230 FT /note="R -> W (in dbSNP:rs33973457)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042235" FT VARIANT 284 FT /note="L -> P (in dbSNP:rs12008095)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_009136" FT VARIANT 296 FT /note="R -> Q (in dbSNP:rs502209)" FT /evidence="ECO:0000269|PubMed:7777544" FT /id="VAR_009137" FT VARIANT 305 FT /note="R -> Q (in dbSNP:rs55966326)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042236" FT VARIANT 308 FT /note="Y -> C (in dbSNP:rs16985750)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030633" FT VARIANT 380 FT /note="Q -> H (in dbSNP:rs2272925)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030634" FT VARIANT 434 FT /note="G -> R (in dbSNP:rs56293008)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042237" FT VARIANT 568 FT /note="G -> D (in a glioblastoma multiforme sample; somatic FT mutation; dbSNP:rs779221554)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042238" FT VARIANT 628 FT /note="R -> Q (in dbSNP:rs7883913)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030635" FT VARIANT 677 FT /note="V -> L (in dbSNP:rs35474112)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042239" FT VARIANT 794 FT /note="E -> K (in dbSNP:rs35726803)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042240" FT VARIANT 872 FT /note="G -> D (in dbSNP:rs148663380)" FT /evidence="ECO:0000269|PubMed:23033978" FT /id="VAR_069424" FT VARIANT 1010 FT /note="A -> V (in dbSNP:rs55735218)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042241" FT VARIANT 1052 FT /note="K -> R (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042242" FT VARIANT 1055 FT /note="E -> D (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042243" SQ SEQUENCE 1108 AA; 124850 MW; B047BBF1A3C009F9 CRC64; MFLGLGRFSR LVLWFAAFRK LLGHHGLASA KFLWCLCLLS VMSLPQQVWT LPYKIGVVGP WACDSLFSKA LPEVAARLAI ERINRDPSFD LSYSFEYVIL NEDCQTSRAL SSFISHHQMA SGFIGPTNPG YCEAASLLGN SWDKGIFSWA CVNYELDNKI SYPTFSRTLP SPIRVLVTVM KYFQWAHAGV ISSDEDIWVH TANRVASALR SHGLPVGVVL TTGQDSQSMR KALQRIHQAD RIRIIIMCMH SALIGGETQM HLLECAHDLK MTDGTYVFVP YDALLYSLPY KHTPYRVLRN NPKLREAYDA VLTITVESQE KTFYQAFTEA AARGEIPEKL EFDQVSPLFG TIYNSIYFIA QAMNNAMKEN GQAGAASLVQ HSRNMQFHGF NQLMRTDSNG NGISEYVILD TNLKEWELHS TYTVDMEMEL LRFGGTPIHF PGGRPPRADA KCWFAEGKIC HGGIDPAFAM MVCLTLLIAL LSINGFAYFI RRRINKIQLI KGPNRILLTL EDVTFINPHF GSKRGSRASV SFQITSEVQS GRSPRLSFSS GSLTPATYEN SNIAIYEGDW VWLKKFSLGD FGDLKSIKSR ASDVFEMMKD LRHENINPLL GFFYDSGMFA IVTEFCSRGS LEDILTNQDV KLDWMFKSSL LLDLIKGMKY LHHREFVHGR LKSRNCVVDG RFVLKVTDYG FNDILEMLRL SEEESSMEEL LWTAPELLRA PRGSRLGSFA GDVYSFAIIM QEVMVRGTPF CMMDLPAQEI INRLKKPPPV YRPVVPPEHA PPECLQLMKQ CWAEAAEQRP TFDEIFNQFK TFNKGKKTNI IDSMLRMLEQ YSSNLEDLIR ERTEELEIEK QKTEKLLTQM LPPSVAESLK KGCTVEPEGF DLVTLYFSDI VGFTTISAMS EPIEVVDLLN DLYTLFDAII GSHDVYKVET IGDAYMVASG LPKRNGSRHA AEIANMSLDI LSSVGTFKMR HMPEVPVRIR IGLHSGPVVA GVVGLTMPRY CLFGDTVNTA SRMESTGLPY RIHVSLSTVT ILQNLSEGYE VELRGRTELK GKGTEETFWL IGKKGFMKPL PVPPPVDKDG QVGHGLQPVE IAAFQRRKAE RQLVRNKP // ID ITA2B_HUMAN Reviewed; 1039 AA. AC P08514; B2RCY8; O95366; Q14443; Q17R67; DT 01-AUG-1988, integrated into UniProtKB/Swiss-Prot. DT 14-APR-2009, sequence version 3. DT 28-JAN-2026, entry version 272. DE RecName: Full=Integrin alpha-IIb {ECO:0000305}; DE AltName: Full=GPalpha IIb; DE Short=GPIIb {ECO:0000303|PubMed:2345548}; DE AltName: Full=Platelet membrane glycoprotein IIb; DE AltName: CD_antigen=CD41; DE Contains: DE RecName: Full=Integrin alpha-IIb heavy chain; DE Contains: DE RecName: Full=Integrin alpha-IIb light chain, form 1; DE Contains: DE RecName: Full=Integrin alpha-IIb light chain, form 2; DE Flags: Precursor; GN Name=ITGA2B {ECO:0000312|HGNC:HGNC:6138}; Synonyms=GP2B, ITGAB; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-313. RX PubMed=2439501; DOI=10.1016/s0021-9258(18)47438-8; RA Poncz M., Eisman R., Heidenreich R., Silver S.M., Vilaire G., Surrey S., RA Schwartz E., Bennett J.S.; RT "Structure of the platelet membrane glycoprotein IIb. Homology to the alpha RT subunits of the vitronectin and fibronectin membrane receptors."; RL J. Biol. Chem. 262:8476-8482(1987). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-313. RX PubMed=2345548; DOI=10.1007/bf00422712; RA Frachet P., Uzan G., Thevenon D., Denarier E., Prandini M.H., Marguerie G.; RT "GPIIb and GPIIIa amino acid sequences deduced from human megakaryocyte RT cDNAs."; RL Mol. Biol. Rep. 14:27-33(1990). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1). RX PubMed=2322558; DOI=10.1021/bi00457a020; RA Heidenreich R., Eisman R., Surrey S., Delgrosso K., Bennett J.S., RA Schwartz E., Poncz M.; RT "Organization of the gene for platelet glycoprotein IIb."; RL Biochemistry 29:1232-1244(1990). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Spleen; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-62 AND 1021-1039. RX PubMed=2845986; DOI=10.1016/s0006-291x(88)80884-2; RA Prandini M.H., Denarier E., Frachet P., Uzan G., Marguerie G.; RT "Isolation of the human platelet glycoprotein IIb gene and characterization RT of the 5' flanking region."; RL Biochem. Biophys. Res. Commun. 156:595-601(1988). RN [8] RP PROTEIN SEQUENCE OF 32-56 AND 903-917. RX PubMed=3534886; DOI=10.1073/pnas.83.21.8351; RA Charo I.F., Fitzgerald L.A., Steiner B., Rall S.C., Bekeart L.S., RA Phillips D.R.; RT "Platelet glycoproteins IIb and IIIa: evidence for a family of RT immunologically and structurally related glycoproteins in mammalian RT cells."; RL Proc. Natl. Acad. Sci. U.S.A. 83:8351-8355(1986). RN [9] RP PROTEIN SEQUENCE OF 32-42. RX PubMed=1953640; DOI=10.1042/bj2790419; RA Catimel B., Parmentier S., Leung L.L., McGregor J.L.; RT "Separation of important new platelet glycoproteins (GPIa, GPIc, GPIc*, RT GPIIa and GMP-140) by F.P.L.C. Characterization by monoclonal antibodies RT and gas-phase sequencing."; RL Biochem. J. 279:419-425(1991). RN [10] RP PROTEIN SEQUENCE OF 32 AND 872. RX PubMed=8620874; DOI=10.1111/j.1432-1033.1996.0205n.x; RA Makogonenko E.M., Yakubenko V.P., Ingham K.C., Medved L.V.; RT "Thermal stability of individual domains in platelet glycoprotein RT IIbIIIa."; RL Eur. J. Biochem. 237:205-211(1996). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 392-1039 (ISOFORM 1). RX PubMed=3422188; DOI=10.1111/j.1432-1033.1988.tb13762.x; RA Uzan G., Frachet P., Lajmanovich A., Prandini M.-H., Denarier E., RA Duperray A., Loftus J., Ginsberg M., Plow E., Marguerie G.; RT "cDNA clones for human platelet GPIIb corresponding to mRNA from RT megakaryocytes and HEL cells. Evidence for an extensive homology to other RT Arg-Gly-Asp adhesion receptors."; RL Eur. J. Biochem. 171:87-93(1988). RN [12] RP PROTEIN SEQUENCE OF 487-501 AND 1026-1038. RX PubMed=3801670; RA Hiraiwa A., Matsukage A., Shiku H., Takahashi T., Naito K., Yamada K.; RT "Purification and partial amino acid sequence of human platelet membrane RT glycoproteins IIb and IIIa."; RL Blood 69:560-564(1987). RN [13] RP NUCLEOTIDE SEQUENCE [MRNA] OF 753-1039 (ISOFORM 3), AND TISSUE SPECIFICITY. RX PubMed=9809974; RA Trikha M., Cai Y., Grignon D., Honn K.V.; RT "Identification of a novel truncated alphaIIb integrin."; RL Cancer Res. 58:4771-4775(1998). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] OF 868-1039 (ISOFORM 1). RX PubMed=3479442; DOI=10.1172/jci113277; RA Bray P.F., Rosa J.P., Johnston G.I., Shiu D.T., Cook R.G., Lau C., RA Kan Y.W., McEver R.P., Shuman M.A.; RT "Platelet glycoprotein IIb. Chromosomal localization and tissue RT expression."; RL J. Clin. Invest. 80:1812-1817(1987). RN [15] RP PROTEIN SEQUENCE OF 903-922 AND 934-939. RX PubMed=2476117; DOI=10.1042/bj2610551; RA Calvete J.J., Alvarez M.V., Rivas G., Hew C.L., Henschen A., RA Gonzalez-Rodriguez J.; RT "Interchain and intrachain disulphide bonds in human platelet glycoprotein RT IIb. Localization of the epitopes for several monoclonal antibodies."; RL Biochem. J. 261:551-560(1989). RN [16] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 938-997 (ISOFORMS 1 AND 2), AND TISSUE RP SPECIFICITY. RC TISSUE=Erythroleukemia; RX PubMed=2351656; DOI=10.1016/s0021-9258(19)38705-8; RA Bray P.F., Leung C.S.-I., Shuman M.A.; RT "Human platelets and megakaryocytes contain alternately spliced RT glycoprotein IIb mRNAs."; RL J. Biol. Chem. 265:9587-9590(1990). RN [17] RP PARTIAL PROTEIN SEQUENCE, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-46; RP ASN-280; ASN-601 AND ASN-711. RX PubMed=2775232; DOI=10.1042/bj2610561; RA Calvete J.J., Henschen A., Gonzalez-Rodriguez J.; RT "Complete localization of the intrachain disulphide bonds and the N- RT glycosylation points in the alpha-subunit of human platelet glycoprotein RT IIb."; RL Biochem. J. 261:561-568(1989). RN [18] RP PARTIAL PROTEIN SEQUENCE, AND GLYCOSYLATION AT SER-878. RX PubMed=7688323; DOI=10.1016/0014-5793(93)80959-x; RA Calvete J.J., Muniz-Diaz E.; RT "Localization of an O-glycosylation site in the alpha-subunit of the human RT platelet integrin GPIIb/IIIa involved in Baka (HPA-3a) alloantigen RT expression."; RL FEBS Lett. 328:30-34(1993). RN [19] RP PROTEOLYTIC CLEAVAGE, AND PYROGLUTAMATE FORMATION AT GLN-891. RX PubMed=2226834; DOI=10.1016/0014-5793(90)80443-m; RA Calvete J.J., Schafer W., Henschen A., Gonzalez-Rodriguez J.; RT "Characterization of the beta-chain N-terminus heterogeneity and the alpha- RT chain C-terminus of human platelet GPIIb. Posttranslational cleavage RT sites."; RL FEBS Lett. 272:37-40(1990). RN [20] RP INTERACTION WITH CIB1. RC TISSUE=Fetal liver; RX PubMed=9030514; DOI=10.1074/jbc.272.8.4651; RA Naik U.P., Patel P.M., Parise L.V.; RT "Identification of a novel calcium-binding protein that interacts with the RT integrin alphaIIb cytoplasmic domain."; RL J. Biol. Chem. 272:4651-4654(1997). RN [21] RP FUNCTION, AND PROTEOLYTIC CLEAVAGE BY ELANE. RX PubMed=9111081; DOI=10.1074/jbc.272.17.11636; RA Si-Tahar M., Pidard D., Balloy V., Moniatte M., Kieffer N., RA Van Dorsselaer A., Chignard M.; RT "Human neutrophil elastase proteolytically activates the platelet integrin RT alphaIIbbeta3 through cleavage of the carboxyl terminus of the alphaIIb RT subunit heavy chain. Involvement in the potentiation of platelet RT aggregation."; RL J. Biol. Chem. 272:11636-11647(1997). RN [22] RP INTERACTION WITH CIB1. RX PubMed=10477286; DOI=10.1042/bj3420729; RA Shock D.D., Naik U.P., Brittain J.E., Alahari S.K., Sondek J., Parise L.V.; RT "Calcium-dependent properties of CIB binding to the integrin alphaIIb RT cytoplasmic domain and translocation to the platelet cytoskeleton."; RL Biochem. J. 342:729-735(1999). RN [23] RP MUTAGENESIS OF 1029-PRO-PRO-1030. RX PubMed=10212286; DOI=10.1074/jbc.274.18.12945; RA Leisner T.M., Wencel-Drake J.D., Wang W., Lam S.C.; RT "Bidirectional transmembrane modulation of integrin alphaIIbbeta3 RT conformations."; RL J. Biol. Chem. 274:12945-12949(1999). RN [24] RP FUNCTION. RX PubMed=12477717; DOI=10.1074/jbc.m211282200; RA Hermand P., Gane P., Huet M., Jallu V., Kaplan C., Sonneborn H.H., RA Cartron J.P., Bailly P.; RT "Red cell ICAM-4 is a novel ligand for platelet-activated alpha IIbbeta 3 RT integrin."; RL J. Biol. Chem. 278:4892-4898(2003). RN [25] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-601. RC TISSUE=Plasma; RX PubMed=16335952; DOI=10.1021/pr0502065; RA Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J., RA Smith R.D.; RT "Human plasma N-glycoproteome analysis by immunoaffinity subtraction, RT hydrazide chemistry, and mass spectrometry."; RL J. Proteome Res. 4:2070-2080(2005). RN [26] RP INTERACTION WITH RNF181. RX PubMed=18331836; DOI=10.1016/j.bbrc.2008.02.142; RA Brophy T.M., Raab M., Daxecker H., Culligan K.G., Lehmann I., Chubb A.J., RA Treumann A., Moran N.; RT "RN181, a novel ubiquitin E3 ligase that interacts with the KVGFFKR motif RT of platelet integrin alpha(IIb)beta3."; RL Biochem. Biophys. Res. Commun. 369:1088-1093(2008). RN [27] RP INTERACTION WITH CIB1. RX PubMed=21388953; DOI=10.1074/jbc.m110.179028; RA Huang H., Ishida H., Yamniuk A.P., Vogel H.J.; RT "Solution structures of Ca2+-CIB1 and Mg2+-CIB1 and their interactions with RT the platelet integrin alphaIIb cytoplasmic domain."; RL J. Biol. Chem. 286:17181-17192(2011). RN [28] RP INTERACTION WITH CIB1; CIB2; CIB3 AND CIB4. RX PubMed=22779914; DOI=10.1139/o2012-021; RA Huang H., Bogstie J.N., Vogel H.J.; RT "Biophysical and structural studies of the human calcium- and integrin- RT binding protein family: understanding their functional similarities and RT differences."; RL Biochem. Cell Biol. 90:646-656(2012). RN [29] RP INTERACTION WITH CIB1. RX PubMed=22283712; DOI=10.1021/ja2111306; RA Huang H., Vogel H.J.; RT "Structural basis for the activation of platelet integrin alphaIIbbeta3 by RT calcium- and integrin-binding protein 1."; RL J. Am. Chem. Soc. 134:3864-3872(2012). RN [30] RP INTERACTION WITH SELP. RX PubMed=37184585; DOI=10.26508/lsa.202201747; RA Takada Y.K., Simon S.I., Takada Y.; RT "The C-type lectin domain of CD62P (P-selectin) functions as an integrin RT ligand."; RL Life. Sci Alliance 6:0-0(2023). RN [31] {ECO:0007744|PDB:1TYE} RP X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 32-483 IN COMPLEX WITH ITGB3 AND RP CALCIUM, GLYCOSYLATION AT ASN-46, AND DISULFIDE BONDS. RX PubMed=15378069; DOI=10.1038/nature02976; RA Xiao T., Takagi J., Coller B.S., Wang J.H., Springer T.A.; RT "Structural basis for allostery in integrins and binding to fibrinogen- RT mimetic therapeutics."; RL Nature 432:59-67(2004). RN [32] {ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU} RP X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 32-989 IN COMPLEX WITH ITGB3 AND RP CALCIUM, GLYCOSYLATION AT ASN-46; ASN-280 AND ASN-601, AND DISULFIDE BONDS. RX PubMed=19111664; DOI=10.1016/j.molcel.2008.11.018; RA Zhu J., Luo B.H., Xiao T., Zhang C., Nishida N., Springer T.A.; RT "Structure of a complete integrin ectodomain in a physiologic resting state RT and activation and deactivation by applied forces."; RL Mol. Cell 32:849-861(2008). RN [33] RP REVIEW ON GT1 VARIANTS. RX PubMed=7878622; RA Bray P.F.; RT "Inherited diseases of platelet glycoproteins: considerations for rapid RT molecular characterization."; RL Thromb. Haemost. 72:492-502(1994). RN [34] RP VARIANT SER-874, POLYMORPHISM, AND DESCRIPTION OF ALLOANTIGEN SYSTEM BAK. RX PubMed=2350579; RA Lyman S., Aster R.H., Visentin G.P., Newman P.J.; RT "Polymorphism of human platelet membrane glycoprotein IIb associated with RT the Baka/Bakb alloantigen system."; RL Blood 75:2343-2348(1990). RN [35] RP POLYMORPHISM, DESCRIPTION OF ALLOANTIGEN SYSTEM BAK, AND INVOLVEMENT IN RP FMAIT2. RX PubMed=7197082; DOI=10.1111/j.1423-0410.1980.tb01845.x; RA von dem Borne A.E., von Riesz E., Verheugt F.W., ten Cate J.W., Koppe J.G., RA Engelfriet C.P., Nijenhuis L.E.; RT "Baka, a new platelet-specific antigen involved in neonatal allo-immune RT thrombocytopenia."; RL Vox Sang. 39:113-120(1980). RN [36] RP VARIANT GT1 ASP-273. RX PubMed=8282784; DOI=10.1172/jci116942; RA Poncz M., Rifat S., Coller B.S., Newman P.J., Shattil S.J., Parrella T., RA Fortina P., Bennett J.S.; RT "Glanzmann thrombasthenia secondary to a Gly273-->Asp mutation adjacent to RT the first calcium-binding domain of platelet glycoprotein IIb."; RL J. Clin. Invest. 93:172-179(1994). RN [37] RP VARIANT GT1 ASP-449. RX PubMed=7508443; DOI=10.1016/s0021-9258(17)41800-x; RA Wilcox D.A., Wautier J.-L., Pidard D., Newman P.J.; RT "A single amino acid substitution flanking the fourth calcium binding RT domain of alpha IIb prevents maturation of the alpha IIb beta 3 integrin RT complex."; RL J. Biol. Chem. 269:4450-4457(1994). RN [38] RP VARIANT MET-868, POLYMORPHISM, AND INVOLVEMENT IN FMAIT2. RX PubMed=7620155; RA Noris P., Simsek S., de Bruijne-Admiraal L.G., Porcelijn L., Huiskes E., RA van der Vlist G.J., van Leeuwen E.F., van der Schoot C.E., RA von dem Borne A.E.; RT "Max(a), a new low-frequency platelet-specific antigen localized on RT glycoprotein IIb, is associated with neonatal alloimmune RT thrombocytopenia."; RL Blood 86:1019-1026(1995). RN [39] RP VARIANT GT1 HIS-358. RX PubMed=7706461; DOI=10.1172/jci117828; RA Wilcox D.A., Paddock C.M., Lyman S., Gill J.C., Newman P.J.; RT "Glanzmann thrombasthenia resulting from a single amino acid substitution RT between the second and third calcium-binding domains of GPIIb. Role of the RT GPIIb amino terminus in integrin subunit association."; RL J. Clin. Invest. 95:1553-1560(1995). RN [40] RP VARIANT GT1 456-VAL-ASP-457 DEL, AND CHARACTERIZATION OF VARIANT GT1 RP 456-VAL-ASP-457 DEL. RX PubMed=8704171; RA Basani R.B., Vilaire G., Shattil S.J., Kolodziej M.A., Bennett J.S., RA Poncz M.; RT "Glanzmann thrombasthenia due to a two amino acid deletion in the fourth RT calcium-binding domain of alpha IIb: demonstration of the importance of RT calcium-binding domains in the conformation of alpha IIb beta 3."; RL Blood 88:167-173(1996). RN [41] RP VARIANTS GT1 ILE-207; THR-596 AND GLN-1026. RX PubMed=9215749; DOI=10.1006/bcmd.1997.0117; RA French D.L., Coller B.S.; RT "Hematologically important mutations: Glanzmann thrombasthenia."; RL Blood Cells Mol. Dis. 23:39-51(1997). RN [42] RP VARIANT GT1 PRO-214, AND CHARACTERIZATION OF VARIANT GT1 PRO-214. RX PubMed=9473221; RA Grimaldi C.M., Chen F., Wu C., Weiss H.J., Coller B.S., French D.L.; RT "Glycoprotein IIb Leu214Pro mutation produces Glanzmann thrombasthenia with RT both quantitative and qualitative abnormalities in GPIIb/IIIa."; RL Blood 91:1562-1571(1998). RN [43] RP VARIANT GT1 PRO-778. RX PubMed=9763559; RA Tadokoro S., Tomiyama Y., Honda S., Arai M., Yamamoto N., Shiraga M., RA Kosugi S., Kanakura Y., Kurata Y., Matsuzawa Y.; RT "A Gln747-->Pro substitution in the IIb subunit is responsible for a RT moderate IIbbeta3 deficiency in Glanzmann thrombasthenia."; RL Blood 92:2750-2758(1998). RN [44] RP VARIANT BDPLT16 GLN-1026, AND CHARACTERIZATION OF VARIANT BDPLT16 GLN-1026. RX PubMed=9834222; RA Peyruchaud O., Nurden A.T., Milet S., Macchi L., Pannochia A., Bray P.F., RA Kieffer N., Bourre F.; RT "R to Q amino acid substitution in the GFFKR sequence of the cytoplasmic RT domain of the integrin IIb subunit in a patient with a Glanzmann's RT thrombasthenia-like syndrome."; RL Blood 92:4178-4187(1998). RN [45] RP VARIANTS GT1 SER-320; LYS-355 AND PRO-778. RX PubMed=9722314; DOI=10.1046/j.1365-2141.1998.00824.x; RA Ambo H., Kamata T., Handa M., Kawai Y., Oda A., Murata M., Takada Y., RA Ikeda Y.; RT "Novel point mutations in the alphaIIb subunit (Phe289-->Ser, Glu324-->Lys RT and Gln747-->Pro) causing thrombasthenic phenotypes in four Japanese RT patients."; RL Br. J. Haematol. 102:829-840(1998). RN [46] RP VARIANTS GT1 LYS-355 AND THR-596. RX PubMed=9734640; DOI=10.1046/j.1365-2141.1998.00852.x; RA Ruan J., Peyruchaud O., Alberio L., Valles G., Clemetson K., Bourre F., RA Nurden A.T.; RT "Double heterozygosity of the GPIIb gene in a Swiss patient with RT Glanzmann's thrombasthenia."; RL Br. J. Haematol. 102:918-925(1998). RN [47] RP VARIANTS ILE-40; SER-874 AND ASN-968. RX PubMed=10391209; DOI=10.1038/10290; RA Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., RA Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., RA Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., RA Lander E.S.; RT "Characterization of single-nucleotide polymorphisms in coding regions of RT human genes."; RL Nat. Genet. 22:231-238(1999). RN [48] RP VARIANT GT1 ARG-705, AND CHARACTERIZATION OF VARIANT GT1 ARG-705. RX PubMed=9920835; RA Gonzalez-Manchon C., Fernandez-Pinel M., Arias-Salgado E.G., Ferrer M., RA Alvarez M.-V., Garcia-Munoz S., Ayuso M.S., Parrilla R.; RT "Molecular genetic analysis of a compound heterozygote for the glycoprotein RT (GP) IIb gene associated with Glanzmann's thrombasthenia: disruption of the RT 674-687 disulfide bridge in GPIIb prevents surface exposure of GPIIb-IIIa RT complexes."; RL Blood 93:866-875(1999). RN [49] RP ERRATUM OF PUBMED:9920835. RA Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., RA Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., RA Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., RA Lander E.S.; RL Nat. Genet. 23:373-373(1999). RN [50] RP VARIANTS GT1 ALA-176 AND LEU-176. RX PubMed=10607701; RA Basani R.B., French D.L., Vilaire G., Brown D.L., Chen F., Coller B.S., RA Derrick J.M., Gartner T.K., Bennett J.S., Poncz M.; RT "A naturally occurring mutation near the amino terminus of alphaIIb defines RT a new region involved in ligand binding to alphaIIbbeta3."; RL Blood 95:180-188(2000). RN [51] RP VARIANTS GT1 TRP-161; LEU-222; ARG-412 AND PRO-847. RX PubMed=11798398; DOI=10.1080/095371001317126383; RA Vinciguerra C., Bordet J.C., Beaune G., Grenier C., Dechavanne M., RA Negrier C.; RT "Description of 10 new mutations in platelet glycoprotein IIb (alphaIIb) RT and glycoprotein IIIa (beta3) genes."; RL Platelets 12:486-495(2001). RN [52] RP VARIANT GT1 PRO-86, AND CHARACTERIZATION OF VARIANT GT1 PRO-86. RX PubMed=12181054; DOI=10.1046/j.1365-2141.2002.03678.x; RA Tanaka S., Hayashi T., Hori Y., Terada C., Han K.S., Ahn H.S., Bourre F., RA Tani Y.; RT "A Leu55 to Pro substitution in the integrin alphaIIb is responsible for a RT case of Glanzmann's thrombasthenia."; RL Br. J. Haematol. 118:833-835(2002). RN [53] RP VARIANTS GT1 VAL-139; ALA-176; GLU-267; ASP-380; THR-405; ASP-581; ARG-705; RP VAL-752 AND PRO-755. RX PubMed=12083483; RA D'Andrea G., Colaizzo D., Vecchione G., Grandone E., Di Minno G., RA Margaglione M.; RT "Glanzmann's thrombasthenia: identification of 19 new mutations in 30 RT patients."; RL Thromb. Haemost. 87:1034-1042(2002). RN [54] RP VARIANTS GT1 PHE-329 AND THR-405, AND CHARACTERIZATION OF VARIANTS GT1 RP PHE-329 AND THR-405. RX PubMed=12424194; DOI=10.1182/blood-2002-07-2266; RA Mitchell W.B., Li J.H., Singh F., Michelson A.D., Bussel J., Coller B.S., RA French D.L.; RT "Two novel mutations in the alpha IIb calcium-binding domains identify RT hydrophobic regions essential for alpha IIbbeta 3 biogenesis."; RL Blood 101:2268-2276(2003). RN [55] RP VARIANT GT1 HIS-174, AND CHARACTERIZATION OF VARIANT GT1 HIS-174. RX PubMed=12506038; DOI=10.1182/blood-2002-07-2144; RA Kiyoi T., Tomiyama Y., Honda S., Tadokoro S., Arai M., Kashiwagi H., RA Kosugi S., Kato H., Kurata Y., Matsuzawa Y.; RT "A naturally occurring Tyr143His alpha IIb mutation abolishes alpha IIb RT beta 3 function for soluble ligands but retains its ability for mediating RT cell adhesion and clot retraction: comparison with other mutations causing RT ligand-binding defects."; RL Blood 101:3485-3491(2003). RN [56] RP POLYMORPHISM. RX PubMed=14516468; DOI=10.1046/j.1423-0410.2003.00331.x; RA Metcalfe P., Watkins N.A., Ouwehand W.H., Kaplan C., Newman P., RA Kekomaki R., De Haas M., Aster R., Shibata Y., Smith J., Kiefel V., RA Santoso S.; RT "Nomenclature of human platelet antigens."; RL Vox Sang. 85:240-245(2003). RN [57] RP VARIANT GT1 MET-982, CHARACTERIZATION OF VARIANT GT1 MET-982, AND VARIANT RP THR-989. RX PubMed=15099289; DOI=10.1046/j.1538-7836.2004.00711.x; RA Nurden A.T., Breillat C., Jacquelin B., Combrie R., Freedman J., RA Blanchette V.S., Schmugge M., Rand M.L.; RT "Triple heterozygosity in the integrin alphaIIb subunit in a patient with RT Glanzmann's thrombasthenia."; RL J. Thromb. Haemost. 2:813-819(2004). RN [58] RP VARIANT GT1 CYS-202, AND CHARACTERIZATION OF VARIANT GT1 CYS-202. RX PubMed=15219201; DOI=10.1111/j.1538-7836.2004.00758.x; RA Rosenberg N., Landau M., Luboshitz J., Rechavi G., Seligsohn U.; RT "A novel Phe171Cys mutation in integrin alpha causes Glanzmann RT thrombasthenia by abrogating alphaIIbbeta3 complex formation."; RL J. Thromb. Haemost. 2:1167-1175(2004). RN [59] RP POLYMORPHISM, DESCRIPTION OF ALLOANTIGEN SYSTEM BAK, AND INVOLVEMENT IN RP FMAIT2. RX PubMed=15569236; DOI=10.1111/j.1365-3148.2004.00537.x; RA Kataoka S., Kobayashi H., Chiba K., Nakamura M., Shinada S., Morita S., RA Lin M., Shibata Y.; RT "Neonatal alloimmune thrombocytopenia due to an antibody against a labile RT component of human platelet antigen-3b (Bak b)."; RL Transfus. Med. 14:419-423(2004). RN [60] RP VARIANT GT1 LEU-943, AND CHARACTERIZATION OF VARIANT GT1 LEU-943. RX PubMed=17018384; RA Jayo A., Pabon D., Lastres P., Jimenez-Yuste V., Gonzalez-Manchon C.; RT "Type II Glanzmann thrombasthenia in a compound heterozygote for the alpha RT IIb gene. A novel missense mutation in exon 27."; RL Haematologica 91:1352-1359(2006). RN [61] RP VARIANTS GT1 THR-405; THR-596; ARG-705; PRO-778; PHE-934; LEU-957; MET-982 RP AND THR-989, CHARACTERIZATION OF VARIANTS GT1 PHE-934 AND LEU-957, AND RP SUBCELLULAR LOCATION. RX PubMed=20020534; DOI=10.1002/humu.21179; RA Jallu V., Dusseaux M., Panzer S., Torchet M.F., Hezard N., Goudemand J., RA de Brevern A.G., Kaplan C.; RT "AlphaIIbbeta3 integrin: new allelic variants in Glanzmann thrombasthenia, RT effects on ITGA2B and ITGB3 mRNA splicing, expression, and structure- RT function."; RL Hum. Mutat. 31:237-246(2010). RN [62] RP VARIANT MET-650, POLYMORPHISM, AND INVOLVEMENT IN FMAIT2. RX PubMed=19821948; DOI=10.1111/j.1537-2995.2009.02438.x; RA Peterson J.A., Gitter M.L., Kanack A., Curtis B., McFarland J., Bougie D., RA Aster R.; RT "New low-frequency platelet glycoprotein polymorphisms associated with RT neonatal alloimmune thrombocytopenia."; RL Transfusion 50:324-333(2010). RN [63] RP VARIANT LEU-771, POLYMORPHISM, AND INVOLVEMENT IN FMAIT2. RX PubMed=23305224; DOI=10.1111/trf.12067; RA Poles A., Wozniak M.J., Walser P., Ridgwell K., Fitzgerald J., Green A., RA Gilmore R., Lucas G.; RT "A V740L mutation in glycoprotein IIb defines a novel epitope (War) RT associated with fetomaternal alloimmune thrombocytopenia."; RL Transfusion 53:1965-1973(2013). RN [64] RP VARIANT BDPLT16 TRP-1026, AND CHARACTERIZATION OF VARIANT BDPLT16 TRP-1026. RX PubMed=21454453; DOI=10.1182/blood-2010-12-323691; RA Kunishima S., Kashiwagi H., Otsu M., Takayama N., Eto K., Onodera M., RA Miyajima Y., Takamatsu Y., Suzumiya J., Matsubara K., Tomiyama Y., RA Saito H.; RT "Heterozygous ITGA2B R995W mutation inducing constitutive activation of the RT alphaIIbbeta3 receptor affects proplatelet formation and causes congenital RT macrothrombocytopenia."; RL Blood 117:5479-5484(2011). CC -!- FUNCTION: Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for CC fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and CC vitronectin. It recognizes the sequence R-G-D in a wide array of CC ligands. It recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in CC fibrinogen gamma chain (By similarity). Following activation integrin CC alpha-IIb/beta-3 brings about platelet/platelet interaction through CC binding of soluble fibrinogen (PubMed:9111081). This step leads to CC rapid platelet aggregation which physically plugs ruptured endothelial CC cell surface (By similarity). Integrin ITGA2B:ITGB3 is also the CC receptor of erythrocyte-specific ICAM4 ligand involved in heterotypic CC cell-cell adhesion between erythrocytes and activated platelets CC (PubMed:12477717). {ECO:0000250|UniProtKB:O54890, CC ECO:0000269|PubMed:12477717, ECO:0000269|PubMed:9111081}. CC -!- SUBUNIT: Heterodimer of an alpha and a beta subunit. The alpha subunit CC is composed of a heavy and a light chain linked by a disulfide bond. CC Alpha-IIb associates with beta-3. Directly interacts with RNF181. CC Interacts (via C-terminus cytoplasmic tail region) with CIB1; the CC interaction is direct and calcium-dependent. Interacts (via C-terminus CC cytoplasmic tail region) with CIB2, CIB3 and CIB4; the interactions are CC stabilized/increased in a calcium and magnesium-dependent manner. CC ITGA2B:ITGB3 interacts with PPIA/CYPA; the interaction is ROS and CC PPIase activity-dependent and is increased in the presence of thrombin CC (By similarity). ITGA2B:ITGB3 interacts with SELP (via C-type lectin CC domain); the interaction mediates cell-cell interaction and adhesion CC (PubMed:37184585). {ECO:0000250|UniProtKB:Q9QUM0, CC ECO:0000269|PubMed:10477286, ECO:0000269|PubMed:18331836, CC ECO:0000269|PubMed:21388953, ECO:0000269|PubMed:22283712, CC ECO:0000269|PubMed:22779914, ECO:0000269|PubMed:37184585, CC ECO:0000269|PubMed:9030514}. CC -!- INTERACTION: CC P08514; P08514: ITGA2B; NbExp=7; IntAct=EBI-702693, EBI-702693; CC P08514; P05106: ITGB3; NbExp=12; IntAct=EBI-702693, EBI-702847; CC P08514-1; P21333: FLNA; NbExp=3; IntAct=EBI-15805658, EBI-350432; CC P08514-1; P05106: ITGB3; NbExp=4; IntAct=EBI-15805658, EBI-702847; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:20020534}; CC Single-pass type I membrane protein {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=P08514-1; Sequence=Displayed; CC Name=2; CC IsoId=P08514-2; Sequence=VSP_002737; CC Name=3; Synonyms=tr-alpha-IIb {ECO:0000303|PubMed:9809974}; CC IsoId=P08514-3; Sequence=VSP_002736; CC -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 are expressed in platelets CC and megakaryocytes, but not in reticulocytes. Not detected in Jurkat, CC nor in U937 cell lines (PubMed:2351656). Isoform 3 is expressed in CC prostate adenocarcinoma, as well as in several erythroleukemia, CC prostate adenocarcinoma and melanoma cell lines, including PC-3, DU- CC 145, HEL, WM983A, WM983B and WM35. Not detected in platelets, nor in CC normal prostate (at protein level) (PubMed:9809974). CC {ECO:0000269|PubMed:2351656, ECO:0000269|PubMed:9809974}. CC -!- PTM: [Integrin alpha-IIb heavy chain]: Cleaved by ELANE; the cleavage CC promotes activation of platelet fibrinogen receptor integrin alpha- CC IIb/beta-3. {ECO:0000269|PubMed:9111081}. CC -!- POLYMORPHISM: Genetic variants in ITGA2B define different platelet- CC specific alloantigen systems that are involved in fetomaternal CC alloimmune thromobocytopenia. Alloantigen system Bak, also known as CC HPA-3 or Lek, is characterized by variant p.Ser874Ile (alloantigen CC Bak(a) or Lek(a) or HPA-3a) and variant p.Ile874Ser (alloantigen Bak(b) CC or Lek(b) or HPA-3b) (PubMed:2350579, PubMed:7197082, PubMed:14516468, CC PubMed:15569236). Additional platelet-specific alloantigens involved in CC fetomaternal alloimmune thromobocytopenia are known (PubMed:7620155, CC PubMed:19821948, PubMed:23305224). {ECO:0000269|PubMed:14516468, CC ECO:0000269|PubMed:15569236, ECO:0000269|PubMed:19821948, CC ECO:0000269|PubMed:23305224, ECO:0000269|PubMed:2350579, CC ECO:0000269|PubMed:7197082, ECO:0000269|PubMed:7620155}. CC -!- DISEASE: Fetomaternal alloimmune thrombocytopenia 2 (FMAIT2) CC [MIM:621266]: A form of fetomaternal alloimmune thrombocytopenia, a CC bleeding disorder caused by maternal/fetal incompatibility for platelet CC alloantigens and arising when a fetus inherits a paternal platelet CC alloantigen that the mother does not possess. During pregnancy, as well CC as parturition, maternal alloantibodies against paternally-inherited CC platelet antigens cause destruction of fetal platelets and CC fetal/neonatal thrombocytopenia. Disease severity and clinical features CC in the fetus or neonate are heterogeneous. While most fetuses remain CC asymptomatic, others develop skin bleedings (petechiae) or internal CC organ bleedings. The most severe symptom is intracranial hemorrhage CC that is mostly discovered postnatally and can result in neurological CC complications or even death. Mothers with circulating platelet CC alloantibodies may experience miscarriage. FMAIT2 transmission pattern CC is consistent with autosomal dominant paternal inheritance. CC {ECO:0000269|PubMed:15569236, ECO:0000269|PubMed:19821948, CC ECO:0000269|PubMed:23305224, ECO:0000269|PubMed:7197082, CC ECO:0000269|PubMed:7620155}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Glanzmann thrombasthenia 1 (GT1) [MIM:273800]: A form of CC Glanzmann thrombasthenia, a disorder characterized by failure of CC platelet aggregation, absent or diminished clot retraction, and CC mucocutaneous bleeding of mild-to-moderate severity. Glanzmann CC thrombasthenia has been classified into clinical types I and II. In CC type I, platelets show absence of glycoprotein IIb-IIIa complexes at CC their surface and lack fibrinogen and clot retraction capability. In CC type II, the platelets express glycoprotein IIb-IIIa complexes at CC reduced levels, have detectable amounts of fibrinogen, and have low or CC moderate clot retraction capability. GT1 inheritance is autosomal CC recessive. {ECO:0000269|PubMed:10607701, ECO:0000269|PubMed:11798398, CC ECO:0000269|PubMed:12083483, ECO:0000269|PubMed:12181054, CC ECO:0000269|PubMed:12424194, ECO:0000269|PubMed:12506038, CC ECO:0000269|PubMed:15099289, ECO:0000269|PubMed:15219201, CC ECO:0000269|PubMed:17018384, ECO:0000269|PubMed:20020534, CC ECO:0000269|PubMed:7508443, ECO:0000269|PubMed:7706461, CC ECO:0000269|PubMed:8282784, ECO:0000269|PubMed:8704171, CC ECO:0000269|PubMed:9215749, ECO:0000269|PubMed:9473221, CC ECO:0000269|PubMed:9722314, ECO:0000269|PubMed:9734640, CC ECO:0000269|PubMed:9763559, ECO:0000269|PubMed:9920835}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Bleeding disorder, platelet-type, 16 (BDPLT16) [MIM:187800]: CC An autosomal dominant form of congenital macrothrombocytopenia CC associated with platelet anisocytosis. It is a disorder of platelet CC production. Affected individuals may have no or only mildly increased CC bleeding tendency. In vitro studies show mild platelet functional CC abnormalities. {ECO:0000269|PubMed:21454453, CC ECO:0000269|PubMed:9834222}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the integrin alpha chain family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; J02764; AAA60114.1; -; mRNA. DR EMBL; M34480; AAA35926.1; -; mRNA. DR EMBL; M34344; AAA53150.1; -; Genomic_DNA. DR EMBL; M33319; AAA53150.1; JOINED; Genomic_DNA. DR EMBL; M33320; AAA53150.1; JOINED; Genomic_DNA. DR EMBL; AK315335; BAG37735.1; -; mRNA. DR EMBL; AC003043; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC117443; AAI17444.1; -; mRNA. DR EMBL; BC126442; AAI26443.1; -; mRNA. DR EMBL; M22568; AAA52587.1; -; Genomic_DNA. DR EMBL; M22569; AAA52588.1; -; Genomic_DNA. DR EMBL; X06831; CAA29987.1; -; mRNA. DR EMBL; AF098114; AAC98507.1; -; mRNA. DR EMBL; M18085; AAA52597.1; -; mRNA. DR EMBL; M54799; AAA52599.1; -; Genomic_DNA. DR CCDS; CCDS32665.1; -. [P08514-1] DR PIR; A34269; A34269. DR RefSeq; NP_000410.2; NM_000419.5. [P08514-1] DR PDB; 1DPK; NMR; -; A=1020-1039. DR PDB; 1DPQ; NMR; -; A=1020-1039. DR PDB; 1KUP; NMR; -; A=1018-1028. DR PDB; 1KUZ; NMR; -; A=1018-1028. DR PDB; 1M8O; NMR; -; A=1020-1039. DR PDB; 1S4W; NMR; -; A=1020-1039. DR PDB; 1TYE; X-ray; 2.90 A; A/C/E=32-483. DR PDB; 2K1A; NMR; -; A=989-1029. DR PDB; 2K9J; NMR; -; A=989-1029. DR PDB; 2KNC; NMR; -; A=991-1039. DR PDB; 2MTP; NMR; -; B=1019-1039. DR PDB; 2N9Y; NMR; -; A=989-1029. DR PDB; 2VC2; X-ray; 3.10 A; A=32-483. DR PDB; 2VDK; X-ray; 2.80 A; A=32-483. DR PDB; 2VDL; X-ray; 2.75 A; A=32-483. DR PDB; 2VDM; X-ray; 2.90 A; A=32-483. DR PDB; 2VDN; X-ray; 2.90 A; A=32-483. DR PDB; 2VDO; X-ray; 2.51 A; A=32-483. DR PDB; 2VDP; X-ray; 2.80 A; A=32-483. DR PDB; 2VDQ; X-ray; 2.59 A; A=32-483. DR PDB; 2VDR; X-ray; 2.40 A; A=32-483. DR PDB; 3FCS; X-ray; 2.55 A; A/C=32-989. DR PDB; 3FCU; X-ray; 2.90 A; A/C/E=32-488. DR PDB; 3NID; X-ray; 2.30 A; A/C=32-488. DR PDB; 3NIF; X-ray; 2.40 A; A/C=32-488. DR PDB; 3NIG; X-ray; 2.25 A; A/C=32-488. DR PDB; 3T3M; X-ray; 2.60 A; A/C=32-488. DR PDB; 3T3P; X-ray; 2.20 A; A/C=32-488. DR PDB; 3ZDX; X-ray; 2.45 A; A/C=32-488. DR PDB; 3ZDY; X-ray; 2.45 A; A/C=32-488. DR PDB; 3ZDZ; X-ray; 2.75 A; A/C=32-488. DR PDB; 3ZE0; X-ray; 2.95 A; A/C=32-488. DR PDB; 3ZE1; X-ray; 3.00 A; A/C=32-488. DR PDB; 3ZE2; X-ray; 2.35 A; A/C=32-488. DR PDB; 4CAK; EM; 20.50 A; A=32-989. DR PDB; 4Z7N; X-ray; 2.60 A; A/C=32-486. DR PDB; 4Z7O; X-ray; 2.85 A; A/C=32-486. DR PDB; 4Z7Q; X-ray; 2.70 A; A/C=32-485. DR PDB; 5HDB; X-ray; 2.70 A; A/C=32-485. DR PDB; 6V4P; EM; 2.80 A; A=1-963. DR PDB; 7KN0; NMR; -; A=989-1029. DR PDB; 7L8P; X-ray; 2.35 A; A/C=32-488. DR PDB; 7LA4; EM; 3.30 A; A=1-1039. DR PDB; 7SC4; X-ray; 1.85 A; A/B=1019-1039. DR PDB; 7SFT; NMR; -; B=1019-1039. DR PDB; 7TCT; X-ray; 2.50 A; A/C=32-488. DR PDB; 7TD8; X-ray; 2.60 A; A/C=32-484. DR PDB; 7THO; X-ray; 2.75 A; A/C=32-485. DR PDB; 7TMZ; X-ray; 2.20 A; A/C=32-485. DR PDB; 7TPD; X-ray; 2.60 A; A/C=32-488. DR PDB; 7U60; X-ray; 2.55 A; A/C=32-486. DR PDB; 7U9F; X-ray; 2.70 A; A/C=32-485. DR PDB; 7U9V; X-ray; 2.25 A; A/C=32-485. DR PDB; 7UBR; X-ray; 2.05 A; A/C=32-485. DR PDB; 7UCY; X-ray; 2.35 A; A/C=32-488. DR PDB; 7UDG; X-ray; 2.80 A; A/C=32-488. DR PDB; 7UDH; X-ray; 2.00 A; A/C=32-488. DR PDB; 7UE0; X-ray; 2.74 A; A/C=32-488. DR PDB; 7UFH; X-ray; 3.00 A; A/C=32-488. DR PDB; 7UH8; X-ray; 2.75 A; A/C=32-488. DR PDB; 7UJE; X-ray; 2.50 A; A/C=32-485. DR PDB; 7UJK; X-ray; 2.43 A; A/C=32-488. DR PDB; 7UK9; X-ray; 2.60 A; A/C=32-488. DR PDB; 7UKO; X-ray; 2.60 A; A/C=32-488. DR PDB; 7UKP; X-ray; 2.80 A; A/C=32-488. DR PDB; 7UKT; X-ray; 2.37 A; A/C=32-488. DR PDB; 8GCD; EM; 2.97 A; A=1-1039. DR PDB; 8GCE; EM; 3.12 A; A=1-1039. DR PDB; 8T2U; EM; 3.10 A; A=32-1039. DR PDB; 8T2V; EM; 3.40 A; A=32-1039. DR PDB; 9AXL; EM; 3.30 A; A=1-1039. DR PDB; 9DAO; EM; 2.80 A; A=32-1039. DR PDB; 9DAX; EM; 3.30 A; A=32-1039. DR PDB; 9DEQ; EM; 4.10 A; A=32-1039. DR PDB; 9DER; EM; 3.90 A; A=32-1039. DR PDBsum; 1DPK; -. DR PDBsum; 1DPQ; -. DR PDBsum; 1KUP; -. DR PDBsum; 1KUZ; -. DR PDBsum; 1M8O; -. DR PDBsum; 1S4W; -. DR PDBsum; 1TYE; -. DR PDBsum; 2K1A; -. DR PDBsum; 2K9J; -. DR PDBsum; 2KNC; -. DR PDBsum; 2MTP; -. DR PDBsum; 2N9Y; -. DR PDBsum; 2VC2; -. DR PDBsum; 2VDK; -. DR PDBsum; 2VDL; -. DR PDBsum; 2VDM; -. DR PDBsum; 2VDN; -. DR PDBsum; 2VDO; -. DR PDBsum; 2VDP; -. DR PDBsum; 2VDQ; -. DR PDBsum; 2VDR; -. DR PDBsum; 3FCS; -. DR PDBsum; 3FCU; -. DR PDBsum; 3NID; -. DR PDBsum; 3NIF; -. DR PDBsum; 3NIG; -. DR PDBsum; 3T3M; -. DR PDBsum; 3T3P; -. DR PDBsum; 3ZDX; -. DR PDBsum; 3ZDY; -. DR PDBsum; 3ZDZ; -. DR PDBsum; 3ZE0; -. DR PDBsum; 3ZE1; -. DR PDBsum; 3ZE2; -. DR PDBsum; 4CAK; -. DR PDBsum; 4Z7N; -. DR PDBsum; 4Z7O; -. DR PDBsum; 4Z7Q; -. DR PDBsum; 5HDB; -. DR PDBsum; 6V4P; -. DR PDBsum; 7KN0; -. DR PDBsum; 7L8P; -. DR PDBsum; 7LA4; -. DR PDBsum; 7SC4; -. DR PDBsum; 7SFT; -. DR PDBsum; 7TCT; -. DR PDBsum; 7TD8; -. DR PDBsum; 7THO; -. DR PDBsum; 7TMZ; -. DR PDBsum; 7TPD; -. DR PDBsum; 7U60; -. DR PDBsum; 7U9F; -. DR PDBsum; 7U9V; -. DR PDBsum; 7UBR; -. DR PDBsum; 7UCY; -. DR PDBsum; 7UDG; -. DR PDBsum; 7UDH; -. DR PDBsum; 7UE0; -. DR PDBsum; 7UFH; -. DR PDBsum; 7UH8; -. DR PDBsum; 7UJE; -. DR PDBsum; 7UJK; -. DR PDBsum; 7UK9; -. DR PDBsum; 7UKO; -. DR PDBsum; 7UKP; -. DR PDBsum; 7UKT; -. DR PDBsum; 8GCD; -. DR PDBsum; 8GCE; -. DR PDBsum; 8T2U; -. DR PDBsum; 8T2V; -. DR PDBsum; 9AXL; -. DR PDBsum; 9DAO; -. DR PDBsum; 9DAX; -. DR PDBsum; 9DEQ; -. DR PDBsum; 9DER; -. DR AlphaFoldDB; P08514; -. DR BMRB; P08514; -. DR EMDB; EMD-21044; -. DR EMDB; EMD-2281; -. DR EMDB; EMD-23245; -. DR EMDB; EMD-29931; -. DR EMDB; EMD-29932; -. DR EMDB; EMD-40988; -. DR EMDB; EMD-40989; -. DR EMDB; EMD-43046; -. DR EMDB; EMD-43969; -. DR EMDB; EMD-43983; -. DR EMDB; EMD-46695; -. DR EMDB; EMD-46701; -. DR EMDB; EMD-46793; -. DR EMDB; EMD-46794; -. DR SMR; P08514; -. DR BioGRID; 109881; 22. DR ComplexPortal; CPX-1799; Integrin alphaIIb-beta3 complex. DR CORUM; P08514; -. DR DIP; DIP-68N; -. DR FunCoup; P08514; 856. DR IntAct; P08514; 6. DR MINT; P08514; -. DR STRING; 9606.ENSP00000262407; -. DR BindingDB; P08514; -. DR ChEMBL; CHEMBL212; -. DR DrugBank; DB00054; Abciximab. DR DrugBank; DB00063; Eptifibatide. DR DrugBank; DB06472; Fradafiban. DR DrugBank; DB09526; Hydroquinone. DR DrugBank; DB04863; Lefradafiban. DR DrugBank; DB00775; Tirofiban. DR DrugCentral; P08514; -. DR GuidetoPHARMACOLOGY; 2441; -. DR GlyCosmos; P08514; 8 sites, 4 glycans. DR GlyGen; P08514; 8 sites, 4 O-linked glycans (2 sites). DR iPTMnet; P08514; -. DR PhosphoSitePlus; P08514; -. DR BioMuta; ITGA2B; -. DR DMDM; 226694183; -. DR OGP; P08514; -. DR jPOST; P08514; -. DR MassIVE; P08514; -. DR PaxDb; 9606-ENSP00000262407; -. DR PeptideAtlas; P08514; -. DR ProteomicsDB; 52113; -. [P08514-1] DR ProteomicsDB; 52114; -. [P08514-2] DR ProteomicsDB; 52115; -. [P08514-3] DR TopDownProteomics; P08514-1; -. [P08514-1] DR ABCD; P08514; 23 sequenced antibodies. DR Antibodypedia; 4350; 2013 antibodies from 53 providers. DR DNASU; 3674; -. DR Ensembl; ENST00000262407.6; ENSP00000262407.5; ENSG00000005961.20. [P08514-1] DR GeneID; 3674; -. DR KEGG; hsa:3674; -. DR MANE-Select; ENST00000262407.6; ENSP00000262407.5; NM_000419.5; NP_000410.2. DR UCSC; uc002igt.2; human. [P08514-1] DR AGR; HGNC:6138; -. DR ClinPGx; PA29938; -. DR CTD; 3674; -. DR DisGeNET; 3674; -. DR GeneCards; ITGA2B; -. DR HGNC; HGNC:6138; ITGA2B. DR HPA; ENSG00000005961; Tissue enhanced (bone marrow, epididymis, lymphoid tissue). DR MalaCards; ITGA2B; -. DR MIM; 187800; phenotype. DR MIM; 273800; phenotype. DR MIM; 607759; gene. DR MIM; 621266; phenotype. DR OpenTargets; ENSG00000005961; -. DR Orphanet; 140957; Autosomal dominant macrothrombocytopenia. DR Orphanet; 853; Fetal and neonatal alloimmune thrombocytopenia. DR Orphanet; 849; Glanzmann thrombasthenia. DR VEuPathDB; HostDB:ENSG00000005961; -. DR eggNOG; KOG3637; Eukaryota. DR GeneTree; ENSGT00940000160724; -. DR HOGENOM; CLU_004111_4_1_1; -. DR InParanoid; P08514; -. DR OMA; LQMDTAN; -. DR OrthoDB; 5317514at2759; -. DR PAN-GO; P08514; 8 GO annotations based on evolutionary models. DR PhylomeDB; P08514; -. DR PathwayCommons; P08514; -. DR Reactome; R-HSA-114608; Platelet degranulation. DR Reactome; R-HSA-216083; Integrin cell surface interactions. DR Reactome; R-HSA-3000178; ECM proteoglycans. DR Reactome; R-HSA-354192; Integrin signaling. DR Reactome; R-HSA-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins. DR Reactome; R-HSA-372708; p130Cas linkage to MAPK signaling for integrins. DR Reactome; R-HSA-445144; Signal transduction by L1. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-8936459; RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR SignaLink; P08514; -. DR SIGNOR; P08514; -. DR Agora; ENSG00000005961; -. DR BioGRID-ORCS; 3674; 20 hits in 1173 CRISPR screens. DR ChiTaRS; ITGA2B; human. DR EvolutionaryTrace; P08514; -. DR GeneWiki; ITGA2B; -. DR GenomeRNAi; 3674; -. DR Pharos; P08514; Tclin. DR PRO; PR:P08514; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P08514; protein. DR Bgee; ENSG00000005961; Expressed in monocyte and 130 other cell types or tissues. DR ExpressionAtlas; P08514; baseline and differential. DR GO; GO:0072562; C:blood microparticle; HDA:UniProtKB. DR GO; GO:0009986; C:cell surface; HDA:UniProtKB. DR GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl. DR GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB. DR GO; GO:0005925; C:focal adhesion; IEA:Ensembl. DR GO; GO:0070442; C:integrin alphaIIb-beta3 complex; IDA:UniProt. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0031092; C:platelet alpha granule membrane; TAS:Reactome. DR GO; GO:0050840; F:extracellular matrix binding; IEA:Ensembl. DR GO; GO:0070051; F:fibrinogen binding; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0060090; F:molecular adaptor activity; EXP:DisProt. DR GO; GO:0038023; F:signaling receptor activity; IBA:GO_Central. DR GO; GO:0001525; P:angiogenesis; IBA:GO_Central. DR GO; GO:0098609; P:cell-cell adhesion; IBA:GO_Central. DR GO; GO:0007160; P:cell-matrix adhesion; NAS:ComplexPortal. DR GO; GO:0007229; P:integrin-mediated signaling pathway; HDA:UniProtKB. DR GO; GO:0002687; P:positive regulation of leukocyte migration; IEA:Ensembl. DR DisProt; DP01841; -. DR FunFam; 2.60.40.1510:FF:000001; Integrin alpha V; 1. DR FunFam; 2.130.10.130:FF:000012; Integrin alpha-IIb; 1. DR FunFam; 1.20.5.930:FF:000001; Integrin subunit alpha V; 1. DR FunFam; 2.60.40.1460:FF:000001; Integrin, alpha V; 1. DR Gene3D; 1.20.5.930; Bicelle-embedded integrin alpha(iib) transmembrane segment; 1. DR Gene3D; 2.130.10.130; Integrin alpha, N-terminal; 1. DR Gene3D; 2.60.40.1460; Integrin domains. Chain A, domain 2; 1. DR Gene3D; 2.60.40.1510; ntegrin, alpha v. Chain A, domain 3; 1. DR Gene3D; 2.60.40.1530; ntegrin, alpha v. Chain A, domain 4; 1. DR InterPro; IPR013517; FG-GAP. DR InterPro; IPR013519; Int_alpha_beta-p. DR InterPro; IPR000413; Integrin_alpha. DR InterPro; IPR018184; Integrin_alpha_C_CS. DR InterPro; IPR013649; Integrin_alpha_Ig-like_1. DR InterPro; IPR048285; Integrin_alpha_Ig-like_2. DR InterPro; IPR048286; Integrin_alpha_Ig-like_3. DR InterPro; IPR028994; Integrin_alpha_N. DR InterPro; IPR032695; Integrin_dom_sf. DR PANTHER; PTHR23220; INTEGRIN ALPHA; 1. DR PANTHER; PTHR23220:SF73; INTEGRIN ALPHA-IIB; 1. DR Pfam; PF01839; FG-GAP; 2. DR Pfam; PF08441; Integrin_A_Ig_1; 1. DR Pfam; PF20805; Integrin_A_Ig_2; 1. DR Pfam; PF20806; Integrin_A_Ig_3; 1. DR Pfam; PF00357; Integrin_alpha; 1. DR PRINTS; PR01185; INTEGRINA. DR SMART; SM00191; Int_alpha; 5. DR SUPFAM; SSF69318; Integrin alpha N-terminal domain; 1. DR SUPFAM; SSF69179; Integrin domains; 3. DR PROSITE; PS51470; FG_GAP; 7. DR PROSITE; PS00242; INTEGRIN_ALPHA; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Calcium; Cell adhesion; Cell membrane; KW Cleavage on pair of basic residues; Direct protein sequencing; KW Disease variant; Disulfide bond; Glycoprotein; Integrin; Membrane; KW Metal-binding; Proteomics identification; Pyrrolidone carboxylic acid; KW Receptor; Reference proteome; Repeat; Signal; Transmembrane; KW Transmembrane helix. FT SIGNAL 1..31 FT /evidence="ECO:0000269|PubMed:1953640, FT ECO:0000269|PubMed:3534886, ECO:0000269|PubMed:8620874" FT CHAIN 32..1039 FT /note="Integrin alpha-IIb" FT /id="PRO_0000016275" FT CHAIN 32..887 FT /note="Integrin alpha-IIb heavy chain" FT /id="PRO_0000016276" FT CHAIN 891..1039 FT /note="Integrin alpha-IIb light chain, form 1" FT /id="PRO_0000292348" FT CHAIN 903..1039 FT /note="Integrin alpha-IIb light chain, form 2" FT /id="PRO_0000016277" FT TOPO_DOM 32..993 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 994..1019 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 1020..1039 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT REPEAT 35..96 FT /note="FG-GAP 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 110..173 FT /note="FG-GAP 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 187..238 FT /note="FG-GAP 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 251..305 FT /note="FG-GAP 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 306..371 FT /note="FG-GAP 5" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 373..432 FT /note="FG-GAP 6" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 435..496 FT /note="FG-GAP 7" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT MOTIF 1022..1026 FT /note="GFFKR motif" FT BINDING 274 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 276 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 278 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 281 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 283 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 328 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 330 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 332 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 334 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 336 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 396 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 398 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 400 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 402 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 404 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 457 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 459 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 461 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 463 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 465 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT MOD_RES 891 FT /note="Pyrrolidone carboxylic acid; in light chain form 1" FT /evidence="ECO:0000269|PubMed:2226834" FT CARBOHYD 46 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0000269|PubMed:2775232, FT ECO:0007744|PDB:1TYE, ECO:0007744|PDB:3FCS, FT ECO:0007744|PDB:3FCU" FT CARBOHYD 280 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0000269|PubMed:2775232, ECO:0007744|PDB:3FCS" FT CARBOHYD 601 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:19111664, ECO:0000269|PubMed:2775232, FT ECO:0007744|PDB:3FCS" FT CARBOHYD 711 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:2775232" FT CARBOHYD 874 FT /note="O-linked (GalNAc...) serine; in variant S-874" FT CARBOHYD 878 FT /note="O-linked (GalNAc...) serine" FT /evidence="ECO:0000269|PubMed:7688323" FT CARBOHYD 962 FT /note="N-linked (GlcNAc...) asparagine" FT DISULFID 87..96 FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0000269|PubMed:2775232, FT ECO:0007744|PDB:1TYE, ECO:0007744|PDB:3FCS, FT ECO:0007744|PDB:3FCU" FT DISULFID 138..161 FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0000269|PubMed:2775232, FT ECO:0007744|PDB:1TYE, ECO:0007744|PDB:3FCS, FT ECO:0007744|PDB:3FCU" FT DISULFID 177..198 FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0000269|PubMed:2775232, FT ECO:0007744|PDB:1TYE, ECO:0007744|PDB:3FCS, FT ECO:0007744|PDB:3FCU" FT DISULFID 504..515 FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0000269|PubMed:2775232, ECO:0007744|PDB:3FCS" FT DISULFID 521..576 FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0000269|PubMed:2775232, ECO:0007744|PDB:3FCS" FT DISULFID 633..639 FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0000269|PubMed:2775232, ECO:0007744|PDB:3FCS" FT DISULFID 705..718 FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0000269|PubMed:2775232, ECO:0007744|PDB:3FCS" FT DISULFID 857..921 FT /note="Interchain (between heavy and light chains)" FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0007744|PDB:3FCS" FT DISULFID 911..916 FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0007744|PDB:3FCS" FT VAR_SEQ 910..1039 FT /note="SCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWF FT NVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWK FT VGFFKRNRPPLEEDDEEGE -> VSRLSGLWPGLPGTHGAEGMGGGRGVRVCCGPLWAT FT LGPWEHFK (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_002736" FT VAR_SEQ 948..981 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_002737" FT VARIANT 40 FT /note="T -> I (in dbSNP:rs5915)" FT /evidence="ECO:0000269|PubMed:10391209" FT /id="VAR_014176" FT VARIANT 86 FT /note="L -> P (in GT1; cells co-transfected with mutated FT alpha-IIb and wild-type beta-3 scarcely expressed the FT alpha-IIb/beta-3 complex; dbSNP:rs1052533574)" FT /evidence="ECO:0000269|PubMed:12181054" FT /id="VAR_030445" FT VARIANT 139 FT /note="A -> V (in GT1; dbSNP:rs2143489510)" FT /evidence="ECO:0000269|PubMed:12083483" FT /id="VAR_030446" FT VARIANT 161 FT /note="C -> W (in GT1; uncertain significance)" FT /evidence="ECO:0000269|PubMed:11798398" FT /id="VAR_030447" FT VARIANT 174 FT /note="Y -> H (in GT1; abolishes the binding function of FT alpha-IIb/beta-3 for soluble ligands without disturbing FT alpha-IIb/beta-3 expression; functional defect is likely FT caused by its allosteric effect rather than by a defect in FT the ligand-binding site itself; dbSNP:rs2048640612)" FT /evidence="ECO:0000269|PubMed:12506038" FT /id="VAR_030448" FT VARIANT 176 FT /note="P -> A (in GT1; impairs surface expression of alpha- FT IIb/beta-3 and abrogates ligand binding to the activated FT integrin; dbSNP:rs2048640485)" FT /evidence="ECO:0000269|PubMed:10607701, FT ECO:0000269|PubMed:12083483" FT /id="VAR_009885" FT VARIANT 176 FT /note="P -> L (in GT1; impairs surface expression of alpha- FT IIb/beta-3; dbSNP:rs148327798)" FT /evidence="ECO:0000269|PubMed:10607701" FT /id="VAR_009886" FT VARIANT 202 FT /note="F -> C (in GT1; results in abrogation of alpha-IIb/ FT beta-3 complex formation)" FT /evidence="ECO:0000269|PubMed:15219201" FT /id="VAR_030449" FT VARIANT 207 FT /note="T -> I (in GT1; dbSNP:rs2143485911)" FT /evidence="ECO:0000269|PubMed:9215749" FT /id="VAR_030450" FT VARIANT 214 FT /note="L -> P (in GT1; disrupts the structural conformation FT and the ligand binding properties of the heterodimeric FT complex; in addition the mutation appears to confer FT susceptibility to proteolysis; dbSNP:rs137852911)" FT /evidence="ECO:0000269|PubMed:9473221" FT /id="VAR_030451" FT VARIANT 222 FT /note="F -> L (in GT1; uncertain significance; FT dbSNP:rs2048633474)" FT /evidence="ECO:0000269|PubMed:11798398" FT /id="VAR_030452" FT VARIANT 267 FT /note="G -> E (in GT1; dbSNP:rs2048627164)" FT /evidence="ECO:0000269|PubMed:12083483" FT /id="VAR_030453" FT VARIANT 273 FT /note="G -> D (in GT1; alters the heterodimer conformation FT thus impairing their intracellular transport; FT dbSNP:rs137852907)" FT /evidence="ECO:0000269|PubMed:8282784" FT /id="VAR_003979" FT VARIANT 313 FT /note="G -> A (in dbSNP:rs1126554)" FT /evidence="ECO:0000269|PubMed:2345548, FT ECO:0000269|PubMed:2439501" FT /id="VAR_054820" FT VARIANT 320 FT /note="F -> S (in GT1; type I; impairs surface expression FT of alpha-IIb/beta-3)" FT /evidence="ECO:0000269|PubMed:9722314" FT /id="VAR_009887" FT VARIANT 329 FT /note="V -> F (in GT1; expression of mutant subunit alpha- FT IIb/bet-3 is 28% of control; mutant pro-alpha-IIb subunit FT is retained in the endoplasmic reticulum; FT dbSNP:rs2048619428)" FT /evidence="ECO:0000269|PubMed:12424194" FT /id="VAR_030454" FT VARIANT 355 FT /note="E -> K (in GT1; type I; impairs surface expression FT of alpha-IIb/beta-3; dbSNP:rs137852910)" FT /evidence="ECO:0000269|PubMed:9722314, FT ECO:0000269|PubMed:9734640" FT /id="VAR_009888" FT VARIANT 358 FT /note="R -> H (in GT1; type II; dbSNP:rs137852908)" FT /evidence="ECO:0000269|PubMed:7706461" FT /id="VAR_003980" FT VARIANT 380 FT /note="G -> D (in GT1; uncertain significance; FT dbSNP:rs766006685)" FT /evidence="ECO:0000269|PubMed:12083483" FT /id="VAR_030455" FT VARIANT 405 FT /note="I -> T (in GT1; expression of mutant subunit alpha- FT IIb/bet-3 is 11% of control; mutant pro-alpha-IIb subunit FT is retained in the endoplasmic reticulum; FT dbSNP:rs75622274)" FT /evidence="ECO:0000269|PubMed:12083483, FT ECO:0000269|PubMed:12424194, ECO:0000269|PubMed:20020534" FT /id="VAR_030456" FT VARIANT 412 FT /note="G -> R (in GT1; dbSNP:rs780786843)" FT /evidence="ECO:0000269|PubMed:11798398" FT /id="VAR_030457" FT VARIANT 449 FT /note="G -> D (in GT1; type I; dbSNP:rs1598380253)" FT /evidence="ECO:0000269|PubMed:7508443" FT /id="VAR_003981" FT VARIANT 456..457 FT /note="Missing (in GT1; alteres the conformation of FT heterodimers such that they were neither recognized by the FT heterodimer-specific antibody A2A9 nor able to undergo FT further intracellular processing or transport to the cell FT surface)" FT /id="VAR_030458" FT VARIANT 581 FT /note="A -> D (in GT1; uncertain significance; FT dbSNP:rs2143458780)" FT /evidence="ECO:0000269|PubMed:12083483" FT /id="VAR_030459" FT VARIANT 596 FT /note="I -> T (in GT1; type I; dbSNP:rs76811038)" FT /evidence="ECO:0000269|PubMed:20020534, FT ECO:0000269|PubMed:9215749, ECO:0000269|PubMed:9734640" FT /id="VAR_030460" FT VARIANT 649 FT /note="V -> L (in dbSNP:rs7207402)" FT /id="VAR_054821" FT VARIANT 650 FT /note="T -> M (risk factor for FMAIT2; alloantigen Kno)" FT /evidence="ECO:0000269|PubMed:19821948" FT /id="VAR_091064" FT VARIANT 705 FT /note="C -> R (in GT1; type II; the rate of subunit FT maturation and the surface exposure of glycoprotein IIb/ FT beta-3 are strongly reduced; dbSNP:rs77961246)" FT /evidence="ECO:0000269|PubMed:12083483, FT ECO:0000269|PubMed:20020534, ECO:0000269|PubMed:9920835" FT /id="VAR_030461" FT VARIANT 752 FT /note="L -> V (in GT1; uncertain significance; FT dbSNP:rs761174160)" FT /evidence="ECO:0000269|PubMed:12083483" FT /id="VAR_030462" FT VARIANT 755 FT /note="R -> P (in GT1; uncertain significance; FT dbSNP:rs763762304)" FT /evidence="ECO:0000269|PubMed:12083483" FT /id="VAR_030463" FT VARIANT 771 FT /note="V -> L (risk factor for FMAIT2; alloantigen War)" FT /evidence="ECO:0000269|PubMed:23305224" FT /id="VAR_091065" FT VARIANT 778 FT /note="Q -> P (in GT1; type II; dbSNP:rs74475415)" FT /evidence="ECO:0000269|PubMed:20020534, FT ECO:0000269|PubMed:9722314, ECO:0000269|PubMed:9763559" FT /id="VAR_003982" FT VARIANT 847 FT /note="L -> P (in GT1; uncertain significance; FT dbSNP:rs1344532070)" FT /evidence="ECO:0000269|PubMed:11798398" FT /id="VAR_030464" FT VARIANT 868 FT /note="V -> M (risk factor for FMAIT2; alloantigen Max(a); FT Max(a)-positive individuals also carry alloantigen Bak(b))" FT /evidence="ECO:0000269|PubMed:7620155" FT /id="VAR_091066" FT VARIANT 874 FT /note="I -> S (risk factor for FMAIT2; alloantigen Bak(b); FT dbSNP:rs5911)" FT /evidence="ECO:0000269|PubMed:10391209, FT ECO:0000269|PubMed:15569236, ECO:0000269|PubMed:2350579" FT /id="VAR_003983" FT VARIANT 934 FT /note="V -> F (in GT1; severe type 1 phenotype; the FT mutation prevented normal ITGA2B/ITGB3 complex expression FT on the cell surface; dbSNP:rs77458039)" FT /evidence="ECO:0000269|PubMed:20020534" FT /id="VAR_069917" FT VARIANT 943 FT /note="P -> L (in GT1; marked reduction in the rate of FT surface expression)" FT /evidence="ECO:0000269|PubMed:17018384" FT /id="VAR_030465" FT VARIANT 957 FT /note="S -> L (in GT1; uncertain significance; severe type FT 1 phenotype; the mutation prevented normal ITGA2B/ITGB3 FT complex expression on the cell surface; the mutation may FT interfere with correct folding of the protein; FT dbSNP:rs80002943)" FT /evidence="ECO:0000269|PubMed:20020534" FT /id="VAR_069918" FT VARIANT 968 FT /note="Y -> N (in dbSNP:rs5914)" FT /evidence="ECO:0000269|PubMed:10391209" FT /id="VAR_014177" FT VARIANT 982 FT /note="V -> M (in GT1; much reduced surface expression of FT alpha-IIb/beta-3 and a block in the maturation of pro- FT alpha-IIb; dbSNP:rs78657866)" FT /evidence="ECO:0000269|PubMed:15099289, FT ECO:0000269|PubMed:20020534" FT /id="VAR_030466" FT VARIANT 989 FT /note="A -> T (in dbSNP:rs78165611)" FT /evidence="ECO:0000269|PubMed:15099289, FT ECO:0000269|PubMed:20020534" FT /id="VAR_030467" FT VARIANT 1026 FT /note="R -> Q (in GT1 and BDPLT16; uncertain significance; FT results in low surface expression of the mutant protein; FT dbSNP:rs879255514)" FT /evidence="ECO:0000269|PubMed:9215749, FT ECO:0000269|PubMed:9834222" FT /id="VAR_030468" FT VARIANT 1026 FT /note="R -> W (in BDPLT16; uncertain significance; results FT in abnormal membrane ruffling and cytoplasmic protrusions FT as well as defective proplatelet formation; FT dbSNP:rs766503255)" FT /evidence="ECO:0000269|PubMed:21454453" FT /id="VAR_069919" FT MUTAGEN 1029..1030 FT /note="PP->AA: Imparts constitutive activity (ligand- FT binding) to alpha-IIb/beta-3." FT /evidence="ECO:0000269|PubMed:10212286" FT CONFLICT 23 FT /note="P -> A (in Ref. 2; AAA35926)" FT /evidence="ECO:0000305" FT CONFLICT 120 FT /note="A -> S (in Ref. 4; BAG37735)" FT /evidence="ECO:0000305" FT CONFLICT 287..288 FT /note="GA -> VP (in Ref. 3; AAA53150)" FT /evidence="ECO:0000305" FT CONFLICT 346 FT /note="E -> D (in Ref. 2; AAA35926)" FT /evidence="ECO:0000305" FT CONFLICT 565 FT /note="N -> D (in Ref. 2; AAA35926)" FT /evidence="ECO:0000305" FT CONFLICT 566 FT /note="L -> V (in Ref. 11; CAA29987)" FT /evidence="ECO:0000305" FT CONFLICT 633 FT /note="C -> S (in Ref. 1; AAA60114)" FT /evidence="ECO:0000305" FT CONFLICT 729 FT /note="Q -> E (in Ref. 11; CAA29987)" FT /evidence="ECO:0000305" FT CONFLICT 971 FT /note="P -> A (in Ref. 3; AAA53150)" FT /evidence="ECO:0000305" FT CONFLICT 1029 FT /note="P -> H (in Ref. 2; AAA35926 and 7; AAA52588)" FT /evidence="ECO:0000305" FT CONFLICT 1030 FT /note="P -> T (in Ref. 7; AAA52588)" FT /evidence="ECO:0000305" FT STRAND 36..38 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 40..43 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 52..58 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 60..62 FT /evidence="ECO:0007829|PDB:1TYE" FT STRAND 64..70 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 78..80 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 82..88 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 91..94 FT /evidence="ECO:0007829|PDB:7UCY" FT STRAND 107..110 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 113..118 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 126..131 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 134..139 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 143..148 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 151..153 FT /evidence="ECO:0007829|PDB:2VDL" FT STRAND 159..165 FT /evidence="ECO:0007829|PDB:7UDH" FT TURN 166..169 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 170..174 FT /evidence="ECO:0007829|PDB:7UDH" FT HELIX 183..188 FT /evidence="ECO:0007829|PDB:7UDH" FT TURN 189..193 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 202..206 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 208..210 FT /evidence="ECO:0007829|PDB:7LA4" FT STRAND 211..216 FT /evidence="ECO:0007829|PDB:7UDH" FT HELIX 219..222 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 225..230 FT /evidence="ECO:0007829|PDB:7UDH" FT HELIX 231..237 FT /evidence="ECO:0007829|PDB:7UDH" FT HELIX 259..261 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 268..273 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 279..281 FT /evidence="ECO:0007829|PDB:7UJE" FT STRAND 283..288 FT /evidence="ECO:0007829|PDB:7UDH" FT HELIX 291..294 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 297..301 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 307..312 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 314..318 FT /evidence="ECO:0007829|PDB:7LA4" FT STRAND 324..327 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 330..333 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 336..341 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 345..348 FT /evidence="ECO:0007829|PDB:7UDH" FT TURN 349..351 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 352..355 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 358..362 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 366..368 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 375..379 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 391..398 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 400..402 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 404..409 FT /evidence="ECO:0007829|PDB:7UDH" FT TURN 413..416 FT /evidence="ECO:0007829|PDB:6V4P" FT STRAND 419..423 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 427..430 FT /evidence="ECO:0007829|PDB:1TYE" FT STRAND 435..439 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 450..456 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 461..463 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 465..470 FT /evidence="ECO:0007829|PDB:7UDH" FT HELIX 471..473 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 475..479 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 484..493 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 495..497 FT /evidence="ECO:0007829|PDB:8T2V" FT STRAND 507..509 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 512..525 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 534..541 FT /evidence="ECO:0007829|PDB:3FCS" FT TURN 542..544 FT /evidence="ECO:0007829|PDB:3FCS" FT HELIX 547..549 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 551..554 FT /evidence="ECO:0007829|PDB:3FCS" FT TURN 555..557 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 559..567 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 575..583 FT /evidence="ECO:0007829|PDB:3FCS" FT HELIX 586..588 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 592..594 FT /evidence="ECO:0007829|PDB:8GCD" FT STRAND 596..603 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 616..619 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 622..627 FT /evidence="ECO:0007829|PDB:3FCS" FT TURN 634..637 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 643..651 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 653..655 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 662..670 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 678..683 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 688..695 FT /evidence="ECO:0007829|PDB:3FCS" FT HELIX 698..700 FT /evidence="ECO:0007829|PDB:8GCD" FT STRAND 705..708 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 710..713 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 715..721 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 728..738 FT /evidence="ECO:0007829|PDB:3FCS" FT HELIX 742..744 FT /evidence="ECO:0007829|PDB:8GCD" FT STRAND 746..755 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 759..761 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 767..774 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 779..792 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 810..819 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 821..823 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 825..836 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 842..854 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 856..861 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 906..909 FT /evidence="ECO:0007829|PDB:3FCS" FT TURN 911..913 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 916..926 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 931..940 FT /evidence="ECO:0007829|PDB:3FCS" FT HELIX 942..945 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 952..965 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 967..969 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 977..988 FT /evidence="ECO:0007829|PDB:3FCS" FT TURN 991..994 FT /evidence="ECO:0007829|PDB:2KNC" FT TURN 996..1001 FT /evidence="ECO:0007829|PDB:8GCD" FT HELIX 1002..1015 FT /evidence="ECO:0007829|PDB:8GCD" FT STRAND 1019..1027 FT /evidence="ECO:0007829|PDB:7SC4" FT HELIX 1028..1031 FT /evidence="ECO:0007829|PDB:1DPK" FT TURN 1035..1038 FT /evidence="ECO:0007829|PDB:1DPQ" SQ SEQUENCE 1039 AA; 113377 MW; 063EE298E026F116 CRC64; MARALCPLQA LWLLEWVLLL LGPCAAPPAW ALNLDPVQLT FYAGPNGSQF GFSLDFHKDS HGRVAIVVGA PRTLGPSQEE TGGVFLCPWR AEGGQCPSLL FDLRDETRNV GSQTLQTFKA RQGLGASVVS WSDVIVACAP WQHWNVLEKT EEAEKTPVGS CFLAQPESGR RAEYSPCRGN TLSRIYVEND FSWDKRYCEA GFSSVVTQAG ELVLGAPGGY YFLGLLAQAP VADIFSSYRP GILLWHVSSQ SLSFDSSNPE YFDGYWGYSV AVGEFDGDLN TTEYVVGAPT WSWTLGAVEI LDSYYQRLHR LRGEQMASYF GHSVAVTDVN GDGRHDLLVG APLYMESRAD RKLAEVGRVY LFLQPRGPHA LGAPSLLLTG TQLYGRFGSA IAPLGDLDRD GYNDIAVAAP YGGPSGRGQV LVFLGQSEGL RSRPSQVLDS PFPTGSAFGF SLRGAVDIDD NGYPDLIVGA YGANQVAVYR AQPVVKASVQ LLVQDSLNPA VKSCVLPQTK TPVSCFNIQM CVGATGHNIP QKLSLNAELQ LDRQKPRQGR RVLLLGSQQA GTTLNLDLGG KHSPICHTTM AFLRDEADFR DKLSPIVLSL NVSLPPTEAG MAPAVVLHGD THVQEQTRIV LDCGEDDVCV PQLQLTASVT GSPLLVGADN VLELQMDAAN EGEGAYEAEL AVHLPQGAHY MRALSNVEGF ERLICNQKKE NETRVVLCEL GNPMKKNAQI GIAMLVSVGN LEEAGESVSF QLQIRSKNSQ NPNSKIVLLD VPVRAEAQVE LRGNSFPASL VVAAEEGERE QNSLDSWGPK VEHTYELHNN GPGTVNGLHL SIHLPGQSQP SDLLYILDIQ PQGGLQCFPQ PPVNPLKVDW GLPIPSPSPI HPAHHKRDRR QIFLPEPEQP SRLQDPVLVS CDSAPCTVVQ CDLQEMARGQ RAMVTVLAFL WLPSLYQRPL DQFVLQSHAW FNVSSLPYAV PPLSLPRGEA QVWTQLLRAL EERAIPIWWV LVGVLGGLLL LTILVLAMWK VGFFKRNRPP LEEDDEEGE // ID ITK_HUMAN Reviewed; 620 AA. AC Q08881; B2R752; Q32ML7; DT 01-OCT-1994, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-1994, sequence version 1. DT 28-JAN-2026, entry version 239. DE RecName: Full=Tyrosine-protein kinase ITK/TSK; DE EC=2.7.10.2; DE AltName: Full=Interleukin-2-inducible T-cell kinase; DE Short=IL-2-inducible T-cell kinase; DE AltName: Full=Kinase EMT; DE AltName: Full=T-cell-specific kinase; DE AltName: Full=Tyrosine-protein kinase Lyk; GN Name=ITK; Synonyms=EMT, LYK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND INDUCTION. RX PubMed=8504851; DOI=10.1016/0014-5793(93)81520-a; RA Tanaka N., Asao H., Ohtani K., Nakamura M., Sugamura K.; RT "A novel human tyrosine kinase gene inducible in T cells by interleukin RT 2."; RL FEBS Lett. 324:1-5(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Thymus; RX PubMed=8364206; RA Gibson S., Leung B., Squire J.A., Hill M., Arima N., Goss P., Hogg D., RA Mills G.B.; RT "Identification, cloning, and characterization of a novel human T-cell- RT specific tyrosine kinase located at the hematopoietin complex on chromosome RT 5q."; RL Blood 82:1561-1572(1993). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Thymus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP PROTEIN SEQUENCE OF 171-192, AND PHOSPHORYLATION AT TYR-180. RX PubMed=12573241; DOI=10.1016/s1570-9639(02)00524-1; RA Nore B.F., Mattsson P.T., Antonsson P., Backesjo C.-M., Westlund A., RA Lennartsson J., Hansson H., Low P., Ronnstrand L., Smith C.I.E.; RT "Identification of phosphorylation sites within the SH3 domains of Tec RT family tyrosine kinases."; RL Biochim. Biophys. Acta 1645:123-132(2003). RN [7] RP PHOSPHORYLATION BY LCK. RX PubMed=9312162; DOI=10.1074/jbc.272.40.25401; RA Heyeck S.D., Wilcox H.M., Bunnell S.C., Berg L.J.; RT "Lck phosphorylates the activation loop tyrosine of the Itk kinase domain RT and activates Itk kinase activity."; RL J. Biol. Chem. 272:25401-25408(1997). RN [8] RP INDUCTION. RX PubMed=9701039; DOI=10.1093/intimm/10.7.1009; RA King P.D., Sadra A., Teng J.M., Bell G.M., Dupont B.; RT "CD2-mediated activation of the Tec-family tyrosine kinase ITK is RT controlled by proline-rich stretch-4 of the CD2 cytoplasmic tail."; RL Int. Immunol. 10:1009-1016(1998). RN [9] RP DOMAIN. RX PubMed=10795735; DOI=10.1016/s1074-7613(00)80189-2; RA Yang W.C., Collette Y., Nunes J.A., Olive D.; RT "Tec kinases: a family with multiple roles in immunity."; RL Immunity 12:373-382(2000). RN [10] RP FUNCTION IN PHOSPHORYLATION OF LAT. RX PubMed=12186560; DOI=10.1021/bi025554o; RA Perez-Villar J.J., Whitney G.S., Sitnick M.T., Dunn R.J., Venkatesan S., RA O'Day K., Schieven G.L., Lin T.A., Kanner S.B.; RT "Phosphorylation of the linker for activation of T-cells by Itk promotes RT recruitment of Vav."; RL Biochemistry 41:10732-10740(2002). RN [11] RP FUNCTION. RX PubMed=12682224; DOI=10.4049/jimmunol.170.8.3971; RA Grasis J.A., Browne C.D., Tsoukas C.D.; RT "Inducible T cell tyrosine kinase regulates actin-dependent cytoskeletal RT events induced by the T cell antigen receptor."; RL J. Immunol. 170:3971-3976(2003). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=15144186; DOI=10.1021/ac035352d; RA Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M., RA Peters E.C.; RT "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from RT human T cells using immobilized metal affinity chromatography and tandem RT mass spectrometry."; RL Anal. Chem. 76:2763-2772(2004). RN [13] RP INTERACTION WITH PPIA/CYPA, AND MUTAGENESIS OF PRO-288. RX PubMed=15308100; DOI=10.1016/j.immuni.2004.07.005; RA Colgan J., Asmal M., Neagu M., Yu B., Schneidkraut J., Lee Y., RA Sokolskaja E., Andreotti A., Luban J.; RT "Cyclophilin A regulates TCR signal strength in CD4+ T cells via a proline- RT directed conformational switch in Itk."; RL Immunity 21:189-201(2004). RN [14] RP INTERACTION WITH VAV1. RX PubMed=15661896; DOI=10.4049/jimmunol.174.3.1385; RA Dombroski D., Houghtling R.A., Labno C.M., Precht P., Takesono A., RA Caplen N.J., Billadeau D.D., Wange R.L., Burkhardt J.K., Schwartzberg P.L.; RT "Kinase-independent functions for Itk in TCR-induced regulation of Vav and RT the actin cytoskeleton."; RL J. Immunol. 174:1385-1392(2005). RN [15] RP SUBCELLULAR LOCATION. RX PubMed=17060314; DOI=10.1074/jbc.m609180200; RA Qi Q., Sahu N., August A.; RT "Tec kinase Itk forms membrane clusters specifically in the vicinity of RT recruiting receptors."; RL J. Biol. Chem. 281:38529-38534(2006). RN [16] RP INTERACTION WITH FASLG. RX PubMed=19807924; DOI=10.1186/1471-2172-10-53; RA Voss M., Lettau M., Janssen O.; RT "Identification of SH3 domain interaction partners of human FasL (CD178) by RT phage display screening."; RL BMC Immunol. 10:53-53(2009). RN [17] RP AUTOPHOSPHORYLATION. RX PubMed=19523959; DOI=10.1016/j.jmb.2009.06.023; RA Joseph R.E., Severin A., Min L., Fulton D.B., Andreotti A.H.; RT "SH2-dependent autophosphorylation within the Tec family kinase Itk."; RL J. Mol. Biol. 391:164-177(2009). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-512 AND SER-565, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [19] RP UBIQUITINATION. RX PubMed=20596523; DOI=10.1371/journal.pone.0011332; RA Del Rincon S.V., Rogers J., Widschwendter M., Sun D., Sieburg H.B., RA Spruck C.; RT "Development and validation of a method for profiling post-translational RT modification activities using protein microarrays."; RL PLoS ONE 5:E11332-E11332(2010). RN [20] RP FUNCTION IN PHOSPHORYLATION OF LCP2. RX PubMed=21725281; DOI=10.1038/emboj.2011.213; RA Sela M., Bogin Y., Beach D., Oellerich T., Lehne J., Smith-Garvin J.E., RA Okumura M., Starosvetsky E., Kosoff R., Libman E., Koretzky G., RA Kambayashi T., Urlaub H., Wienands J., Chernoff J., Yablonski D.; RT "Sequential phosphorylation of SLP-76 at tyrosine 173 is required for RT activation of T and mast cells."; RL EMBO J. 30:3160-3172(2011). RN [21] RP STRUCTURE BY NMR OF 113-239. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the BTK motif and the SH3 domain of tyrosine-protein RT kinase ITK from human."; RL Submitted (OCT-2007) to the PDB data bank. RN [22] RP VARIANTS [LARGE SCALE ANALYSIS] LYS-19; LEU-23; GLN-451; TRP-581 AND RP ILE-587. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [23] RP VARIANT LPFS1 TRP-335, AND CHARACTERIZATION OF VARIANT LPSA1 TRP-335. RX PubMed=19425169; DOI=10.1172/jci37901; RA Huck K., Feyen O., Niehues T., Rueschendorf F., Huebner N., Laws H.-J., RA Telieps T., Knapp S., Wacker H.-H., Meindl A., Jumaa H., Borkhardt A.; RT "Girls homozygous for an IL-2-inducible T cell kinase mutation that leads RT to protein deficiency develop fatal EBV-associated lymphoproliferation."; RL J. Clin. Invest. 119:1350-1358(2009). CC -!- FUNCTION: Tyrosine kinase that plays an essential role in regulation of CC the adaptive immune response. Regulates the development, function and CC differentiation of conventional T-cells and nonconventional NKT-cells. CC When antigen presenting cells (APC) activate T-cell receptor (TCR), a CC series of phosphorylation lead to the recruitment of ITK to the cell CC membrane, in the vicinity of the stimulated TCR receptor, where it is CC phosphorylated by LCK. Phosphorylation leads to ITK autophosphorylation CC and full activation. Once activated, phosphorylates PLCG1, leading to CC the activation of this lipase and subsequent cleavage of its CC substrates. In turn, the endoplasmic reticulum releases calcium in the CC cytoplasm and the nuclear activator of activated T-cells (NFAT) CC translocates into the nucleus to perform its transcriptional duty. CC Phosphorylates 2 essential adapter proteins: the linker for activation CC of T-cells/LAT protein and LCP2. Then, a large number of signaling CC molecules such as VAV1 are recruited and ultimately lead to lymphokine CC production, T-cell proliferation and differentiation (PubMed:12186560, CC PubMed:12682224, PubMed:21725281). Required for TCR-mediated calcium CC response in gamma-delta T-cells, may also be involved in the modulation CC of the transcriptomic signature in the Vgamma2-positive subset of CC immature gamma-delta T-cells (By similarity). Phosphorylates TBX21 at CC 'Tyr-530' and mediates its interaction with GATA3 (By similarity). CC {ECO:0000250|UniProtKB:Q03526, ECO:0000269|PubMed:12186560, CC ECO:0000269|PubMed:12682224, ECO:0000269|PubMed:21725281}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000250}; CC -!- SUBUNIT: Homooligomerizes; this association negatively regulates kinase CC activity (By similarity). Interacts with PPIA/CYPA; this interaction CC regulates TCR signal strength via a proline-directed conformational CC switch in ITK. Interacts with THEMIS (By similarity). Interacts with CC FASLG. Interacts with VAV1; this interaction is important for VAV1 CC localization and TCR-induced actin polarization. Interacts with TBX21 CC (By similarity). {ECO:0000250|UniProtKB:Q03526, CC ECO:0000269|PubMed:15308100, ECO:0000269|PubMed:15661896, CC ECO:0000269|PubMed:19807924}. CC -!- INTERACTION: CC Q08881; P04626: ERBB2; NbExp=2; IntAct=EBI-968552, EBI-641062; CC Q08881; P48023: FASLG; NbExp=3; IntAct=EBI-968552, EBI-495538; CC Q08881; P08238: HSP90AB1; NbExp=3; IntAct=EBI-968552, EBI-352572; CC Q08881; Q13094: LCP2; NbExp=4; IntAct=EBI-968552, EBI-346946; CC Q08881; P31947: SFN; NbExp=2; IntAct=EBI-968552, EBI-476295; CC Q08881; P62258: YWHAE; NbExp=2; IntAct=EBI-968552, EBI-356498; CC Q08881; P10686: Plcg1; Xeno; NbExp=2; IntAct=EBI-968552, EBI-520788; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17060314}. Nucleus CC {ECO:0000250|UniProtKB:Q03526}. Note=Localizes in the vicinity of cell CC surface receptors in the plasma membrane after receptor stimulation. CC -!- TISSUE SPECIFICITY: T-cell lines and natural killer cell lines. CC -!- INDUCTION: Through a myriad of surface receptors including the TCR/CD3 CC signaling complex, coreceptors, or chemokine receptors. CC {ECO:0000269|PubMed:8504851, ECO:0000269|PubMed:9701039}. CC -!- DOMAIN: The N-terminal PH domain allows ITK to be recruited to the CC plasma membrane by an activated PI3 kinase. This domain also contains a CC proline-rich region (PRR). The adjoining domain is a SH3 domain, which CC binds to PRR (from itself or from other proteins). Next, a SH2 domain CC is required for binding tyrosine-phosphorylated substrates. In the C- CC terminal region, the kinase domain is required for tyrosine CC phosphorylation. {ECO:0000269|PubMed:10795735}. CC -!- PTM: Phosphorylated at Tyr-512 in the activation loop of the kinase CC domain by LCK. Subsequent autophosphorylation at Tyr-180 leads to the CC kinase activation. The autophosphorylated Tyr-180 lies within the CC substrate binding sequence of the SH3 domain. CC {ECO:0000269|PubMed:12573241, ECO:0000269|PubMed:9312162}. CC -!- PTM: Ubiquitinated. {ECO:0000269|PubMed:20596523}. CC -!- DISEASE: Lymphoproliferative syndrome 1 (LPFS1) [MIM:613011]: A rare CC immunodeficiency characterized by extreme susceptibility to infection CC with Epstein-Barr virus (EBV). Inadequate immune response to EBV can CC have a fatal outcome. Clinical features include splenomegaly, CC lymphadenopathy, anemia, thrombocytopenia, pancytopenia, recurrent CC infections. There is an increased risk for lymphoma. CC {ECO:0000269|PubMed:19425169}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. TEC subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/43329/ITK"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D13720; BAA02873.1; -; mRNA. DR EMBL; L10717; AAA36748.1; -; mRNA. DR EMBL; S65186; AAB28072.2; -; mRNA. DR EMBL; AK312846; BAG35699.1; -; mRNA. DR EMBL; CH471062; EAW61608.1; -; Genomic_DNA. DR EMBL; BC109077; AAI09078.1; -; mRNA. DR EMBL; BC109078; AAI09079.1; -; mRNA. DR CCDS; CCDS4336.1; -. DR PIR; S33253; S33253. DR RefSeq; NP_005537.3; NM_005546.3. DR PDB; 1SM2; X-ray; 2.30 A; A/B=357-620. DR PDB; 1SNU; X-ray; 2.50 A; A/B=357-620. DR PDB; 1SNX; X-ray; 3.20 A; A/B=357-620. DR PDB; 2E6I; NMR; -; A=113-169. DR PDB; 2LMJ; NMR; -; A=171-231. DR PDB; 2YUQ; NMR; -; A=162-239. DR PDB; 3MIY; X-ray; 1.67 A; A/B=357-620. DR PDB; 3MJ1; X-ray; 1.72 A; A=357-620. DR PDB; 3MJ2; X-ray; 1.90 A; A=357-620. DR PDB; 3QGW; X-ray; 2.10 A; A/B=357-620. DR PDB; 3QGY; X-ray; 2.10 A; A/B=357-620. DR PDB; 3T9T; X-ray; 1.65 A; A=354-620. DR PDB; 3V5J; X-ray; 2.59 A; A/B=357-620. DR PDB; 3V5L; X-ray; 1.86 A; A/B/C/D=357-620. DR PDB; 3V8T; X-ray; 2.00 A; A/B=357-620. DR PDB; 3V8W; X-ray; 2.27 A; A/B=357-620. DR PDB; 4HCT; X-ray; 1.48 A; A=354-620. DR PDB; 4HCU; X-ray; 1.43 A; A=354-620. DR PDB; 4HCV; X-ray; 1.48 A; A=354-620. DR PDB; 4KIO; X-ray; 2.18 A; A/B/C/D=357-620. DR PDB; 4L7S; X-ray; 2.03 A; A/B=357-620. DR PDB; 4M0Y; X-ray; 1.70 A; A=354-620. DR PDB; 4M0Z; X-ray; 2.00 A; A=354-620. DR PDB; 4M12; X-ray; 2.15 A; A=354-620. DR PDB; 4M13; X-ray; 1.85 A; A=354-620. DR PDB; 4M14; X-ray; 1.55 A; A=354-620. DR PDB; 4M15; X-ray; 1.52 A; A=354-620. DR PDB; 4MF0; X-ray; 2.67 A; A/B=357-620. DR PDB; 4MF1; X-ray; 2.11 A; A/B=357-620. DR PDB; 4PP9; X-ray; 2.58 A; A/B=357-620. DR PDB; 4PPA; X-ray; 2.67 A; A/B=357-620. DR PDB; 4PPB; X-ray; 2.82 A; A/B=357-620. DR PDB; 4PPC; X-ray; 2.95 A; A/B=357-620. DR PDB; 4PQN; X-ray; 1.71 A; A=357-620. DR PDB; 4QD6; X-ray; 2.45 A; A/B=357-620. DR PDB; 4RFM; X-ray; 2.10 A; A=357-620. DR PDBsum; 1SM2; -. DR PDBsum; 1SNU; -. DR PDBsum; 1SNX; -. DR PDBsum; 2E6I; -. DR PDBsum; 2LMJ; -. DR PDBsum; 2YUQ; -. DR PDBsum; 3MIY; -. DR PDBsum; 3MJ1; -. DR PDBsum; 3MJ2; -. DR PDBsum; 3QGW; -. DR PDBsum; 3QGY; -. DR PDBsum; 3T9T; -. DR PDBsum; 3V5J; -. DR PDBsum; 3V5L; -. DR PDBsum; 3V8T; -. DR PDBsum; 3V8W; -. DR PDBsum; 4HCT; -. DR PDBsum; 4HCU; -. DR PDBsum; 4HCV; -. DR PDBsum; 4KIO; -. DR PDBsum; 4L7S; -. DR PDBsum; 4M0Y; -. DR PDBsum; 4M0Z; -. DR PDBsum; 4M12; -. DR PDBsum; 4M13; -. DR PDBsum; 4M14; -. DR PDBsum; 4M15; -. DR PDBsum; 4MF0; -. DR PDBsum; 4MF1; -. DR PDBsum; 4PP9; -. DR PDBsum; 4PPA; -. DR PDBsum; 4PPB; -. DR PDBsum; 4PPC; -. DR PDBsum; 4PQN; -. DR PDBsum; 4QD6; -. DR PDBsum; 4RFM; -. DR AlphaFoldDB; Q08881; -. DR BMRB; Q08881; -. DR SMR; Q08881; -. DR BioGRID; 109907; 55. DR CORUM; Q08881; -. DR DIP; DIP-29974N; -. DR FunCoup; Q08881; 1866. DR IntAct; Q08881; 45. DR MINT; Q08881; -. DR STRING; 9606.ENSP00000398655; -. DR BindingDB; Q08881; -. DR ChEMBL; CHEMBL2959; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB06589; Pazopanib. DR DrugBank; DB14924; Ritlecitinib. DR DrugBank; DB02010; Staurosporine. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; Q08881; -. DR GuidetoPHARMACOLOGY; 2046; -. DR GlyGen; Q08881; 1 site. DR iPTMnet; Q08881; -. DR PhosphoSitePlus; Q08881; -. DR BioMuta; ITK; -. DR DMDM; 585361; -. DR CPTAC; CPTAC-2862; -. DR CPTAC; CPTAC-2863; -. DR jPOST; Q08881; -. DR MassIVE; Q08881; -. DR PaxDb; 9606-ENSP00000398655; -. DR PeptideAtlas; Q08881; -. DR ProteomicsDB; 58650; -. DR Pumba; Q08881; -. DR ABCD; Q08881; 4 sequenced antibodies. DR Antibodypedia; 16533; 527 antibodies from 42 providers. DR DNASU; 3702; -. DR Ensembl; ENST00000422843.8; ENSP00000398655.4; ENSG00000113263.15. DR GeneID; 3702; -. DR KEGG; hsa:3702; -. DR MANE-Select; ENST00000422843.8; ENSP00000398655.4; NM_005546.4; NP_005537.3. DR UCSC; uc003lwo.2; human. DR AGR; HGNC:6171; -. DR ClinPGx; PA29968; -. DR CTD; 3702; -. DR DisGeNET; 3702; -. DR GeneCards; ITK; -. DR HGNC; HGNC:6171; ITK. DR HPA; ENSG00000113263; Tissue enriched (lymphoid). DR MalaCards; ITK; -. DR MIM; 186973; gene. DR MIM; 613011; phenotype. DR OpenTargets; ENSG00000113263; -. DR Orphanet; 538963; Combined immunodeficiency due to ITK deficiency. DR VEuPathDB; HostDB:ENSG00000113263; -. DR eggNOG; KOG0197; Eukaryota. DR GeneTree; ENSGT00940000158850; -. DR HOGENOM; CLU_000288_7_2_1; -. DR InParanoid; Q08881; -. DR OMA; GYWLEKT; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q08881; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q08881; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; Q08881; -. DR Reactome; R-HSA-202433; Generation of second messenger molecules. DR Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization. DR SignaLink; Q08881; -. DR SIGNOR; Q08881; -. DR Agora; ENSG00000113263; -. DR BioGRID-ORCS; 3702; 17 hits in 1184 CRISPR screens. DR CD-CODE; F345034F; Signaling cluster. DR ChiTaRS; ITK; human. DR EvolutionaryTrace; Q08881; -. DR GeneWiki; ITK_(gene); -. DR GenomeRNAi; 3702; -. DR Pharos; Q08881; Tclin. DR PRO; PR:Q08881; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; Q08881; protein. DR Bgee; ENSG00000113263; Expressed in granulocyte and 129 other cell types or tissues. DR ExpressionAtlas; Q08881; baseline and differential. DR GO; GO:0005911; C:cell-cell junction; IEA:Ensembl. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0002250; P:adaptive immune response; ISS:UniProtKB. DR GO; GO:0050853; P:B cell receptor signaling pathway; IBA:GO_Central. DR GO; GO:0006968; P:cellular defense response; TAS:ProtInc. DR GO; GO:0046629; P:gamma-delta T cell activation; ISS:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro. DR GO; GO:0001865; P:NK T cell differentiation; IBA:GO_Central. DR GO; GO:0001819; P:positive regulation of cytokine production; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0042110; P:T cell activation; TAS:UniProtKB. DR GO; GO:0050852; P:T cell receptor signaling pathway; ISS:UniProtKB. DR CDD; cd01238; PH_Btk; 1. DR CDD; cd05112; PTKc_Itk; 1. DR CDD; cd10396; SH2_Tec_Itk; 1. DR CDD; cd11908; SH3_ITK; 1. DR FunFam; 1.10.510.10:FF:000052; Tyrosine-protein kinase; 1. DR FunFam; 2.30.29.30:FF:000244; Tyrosine-protein kinase; 1. DR FunFam; 2.30.30.40:FF:000176; Tyrosine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000053; Tyrosine-protein kinase; 1. DR FunFam; 3.30.505.10:FF:000061; Tyrosine-protein kinase; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR Gene3D; 3.30.505.10; SH2 domain; 1. DR Gene3D; 2.30.30.40; SH3 Domains; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR042785; ITK_PTKc. DR InterPro; IPR035583; ITK_SH3. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050198; Non-receptor_tyrosine_kinases. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR001849; PH_domain. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR000980; SH2. DR InterPro; IPR036860; SH2_dom_sf. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR001562; Znf_Btk_motif. DR PANTHER; PTHR24418; TYROSINE-PROTEIN KINASE; 1. DR Pfam; PF00779; BTK; 1. DR Pfam; PF00169; PH; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00017; SH2; 1. DR Pfam; PF00018; SH3_1; 1. DR PRINTS; PR00401; SH2DOMAIN. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00107; BTK; 1. DR SMART; SM00233; PH; 1. DR SMART; SM00252; SH2; 1. DR SMART; SM00326; SH3; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF55550; SH2 domain; 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS50003; PH_DOMAIN; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS50001; SH2; 1. DR PROSITE; PS50002; SH3; 1. DR PROSITE; PS51113; ZF_BTK; 1. PE 1: Evidence at protein level; KW 3D-structure; Adaptive immunity; ATP-binding; Cytoplasm; KW Direct protein sequencing; Disease variant; Immunity; Kinase; KW Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; SH2 domain; SH3 domain; KW Transferase; Tyrosine-protein kinase; Ubl conjugation; Zinc; Zinc-finger. FT CHAIN 1..620 FT /note="Tyrosine-protein kinase ITK/TSK" FT /id="PRO_0000088106" FT DOMAIN 4..111 FT /note="PH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT DOMAIN 171..231 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 239..338 FT /note="SH2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00191" FT DOMAIN 363..615 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 113..149 FT /note="Btk-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT ACT_SITE 482 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 121 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 132 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 133 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 143 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 369..377 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 391 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 180 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12573241" FT MOD_RES 512 FT /note="Phosphotyrosine; by LCK" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 565 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT VARIANT 19 FT /note="R -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1753502279)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041710" FT VARIANT 23 FT /note="P -> L (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041711" FT VARIANT 193 FT /note="R -> Q (in dbSNP:rs17054374)" FT /id="VAR_051696" FT VARIANT 335 FT /note="R -> W (in LPFS1; shows nearly undetectable mutant FT ITK protein consistent with severe protein instability; FT dbSNP:rs121908191)" FT /evidence="ECO:0000269|PubMed:19425169" FT /id="VAR_063424" FT VARIANT 451 FT /note="R -> Q (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs779372373)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041712" FT VARIANT 581 FT /note="R -> W (in dbSNP:rs34482255)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041713" FT VARIANT 587 FT /note="V -> I (in dbSNP:rs56005928)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041714" FT MUTAGEN 288 FT /note="P->G: Complete loss of interaction with PPIA/CYPA." FT /evidence="ECO:0000269|PubMed:15308100" FT CONFLICT 171..172 FT /note="PE -> GS (in Ref. 6; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 331 FT /note="V -> W (in Ref. 2; AAB28072)" FT /evidence="ECO:0000305" FT STRAND 127..133 FT /evidence="ECO:0007829|PDB:2E6I" FT STRAND 148..152 FT /evidence="ECO:0007829|PDB:2E6I" FT STRAND 171..173 FT /evidence="ECO:0007829|PDB:2YUQ" FT STRAND 175..180 FT /evidence="ECO:0007829|PDB:2LMJ" FT STRAND 187..189 FT /evidence="ECO:0007829|PDB:2YUQ" FT STRAND 197..205 FT /evidence="ECO:0007829|PDB:2LMJ" FT STRAND 208..212 FT /evidence="ECO:0007829|PDB:2LMJ" FT STRAND 214..216 FT /evidence="ECO:0007829|PDB:2LMJ" FT STRAND 218..221 FT /evidence="ECO:0007829|PDB:2LMJ" FT HELIX 223..225 FT /evidence="ECO:0007829|PDB:2LMJ" FT STRAND 226..228 FT /evidence="ECO:0007829|PDB:2LMJ" FT HELIX 360..362 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 363..371 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 373..375 FT /evidence="ECO:0007829|PDB:4KIO" FT STRAND 376..382 FT /evidence="ECO:0007829|PDB:4HCU" FT TURN 383..385 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 386..393 FT /evidence="ECO:0007829|PDB:4HCU" FT TURN 395..397 FT /evidence="ECO:0007829|PDB:3T9T" FT HELIX 400..411 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 421..425 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 427..436 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 443..448 FT /evidence="ECO:0007829|PDB:4HCU" FT TURN 449..452 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 456..475 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 485..487 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 488..490 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 492..494 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 496..498 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 503..506 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 510..513 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 522..524 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 527..532 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 537..552 FT /evidence="ECO:0007829|PDB:4HCU" FT TURN 553..555 FT /evidence="ECO:0007829|PDB:4PQN" FT TURN 558..561 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 564..572 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 581..583 FT /evidence="ECO:0007829|PDB:3V8W" FT HELIX 585..594 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 599..601 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 605..617 FT /evidence="ECO:0007829|PDB:4HCU" SQ SEQUENCE 620 AA; 71831 MW; DAE396BD2309319D CRC64; MNNFILLEEQ LIKKSQQKRR TSPSNFKVRF FVLTKASLAY FEDRHGKKRT LKGSIELSRI KCVEIVKSDI SIPCHYKYPF QVVHDNYLLY VFAPDRESRQ RWVLALKEET RNNNSLVPKY HPNFWMDGKW RCCSQLEKLA TGCAQYDPTK NASKKPLPPT PEDNRRPLWE PEETVVIALY DYQTNDPQEL ALRRNEEYCL LDSSEIHWWR VQDRNGHEGY VPSSYLVEKS PNNLETYEWY NKSISRDKAE KLLLDTGKEG AFMVRDSRTA GTYTVSVFTK AVVSENNPCI KHYHIKETND NPKRYYVAEK YVFDSIPLLI NYHQHNGGGL VTRLRYPVCF GRQKAPVTAG LRYGKWVIDP SELTFVQEIG SGQFGLVHLG YWLNKDKVAI KTIREGAMSE EDFIEEAEVM MKLSHPKLVQ LYGVCLEQAP ICLVFEFMEH GCLSDYLRTQ RGLFAAETLL GMCLDVCEGM AYLEEACVIH RDLAARNCLV GENQVIKVSD FGMTRFVLDD QYTSSTGTKF PVKWASPEVF SFSRYSSKSD VWSFGVLMWE VFSEGKIPYE NRSNSEVVED ISTGFRLYKP RLASTHVYQI MNHCWKERPE DRPAFSRLLR QLAEIAESGL // ID JUPI2_HUMAN Reviewed; 190 AA. AC Q9H910; B1AJY2; B4DLH4; Q6EIC7; DT 19-JUL-2005, integrated into UniProtKB/Swiss-Prot. DT 01-MAR-2001, sequence version 1. DT 28-JAN-2026, entry version 172. DE RecName: Full=Jupiter microtubule associated homolog 2 {ECO:0000312|HGNC:HGNC:14137}; DE AltName: Full=Hematological and neurological expressed 1-like protein {ECO:0000303|PubMed:15094197}; DE Short=HN1-like protein; GN Name=JPT2 {ECO:0000312|HGNC:HGNC:14137}; GN Synonyms=C16orf34, HN1L {ECO:0000303|PubMed:15094197}; ORFNames=L11; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2), SUBCELLULAR RP LOCATION, AND TISSUE SPECIFICITY. RC TISSUE=Brain, and Liver; RX PubMed=15094197; DOI=10.1016/j.gene.2004.02.025; RA Zhou G., Wang J., Zhang Y., Zhong C., Ni J., Wang L., Guo J., Zhang K., RA Yu L., Zhao S.; RT "Cloning, expression and subcellular localization of HN1 and HN1L genes, as RT well as characterization of their orthologs, defining an evolutionarily RT conserved gene family."; RL Gene 331:115-123(2004). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INDUCTION, AND SUBCELLULAR RP LOCATION. RX PubMed=15334068; DOI=10.1038/sj.onc.1207921; RA Petroziello J., Yamane A., Westendorf L., Thompson M., McDonagh C., RA Cerveny C., Law C.-L., Wahl A., Carter P.; RT "Suppression subtractive hybridization and expression profiling identifies RT a unique set of genes overexpressed in non-small-cell lung cancer."; RL Oncogene 23:7734-7745(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Teratocarcinoma, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11157797; DOI=10.1093/hmg/10.4.339; RA Daniels R.J., Peden J.F., Lloyd C., Horsley S.W., Clark K., Tufarelli C., RA Kearney L., Buckle V.J., Doggett N.A., Flint J., Higgs D.R.; RT "Sequence, structure and pathology of the fully annotated terminal 2 Mb of RT the short arm of human chromosome 16."; RL Hum. Mol. Genet. 10:339-352(2001). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15616553; DOI=10.1038/nature03187; RA Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G., RA Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E., RA Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M., RA Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C., RA Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M., RA Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M., RA Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D., RA Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., RA Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., RA Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., RA Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., RA Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J., RA Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D., RA Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S., RA Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A., RA Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M., RA Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H., RA Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A., RA Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J., RA DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J., RA Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., RA Myers R.M., Rubin E.M., Pennacchio L.A.; RT "The sequence and analysis of duplication-rich human chromosome 16."; RL Nature 432:988-994(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Skin, and Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-97, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17924679; DOI=10.1021/pr070152u; RA Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.; RT "Improved titanium dioxide enrichment of phosphopeptides from HeLa cells RT and high confident phosphopeptide identification by cross-validation of RT MS/MS and MS/MS/MS spectra."; RL J. Proteome Res. 6:4150-4162(2007). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-97, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-30; THR-35; SER-97 AND RP SER-144, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-97, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-97, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-132, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [16] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-45; SER-69; SER-97; SER-132 RP AND SER-144, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [18] RP FUNCTION, FUNCTION (MICROBIAL INFECTION), SUBUNIT, AND INTERACTION WITH RP TPCN1. RX PubMed=33758061; DOI=10.1126/scisignal.abd5605; RA Gunaratne G.S., Brailoiu E., He S., Unterwald E.M., Patel S., Slama J.T., RA Walseth T.F., Marchant J.S.; RT "Essential requirement for JPT2 in NAADP-evoked Ca2+ signaling."; RL Sci. Signal. 14:0-0(2021). RN [19] RP FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION. RX PubMed=33758062; DOI=10.1126/scisignal.abd5647; RA Roggenkamp H.G., Khansahib I., Hernandez C.L.C., Zhang Y., Lodygin D., RA Krueger A., Gu F., Moeckl F., Loehndorf A., Wolters V., Woike D., RA Rosche A., Bauche A., Schetelig D., Werner R., Schlueter H., Failla A.V., RA Meier C., Fliegert R., Walseth T.F., Fluegel A., Diercks B.P., Guse A.H.; RT "HN1L/JPT2: A signaling protein that connects NAADP generation to Ca2+ RT microdomain formation."; RL Sci. Signal. 14:0-0(2021). CC -!- FUNCTION: Nicotinic acid adenine dinucleotide phosphate (NAADP) binding CC protein required for NAADP-evoked intracellular calcium release CC (PubMed:33758061, PubMed:33758062). Confers NAADP-sensitivity to the CC two pore channels (TPCs) complex (PubMed:33758061). Enables NAADP to CC activate Ca(2+) release from the endoplasmic reticulum through CC ryanodine receptors (PubMed:33758062). {ECO:0000269|PubMed:33758061, CC ECO:0000269|PubMed:33758062}. CC -!- FUNCTION: (Microbial infection) Involved in the endolysosomal CC trafficking of human coronavirus SARS-CoV-2. CC {ECO:0000269|PubMed:33758061}. CC -!- SUBUNIT: Monomer (PubMed:33758062). Dimer (PubMed:33758062). Interacts CC with TPCN1 (PubMed:33758061). {ECO:0000269|PubMed:33758061, CC ECO:0000269|PubMed:33758062}. CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15094197, CC ECO:0000269|PubMed:33758062}. Nucleus {ECO:0000269|PubMed:15094197}. CC Note=Colocalizes with type 1 ryanodine receptor (RYR1). CC {ECO:0000269|PubMed:33758062}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=HN1LA; CC IsoId=Q9H910-1; Sequence=Displayed; CC Name=2; Synonyms=HN1LB, HN1LC; CC IsoId=Q9H910-2; Sequence=VSP_014706; CC Name=3; CC IsoId=Q9H910-3; Sequence=VSP_057423; CC -!- TISSUE SPECIFICITY: Expressed in liver, kidney, prostate, testis and CC uterus. {ECO:0000269|PubMed:15094197}. CC -!- INDUCTION: Up-regulated in squamous cell carcinoma (SCC) adenocarcinoma CC (AC), adenosquamous cell carcinoma (ASCC), bronchioalveolar carcinoma CC (BAC), breast and uterus tumors. {ECO:0000269|PubMed:15334068}. CC -!- SIMILARITY: Belongs to the JUPITER family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY323831; AAP72616.1; -; Genomic_DNA. DR EMBL; AY323978; AAP83791.1; -; mRNA. DR EMBL; AY323979; AAP83792.1; -; mRNA. DR EMBL; AY598330; AAT06741.1; -; mRNA. DR EMBL; AK023154; BAB14434.1; -; mRNA. DR EMBL; AE006639; AAK61289.1; -; Genomic_DNA. DR EMBL; AK296998; BAG59536.1; -; mRNA. DR EMBL; AL031009; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL031710; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471112; EAW85635.1; -; Genomic_DNA. DR EMBL; CH471112; EAW85638.1; -; Genomic_DNA. DR EMBL; BC014438; AAH14438.1; -; mRNA. DR EMBL; BC060853; AAH60853.1; -; mRNA. DR CCDS; CCDS10441.1; -. [Q9H910-1] DR RefSeq; NP_001421594.1; NM_001434665.1. [Q9H910-3] DR RefSeq; NP_653171.1; NM_144570.3. [Q9H910-1] DR AlphaFoldDB; Q9H910; -. DR BioGRID; 124774; 60. DR FunCoup; Q9H910; 2606. DR IntAct; Q9H910; 16. DR MINT; Q9H910; -. DR STRING; 9606.ENSP00000248098; -. DR ChEMBL; CHEMBL4295946; -. DR TCDB; 8.A.242.1.1; the naadp-binding protein (jpt2) family. DR GlyGen; Q9H910; 11 sites, 2 O-linked glycans (10 sites). DR iPTMnet; Q9H910; -. DR MetOSite; Q9H910; -. DR PhosphoSitePlus; Q9H910; -. DR BioMuta; JPT2; -. DR jPOST; Q9H910; -. DR MassIVE; Q9H910; -. DR PaxDb; 9606-ENSP00000248098; -. DR PeptideAtlas; Q9H910; -. DR ProteomicsDB; 4534; -. DR ProteomicsDB; 81270; -. [Q9H910-1] DR ProteomicsDB; 81271; -. [Q9H910-2] DR Pumba; Q9H910; -. DR TopDownProteomics; Q9H910-1; -. [Q9H910-1] DR Antibodypedia; 23196; 79 antibodies from 14 providers. DR DNASU; 90861; -. DR Ensembl; ENST00000248098.8; ENSP00000248098.3; ENSG00000206053.14. [Q9H910-1] DR Ensembl; ENST00000382711.9; ENSP00000372158.5; ENSG00000206053.14. [Q9H910-2] DR Ensembl; ENST00000562684.5; ENSP00000457694.1; ENSG00000206053.14. [Q9H910-3] DR GeneID; 90861; -. DR KEGG; hsa:90861; -. DR MANE-Select; ENST00000248098.8; ENSP00000248098.3; NM_144570.3; NP_653171.1. DR UCSC; uc002cmg.4; human. [Q9H910-1] DR UCSC; uc010uvi.3; human. DR AGR; HGNC:14137; -. DR ClinPGx; PA162391043; -. DR CTD; 90861; -. DR DisGeNET; 90861; -. DR GeneCards; JPT2; -. DR HGNC; HGNC:14137; JPT2. DR HPA; ENSG00000206053; Tissue enhanced (brain). DR MIM; 619241; gene. DR OpenTargets; ENSG00000206053; -. DR VEuPathDB; HostDB:ENSG00000206053; -. DR eggNOG; ENOG502S1G7; Eukaryota. DR GeneTree; ENSGT00390000007652; -. DR HOGENOM; CLU_111612_0_0_1; -. DR InParanoid; Q9H910; -. DR OMA; RQFINPP; -. DR OrthoDB; 6367565at2759; -. DR PAN-GO; Q9H910; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q9H910; -. DR PathwayCommons; Q9H910; -. DR SignaLink; Q9H910; -. DR Agora; ENSG00000206053; -. DR BioGRID-ORCS; 90861; 10 hits in 1144 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; HN1L; human. DR GeneWiki; HN1L; -. DR GenomeRNAi; 90861; -. DR Pharos; Q9H910; Tbio. DR PRO; PR:Q9H910; -. DR Proteomes; UP000005640; Chromosome 16. DR RNAct; Q9H910; protein. DR Bgee; ENSG00000206053; Expressed in epithelium of bronchus and 199 other cell types or tissues. DR ExpressionAtlas; Q9H910; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0075509; P:endocytosis involved in viral entry into host cell; IDA:UniProtKB. DR GO; GO:0050848; P:regulation of calcium-mediated signaling; IMP:UniProtKB. DR InterPro; IPR033335; JUPITER. DR PANTHER; PTHR34930; GEO05313P1; 1. DR PANTHER; PTHR34930:SF5; JUPITER MICROTUBULE ASSOCIATED HOMOLOG 2; 1. DR Pfam; PF17054; JUPITER; 1. PE 1: Evidence at protein level; KW Acetylation; Alternative splicing; Cytoplasm; Host-virus interaction; KW Nucleus; Phosphoprotein; Proteomics identification; Reference proteome. FT CHAIN 1..190 FT /note="Jupiter microtubule associated homolog 2" FT /id="PRO_0000054921" FT REGION 1..190 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 35..44 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 110..129 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 139..167 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 30 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 35 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 45 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 69 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 97 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17924679, FT ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 132 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 144 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..17 FT /note="MFQVPDSEGGRAGSRAM -> M (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15094197" FT /id="VSP_014706" FT VAR_SEQ 14 FT /note="S -> SRKWQLLTGSLASTSPSLLSGQGPWAPLQ (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_057423" SQ SEQUENCE 190 AA; 20063 MW; 9132F17687193192 CRC64; MFQVPDSEGG RAGSRAMKPP GGESSNLFGS PEEATPSSRP NRMASNIFGP TEEPQNIPKR TNPPGGKGSG IFDESTPVQT RQHLNPPGGK TSDIFGSPVT ATSRLAHPNK PKDHVFLCEG EEPKSDLKAA RSIPAGAEPG EKGSARKAGP AKEQEPMPTV DSHEPRLGPR PRSHNKVLNP PGGKSSISFY // ID KCC2B_HUMAN Reviewed; 666 AA. AC Q13554; A4D2K0; A4D2K1; A4D2K2; A4D2K3; A4D2K4; A4D2K5; A4D2K6; O95437; AC O95438; O95599; Q9UGH7; Q9UGH8; Q9UGH9; Q9UNX0; Q9UNX7; Q9UP00; Q9Y5N4; AC Q9Y6F4; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 31-MAY-2011, sequence version 3. DT 28-JAN-2026, entry version 235. DE RecName: Full=Calcium/calmodulin-dependent protein kinase type II subunit beta; DE Short=CaM kinase II subunit beta; DE Short=CaMK-II subunit beta; DE EC=2.7.11.17 {ECO:0000269|PubMed:31930741}; GN Name=CAMK2B; Synonyms=CAM2, CAMK2, CAMKB; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 5; 6 AND 7). RC TISSUE=Brain; RX PubMed=10858498; DOI=10.1016/s0014-5793(00)01634-3; RA Wang P., Wu Y., Zhou T.H., Sun Y., Pei G.; RT "Identification of alternative splicing variants of the beta subunit of RT human Ca(2+)/calmodulin-dependent protein kinase II with different RT activities."; RL FEBS Lett. 475:107-110(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4). RC TISSUE=Skeletal muscle; RA Leddy J.J., Salih M., Tuana B.S.; RL Submitted (MAR-1995) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 5). RC TISSUE=Brain; RA Li G.Y., Cooper N.G.F.; RT "Molecular cloning and sequencing of human calcium/calmodulin dependent RT protein kinase II beta subunit."; RL Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 5). RC TISSUE=Insulinoma; RX PubMed=10819240; DOI=10.1007/s001250051330; RA Rochlitz H., Voigt A., Lankat-Buttgereit B., Goeke B., Heimberg H., RA Nauck M.A., Schiemann U., Schatz H., Pfeiffer A.F.; RT "Cloning and quantitative determination of the human Ca2+/calmodulin- RT dependent protein kinase II (CaMK II) isoforms in human beta cells."; RL Diabetologia 43:465-473(2000). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Testis, and Thalamus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 302-605 (ISOFORM 2). RX PubMed=9060999; DOI=10.1016/s0167-4889(96)00141-3; RA Tombes R.M., Krystal G.W.; RT "Identification of novel human tumor cell-specific CaMK-II variants."; RL Biochim. Biophys. Acta 1355:281-292(1997). RN [9] RP ACTIVITY REGULATION, SUBUNIT, AND AUTOPHOSPHORYLATION. RX PubMed=14722083; DOI=10.1074/jbc.m313597200; RA Gaertner T.R., Kolodziej S.J., Wang D., Kobayashi R., Koomen J.M., RA Stoops J.K., Waxham M.N.; RT "Comparative analyses of the three-dimensional structures and enzymatic RT properties of alpha, beta, gamma and delta isoforms of Ca2+-calmodulin- RT dependent protein kinase II."; RL J. Biol. Chem. 279:12484-12494(2004). RN [10] RP INTERACTION WITH MPDZ. RX PubMed=15312654; DOI=10.1016/j.neuron.2004.08.003; RA Krapivinsky G., Medina I., Krapivinsky L., Gapon S., Clapham D.E.; RT "SynGAP-MUPP1-CaMKII synaptic complexes regulate p38 MAP kinase activity RT and NMDA receptor-dependent synaptic AMPA receptor potentiation."; RL Neuron 43:563-574(2004). RN [11] RP FUNCTION IN SKELETAL MUSCLE, PHOSPHORYLATION AT THR-287, FUNCTION IN RP PHOSPHORYLATION OF PLN, TISSUE SPECIFICITY, AND INDUCTION. RX PubMed=16690701; DOI=10.1113/jphysiol.2006.111757; RA Rose A.J., Kiens B., Richter E.A.; RT "Ca2+-calmodulin-dependent protein kinase expression and signalling in RT skeletal muscle during exercise."; RL J. Physiol. (Lond.) 574:889-903(2006). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [13] RP SUBCELLULAR LOCATION. RX PubMed=21529938; DOI=10.1016/j.ceca.2011.02.007; RA Wayman G.A., Tokumitsu H., Davare M.A., Soderling T.R.; RT "Analysis of CaM-kinase signaling in cells."; RL Cell Calcium 50:1-8(2011). RN [14] RP REVIEW ON FUNCTION IN SKELETAL MUSCLE. RX PubMed=15294044; DOI=10.1079/pns2004335; RA Chin E.R.; RT "The role of calcium and calcium/calmodulin-dependent kinases in skeletal RT muscle plasticity and mitochondrial biogenesis."; RL Proc. Nutr. Soc. 63:279-286(2004). RN [15] RP REVIEW ON FUNCTION IN SKELETAL MUSCLE. RA Sacchetto R., Bovo E., Damiani E.; RT "The Ca2+-calmodulin dependent protein kinase II system of skeletal muscle RT sarcoplasmic reticulum."; RL Basic Appl. Myol. 15:5-17(2005). RN [16] RP REVIEW ON FUNCTION IN NEURONAL PLASTICITY. RX PubMed=18817731; DOI=10.1016/j.neuron.2008.08.021; RA Wayman G.A., Lee Y.S., Tokumitsu H., Silva A.J., Silva A., Soderling T.R.; RT "Calmodulin-kinases: modulators of neuronal development and plasticity."; RL Neuron 59:914-931(2008). RN [17] RP REVIEW ON FUNCTION IN NEURONAL PLASTICITY. RX PubMed=19996366; DOI=10.1152/physiol.00029.2009; RA Okamoto K., Bosch M., Hayashi Y.; RT "The roles of CaMKII and F-actin in the structural plasticity of dendritic RT spines: a potential molecular identity of a synaptic tag?"; RL Physiology (Bethesda) 24:357-366(2009). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [19] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=31930741; DOI=10.15252/embj.2019102608; RA Jiang X., Wang X., Ding X., Du M., Li B., Weng X., Zhang J., Li L., RA Tian R., Zhu Q., Chen S., Wang L., Liu W., Fang L., Neculai D., Sun Q.; RT "FAM134B oligomerization drives endoplasmic reticulum membrane scission for RT ER-phagy."; RL EMBO J. 39:e102608-e102608(2020). RN [20] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 11-303 IN COMPLEX WITH INHIBITOR. RG Structural genomics consortium (SGC); RT "Crystal structure of human calcium/calmodulin-dependent protein kinase IIb RT isoform 1 (CAMK2B)."; RL Submitted (DEC-2007) to the PDB data bank. RN [21] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-489 AND LYS-510. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [22] RP INVOLVEMENT IN MRD54, VARIANTS MRD54 29-ARG--GLN-666 DEL; LYS-110; LEU-139; RP LYS-237 AND GLU-301, CHARACTERIZATION OF VARIANTS MRD54 LYS-110; LEU-139; RP LYS-237 AND GLU-301, AND FUNCTION. RX PubMed=29100089; DOI=10.1016/j.ajhg.2017.10.003; RG Undiagnosed Diseases Network; RG GEM HUGO; RG Deciphering Developmental Disorders Study; RA Kuery S., van Woerden G.M., Besnard T., Proietti Onori M., Latypova X., RA Towne M.C., Cho M.T., Prescott T.E., Ploeg M.A., Sanders S., RA Stessman H.A.F., Pujol A., Distel B., Robak L.A., Bernstein J.A., RA Denomme-Pichon A.S., Lesca G., Sellars E.A., Berg J., Carre W., Busk O.L., RA van Bon B.W.M., Waugh J.L., Deardorff M., Hoganson G.E., Bosanko K.B., RA Johnson D.S., Dabir T., Holla O.L., Sarkar A., Tveten K., de Bellescize J., RA Braathen G.J., Terhal P.A., Grange D.K., van Haeringen A., Lam C., RA Mirzaa G., Burton J., Bhoj E.J., Douglas J., Santani A.B., Nesbitt A.I., RA Helbig K.L., Andrews M.V., Begtrup A., Tang S., van Gassen K.L.I., RA Juusola J., Foss K., Enns G.M., Moog U., Hinderhofer K., Paramasivam N., RA Lincoln S., Kusako B.H., Lindenbaum P., Charpentier E., Nowak C.B., RA Cherot E., Simonet T., Ruivenkamp C.A.L., Hahn S., Brownstein C.A., Xia F., RA Schmitt S., Deb W., Bonneau D., Nizon M., Quinquis D., Chelly J., RA Rudolf G., Sanlaville D., Parent P., Gilbert-Dussardier B., Toutain A., RA Sutton V.R., Thies J., Peart-Vissers L.E.L.M., Boisseau P., Vincent M., RA Grabrucker A.M., Dubourg C., Tan W.H., Verbeek N.E., Granzow M., RA Santen G.W.E., Shendure J., Isidor B., Pasquier L., Redon R., Yang Y., RA State M.W., Kleefstra T., Cogne B., Petrovski S., Retterer K., RA Eichler E.E., Rosenfeld J.A., Agrawal P.B., Bezieau S., Odent S., RA Elgersma Y., Mercier S.; RT "De Novo Mutations in Protein Kinase Genes CAMK2A and CAMK2B Cause RT Intellectual Disability."; RL Am. J. Hum. Genet. 101:768-788(2017). RN [23] RP INVOLVEMENT IN MRD54, AND VARIANTS MRD54 LEU-213 AND SER-284. RX PubMed=29560374; DOI=10.1002/acn3.528; RA Akita T., Aoto K., Kato M., Shiina M., Mutoh H., Nakashima M., Kuki I., RA Okazaki S., Magara S., Shiihara T., Yokochi K., Aiba K., Tohyama J., RA Ohba C., Miyatake S., Miyake N., Ogata K., Fukuda A., Matsumoto N., RA Saitsu H.; RT "De novo variants in CAMK2A and CAMK2B cause neurodevelopmental RT disorders."; RL Ann. Clin. Transl. Neurol. 5:280-296(2018). CC -!- FUNCTION: Calcium/calmodulin-dependent protein kinase that functions CC autonomously after Ca(2+)/calmodulin-binding and autophosphorylation, CC and is involved in dendritic spine and synapse formation, neuronal CC plasticity and regulation of sarcoplasmic reticulum Ca(2+) transport in CC skeletal muscle (PubMed:16690701). In neurons, plays an essential CC structural role in the reorganization of the actin cytoskeleton during CC plasticity by binding and bundling actin filaments in a kinase- CC independent manner. This structural function is required for correct CC targeting of CaMK2A, which acts downstream of NMDAR to promote CC dendritic spine and synapse formation and maintain synaptic plasticity CC which enables long-term potentiation (LTP) and hippocampus-dependent CC learning. In developing hippocampal neurons, promotes arborization of CC the dendritic tree and in mature neurons, promotes dendritic CC remodeling. Also regulates the migration of developing neurons CC (PubMed:29100089). Participates in the modulation of skeletal muscle CC function in response to exercise (PubMed:16690701). In slow-twitch CC muscles, is involved in regulation of sarcoplasmic reticulum (SR) CC Ca(2+) transport and in fast-twitch muscle participates in the control CC of Ca(2+) release from the SR through phosphorylation of triadin, a CC ryanodine receptor-coupling factor, and phospholamban (PLN/PLB), an CC endogenous inhibitor of SERCA2A/ATP2A2. In response to interferon-gamma CC (IFN-gamma) stimulation, catalyzes phosphorylation of STAT1, CC stimulating the JAK-STAT signaling pathway (By similarity). CC Phosphorylates reticulophagy regulator RETREG1 at 'Ser-151' under CC endoplasmic reticulum stress conditions which enhances RETREG1 CC oligomerization and its membrane scission and reticulophagy activity CC (PubMed:31930741). {ECO:0000250|UniProtKB:P08413, CC ECO:0000269|PubMed:16690701, ECO:0000269|PubMed:29100089, CC ECO:0000269|PubMed:31930741}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.17; CC Evidence={ECO:0000269|PubMed:31930741}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.17; CC -!- ACTIVITY REGULATION: Activated by Ca(2+)/calmodulin. Binding of CC calmodulin results in conformational change that relieves intrasteric CC autoinhibition and allows autophosphorylation of Thr-287 which turns CC the kinase in a constitutively active form and confers to the kinase a CC Ca(2+)-independent activity. {ECO:0000269|PubMed:14722083}. CC -!- SUBUNIT: CAMK2 is composed of 4 different chains: alpha (CAMK2A), beta CC (CAMK2B), gamma (CAMK2G), and delta (CAMK2D). The different isoforms CC assemble into homo- or heteromultimeric holoenzymes composed of 12 CC subunits with two hexameric rings stacked one on top of the other CC (PubMed:14722083, Ref.20). Interacts with SYNGAP1 and CAMK2N2 (By CC similarity). Interacts with MPDZ (PubMed:15312654). Interacts with CC FOXO3 (By similarity). Interacts (when in a kinase inactive state not CC associated with calmodulin) with ARC; leading to target ARC to inactive CC synapses (By similarity). Interacts with CAMK2N1; this interaction CC requires CAMK2B activation by Ca(2+) (By similarity). CC {ECO:0000250|UniProtKB:P08413, ECO:0000250|UniProtKB:P28652, CC ECO:0000269|PubMed:14722083, ECO:0000269|PubMed:15312654, CC ECO:0000269|Ref.20}. CC -!- INTERACTION: CC Q13554; O00154: ACOT7; NbExp=3; IntAct=EBI-1058722, EBI-948905; CC Q13554; Q2VPB7: AP5B1; NbExp=4; IntAct=EBI-1058722, EBI-5917279; CC Q13554; P62158: CALM3; NbExp=2; IntAct=EBI-1058722, EBI-397435; CC Q13554; Q9UQM7: CAMK2A; NbExp=7; IntAct=EBI-1058722, EBI-1383687; CC Q13554; Q13554: CAMK2B; NbExp=2; IntAct=EBI-1058722, EBI-1058722; CC Q13554; Q13557: CAMK2D; NbExp=6; IntAct=EBI-1058722, EBI-351018; CC Q13554; Q8N0U1: FAM171A2; NbExp=3; IntAct=EBI-1058722, EBI-10264767; CC Q13554; P60412: KRTAP10-11; NbExp=3; IntAct=EBI-1058722, EBI-10217483; CC Q13554; Q3LI72: KRTAP19-5; NbExp=3; IntAct=EBI-1058722, EBI-1048945; CC Q13554; Q3SYF9: KRTAP19-7; NbExp=3; IntAct=EBI-1058722, EBI-10241353; CC Q13554; Q9UI95: MAD2L2; NbExp=3; IntAct=EBI-1058722, EBI-77889; CC Q13554; Q9BUE0: MED18; NbExp=3; IntAct=EBI-1058722, EBI-394640; CC Q13554; Q9UBU8: MORF4L1; NbExp=3; IntAct=EBI-1058722, EBI-399246; CC Q13554; Q9UBU8-2: MORF4L1; NbExp=3; IntAct=EBI-1058722, EBI-10288852; CC Q13554; Q9Y3B7: MRPL11; NbExp=3; IntAct=EBI-1058722, EBI-5453723; CC Q13554; Q93100: PHKB; NbExp=3; IntAct=EBI-1058722, EBI-740559; CC Q13554; Q969H6: POP5; NbExp=3; IntAct=EBI-1058722, EBI-366525; CC Q13554; P61225: RAP2B; NbExp=3; IntAct=EBI-1058722, EBI-750871; CC Q13554; O43251: RBFOX2; NbExp=3; IntAct=EBI-1058722, EBI-746056; CC Q13554; Q93062: RBPMS; NbExp=3; IntAct=EBI-1058722, EBI-740322; CC Q13554; P62913: RPL11; NbExp=3; IntAct=EBI-1058722, EBI-354380; CC Q13554; Q9NTN9-3: SEMA4G; NbExp=3; IntAct=EBI-1058722, EBI-9089805; CC Q13554; Q5W111: SPRYD7; NbExp=3; IntAct=EBI-1058722, EBI-10248098; CC Q13554; Q8N0Z6: TTC5; NbExp=3; IntAct=EBI-1058722, EBI-9526213; CC Q13554; B3KWQ7; NbExp=3; IntAct=EBI-1058722, EBI-10175974; CC Q13554-3; O00154-4: ACOT7; NbExp=3; IntAct=EBI-11523526, EBI-12007918; CC Q13554-3; P15289: ARSA; NbExp=3; IntAct=EBI-11523526, EBI-2117357; CC Q13554-3; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-11523526, EBI-1383687; CC Q13554-3; Q13557-8: CAMK2D; NbExp=4; IntAct=EBI-11523526, EBI-11534483; CC Q13554-3; Q13555-5: CAMK2G; NbExp=3; IntAct=EBI-11523526, EBI-12020154; CC Q13554-3; Q9NUG4: CCM2L; NbExp=3; IntAct=EBI-11523526, EBI-350645; CC Q13554-3; Q16543: CDC37; NbExp=3; IntAct=EBI-11523526, EBI-295634; CC Q13554-3; Q6P1R4: DUS1L; NbExp=3; IntAct=EBI-11523526, EBI-6660325; CC Q13554-3; O43790: KRT86; NbExp=3; IntAct=EBI-11523526, EBI-9996498; CC Q13554-3; Q07627: KRTAP1-1; NbExp=3; IntAct=EBI-11523526, EBI-11959885; CC Q13554-3; Q7Z4W3: KRTAP19-3; NbExp=3; IntAct=EBI-11523526, EBI-12020132; CC Q13554-3; Q3LI66: KRTAP6-2; NbExp=3; IntAct=EBI-11523526, EBI-11962084; CC Q13554-3; Q3LI67: KRTAP6-3; NbExp=3; IntAct=EBI-11523526, EBI-22311199; CC Q13554-3; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-11523526, EBI-16439278; CC Q13554-3; Q9UBU8-2: MORF4L1; NbExp=3; IntAct=EBI-11523526, EBI-10288852; CC Q13554-3; Q15014: MORF4L2; NbExp=3; IntAct=EBI-11523526, EBI-399257; CC Q13554-3; Q9Y3B7: MRPL11; NbExp=3; IntAct=EBI-11523526, EBI-5453723; CC Q13554-3; Q96T60: PNKP; NbExp=3; IntAct=EBI-11523526, EBI-1045072; CC Q13554-3; Q9BUI4: POLR3C; NbExp=3; IntAct=EBI-11523526, EBI-5452779; CC Q13554-3; P61225: RAP2B; NbExp=3; IntAct=EBI-11523526, EBI-750871; CC Q13554-3; P78317: RNF4; NbExp=3; IntAct=EBI-11523526, EBI-2340927; CC Q13554-3; O14787-2: TNPO2; NbExp=3; IntAct=EBI-11523526, EBI-12076664; CC Q13554-3; Q9Y5L0: TNPO3; NbExp=3; IntAct=EBI-11523526, EBI-1042571; CC Q13554-3; Q8N0Z6: TTC5; NbExp=3; IntAct=EBI-11523526, EBI-9526213; CC Q13554-3; P26640: VARS1; NbExp=3; IntAct=EBI-11523526, EBI-355765; CC Q13554-3; A0A0C4DGF1: ZBTB32; NbExp=3; IntAct=EBI-11523526, EBI-10188476; CC Q13554-3; Q9UJ78-2: ZMYM5; NbExp=3; IntAct=EBI-11523526, EBI-17634549; CC Q13554-3; P32502: GCD7; Xeno; NbExp=3; IntAct=EBI-11523526, EBI-6260; CC Q13554-3; P16622: HEM15; Xeno; NbExp=3; IntAct=EBI-11523526, EBI-8261; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton CC {ECO:0000269|PubMed:21529938}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome {ECO:0000250}. Sarcoplasmic reticulum CC membrane {ECO:0000269|PubMed:21529938}; Peripheral membrane protein CC {ECO:0000269|PubMed:21529938}; Cytoplasmic side CC {ECO:0000269|PubMed:21529938}. Synapse {ECO:0000250|UniProtKB:P08413}. CC Note=In slow-twitch muscle, evenly distributed between longitudinal SR CC and junctional SR. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=8; CC Comment=The variable region of the CAMK2B protein is encoded by at CC least 7 exons (V1 to V7). Alternative splicing within this region CC gives rise to CAMK2B isoforms.; CC Name=4; CC IsoId=Q13554-1; Sequence=Displayed; CC Name=1; Synonyms=Beta; CC IsoId=Q13554-2; Sequence=VSP_004776; CC Name=2; Synonyms=Beta1, Beta'E; CC IsoId=Q13554-3; Sequence=VSP_004770, VSP_004771, VSP_004775, CC VSP_004776; CC Name=3; Synonyms=Beta2; CC IsoId=Q13554-4; Sequence=VSP_004770, VSP_004771, VSP_004774, CC VSP_004776; CC Name=5; Synonyms=Beta4, BetaE; CC IsoId=Q13554-5; Sequence=VSP_004770, VSP_004771, VSP_004776; CC Name=6; Synonyms=Beta6; CC IsoId=Q13554-6; Sequence=VSP_004773, VSP_004776, VSP_004777; CC Name=7; Synonyms=Beta7; CC IsoId=Q13554-7; Sequence=VSP_004770, VSP_004772; CC Name=8; CC IsoId=Q13554-8; Sequence=VSP_041219, VSP_004776; CC -!- TISSUE SPECIFICITY: Widely expressed. Expressed in adult and fetal CC brain. Expression is slightly lower in fetal brain. Expressed in CC skeletal muscle. {ECO:0000269|PubMed:16690701}. CC -!- INDUCTION: Activity is induced in skeletal muscle during exercise. CC {ECO:0000269|PubMed:16690701}. CC -!- DOMAIN: The CAMK2 protein kinases contain a unique C-terminal subunit CC association domain responsible for oligomerization. CC -!- PTM: Autophosphorylation of Thr-287 following activation by CC Ca(2+)/calmodulin. Phosphorylation of Thr-287 locks the kinase into an CC activated state. {ECO:0000269|PubMed:14722083, CC ECO:0000269|PubMed:16690701}. CC -!- DISEASE: Intellectual developmental disorder, autosomal dominant 54 CC (MRD54) [MIM:617799]: A disorder characterized by significantly below CC average general intellectual functioning associated with impairments in CC adaptive behavior and manifested during the developmental period. CC {ECO:0000269|PubMed:29100089, ECO:0000269|PubMed:29560374}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. CaMK subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC99802.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF078803; AAD42035.1; -; mRNA. DR EMBL; AF081572; AAD42036.1; -; mRNA. DR EMBL; AF081924; AAD42037.1; -; mRNA. DR EMBL; AF083419; AAD42038.1; -; mRNA. DR EMBL; AF140350; AAD42070.1; -; mRNA. DR EMBL; U23460; AAC99802.1; ALT_FRAME; mRNA. DR EMBL; AF112472; AAD03744.1; -; mRNA. DR EMBL; AF112471; AAD03743.1; -; mRNA. DR EMBL; AJ252236; CAB65120.1; -; mRNA. DR EMBL; AJ252237; CAB65121.1; -; mRNA. DR EMBL; AJ252238; CAB65122.1; -; mRNA. DR EMBL; AK290148; BAF82837.1; -; mRNA. DR EMBL; AK315663; BAG38029.1; -; mRNA. DR EMBL; CH236960; EAL23756.1; -; Genomic_DNA. DR EMBL; CH236960; EAL23757.1; -; Genomic_DNA. DR EMBL; CH236960; EAL23758.1; -; Genomic_DNA. DR EMBL; CH236960; EAL23759.1; -; Genomic_DNA. DR EMBL; CH236960; EAL23760.1; -; Genomic_DNA. DR EMBL; CH236960; EAL23761.1; -; Genomic_DNA. DR EMBL; CH236960; EAL23762.1; -; Genomic_DNA. DR EMBL; BC019070; AAH19070.1; -; mRNA. DR EMBL; U50358; AAB16863.1; -; mRNA. DR CCDS; CCDS43573.1; -. [Q13554-8] DR CCDS; CCDS5483.1; -. [Q13554-1] DR CCDS; CCDS5484.1; -. [Q13554-2] DR CCDS; CCDS5485.1; -. [Q13554-5] DR CCDS; CCDS5486.1; -. [Q13554-3] DR CCDS; CCDS5487.1; -. [Q13554-6] DR CCDS; CCDS5488.1; -. [Q13554-4] DR CCDS; CCDS5489.1; -. [Q13554-7] DR RefSeq; NP_001211.3; NM_001220.4. [Q13554-1] DR RefSeq; NP_001280099.1; NM_001293170.2. [Q13554-2] DR RefSeq; NP_742075.1; NM_172078.3. [Q13554-2] DR RefSeq; NP_742076.1; NM_172079.3. [Q13554-5] DR RefSeq; NP_742077.1; NM_172080.3. [Q13554-8] DR RefSeq; NP_742078.1; NM_172081.3. [Q13554-3] DR RefSeq; NP_742079.1; NM_172082.3. [Q13554-6] DR RefSeq; NP_742080.1; NM_172083.3. [Q13554-4] DR RefSeq; NP_742081.1; NM_172084.3. [Q13554-7] DR PDB; 3BHH; X-ray; 2.40 A; A/B/C/D=11-303. DR PDB; 7URW; X-ray; 3.11 A; A/B/C/D/E/F/G=534-666. DR PDB; 7URY; X-ray; 2.64 A; A/B/C/D/E/F/G=534-666. DR PDB; 7URZ; X-ray; 3.45 A; A/B/C/G=534-666. DR PDBsum; 3BHH; -. DR PDBsum; 7URW; -. DR PDBsum; 7URY; -. DR PDBsum; 7URZ; -. DR AlphaFoldDB; Q13554; -. DR SMR; Q13554; -. DR BioGRID; 107266; 186. DR DIP; DIP-39770N; -. DR FunCoup; Q13554; 2064. DR IntAct; Q13554; 131. DR MINT; Q13554; -. DR STRING; 9606.ENSP00000379098; -. DR BindingDB; Q13554; -. DR ChEMBL; CHEMBL4121; -. DR DrugBank; DB07168; [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(methylamino)pyrimidin-2-yl}amino)phenyl]acetonitrile. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB12571; Rimacalib. DR DrugCentral; Q13554; -. DR GuidetoPHARMACOLOGY; 1556; -. DR GlyCosmos; Q13554; 2 sites, 1 glycan. DR GlyGen; Q13554; 7 sites, 1 O-linked glycan (5 sites). DR iPTMnet; Q13554; -. DR PhosphoSitePlus; Q13554; -. DR SwissPalm; Q13554; -. DR BioMuta; CAMK2B; -. DR DMDM; 334302890; -. DR jPOST; Q13554; -. DR MassIVE; Q13554; -. DR PaxDb; 9606-ENSP00000379098; -. DR PeptideAtlas; Q13554; -. DR ProteomicsDB; 59530; -. [Q13554-1] DR ProteomicsDB; 59531; -. [Q13554-2] DR ProteomicsDB; 59532; -. [Q13554-3] DR ProteomicsDB; 59533; -. [Q13554-4] DR ProteomicsDB; 59534; -. [Q13554-5] DR ProteomicsDB; 59535; -. [Q13554-6] DR ProteomicsDB; 59536; -. [Q13554-7] DR ProteomicsDB; 59537; -. [Q13554-8] DR Pumba; Q13554; -. DR Antibodypedia; 3482; 548 antibodies from 39 providers. DR DNASU; 816; -. DR Ensembl; ENST00000258682.10; ENSP00000258682.6; ENSG00000058404.22. [Q13554-8] DR Ensembl; ENST00000346990.8; ENSP00000326518.5; ENSG00000058404.22. [Q13554-7] DR Ensembl; ENST00000347193.8; ENSP00000326544.6; ENSG00000058404.22. [Q13554-6] DR Ensembl; ENST00000350811.7; ENSP00000326375.5; ENSG00000058404.22. [Q13554-2] DR Ensembl; ENST00000353625.8; ENSP00000326427.5; ENSG00000058404.22. [Q13554-4] DR Ensembl; ENST00000358707.7; ENSP00000351542.3; ENSG00000058404.22. [Q13554-3] DR Ensembl; ENST00000395747.6; ENSP00000379096.2; ENSG00000058404.22. [Q13554-5] DR Ensembl; ENST00000395749.7; ENSP00000379098.2; ENSG00000058404.22. [Q13554-1] DR Ensembl; ENST00000440254.6; ENSP00000397937.2; ENSG00000058404.22. [Q13554-2] DR Ensembl; ENST00000700285.1; ENSP00000514918.1; ENSG00000058404.22. [Q13554-2] DR GeneID; 816; -. DR KEGG; hsa:816; -. DR MANE-Select; ENST00000395749.7; ENSP00000379098.2; NM_001220.5; NP_001211.3. DR UCSC; uc003tkp.3; human. [Q13554-1] DR AGR; HGNC:1461; -. DR ClinPGx; PA91; -. DR CTD; 816; -. DR DisGeNET; 816; -. DR GeneCards; CAMK2B; -. DR HGNC; HGNC:1461; CAMK2B. DR HPA; ENSG00000058404; Group enriched (brain, heart muscle, skeletal muscle, tongue). DR MalaCards; CAMK2B; -. DR MIM; 607707; gene. DR MIM; 617799; phenotype. DR OpenTargets; ENSG00000058404; -. DR Orphanet; 178469; Autosomal dominant non-syndromic intellectual disability. DR VEuPathDB; HostDB:ENSG00000058404; -. DR eggNOG; KOG0033; Eukaryota. DR GeneTree; ENSGT00940000158973; -. DR HOGENOM; CLU_000288_71_0_1; -. DR InParanoid; Q13554; -. DR OMA; MEFHRFY; -. DR OrthoDB; 336747at2759; -. DR PAN-GO; Q13554; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q13554; -. DR BRENDA; 2.7.11.17; 2681. DR PathwayCommons; Q13554; -. DR Reactome; R-HSA-111932; CaMK IV-mediated phosphorylation of CREB. DR Reactome; R-HSA-3371571; HSF1-dependent transactivation. DR Reactome; R-HSA-399719; Trafficking of AMPA receptors. DR Reactome; R-HSA-438066; Unblocking of NMDA receptors, glutamate binding and activation. DR Reactome; R-HSA-442729; CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde. DR Reactome; R-HSA-442982; Ras activation upon Ca2+ influx through NMDA receptor. DR Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation. DR Reactome; R-HSA-5578775; Ion homeostasis. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-877300; Interferon gamma signaling. DR Reactome; R-HSA-9022692; Regulation of MECP2 expression and activity. DR Reactome; R-HSA-936837; Ion transport by P-type ATPases. DR Reactome; R-HSA-9609736; Assembly and cell surface presentation of NMDA receptors. DR Reactome; R-HSA-9617324; Negative regulation of NMDA receptor-mediated neuronal transmission. DR Reactome; R-HSA-9620244; Long-term potentiation. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR SignaLink; Q13554; -. DR SIGNOR; Q13554; -. DR Agora; ENSG00000058404; -. DR BioGRID-ORCS; 816; 18 hits in 1181 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; CAMK2B; human. DR EvolutionaryTrace; Q13554; -. DR GeneWiki; CAMK2B; -. DR GenomeRNAi; 816; -. DR Pharos; Q13554; Tchem. DR PRO; PR:Q13554; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; Q13554; protein. DR Bgee; ENSG00000058404; Expressed in cerebellar cortex and 171 other cell types or tissues. DR ExpressionAtlas; Q13554; baseline and differential. DR GO; GO:0005954; C:calcium- and calmodulin-dependent protein kinase complex; IDA:BHF-UCL. DR GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome. DR GO; GO:0043005; C:neuron projection; IBA:GO_Central. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0014069; C:postsynaptic density; IBA:GO_Central. DR GO; GO:0033017; C:sarcoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0003779; F:actin binding; IEA:UniProtKB-KW. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004683; F:calcium/calmodulin-dependent protein kinase activity; IDA:UniProtKB. DR GO; GO:0005516; F:calmodulin binding; IBA:GO_Central. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0060291; P:long-term synaptic potentiation; TAS:BHF-UCL. DR GO; GO:0007399; P:nervous system development; IEA:UniProtKB-KW. DR GO; GO:0061003; P:positive regulation of dendritic spine morphogenesis; ISS:UniProtKB. DR GO; GO:0010976; P:positive regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0090129; P:positive regulation of synapse maturation; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0051924; P:regulation of calcium ion transport; TAS:UniProtKB. DR GO; GO:0060998; P:regulation of dendritic spine development; TAS:UniProtKB. DR GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; TAS:UniProtKB. DR GO; GO:2001222; P:regulation of neuron migration; IMP:UniProtKB. DR GO; GO:0048168; P:regulation of neuronal synaptic plasticity; IBA:GO_Central. DR GO; GO:1903076; P:regulation of protein localization to plasma membrane; IBA:GO_Central. DR GO; GO:0014733; P:regulation of skeletal muscle adaptation; TAS:UniProtKB. DR GO; GO:0051823; P:regulation of synapse structural plasticity; TAS:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd14086; STKc_CaMKII; 1. DR FunFam; 1.10.510.10:FF:000001; Calcium/calmodulin-dependent protein kinase type II subunit delta; 1. DR FunFam; 3.30.200.20:FF:000002; Calcium/calmodulin-dependent protein kinase type II subunit delta isoform 2; 1. DR FunFam; 3.10.450.50:FF:000001; calcium/calmodulin-dependent protein kinase type II subunit gamma isoform X1; 1. DR Gene3D; 3.10.450.50; -; 1. DR Gene3D; 6.10.140.620; -; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR013543; Ca/CaM-dep_prot_kinase-assoc. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR032710; NTF2-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24347; SERINE/THREONINE-PROTEIN KINASE; 1. DR Pfam; PF08332; CaMKII_AD; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF54427; NTF2-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Actin-binding; Alternative splicing; ATP-binding; KW Calmodulin-binding; Cytoplasm; Cytoskeleton; Developmental protein; KW Differentiation; Intellectual disability; Kinase; Membrane; Neurogenesis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Sarcoplasmic reticulum; KW Serine/threonine-protein kinase; Synapse; Transferase. FT CHAIN 1..666 FT /note="Calcium/calmodulin-dependent protein kinase type II FT subunit beta" FT /id="PRO_0000086096" FT DOMAIN 14..272 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 283..292 FT /note="Autoinhibitory domain" FT /evidence="ECO:0000250" FT REGION 291..301 FT /note="Calmodulin-binding" FT REGION 349..534 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 354..369 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 432..447 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 479..491 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 514..531 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 136 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 20..28 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 43 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 17 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:P28652" FT MOD_RES 287 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16690701" FT MOD_RES 306 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 307 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 367 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P08413" FT MOD_RES 394 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P28652" FT MOD_RES 397 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P08413" FT MOD_RES 400 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P28652" FT MOD_RES 401 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT VAR_SEQ 316..340 FT /note="Missing (in isoform 8)" FT /evidence="ECO:0000305" FT /id="VSP_041219" FT VAR_SEQ 316 FT /note="V -> A (in isoform 2, isoform 3, isoform 5 and FT isoform 7)" FT /evidence="ECO:0000303|PubMed:10819240, FT ECO:0000303|PubMed:10858498, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:9060999, FT ECO:0000303|Ref.3" FT /id="VSP_004770" FT VAR_SEQ 317..533 FT /note="Missing (in isoform 7)" FT /evidence="ECO:0000303|PubMed:10858498" FT /id="VSP_004772" FT VAR_SEQ 317..340 FT /note="Missing (in isoform 2, isoform 3 and isoform 5)" FT /evidence="ECO:0000303|PubMed:10819240, FT ECO:0000303|PubMed:10858498, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:9060999, FT ECO:0000303|Ref.3" FT /id="VSP_004771" FT VAR_SEQ 354..392 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:10819240" FT /id="VSP_004774" FT VAR_SEQ 354..377 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:10858498" FT /id="VSP_004773" FT VAR_SEQ 379..393 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10819240, FT ECO:0000303|PubMed:10858498, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:9060999" FT /id="VSP_004775" FT VAR_SEQ 410..533 FT /note="Missing (in isoform 1, isoform 2, isoform 3, isoform FT 5, isoform 6 and isoform 8)" FT /evidence="ECO:0000303|PubMed:10819240, FT ECO:0000303|PubMed:10858498, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:9060999, FT ECO:0000303|Ref.3" FT /id="VSP_004776" FT VAR_SEQ 559..584 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:10858498" FT /id="VSP_004777" FT VARIANT 29..666 FT /note="Missing (in MRD54)" FT /evidence="ECO:0000269|PubMed:29100089" FT /id="VAR_080588" FT VARIANT 110 FT /note="E -> K (in MRD54; decreased protein abundance; FT increased autophosphorylation; decreased neuronal FT migration; dbSNP:rs1554402092)" FT /evidence="ECO:0000269|PubMed:29100089" FT /id="VAR_080589" FT VARIANT 139 FT /note="P -> L (in MRD54; decreased protein abundance; FT increased autophosphorylation; decreased neuronal FT migration; dbSNP:rs1554389088)" FT /evidence="ECO:0000269|PubMed:29100089" FT /id="VAR_080590" FT VARIANT 213 FT /note="P -> L (in MRD54; dbSNP:rs1554387293)" FT /evidence="ECO:0000269|PubMed:29560374" FT /id="VAR_081162" FT VARIANT 237 FT /note="E -> K (in MRD54; no effect on protein abundance; FT increased autophosphorylation; decreased neuronal FT migration; dbSNP:rs1554386687)" FT /evidence="ECO:0000269|PubMed:29100089" FT /id="VAR_080591" FT VARIANT 284 FT /note="R -> S (in MRD54; dbSNP:rs1554385203)" FT /evidence="ECO:0000269|PubMed:29560374" FT /id="VAR_081163" FT VARIANT 301 FT /note="K -> E (in MRD54; no effect on protein abundance; FT loss of autophosphorylation; changed function in neuronal FT migration; dbSNP:rs1554385111)" FT /evidence="ECO:0000269|PubMed:29100089" FT /id="VAR_080592" FT VARIANT 489 FT /note="P -> L (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs555460132)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045581" FT VARIANT 510 FT /note="E -> K (in dbSNP:rs35452727)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045582" FT CONFLICT 68 FT /note="L -> V (in Ref. 3; AAD03744/AAD03743)" FT /evidence="ECO:0000305" FT CONFLICT 535 FT /note="K -> N (in Ref. 8; AAB16863)" FT /evidence="ECO:0000305" FT STRAND 14..19 FT /evidence="ECO:0007829|PDB:3BHH" FT STRAND 27..33 FT /evidence="ECO:0007829|PDB:3BHH" FT TURN 34..36 FT /evidence="ECO:0007829|PDB:3BHH" FT STRAND 39..46 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 52..67 FT /evidence="ECO:0007829|PDB:3BHH" FT STRAND 76..81 FT /evidence="ECO:0007829|PDB:3BHH" FT STRAND 83..91 FT /evidence="ECO:0007829|PDB:3BHH" FT STRAND 95..97 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 98..102 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 110..129 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 139..141 FT /evidence="ECO:0007829|PDB:3BHH" FT STRAND 142..145 FT /evidence="ECO:0007829|PDB:3BHH" FT STRAND 153..155 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 178..180 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 183..186 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 194..209 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 219..228 FT /evidence="ECO:0007829|PDB:3BHH" FT TURN 235..238 FT /evidence="ECO:0007829|PDB:3BHH" FT STRAND 239..241 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 243..252 FT /evidence="ECO:0007829|PDB:3BHH" FT TURN 257..259 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 263..266 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 270..273 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 275..278 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 285..298 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 534..551 FT /evidence="ECO:0007829|PDB:7URY" FT HELIX 554..560 FT /evidence="ECO:0007829|PDB:7URY" FT STRAND 561..568 FT /evidence="ECO:0007829|PDB:7URY" FT HELIX 570..572 FT /evidence="ECO:0007829|PDB:7URY" FT STRAND 577..580 FT /evidence="ECO:0007829|PDB:7URY" FT HELIX 581..588 FT /evidence="ECO:0007829|PDB:7URY" FT HELIX 592..594 FT /evidence="ECO:0007829|PDB:7URY" FT STRAND 598..609 FT /evidence="ECO:0007829|PDB:7URY" FT STRAND 611..626 FT /evidence="ECO:0007829|PDB:7URY" FT STRAND 632..646 FT /evidence="ECO:0007829|PDB:7URY" FT STRAND 649..659 FT /evidence="ECO:0007829|PDB:7URY" FT CONFLICT Q13554-3:316 FT /note="A -> V (in Ref. 1; AAD42036)" FT /evidence="ECO:0000305" SQ SEQUENCE 666 AA; 72678 MW; 8CACFC3E392C3857 CRC64; MATTVTCTRF TDEYQLYEDI GKGAFSVVRR CVKLCTGHEY AAKIINTKKL SARDHQKLER EARICRLLKH SNIVRLHDSI SEEGFHYLVF DLVTGGELFE DIVAREYYSE ADASHCIQQI LEAVLHCHQM GVVHRDLKPE NLLLASKCKG AAVKLADFGL AIEVQGDQQA WFGFAGTPGY LSPEVLRKEA YGKPVDIWAC GVILYILLVG YPPFWDEDQH KLYQQIKAGA YDFPSPEWDT VTPEAKNLIN QMLTINPAKR ITAHEALKHP WVCQRSTVAS MMHRQETVEC LKKFNARRKL KGAILTTMLA TRNFSVGRQT TAPATMSTAA SGTTMGLVEQ AKSLLNKKAD GVKPQTNSTK NSAAATSPKG TLPPAALEPQ TTVIHNPVDG IKESSDSANT TIEDEDAKAP RVPDILSSVR RGSGAPEAEG PLPCPSPAPF SPLPAPSPRI SDILNSVRRG SGTPEAEGPL SAGPPPCLSP ALLGPLSSPS PRISDILNSV RRGSGTPEAE GPSPVGPPPC PSPTIPGPLP TPSRKQEIIK TTEQLIEAVN NGDFEAYAKI CDPGLTSFEP EALGNLVEGM DFHRFYFENL LAKNSKPIHT TILNPHVHVI GEDAACIAYI RLTQYIDGQG RPRTSQSEET RVWHRRDGKW QNVHFHCSGA PVAPLQ // ID KCC4_HUMAN Reviewed; 473 AA. AC Q16566; D3DSZ7; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 215. DE RecName: Full=Calcium/calmodulin-dependent protein kinase type IV; DE Short=CaMK IV; DE EC=2.7.11.17; DE AltName: Full=CaM kinase-GR; GN Name=CAMK4; Synonyms=CAMK, CAMK-GR, CAMKIV; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=8089075; DOI=10.1093/oxfordjournals.jbchem.a124387; RA Kitani T., Okuno S., Fujisawa H.; RT "cDNA cloning and expression of human calmodulin-dependent protein kinase RT IV."; RL J. Biochem. 115:637-640(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Cerebellum, and Thymus; RX PubMed=8194751; DOI=10.1016/0378-1119(94)90260-7; RA Bland M.M., Monroe R.S., Ohmstede C.A.; RT "The cDNA sequence and characterization of the Ca2+/calmodulin-dependent RT protein kinase-Gr from human brain and thymus."; RL Gene 142:191-197(1994). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Blood; RX PubMed=8107230; DOI=10.1128/jvi.68.3.1697-1705.1994; RA Mosialos G., Hanissian S.H., Jawahar S., Vara L., Kieff E., Chatila T.A.; RT "A Ca2+/calmodulin-dependent protein kinase, CaM kinase-Gr, expressed after RT transformation of primary human B lymphocytes by Epstein-Barr virus (EBV) RT is induced by the EBV oncogene LMP1."; RL J. Virol. 68:1697-1705(1994). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain, and Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP TISSUE SPECIFICITY. RX PubMed=8397199; DOI=10.1016/s0021-9258(20)80693-0; RA Hanissian S.H., Frangakis M., Bland M.M., Jawahar S., Chatila T.A.; RT "Expression of a Ca2+/calmodulin-dependent protein kinase, CaM kinase-Gr, RT in human T lymphocytes. Regulation of kinase activity by T cell receptor RT signaling."; RL J. Biol. Chem. 268:20055-20063(1993). RN [7] RP FUNCTION, TISSUE SPECIFICITY, DOMAIN AUTOINHIBITORY, AND MUTAGENESIS OF RP 309-HIS--THR-312 AND 320-PHE-ASN-321. RX PubMed=7961813; DOI=10.1016/s0021-9258(19)61953-8; RA Tokumitsu H., Brickey D.A., Glod J., Hidaka H., Sikela J., Soderling T.R.; RT "Activation mechanisms for Ca2+/calmodulin-dependent protein kinase IV. RT Identification of a brain CaM-kinase IV kinase."; RL J. Biol. Chem. 269:28640-28647(1994). RN [8] RP FUNCTION IN PHOSPHORYLATION OF CREB1, AND SUBCELLULAR LOCATION. RX PubMed=8065343; DOI=10.1128/mcb.14.9.6107-6116.1994; RA Matthews R.P., Guthrie C.R., Wailes L.M., Zhao X., Means A.R., RA McKnight G.S.; RT "Calcium/calmodulin-dependent protein kinase types II and IV differentially RT regulate CREB-dependent gene expression."; RL Mol. Cell. Biol. 14:6107-6116(1994). RN [9] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=8980227; DOI=10.1016/s0092-8674(00)81816-4; RA Bito H., Deisseroth K., Tsien R.W.; RT "CREB phosphorylation and dephosphorylation: a Ca(2+)- and stimulus RT duration-dependent switch for hippocampal gene expression."; RL Cell 87:1203-1214(1996). RN [10] RP ACTIVITY REGULATION, PHOSPHORYLATION AT SER-12; SER-13 AND THR-200, AND RP MUTAGENESIS OF SER-12 AND SER-13. RX PubMed=8702940; DOI=10.1074/jbc.271.35.21542; RA Chatila T., Anderson K.A., Ho N., Means A.R.; RT "A unique phosphorylation-dependent mechanism for the activation of RT Ca2+/calmodulin-dependent protein kinase type IV/GR."; RL J. Biol. Chem. 271:21542-21548(1996). RN [11] RP FUNCTION IN PHOSPHORYLATION OF ELK1; JUN AND ATF2, AND MUTAGENESIS OF RP THR-200. RX PubMed=8855261; DOI=10.1073/pnas.93.20.10803; RA Enslen H., Tokumitsu H., Stork P.J., Davis R.J., Soderling T.R.; RT "Regulation of mitogen-activated protein kinases by a calcium/calmodulin- RT dependent protein kinase cascade."; RL Proc. Natl. Acad. Sci. U.S.A. 93:10803-10808(1996). RN [12] RP FUNCTION IN PHOSPHORYLATION OF STMN1. RX PubMed=9154845; DOI=10.1128/mcb.17.6.3459; RA Melander Gradin H., Marklund U., Larsson N., Chatila T.A., Gullberg M.; RT "Regulation of microtubule dynamics by Ca2+/calmodulin-dependent kinase RT IV/Gr-dependent phosphorylation of oncoprotein 18."; RL Mol. Cell. Biol. 17:3459-3467(1997). RN [13] RP FUNCTION IN PHOSPHORYLATION OF MEF2D, AND MUTAGENESIS OF LYS-75. RX PubMed=10617605; DOI=10.1074/jbc.275.1.197; RA Blaeser F., Ho N., Prywes R., Chatila T.A.; RT "Ca(2+)-dependent gene expression mediated by MEF2 transcription factors."; RL J. Biol. Chem. 275:197-209(2000). RN [14] RP TISSUE SPECIFICITY. RX PubMed=12065094; DOI=10.1016/s0304-3835(02)00107-6; RA Takai N., Miyazaki T., Nishida M., Nasu K., Miyakawa I.; RT "Ca(2+)/calmodulin-dependent protein kinase IV expression in epithelial RT ovarian cancer."; RL Cancer Lett. 183:185-193(2002). RN [15] RP ACTIVITY REGULATION, INTERACTION WITH PROTEIN PHOSPHATASE 2A, RP PHOSPHORYLATION AT THR-200, AND MUTAGENESIS OF 320-PHE-ASN-321. RX PubMed=15143065; DOI=10.1074/jbc.m404523200; RA Anderson K.A., Noeldner P.K., Reece K., Wadzinski B.E., Means A.R.; RT "Regulation and function of the calcium/calmodulin-dependent protein kinase RT IV/protein serine/threonine phosphatase 2A signaling complex."; RL J. Biol. Chem. 279:31708-31716(2004). RN [16] RP ACTIVITY REGULATION, AND PROTEIN PHOSPHATASE 2A BINDING DOMAIN. RX PubMed=15769749; DOI=10.1074/jbc.m500067200; RA Chow F.A., Anderson K.A., Noeldner P.K., Means A.R.; RT "The autonomous activity of calcium/calmodulin-dependent protein kinase IV RT is required for its role in transcription."; RL J. Biol. Chem. 280:20530-20538(2005). RN [17] RP FUNCTION IN DENDRITIC CELLS LIFESPAN REGULATION, AND DEVELOPMENTAL STAGE. RX PubMed=17909078; DOI=10.1182/blood-2007-05-091173; RA Illario M., Giardino-Torchia M.L., Sankar U., Ribar T.J., Galgani M., RA Vitiello L., Masci A.M., Bertani F.R., Ciaglia E., Astone D., Maulucci G., RA Cavallo A., Vitale M., Cimini V., Pastore L., Means A.R., Rossi G., RA Racioppi L.; RT "Calmodulin-dependent kinase IV links Toll-like receptor 4 signaling with RT survival pathway of activated dendritic cells."; RL Blood 111:723-731(2008). RN [18] RP FUNCTION. RX PubMed=18829949; DOI=10.1523/jneurosci.2625-08.2008; RA Fukushima H., Maeda R., Suzuki R., Suzuki A., Nomoto M., Toyoda H., RA Wu L.J., Xu H., Zhao M.G., Ueda K., Kitamoto A., Mamiya N., Yoshida T., RA Homma S., Masushige S., Zhuo M., Kida S.; RT "Upregulation of calcium/calmodulin-dependent protein kinase IV improves RT memory formation and rescues memory loss with aging."; RL J. Neurosci. 28:9910-9919(2008). RN [19] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [20] RP GLYCOSYLATION AT THR-57 SER-58; SER-137; SER-189; SER-344; SER-345 AND RP SER-356, PHOSPHORYLATION AT THR-200, IDENTIFICATION BY MASS SPECTROMETRY, RP AND MUTAGENESIS OF 57-THR-SER-58 AND SER-189. RX PubMed=19506079; DOI=10.1074/jbc.m109.007310; RA Dias W.B., Cheung W.D., Wang Z., Hart G.W.; RT "Regulation of calcium/calmodulin-dependent kinase IV by O-GlcNAc RT modification."; RL J. Biol. Chem. 284:21327-21337(2009). RN [21] RP REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION. RX PubMed=9920409; DOI=10.1016/s0167-4889(98)00142-6; RA Krebs J.; RT "Calmodulin-dependent protein kinase IV: regulation of function and RT expression."; RL Biochim. Biophys. Acta 1448:183-189(1998). RN [22] RP REVIEW ON FUNCTION IN NEURONAL PLASTICITY. RX PubMed=18817731; DOI=10.1016/j.neuron.2008.08.021; RA Wayman G.A., Lee Y.S., Tokumitsu H., Silva A.J., Silva A., Soderling T.R.; RT "Calmodulin-kinases: modulators of neuronal development and plasticity."; RL Neuron 59:914-931(2008). RN [23] RP REVIEW ON INVOLVEMENT IN IMMUNE AND INFLAMMATORY RESPONSE. RX PubMed=18930438; DOI=10.1016/j.it.2008.08.005; RA Racioppi L., Means A.R.; RT "Calcium/calmodulin-dependent kinase IV in immune and inflammatory RT responses: novel routes for an ancient traveller."; RL Trends Immunol. 29:600-607(2008). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-360, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [27] RP X-RAY CRYSTALLOGRAPHY (2.17 ANGSTROMS) OF 15-340 IN COMPLEX WITH INHIBITOR. RA Muniz J.R.C., Rellos P., Gileadi O., Fedorov O., Filippakopoulos P., RA Salah E., Pike A., Phillips C., Niesen F., Shrestha L., Burgess-Brown N., RA Bullock A., Berridge G., Vondelft F., Edwards A.M., Bountra C., RA Arrowsmith C.H., Weigelt J., Knapp S.; RT "Crystal structure of human CAMK4 in complex with 4-amino(sulfamoyl- RT phenylamino)-triazole-carbothioic acid (2,6-difluoro-phenyl)-amide)."; RL Submitted (NOV-2008) to the PDB data bank. RN [28] RP VARIANTS [LARGE SCALE ANALYSIS] GLY-150; ASN-178; ARG-465 AND MET-469. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium/calmodulin-dependent protein kinase that operates in CC the calcium-triggered CaMKK-CaMK4 signaling cascade and regulates, CC mainly by phosphorylation, the activity of several transcription CC activators, such as CREB1, MEF2D, JUN and RORA, which play pivotal CC roles in immune response, inflammation, and memory consolidation. In CC the thymus, regulates the CD4(+)/CD8(+) double positive thymocytes CC selection threshold during T-cell ontogeny. In CD4 memory T-cells, is CC required to link T-cell antigen receptor (TCR) signaling to the CC production of IL2, IFNG and IL4 (through the regulation of CREB and CC MEF2). Regulates the differentiation and survival phases of osteoclasts CC and dendritic cells (DCs). Mediates DCs survival by linking TLR4 and CC the regulation of temporal expression of BCL2. Phosphorylates the CC transcription activator CREB1 on 'Ser-133' in hippocampal neuron nuclei CC and contribute to memory consolidation and long term potentiation (LTP) CC in the hippocampus. Can activate the MAP kinases MAPK1/ERK2, MAPK8/JNK1 CC and MAPK14/p38 and stimulate transcription through the phosphorylation CC of ELK1 and ATF2. Can also phosphorylate in vitro CREBBP, PRM2, MEF2A CC and STMN1/OP18. {ECO:0000269|PubMed:10617605, CC ECO:0000269|PubMed:17909078, ECO:0000269|PubMed:18829949, CC ECO:0000269|PubMed:7961813, ECO:0000269|PubMed:8065343, CC ECO:0000269|PubMed:8855261, ECO:0000269|PubMed:8980227, CC ECO:0000269|PubMed:9154845}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.17; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.17; CC -!- ACTIVITY REGULATION: Activated by Ca(2+)/calmodulin. Binding of CC calmodulin results in conformational change that relieves intrasteric CC autoinhibition and allows phosphorylation of Thr-200 within the CC activation loop by CaMKK1 or CaMKK2. Phosphorylation of Thr-200 results CC in a 10-20-fold increase in total activity to generate CC Ca(2+)/calmodulin-independent activity. Autophosphorylation of the N- CC terminus Ser-12 and Ser-13 is required for full activation. Inactivated CC by protein phosphatase 2A (PPP2CA/PPP2CB) which dephosphorylates Thr- CC 200, thereby terminating autonomous activity and helping to maintain CC the enzyme in its autoinhibited state. {ECO:0000269|PubMed:15143065, CC ECO:0000269|PubMed:15769749, ECO:0000269|PubMed:8702940}. CC -!- SUBUNIT: Monomer (By similarity). Interacts with protein phosphatase 2A CC (PPP2CA/PPP2CB); the interaction is mutually exclusive with binding to CC Ca(2+)/calmodulin. {ECO:0000250, ECO:0000269|PubMed:15143065, CC ECO:0000269|Ref.27}. CC -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Localized in hippocampal CC neuron nuclei. In spermatids, associated with chromatin and nuclear CC matrix (By similarity). {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Expressed in brain, thymus, CD4 T-cells, testis and CC epithelial ovarian cancer tissue. {ECO:0000269|PubMed:12065094, CC ECO:0000269|PubMed:7961813, ECO:0000269|PubMed:8397199}. CC -!- DEVELOPMENTAL STAGE: Expressed during differentiation of monocyte- CC derived dendritic cells (at protein level). CC {ECO:0000269|PubMed:17909078}. CC -!- DOMAIN: The autoinhibitory domain overlaps with the calmodulin binding CC region and interacts in the inactive folded state with the catalytic CC domain as a pseudosubstrate. {ECO:0000269|PubMed:7961813}. CC -!- PTM: Phosphorylated by CaMKK1 and CaMKK2 on Thr-200. Dephosphorylated CC by protein phosphatase 2A. Autophosphorylated on Ser-12 and Ser-13. CC {ECO:0000269|PubMed:15143065, ECO:0000269|PubMed:19506079, CC ECO:0000269|PubMed:8702940}. CC -!- PTM: Glycosylation at Ser-189 modulates the phosphorylation of CaMK4 at CC Thr-200 and negatively regulates its activity toward CREB1 in basal CC conditions and during early inomycin stimulation. CC {ECO:0000269|PubMed:15143065, ECO:0000269|PubMed:19506079, CC ECO:0000269|PubMed:8702940}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. CaMK subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH16695.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D30742; BAA06403.1; -; mRNA. DR EMBL; L17000; AAA35639.1; -; mRNA. DR EMBL; L24959; AAA18251.1; -; mRNA. DR EMBL; CH471086; EAW49033.1; -; Genomic_DNA. DR EMBL; CH471086; EAW49034.1; -; Genomic_DNA. DR EMBL; BC016695; AAH16695.2; ALT_INIT; mRNA. DR EMBL; BC025687; AAH25687.1; -; mRNA. DR CCDS; CCDS4103.1; -. DR PIR; A53036; A53036. DR RefSeq; NP_001310303.1; NM_001323374.2. DR RefSeq; NP_001310304.1; NM_001323375.2. DR RefSeq; NP_001735.1; NM_001744.6. DR PDB; 2W4O; X-ray; 2.17 A; A=15-340. DR PDBsum; 2W4O; -. DR AlphaFoldDB; Q16566; -. DR SMR; Q16566; -. DR BioGRID; 107264; 53. DR CORUM; Q16566; -. DR DIP; DIP-41997N; -. DR FunCoup; Q16566; 1741. DR IntAct; Q16566; 42. DR STRING; 9606.ENSP00000282356; -. DR BindingDB; Q16566; -. DR ChEMBL; CHEMBL2494; -. DR DrugBank; DB07676; 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one. DR DrugBank; DB07664; K-00546. DR DrugCentral; Q16566; -. DR GlyCosmos; Q16566; 7 sites, 1 glycan. DR GlyGen; Q16566; 7 sites, 1 O-linked glycan (7 sites). DR iPTMnet; Q16566; -. DR MetOSite; Q16566; -. DR PhosphoSitePlus; Q16566; -. DR BioMuta; CAMK4; -. DR DMDM; 2499586; -. DR jPOST; Q16566; -. DR MassIVE; Q16566; -. DR PaxDb; 9606-ENSP00000282356; -. DR PeptideAtlas; Q16566; -. DR ProteomicsDB; 60921; -. DR Pumba; Q16566; -. DR Antibodypedia; 2084; 637 antibodies from 43 providers. DR DNASU; 814; -. DR Ensembl; ENST00000282356.9; ENSP00000282356.4; ENSG00000152495.12. DR Ensembl; ENST00000512453.5; ENSP00000422634.1; ENSG00000152495.12. DR GeneID; 814; -. DR KEGG; hsa:814; -. DR MANE-Select; ENST00000282356.9; ENSP00000282356.4; NM_001744.6; NP_001735.1. DR UCSC; uc003kpf.4; human. DR AGR; HGNC:1464; -. DR ClinPGx; PA26050; -. DR CTD; 814; -. DR DisGeNET; 814; -. DR GeneCards; CAMK4; -. DR HGNC; HGNC:1464; CAMK4. DR HPA; ENSG00000152495; Group enriched (brain, lymphoid tissue). DR MalaCards; CAMK4; -. DR MIM; 114080; gene. DR OpenTargets; ENSG00000152495; -. DR VEuPathDB; HostDB:ENSG00000152495; -. DR eggNOG; KOG0032; Eukaryota. DR GeneTree; ENSGT00940000160006; -. DR HOGENOM; CLU_000288_63_0_1; -. DR InParanoid; Q16566; -. DR OMA; VVPDYWI; -. DR OrthoDB; 40902at2759; -. DR PAN-GO; Q16566; 8 GO annotations based on evolutionary models. DR PhylomeDB; Q16566; -. DR BRENDA; 2.7.11.17; 2681. DR PathwayCommons; Q16566; -. DR Reactome; R-HSA-111932; CaMK IV-mediated phosphorylation of CREB. DR Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis. DR Reactome; R-HSA-442729; CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde. DR Reactome; R-HSA-9022535; Loss of phosphorylation of MECP2 at T308. DR Reactome; R-HSA-9022692; Regulation of MECP2 expression and activity. DR Reactome; R-HSA-9617324; Negative regulation of NMDA receptor-mediated neuronal transmission. DR SignaLink; Q16566; -. DR SIGNOR; Q16566; -. DR Agora; ENSG00000152495; -. DR BioGRID-ORCS; 814; 8 hits in 1186 CRISPR screens. DR ChiTaRS; CAMK4; human. DR EvolutionaryTrace; Q16566; -. DR GeneWiki; CAMK4; -. DR GenomeRNAi; 814; -. DR Pharos; Q16566; Tbio. DR PRO; PR:Q16566; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; Q16566; protein. DR Bgee; ENSG00000152495; Expressed in cerebellar vermis and 140 other cell types or tissues. DR ExpressionAtlas; Q16566; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0001650; C:fibrillar center; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0009931; F:calcium-dependent protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0004683; F:calcium/calmodulin-dependent protein kinase activity; IDA:CACAO. DR GO; GO:0005516; F:calmodulin binding; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW. DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0007616; P:long-term memory; IGI:UniProtKB. DR GO; GO:0043011; P:myeloid dendritic cell differentiation; IMP:UniProtKB. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0045670; P:regulation of osteoclast differentiation; TAS:UniProtKB. DR GO; GO:0033081; P:regulation of T cell differentiation in thymus; TAS:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd14085; STKc_CaMKIV; 1. DR FunFam; 1.10.510.10:FF:000255; Calcium/calmodulin-dependent protein kinase type IV; 1. DR FunFam; 3.30.200.20:FF:000279; Calcium/calmodulin-dependent protein kinase type IV; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24347; SERINE/THREONINE-PROTEIN KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Adaptive immunity; ATP-binding; Calcium; Calmodulin-binding; KW Cytoplasm; Glycoprotein; Immunity; Inflammatory response; Kinase; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase. FT CHAIN 1..473 FT /note="Calcium/calmodulin-dependent protein kinase type IV" FT /id="PRO_0000086106" FT DOMAIN 46..300 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 305..321 FT /note="Autoinhibitory domain" FT REGION 306..323 FT /note="PP2A-binding" FT REGION 322..341 FT /note="Calmodulin-binding" FT /evidence="ECO:0000255" FT REGION 341..368 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 445..473 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 341..350 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 164 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 52..60 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 75 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 12 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:8702940" FT MOD_RES 13 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:8702940" FT MOD_RES 200 FT /note="Phosphothreonine; by CaMKK1 and CaMKK2" FT /evidence="ECO:0000269|PubMed:15143065, FT ECO:0000269|PubMed:19506079, ECO:0000269|PubMed:8702940" FT MOD_RES 336 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:P13234" FT MOD_RES 341 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P13234" FT MOD_RES 360 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT CARBOHYD 57 FT /note="O-linked (GlcNAc) threonine" FT /evidence="ECO:0000269|PubMed:19506079" FT CARBOHYD 58 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:19506079" FT CARBOHYD 137 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:19506079" FT CARBOHYD 189 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:19506079" FT CARBOHYD 344 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:19506079" FT CARBOHYD 345 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:19506079" FT CARBOHYD 356 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:19506079" FT VARIANT 150 FT /note="E -> G (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040604" FT VARIANT 178 FT /note="D -> N (in dbSNP:rs35548075)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040605" FT VARIANT 465 FT /note="Q -> R (in dbSNP:rs56360861)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040606" FT VARIANT 469 FT /note="I -> M (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs1239950009)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040607" FT MUTAGEN 12 FT /note="S->A: Loss of activity." FT /evidence="ECO:0000269|PubMed:8702940" FT MUTAGEN 13 FT /note="S->A: Loss of activity." FT /evidence="ECO:0000269|PubMed:8702940" FT MUTAGEN 57..58 FT /note="TS->AA: Loss of phosphorylation of CREB1." FT /evidence="ECO:0000269|PubMed:19506079" FT MUTAGEN 75 FT /note="K->E: Loss of activity; dominant negative form." FT /evidence="ECO:0000269|PubMed:10617605" FT MUTAGEN 189 FT /note="S->A: Increases phosphorylation of CREB1 2-fold. FT Decreases total O-linked glycosylation 2-fold. Increases FT ATP-binding affinity." FT /evidence="ECO:0000269|PubMed:19506079" FT MUTAGEN 200 FT /note="T->A: Loss of activation by CaMKK1 or CaMKK2." FT /evidence="ECO:0000269|PubMed:8855261" FT MUTAGEN 309..312 FT /note="HMDT->DEDD: Fully active Ca2+/CaM-independent FT kinase; when associated with 320-A-A-321." FT /evidence="ECO:0000269|PubMed:7961813" FT MUTAGEN 320..321 FT /note="FN->DD: Fully active Ca2+/CaM-independent kinase; FT when associated with 309-A--A-312. Loss of interaction with FT PPP2CA/PPP2CB." FT /evidence="ECO:0000269|PubMed:15143065, FT ECO:0000269|PubMed:7961813" FT STRAND 36..38 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 42..44 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 46..54 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 56..65 FT /evidence="ECO:0007829|PDB:2W4O" FT TURN 66..68 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 71..78 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 91..95 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 104..109 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 111..118 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 126..130 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 138..157 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 167..169 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 170..176 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 181..183 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 205..207 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 210..213 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 221..236 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 247..255 FT /evidence="ECO:0007829|PDB:2W4O" FT TURN 263..268 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 271..278 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 285..287 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 291..296 FT /evidence="ECO:0007829|PDB:2W4O" FT TURN 298..301 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 311..335 FT /evidence="ECO:0007829|PDB:2W4O" SQ SEQUENCE 473 AA; 51926 MW; EFEE51E5612326DC CRC64; MLKVTVPSCS ASSCSSVTAS AAPGTASLVP DYWIDGSNRD ALSDFFEVES ELGRGATSIV YRCKQKGTQK PYALKVLKKT VDKKIVRTEI GVLLRLSHPN IIKLKEIFET PTEISLVLEL VTGGELFDRI VEKGYYSERD AADAVKQILE AVAYLHENGI VHRDLKPENL LYATPAPDAP LKIADFGLSK IVEHQVLMKT VCGTPGYCAP EILRGCAYGP EVDMWSVGII TYILLCGFEP FYDERGDQFM FRRILNCEYY FISPWWDEVS LNAKDLVRKL IVLDPKKRLT TFQALQHPWV TGKAANFVHM DTAQKKLQEF NARRKLKAAV KAVVASSRLG SASSSHGSIQ ESHKASRDPS PIQDGNEDMK AIPEGEKIQG DGAQAAVKGA QAELMKVQAL EKVKGADINA EEAPKMVPKA VEDGIKVADL ELEEGLAEEK LKTVEEAAAP REGQGSSAVG FEVPQQDVIL PEY // ID KKCC2_HUMAN Reviewed; 588 AA. AC Q96RR4; A8K7Q7; O94883; Q8IUG2; Q8IUG3; Q8N3I4; Q8WY03; Q8WY04; Q8WY05; AC Q8WY06; Q96RP1; Q96RP2; Q96RR3; Q9BWE9; Q9UER3; Q9UES2; Q9Y5N2; DT 07-DEC-2004, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2011, sequence version 2. DT 28-JAN-2026, entry version 201. DE RecName: Full=Calcium/calmodulin-dependent protein kinase kinase 2; DE Short=CaM-KK 2; DE Short=CaM-kinase kinase 2; DE Short=CaMKK 2; DE EC=2.7.11.17; DE AltName: Full=Calcium/calmodulin-dependent protein kinase kinase beta; DE Short=CaM-KK beta; DE Short=CaM-kinase kinase beta; DE Short=CaMKK beta; GN Name=CAMKK2; Synonyms=CAMKKB, KIAA0787; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1; 2; 3; 4; 5 AND 6), RP FUNCTION, AND VARIANT SER-85. RX PubMed=11395482; DOI=10.1074/jbc.m011720200; RA Hsu L.-S., Chen G.-D., Lee L.-S., Chi C.-W., Cheng J.-F., Chen J.-Y.; RT "Human Ca2+/calmodulin-dependent protein kinase kinase beta gene encodes RT multiple isoforms that display distinct kinase activity."; RL J. Biol. Chem. 276:31113-31123(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Brain cortex; RX PubMed=9822657; DOI=10.1074/jbc.273.48.31880; RA Anderson K.A., Means R.L., Huang Q.-H., Kemp B.E., Goldstein E.G., RA Selbert M.A., Edelman A.M., Fremeau R.T., Means A.R.; RT "Components of a calmodulin-dependent protein kinase cascade. Molecular RT cloning, functional characterization and cellular localization of RT Ca2+/calmodulin-dependent protein kinase kinase beta."; RL J. Biol. Chem. 273:31880-31889(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND FUNCTION IN PHOSPHORYLATION OF RP CAMK1D. RX PubMed=12935886; DOI=10.1016/s0014-5793(03)00817-2; RA Ishikawa Y., Tokumitsu H., Inuzuka H., Murata-Hori M., Hosoya H., RA Kobayashi R.; RT "Identification and characterization of novel components of a RT Ca2+/calmodulin-dependent protein kinase cascade in HeLa cells."; RL FEBS Lett. 550:57-63(2003). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 7), AND VARIANT SER-85. RC TISSUE=Brain; RX PubMed=9872452; DOI=10.1093/dnares/5.5.277; RA Nagase T., Ishikawa K., Suyama M., Kikuno R., Miyajima N., Tanaka A., RA Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XI. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 5:277-286(1998). RN [5] RP SEQUENCE REVISION. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Stomach; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16541075; DOI=10.1038/nature04569; RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y., RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C., RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K., RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D., RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R., RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E., RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N., RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N., RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R., RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S., RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H., RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P., RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G., RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E., RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S., RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J., RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A., RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M., RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I., RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A., RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y., RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A., RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F., RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L., RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G., RA Gibbs R.A.; RT "The finished DNA sequence of human chromosome 12."; RL Nature 440:346-351(2006). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 233-588 (ISOFORM 5), AND VARIANT SER-85. RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 117-588 (ISOFORM 2), FUNCTION IN RP PHOSPHORYLATION OF CAMK1, AND TISSUE SPECIFICITY. RX PubMed=9662074; DOI=10.1007/bf02258368; RA Hsu L.-S., Tsou A.-P., Chi C.-W., Lee C.-H., Chen J.-Y.; RT "Cloning, expression and chromosomal localization of human Ca2+/calmodulin- RT dependent protein kinase kinase."; RL J. Biomed. Sci. 5:141-149(1998). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 254-588 (ISOFORM 7). RC TISSUE=Amygdala; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 338-533 (ISOFORM 2). RA Barrow I.K.-P., Boguski M.S., Touchman J.W., Spencer F.; RT "Full-insert sequence of mapped XREF EST."; RL Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases. RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-495, PHOSPHORYLATION [LARGE RP SCALE ANALYSIS] AT SER-522 (ISOFORM 3), PHOSPHORYLATION [LARGE SCALE RP ANALYSIS] AT SER-479 (ISOFORM 5), AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [14] RP FUNCTION, SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, PHOSPHORYLATION BY RP PKA, AND INDUCTION OF ISOFORM 1. RX PubMed=21957496; DOI=10.4161/rna.8.6.16691; RA Cao W., Sohail M., Liu G., Koumbadinga G.A., Lobo V.G., Xie J.; RT "Differential effects of PKA-controlled CaMKK2 variants on neuronal RT differentiation."; RL RNA Biol. 8:1061-1072(2011). RN [15] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-114; SER-129; SER-495 AND RP SER-511, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-495, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [18] RP VARIANTS [LARGE SCALE ANALYSIS] ASN-10; SER-85; TYR-123; LEU-127; THR-182 RP AND HIS-492. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium/calmodulin-dependent protein kinase belonging to a CC proposed calcium-triggered signaling cascade involved in a number of CC cellular processes. Isoform 1, isoform 2 and isoform 3 phosphorylate CC CAMK1 and CAMK4. Isoform 3 phosphorylates CAMK1D. Isoform 4, isoform 5 CC and isoform 6 lacking part of the calmodulin-binding domain are CC inactive. Efficiently phosphorylates 5'-AMP-activated protein kinase CC (AMPK) trimer, including that consisting of PRKAA1, PRKAB1 and PRKAG1. CC This phosphorylation is stimulated in response to Ca(2+) signals (By CC similarity). Seems to be involved in hippocampal activation of CREB1 CC (By similarity). May play a role in neurite growth. Isoform 3 may CC promote neurite elongation, while isoform 1 may promoter neurite CC branching. {ECO:0000250, ECO:0000269|PubMed:11395482, CC ECO:0000269|PubMed:12935886, ECO:0000269|PubMed:21957496, CC ECO:0000269|PubMed:9662074}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.17; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.17; CC -!- ACTIVITY REGULATION: Activated by Ca(2+)/calmodulin. Binding of CC calmodulin may relieve intrasteric autoinhibition. Autophosphorylation CC does not alter activity or regulation by Ca(2+)/calmodulin. In part, CC activity is independent on Ca(2+)/calmodulin (By similarity). CC {ECO:0000250}. CC -!- SUBUNIT: Interacts with calmodulin. {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:21957496}. Cytoplasm CC {ECO:0000269|PubMed:21957496}. Cell projection, neuron projection CC {ECO:0000269|PubMed:21957496}. Note=Predominantly nuclear in CC unstimulated cells, relocalizes into cytoplasm and neurites after CC forskolin induction. {ECO:0000269|PubMed:21957496}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Name=1; Synonyms=Beta1, CAMKK2+E16; CC IsoId=Q96RR4-1; Sequence=Displayed; CC Name=2; Synonyms=Beta2; CC IsoId=Q96RR4-2; Sequence=VSP_012146, VSP_012147, VSP_012149; CC Name=3; Synonyms=Beta1delta16, CAMKK2-E16; CC IsoId=Q96RR4-3; Sequence=VSP_012143, VSP_012144, VSP_012145, CC VSP_012149; CC Name=4; Synonyms=Beta1delta14; CC IsoId=Q96RR4-4; Sequence=VSP_012142; CC Name=5; Synonyms=Beta1delta14/16, beta-3x; CC IsoId=Q96RR4-5; Sequence=VSP_012142, VSP_012143, VSP_012144, CC VSP_012145, VSP_012149; CC Name=6; Synonyms=Beta2delta14; CC IsoId=Q96RR4-6; Sequence=VSP_012142, VSP_012146, VSP_012147, CC VSP_012149; CC Name=7; CC IsoId=Q96RR4-7; Sequence=VSP_012148, VSP_012149; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed with higher levels in the CC brain. Intermediate levels are detected in spleen, prostate, thyroid CC and leukocytes. The lowest level is in lung. CC {ECO:0000269|PubMed:9662074}. CC -!- INDUCTION: [Isoform 1]: Up-regulated by PKA pathway. CC {ECO:0000269|PubMed:21957496}. CC -!- DOMAIN: The autoinhibitory domain overlaps with the calmodulin binding CC region and may be involved in intrasteric autoinhibition. CC -!- DOMAIN: The RP domain (arginine/proline-rich) is involved in the CC recognition of CAMKI and CAMK4 as substrates. {ECO:0000250}. CC -!- PTM: Autophosphorylated and phosphorylated by PKA. Each isoform may CC show a different pattern of phosphorylation. CC {ECO:0000269|PubMed:21957496}. CC -!- MISCELLANEOUS: [Isoform 1]: Major isoform. CC -!- MISCELLANEOUS: [Isoform 2]: Major isoform. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 5]: Inactive. Does not activate CAMK1 and CC CAMK4. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 6]: Inactive. Does not activate CAMK1 and CC CAMK4. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC72943.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAA34507.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAD38990.1; Type=Miscellaneous discrepancy; Note=Intron retention.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB081337; BAC19841.1; -; mRNA. DR EMBL; AF287630; AAK64600.1; -; mRNA. DR EMBL; AF287631; AAK64601.1; -; mRNA. DR EMBL; AF321385; AAL37215.1; -; mRNA. DR EMBL; AF321386; AAL37216.1; -; mRNA. DR EMBL; AF321387; AAL37217.1; -; mRNA. DR EMBL; AF321388; AAL37218.1; -; mRNA. DR EMBL; AF321401; AAK91830.1; -; Genomic_DNA. DR EMBL; AF321390; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321391; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321392; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321393; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321394; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321395; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321396; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321397; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321398; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321399; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321400; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321575; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321576; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321577; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321578; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321402; AAK91829.1; -; Genomic_DNA. DR EMBL; AF321390; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321391; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321392; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321393; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321394; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321395; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321396; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321397; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321398; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321399; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321400; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321575; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321576; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321577; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321578; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF140507; AAD31507.1; -; mRNA. DR EMBL; AB081336; BAC19840.1; -; mRNA. DR EMBL; AB018330; BAA34507.2; ALT_INIT; mRNA. DR EMBL; AK292072; BAF84761.1; -; mRNA. DR EMBL; AC069209; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC000318; AAH00318.2; -; mRNA. DR EMBL; BC026060; AAH26060.1; -; mRNA. DR EMBL; AF101264; AAD04566.1; -; mRNA. DR EMBL; AL834322; CAD38990.1; ALT_SEQ; mRNA. DR EMBL; AF091074; AAC72943.1; ALT_INIT; mRNA. DR CCDS; CCDS44999.1; -. [Q96RR4-2] DR CCDS; CCDS53837.1; -. [Q96RR4-6] DR CCDS; CCDS58283.1; -. [Q96RR4-7] DR CCDS; CCDS9216.1; -. [Q96RR4-1] DR CCDS; CCDS9217.1; -. [Q96RR4-4] DR CCDS; CCDS9218.1; -. [Q96RR4-3] DR CCDS; CCDS9219.1; -. [Q96RR4-5] DR PIR; JE0191; JE0191. DR RefSeq; NP_001257414.1; NM_001270485.2. [Q96RR4-1] DR RefSeq; NP_001257415.1; NM_001270486.1. [Q96RR4-7] DR RefSeq; NP_006540.3; NM_006549.3. [Q96RR4-1] DR RefSeq; NP_705719.2; NM_153499.2. [Q96RR4-3] DR RefSeq; NP_705720.1; NM_153500.2. [Q96RR4-5] DR RefSeq; NP_757363.1; NM_172214.3. [Q96RR4-2] DR RefSeq; NP_757364.1; NM_172215.3. [Q96RR4-6] DR RefSeq; NP_757365.1; NM_172216.2. [Q96RR4-4] DR RefSeq; NP_757380.1; NM_172226.3. [Q96RR4-3] DR RefSeq; XP_005253879.1; XM_005253822.3. [Q96RR4-4] DR RefSeq; XP_005253880.1; XM_005253823.1. [Q96RR4-2] DR RefSeq; XP_005253881.1; XM_005253824.3. [Q96RR4-5] DR RefSeq; XP_011536065.1; XM_011537763.1. [Q96RR4-7] DR RefSeq; XP_016874191.1; XM_017018702.3. [Q96RR4-7] DR RefSeq; XP_047284057.1; XM_047428101.1. [Q96RR4-1] DR RefSeq; XP_047284058.1; XM_047428102.1. [Q96RR4-7] DR RefSeq; XP_047284059.1; XM_047428103.1. [Q96RR4-3] DR RefSeq; XP_047284060.1; XM_047428104.1. [Q96RR4-2] DR RefSeq; XP_047284063.1; XM_047428107.1. [Q96RR4-5] DR RefSeq; XP_047284064.1; XM_047428108.1. [Q96RR4-6] DR RefSeq; XP_054226771.1; XM_054370796.1. [Q96RR4-1] DR RefSeq; XP_054226772.1; XM_054370797.1. [Q96RR4-7] DR RefSeq; XP_054226773.1; XM_054370798.1. [Q96RR4-7] DR RefSeq; XP_054226774.1; XM_054370799.1. [Q96RR4-7] DR RefSeq; XP_054226775.1; XM_054370800.1. [Q96RR4-4] DR RefSeq; XP_054226776.1; XM_054370801.1. [Q96RR4-3] DR RefSeq; XP_054226777.1; XM_054370802.1. [Q96RR4-2] DR RefSeq; XP_054226778.1; XM_054370803.1. [Q96RR4-2] DR RefSeq; XP_054226781.1; XM_054370806.1. [Q96RR4-5] DR RefSeq; XP_054226782.1; XM_054370807.1. [Q96RR4-5] DR RefSeq; XP_054226783.1; XM_054370808.1. [Q96RR4-6] DR PDB; 2ZV2; X-ray; 2.40 A; A=158-448. DR PDB; 5UY6; X-ray; 1.70 A; A=161-449. DR PDB; 5UYJ; X-ray; 1.60 A; A=161-449. DR PDB; 5VT1; X-ray; 1.90 A; A=161-449. DR PDB; 5YV8; X-ray; 1.93 A; A=158-448. DR PDB; 5YV9; X-ray; 2.53 A; A=158-448. DR PDB; 5YVA; X-ray; 2.57 A; A=158-448. DR PDB; 5YVB; X-ray; 2.02 A; A=158-448. DR PDB; 5YVC; X-ray; 2.02 A; A=158-448. DR PDB; 6BKU; X-ray; 2.00 A; A=162-449. DR PDB; 6BLE; X-ray; 1.90 A; A=161-449. DR PDB; 6BQL; X-ray; 2.00 A; A=161-449. DR PDB; 6BQP; X-ray; 1.95 A; A=161-449. DR PDB; 6BQQ; X-ray; 1.80 A; A=161-449. DR PDB; 6BRC; X-ray; 2.20 A; A/B=161-449. DR PDB; 6CMJ; X-ray; 2.40 A; A/B=149-465. DR PDB; 6EF5; X-ray; 2.44 A; Q/S=508-514. DR PDB; 6EWW; X-ray; 2.68 A; E/F/G/H=97-104. DR PDB; 6FEL; X-ray; 2.84 A; E/F/G/H=508-515. DR PDB; 6Y3O; X-ray; 1.50 A; P=97-104. DR PDB; 6Y4K; X-ray; 3.00 A; E/F=97-104. DR PDB; 6Y6B; X-ray; 3.08 A; C/D=97-104. DR PDB; 6Y8A; X-ray; 1.50 A; P=508-515. DR PDB; 8TUC; X-ray; 1.50 A; A=161-449. DR PDBsum; 2ZV2; -. DR PDBsum; 5UY6; -. DR PDBsum; 5UYJ; -. DR PDBsum; 5VT1; -. DR PDBsum; 5YV8; -. DR PDBsum; 5YV9; -. DR PDBsum; 5YVA; -. DR PDBsum; 5YVB; -. DR PDBsum; 5YVC; -. DR PDBsum; 6BKU; -. DR PDBsum; 6BLE; -. DR PDBsum; 6BQL; -. DR PDBsum; 6BQP; -. DR PDBsum; 6BQQ; -. DR PDBsum; 6BRC; -. DR PDBsum; 6CMJ; -. DR PDBsum; 6EF5; -. DR PDBsum; 6EWW; -. DR PDBsum; 6FEL; -. DR PDBsum; 6Y3O; -. DR PDBsum; 6Y4K; -. DR PDBsum; 6Y6B; -. DR PDBsum; 6Y8A; -. DR PDBsum; 8TUC; -. DR AlphaFoldDB; Q96RR4; -. DR SASBDB; Q96RR4; -. DR SMR; Q96RR4; -. DR BioGRID; 115889; 77. DR FunCoup; Q96RR4; 2743. DR IntAct; Q96RR4; 51. DR STRING; 9606.ENSP00000312741; -. DR BindingDB; Q96RR4; -. DR ChEMBL; CHEMBL5284; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q96RR4; -. DR GuidetoPHARMACOLOGY; 1957; -. DR GlyCosmos; Q96RR4; 1 site, 1 glycan. DR GlyGen; Q96RR4; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q96RR4; -. DR PhosphoSitePlus; Q96RR4; -. DR SwissPalm; Q96RR4; -. DR BioMuta; CAMKK2; -. DR DMDM; 317373374; -. DR jPOST; Q96RR4; -. DR MassIVE; Q96RR4; -. DR PaxDb; 9606-ENSP00000312741; -. DR PeptideAtlas; Q96RR4; -. DR ProteomicsDB; 78009; -. [Q96RR4-1] DR ProteomicsDB; 78010; -. [Q96RR4-2] DR ProteomicsDB; 78011; -. [Q96RR4-3] DR ProteomicsDB; 78012; -. [Q96RR4-4] DR ProteomicsDB; 78013; -. [Q96RR4-5] DR ProteomicsDB; 78014; -. [Q96RR4-6] DR ProteomicsDB; 78015; -. [Q96RR4-7] DR Pumba; Q96RR4; -. DR Antibodypedia; 19059; 384 antibodies from 36 providers. DR DNASU; 10645; -. DR Ensembl; ENST00000324774.9; ENSP00000312741.5; ENSG00000110931.20. [Q96RR4-1] DR Ensembl; ENST00000337174.7; ENSP00000336634.3; ENSG00000110931.20. [Q96RR4-3] DR Ensembl; ENST00000347034.6; ENSP00000321230.3; ENSG00000110931.20. [Q96RR4-4] DR Ensembl; ENST00000392473.2; ENSP00000376265.2; ENSG00000110931.20. [Q96RR4-2] DR Ensembl; ENST00000392474.6; ENSP00000376266.2; ENSG00000110931.20. [Q96RR4-7] DR Ensembl; ENST00000402834.8; ENSP00000384591.4; ENSG00000110931.20. [Q96RR4-1] DR Ensembl; ENST00000404169.8; ENSP00000384600.3; ENSG00000110931.20. [Q96RR4-1] DR Ensembl; ENST00000412367.6; ENSP00000388368.2; ENSG00000110931.20. [Q96RR4-3] DR Ensembl; ENST00000446440.6; ENSP00000388273.2; ENSG00000110931.20. [Q96RR4-6] DR Ensembl; ENST00000538733.5; ENSP00000445944.1; ENSG00000110931.20. [Q96RR4-5] DR Ensembl; ENST00000652382.1; ENSP00000498824.1; ENSG00000110931.20. [Q96RR4-1] DR GeneID; 10645; -. DR KEGG; hsa:10645; -. DR MANE-Select; ENST00000404169.8; ENSP00000384600.3; NM_001270485.2; NP_001257414.1. DR UCSC; uc001tzt.4; human. [Q96RR4-1] DR AGR; HGNC:1470; -. DR ClinPGx; PA26052; -. DR CTD; 10645; -. DR DisGeNET; 10645; -. DR GeneCards; CAMKK2; -. DR HGNC; HGNC:1470; CAMKK2. DR HPA; ENSG00000110931; Tissue enriched (brain). DR MIM; 615002; gene. DR OpenTargets; ENSG00000110931; -. DR VEuPathDB; HostDB:ENSG00000110931; -. DR eggNOG; KOG0585; Eukaryota. DR GeneTree; ENSGT00940000161828; -. DR HOGENOM; CLU_000288_63_0_1; -. DR InParanoid; Q96RR4; -. DR OMA; EPRSECR; -. DR OrthoDB; 68483at2759; -. DR PAN-GO; Q96RR4; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q96RR4; -. DR BRENDA; 2.7.11.17; 2681. DR PathwayCommons; Q96RR4; -. DR Reactome; R-HSA-111932; CaMK IV-mediated phosphorylation of CREB. DR Reactome; R-HSA-442729; CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde. DR Reactome; R-HSA-9619229; Activation of RAC1 downstream of NMDARs. DR Reactome; R-HSA-9619483; Activation of AMPK downstream of NMDARs. DR SignaLink; Q96RR4; -. DR SIGNOR; Q96RR4; -. DR Agora; ENSG00000110931; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 10645; 17 hits in 1185 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; CAMKK2; human. DR EvolutionaryTrace; Q96RR4; -. DR GeneWiki; CAMKK2; -. DR GenomeRNAi; 10645; -. DR Pharos; Q96RR4; Tchem. DR PRO; PR:Q96RR4; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q96RR4; protein. DR Bgee; ENSG00000110931; Expressed in cerebellar cortex and 202 other cell types or tissues. DR ExpressionAtlas; Q96RR4; baseline and differential. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0043005; C:neuron projection; IEA:UniProtKB-SubCell. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB. DR GO; GO:0004683; F:calcium/calmodulin-dependent protein kinase activity; IEA:UniProtKB-EC. DR GO; GO:0005516; F:calmodulin binding; TAS:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0004713; F:protein tyrosine kinase activity; TAS:UniProtKB. DR GO; GO:0019722; P:calcium-mediated signaling; TAS:UniProtKB. DR GO; GO:0061762; P:CAMKK-AMPK signaling cascade; IMP:ParkinsonsUK-UCL. DR GO; GO:0034614; P:cellular response to reactive oxygen species; TAS:ParkinsonsUK-UCL. DR GO; GO:0000165; P:MAPK cascade; TAS:UniProtKB. DR GO; GO:1903599; P:positive regulation of autophagy of mitochondrion; IMP:ParkinsonsUK-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; TAS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0045859; P:regulation of protein kinase activity; TAS:UniProtKB. DR CDD; cd14199; STKc_CaMKK2; 1. DR FunFam; 3.30.200.20:FF:000429; Calcium/calmodulin-dependent protein kinase kinase; 1. DR FunFam; 1.10.510.10:FF:000091; Calcium/calmodulin-dependent protein kinase kinase 2 isoform 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR43895; CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE-RELATED; 1. DR PANTHER; PTHR43895:SF39; CALCIUM_CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; KW Calmodulin-binding; Cell projection; Cytoplasm; Kinase; Nucleotide-binding; KW Nucleus; Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..588 FT /note="Calcium/calmodulin-dependent protein kinase kinase FT 2" FT /id="PRO_0000086144" FT DOMAIN 165..446 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..33 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 78..100 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 128..149 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 204..226 FT /note="RP domain" FT REGION 205..225 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 472..477 FT /note="Autoinhibitory domain" FT /evidence="ECO:0000250" FT REGION 475..500 FT /note="Calmodulin-binding" FT /evidence="ECO:0000250" FT REGION 497..588 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..14 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 128..139 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 521..536 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 579..588 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 312 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 171..179 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 194 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 100 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8C078" FT MOD_RES 114 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 129 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 133 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8C078" FT MOD_RES 137 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8C078" FT MOD_RES 495 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 511 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 572 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8C078" FT VAR_SEQ 442..484 FT /note="Missing (in isoform 4, isoform 5 and isoform 6)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:15489334" FT /id="VSP_012142" FT VAR_SEQ 520..532 FT /note="KPTRECESLSELK -> QGSEDNLQGTDPP (in isoform 3 and FT isoform 5)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:12935886, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_012143" FT VAR_SEQ 533..554 FT /note="EARQRRQPPGHRPAPRGGGGSA -> GTKKKKGLDSMTSTVAAGWLDRRV FT (in isoform 7)" FT /evidence="ECO:0000303|PubMed:17974005, FT ECO:0000303|PubMed:9872452" FT /id="VSP_012148" FT VAR_SEQ 533..541 FT /note="EARQRRQPP -> PVGEEEVLL (in isoform 3 and isoform 5)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:12935886, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_012144" FT VAR_SEQ 533 FT /note="E -> T (in isoform 2 and isoform 6)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:9662074, ECO:0000303|Ref.11" FT /id="VSP_012146" FT VAR_SEQ 534..554 FT /note="Missing (in isoform 2 and isoform 6)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:9662074, ECO:0000303|Ref.11" FT /id="VSP_012147" FT VAR_SEQ 542..554 FT /note="Missing (in isoform 3 and isoform 5)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:12935886, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_012145" FT VAR_SEQ 555..588 FT /note="Missing (in isoform 2, isoform 3, isoform 5, isoform FT 6 and isoform 7)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:12935886, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:17974005, FT ECO:0000303|PubMed:9662074, ECO:0000303|PubMed:9872452, FT ECO:0000303|Ref.11" FT /id="VSP_012149" FT VARIANT 10 FT /note="S -> N (in dbSNP:rs28360477)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032788" FT VARIANT 85 FT /note="T -> S (in dbSNP:rs3817190)" FT /evidence="ECO:0000269|PubMed:11395482, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9872452" FT /id="VAR_020532" FT VARIANT 123 FT /note="C -> Y (in dbSNP:rs35403710)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040610" FT VARIANT 127 FT /note="P -> L (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040611" FT VARIANT 182 FT /note="A -> T (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1207121718)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040612" FT VARIANT 363 FT /note="R -> C (in dbSNP:rs1132780)" FT /id="VAR_020533" FT VARIANT 492 FT /note="R -> H (in dbSNP:rs34129994)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040613" FT CONFLICT 206 FT /note="G -> A (in Ref. 2; AAD31507)" FT /evidence="ECO:0000305" FT CONFLICT 331 FT /note="F -> I (in Ref. 6; BAF84761)" FT /evidence="ECO:0000305" FT CONFLICT 347 FT /note="T -> Y (in Ref. 2; AAD31507)" FT /evidence="ECO:0000305" FT CONFLICT 371 FT /note="L -> K (in Ref. 2; AAD31507)" FT /evidence="ECO:0000305" FT CONFLICT 554 FT /note="A -> H (in Ref. 1; AAK91829)" FT /evidence="ECO:0000305" FT CONFLICT 557 FT /note="R -> N (in Ref. 1; AAK91829)" FT /evidence="ECO:0000305" FT STRAND 165..172 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 175..184 FT /evidence="ECO:0007829|PDB:8TUC" FT TURN 185..188 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 189..197 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 198..204 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 231..242 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 251..255 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 260..268 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 273..275 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 286..305 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 315..317 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 318..320 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 326..328 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 338..341 FT /evidence="ECO:0007829|PDB:5UY6" FT STRAND 343..346 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 351..353 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 356..358 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 364..367 FT /evidence="ECO:0007829|PDB:6CMJ" FT HELIX 368..385 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 395..404 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 411..413 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 417..426 FT /evidence="ECO:0007829|PDB:8TUC" FT TURN 431..433 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 437..440 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 444..447 FT /evidence="ECO:0007829|PDB:8TUC" FT TURN 448..451 FT /evidence="ECO:0007829|PDB:6CMJ" FT HELIX 457..461 FT /evidence="ECO:0007829|PDB:6CMJ" FT MOD_RES Q96RR4-3:522 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES Q96RR4-5:479 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" SQ SEQUENCE 588 AA; 64746 MW; 04E3583561341167 CRC64; MSSCVSSQPS SNRAAPQDEL GGRGSSSSES QKPCEALRGL SSLSIHLGME SFIVVTECEP GCAVDLGLAR DRPLEADGQE VPLDTSGSQA RPHLSGRKLS LQERSQGGLA AGGSLDMNGR CICPSLPYSP VSSPQSSPRL PRRPTVESHH VSITGMQDCV QLNQYTLKDE IGKGSYGVVK LAYNENDNTY YAMKVLSKKK LIRQAGFPRR PPPRGTRPAP GGCIQPRGPI EQVYQEIAIL KKLDHPNVVK LVEVLDDPNE DHLYMVFELV NQGPVMEVPT LKPLSEDQAR FYFQDLIKGI EYLHYQKIIH RDIKPSNLLV GEDGHIKIAD FGVSNEFKGS DALLSNTVGT PAFMAPESLS ETRKIFSGKA LDVWAMGVTL YCFVFGQCPF MDERIMCLHS KIKSQALEFP DQPDIAEDLK DLITRMLDKN PESRIVVPEI KLHPWVTRHG AEPLPSEDEN CTLVEVTEEE VENSVKHIPS LATVILVKTM IRKRSFGNPF EGSRREERSL SAPGNLLTKK PTRECESLSE LKEARQRRQP PGHRPAPRGG GGSALVRGSP CVESCWAPAP GSPARMHPLR PEEAMEPE // ID KPCA_HUMAN Reviewed; 672 AA. AC P17252; B5BU22; Q15137; Q32M72; Q96RE4; DT 01-AUG-1990, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2011, sequence version 4. DT 28-JAN-2026, entry version 258. DE RecName: Full=Protein kinase C alpha type; DE Short=PKC-A; DE Short=PKC-alpha; DE EC=2.7.11.13 {ECO:0000269|PubMed:25313067, ECO:0000269|PubMed:36040231}; GN Name=PRKCA; Synonyms=PKCA, PRKACA; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ILE-568. RC TISSUE=Blood; RX PubMed=2336401; DOI=10.1093/nar/18.8.2183; RA Finkenzeller G., Marme D., Hug H.; RT "Sequence of human protein kinase C alpha."; RL Nucleic Acids Res. 18:2183-2183(1990). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-568. RX PubMed=19054851; DOI=10.1038/nmeth.1273; RA Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., RA Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., RA Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B., RA Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., RA Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., RA Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., RA Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., RA Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., RA Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., RA Nomura N.; RT "Human protein factory for converting the transcriptome into an in vitro- RT expressed proteome."; RL Nat. Methods 5:1011-1017(2008). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ILE-568. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-568. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 15-445. RX PubMed=1714454; DOI=10.1016/s0021-9258(18)98596-0; RA McSwine-Kennick R.L., McKeegan E.M., Johnson M.D., Morin M.J.; RT "Phorbol diester-induced alterations in the expression of protein kinase C RT isozymes and their mRNAs. Analysis in wild-type and phorbol diester- RT resistant HL-60 cell clones."; RL J. Biol. Chem. 266:15135-15143(1991). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-57. RA Haridasse V., Hackenbruck J., Glazer R.I.; RT "Homo sapiens protein kinase C alpha 5-flanking sequence."; RL Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases. RN [8] RP PROTEIN SEQUENCE OF 2-19. RC TISSUE=Platelet; RX PubMed=12665801; DOI=10.1038/nbt810; RA Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R., RA Vandekerckhove J.; RT "Exploring proteomes and analyzing protein processing by mass spectrometric RT identification of sorted N-terminal peptides."; RL Nat. Biotechnol. 21:566-569(2003). RN [9] RP FUNCTION IN APOPTOSIS, AND SUBCELLULAR LOCATION. RX PubMed=9738012; DOI=10.1074/jbc.273.39.25436; RA Ruvolo P.P., Deng X., Carr B.K., May W.S.; RT "A functional role for mitochondrial protein kinase Calpha in Bcl2 RT phosphorylation and suppression of apoptosis."; RL J. Biol. Chem. 273:25436-25442(1998). RN [10] RP FUNCTION IN INFLAMMATORY RESPONSE. RX PubMed=9830023; DOI=10.1074/jbc.273.49.32787; RA St-Denis A., Chano F., Tremblay P., St-Pierre Y., Descoteaux A.; RT "Protein kinase C-alpha modulates lipopolysaccharide-induced functions in a RT murine macrophage cell line."; RL J. Biol. Chem. 273:32787-32792(1998). RN [11] RP FUNCTION IN INFLAMMATORY RESPONSE. RX PubMed=9873035; DOI=10.1074/jbc.274.2.939; RA Han Y., Meng T., Murray N.R., Fields A.P., Brasier A.R.; RT "Interleukin-1-induced nuclear factor-kappaB-IkappaBalpha autoregulatory RT feedback loop in hepatocytes. A role for protein kinase calpha in post- RT transcriptional regulation of ikappabalpha resynthesis."; RL J. Biol. Chem. 274:939-947(1999). RN [12] RP FUNCTION IN APOPTOSIS. RX PubMed=9927633; DOI=10.1124/mol.55.2.396; RA Shen L., Dean N.M., Glazer R.I.; RT "Induction of p53-dependent, insulin-like growth factor-binding protein-3- RT mediated apoptosis in glioblastoma multiforme cells by a protein kinase RT Calpha antisense oligonucleotide."; RL Mol. Pharmacol. 55:396-402(1999). RN [13] RP FUNCTION IN CELL CYCLE PROGRESSION. RX PubMed=10848585; DOI=10.1128/mcb.20.13.4580-4590.2000; RA Besson A., Yong V.W.; RT "Involvement of p21(Waf1/Cip1) in protein kinase C alpha-induced cell cycle RT progression."; RL Mol. Cell. Biol. 20:4580-4590(2000). RN [14] RP FUNCTION IN ANGIOGENESIS. RX PubMed=11909826; DOI=10.1161/01.res.0000012503.30315.e8; RA Wang A., Nomura M., Patan S., Ware J.A.; RT "Inhibition of protein kinase Calpha prevents endothelial cell migration RT and vascular tube formation in vitro and myocardial neovascularization in RT vivo."; RL Circ. Res. 90:609-616(2002). RN [15] RP INTERACTION WITH ADAP1. RX PubMed=12893243; DOI=10.1016/s0006-291x(03)01187-2; RA Zemlickova E., Dubois T., Kerai P., Clokie S., Cronshaw A.D., RA Wakefield R.I.D., Johannes F.-J., Aitken A.; RT "Centaurin-alpha(1) associates with and is phosphorylated by isoforms of RT protein kinase C."; RL Biochem. Biophys. Res. Commun. 307:459-465(2003). RN [16] RP FUNCTION IN PLATELET AGGREGATION. RX PubMed=12724315; DOI=10.1074/jbc.m212407200; RA Tabuchi A., Yoshioka A., Higashi T., Shirakawa R., Nishioka H., Kita T., RA Horiuchi H.; RT "Direct demonstration of involvement of protein kinase Calpha in the Ca2+- RT induced platelet aggregation."; RL J. Biol. Chem. 278:26374-26379(2003). RN [17] RP FUNCTION IN PHOSPHORYLATION OF TNNT2/CTNT. RX PubMed=12832403; DOI=10.1074/jbc.m306325200; RA Sumandea M.P., Pyle W.G., Kobayashi T., de Tombe P.P., Solaro R.J.; RT "Identification of a functionally critical protein kinase C phosphorylation RT residue of cardiac troponin T."; RL J. Biol. Chem. 278:35135-35144(2003). RN [18] RP FUNCTION IN KIT SIGNALING. RX PubMed=15526160; DOI=10.1007/s00018-004-4189-6; RA Ronnstrand L.; RT "Signal transduction via the stem cell factor receptor/c-Kit."; RL Cell. Mol. Life Sci. 61:2535-2548(2004). RN [19] RP FUNCTION IN PHOSPHORYLATION OF TRPC1. RX PubMed=15016832; DOI=10.1074/jbc.m313975200; RA Ahmmed G.U., Mehta D., Vogel S., Holinstat M., Paria B.C., Tiruppathi C., RA Malik A.B.; RT "Protein kinase Calpha phosphorylates the TRPC1 channel and regulates RT store-operated Ca2+ entry in endothelial cells."; RL J. Biol. Chem. 279:20941-20949(2004). RN [20] RP INTERACTION WITH PICK1. RX PubMed=15247289; DOI=10.1074/jbc.m404499200; RA Dev K.K., Nakanishi S., Henley J.M.; RT "The PDZ domain of PICK1 differentially accepts protein kinase C-alpha and RT GluR2 as interacting ligands."; RL J. Biol. Chem. 279:41393-41397(2004). RN [21] RP FUNCTION IN PHOSPHORYLATION OF CSPG4, AND INTERACTION WITH CSPG4. RX PubMed=15504744; DOI=10.1074/jbc.m411045200; RA Makagiansar I.T., Williams S., Dahlin-Huppe K., Fukushi J., Mustelin T., RA Stallcup W.B.; RT "Phosphorylation of NG2 proteoglycan by protein kinase C-alpha regulates RT polarized membrane distribution and cell motility."; RL J. Biol. Chem. 279:55262-55270(2004). RN [22] RP REVIEW ON ROLE IN KIT SIGNALING. RX PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055; RA Roskoski R. Jr.; RT "Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor."; RL Biochem. Biophys. Res. Commun. 337:1-13(2005). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [24] RP INTERACTION WITH TRIM41. RX PubMed=17893151; DOI=10.1074/jbc.m703320200; RA Chen D., Gould C., Garza R., Gao T., Hampton R.Y., Newton A.C.; RT "Amplitude control of protein kinase C by RINCK, a novel E3 ubiquitin RT ligase."; RL J. Biol. Chem. 282:33776-33787(2007). RN [25] RP FUNCTION IN ANGIOGENESIS. RX PubMed=18056764; DOI=10.1093/cvr/cvm085; RA Xu H., Czerwinski P., Hortmann M., Sohn H.Y., Foerstermann U., Li H.; RT "Protein kinase C alpha promotes angiogenic activity of human endothelial RT cells via induction of vascular endothelial growth factor."; RL Cardiovasc. Res. 78:349-355(2008). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Platelet; RX PubMed=18088087; DOI=10.1021/pr0704130; RA Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J., RA Schuetz C., Walter U., Gambaryan S., Sickmann A.; RT "Phosphoproteome of resting human platelets."; RL J. Proteome Res. 7:526-534(2008). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-638 AND SER-651, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [29] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [30] RP FUNCTION. RX PubMed=19176525; DOI=10.1074/jbc.m808719200; RA Yamasaki T., Takahashi A., Pan J., Yamaguchi N., Yokoyama K.K.; RT "Phosphorylation of activation transcription factor-2 at serine 121 by RT protein kinase c controls c-Jun-mediated activation of transcription."; RL J. Biol. Chem. 284:8567-8581(2009). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [32] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-628, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226 AND THR-638, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [34] RP FUNCTION, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-657, AND MUTAGENESIS RP OF LYS-368. RX PubMed=21806543; DOI=10.1042/bj20110678; RA Cameron A.J., Linch M.D., Saurin A.T., Escribano C., Parker P.J.; RT "mTORC2 targets AGC kinases through Sin1-dependent recruitment."; RL Biochem. J. 439:287-297(2011). RN [35] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [36] RP FUNCTION IN PHOSPHORYLATION OF EIF4G1. RX PubMed=21576361; DOI=10.1128/mcb.05589-11; RA Dobrikov M., Dobrikova E., Shveygert M., Gromeier M.; RT "Phosphorylation of eukaryotic translation initiation factor 4G1 (eIF4G1) RT by protein kinase C{alpha} regulates eIF4G1 binding to Mnk1."; RL Mol. Cell. Biol. 31:2947-2959(2011). RN [37] RP REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION. RX PubMed=12417014; DOI=10.1093/oxfordjournals.jbchem.a003272; RA Nakashima S.; RT "Protein kinase C alpha (PKC alpha): regulation and biological function."; RL J. Biochem. 132:669-675(2002). RN [38] RP REVIEW ON FUNCTION. RX PubMed=19969380; DOI=10.1016/j.tips.2009.10.006; RA Konopatskaya O., Poole A.W.; RT "Protein kinase Calpha: disease regulator and therapeutic target."; RL Trends Pharmacol. Sci. 31:8-14(2010). RN [39] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [40] RP FUNCTION IN CELL MIGRATION, AND SUBCELLULAR LOCATION. RX PubMed=23990668; DOI=10.1093/jnci/djt224; RA Evensen N.A., Kuscu C., Nguyen H.L., Zarrabi K., Dufour A., Kadam P., RA Hu Y.J., Pulkoski-Gross A., Bahou W.F., Zucker S., Cao J.; RT "Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in RT cancer cell migration."; RL J. Natl. Cancer Inst. 105:1402-1416(2013). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-10 AND SER-226, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [42] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226; THR-638 AND SER-657, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [43] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=25313067; DOI=10.1073/pnas.1418342111; RA Shibata S., Arroyo J.P., Castaneda-Bueno M., Puthumana J., Zhang J., RA Uchida S., Stone K.L., Lam T.T., Lifton R.P.; RT "Angiotensin II signaling via protein kinase C phosphorylates Kelch-like 3, RT preventing WNK4 degradation."; RL Proc. Natl. Acad. Sci. U.S.A. 111:15556-15561(2014). RN [44] RP INTERACTION WITH PARD3. RX PubMed=27925688; DOI=10.1002/humu.23153; RA Chen X., An Y., Gao Y., Guo L., Rui L., Xie H., Sun M., Lam Hung S., RA Sheng X., Zou J., Bao Y., Guan H., Niu B., Li Z., Finnell R.H., RA Gusella J.F., Wu B.L., Zhang T.; RT "Rare deleterious PARD3 variants in the aPKC-binding region are implicated RT in the pathogenesis of human cranial neural tube defects via disrupting RT apical tight junction formation."; RL Hum. Mutat. 38:378-389(2017). RN [45] RP FUNCTION. RX PubMed=28028151; DOI=10.1084/jem.20160068; RA Xu X., Han L., Zhao G., Xue S., Gao Y., Xiao J., Zhang S., Chen P., RA Wu Z.Y., Ding J., Hu R., Wei B., Wang H.; RT "LRCH1 interferes with DOCK8-Cdc42-induced T cell migration and ameliorates RT experimental autoimmune encephalomyelitis."; RL J. Exp. Med. 214:209-226(2017). RN [46] RP FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION. RX PubMed=36040231; DOI=10.1042/bcj20220308; RA Malik A.U., Karapetsas A., Nirujogi R.S., Chatterjee D., Phung T.K., RA Wightman M., Gourlay R., Morrice N., Mathea S., Knapp S., Alessi D.R.; RT "PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues RT (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain."; RL Biochem. J. 479:1941-1965(2022). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 320-672 IN COMPLEX WITH RP INHIBITOR. RX PubMed=19827831; DOI=10.1021/jm901108b; RA Wagner J., von Matt P., Sedrani R., Albert R., Cooke N., Ehrhardt C., RA Geiser M., Rummel G., Stark W., Strauss A., Cowan-Jacob S.W., Beerli C., RA Weckbecker G., Evenou J.P., Zenke G., Cottens S.; RT "Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4- RT yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein RT kinase C isotypes."; RL J. Med. Chem. 52:6193-6196(2009). RN [48] RP STRUCTURE BY NMR OF 88-169. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the second phorbol esters/diacylglycerol binding RT domain of human protein kinase C alpha type."; RL Submitted (APR-2008) to the PDB data bank. RN [49] RP VARIANTS [LARGE SCALE ANALYSIS] SER-98; ASN-467 AND VAL-489. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium-activated, phospholipid- and diacylglycerol (DAG)- CC dependent serine/threonine-protein kinase that is involved in positive CC and negative regulation of cell proliferation, apoptosis, CC differentiation, migration and adhesion, tumorigenesis, cardiac CC hypertrophy, angiogenesis, platelet function and inflammation, by CC directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, CC or activating signaling cascade involving MAPK1/3 (ERK1/2) and RAP1GAP. CC Involved in cell proliferation and cell growth arrest by positive and CC negative regulation of the cell cycle. Can promote cell growth by CC phosphorylating and activating RAF1, which mediates the activation of CC the MAPK/ERK signaling cascade, and/or by up-regulating CDKN1A, which CC facilitates active cyclin-dependent kinase (CDK) complex formation in CC glioma cells. In intestinal cells stimulated by the phorbol ester PMA, CC can trigger a cell cycle arrest program which is associated with the CC accumulation of the hyper-phosphorylated growth-suppressive form of RB1 CC and induction of the CDK inhibitors CDKN1A and CDKN1B. Exhibits anti- CC apoptotic function in glioma cells and protects them from apoptosis by CC suppressing the p53/TP53-mediated activation of IGFBP3, and in leukemia CC cells mediates anti-apoptotic action by phosphorylating BCL2. During CC macrophage differentiation induced by macrophage colony-stimulating CC factor (CSF1), is translocated to the nucleus and is associated with CC macrophage development. After wounding, translocates from focal CC contacts to lamellipodia and participates in the modulation of CC desmosomal adhesion. Plays a role in cell motility by phosphorylating CC CSPG4, which induces association of CSPG4 with extensive lamellipodia CC at the cell periphery and polarization of the cell accompanied by CC increases in cell motility. During chemokine-induced CD4(+) T cell CC migration, phosphorylates CDC42-guanine exchange factor DOCK8 resulting CC in its dissociation from LRCH1 and the activation of GTPase CDC42 CC (PubMed:28028151). Is highly expressed in a number of cancer cells CC where it can act as a tumor promoter and is implicated in malignant CC phenotypes of several tumors such as gliomas and breast cancers. CC Negatively regulates myocardial contractility and positively regulates CC angiogenesis, platelet aggregation and thrombus formation in arteries. CC Mediates hypertrophic growth of neonatal cardiomyocytes, in part CC through a MAPK1/3 (ERK1/2)-dependent signaling pathway, and upon PMA CC treatment, is required to induce cardiomyocyte hypertrophy up to heart CC failure and death, by increasing protein synthesis, protein-DNA ratio CC and cell surface area. Regulates cardiomyocyte function by CC phosphorylating cardiac troponin T (TNNT2/CTNT), which induces CC significant reduction in actomyosin ATPase activity, myofilament CC calcium sensitivity and myocardial contractility. In angiogenesis, is CC required for full endothelial cell migration, adhesion to vitronectin CC (VTN), and vascular endothelial growth factor A (VEGFA)-dependent CC regulation of kinase activation and vascular tube formation. Involved CC in the stabilization of VEGFA mRNA at post-transcriptional level and CC mediates VEGFA-induced cell proliferation. In the regulation of CC calcium-induced platelet aggregation, mediates signals from the CC CD36/GP4 receptor for granule release, and activates the integrin CC heterodimer ITGA2B-ITGB3 through the RAP1GAP pathway for adhesion. CC During response to lipopolysaccharides (LPS), may regulate selective CC LPS-induced macrophage functions involved in host defense and CC inflammation. But in some inflammatory responses, may negatively CC regulate NF-kappa-B-induced genes, through IL1A-dependent induction of CC NF-kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O- CC tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1, which CC modulates EIF4G1 binding to MKNK1 and may be involved in the regulation CC of EIF4E phosphorylation. Phosphorylates KIT, leading to inhibition of CC KIT activity. Phosphorylates ATF2 which promotes cooperation between CC ATF2 and JUN, activating transcription. Phosphorylates SOCS2 at 'Ser- CC 52' facilitating its ubiquitination and proteasomal degradation (By CC similarity). Phosphorylates KLHL3 in response to angiotensin II CC signaling, decreasing the interaction between KLHL3 and WNK4 CC (PubMed:25313067). Phosphorylates and activates LRRK1, which CC phosphorylates RAB proteins involved in intracellular trafficking CC (PubMed:36040231). {ECO:0000250|UniProtKB:P20444, CC ECO:0000269|PubMed:10848585, ECO:0000269|PubMed:11909826, CC ECO:0000269|PubMed:12724315, ECO:0000269|PubMed:12832403, CC ECO:0000269|PubMed:15016832, ECO:0000269|PubMed:15504744, CC ECO:0000269|PubMed:15526160, ECO:0000269|PubMed:18056764, CC ECO:0000269|PubMed:19176525, ECO:0000269|PubMed:21576361, CC ECO:0000269|PubMed:21806543, ECO:0000269|PubMed:23990668, CC ECO:0000269|PubMed:25313067, ECO:0000269|PubMed:28028151, CC ECO:0000269|PubMed:36040231, ECO:0000269|PubMed:9738012, CC ECO:0000269|PubMed:9830023, ECO:0000269|PubMed:9873035, CC ECO:0000269|PubMed:9927633}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:36040231}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:25313067, ECO:0000269|PubMed:36040231}; CC -!- COFACTOR: CC Name=Ca(2+); Xref=ChEBI:CHEBI:29108; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU00041}; CC Note=Binds 3 Ca(2+) ions per subunit. The ions are bound to the C2 CC domain. {ECO:0000250|UniProtKB:P05696}; CC -!- ACTIVITY REGULATION: Classical (or conventional) PKCs (PRKCA, PRKCB and CC PRKCG) are activated by calcium and diacylglycerol (DAG) in the CC presence of phosphatidylserine. Three specific sites; Thr-497 CC (activation loop of the kinase domain), Thr-638 (turn motif) and Ser- CC 657 (hydrophobic region), need to be phosphorylated for its full CC activation. {ECO:0000269|PubMed:21806543}. CC -!- SUBUNIT: Recruited in a circadian manner into a nuclear complex which CC also includes BMAL1 and RACK1 (By similarity). Interacts with CC ADAP1/CENTA1 (PubMed:12893243). Interacts with CSPG4 (PubMed:15504744). CC Binds to CAVIN2 in the presence of phosphatidylserine (By similarity). CC Interacts with PRKCABP/PICK1 (via PDZ domain) (PubMed:15247289). CC Interacts with TRIM41 (PubMed:17893151). Interacts with PARD3 CC (PubMed:27925688). Interacts with SOCS2 (By similarity). CC {ECO:0000250|UniProtKB:P05696, ECO:0000250|UniProtKB:P20444, CC ECO:0000269|PubMed:12893243, ECO:0000269|PubMed:15247289, CC ECO:0000269|PubMed:15504744, ECO:0000269|PubMed:17893151, CC ECO:0000269|PubMed:27925688}. CC -!- INTERACTION: CC P17252; Q15027: ACAP1; NbExp=3; IntAct=EBI-1383528, EBI-751746; CC P17252; Q06481-5: APLP2; NbExp=3; IntAct=EBI-1383528, EBI-25646567; CC P17252; Q66PJ3-4: ARL6IP4; NbExp=3; IntAct=EBI-1383528, EBI-5280499; CC P17252; Q13072: BAGE; NbExp=3; IntAct=EBI-1383528, EBI-25884811; CC P17252; Q8N9N5-2: BANP; NbExp=3; IntAct=EBI-1383528, EBI-11524452; CC P17252; Q96A33: CCDC47; NbExp=3; IntAct=EBI-1383528, EBI-720151; CC P17252; Q96LY2-2: CCDC74B; NbExp=3; IntAct=EBI-1383528, EBI-17967022; CC P17252; P15169: CPN1; NbExp=3; IntAct=EBI-1383528, EBI-2116369; CC P17252; P43234: CTSO; NbExp=3; IntAct=EBI-1383528, EBI-2874283; CC P17252; O95424: DEXI; NbExp=3; IntAct=EBI-1383528, EBI-724515; CC P17252; P78352: DLG4; NbExp=2; IntAct=EBI-1383528, EBI-80389; CC P17252; O43598: DNPH1; NbExp=3; IntAct=EBI-1383528, EBI-748674; CC P17252; P21728: DRD1; NbExp=3; IntAct=EBI-1383528, EBI-6624459; CC P17252; P00533: EGFR; NbExp=3; IntAct=EBI-1383528, EBI-297353; CC P17252; P60228: EIF3E; NbExp=3; IntAct=EBI-1383528, EBI-347740; CC P17252; Q96J88-3: EPSTI1; NbExp=3; IntAct=EBI-1383528, EBI-25885343; CC P17252; Q8IVH2-2: FOXP4; NbExp=3; IntAct=EBI-1383528, EBI-25885364; CC P17252; Q96NE9-2: FRMD6; NbExp=3; IntAct=EBI-1383528, EBI-13213391; CC P17252; O14926: FSCN2; NbExp=3; IntAct=EBI-1383528, EBI-21017948; CC P17252; Q06547-3: GABPB1; NbExp=3; IntAct=EBI-1383528, EBI-9088619; CC P17252; P19440-3: GGT1; NbExp=3; IntAct=EBI-1383528, EBI-21558069; CC P17252; Q9UJ42: GPR160; NbExp=3; IntAct=EBI-1383528, EBI-25885139; CC P17252; P62805: H4C9; NbExp=3; IntAct=EBI-1383528, EBI-302023; CC P17252; Q9UBN7: HDAC6; NbExp=2; IntAct=EBI-1383528, EBI-301697; CC P17252; P52597: HNRNPF; NbExp=3; IntAct=EBI-1383528, EBI-352986; CC P17252; Q92826: HOXB13; NbExp=3; IntAct=EBI-1383528, EBI-11317274; CC P17252; Q02363: ID2; NbExp=3; IntAct=EBI-1383528, EBI-713450; CC P17252; Q96FT9-2: IFT43; NbExp=3; IntAct=EBI-1383528, EBI-11944538; CC P17252; P17936: IGFBP3; NbExp=3; IntAct=EBI-1383528, EBI-715709; CC P17252; P26951: IL3RA; NbExp=3; IntAct=EBI-1383528, EBI-1757512; CC P17252; Q9BYR8: KRTAP3-1; NbExp=3; IntAct=EBI-1383528, EBI-9996449; CC P17252; Q9Y234: LIPT1; NbExp=4; IntAct=EBI-1383528, EBI-727376; CC P17252; P51884: LUM; NbExp=3; IntAct=EBI-1383528, EBI-725780; CC P17252; Q9H213: MAGEH1; NbExp=3; IntAct=EBI-1383528, EBI-473834; CC P17252; P80192: MAP3K9; NbExp=3; IntAct=EBI-1383528, EBI-3951604; CC P17252; Q15759: MAPK11; NbExp=3; IntAct=EBI-1383528, EBI-298304; CC P17252; A0JLT2-2: MED19; NbExp=3; IntAct=EBI-1383528, EBI-13288755; CC P17252; Q8N983-3: MRPL43; NbExp=3; IntAct=EBI-1383528, EBI-11109389; CC P17252; P49821: NDUFV1; NbExp=3; IntAct=EBI-1383528, EBI-748312; CC P17252; Q2M1J6: OXA1L; NbExp=3; IntAct=EBI-1383528, EBI-9978021; CC P17252; Q9BRX2: PELO; NbExp=3; IntAct=EBI-1383528, EBI-1043580; CC P17252; Q9Y6X2: PIAS3; NbExp=3; IntAct=EBI-1383528, EBI-2803703; CC P17252; P11309-2: PIM1; NbExp=2; IntAct=EBI-1383528, EBI-1018633; CC P17252; Q6P1J6-2: PLB1; NbExp=3; IntAct=EBI-1383528, EBI-10694821; CC P17252; Q9UNA4: POLI; NbExp=3; IntAct=EBI-1383528, EBI-741774; CC P17252; Q02156: PRKCE; NbExp=2; IntAct=EBI-1383528, EBI-706254; CC P17252; P05129: PRKCG; NbExp=6; IntAct=EBI-1383528, EBI-949799; CC P17252; P07225: PROS1; NbExp=3; IntAct=EBI-1383528, EBI-2803380; CC P17252; Q3YEC7-3: RABL6; NbExp=3; IntAct=EBI-1383528, EBI-25885259; CC P17252; O94844: RHOBTB1; NbExp=3; IntAct=EBI-1383528, EBI-6426999; CC P17252; Q9NWS8-3: RMND1; NbExp=3; IntAct=EBI-1383528, EBI-25884400; CC P17252; Q9ULK6-3: RNF150; NbExp=3; IntAct=EBI-1383528, EBI-36513929; CC P17252; P18077: RPL35A; NbExp=3; IntAct=EBI-1383528, EBI-353383; CC P17252; Q14160: SCRIB; NbExp=3; IntAct=EBI-1383528, EBI-357345; CC P17252; P31431: SDC4; NbExp=2; IntAct=EBI-1383528, EBI-3913237; CC P17252; Q99643: SDHC; NbExp=3; IntAct=EBI-1383528, EBI-1224539; CC P17252; Q14141: SEPTIN6; NbExp=3; IntAct=EBI-1383528, EBI-745901; CC P17252; Q01105-2: SET; NbExp=3; IntAct=EBI-1383528, EBI-7481343; CC P17252; P37840: SNCA; NbExp=3; IntAct=EBI-1383528, EBI-985879; CC P17252; Q9Y5X0: SNX10; NbExp=3; IntAct=EBI-1383528, EBI-10329478; CC P17252; P56693: SOX10; NbExp=3; IntAct=EBI-1383528, EBI-1167533; CC P17252; Q9BRW5: SP2; NbExp=3; IntAct=EBI-1383528, EBI-25868254; CC P17252; O43761: SYNGR3; NbExp=3; IntAct=EBI-1383528, EBI-11321949; CC P17252; P15884: TCF4; NbExp=3; IntAct=EBI-1383528, EBI-533224; CC P17252; Q3YBM2: TMEM176B; NbExp=3; IntAct=EBI-1383528, EBI-2821479; CC P17252; Q9H8H3: TMT1A; NbExp=3; IntAct=EBI-1383528, EBI-1390168; CC P17252; P0CG48: UBC; NbExp=2; IntAct=EBI-1383528, EBI-3390054; CC P17252; P13051-2: UNG; NbExp=3; IntAct=EBI-1383528, EBI-25834258; CC P17252; Q8NB14: USP38; NbExp=3; IntAct=EBI-1383528, EBI-2512509; CC P17252; O95498: VNN2; NbExp=3; IntAct=EBI-1383528, EBI-21494555; CC P17252; Q9NZC7-5: WWOX; NbExp=3; IntAct=EBI-1383528, EBI-12040603; CC P17252; Q9BQ24: ZFYVE21; NbExp=3; IntAct=EBI-1383528, EBI-2849569; CC P17252; Q05CR2: ZNF248; NbExp=3; IntAct=EBI-1383528, EBI-25835471; CC P17252; Q8N0Y2-2: ZNF444; NbExp=3; IntAct=EBI-1383528, EBI-12010736; CC P17252; O15535: ZSCAN9; NbExp=3; IntAct=EBI-1383528, EBI-751531; CC P17252; Q24008: inaD; Xeno; NbExp=2; IntAct=EBI-1383528, EBI-195326; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:23990668}. Cell CC membrane {ECO:0000269|PubMed:23990668, ECO:0000269|PubMed:36040231}; CC Peripheral membrane protein {ECO:0000305|PubMed:23990668, CC ECO:0000305|PubMed:36040231}. Mitochondrion membrane CC {ECO:0000269|PubMed:9738012}; Peripheral membrane protein CC {ECO:0000305|PubMed:9738012}. Nucleus {ECO:0000250|UniProtKB:P20444}. CC -!- PTM: In response to growth factors, phosphorylated at Thr-631 and Ser- CC 657 by the mTORC2 complex, promoting autophosphorylation and activation CC of PRKCA. {ECO:0000269|PubMed:21806543}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X52479; CAA36718.1; -; mRNA. DR EMBL; AB451258; BAG70072.1; -; mRNA. DR EMBL; AB451383; BAG70197.1; -; mRNA. DR EMBL; AC005918; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC005988; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC006263; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC006947; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC009452; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC060796; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471099; EAW89014.1; -; Genomic_DNA. DR EMBL; BC109273; AAI09274.1; -; mRNA. DR EMBL; BC109274; AAI09275.1; -; mRNA. DR EMBL; M22199; AAA60098.1; -; mRNA. DR EMBL; AF395829; AAK84184.1; -; Genomic_DNA. DR CCDS; CCDS11664.1; -. DR PIR; S09496; KIHUCA. DR RefSeq; NP_002728.2; NM_002737.3. DR PDB; 2ELI; NMR; -; A=93-169. DR PDB; 3IW4; X-ray; 2.80 A; A/B/C=320-672. DR PDB; 4DNL; X-ray; 1.90 A; A=155-293. DR PDB; 4RA4; X-ray; 2.63 A; A=318-672. DR PDB; 8U37; X-ray; 2.48 A; A=320-672. DR PDB; 8UAK; X-ray; 2.82 A; A=320-672. DR PDBsum; 2ELI; -. DR PDBsum; 3IW4; -. DR PDBsum; 4DNL; -. DR PDBsum; 4RA4; -. DR PDBsum; 8U37; -. DR PDBsum; 8UAK; -. DR AlphaFoldDB; P17252; -. DR BMRB; P17252; -. DR SMR; P17252; -. DR BioGRID; 111564; 342. DR CORUM; P17252; -. DR DIP; DIP-531N; -. DR FunCoup; P17252; 2547. DR IntAct; P17252; 209. DR MINT; P17252; -. DR STRING; 9606.ENSP00000408695; -. DR BindingDB; P17252; -. DR ChEMBL; CHEMBL299; -. DR DrugBank; DB12996; Acteoside. DR DrugBank; DB14001; alpha-Tocopherol succinate. DR DrugBank; DB06451; Aprinocarsen. DR DrugBank; DB09096; Benzoyl peroxide. DR DrugBank; DB11752; Bryostatin 1. DR DrugBank; DB12429; CI-1040. DR DrugBank; DB14002; D-alpha-Tocopherol acetate. DR DrugBank; DB04209; Dequalinium. DR DrugBank; DB08846; Ellagic acid. DR DrugBank; DB05013; Ingenol mebutate. DR DrugBank; DB06595; Midostaurin. DR DrugBank; DB06641; Perifosine. DR DrugBank; DB06819; Phenylbutyric acid. DR DrugBank; DB00144; Phosphatidyl serine. DR DrugBank; DB12369; Sotrastaurin. DR DrugBank; DB02010; Staurosporine. DR DrugBank; DB00675; Tamoxifen. DR DrugBank; DB04462; Tetrabromo-2-Benzotriazole. DR DrugBank; DB00163; Vitamin E. DR DrugCentral; P17252; -. DR GuidetoPHARMACOLOGY; 1482; -. DR GlyGen; P17252; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P17252; -. DR MetOSite; P17252; -. DR PhosphoSitePlus; P17252; -. DR SwissPalm; P17252; -. DR BioMuta; PRKCA; -. DR DMDM; 317373571; -. DR CPTAC; CPTAC-1615; -. DR CPTAC; CPTAC-3172; -. DR CPTAC; CPTAC-3173; -. DR jPOST; P17252; -. DR MassIVE; P17252; -. DR PaxDb; 9606-ENSP00000408695; -. DR PeptideAtlas; P17252; -. DR ProteomicsDB; 53464; -. DR Pumba; P17252; -. DR Antibodypedia; 1464; 1251 antibodies from 49 providers. DR DNASU; 5578; -. DR Ensembl; ENST00000413366.8; ENSP00000408695.3; ENSG00000154229.13. DR GeneID; 5578; -. DR KEGG; hsa:5578; -. DR MANE-Select; ENST00000413366.8; ENSP00000408695.3; NM_002737.3; NP_002728.2. DR UCSC; uc002jfp.2; human. DR AGR; HGNC:9393; -. DR ClinPGx; PA33759; -. DR CTD; 5578; -. DR DisGeNET; 5578; -. DR GeneCards; PRKCA; -. DR HGNC; HGNC:9393; PRKCA. DR HPA; ENSG00000154229; Tissue enhanced (brain). DR MalaCards; PRKCA; -. DR MIM; 176960; gene. DR OpenTargets; ENSG00000154229; -. DR VEuPathDB; HostDB:ENSG00000154229; -. DR eggNOG; KOG0696; Eukaryota. DR GeneTree; ENSGT00940000156104; -. DR HOGENOM; CLU_000288_54_2_1; -. DR InParanoid; P17252; -. DR OMA; VHEIKSH; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; P17252; 3 GO annotations based on evolutionary models. DR PhylomeDB; P17252; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; P17252; -. DR Reactome; R-HSA-111933; Calmodulin induced events. DR Reactome; R-HSA-114516; Disinhibition of SNARE formation. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-1433559; Regulation of KIT signaling. DR Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin. DR Reactome; R-HSA-2514859; Inactivation, recovery and regulation of the phototransduction cascade. DR Reactome; R-HSA-3000170; Syndecan interactions. DR Reactome; R-HSA-399997; Acetylcholine regulates insulin secretion. DR Reactome; R-HSA-4086398; Ca2+ pathway. DR Reactome; R-HSA-416993; Trafficking of GluR2-containing AMPA receptors. DR Reactome; R-HSA-418597; G alpha (z) signalling events. DR Reactome; R-HSA-4419969; Depolymerization of the Nuclear Lamina. DR Reactome; R-HSA-450520; HuR (ELAVL1) binds and stabilizes mRNA. DR Reactome; R-HSA-5099900; WNT5A-dependent internalization of FZD4. DR Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation. DR Reactome; R-HSA-5668599; RHO GTPases Activate NADPH Oxidases. DR Reactome; R-HSA-76005; Response to elevated platelet cytosolic Ca2+. DR Reactome; R-HSA-8853659; RET signaling. DR Reactome; R-HSA-9010642; ROBO receptors bind AKAP5. DR SABIO-RK; P17252; -. DR SignaLink; P17252; -. DR SIGNOR; P17252; -. DR Agora; ENSG00000154229; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 5578; 13 hits in 1191 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; PRKCA; human. DR EvolutionaryTrace; P17252; -. DR GeneWiki; PKC_alpha; -. DR GenomeRNAi; 5578; -. DR Pharos; P17252; Tchem. DR PRO; PR:P17252; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P17252; protein. DR Bgee; ENSG00000154229; Expressed in CA1 field of hippocampus and 192 other cell types or tissues. DR ExpressionAtlas; P17252; baseline and differential. DR GO; GO:0035866; C:alphav-beta3 integrin-PKCalpha complex; ISS:BHF-UCL. DR GO; GO:0036064; C:ciliary basal body; IDA:UniProt. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:BHF-UCL. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0031966; C:mitochondrial membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005739; C:mitochondrion; HDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004698; F:calcium,diacylglycerol-dependent serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0019992; F:diacylglycerol binding; TAS:Reactome. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; EXP:Reactome. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0035403; F:histone H3T6 kinase activity; IDA:UniProtKB. DR GO; GO:0005178; F:integrin binding; ISS:BHF-UCL. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW. DR GO; GO:0097190; P:apoptotic signaling pathway; TAS:ProtInc. DR GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW. DR GO; GO:0021955; P:central nervous system neuron axonogenesis; IEA:Ensembl. DR GO; GO:0002159; P:desmosome assembly; IMP:BHF-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0007611; P:learning or memory; IEA:Ensembl. DR GO; GO:0007077; P:mitotic nuclear membrane disassembly; TAS:Reactome. DR GO; GO:1900016; P:negative regulation of cytokine production involved in inflammatory response; IEA:Ensembl. DR GO; GO:0034351; P:negative regulation of glial cell apoptotic process; IMP:UniProtKB. DR GO; GO:0017148; P:negative regulation of translation; IEA:Ensembl. DR GO; GO:0106071; P:positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway; ISS:BHF-UCL. DR GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB. DR GO; GO:0110063; P:positive regulation of angiotensin-activated signaling pathway; IDA:UniProt. DR GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:DFLAT. DR GO; GO:0045780; P:positive regulation of bone resorption; ISS:BHF-UCL. DR GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; ISS:UniProtKB. DR GO; GO:0045785; P:positive regulation of cell adhesion; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB. DR GO; GO:1900017; P:positive regulation of cytokine production involved in inflammatory response; IEA:Ensembl. DR GO; GO:2000707; P:positive regulation of dense core granule biogenesis; ISS:UniProtKB. DR GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB. DR GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB. DR GO; GO:0045921; P:positive regulation of exocytosis; IEA:Ensembl. DR GO; GO:0032024; P:positive regulation of insulin secretion; TAS:Reactome. DR GO; GO:0031666; P:positive regulation of lipopolysaccharide-mediated signaling pathway; IMP:UniProtKB. DR GO; GO:0045651; P:positive regulation of macrophage differentiation; ISS:UniProtKB. DR GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IEA:Ensembl. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl. DR GO; GO:0070528; P:protein kinase C signaling; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0043488; P:regulation of mRNA stability; TAS:Reactome. DR GO; GO:0090330; P:regulation of platelet aggregation; IDA:UniProtKB. DR GO; GO:0051412; P:response to corticosterone; IEA:Ensembl. DR GO; GO:0032355; P:response to estradiol; IEA:Ensembl. DR GO; GO:0045471; P:response to ethanol; IEA:Ensembl. DR GO; GO:0070555; P:response to interleukin-1; IMP:BHF-UCL. DR GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl. DR GO; GO:0043434; P:response to peptide hormone; IEA:Ensembl. DR GO; GO:1904627; P:response to phorbol 13-acetate 12-myristate; IEA:Ensembl. DR GO; GO:0000302; P:response to reactive oxygen species; IEA:Ensembl. DR GO; GO:0009636; P:response to toxic substance; IEA:Ensembl. DR CDD; cd20833; C1_cPKC_rpt1; 1. DR CDD; cd20836; C1_cPKC_rpt2; 1. DR CDD; cd04026; C2_PKC_alpha_gamma; 1. DR CDD; cd05615; STKc_cPKC_alpha; 1. DR FunFam; 2.60.40.150:FF:000012; Kinase C alpha type; 1. DR FunFam; 1.10.510.10:FF:000023; Protein kinase C; 1. DR FunFam; 3.30.200.20:FF:000080; Protein kinase C; 1. DR FunFam; 3.30.200.20:FF:000103; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000006; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000031; Protein kinase C alpha; 1. DR Gene3D; 3.30.60.20; -; 2. DR Gene3D; 2.60.40.150; C2 domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR034663; cPKC_alpha. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR014375; Protein_kinase_C_a/b/g. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00130; C1_1; 2. DR Pfam; PF00168; C2; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000550; PKC_alpha; 1. DR PRINTS; PR00360; C2DOMAIN. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 2. DR SMART; SM00239; C2; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50004; C2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 2. DR PROSITE; PS50081; ZF_DAG_PE_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Angiogenesis; Apoptosis; ATP-binding; Calcium; KW Cell adhesion; Cell membrane; Cytoplasm; Direct protein sequencing; Kinase; KW Membrane; Metal-binding; Mitochondrion; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Proto-oncogene; KW Reference proteome; Repeat; Serine/threonine-protein kinase; Transferase; KW Zinc; Zinc-finger. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|PubMed:12665801, FT ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:22814378" FT CHAIN 2..672 FT /note="Protein kinase C alpha type" FT /id="PRO_0000055679" FT DOMAIN 158..275 FT /note="C2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 339..597 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 598..668 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT ZN_FING 36..86 FT /note="Phorbol-ester/DAG-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT ZN_FING 101..151 FT /note="Phorbol-ester/DAG-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT ACT_SITE 463 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 186 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 187 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 187 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 193 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 195 FT /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- FT inositol-4,5-bisphosphate)" FT /ligand_id="ChEBI:CHEBI:58456" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 245 FT /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- FT inositol-4,5-bisphosphate)" FT /ligand_id="ChEBI:CHEBI:58456" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 246 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 246 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 247 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 248 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 248 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 248 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 252 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 254 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 254 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 345..353 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 368 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:21806543" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT MOD_RES 10 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 226 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 319 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P05696" FT MOD_RES 494 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P04409" FT MOD_RES 495 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P04409" FT MOD_RES 497 FT /note="Phosphothreonine; by PDPK1" FT /evidence="ECO:0000250|UniProtKB:P04409, ECO:0000305" FT MOD_RES 501 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P05771" FT MOD_RES 628 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 631 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P20444" FT MOD_RES 638 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:24275569" FT MOD_RES 651 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 657 FT /note="Phosphoserine; by MTOR" FT /evidence="ECO:0000269|PubMed:21806543, FT ECO:0007744|PubMed:24275569" FT MOD_RES 658 FT /note="Phosphotyrosine; by SYK" FT /evidence="ECO:0000250|UniProtKB:P20444" FT VARIANT 98 FT /note="P -> S (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042301" FT VARIANT 467 FT /note="D -> N (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042302" FT VARIANT 489 FT /note="M -> V (in dbSNP:rs34406842)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042303" FT VARIANT 568 FT /note="V -> I (in dbSNP:rs6504459)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:19054851, ECO:0000269|PubMed:2336401, FT ECO:0000269|Ref.4" FT /id="VAR_050558" FT MUTAGEN 368 FT /note="K->M: Abolished protein kinase activity." FT /evidence="ECO:0000269|PubMed:21806543" FT CONFLICT 50 FT /note="C -> S (in Ref. 6; AAA60098)" FT /evidence="ECO:0000305" FT TURN 98..100 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 116..118 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 125..127 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 129..131 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 138..140 FT /evidence="ECO:0007829|PDB:2ELI" FT TURN 141..146 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 161..169 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 172..182 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 194..202 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 222..230 FT /evidence="ECO:0007829|PDB:4DNL" FT HELIX 233..237 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 239..246 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 249..251 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 254..262 FT /evidence="ECO:0007829|PDB:4DNL" FT HELIX 263..268 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 271..276 FT /evidence="ECO:0007829|PDB:4DNL" FT HELIX 282..284 FT /evidence="ECO:0007829|PDB:4DNL" FT HELIX 336..338 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 339..348 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 351..358 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 364..371 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 372..378 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 381..392 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 403..408 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 410..418 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 422..424 FT /evidence="ECO:0007829|PDB:3IW4" FT HELIX 425..430 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 437..456 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 466..468 FT /evidence="ECO:0007829|PDB:4RA4" FT STRAND 469..471 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 477..479 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 502..504 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 507..510 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 518..533 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 543..552 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 563..572 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 577..579 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 587..592 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 595..597 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 602..606 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 642..645 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 650..653 FT /evidence="ECO:0007829|PDB:8U37" SQ SEQUENCE 672 AA; 76750 MW; 9EB157789A062349 CRC64; MADVFPGNDS TASQDVANRF ARKGALRQKN VHEVKDHKFI ARFFKQPTFC SHCTDFIWGF GKQGFQCQVC CFVVHKRCHE FVTFSCPGAD KGPDTDDPRS KHKFKIHTYG SPTFCDHCGS LLYGLIHQGM KCDTCDMNVH KQCVINVPSL CGMDHTEKRG RIYLKAEVAD EKLHVTVRDA KNLIPMDPNG LSDPYVKLKL IPDPKNESKQ KTKTIRSTLN PQWNESFTFK LKPSDKDRRL SVEIWDWDRT TRNDFMGSLS FGVSELMKMP ASGWYKLLNQ EEGEYYNVPI PEGDEEGNME LRQKFEKAKL GPAGNKVISP SEDRKQPSNN LDRVKLTDFN FLMVLGKGSF GKVMLADRKG TEELYAIKIL KKDVVIQDDD VECTMVEKRV LALLDKPPFL TQLHSCFQTV DRLYFVMEYV NGGDLMYHIQ QVGKFKEPQA VFYAAEISIG LFFLHKRGII YRDLKLDNVM LDSEGHIKIA DFGMCKEHMM DGVTTRTFCG TPDYIAPEII AYQPYGKSVD WWAYGVLLYE MLAGQPPFDG EDEDELFQSI MEHNVSYPKS LSKEAVSVCK GLMTKHPAKR LGCGPEGERD VREHAFFRRI DWEKLENREI QPPFKPKVCG KGAENFDKFF TRGQPVLTPP DQLVIANIDQ SDFEGFSYVN PQFVHPILQS AV // ID KPCB_HUMAN Reviewed; 671 AA. AC P05771; C5IFJ8; D3DWF5; O43744; P05127; Q15138; Q93060; Q9UE49; Q9UE50; AC Q9UEH8; Q9UJ30; Q9UJ33; DT 13-AUG-1987, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2007, sequence version 4. DT 28-JAN-2026, entry version 270. DE RecName: Full=Protein kinase C beta type; DE Short=PKC-B; DE Short=PKC-beta; DE EC=2.7.11.13 {ECO:0000269|PubMed:20228790, ECO:0000269|PubMed:25313067, ECO:0000269|PubMed:25982116, ECO:0000269|PubMed:36040231}; GN Name=PRKCB; Synonyms=PKCB, PRKCB1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-II). RX PubMed=3755548; DOI=10.1126/science.3755548; RA Coussens L., Parker P.J., Rhee L., Yang-Feng T.L., Chen E., RA Waterfield M.D., Francke U., Ullrich A.; RT "Multiple, distinct forms of bovine and human protein kinase C suggest RT diversity in cellular signaling pathways."; RL Science 233:859-866(1986). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS BETA-I AND BETA-II). RX PubMed=3666134; DOI=10.1016/0014-5793(87)80524-0; RA Kubo K., Ohno S., Suzuki K.; RT "Primary structures of human protein kinase C beta I and beta II differ RT only in their C-terminal sequences."; RL FEBS Lett. 223:138-142(1987). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (APR-2009) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=10493829; DOI=10.1006/geno.1999.5927; RA Loftus B.J., Kim U.-J., Sneddon V.P., Kalush F., Brandon R., Fuhrmann J., RA Mason T., Crosby M.L., Barnstead M., Cronin L., Mays A.D., Cao Y., Xu R.X., RA Kang H.-L., Mitchell S., Eichler E.E., Harris P.C., Venter J.C., RA Adams M.D.; RT "Genome duplications and other features in 12 Mb of DNA sequence from human RT chromosome 16p and 16q."; RL Genomics 60:295-308(1999). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Hippocampus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-69. RX PubMed=7880442; DOI=10.1089/dna.1995.14.213; RA Mahajna J., King P., Parker P., Haley J.; RT "Autoregulation of cloned human protein kinase C beta and gamma gene RT promoters in U937 cells."; RL DNA Cell Biol. 14:213-222(1995). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-58. RX PubMed=1556124; DOI=10.1016/s0021-9258(18)42675-0; RA Niino Y.S., Ohno S., Suzuki K.; RT "Positive and negative regulation of the transcription of the human protein RT kinase C beta gene."; RL J. Biol. Chem. 267:6158-6163(1992). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-57. RX PubMed=1400396; DOI=10.1016/s0021-9258(19)36758-4; RA Obeid L.M., Blobe G.C., Karolak L.A., Hannun Y.A.; RT "Cloning and characterization of the major promoter of the human protein RT kinase C beta gene. Regulation by phorbol esters."; RL J. Biol. Chem. 267:20804-20810(1992). RN [10] RP PROTEIN SEQUENCE OF 2-19, AND ACETYLATION AT ALA-2. RC TISSUE=Platelet; RX PubMed=12665801; DOI=10.1038/nbt810; RA Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R., RA Vandekerckhove J.; RT "Exploring proteomes and analyzing protein processing by mass spectrometric RT identification of sorted N-terminal peptides."; RL Nat. Biotechnol. 21:566-569(2003). RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 97-176. RA Greenham J.A., Adams M.D., Doggett N.A., Mole S.E.; RT "The genomic structure of the human protein kinase C beta gene (PRKCB)."; RL Submitted (NOV-1997) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 609-671. RC TISSUE=Fetal brain; RX PubMed=3677994; DOI=10.1089/dna.1987.6.389; RA Coussens L., Rhee L., Parker P.J., Ullrich A.; RT "Alternative splicing increases the diversity of the human protein kinase C RT family."; RL DNA 6:389-394(1987). RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 622-671. RX PubMed=3658678; DOI=10.1093/nar/15.17.7179; RA Kubo K., Ohno S., Suzuki K.; RT "Nucleotide sequence of the 3' portion of a human gene for protein kinase C RT beta-I/beta-II."; RL Nucleic Acids Res. 15:7179-7180(1987). RN [14] RP FUNCTION IN PHOSPHORYLATION OF BTK. RX PubMed=11598012; DOI=10.1093/emboj/20.20.5692; RA Kang S.W., Wahl M.I., Chu J., Kitaura J., Kawakami Y., Kato R.M., RA Tabuchi R., Tarakhovsky A., Kawakami T., Turck C.W., Witte O.N., RA Rawlings D.J.; RT "PKCbeta modulates antigen receptor signaling via regulation of Btk RT membrane localization."; RL EMBO J. 20:5692-5702(2001). RN [15] RP ACTIVITY REGULATION. RX PubMed=16103100; DOI=10.1158/0008-5472.can-05-0071; RA Graff J.R., McNulty A.M., Hanna K.R., Konicek B.W., Lynch R.L., RA Bailey S.N., Banks C., Capen A., Goode R., Lewis J.E., Sams L., Huss K.L., RA Campbell R.M., Iversen P.W., Neubauer B.L., Brown T.J., Musib L., RA Geeganage S., Thornton D.; RT "The protein kinase Cbeta-selective inhibitor, enzastaurin (LY317615.HCl), RT suppresses signaling through the AKT pathway, induces apoptosis, and RT suppresses growth of human colon cancer and glioblastoma xenografts."; RL Cancer Res. 65:7462-7469(2005). RN [16] RP INTERACTION WITH PHLPP1 AND PHLPP2. RX PubMed=18162466; DOI=10.1074/jbc.m707319200; RA Gao T., Brognard J., Newton A.C.; RT "The phosphatase PHLPP controls the cellular levels of protein kinase C."; RL J. Biol. Chem. 283:6300-6311(2008). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Platelet; RX PubMed=18088087; DOI=10.1021/pr0704130; RA Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J., RA Schuetz C., Walter U., Gambaryan S., Sickmann A.; RT "Phosphoproteome of resting human platelets."; RL J. Proteome Res. 7:526-534(2008). RN [18] RP FUNCTION. RX PubMed=19176525; DOI=10.1074/jbc.m808719200; RA Yamasaki T., Takahashi A., Pan J., Yamaguchi N., Yokoyama K.K.; RT "Phosphorylation of activation transcription factor-2 at serine 121 by RT protein kinase c controls c-Jun-mediated activation of transcription."; RL J. Biol. Chem. 284:8567-8581(2009). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-504, PHOSPHORYLATION [LARGE RP SCALE ANALYSIS] AT THR-641 AND SER-660 (ISOFORM BETA-II), AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [20] RP FUNCTION IN HISTONE H3 PHOSPHORYLATION, CATALYTIC ACTIVITY, SUBCELLULAR RP LOCATION, AND INTERACTION WITH KDM1A; PKN1 AND AR. RX PubMed=20228790; DOI=10.1038/nature08839; RA Metzger E., Imhof A., Patel D., Kahl P., Hoffmeyer K., Friedrichs N., RA Muller J.M., Greschik H., Kirfel J., Ji S., Kunowska N., RA Beisenherz-Huss C., Gunther T., Buettner R., Schule R.; RT "Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at RT histone H3K4."; RL Nature 464:792-796(2010). RN [21] RP REVIEW ON FUNCTION. RX PubMed=12417015; DOI=10.1093/oxfordjournals.jbchem.a003273; RA Kawakami T., Kawakami Y., Kitaura J.; RT "Protein kinase C beta (PKC beta): normal functions and diseases."; RL J. Biochem. 132:677-682(2002). RN [22] RP REVIEW ON FUNCTION. RX PubMed=20186491; DOI=10.1007/s11154-010-9134-4; RA Tabit C.E., Chung W.B., Hamburg N.M., Vita J.A.; RT "Endothelial dysfunction in diabetes mellitus: molecular mechanisms and RT clinical implications."; RL Rev. Endocr. Metab. Disord. 11:61-74(2010). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11; THR-17; SER-206; SER-311; RP THR-314 AND THR-642, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-641 AND SER-660 (ISOFORM RP BETA-II), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [26] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=25313067; DOI=10.1073/pnas.1418342111; RA Shibata S., Arroyo J.P., Castaneda-Bueno M., Puthumana J., Zhang J., RA Uchida S., Stone K.L., Lam T.T., Lifton R.P.; RT "Angiotensin II signaling via protein kinase C phosphorylates Kelch-like 3, RT preventing WNK4 degradation."; RL Proc. Natl. Acad. Sci. U.S.A. 111:15556-15561(2014). RN [27] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=25982116; DOI=10.1016/j.molcel.2015.04.015; RA Lee E.E., Ma J., Sacharidou A., Mi W., Salato V.K., Nguyen N., Jiang Y., RA Pascual J.M., North P.E., Shaul P.W., Mettlen M., Wang R.C.; RT "A protein kinase C phosphorylation motif in GLUT1 affects glucose RT transport and is mutated in GLUT1 deficiency syndrome."; RL Mol. Cell 58:845-853(2015). RN [28] RP FUNCTION IN PHOSPHORYLATION OF LRRK1, AND CATALYTIC ACTIVITY. RX PubMed=36040231; DOI=10.1042/bcj20220308; RA Malik A.U., Karapetsas A., Nirujogi R.S., Chatterjee D., Phung T.K., RA Wightman M., Gourlay R., Morrice N., Mathea S., Knapp S., Alessi D.R.; RT "PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues RT (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain."; RL Biochem. J. 479:1941-1965(2022). RN [29] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=35027735; DOI=10.1038/s41556-021-00818-3; RA Zhang H.L., Hu B.X., Li Z.L., Du T., Shan J.L., Ye Z.P., Peng X.D., Li X., RA Huang Y., Zhu X.Y., Chen Y.H., Feng G.K., Yang D., Deng R., Zhu X.F.; RT "PKCbetaII phosphorylates ACSL4 to amplify lipid peroxidation to induce RT ferroptosis."; RL Nat. Cell Biol. 24:88-98(2022). RN [30] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=40246981; DOI=10.1038/s41589-025-01888-2; RA Zhang H.L., Guo Y.Q., Liu S., Ye Z.P., Li L.C., Hu B.X., Li Z.L., RA Chen Y.H., Feng G.K., Shen H.Q., Deng R., Zhu X.F.; RT "Galectin-13 reduces membrane localization of SLC7A11 for ferroptosis RT propagation."; RL Nat. Chem. Biol. 0:0-0(2025). RN [31] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 321-660 IN COMPLEX WITH INHIBITOR, RP AND PHOSPHORYLATION AT THR-500; THR-642 AND SER-661. RX PubMed=17115692; DOI=10.1021/bi061128h; RA Grodsky N., Li Y., Bouzida D., Love R., Jensen J., Nodes B., Nonomiya J., RA Grant S.; RT "Structure of the catalytic domain of human protein kinase C beta II RT complexed with a bisindolylmaleimide inhibitor."; RL Biochemistry 45:13970-13981(2006). RN [32] RP VARIANTS [LARGE SCALE ANALYSIS] MET-144; MET-496 AND HIS-588. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium-activated, phospholipid- and diacylglycerol (DAG)- CC dependent serine/threonine-protein kinase involved in various cellular CC processes such as regulation of the B-cell receptor (BCR) signalosome, CC oxidative stress-induced apoptosis, androgen receptor-dependent CC transcription regulation, insulin signaling and endothelial cells CC proliferation. Plays a key role in B-cell activation by regulating BCR- CC induced NF-kappa-B activation. Mediates the activation of the canonical CC NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11/CARMA1 CC at 'Ser-559', 'Ser-644' and 'Ser-652'. Phosphorylation induces CC CARD11/CARMA1 association with lipid rafts and recruitment of the CC BCL10-MALT1 complex as well as MAP3K7/TAK1, which then activates IKK CC complex, resulting in nuclear translocation and activation of NFKB1. CC Plays a direct role in the negative feedback regulation of the BCR CC signaling, by down-modulating BTK function via direct phosphorylation CC of BTK at 'Ser-180', which results in the alteration of BTK plasma CC membrane localization and in turn inhibition of BTK activity CC (PubMed:11598012). Involved in apoptosis following oxidative damage: in CC case of oxidative conditions, specifically phosphorylates 'Ser-36' of CC isoform p66Shc of SHC1, leading to mitochondrial accumulation of CC p66Shc, where p66Shc acts as a reactive oxygen species producer. Acts CC as a coactivator of androgen receptor (AR)-dependent transcription, by CC being recruited to AR target genes and specifically mediating CC phosphorylation of 'Thr-6' of histone H3 (H3T6ph), a specific tag for CC epigenetic transcriptional activation that prevents demethylation of CC histone H3 'Lys-4' (H3K4me) by LSD1/KDM1A (PubMed:20228790). In insulin CC signaling, may function downstream of IRS1 in muscle cells and mediate CC insulin-dependent DNA synthesis through the RAF1-MAPK/ERK signaling CC cascade. Participates in the regulation of glucose transport in CC adipocytes by negatively modulating the insulin-stimulated CC translocation of the glucose transporter SLC2A4/GLUT4. Phosphorylates CC SLC2A1/GLUT1, promoting glucose uptake by SLC2A1/GLUT1 CC (PubMed:25982116). Under high glucose in pancreatic beta-cells, is CC probably involved in the inhibition of the insulin gene transcription, CC via regulation of MYC expression. In endothelial cells, activation of CC PRKCB induces increased phosphorylation of RB1, increased VEGFA-induced CC cell proliferation, and inhibits PI3K/AKT-dependent nitric oxide CC synthase (NOS3/eNOS) regulation by insulin, which causes endothelial CC dysfunction. Also involved in triglyceride homeostasis (By similarity). CC Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, CC activating transcription (PubMed:19176525). Phosphorylates KLHL3 in CC response to angiotensin II signaling, decreasing the interaction CC between KLHL3 and WNK4 (PubMed:25313067). Phosphorylates and activates CC LRRK1, which phosphorylates RAB proteins involved in intracellular CC trafficking (PubMed:36040231). {ECO:0000250|UniProtKB:P68404, CC ECO:0000269|PubMed:11598012, ECO:0000269|PubMed:19176525, CC ECO:0000269|PubMed:20228790, ECO:0000269|PubMed:25313067, CC ECO:0000269|PubMed:25982116, ECO:0000269|PubMed:36040231}. CC -!- FUNCTION: [Isoform Beta-II]: Acts as an activator of ferroptosis by CC mediating phosphorylation and activation of ACSL4 (PubMed:35027735). CC Also stimulates ferroptosis propagation by catalyzing phosphorylation CC of FOXK1, thereby promoting LGALS13 secretion (PubMed:40246981). CC {ECO:0000269|PubMed:35027735, ECO:0000269|PubMed:40246981}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:20228790, ECO:0000269|PubMed:25982116, CC ECO:0000269|PubMed:36040231}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:20228790, ECO:0000269|PubMed:25982116}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:20228790, ECO:0000269|PubMed:25313067, CC ECO:0000269|PubMed:36040231}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:20228790}; CC -!- CATALYTIC ACTIVITY: [Isoform Beta-II]: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:40246981}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:40246981}; CC -!- CATALYTIC ACTIVITY: [Isoform Beta-II]: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:35027735}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:35027735}; CC -!- COFACTOR: CC Name=Ca(2+); Xref=ChEBI:CHEBI:29108; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU00041}; CC Note=Binds 3 Ca(2+) ions per subunit. The ions are bound to the C2 CC domain. {ECO:0000250|UniProtKB:P68403}; CC -!- ACTIVITY REGULATION: Classical (or conventional) PKCs (PRKCA, PRKCB and CC PRKCG) are activated by calcium and diacylglycerol (DAG) in the CC presence of phosphatidylserine. Three specific sites; Thr-500 CC (activation loop of the kinase domain), Thr-642 (turn motif) and Ser- CC 661 (hydrophobic region), need to be phosphorylated for its full CC activation. Specifically inhibited by enzastaurin (LY317615). CC {ECO:0000269|PubMed:16103100}. CC -!- SUBUNIT: Interacts with PDPK1/PDK1 (By similarity). Interacts in vitro CC with PRKCBP1. Interacts with PHLPP1 and PHLPP2; both proteins mediate CC its dephosphorylation. Interacts with KDM1A/LSD1, PKN1 and AR. CC {ECO:0000250, ECO:0000269|PubMed:17115692, ECO:0000269|PubMed:18162466, CC ECO:0000269|PubMed:20228790}. CC -!- INTERACTION: CC P05771; Q8NEM2: SHCBP1; NbExp=3; IntAct=EBI-706216, EBI-744700; CC P05771; Q9BSI4: TINF2; NbExp=2; IntAct=EBI-706216, EBI-717399; CC P05771-1; O60341-1: KDM1A; NbExp=2; IntAct=EBI-5774492, EBI-15599570; CC P05771-2; Q6DHV7-2: ADAL; NbExp=3; IntAct=EBI-5774511, EBI-18899653; CC P05771-2; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-5774511, EBI-1383687; CC P05771-2; Q6ZQX7-4: LIAT1; NbExp=3; IntAct=EBI-5774511, EBI-25830459; CC P05771-2; O60346: PHLPP1; NbExp=5; IntAct=EBI-5774511, EBI-2511516; CC P05771-2; Q6ZVD8: PHLPP2; NbExp=2; IntAct=EBI-5774511, EBI-2511496; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus CC {ECO:0000269|PubMed:20228790}. Membrane {ECO:0000250}; Peripheral CC membrane protein {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=Beta-I; Synonyms=PRKCB1; CC IsoId=P05771-1; Sequence=Displayed; CC Name=Beta-II; Synonyms=PRKCB2; CC IsoId=P05771-2; Sequence=VSP_004738; CC -!- PTM: Phosphorylation on Thr-500 within the activation loop renders it CC competent to autophosphorylate. Subsequent autophosphorylation of Thr- CC 642 maintains catalytic competence, and autophosphorylation on Ser-661 CC appears to release the kinase into the cytosol. Autophosphorylation on CC other sites i.e. in the N-terminal and hinge regions have no effect on CC enzyme activity. Phosphorylation at Tyr-662 by SYK induces binding with CC GRB2 and contributes to the activation of MAPK/ERK signaling cascade CC (By similarity). {ECO:0000250}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M13975; AAA60095.1; -; mRNA. DR EMBL; X06318; CAA29634.1; -; mRNA. DR EMBL; X07109; CAA30130.1; -; mRNA. DR EMBL; FJ907246; ACS14045.1; -; Genomic_DNA. DR EMBL; AC130454; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC002299; AAB97933.1; -; Genomic_DNA. DR EMBL; AC002299; AAB97934.1; -; Genomic_DNA. DR EMBL; CH471145; EAW55797.1; -; Genomic_DNA. DR EMBL; CH471145; EAW55798.1; -; Genomic_DNA. DR EMBL; BC036472; AAH36472.1; -; mRNA. DR EMBL; X62532; CAA44393.1; -; Genomic_DNA. DR EMBL; S47311; AAD13852.1; -; Genomic_DNA. DR EMBL; D10022; BAA00912.1; -; Genomic_DNA. DR EMBL; AJ002799; CAA05725.1; -; Genomic_DNA. DR EMBL; AJ002800; CAA05725.1; JOINED; Genomic_DNA. DR EMBL; M18254; AAA60096.1; -; Genomic_DNA. DR EMBL; M18255; AAA60097.1; -; Genomic_DNA. DR EMBL; X05972; CAA29396.1; -; Genomic_DNA. DR EMBL; X05971; CAA29395.1; -; Genomic_DNA. DR CCDS; CCDS10618.1; -. [P05771-1] DR CCDS; CCDS10619.1; -. [P05771-2] DR PIR; B24664; KIHUC2. DR PIR; S00159; KIHUC1. DR RefSeq; NP_002729.2; NM_002738.6. [P05771-2] DR RefSeq; NP_997700.1; NM_212535.3. [P05771-1] DR PDB; 2I0E; X-ray; 2.60 A; A/B=321-671. DR PDB; 8SE1; X-ray; 3.32 A; A/B=2-668. DR PDB; 8SE2; X-ray; 2.95 A; A/B=2-671. DR PDB; 8SE3; X-ray; 2.60 A; A=2-671. DR PDB; 8SE4; X-ray; 2.68 A; A/B=2-671. DR PDB; 8SG2; NMR; -; B=641-662. DR PDBsum; 2I0E; -. DR PDBsum; 8SE1; -. DR PDBsum; 8SE2; -. DR PDBsum; 8SE3; -. DR PDBsum; 8SE4; -. DR PDBsum; 8SG2; -. DR AlphaFoldDB; P05771; -. DR SMR; P05771; -. DR BioGRID; 111565; 207. DR CORUM; P05771; -. DR DIP; DIP-34187N; -. DR FunCoup; P05771; 3545. DR IntAct; P05771; 155. DR MINT; P05771; -. DR STRING; 9606.ENSP00000496129; -. DR BindingDB; P05771; -. DR ChEMBL; CHEMBL3045; -. DR DrugBank; DB14001; alpha-Tocopherol succinate. DR DrugBank; DB09096; Benzoyl peroxide. DR DrugBank; DB08862; Cholecystokinin. DR DrugBank; DB14002; D-alpha-Tocopherol acetate. DR DrugBank; DB04209; Dequalinium. DR DrugBank; DB08846; Ellagic acid. DR DrugBank; DB06486; Enzastaurin. DR DrugBank; DB01738; Phosphorylcolamine. DR DrugBank; DB11829; Ruboxistaurin. DR DrugBank; DB12369; Sotrastaurin. DR DrugBank; DB02010; Staurosporine. DR DrugBank; DB00675; Tamoxifen. DR DrugBank; DB00163; Vitamin E. DR DrugCentral; P05771; -. DR GuidetoPHARMACOLOGY; 1483; -. DR TCDB; 8.A.104.1.4; the 5'-amp-activated protein kinase (ampk) family. DR iPTMnet; P05771; -. DR MetOSite; P05771; -. DR PhosphoSitePlus; P05771; -. DR SwissPalm; P05771; -. DR BioMuta; PRKCB; -. DR DMDM; 20141488; -. DR CPTAC; CPTAC-1338; -. DR CPTAC; CPTAC-3051; -. DR CPTAC; CPTAC-3052; -. DR jPOST; P05771; -. DR MassIVE; P05771; -. DR PaxDb; 9606-ENSP00000305355; -. DR PeptideAtlas; P05771; -. DR ProteomicsDB; 51855; -. [P05771-1] DR ProteomicsDB; 51856; -. [P05771-2] DR Pumba; P05771; -. DR Antibodypedia; 3547; 873 antibodies from 46 providers. DR DNASU; 5579; -. DR Ensembl; ENST00000321728.12; ENSP00000318315.7; ENSG00000166501.15. [P05771-1] DR Ensembl; ENST00000643927.1; ENSP00000496129.1; ENSG00000166501.15. [P05771-2] DR GeneID; 5579; -. DR KEGG; hsa:5579; -. DR MANE-Select; ENST00000643927.1; ENSP00000496129.1; NM_002738.7; NP_002729.2. [P05771-2] DR UCSC; uc002dmd.4; human. [P05771-1] DR AGR; HGNC:9395; -. DR CIViC; 5579; 3 evidence items across 2 molecular profiles. DR ClinPGx; PA33761; -. DR CTD; 5579; -. DR DisGeNET; 5579; -. DR GeneCards; PRKCB; -. DR HGNC; HGNC:9395; PRKCB. DR HPA; ENSG00000166501; Tissue enhanced (brain, lymphoid tissue). DR MalaCards; PRKCB; -. DR MIM; 176970; gene. DR OpenTargets; ENSG00000166501; -. DR VEuPathDB; HostDB:ENSG00000166501; -. DR eggNOG; KOG0696; Eukaryota. DR GeneTree; ENSGT00940000155217; -. DR HOGENOM; CLU_000288_54_2_1; -. DR InParanoid; P05771; -. DR OMA; VVXQLKE; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; P05771; 3 GO annotations based on evolutionary models. DR PhylomeDB; P05771; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; P05771; -. DR Reactome; R-HSA-114516; Disinhibition of SNARE formation. DR Reactome; R-HSA-1169091; Activation of NF-kappaB in B cells. DR Reactome; R-HSA-416993; Trafficking of GluR2-containing AMPA receptors. DR Reactome; R-HSA-418597; G alpha (z) signalling events. DR Reactome; R-HSA-4419969; Depolymerization of the Nuclear Lamina. DR Reactome; R-HSA-5099900; WNT5A-dependent internalization of FZD4. DR Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation. DR Reactome; R-HSA-5668599; RHO GTPases Activate NADPH Oxidases. DR Reactome; R-HSA-76005; Response to elevated platelet cytosolic Ca2+. DR Reactome; R-HSA-8939246; RUNX1 regulates transcription of genes involved in differentiation of myeloid cells. DR SABIO-RK; P05771; -. DR SignaLink; P05771; -. DR SIGNOR; P05771; -. DR Agora; ENSG00000166501; -. DR BioGRID-ORCS; 5579; 18 hits in 1197 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; PRKCB; human. DR EvolutionaryTrace; P05771; -. DR GeneWiki; PRKCB1; -. DR GenomeRNAi; 5579; -. DR Pharos; P05771; Tchem. DR PRO; PR:P05771; -. DR Proteomes; UP000005640; Chromosome 16. DR RNAct; P05771; protein. DR Bgee; ENSG00000166501; Expressed in middle temporal gyrus and 189 other cell types or tissues. DR ExpressionAtlas; P05771; baseline and differential. DR GO; GO:0044305; C:calyx of Held; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0099523; C:presynaptic cytosol; IEA:Ensembl. DR GO; GO:0008091; C:spectrin; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005246; F:calcium channel regulator activity; IEA:Ensembl. DR GO; GO:0004698; F:calcium,diacylglycerol-dependent serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; EXP:Reactome. DR GO; GO:0042393; F:histone binding; IDA:UniProtKB. DR GO; GO:0035403; F:histone H3T6 kinase activity; IDA:UniProtKB. DR GO; GO:0050681; F:nuclear androgen receptor binding; IDA:UniProtKB. DR GO; GO:0005080; F:protein kinase C binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0003713; F:transcription coactivator activity; IMP:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0042113; P:B cell activation; ISS:UniProtKB. DR GO; GO:0050853; P:B cell receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0006816; P:calcium ion transport; IEA:Ensembl. DR GO; GO:0071322; P:cellular response to carbohydrate stimulus; IEA:Ensembl. DR GO; GO:0006874; P:intracellular calcium ion homeostasis; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0042953; P:lipoprotein transport; TAS:BHF-UCL. DR GO; GO:0007077; P:mitotic nuclear membrane disassembly; TAS:Reactome. DR GO; GO:0010829; P:negative regulation of D-glucose transmembrane transport; ISS:UniProtKB. DR GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0007207; P:phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway; IEA:Ensembl. DR GO; GO:0045766; P:positive regulation of angiogenesis; ISS:UniProtKB. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; ISS:UniProtKB. DR GO; GO:0160020; P:positive regulation of ferroptosis; IDA:UniProtKB. DR GO; GO:0032024; P:positive regulation of insulin secretion; IEA:Ensembl. DR GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0099171; P:presynaptic modulation of chemical synaptic transmission; IEA:Ensembl. DR GO; GO:0070528; P:protein kinase C signaling; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0010827; P:regulation of D-glucose transmembrane transport; IDA:UniProtKB. DR GO; GO:2000300; P:regulation of synaptic vesicle exocytosis; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IMP:UniProtKB. DR GO; GO:0007165; P:signal transduction; NAS:ProtInc. DR CDD; cd20833; C1_cPKC_rpt1; 1. DR CDD; cd20836; C1_cPKC_rpt2; 1. DR CDD; cd04026; C2_PKC_alpha_gamma; 1. DR CDD; cd05616; STKc_cPKC_beta; 1. DR FunFam; 2.60.40.150:FF:000012; Kinase C alpha type; 1. DR FunFam; 1.10.510.10:FF:000023; Protein kinase C; 1. DR FunFam; 3.30.200.20:FF:000080; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000006; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000031; Protein kinase C alpha; 1. DR Gene3D; 3.30.60.20; -; 2. DR Gene3D; 2.60.40.150; C2 domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR034664; cPKC-beta. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR014375; Protein_kinase_C_a/b/g. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00130; C1_1; 2. DR Pfam; PF00168; C2; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000550; PKC_alpha; 1. DR PRINTS; PR00360; C2DOMAIN. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 2. DR SMART; SM00239; C2; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50004; C2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 2. DR PROSITE; PS50081; ZF_DAG_PE_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Adaptive immunity; Alternative splicing; KW Apoptosis; ATP-binding; Calcium; Chromatin regulator; Cytoplasm; KW Direct protein sequencing; Immunity; Kinase; Membrane; Metal-binding; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Serine/threonine-protein kinase; Transcription; KW Transcription regulation; Transferase; Zinc; Zinc-finger. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|PubMed:12665801" FT CHAIN 2..671 FT /note="Protein kinase C beta type" FT /id="PRO_0000055684" FT DOMAIN 158..275 FT /note="C2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 342..600 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 601..671 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT ZN_FING 36..86 FT /note="Phorbol-ester/DAG-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT ZN_FING 101..151 FT /note="Phorbol-ester/DAG-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 311..330 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 614..635 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 623..635 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 466 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 186 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 187 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 187 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 193 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 246 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 246 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 247 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 248 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 248 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 248 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 251 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 252 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 254 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 254 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 348..356 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 371 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000269|PubMed:12665801" FT MOD_RES 11 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 16 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:P68403, ECO:0000255" FT MOD_RES 17 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 206 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 250 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 311 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 314 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 324 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:P68403, ECO:0000255" FT MOD_RES 500 FT /note="Phosphothreonine; by PDPK1" FT /evidence="ECO:0000305|PubMed:17115692" FT MOD_RES 504 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 635 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:P68403" FT MOD_RES 642 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:17115692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 661 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17115692" FT MOD_RES 662 FT /note="Phosphotyrosine; by SYK" FT /evidence="ECO:0000250|UniProtKB:P68404" FT VAR_SEQ 622..671 FT /note="RDKRDTSNFDKEFTRQPVELTPTDKLFIMNLDQNEFAGFSYTNPEFVINV FT -> CGRNAENFDRFFTRHPPVLTPPDQEVIRNIDQSEFEGFSFVNSEFLKPEVKS (in FT isoform Beta-II)" FT /evidence="ECO:0000303|PubMed:3666134, FT ECO:0000303|PubMed:3755548" FT /id="VSP_004738" FT VARIANT 144 FT /note="V -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs764534677)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042304" FT VARIANT 496 FT /note="V -> M (in a glioblastoma multiforme sample; somatic FT mutation; dbSNP:rs1466858740)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042305" FT VARIANT 588 FT /note="P -> H (in dbSNP:rs35631544)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042306" FT CONFLICT 69 FT /note="V -> G (in Ref. 7; CAA44393)" FT /evidence="ECO:0000305" FT STRAND 342..351 FT /evidence="ECO:0007829|PDB:2I0E" FT STRAND 354..361 FT /evidence="ECO:0007829|PDB:2I0E" FT STRAND 364..374 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 375..380 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 384..394 FT /evidence="ECO:0007829|PDB:2I0E" FT STRAND 406..411 FT /evidence="ECO:0007829|PDB:2I0E" FT STRAND 413..421 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 428..435 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 440..459 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 469..471 FT /evidence="ECO:0007829|PDB:2I0E" FT STRAND 472..474 FT /evidence="ECO:0007829|PDB:2I0E" FT STRAND 480..482 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 505..507 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 510..513 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 521..536 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 546..555 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 566..575 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 590..595 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 598..600 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 605..609 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 629..636 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 646..651 FT /evidence="ECO:0007829|PDB:2I0E" FT TURN 654..657 FT /evidence="ECO:0007829|PDB:2I0E" FT STRAND 658..660 FT /evidence="ECO:0007829|PDB:8SG2" FT MOD_RES P05771-2:641 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:24275569" FT MOD_RES P05771-2:660 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:24275569" SQ SEQUENCE 671 AA; 76869 MW; 3937E7B667108C68 CRC64; MADPAAGPPP SEGEESTVRF ARKGALRQKN VHEVKNHKFT ARFFKQPTFC SHCTDFIWGF GKQGFQCQVC CFVVHKRCHE FVTFSCPGAD KGPASDDPRS KHKFKIHTYS SPTFCDHCGS LLYGLIHQGM KCDTCMMNVH KRCVMNVPSL CGTDHTERRG RIYIQAHIDR DVLIVLVRDA KNLVPMDPNG LSDPYVKLKL IPDPKSESKQ KTKTIKCSLN PEWNETFRFQ LKESDKDRRL SVEIWDWDLT SRNDFMGSLS FGISELQKAS VDGWFKLLSQ EEGEYFNVPV PPEGSEANEE LRQKFERAKI SQGTKVPEEK TTNTVSKFDN NGNRDRMKLT DFNFLMVLGK GSFGKVMLSE RKGTDELYAV KILKKDVVIQ DDDVECTMVE KRVLALPGKP PFLTQLHSCF QTMDRLYFVM EYVNGGDLMY HIQQVGRFKE PHAVFYAAEI AIGLFFLQSK GIIYRDLKLD NVMLDSEGHI KIADFGMCKE NIWDGVTTKT FCGTPDYIAP EIIAYQPYGK SVDWWAFGVL LYEMLAGQAP FEGEDEDELF QSIMEHNVAY PKSMSKEAVA ICKGLMTKHP GKRLGCGPEG ERDIKEHAFF RYIDWEKLER KEIQPPYKPK ARDKRDTSNF DKEFTRQPVE LTPTDKLFIM NLDQNEFAGF SYTNPEFVIN V // ID KPCL_HUMAN Reviewed; 683 AA. AC P24723; B4DJN5; Q16246; Q8NE03; DT 01-MAR-1992, integrated into UniProtKB/Swiss-Prot. DT 15-DEC-2009, sequence version 4. DT 28-JAN-2026, entry version 232. DE RecName: Full=Protein kinase C eta type; DE EC=2.7.11.13 {ECO:0000269|PubMed:34593629}; DE AltName: Full=PKC-L; DE AltName: Full=nPKC-eta; GN Name=PRKCH; Synonyms=PKCL, PRKCL; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY. RC TISSUE=Lung; RX PubMed=1986216; DOI=10.1128/mcb.11.1.126-133.1991; RA Bacher N., Zisman Y., Berent E., Livneh E.; RT "Isolation and characterization of PKC-L, a new member of the protein RT kinase C-related gene family specifically expressed in lung, skin, and RT heart."; RL Mol. Cell. Biol. 11:126-133(1991). RN [2] RP ERRATUM OF PUBMED:1986216, AND SEQUENCE REVISION. RX PubMed=1545821; DOI=10.1128/mcb.12.3.1404-.1992; RA Bacher N., Zisman Y., Berent E., Livneh E.; RL Mol. Cell. Biol. 12:1404-1404(1992). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Thalamus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12508121; DOI=10.1038/nature01348; RA Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C., RA Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A., RA Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H., RA Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T., RA Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B., RA Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D., RA Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R., RA Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S., RA Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C., RA Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S., RA Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., RA Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., RA Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M., RA Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V., RA Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J., RA Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F., RA Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F., RA Waterston R., Hood L., Weissenbach J.; RT "The DNA sequence and analysis of human chromosome 14."; RL Nature 421:601-607(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 438-539 (ISOFORM 1). RX PubMed=7988719; DOI=10.1016/0014-5793(94)01202-4; RA Palmer R.H., Ridden J., Parker P.J.; RT "Identification of multiple, novel, protein kinase C-related gene RT products."; RL FEBS Lett. 356:5-8(1994). RN [8] RP FUNCTION. RX PubMed=11112424; DOI=10.1006/bbrc.2000.3903; RA Akkaraju G.R., Basu A.; RT "Overexpression of protein kinase C-eta attenuates caspase activation and RT tumor necrosis factor-alpha-induced cell death."; RL Biochem. Biophys. Res. Commun. 279:103-107(2000). RN [9] RP FUNCTION IN CELL PROLIFERATION. RX PubMed=10806212; DOI=10.1074/jbc.m003203200; RA Hussaini I.M., Karns L.R., Vinton G., Carpenter J.E., Redpath G.T., RA Sando J.J., VandenBerg S.R.; RT "Phorbol 12-myristate 13-acetate induces protein kinase ceta-specific RT proliferative response in astrocytic tumor cells."; RL J. Biol. Chem. 275:22348-22354(2000). RN [10] RP FUNCTION. RX PubMed=11772428; DOI=10.1093/neuonc/4.1.9; RA Hussaini I.M., Carpenter J.E., Redpath G.T., Sando J.J., Shaffrey M.E., RA Vandenberg S.R.; RT "Protein kinase C-eta regulates resistance to UV- and gamma-irradiation- RT induced apoptosis in glioblastoma cells by preventing caspase-9 RT activation."; RL Neuro-oncol. 4:9-21(2002). RN [11] RP FUNCTION IN CELL PROLIFERATION. RX PubMed=15489897; DOI=10.1038/sj.onc.1208093; RA Aeder S.E., Martin P.M., Soh J.W., Hussaini I.M.; RT "PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR RT signaling pathways."; RL Oncogene 23:9062-9069(2004). RN [12] RP INTERACTION WITH DGKQ. RX PubMed=15632189; DOI=10.1074/jbc.m409301200; RA van Baal J., de Widt J., Divecha N., van Blitterswijk W.J.; RT "Translocation of diacylglycerol kinase theta from cytosol to plasma RT membrane in response to activation of G protein-coupled receptors and RT protein kinase C."; RL J. Biol. Chem. 280:9870-9878(2005). RN [13] RP FUNCTION. RX PubMed=17146445; DOI=10.1038/sj.onc.1210090; RA Uht R.M., Amos S., Martin P.M., Riggan A.E., Hussaini I.M.; RT "The protein kinase C-eta isoform induces proliferation in glioblastoma RT cell lines through an ERK/Elk-1 pathway."; RL Oncogene 26:2885-2893(2007). RN [14] RP FUNCTION IN B-CELL SIGNALING. RX PubMed=18780722; DOI=10.1093/intimm/dxn101; RA Oda A., Ono T., Yamamoto M., Goitsuka R., Kitamura D.; RT "PKC eta directs induction of IRF-4 expression and Ig kappa gene RT rearrangement in pre-BCR signaling pathway."; RL Int. Immunol. 20:1417-1426(2008). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [16] RP INDUCTION. RX PubMed=19797084; DOI=10.1128/mcb.01044-09; RA Raveh-Amit H., Maissel A., Poller J., Marom L., Elroy-Stein O., Shapira M., RA Livneh E.; RT "Translational control of protein kinase Ceta by two upstream open reading RT frames."; RL Mol. Cell. Biol. 29:6140-6148(2009). RN [17] RP FUNCTION IN PHOSPHORYLATION OF OCLN. RX PubMed=19114660; DOI=10.1073/pnas.0802741106; RA Suzuki T., Elias B.C., Seth A., Shen L., Turner J.R., Giorgianni F., RA Desiderio D., Guntaka R., Rao R.; RT "PKC eta regulates occludin phosphorylation and epithelial tight junction RT integrity."; RL Proc. Natl. Acad. Sci. U.S.A. 106:61-66(2009). RN [18] RP FUNCTION. RX PubMed=20558593; DOI=10.1124/mol.110.064394; RA Lee H.K., Yeo S., Kim J.S., Lee J.G., Bae Y.S., Lee C., Baek S.H.; RT "Protein kinase C-eta and phospholipase D2 pathway regulates foam cell RT formation via regulator of G protein signaling 2."; RL Mol. Pharmacol. 78:478-485(2010). RN [19] RP FUNCTION. RX PubMed=21820409; DOI=10.1016/j.bbrc.2011.07.090; RA Raveh-Amit H., Hai N., Rotem-Dai N., Shahaf G., Gopas J., Livneh E.; RT "Protein kinase C? activates NF-?B in response to camptothecin-induced DNA RT damage."; RL Biochem. Biophys. Res. Commun. 412:313-317(2011). RN [20] RP REVIEW. RX PubMed=12473186; DOI=10.1093/oxfordjournals.jbchem.a003297; RA Kashiwagi M., Ohba M., Chida K., Kuroki T.; RT "Protein kinase C eta (PKC eta): its involvement in keratinocyte RT differentiation."; RL J. Biochem. 132:853-857(2002). RN [21] RP FUNCTION. RX PubMed=22304920; DOI=10.1016/j.cell.2012.01.016; RA Lau E., Kluger H., Varsano T., Lee K., Scheffler I., Rimm D.L., Ideker T., RA Ronai Z.A.; RT "PKCepsilon promotes oncogenic functions of ATF2 in the nucleus while RT blocking its apoptotic function at mitochondria."; RL Cell 148:543-555(2012). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-28, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-656, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [24] RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, INTERACTION WITH PRKCH UPSTREAM RP OPEN READING FRAME 2, AND PHOSPHORYLATION AT THR-656 AND SER-675. RX PubMed=34593629; DOI=10.1073/pnas.2018899118; RA Jayaram D.R., Frost S., Argov C., Liju V.B., Anto N.P., Muraleedharan A., RA Ben-Ari A., Sinay R., Smoly I., Novoplansky O., Isakov N., Toiber D., RA Keasar C., Elkabets M., Yeger-Lotem E., Livneh E.; RT "Unraveling the hidden role of a uORF-encoded peptide as a kinase inhibitor RT of PKCs."; RL Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021). RN [25] RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 1-138, PHOSPHORYLATION AT SER-28 RP AND SER-32, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=16973127; DOI=10.1016/j.bbrc.2006.08.160; RA Littler D.R., Walker J.R., She Y.-M., Finerty P.J. Jr., Newman E.M., RA Dhe-Paganon S.; RT "Structure of human protein kinase C eta (PKCeta) C2 domain and RT identification of phosphorylation sites."; RL Biochem. Biophys. Res. Commun. 349:1182-1189(2006). RN [26] RP ASSOCIATION OF VARIANT ILE-374 WITH ISCHSTR, AND CHARACTERIZATION OF RP VARIANT ILE-374. RX PubMed=17206144; DOI=10.1038/ng1945; RA Kubo M., Hata J., Ninomiya T., Matsuda K., Yonemoto K., Nakano T., RA Matsushita T., Yamazaki K., Ohnishi Y., Saito S., Kitazono T., Ibayashi S., RA Sueishi K., Iida M., Nakamura Y., Kiyohara Y.; RT "A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of RT cerebral infarction."; RL Nat. Genet. 39:212-217(2007). RN [27] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-19; ARG-65; GLN-149; GLN-359; ILE-374; RP ALA-575; ILE-594 AND SER-612. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium-independent, phospholipid- and diacylglycerol (DAG)- CC dependent serine/threonine-protein kinase that is involved in the CC regulation of cell differentiation in keratinocytes and pre-B cell CC receptor, mediates regulation of epithelial tight junction integrity CC and foam cell formation, and is required for glioblastoma proliferation CC and apoptosis prevention in MCF-7 cells. In keratinocytes, binds and CC activates the tyrosine kinase FYN, which in turn blocks epidermal CC growth factor receptor (EGFR) signaling and leads to keratinocyte CC growth arrest and differentiation. Associates with the cyclin CCNE1- CC CDK2-CDKN1B complex and inhibits CDK2 kinase activity, leading to RB1 CC dephosphorylation and thereby G1 arrest in keratinocytes. In CC association with RALA activates actin depolymerization, which is CC necessary for keratinocyte differentiation. In the pre-B cell receptor CC signaling, functions downstream of BLNK by up-regulating IRF4, which in CC turn activates L chain gene rearrangement. Regulates epithelial tight CC junctions (TJs) by phosphorylating occludin (OCLN) on threonine CC residues, which is necessary for the assembly and maintenance of TJs. CC In association with PLD2 and via TLR4 signaling, is involved in CC lipopolysaccharide (LPS)-induced RGS2 down-regulation and foam cell CC formation. Upon PMA stimulation, mediates glioblastoma cell CC proliferation by activating the mTOR pathway, the PI3K/AKT pathway and CC the ERK1-dependent phosphorylation of ELK1. Involved in the protection CC of glioblastoma cells from irradiation-induced apoptosis by preventing CC caspase-9 activation. In camptothecin-treated MCF-7 cells, regulates CC NF-kappa-B upstream signaling by activating IKBKB, and confers CC protection against DNA damage-induced apoptosis. Promotes oncogenic CC functions of ATF2 in the nucleus while blocking its apoptotic function CC at mitochondria. Phosphorylates ATF2 which promotes its nuclear CC retention and transcriptional activity and negatively regulates its CC mitochondrial localization. {ECO:0000269|PubMed:10806212, CC ECO:0000269|PubMed:11112424, ECO:0000269|PubMed:11772428, CC ECO:0000269|PubMed:15489897, ECO:0000269|PubMed:17146445, CC ECO:0000269|PubMed:18780722, ECO:0000269|PubMed:19114660, CC ECO:0000269|PubMed:20558593, ECO:0000269|PubMed:21820409, CC ECO:0000269|PubMed:22304920}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:34593629}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:34593629}; CC -!- ACTIVITY REGULATION: Novel PKCs (PRKCD, PRKCE, PRKCH and PRKCQ) are CC calcium-insensitive, but activated by diacylglycerol (DAG) and CC phosphatidylserine. Three specific sites; Thr-513 (activation loop of CC the kinase domain), Thr-656 (turn motif) and Ser-675 (hydrophobic CC region), need to be phosphorylated for its full activation. Inhibited CC by PRKCH upstream open reading frame 2 (PubMed:34593629). CC {ECO:0000269|PubMed:34593629}. CC -!- SUBUNIT: Interacts with FYN (By similarity). Interacts with RALA (By CC similarity). Interacts with DGKQ (PubMed:15632189). Interacts with CC PRKCH upstream open reading frame 2; the interaction leads to CC inhibition of kinase activity (PubMed:34593629). CC {ECO:0000250|UniProtKB:P23298, ECO:0000269|PubMed:15632189, CC ECO:0000269|PubMed:34593629}. CC -!- INTERACTION: CC P24723; Q16625-1: OCLN; NbExp=2; IntAct=EBI-2865850, EBI-16115673; CC P24723; Q28269: OCLN; Xeno; NbExp=2; IntAct=EBI-2865850, EBI-16222162; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P24723-1; Sequence=Displayed; CC Name=2; CC IsoId=P24723-2; Sequence=VSP_056572; CC -!- TISSUE SPECIFICITY: Most abundant in lung, less in heart and skin. CC {ECO:0000269|PubMed:1986216}. CC -!- INDUCTION: By stress conditions caused by amino acid starvation (at CC protein level). {ECO:0000269|PubMed:19797084}. CC -!- DOMAIN: The C1 domain, containing the phorbol ester/DAG-type region 1 CC (C1A) and 2 (C1B), is the diacylglycerol sensor and the C2 domain is a CC non-calcium binding domain. CC -!- DISEASE: Ischemic stroke (ISCHSTR) [MIM:601367]: A stroke is an acute CC neurologic event leading to death of neural tissue of the brain and CC resulting in loss of motor, sensory and/or cognitive function. Ischemic CC strokes, resulting from vascular occlusion, is considered to be a CC highly complex disease consisting of a group of heterogeneous disorders CC with multiple genetic and environmental risk factors. CC {ECO:0000269|PubMed:17206144}. Note=Disease susceptibility is CC associated with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M55284; AAA60100.1; -; mRNA. DR EMBL; AK290183; BAF82872.1; -; mRNA. DR EMBL; AK296158; BAG58897.1; -; mRNA. DR EMBL; AL138996; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL355916; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL359220; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471061; EAW80800.1; -; Genomic_DNA. DR EMBL; CH471061; EAW80801.1; -; Genomic_DNA. DR EMBL; BC037268; AAH37268.1; -; mRNA. DR EMBL; S74620; AAB32724.1; -; mRNA. DR CCDS; CCDS9752.1; -. [P24723-1] DR PIR; A39666; A39666. DR RefSeq; NP_006246.2; NM_006255.4. [P24723-1] DR RefSeq; XP_024305429.1; XM_024449661.2. [P24723-2] DR RefSeq; XP_024305430.1; XM_024449662.2. [P24723-2] DR RefSeq; XP_054232364.1; XM_054376389.1. [P24723-2] DR RefSeq; XP_054232365.1; XM_054376390.1. [P24723-2] DR PDB; 2FK9; X-ray; 1.75 A; A=1-138. DR PDB; 3TXO; X-ray; 2.05 A; A=333-683. DR PDB; 8FP1; X-ray; 1.85 A; A=333-683. DR PDB; 8FP3; X-ray; 2.30 A; A=333-683. DR PDBsum; 2FK9; -. DR PDBsum; 3TXO; -. DR PDBsum; 8FP1; -. DR PDBsum; 8FP3; -. DR AlphaFoldDB; P24723; -. DR SMR; P24723; -. DR BioGRID; 111569; 31. DR DIP; DIP-44588N; -. DR FunCoup; P24723; 864. DR IntAct; P24723; 14. DR MINT; P24723; -. DR STRING; 9606.ENSP00000329127; -. DR BindingDB; P24723; -. DR ChEMBL; CHEMBL3616; -. DR DrugCentral; P24723; -. DR GuidetoPHARMACOLOGY; 1487; -. DR GlyGen; P24723; 3 sites, 3 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; P24723; -. DR PhosphoSitePlus; P24723; -. DR BioMuta; PRKCH; -. DR DMDM; 281185512; -. DR CPTAC; CPTAC-3187; -. DR CPTAC; CPTAC-3188; -. DR jPOST; P24723; -. DR MassIVE; P24723; -. DR PaxDb; 9606-ENSP00000329127; -. DR PeptideAtlas; P24723; -. DR ProteomicsDB; 4395; -. DR ProteomicsDB; 54223; -. [P24723-1] DR Pumba; P24723; -. DR Antibodypedia; 24422; 309 antibodies from 34 providers. DR DNASU; 5583; -. DR Ensembl; ENST00000332981.11; ENSP00000329127.5; ENSG00000027075.18. [P24723-1] DR Ensembl; ENST00000555082.6; ENSP00000450981.1; ENSG00000027075.18. [P24723-2] DR GeneID; 5583; -. DR KEGG; hsa:5583; -. DR MANE-Select; ENST00000332981.11; ENSP00000329127.5; NM_006255.5; NP_006246.2. DR UCSC; uc001xfn.4; human. [P24723-1] DR AGR; HGNC:9403; -. DR ClinPGx; PA33767; -. DR CTD; 5583; -. DR DisGeNET; 5583; -. DR GeneCards; PRKCH; -. DR HGNC; HGNC:9403; PRKCH. DR HPA; ENSG00000027075; Low tissue specificity. DR MalaCards; PRKCH; -. DR MIM; 601367; phenotype. DR MIM; 605437; gene. DR OpenTargets; ENSG00000027075; -. DR VEuPathDB; HostDB:ENSG00000027075; -. DR eggNOG; KOG0694; Eukaryota. DR GeneTree; ENSGT00940000158220; -. DR HOGENOM; CLU_000288_54_4_1; -. DR InParanoid; P24723; -. DR OMA; MTKNPNM; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; P24723; 3 GO annotations based on evolutionary models. DR PhylomeDB; P24723; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; P24723; -. DR Reactome; R-HSA-114508; Effects of PIP2 hydrolysis. DR Reactome; R-HSA-418597; G alpha (z) signalling events. DR SABIO-RK; P24723; -. DR SignaLink; P24723; -. DR SIGNOR; P24723; -. DR Agora; ENSG00000027075; -. DR BioGRID-ORCS; 5583; 14 hits in 1196 CRISPR screens. DR ChiTaRS; PRKCH; human. DR EvolutionaryTrace; P24723; -. DR GeneWiki; PRKCH; -. DR GenomeRNAi; 5583; -. DR Pharos; P24723; Tchem. DR PRO; PR:P24723; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; P24723; protein. DR Bgee; ENSG00000027075; Expressed in parotid gland and 189 other cell types or tissues. DR ExpressionAtlas; P24723; baseline and differential. DR GO; GO:0005911; C:cell-cell junction; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; ISS:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; TAS:ProtInc. DR GO; GO:0004699; F:diacylglycerol-dependent, calcium-independent serine/threonine kinase activity; IEA:Ensembl. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0031267; F:small GTPase binding; IEA:Ensembl. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0034351; P:negative regulation of glial cell apoptotic process; IMP:UniProtKB. DR GO; GO:0141212; P:phospholipase C/protein kinase C signal transduction; IEA:Ensembl. DR GO; GO:0050861; P:positive regulation of B cell receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0060252; P:positive regulation of glial cell proliferation; IMP:UniProtKB. DR GO; GO:0045618; P:positive regulation of keratinocyte differentiation; ISS:UniProtKB. DR GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; ISS:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; TAS:ParkinsonsUK-UCL. DR GO; GO:0006468; P:protein phosphorylation; IMP:UniProtKB. DR GO; GO:2000810; P:regulation of bicellular tight junction assembly; IMP:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd20835; C1_nPKC_epsilon-like_rpt1; 1. DR CDD; cd20838; C1_nPKC_epsilon-like_rpt2; 1. DR CDD; cd04014; C2_PKC_epsilon; 1. DR CDD; cd05590; STKc_nPKC_eta; 1. DR FunFam; 3.30.200.20:FF:000080; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000003; Protein kinase C delta; 1. DR FunFam; 1.10.510.10:FF:000126; Protein kinase C epsilon; 1. DR FunFam; 2.60.40.150:FF:000056; Protein kinase C epsilon; 1. DR FunFam; 3.30.60.20:FF:000024; Protein kinase C epsilon; 1. DR Gene3D; 3.30.60.20; -; 2. DR Gene3D; 2.60.40.150; C2 domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR034665; nPKC_eta. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR027431; PKC_eta. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR014376; Prot_kin_PKC_delta. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00130; C1_1; 2. DR Pfam; PF00168; C2; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000551; PKC_delta; 1. DR PIRSF; PIRSF501107; Protein_kin_C_eta; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 2. DR SMART; SM00239; C2; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50004; C2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 2. DR PROSITE; PS50081; ZF_DAG_PE_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cytoplasm; KW Differentiation; Kinase; Metal-binding; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..683 FT /note="Protein kinase C eta type" FT /id="PRO_0000055705" FT DOMAIN 1..118 FT /note="C2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 355..614 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 615..683 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT ZN_FING 171..222 FT /note="Phorbol-ester/DAG-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT ZN_FING 245..295 FT /note="Phorbol-ester/DAG-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 320..342 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 479 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 361..369 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 384 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 28 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:16973127, FT ECO:0007744|PubMed:23186163" FT MOD_RES 32 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:16973127" FT MOD_RES 317 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P23298" FT MOD_RES 513 FT /note="Phosphothreonine; by PDPK1" FT /evidence="ECO:0000305" FT MOD_RES 656 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:34593629, FT ECO:0007744|PubMed:24275569" FT MOD_RES 675 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:34593629" FT VAR_SEQ 1..161 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_056572" FT VARIANT 19 FT /note="A -> V (in dbSNP:rs55645551)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042312" FT VARIANT 65 FT /note="K -> R (in dbSNP:rs55737090)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042313" FT VARIANT 149 FT /note="R -> Q (in dbSNP:rs55848048)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042314" FT VARIANT 359 FT /note="R -> Q (in dbSNP:rs55818778)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042315" FT VARIANT 374 FT /note="V -> I (risk factor for ischemic stroke; increases FT autophosphorylation and kinase activity; dbSNP:rs2230500)" FT /evidence="ECO:0000269|PubMed:17206144, FT ECO:0000269|PubMed:17344846" FT /id="VAR_034604" FT VARIANT 497 FT /note="D -> Y (in dbSNP:rs11846991)" FT /id="VAR_060736" FT VARIANT 575 FT /note="T -> A (in a aLL TEL/AML1+ sample; somatic mutation; FT dbSNP:rs1378993559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042316" FT VARIANT 594 FT /note="T -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042317" FT VARIANT 612 FT /note="P -> S (in dbSNP:rs34159231)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042318" FT VARIANT 645 FT /note="D -> V (in dbSNP:rs35561533)" FT /id="VAR_042438" FT CONFLICT 96 FT /note="Missing (in Ref. 1; AAA60100)" FT /evidence="ECO:0000305" FT CONFLICT 109 FT /note="L -> R (in Ref. 1; AAA60100)" FT /evidence="ECO:0000305" FT CONFLICT 110 FT /note="R -> G (in Ref. 1; AAA60100)" FT /evidence="ECO:0000305" FT CONFLICT 393 FT /note="Q -> L (in Ref. 1; AAA60100)" FT /evidence="ECO:0000305" FT CONFLICT 472 FT /note="D -> E (in Ref. 7; AAB32724)" FT /evidence="ECO:0000305" FT STRAND 8..20 FT /evidence="ECO:0007829|PDB:2FK9" FT HELIX 26..30 FT /evidence="ECO:0007829|PDB:2FK9" FT TURN 31..33 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 34..37 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 43..49 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 52..56 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 67..79 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 81..88 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 91..94 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 96..104 FT /evidence="ECO:0007829|PDB:2FK9" FT HELIX 105..112 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 116..123 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 125..127 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 129..137 FT /evidence="ECO:0007829|PDB:2FK9" FT HELIX 352..354 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 355..364 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 367..374 FT /evidence="ECO:0007829|PDB:8FP1" FT TURN 375..377 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 380..387 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 388..393 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 397..409 FT /evidence="ECO:0007829|PDB:8FP1" FT TURN 410..412 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 419..424 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 426..434 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 438..440 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 441..448 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 453..472 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 482..484 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 485..487 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 493..495 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 518..520 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 523..526 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 534..549 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 559..568 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 579..588 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 593..595 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 600..602 FT /evidence="ECO:0007829|PDB:8FP1" FT TURN 603..605 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 606..609 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 612..614 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 619..623 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 646..648 FT /evidence="ECO:0007829|PDB:8FP1" FT TURN 660..662 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 663..665 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 668..671 FT /evidence="ECO:0007829|PDB:8FP1" SQ SEQUENCE 683 AA; 77828 MW; 0A29806CE31912F2 CRC64; MSSGTMKFNG YLRVRIGEAV GLQPTRWSLR HSLFKKGHQL LDPYLTVSVD QVRVGQTSTK QKTNKPTYNE EFCANVTDGG HLELAVFHET PLGYDHFVAN CTLQFQELLR TTGASDTFEG WVDLEPEGKV FVVITLTGSF TEATLQRDRI FKHFTRKRQR AMRRRVHQIN GHKFMATYLR QPTYCSHCRE FIWGVFGKQG YQCQVCTCVV HKRCHHLIVT ACTCQNNINK VDSKIAEQRF GINIPHKFSI HNYKVPTFCD HCGSLLWGIM RQGLQCKICK MNVHIRCQAN VAPNCGVNAV ELAKTLAGMG LQPGNISPTS KLVSRSTLRR QGKESSKEGN GIGVNSSNRL GIDNFEFIRV LGKGSFGKVM LARVKETGDL YAVKVLKKDV ILQDDDVECT MTEKRILSLA RNHPFLTQLF CCFQTPDRLF FVMEFVNGGD LMFHIQKSRR FDEARARFYA AEIISALMFL HDKGIIYRDL KLDNVLLDHE GHCKLADFGM CKEGICNGVT TATFCGTPDY IAPEILQEML YGPAVDWWAM GVLLYEMLCG HAPFEAENED DLFEAILNDE VVYPTWLHED ATGILKSFMT KNPTMRLGSL TQGGEHAILR HPFFKEIDWA QLNHRQIEPP FRPRIKSRED VSNFDPDFIK EEPVLTPIDE GHLPMINQDE FRNFSYVSPE LQP // ID KPCT_HUMAN Reviewed; 706 AA. AC Q04759; B4DF52; Q14DH6; Q3MJF1; Q64FY5; Q9H508; Q9H549; DT 01-OCT-1993, integrated into UniProtKB/Swiss-Prot. DT 27-MAR-2002, sequence version 3. DT 28-JAN-2026, entry version 247. DE RecName: Full=Protein kinase C theta type; DE EC=2.7.11.13 {ECO:0000269|PubMed:23509302, ECO:0000269|PubMed:34593629, ECO:0000269|PubMed:36040231}; DE AltName: Full=nPKC-theta; GN Name=PRKCQ; Synonyms=PRKCT; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANT RP LEU-330. RX PubMed=7686153; DOI=10.1016/s0021-9258(19)85228-6; RA Chang J.D., Xu Y., Raychowdhury M.K., Ware J.A.; RT "Molecular cloning and expression of a cDNA encoding a novel isoenzyme of RT protein kinase C (nPKC). A new member of the nPKC family expressed in RT skeletal muscle, megakaryoblastic cells, and platelets."; RL J. Biol. Chem. 268:14208-14214(1993). RN [2] RP ERRATUM OF PUBMED:7686153, AND SEQUENCE REVISION. RX PubMed=7983077; DOI=10.1016/s0021-9258(18)47426-1; RA Chang J.D., Xu Y., Raychowdhury M.K., Ware J.A.; RL J. Biol. Chem. 269:31322-31322(1994). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Blood; RX PubMed=8444877; DOI=10.1016/s0021-9258(18)53494-3; RA Baier G., Telford D., Giampa L., Coggeshall K.M., Baier-Bitterlich G., RA Isakov N., Altman A.; RT "Molecular cloning and characterization of PKC theta, a novel member of the RT protein kinase C (PKC) gene family expressed predominantly in hematopoietic RT cells."; RL J. Biol. Chem. 268:4997-5004(1993). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT LEU-330. RA Li H., Ke R., Zhou G., Shen C., Zhong G., Lin L., Yang S.; RL Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Cerebellum; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP FUNCTION IN ACTIVATION OF JUN. RX PubMed=8657160; DOI=10.1128/mcb.16.4.1842; RA Baier-Bitterlich G., Uberall F., Bauer B., Fresser F., Wachter H., RA Grunicke H., Utermann G., Altman A., Baier G.; RT "Protein kinase C-theta isoenzyme selective stimulation of the RT transcription factor complex AP-1 in T lymphocytes."; RL Mol. Cell. Biol. 16:1842-1850(1996). RN [9] RP INTERACTION WITH GLRX3. RX PubMed=10636891; DOI=10.1074/jbc.275.3.1902; RA Witte S., Villalba M., Bi K., Liu Y., Isakov N., Altman A.; RT "Inhibition of the c-Jun N-terminal kinase/AP-1 and NF-kappaB pathways by RT PICOT, a novel protein kinase C-interacting protein with a thioredoxin RT homology domain."; RL J. Biol. Chem. 275:1902-1909(2000). RN [10] RP PHOSPHORYLATION AT TYR-90, AND MUTAGENESIS OF TYR-90; ALA-148 AND LYS-409. RX PubMed=10652356; DOI=10.1074/jbc.275.5.3603; RA Liu Y., Witte S., Liu Y.C., Doyle M., Elly C., Altman A.; RT "Regulation of protein kinase Ctheta function during T cell activation by RT Lck-mediated tyrosine phosphorylation."; RL J. Biol. Chem. 275:3603-3609(2000). RN [11] RP FUNCTION IN PHOSPHORYLATION OF BAD. RX PubMed=11342610; DOI=10.4049/jimmunol.166.10.5955; RA Villalba M., Bushway P., Altman A.; RT "Protein kinase C-theta mediates a selective T cell survival signal via RT phosphorylation of BAD."; RL J. Immunol. 166:5955-5963(2001). RN [12] RP PHOSPHORYLATION AT THR-538; SER-676 AND SER-695, AND MUTAGENESIS OF THR-538 RP AND SER-695. RX PubMed=11772397; DOI=10.1042/bj3610255; RA Liu Y., Graham C., Li A., Fisher R.J., Shaw S.; RT "Phosphorylation of the protein kinase C-theta activation loop and RT hydrophobic motif regulates its kinase activity, but only activation loop RT phosphorylation is critical to in vivo nuclear-factor-kappaB induction."; RL Biochem. J. 361:255-265(2002). RN [13] RP FUNCTION IN PHOSPHORYLATION OF STK39/SPAK. RX PubMed=14988727; DOI=10.1038/sj.emboj.7600125; RA Li Y., Hu J., Vita R., Sun B., Tabata H., Altman A.; RT "SPAK kinase is a substrate and target of PKCtheta in T-cell receptor- RT induced AP-1 activation pathway."; RL EMBO J. 23:1112-1122(2004). RN [14] RP FUNCTION IN PHOSPHORYLATION OF IRS1. RX PubMed=15364919; DOI=10.1074/jbc.c400186200; RA Li Y., Soos T.J., Li X., Wu J., Degennaro M., Sun X., Littman D.R., RA Birnbaum M.J., Polakiewicz R.D.; RT "Protein kinase C Theta inhibits insulin signaling by phosphorylating IRS1 RT at Ser(1101)."; RL J. Biol. Chem. 279:45304-45307(2004). RN [15] RP INTERACTION WITH ECT2. RX PubMed=15254234; DOI=10.1128/mcb.24.15.6665-6675.2004; RA Liu X.F., Ishida H., Raziuddin R., Miki T.; RT "Nucleotide exchange factor ECT2 interacts with the polarity protein RT complex Par6/Par3/protein kinase Czeta (PKCzeta) and regulates PKCzeta RT activity."; RL Mol. Cell. Biol. 24:6665-6675(2004). RN [16] RP FUNCTION, PHOSPHORYLATION AT THR-219; THR-538; SER-676 AND SER-695, AND RP MUTAGENESIS OF THR-219; THR-538; SER-676 AND SER-695. RX PubMed=16252004; DOI=10.1038/sj.emboj.7600856; RA Thuille N., Heit I., Fresser F., Krumbock N., Bauer B., Leuthaeusser S., RA Dammeier S., Graham C., Copeland T.D., Shaw S., Baier G.; RT "Critical role of novel Thr-219 autophosphorylation for the cellular RT function of PKCtheta in T lymphocytes."; RL EMBO J. 24:3869-3880(2005). RN [17] RP FUNCTION IN PHOSPHORYLATION OF CARD11, AND SUBUNIT. RX PubMed=16356855; DOI=10.1016/j.immuni.2005.09.014; RA Sommer K., Guo B., Pomerantz J.L., Bandaranayake A.D., Moreno-Garcia M.E., RA Ovechkina Y.L., Rawlings D.J.; RT "Phosphorylation of the CARMA1 linker controls NF-kappaB activation."; RL Immunity 23:561-574(2005). RN [18] RP FUNCTION IN ACTIVATION OF BCL-X(L)/BCL2L1. RX PubMed=16709830; DOI=10.4049/jimmunol.176.11.6709; RA Manicassamy S., Gupta S., Huang Z., Sun Z.; RT "Protein kinase C-theta-mediated signals enhance CD4+ T cell survival by RT up-regulating Bcl-xL."; RL J. Immunol. 176:6709-6716(2006). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-348; SER-685 AND SER-695, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-676 AND SER-695, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [21] RP FUNCTION IN PHOSPHORYLATION OF CBLB. RX PubMed=19549985; DOI=10.1126/scisignal.2000046; RA Gruber T., Hermann-Kleiter N., Hinterleitner R., Fresser F., Schneider R., RA Gastl G., Penninger J.M., Baier G.; RT "PKC-theta modulates the strength of T cell responses by targeting Cbl-b RT for ubiquitination and degradation."; RL Sci. Signal. 2:RA30-RA30(2009). RN [22] RP FUNCTION, AND INTERACTION WITH CD28. RX PubMed=21964608; DOI=10.1038/ni.2120; RA Kong K.F., Yokosuka T., Canonigo-Balancio A.J., Isakov N., Saito T., RA Altman A.; RT "A motif in the V3 domain of the kinase PKC-theta determines its RT localization in the immunological synapse and functions in T cells via RT association with CD28."; RL Nat. Immunol. 12:1105-1112(2011). RN [23] RP REVIEW ON FUNCTION. RX PubMed=11861617; DOI=10.1146/annurev.immunol.20.100301.064807; RA Isakov N., Altman A.; RT "Protein kinase C(theta) in T cell activation."; RL Annu. Rev. Immunol. 20:761-794(2002). RN [24] RP REVIEW ON FUNCTION. RX PubMed=12473184; DOI=10.1093/oxfordjournals.jbchem.a003295; RA Altman A., Villalba M.; RT "Protein kinase C-theta (PKC theta): a key enzyme in T cell life and RT death."; RL J. Biochem. 132:841-846(2002). RN [25] RP REVIEW. RX PubMed=15282562; DOI=10.1038/ni1097; RA Spitaler M., Cantrell D.A.; RT "Protein kinase C and beyond."; RL Nat. Immunol. 5:785-790(2004). RN [26] RP REVIEW ON FUNCTION. RX PubMed=16978534; RA Manicassamy S., Gupta S., Sun Z.; RT "Selective function of PKC-theta in T cells."; RL Cell. Mol. Immunol. 3:263-270(2006). RN [27] RP REVIEW ON FUNCTION. RX PubMed=17544292; DOI=10.1016/j.phrs.2007.04.009; RA Hayashi K., Altman A.; RT "Protein kinase C theta (PKCtheta): a key player in T cell life and RT death."; RL Pharmacol. Res. 55:537-544(2007). RN [28] RP REVIEW ON FUNCTION. RX PubMed=18328786; DOI=10.1016/j.it.2008.01.005; RA Marsland B.J., Kopf M.; RT "T-cell fate and function: PKC-theta and beyond."; RL Trends Immunol. 29:179-185(2008). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-685, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [30] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [31] RP REVIEW ON FUNCTION IN PLATELET ACTIVATION. RX PubMed=21944869; DOI=10.1016/j.febslet.2011.09.014; RA Cohen S., Braiman A., Shubinsky G., Isakov N.; RT "Protein kinase C-theta in platelet activation."; RL FEBS Lett. 585:3208-3215(2011). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-685 AND SER-695, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-676; SER-685 AND SER-695, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [34] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH CCDC88A. RX PubMed=23509302; DOI=10.1073/pnas.1303392110; RA Lopez-Sanchez I., Garcia-Marcos M., Mittal Y., Aznar N., Farquhar M.G., RA Ghosh P.; RT "Protein kinase C-theta (PKCtheta) phosphorylates and inhibits the guanine RT exchange factor, GIV/Girdin."; RL Proc. Natl. Acad. Sci. U.S.A. 110:5510-5515(2013). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-695, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [36] RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND INTERACTION WITH PRKCH RP UPSTREAM OPEN READING FRAME 2. RX PubMed=34593629; DOI=10.1073/pnas.2018899118; RA Jayaram D.R., Frost S., Argov C., Liju V.B., Anto N.P., Muraleedharan A., RA Ben-Ari A., Sinay R., Smoly I., Novoplansky O., Isakov N., Toiber D., RA Keasar C., Elkabets M., Yeger-Lotem E., Livneh E.; RT "Unraveling the hidden role of a uORF-encoded peptide as a kinase inhibitor RT of PKCs."; RL Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021). RN [37] RP FUNCTION IN PHOSPHORYLATION OF LRRK1. RX PubMed=36040231; DOI=10.1042/bcj20220308; RA Malik A.U., Karapetsas A., Nirujogi R.S., Chatterjee D., Phung T.K., RA Wightman M., Gourlay R., Morrice N., Mathea S., Knapp S., Alessi D.R.; RT "PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues RT (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain."; RL Biochem. J. 479:1941-1965(2022). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 362-706, AND PHOSPHORYLATION AT RP THR-538 AND SER-695. RX PubMed=15364937; DOI=10.1074/jbc.m409216200; RA Xu Z.B., Chaudhary D., Olland S., Wolfrom S., Czerwinski R., Malakian K., RA Lin L., Stahl M.L., Joseph-McCarthy D., Benander C., Fitz L., Greco R., RA Somers W.S., Mosyak L.; RT "Catalytic domain crystal structure of protein kinase C-theta (PKCtheta)."; RL J. Biol. Chem. 279:50401-50409(2004). RN [39] RP X-RAY CRYSTALLOGRAPHY (2.32 ANGSTROMS) OF 361-706, AND PHOSPHORYLATION AT RP SER-676 AND SER-695. RA Stark W., Bitsch F., Berner A., Buelens F., Graff P., Depersin H., RA Fendrich G., Geiser M., Knecht R., Rahuel J., Rummel G., Schlaeppi J.M., RA Schmitz R., Strauss A., Wagner J.; RT "The crystal structure of the kinase domain of the protein kinase C theta RT in complex with Nvp-Xaa228."; RL Submitted (JAN-2007) to the PDB data bank. RN [40] RP VARIANTS [LARGE SCALE ANALYSIS] ASN-240; VAL-306; LEU-330 AND ASN-354. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium-independent, phospholipid- and diacylglycerol (DAG)- CC dependent serine/threonine-protein kinase that mediates non-redundant CC functions in T-cell receptor (TCR) signaling, including T-cells CC activation, proliferation, differentiation and survival, by mediating CC activation of multiple transcription factors such as NF-kappa-B, JUN, CC NFATC1 and NFATC2. In TCR-CD3/CD28-co-stimulated T-cells, is required CC for the activation of NF-kappa-B and JUN, which in turn are essential CC for IL2 production, and participates in the calcium-dependent NFATC1 CC and NFATC2 transactivation (PubMed:21964608). Mediates the activation CC of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation CC of CARD11 on several serine residues, inducing CARD11 association with CC lipid rafts and recruitment of the BCL10-MALT1 complex, which then CC activates IKK complex, resulting in nuclear translocation and CC activation of NFKB1. May also play an indirect role in activation of CC the non-canonical NF-kappa-B (NFKB2) pathway. In the signaling pathway CC leading to JUN activation, acts by phosphorylating the mediator CC STK39/SPAK and may not act through MAP kinases signaling. Plays a CC critical role in TCR/CD28-induced NFATC1 and NFATC2 transactivation by CC participating in the regulation of reduced inositol 1,4,5-trisphosphate CC generation and intracellular calcium mobilization. After costimulation CC of T-cells through CD28 can phosphorylate CBLB and is required for the CC ubiquitination and subsequent degradation of CBLB, which is a CC prerequisite for the activation of TCR. During T-cells differentiation, CC plays an important role in the development of T-helper 2 (Th2) cells CC following immune and inflammatory responses, and, in the development of CC inflammatory autoimmune diseases, is necessary for the activation of CC IL17-producing Th17 cells. May play a minor role in Th1 response. Upon CC TCR stimulation, mediates T-cell protective survival signal by CC phosphorylating BAD, thus protecting T-cells from BAD-induced CC apoptosis, and by up-regulating BCL-X(L)/BCL2L1 levels through NF- CC kappa-B and JUN pathways. In platelets, regulates signal transduction CC downstream of the ITGA2B, CD36/GP4, F2R/PAR1 and F2RL3/PAR4 receptors, CC playing a positive role in 'outside-in' signaling and granule secretion CC signal transduction. May relay signals from the activated ITGA2B CC receptor by regulating the uncoupling of WASP and WIPF1, thereby CC permitting the regulation of actin filament nucleation and branching CC activity of the Arp2/3 complex. May mediate inhibitory effects of free CC fatty acids on insulin signaling by phosphorylating IRS1, which in turn CC blocks IRS1 tyrosine phosphorylation and downstream activation of the CC PI3K/AKT pathway. Phosphorylates MSN (moesin) in the presence of CC phosphatidylglycerol or phosphatidylinositol. Phosphorylates PDPK1 at CC 'Ser-504' and 'Ser-532' and negatively regulates its ability to CC phosphorylate PKB/AKT1. Phosphorylates CCDC88A/GIV and inhibits its CC guanine nucleotide exchange factor activity (PubMed:23509302). CC Phosphorylates and activates LRRK1, which phosphorylates RAB proteins CC involved in intracellular trafficking (PubMed:36040231). CC {ECO:0000269|PubMed:11342610, ECO:0000269|PubMed:14988727, CC ECO:0000269|PubMed:15364919, ECO:0000269|PubMed:16252004, CC ECO:0000269|PubMed:16356855, ECO:0000269|PubMed:16709830, CC ECO:0000269|PubMed:19549985, ECO:0000269|PubMed:21964608, CC ECO:0000269|PubMed:23509302, ECO:0000269|PubMed:36040231, CC ECO:0000269|PubMed:8657160}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:23509302, ECO:0000269|PubMed:34593629, CC ECO:0000269|PubMed:36040231}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:34593629, ECO:0000269|PubMed:36040231}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Novel PKCs (PRKCD, PRKCE, PRKCH and PRKCQ) are CC calcium-insensitive, but activated by diacylglycerol (DAG) and CC phosphatidylserine. Three specific sites; Thr-538 (activation loop of CC the kinase domain), Ser-676 (turn motif) and Ser-695 (hydrophobic CC region), need to be phosphorylated for its full activation. Inhibited CC by PRKCH upstream open reading frame 2 (PubMed:34593629). CC {ECO:0000269|PubMed:34593629}. CC -!- SUBUNIT: Part of a lipid raft complex composed at least of BCL10, CC CARD11, MALT1 and IKBKB (PubMed:16356855). Interacts with GLRX3 (via N- CC terminus) (PubMed:10636891). Interacts with ECT2 (PubMed:15254234). CC Interacts with CCDC88A/GIV; the interaction leads to phosphorylation of CC CCDC88A and inhibition of its guanine nucleotide exchange factor CC activity (PubMed:23509302). Interacts with PRKCH upstream open reading CC frame 2; the interaction leads to inhibition of kinase activity CC (PubMed:34593629). Interacts with CD28 (PubMed:21964608). CC {ECO:0000269|PubMed:10636891, ECO:0000269|PubMed:15254234, CC ECO:0000269|PubMed:16356855, ECO:0000269|PubMed:21964608, CC ECO:0000269|PubMed:23509302, ECO:0000269|PubMed:34593629}. CC -!- INTERACTION: CC Q04759; Q06187: BTK; NbExp=2; IntAct=EBI-374762, EBI-624835; CC Q04759; P06241: FYN; NbExp=7; IntAct=EBI-374762, EBI-515315; CC Q04759; O76003: GLRX3; NbExp=5; IntAct=EBI-374762, EBI-374781; CC Q04759; Q00613: HSF1; NbExp=2; IntAct=EBI-374762, EBI-719620; CC Q04759; P06239: LCK; NbExp=2; IntAct=EBI-374762, EBI-1348; CC Q04759; Q8IVH8: MAP4K3; NbExp=4; IntAct=EBI-374762, EBI-1758170; CC Q04759; Q05513: PRKCZ; NbExp=3; IntAct=EBI-374762, EBI-295351; CC Q04759; P35570: Irs1; Xeno; NbExp=2; IntAct=EBI-374762, EBI-520230; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane; Peripheral membrane CC protein. Note=In resting T-cells, mostly localized in cytoplasm. In CC response to TCR stimulation, associates with lipid rafts and then CC localizes in the immunological synapse. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q04759-1; Sequence=Displayed; CC Name=2; CC IsoId=Q04759-2; Sequence=VSP_017294; CC Name=3; CC IsoId=Q04759-3; Sequence=VSP_054550; CC -!- TISSUE SPECIFICITY: Expressed in skeletal muscle, T-cells, CC megakaryoblastic cells and platelets. {ECO:0000269|PubMed:7686153}. CC -!- DOMAIN: The C1 domain, containing the phorbol ester/DAG-type region 1 CC (C1A) and 2 (C1B), is the diacylglycerol sensor and the C2 domain is a CC non-calcium binding domain. CC -!- PTM: Autophosphorylation at Thr-219 is required for targeting to the CC TCR and cellular function of PRKCQ upon antigen receptor ligation. CC Following TCR stimulation, phosphorylated at Tyr-90 and Ser-685. CC {ECO:0000269|PubMed:10652356, ECO:0000269|PubMed:11772397, CC ECO:0000269|PubMed:15364937, ECO:0000269|PubMed:16252004, CC ECO:0000269|Ref.39}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L01087; AAA75571.1; -; mRNA. DR EMBL; L07032; AAA60101.1; -; mRNA. DR EMBL; AY702977; AAU29340.1; -; mRNA. DR EMBL; AK293935; BAG57313.1; -; mRNA. DR EMBL; AL158043; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL137145; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC101465; AAI01466.1; -; mRNA. DR EMBL; BC113359; AAI13360.1; -; mRNA. DR CCDS; CCDS55701.1; -. [Q04759-2] DR CCDS; CCDS60482.1; -. [Q04759-3] DR CCDS; CCDS7079.1; -. [Q04759-1] DR PIR; A45416; A45416. DR RefSeq; NP_001229342.1; NM_001242413.2. [Q04759-2] DR RefSeq; NP_001269573.1; NM_001282644.1. DR RefSeq; NP_001269574.1; NM_001282645.1. [Q04759-3] DR RefSeq; NP_001310194.1; NM_001323265.1. [Q04759-1] DR RefSeq; NP_001310195.1; NM_001323266.2. [Q04759-3] DR RefSeq; NP_006248.1; NM_006257.5. [Q04759-1] DR PDB; 1XJD; X-ray; 2.00 A; A=362-706. DR PDB; 2ENJ; NMR; -; A=1-125. DR PDB; 2ENN; NMR; -; A=144-213. DR PDB; 2ENZ; NMR; -; A=227-284. DR PDB; 2JED; X-ray; 2.32 A; A/B=361-706. DR PDB; 4Q9Z; X-ray; 2.60 A; A/B=374-706. DR PDB; 4RA5; X-ray; 2.61 A; A/B=374-706. DR PDB; 5F9E; X-ray; 2.00 A; A/B=361-706. DR PDBsum; 1XJD; -. DR PDBsum; 2ENJ; -. DR PDBsum; 2ENN; -. DR PDBsum; 2ENZ; -. DR PDBsum; 2JED; -. DR PDBsum; 4Q9Z; -. DR PDBsum; 4RA5; -. DR PDBsum; 5F9E; -. DR AlphaFoldDB; Q04759; -. DR SMR; Q04759; -. DR BioGRID; 111574; 62. DR CORUM; Q04759; -. DR FunCoup; Q04759; 797. DR IntAct; Q04759; 27. DR MINT; Q04759; -. DR STRING; 9606.ENSP00000263125; -. DR BindingDB; Q04759; -. DR ChEMBL; CHEMBL3920; -. DR DrugBank; DB09096; Benzoyl peroxide. DR DrugBank; DB04209; Dequalinium. DR DrugBank; DB04522; Dexfosfoserine. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB02482; Phosphonothreonine. DR DrugBank; DB12369; Sotrastaurin. DR DrugBank; DB02010; Staurosporine. DR DrugBank; DB00675; Tamoxifen. DR DrugCentral; Q04759; -. DR GuidetoPHARMACOLOGY; 1488; -. DR CarbonylDB; Q04759; -. DR GlyGen; Q04759; 3 sites, 1 O-linked glycan (2 sites). DR iPTMnet; Q04759; -. DR PhosphoSitePlus; Q04759; -. DR BioMuta; PRKCQ; -. DR DMDM; 20141582; -. DR CPTAC; CPTAC-2825; -. DR CPTAC; non-CPTAC-2890; -. DR jPOST; Q04759; -. DR MassIVE; Q04759; -. DR PaxDb; 9606-ENSP00000263125; -. DR PeptideAtlas; Q04759; -. DR ProteomicsDB; 4008; -. DR ProteomicsDB; 58279; -. [Q04759-1] DR ProteomicsDB; 58280; -. [Q04759-2] DR Pumba; Q04759; -. DR Antibodypedia; 10940; 860 antibodies from 42 providers. DR DNASU; 5588; -. DR Ensembl; ENST00000263125.10; ENSP00000263125.5; ENSG00000065675.17. [Q04759-1] DR Ensembl; ENST00000397176.6; ENSP00000380361.2; ENSG00000065675.17. [Q04759-2] DR Ensembl; ENST00000539722.5; ENSP00000441752.1; ENSG00000065675.17. [Q04759-3] DR GeneID; 5588; -. DR KEGG; hsa:5588; -. DR MANE-Select; ENST00000263125.10; ENSP00000263125.5; NM_006257.5; NP_006248.1. DR UCSC; uc001ijj.3; human. [Q04759-1] DR AGR; HGNC:9410; -. DR ClinPGx; PA33773; -. DR CTD; 5588; -. DR DisGeNET; 5588; -. DR GeneCards; PRKCQ; -. DR HGNC; HGNC:9410; PRKCQ. DR HPA; ENSG00000065675; Group enriched (lymphoid tissue, skeletal muscle, tongue). DR MalaCards; PRKCQ; -. DR MIM; 600448; gene. DR OpenTargets; ENSG00000065675; -. DR VEuPathDB; HostDB:ENSG00000065675; -. DR eggNOG; KOG0694; Eukaryota. DR GeneTree; ENSGT00940000157638; -. DR HOGENOM; CLU_000288_54_4_1; -. DR InParanoid; Q04759; -. DR OMA; EIWIELK; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; Q04759; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q04759; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; Q04759; -. DR Reactome; R-HSA-111465; Apoptotic cleavage of cellular proteins. DR Reactome; R-HSA-114508; Effects of PIP2 hydrolysis. DR Reactome; R-HSA-202424; Downstream TCR signaling. DR Reactome; R-HSA-2514859; Inactivation, recovery and regulation of the phototransduction cascade. DR Reactome; R-HSA-2871837; FCERI mediated NF-kB activation. DR Reactome; R-HSA-373752; Netrin-1 signaling. DR Reactome; R-HSA-418597; G alpha (z) signalling events. DR Reactome; R-HSA-8936459; RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function. DR Reactome; R-HSA-9648002; RAS processing. DR SABIO-RK; Q04759; -. DR SignaLink; Q04759; -. DR SIGNOR; Q04759; -. DR Agora; ENSG00000065675; -. DR BioGRID-ORCS; 5588; 12 hits in 1187 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; PRKCQ; human. DR EvolutionaryTrace; Q04759; -. DR GeneWiki; PRKCQ; -. DR GenomeRNAi; 5588; -. DR Pharos; Q04759; Tchem. DR PRO; PR:Q04759; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; Q04759; protein. DR Bgee; ENSG00000065675; Expressed in triceps brachii and 170 other cell types or tissues. DR ExpressionAtlas; Q04759; baseline and differential. DR GO; GO:0016235; C:aggresome; IDA:HPA. DR GO; GO:0034451; C:centriolar satellite; IDA:HPA. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0001772; C:immunological synapse; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; TAS:Reactome. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; EXP:Reactome. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0007411; P:axon guidance; TAS:Reactome. DR GO; GO:0035739; P:CD4-positive, alpha-beta T cell proliferation; IEA:Ensembl. DR GO; GO:0060326; P:cell chemotaxis; IMP:UniProtKB. DR GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome. DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0006509; P:membrane protein ectodomain proteolysis; ISS:BHF-UCL. DR GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0070233; P:negative regulation of T cell apoptotic process; IMP:UniProtKB. DR GO; GO:2000563; P:positive regulation of CD4-positive, alpha-beta T cell proliferation; IEA:Ensembl. DR GO; GO:0032740; P:positive regulation of interleukin-17 production; ISS:UniProtKB. DR GO; GO:0032743; P:positive regulation of interleukin-2 production; IEA:Ensembl. DR GO; GO:0032753; P:positive regulation of interleukin-4 production; ISS:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB. DR GO; GO:0050870; P:positive regulation of T cell activation; ISS:UniProtKB. DR GO; GO:2000318; P:positive regulation of T-helper 17 type immune response; ISS:UniProtKB. DR GO; GO:2000570; P:positive regulation of T-helper 2 cell activation; ISS:UniProtKB. DR GO; GO:0032206; P:positive regulation of telomere maintenance; IMP:BHF-UCL. DR GO; GO:0001558; P:regulation of cell growth; NAS:UniProtKB. DR GO; GO:0006355; P:regulation of DNA-templated transcription; ISS:UniProtKB. DR GO; GO:0090330; P:regulation of platelet aggregation; ISS:UniProtKB. DR CDD; cd20834; C1_nPKC_theta-like_rpt1; 1. DR CDD; cd20837; C1_nPKC_theta-like_rpt2; 1. DR CDD; cd05619; STKc_nPKC_theta; 1. DR FunFam; 3.30.200.20:FF:000360; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000003; Protein kinase C delta; 1. DR FunFam; 2.60.40.150:FF:000049; Protein kinase C delta type; 1. DR FunFam; 3.30.60.20:FF:000008; Protein kinase C theta; 1. DR FunFam; 1.10.510.10:FF:000150; Protein kinase C, theta; 1. DR Gene3D; 3.30.60.20; -; 2. DR Gene3D; 2.60.40.150; C2 domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR034668; nPKC_theta. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR027264; PKC_theta. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR014376; Prot_kin_PKC_delta. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00130; C1_1; 2. DR Pfam; PF21494; PKC_C2; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000551; PKC_delta; 1. DR PIRSF; PIRSF501105; Protein_kin_C_theta; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 2. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50004; C2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 2. DR PROSITE; PS50081; ZF_DAG_PE_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; Cytoplasm; KW Immunity; Inflammatory response; Kinase; Magnesium; Membrane; KW Metal-binding; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..706 FT /note="Protein kinase C theta type" FT /id="PRO_0000055708" FT DOMAIN 1..107 FT /note="C2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 380..634 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 635..706 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT ZN_FING 159..209 FT /note="Phorbol-ester/DAG-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT ZN_FING 231..281 FT /note="Phorbol-ester/DAG-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT ACT_SITE 504 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 386..394 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 409 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 90 FT /note="Phosphotyrosine; by LCK" FT /evidence="ECO:0000269|PubMed:10652356" FT MOD_RES 219 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16252004" FT MOD_RES 348 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 538 FT /note="Phosphothreonine; by PDPK1" FT /evidence="ECO:0000305|PubMed:11772397, FT ECO:0000305|PubMed:15364937, ECO:0000305|PubMed:16252004" FT MOD_RES 676 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:11772397, FT ECO:0000269|PubMed:16252004, ECO:0000269|Ref.39, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163" FT MOD_RES 685 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 695 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:11772397, FT ECO:0000269|PubMed:15364937, ECO:0000269|PubMed:16252004, FT ECO:0000269|Ref.39, ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT VAR_SEQ 2..126 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_054550" FT VAR_SEQ 550..612 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.4" FT /id="VSP_017294" FT VARIANT 240 FT /note="K -> N (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042319" FT VARIANT 306 FT /note="D -> V (in dbSNP:rs45590231)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042320" FT VARIANT 330 FT /note="P -> L (in dbSNP:rs2236379)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7686153, ECO:0000269|Ref.4" FT /id="VAR_020401" FT VARIANT 354 FT /note="D -> N (in dbSNP:rs34524148)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042321" FT MUTAGEN 90 FT /note="Y->F: Loss of function in T-cells proliferation. No FT effect on kinase activity." FT /evidence="ECO:0000269|PubMed:10652356" FT MUTAGEN 148 FT /note="A->E: Constitutively active form." FT /evidence="ECO:0000269|PubMed:10652356" FT MUTAGEN 219 FT /note="T->A: Loss of transactivation of the IL2 promoter FT and translocation to the plasma membrane. No effect on FT kinase activity." FT /evidence="ECO:0000269|PubMed:16252004" FT MUTAGEN 409 FT /note="K->A,E: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:10652356" FT MUTAGEN 538 FT /note="T->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:11772397, FT ECO:0000269|PubMed:16252004" FT MUTAGEN 676 FT /note="S->A: Reduction in kinase activity." FT /evidence="ECO:0000269|PubMed:16252004" FT MUTAGEN 695 FT /note="S->A: Reduction in kinase activity." FT /evidence="ECO:0000269|PubMed:11772397, FT ECO:0000269|PubMed:16252004" FT CONFLICT 700 FT /note="G -> R (in Ref. 1; AAA75571 and 4; AAU29340)" FT /evidence="ECO:0000305" FT STRAND 5..13 FT /evidence="ECO:0007829|PDB:2ENJ" FT STRAND 28..39 FT /evidence="ECO:0007829|PDB:2ENJ" FT STRAND 42..52 FT /evidence="ECO:0007829|PDB:2ENJ" FT STRAND 56..62 FT /evidence="ECO:0007829|PDB:2ENJ" FT STRAND 69..75 FT /evidence="ECO:0007829|PDB:2ENJ" FT STRAND 83..89 FT /evidence="ECO:0007829|PDB:2ENJ" FT HELIX 90..98 FT /evidence="ECO:0007829|PDB:2ENJ" FT TURN 99..101 FT /evidence="ECO:0007829|PDB:2ENJ" FT STRAND 103..108 FT /evidence="ECO:0007829|PDB:2ENJ" FT STRAND 110..112 FT /evidence="ECO:0007829|PDB:2ENJ" FT STRAND 114..121 FT /evidence="ECO:0007829|PDB:2ENJ" FT STRAND 155..159 FT /evidence="ECO:0007829|PDB:2ENN" FT STRAND 161..165 FT /evidence="ECO:0007829|PDB:2ENN" FT STRAND 174..176 FT /evidence="ECO:0007829|PDB:2ENN" FT STRAND 187..189 FT /evidence="ECO:0007829|PDB:2ENN" FT STRAND 191..193 FT /evidence="ECO:0007829|PDB:2ENN" FT STRAND 196..199 FT /evidence="ECO:0007829|PDB:2ENN" FT HELIX 200..202 FT /evidence="ECO:0007829|PDB:2ENN" FT STRAND 234..236 FT /evidence="ECO:0007829|PDB:2ENZ" FT STRAND 246..248 FT /evidence="ECO:0007829|PDB:2ENZ" FT STRAND 255..257 FT /evidence="ECO:0007829|PDB:2ENZ" FT STRAND 259..265 FT /evidence="ECO:0007829|PDB:2ENZ" FT TURN 271..276 FT /evidence="ECO:0007829|PDB:2ENZ" FT TURN 281..283 FT /evidence="ECO:0007829|PDB:2ENZ" FT HELIX 377..379 FT /evidence="ECO:0007829|PDB:5F9E" FT STRAND 380..388 FT /evidence="ECO:0007829|PDB:1XJD" FT STRAND 390..399 FT /evidence="ECO:0007829|PDB:1XJD" FT TURN 400..402 FT /evidence="ECO:0007829|PDB:1XJD" FT STRAND 405..412 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 413..418 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 422..435 FT /evidence="ECO:0007829|PDB:1XJD" FT STRAND 444..449 FT /evidence="ECO:0007829|PDB:1XJD" FT STRAND 451..459 FT /evidence="ECO:0007829|PDB:1XJD" FT STRAND 463..465 FT /evidence="ECO:0007829|PDB:5F9E" FT HELIX 466..473 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 478..497 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 507..509 FT /evidence="ECO:0007829|PDB:1XJD" FT STRAND 510..512 FT /evidence="ECO:0007829|PDB:1XJD" FT STRAND 518..520 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 543..545 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 548..551 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 559..574 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 584..593 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 604..613 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 618..620 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 628..630 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 632..634 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 639..643 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 666..669 FT /evidence="ECO:0007829|PDB:5F9E" FT HELIX 680..685 FT /evidence="ECO:0007829|PDB:5F9E" FT TURN 690..693 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 699..706 FT /evidence="ECO:0007829|PDB:5F9E" SQ SEQUENCE 706 AA; 81865 MW; B3C53AB892D5210A CRC64; MSPFLRIGLS NFDCGSCQSC QGEAVNPYCA VLVKEYVESE NGQMYIQKKP TMYPPWDSTF DAHINKGRVM QIIVKGKNVD LISETTVELY SLAERCRKNN GKTEIWLELK PQGRMLMNAR YFLEMSDTKD MNEFETEGFF ALHQRRGAIK QAKVHHVKCH EFTATFFPQP TFCSVCHEFV WGLNKQGYQC RQCNAAIHKK CIDKVIAKCT GSAINSRETM FHKERFKIDM PHRFKVYNYK SPTFCEHCGT LLWGLARQGL KCDACGMNVH HRCQTKVANL CGINQKLMAE ALAMIESTQQ ARCLRDTEQI FREGPVEIGL PCSIKNEARP PCLPTPGKRE PQGISWESPL DEVDKMCHLP EPELNKERPS LQIKLKIEDF ILHKMLGKGS FGKVFLAEFK KTNQFFAIKA LKKDVVLMDD DVECTMVEKR VLSLAWEHPF LTHMFCTFQT KENLFFVMEY LNGGDLMYHI QSCHKFDLSR ATFYAAEIIL GLQFLHSKGI VYRDLKLDNI LLDKDGHIKI ADFGMCKENM LGDAKTNTFC GTPDYIAPEI LLGQKYNHSV DWWSFGVLLY EMLIGQSPFH GQDEEELFHS IRMDNPFYPR WLEKEAKDLL VKLFVREPEK RLGVRGDIRQ HPLFREINWE ELERKEIDPP FRPKVKSPFD CSNFDKEFLN EKPRLSFADR ALINSMDQNM FRNFSFMNPG MERLIS // ID KPCZ_HUMAN Reviewed; 592 AA. AC Q05513; A8K4N0; A8MU64; B7Z2J7; E9PCW2; Q15207; Q5SYT5; Q969S4; DT 01-FEB-1994, integrated into UniProtKB/Swiss-Prot. DT 21-JUN-2005, sequence version 4. DT 28-JAN-2026, entry version 253. DE RecName: Full=Protein kinase C zeta type; DE EC=2.7.11.13 {ECO:0000269|PubMed:15084291, ECO:0000269|PubMed:15324659, ECO:0000269|PubMed:36040231}; DE AltName: Full=nPKC-zeta; GN Name=PRKCZ; Synonyms=PKC2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Frontal cortex; RX PubMed=8224878; DOI=10.1016/0378-1119(93)90213-m; RA Barbee J.L., Loomis C.R., Deutscher S.L., Burns D.J.; RT "The cDNA sequence encoding human protein kinase C-zeta."; RL Gene 132:305-306(1993). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3). RC TISSUE=Brain, and Teratocarcinoma; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Colon, and Ovary; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 7-592. RC TISSUE=Hippocampus; RX PubMed=8375396; DOI=10.1111/j.1432-1033.1993.tb18179.x; RA Kochs G., Hummel R., Meyer D., Hug H., Marme D., Sarre T.F.; RT "Activation and substrate specificity of the human protein kinase C alpha RT and zeta isoenzymes."; RL Eur. J. Biochem. 216:597-606(1993). RN [7] RP SUBCELLULAR LOCATION. RX PubMed=7597083; DOI=10.1073/pnas.92.13.6072; RA Stuart R.O., Nigam S.K.; RT "Regulated assembly of tight junctions by protein kinase C."; RL Proc. Natl. Acad. Sci. U.S.A. 92:6072-6076(1995). RN [8] RP FUNCTION IN ACTIVATION OF MAP2K1/MEK1 AND MAPK1/ERK2. RX PubMed=9447975; DOI=10.1128/mcb.18.2.790; RA Schoenwasser D.C., Marais R.M., Marshall C.J., Parker P.J.; RT "Activation of the mitogen-activated protein kinase/extracellular signal- RT regulated kinase pathway by conventional, novel, and atypical protein RT kinase C isotypes."; RL Mol. Cell. Biol. 18:790-798(1998). RN [9] RP INTERACTION WITH SQSTM1, AND SUBCELLULAR LOCATION. RX PubMed=9566925; DOI=10.1128/mcb.18.5.3069; RA Sanchez P., De Carcer G., Sandoval I.V., Moscat J., Diaz-Meco M.T.; RT "Localization of atypical protein kinase C isoforms into lysosome-targeted RT endosomes through interaction with p62."; RL Mol. Cell. Biol. 18:3069-3080(1998). RN [10] RP PHOSPHORYLATION AT THR-410 BY PDPK1. RX PubMed=9768361; DOI=10.1016/s0960-9822(98)70444-0; RA Chou M.M., Hou W., Johnson J., Graham L.K., Lee M.H., Chen C.S., RA Newton A.C., Schaffhausen B.S., Toker A.; RT "Regulation of protein kinase C zeta by PI 3-kinase and PDK-1."; RL Curr. Biol. 8:1069-1077(1998). RN [11] RP INTERACTION WITH SQSTM1 AND IKBKB. RX PubMed=10356400; DOI=10.1093/emboj/18.11.3044; RA Sanz L., Sanchez P., Lallena M.-J., Diaz-Meco M.T., Moscat J.; RT "The interaction of p62 with RIP links the atypical PKCs to NF-kappaB RT activation."; RL EMBO J. 18:3044-3053(1999). RN [12] RP FUNCTION IN ACTIVATION OF MAPK1/ERK2. RX PubMed=11035106; DOI=10.4049/jimmunol.165.8.4632; RA Monick M.M., Carter A.B., Flaherty D.M., Peterson M.W., Hunninghake G.W.; RT "Protein kinase C zeta plays a central role in activation of the p42/44 RT mitogen-activated protein kinase by endotoxin in alveolar macrophages."; RL J. Immunol. 165:4632-4639(2000). RN [13] RP INTERACTION WITH PARD6A; PARD6B AND PARD6G. RC TISSUE=Neuroblastoma; RX PubMed=11260256; DOI=10.1046/j.1365-2443.2001.00404.x; RA Noda Y., Takeya R., Ohno S., Naito S., Ito T., Sumimoto H.; RT "Human homologues of the Caenorhabditis elegans cell polarity protein PAR6 RT as an adaptor that links the small GTPases Rac and Cdc42 to atypical RT protein kinase C."; RL Genes Cells 6:107-119(2001). RN [14] RP INTERACTION WITH PDPK1, AND PHOSPHORYLATION. RX PubMed=11781095; DOI=10.1021/bi010719z; RA Hodgkinson C.P., Sale G.J.; RT "Regulation of both PDK1 and the phosphorylation of PKC-zeta and -delta by RT a C-terminal PRK2 fragment."; RL Biochemistry 41:561-569(2002). RN [15] RP FUNCTION IN ACTIVATION OF AKT3. RX PubMed=12162751; DOI=10.1021/bi026065r; RA Hodgkinson C.P., Sale E.M., Sale G.J.; RT "Characterization of PDK2 activity against protein kinase B gamma."; RL Biochemistry 41:10351-10359(2002). RN [16] RP INTERACTION WITH SQSTM1 AND PAWR. RX PubMed=11755531; DOI=10.1016/s0014-5793(01)03224-0; RA Chang S., Kim J.H., Shin J.; RT "p62 forms a ternary complex with PKCzeta and PAR-4 and antagonizes PAR-4- RT induced PKCzeta inhibition."; RL FEBS Lett. 510:57-61(2002). RN [17] RP INTERACTION WITH PARD3. RX PubMed=12234671; DOI=10.1016/s0378-1119(02)00681-9; RA Gao L., Macara I.G., Joberty G.; RT "Multiple splice variants of Par3 and of a novel related gene, Par3L, RT produce proteins with different binding properties."; RL Gene 294:99-107(2002). RN [18] RP INTERACTION WITH ADAP1. RX PubMed=12893243; DOI=10.1016/s0006-291x(03)01187-2; RA Zemlickova E., Dubois T., Kerai P., Clokie S., Cronshaw A.D., RA Wakefield R.I.D., Johannes F.-J., Aitken A.; RT "Centaurin-alpha(1) associates with and is phosphorylated by isoforms of RT protein kinase C."; RL Biochem. Biophys. Res. Commun. 307:459-465(2003). RN [19] RP INTERACTION WITH SQSTM1 AND PARD6B, DOMAIN, AND MUTAGENESIS OF LYS-19; RP ASP-62 AND ASP-66. RX PubMed=12887891; DOI=10.1016/s1097-2765(03)00246-6; RA Wilson M.I., Gill D.J., Perisic O., Quinn M.T., Williams R.L.; RT "PB1 domain-mediated heterodimerization in NADPH oxidase and signaling RT complexes of atypical protein kinase C with Par6 and p62."; RL Mol. Cell 12:39-50(2003). RN [20] RP FUNCTION IN PHOSPHORYLATION OF MARK2 AND MARK3, AND CATALYTIC ACTIVITY. RX PubMed=15084291; DOI=10.1016/j.cub.2004.04.007; RA Hurov J.B., Watkins J.L., Piwnica-Worms H.; RT "Atypical PKC phosphorylates PAR-1 kinases to regulate localization and RT activity."; RL Curr. Biol. 14:736-741(2004). RN [21] RP FUNCTION IN PHOSPHORYLATION OF MARK2, AND CATALYTIC ACTIVITY. RX PubMed=15324659; DOI=10.1016/j.cub.2004.08.021; RA Suzuki A., Hirata M., Kamimura K., Maniwa R., Yamanaka T., Mizuno K., RA Kishikawa M., Hirose H., Amano Y., Izumi N., Miwa Y., Ohno S.; RT "aPKC acts upstream of PAR-1b in both the establishment and maintenance of RT mammalian epithelial polarity."; RL Curr. Biol. 14:1425-1435(2004). RN [22] RP PHOSPHORYLATION AT THR-410 BY PI3K. RX PubMed=15314172; DOI=10.1128/mcb.24.17.7643-7653.2004; RA Castoria G., Migliaccio A., Di Domenico M., Lombardi M., de Falco A., RA Varricchio L., Bilancio A., Barone M.V., Auricchio F.; RT "Role of atypical protein kinase C in estradiol-triggered G1/S progression RT of MCF-7 cells."; RL Mol. Cell. Biol. 24:7643-7653(2004). RN [23] RP INTERACTION WITH WDFY2. RX PubMed=16792529; DOI=10.1042/bj20060511; RA Fritzius T., Burkard G., Haas E., Heinrich J., Schweneker M., Bosse M., RA Zimmermann S., Frey A.D., Caelers A., Bachmann A.S., Moelling K.; RT "A WD-FYVE protein binds to the kinases Akt and PKCzeta/lambda."; RL Biochem. J. 399:9-20(2006). RN [24] RP FUNCTION, INTERACTION WITH VAMP2, COMPLEX FORMATION WITH VAMP2 AND WDFY2, RP AND SUBCELLULAR LOCATION. RX PubMed=17313651; DOI=10.1111/j.1742-4658.2007.05702.x; RA Fritzius T., Frey A.D., Schweneker M., Mayer D., Moelling K.; RT "WD-repeat-propeller-FYVE protein, ProF, binds VAMP2 and protein kinase RT Czeta."; RL FEBS J. 274:1552-1566(2007). RN [25] RP INTERACTION WITH WWC1 AND DDR1. RX PubMed=18190796; DOI=10.1016/j.bbamcr.2007.12.007; RA Hilton H.N., Stanford P.M., Harris J., Oakes S.R., Kaplan W., Daly R.J., RA Ormandy C.J.; RT "KIBRA interacts with discoidin domain receptor 1 to modulate collagen- RT induced signalling."; RL Biochim. Biophys. Acta 1783:383-393(2008). RN [26] RP RETRACTED PAPER. RX PubMed=18321849; DOI=10.1074/jbc.m708208200; RA Song P., Xie Z., Wu Y., Xu J., Dong Y., Zou M.H.; RT "Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases RT LKB1 nucleus export and apoptosis in endothelial cells."; RL J. Biol. Chem. 283:12446-12455(2008). RN [27] RP RETRACTION NOTICE OF PUBMED:18321849. RX PubMed=31519760; DOI=10.1074/jbc.w119.010661; RA Song P., Xie Z., Wu Y., Dong Y., Zou M.H.; RT "Withdrawal: Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation RT increases LKB1 nucleus export and apoptosis in endothelial cells."; RL J. Biol. Chem. 294:13831-13831(2019). RN [28] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-560, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [30] RP SUBCELLULAR LOCATION, SUBUNIT, AND PHOSPHORYLATION AT THR-410. RX PubMed=20332120; DOI=10.1242/jcs.059329; RA Lampugnani M.G., Orsenigo F., Rudini N., Maddaluno L., Boulday G., RA Chapon F., Dejana E.; RT "CCM1 regulates vascular-lumen organization by inducing endothelial RT polarity."; RL J. Cell Sci. 123:1073-1080(2010). RN [31] RP REVIEW ON FUNCTION. RX PubMed=12761192; DOI=10.1093/jb/mvg017; RA Hirai T., Chida K.; RT "Protein kinase Czeta (PKCzeta): activation mechanisms and cellular RT functions."; RL J. Biochem. 133:1-7(2003). RN [32] RP REVIEW ON FUNCTION. RX PubMed=16903823; DOI=10.1134/s0006297906070017; RA Liu L.Z., He A.B., Liu X.J., Li Y., Chang Y.S., Fang F.D.; RT "Protein kinase Czeta and glucose uptake."; RL Biochemistry (Mosc.) 71:701-706(2006). RN [33] RP REVIEW ON FUNCTION. RX PubMed=16322752; DOI=10.1038/sj.cdd.4401823; RA Moscat J., Rennert P., Diaz-Meco M.T.; RT "PKCzeta at the crossroad of NF-kappaB and Jak1/Stat6 signaling pathways."; RL Cell Death Differ. 13:702-711(2006). RN [34] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-560, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [36] RP INTERACTION WITH WWC1; WWC2 AND WWC3. RX PubMed=24682284; DOI=10.1093/molbev/msu115; RA Wennmann D.O., Schmitz J., Wehr M.C., Krahn M.P., Koschmal N., RA Gromnitza S., Schulze U., Weide T., Chekuri A., Skryabin B.V., Gerke V., RA Pavenstadt H., Duning K., Kremerskothen J.; RT "Evolutionary and Molecular Facts Link the WWC Protein Family to Hippo RT Signaling."; RL Mol. Biol. Evol. 31:1710-1723(2014). RN [37] RP INTERACTION WITH APPL1. RX PubMed=26583432; DOI=10.18632/oncotarget.6346; RA Song J., Mu Y., Li C., Bergh A., Miaczynska M., Heldin C.H., Landstroem M.; RT "APPL proteins promote TGFbeta-induced nuclear transport of the TGFbeta RT type I receptor intracellular domain."; RL Oncotarget 7:279-292(2016). RN [38] RP FUNCTION IN PHOSPHORYLATION OF LRRK1, AND CATALYTIC ACTIVITY. RX PubMed=36040231; DOI=10.1042/bcj20220308; RA Malik A.U., Karapetsas A., Nirujogi R.S., Chatterjee D., Phung T.K., RA Wightman M., Gourlay R., Morrice N., Mathea S., Knapp S., Alessi D.R.; RT "PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues RT (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain."; RL Biochem. J. 479:1941-1965(2022). RN [39] RP VARIANT [LARGE SCALE ANALYSIS] PHE-514. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [40] RP VARIANTS [LARGE SCALE ANALYSIS] HIS-84 AND CYS-519. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium- and diacylglycerol-independent serine/threonine- CC protein kinase that functions in phosphatidylinositol 3-kinase (PI3K) CC pathway and mitogen-activated protein (MAP) kinase cascade, and is CC involved in NF-kappa-B activation, mitogenic signaling, cell CC proliferation, cell polarity, inflammatory response and maintenance of CC long-term potentiation (LTP). Upon lipopolysaccharide (LPS) treatment CC in macrophages, or following mitogenic stimuli, functions downstream of CC PI3K to activate MAP2K1/MEK1-MAPK1/ERK2 signaling cascade independently CC of RAF1 activation. Required for insulin-dependent activation of AKT3, CC but may function as an adapter rather than a direct activator. Upon CC insulin treatment may act as a downstream effector of PI3K and CC contribute to the activation of translocation of the glucose CC transporter SLC2A4/GLUT4 and subsequent glucose transport in CC adipocytes. In EGF-induced cells, binds and activates MAP2K5/MEK5- CC MAPK7/ERK5 independently of its kinase activity and can activate JUN CC promoter through MEF2C. Through binding with SQSTM1/p62, functions in CC interleukin-1 signaling and activation of NF-kappa-B with the specific CC adapters RIPK1 and TRAF6. Participates in TNF-dependent transactivation CC of NF-kappa-B by phosphorylating and activating IKBKB kinase, which in CC turn leads to the degradation of NF-kappa-B inhibitors. In migrating CC astrocytes, forms a cytoplasmic complex with PARD6A and is recruited by CC CDC42 to function in the establishment of cell polarity along with the CC microtubule motor and dynein. In association with FEZ1, stimulates CC neuronal differentiation in PC12 cells. In the inflammatory response, CC is required for the T-helper 2 (Th2) differentiation process, including CC interleukin production, efficient activation of JAK1 and the subsequent CC phosphorylation and nuclear translocation of STAT6. May be involved in CC development of allergic airway inflammation (asthma), a process CC dependent on Th2 immune response. In the NF-kappa-B-mediated CC inflammatory response, can relieve SETD6-dependent repression of NF- CC kappa-B target genes by phosphorylating the RELA subunit at 'Ser-311'. CC Phosphorylates VAMP2 in vitro (PubMed:17313651). Phosphorylates and CC activates LRRK1, which phosphorylates RAB proteins involved in CC intracellular trafficking (PubMed:36040231). CC {ECO:0000269|PubMed:11035106, ECO:0000269|PubMed:12162751, CC ECO:0000269|PubMed:15084291, ECO:0000269|PubMed:15324659, CC ECO:0000269|PubMed:17313651, ECO:0000269|PubMed:36040231, CC ECO:0000269|PubMed:9447975}. CC -!- FUNCTION: [Isoform 2]: Involved in late synaptic long term potention CC phase in CA1 hippocampal cells and long term memory maintenance. CC {ECO:0000250|UniProtKB:Q02956}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:15084291, ECO:0000269|PubMed:15324659, CC ECO:0000269|PubMed:36040231}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:15084291, ECO:0000269|PubMed:15324659, CC ECO:0000269|PubMed:36040231}; CC -!- ACTIVITY REGULATION: Atypical PKCs (PRKCI and PRKCZ) exhibit an CC elevated basal enzymatic activity (that may be due to the interaction CC with SMG1 or SQSTM1) and are not regulated by diacylglycerol, CC phosphatidylserine, phorbol esters or calcium ions. Two specific sites, CC Thr-410 (activation loop of the kinase domain) and Thr-560 (turn CC motif), need to be phosphorylated for its full activation. CC Phosphatidylinositol 3,4,5-trisphosphate might be a physiological CC activator (By similarity). Isoform 2: Constitutively active (By CC similarity). {ECO:0000250|UniProtKB:Q02956}. CC -!- SUBUNIT: Forms a ternary complex with SQSTM1 and KCNAB2. Forms another CC ternary complex with SQSTM1 and GABRR3. Forms a complex with SQSTM1 and CC MAP2K5 (By similarity). Interacts with PARD6A, PARD6B, PARD6G and CC SQSTM1. Part of a complex with PARD3, PARD6A or PARD6B or PARD6G and CC CDC42 or RAC1. Interacts with ADAP1/CENTA1. Forms a ternary complex CC composed of SQSTM1 and PAWR. Interacts directly with SQSTM1 (Probable). CC Interacts with IKBKB. Interacts (via the protein kinase domain) with CC WWC1. Forms a tripartite complex with WWC1 and DDR1, but predominantly CC in the absence of collagen. Component of the Par polarity complex, CC composed of at least phosphorylated PRKCZ, PARD3 and TIAM1. Interacts CC with PDPK1 (via N-terminal region). Interacts with WDFY2 (via WD CC repeats 1-3) (PubMed:16792529). Interacts with VAMP2 (PubMed:17313651). CC Forms a complex with WDFY2 and VAMP2 (PubMed:17313651). Interacts with CC APPL1 (PubMed:26583432). Interacts with WWC1, WWC2 and WWC3 CC (PubMed:24682284). {ECO:0000250|UniProtKB:P09217, CC ECO:0000269|PubMed:10356400, ECO:0000269|PubMed:11260256, CC ECO:0000269|PubMed:11755531, ECO:0000269|PubMed:11781095, CC ECO:0000269|PubMed:12234671, ECO:0000269|PubMed:12887891, CC ECO:0000269|PubMed:12893243, ECO:0000269|PubMed:16792529, CC ECO:0000269|PubMed:17313651, ECO:0000269|PubMed:18190796, CC ECO:0000269|PubMed:20332120, ECO:0000269|PubMed:24682284, CC ECO:0000269|PubMed:26583432, ECO:0000269|PubMed:9566925, ECO:0000305}. CC -!- INTERACTION: CC Q05513; Q15109: AGER; NbExp=6; IntAct=EBI-295351, EBI-1646426; CC Q05513; P31749: AKT1; NbExp=2; IntAct=EBI-295351, EBI-296087; CC Q05513; O95999: BCL10; NbExp=3; IntAct=EBI-295351, EBI-958922; CC Q05513; Q07021: C1QBP; NbExp=4; IntAct=EBI-295351, EBI-347528; CC Q05513; P08238: HSP90AB1; NbExp=2; IntAct=EBI-295351, EBI-352572; CC Q05513; P14598: NCF1; NbExp=3; IntAct=EBI-295351, EBI-395044; CC Q05513; P49757-1: NUMB; NbExp=4; IntAct=EBI-295351, EBI-7199607; CC Q05513; Q9NPB6: PARD6A; NbExp=10; IntAct=EBI-295351, EBI-81876; CC Q05513; Q9BYG5: PARD6B; NbExp=18; IntAct=EBI-295351, EBI-295391; CC Q05513; Q9BYG4: PARD6G; NbExp=9; IntAct=EBI-295351, EBI-295417; CC Q05513; P41743: PRKCI; NbExp=10; IntAct=EBI-295351, EBI-286199; CC Q05513; Q04759: PRKCQ; NbExp=3; IntAct=EBI-295351, EBI-374762; CC Q05513; P40337: VHL; NbExp=3; IntAct=EBI-295351, EBI-301246; CC Q05513; P16554: numb; Xeno; NbExp=2; IntAct=EBI-295351, EBI-429581; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17313651, CC ECO:0000269|PubMed:9566925}. Endosome {ECO:0000269|PubMed:9566925}. CC Cell junction {ECO:0000269|PubMed:7597083}. Membrane CC {ECO:0000250|UniProtKB:P09217}; Peripheral membrane protein CC {ECO:0000305}. Note=In the retina, localizes in the terminals of the CC rod bipolar cells (By similarity). Associates with endosomes CC (PubMed:9566925). Presence of KRIT1, CDH5 and RAP1B is required for its CC localization to the cell junction (PubMed:7597083). Colocalizes with CC VAMP2 and WDFY2 in intracellular vesicles (PubMed:17313651). CC Transiently translocates to the membrane of CA1 hippocampal cells in CC response to the induction of long term potentiation (By similarity). CC {ECO:0000250|UniProtKB:P09217, ECO:0000269|PubMed:17313651, CC ECO:0000269|PubMed:7597083, ECO:0000269|PubMed:9566925}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm CC {ECO:0000250|UniProtKB:P09217}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q05513-1; Sequence=Displayed; CC Name=2; Synonyms=PKMzeta {ECO:0000250|UniProtKB:P09217}; CC IsoId=Q05513-2; Sequence=VSP_041904; CC Name=3; CC IsoId=Q05513-3; Sequence=VSP_046347; CC -!- TISSUE SPECIFICITY: Expressed in brain, and to a lesser extent in lung, CC kidney and testis. CC -!- DOMAIN: The PB1 domain mediate mutually exclusive interactions with CC SQSTM1 and PARD6B. {ECO:0000269|PubMed:12887891}. CC -!- DOMAIN: The C1 domain does not bind the diacylglycerol (DAG). CC {ECO:0000269|PubMed:12887891}. CC -!- PTM: CDH5 is required for its phosphorylation at Thr-410. CC Phosphorylated by protein kinase PDPK1; phosphorylation is inhibited by CC the apoptotic C-terminal cleavage product of PKN2. Phosphorylation at CC Thr-410 by PI3K activates the kinase. {ECO:0000269|PubMed:11781095, CC ECO:0000269|PubMed:15314172, ECO:0000269|PubMed:20332120, CC ECO:0000269|PubMed:9768361}. CC -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative promoter usage. CC {ECO:0000250|UniProtKB:P09217}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC -!- CAUTION: Reported to phosphorylate STK11 leading to nuclear export of CC STK11, subsequent inhibition of PI3K/Akt signaling, and increased CC apoptosis in vein endothelial cells treated with the oxidant CC peroxynitrite (PubMed:18321849). However this paper was withdrawn by CC the authors due to concerns of image duplication in the figures. Its CC role in protein phosphorylation has been confirmed in other studies CC (PubMed:15084291, PubMed:15324659). {ECO:0000269|PubMed:15084291, CC ECO:0000269|PubMed:15324659, ECO:0000269|PubMed:18321849, CC ECO:0000305|PubMed:31519760}. CC -!- SEQUENCE CAUTION: CC Sequence=CAA78813.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L14283; AAA36488.1; -; mRNA. DR EMBL; BT007082; AAP35745.1; -; mRNA. DR EMBL; AK290995; BAF83684.1; -; mRNA. DR EMBL; AK294649; BAH11833.1; -; mRNA. DR EMBL; AK294782; BAH11883.1; -; mRNA. DR EMBL; AL162271; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL391845; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL590822; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL645703; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC008058; AAH08058.1; -; mRNA. DR EMBL; BC014270; AAH14270.1; -; mRNA. DR EMBL; Z15108; CAA78813.1; ALT_INIT; mRNA. DR CCDS; CCDS37.1; -. [Q05513-1] DR CCDS; CCDS41229.1; -. [Q05513-2] DR CCDS; CCDS55563.1; -. [Q05513-3] DR PIR; JN0877; JN0877. DR RefSeq; NP_001028753.1; NM_001033581.3. [Q05513-2] DR RefSeq; NP_001028754.1; NM_001033582.3. [Q05513-2] DR RefSeq; NP_001229803.1; NM_001242874.3. [Q05513-3] DR RefSeq; NP_002735.3; NM_002744.4. [Q05513-1] DR RefSeq; XP_047281304.1; XM_047425348.1. [Q05513-2] DR RefSeq; XP_054193674.1; XM_054337699.1. [Q05513-2] DR AlphaFoldDB; Q05513; -. DR SMR; Q05513; -. DR BioGRID; 111576; 381. DR ComplexPortal; CPX-6195; PAR cell polarity complex, PARD6G-PRKCZ variant. DR ComplexPortal; CPX-6196; PAR cell polarity complex, PARD6B-PRKCZ variant. DR ComplexPortal; CPX-6197; PAR cell polarity complex, PARD6A-PRKCZ variant. DR CORUM; Q05513; -. DR ELM; Q05513; -. DR FunCoup; Q05513; 1725. DR IntAct; Q05513; 231. DR MINT; Q05513; -. DR STRING; 9606.ENSP00000367830; -. DR BindingDB; Q05513; -. DR ChEMBL; CHEMBL3438; -. DR DrugBank; DB09096; Benzoyl peroxide. DR DrugBank; DB03777; Bisindolylmaleimide I. DR DrugBank; DB04209; Dequalinium. DR DrugBank; DB17029; Go-6976. DR DrugBank; DB02010; Staurosporine. DR DrugBank; DB00675; Tamoxifen. DR DrugCentral; Q05513; -. DR GuidetoPHARMACOLOGY; 1491; -. DR MoonDB; Q05513; Predicted. DR GlyGen; Q05513; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q05513; -. DR PhosphoSitePlus; Q05513; -. DR BioMuta; PRKCZ; -. DR DMDM; 68067736; -. DR jPOST; Q05513; -. DR MassIVE; Q05513; -. DR PaxDb; 9606-ENSP00000367830; -. DR PeptideAtlas; Q05513; -. DR ProteomicsDB; 19529; -. DR ProteomicsDB; 58330; -. [Q05513-1] DR ProteomicsDB; 58331; -. [Q05513-2] DR Pumba; Q05513; -. DR Antibodypedia; 3869; 858 antibodies from 46 providers. DR DNASU; 5590; -. DR Ensembl; ENST00000378567.8; ENSP00000367830.3; ENSG00000067606.18. [Q05513-1] DR Ensembl; ENST00000400921.6; ENSP00000383712.2; ENSG00000067606.18. [Q05513-2] DR Ensembl; ENST00000461106.6; ENSP00000426412.1; ENSG00000067606.18. [Q05513-3] DR GeneID; 5590; -. DR KEGG; hsa:5590; -. DR MANE-Select; ENST00000378567.8; ENSP00000367830.3; NM_002744.6; NP_002735.3. DR UCSC; uc001aiq.3; human. [Q05513-1] DR AGR; HGNC:9412; -. DR ClinPGx; PA33775; -. DR CTD; 5590; -. DR DisGeNET; 5590; -. DR GeneCards; PRKCZ; -. DR HGNC; HGNC:9412; PRKCZ. DR HPA; ENSG00000067606; Tissue enhanced (brain). DR MalaCards; PRKCZ; -. DR MIM; 176982; gene. DR OpenTargets; ENSG00000067606; -. DR Orphanet; 1606; 1p36 deletion syndrome. DR VEuPathDB; HostDB:ENSG00000067606; -. DR eggNOG; KOG0695; Eukaryota. DR GeneTree; ENSGT00940000153497; -. DR HOGENOM; CLU_000288_63_5_1; -. DR InParanoid; Q05513; -. DR OMA; DKMAGLC; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; Q05513; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q05513; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; Q05513; -. DR Reactome; R-HSA-114604; GPVI-mediated activation cascade. DR Reactome; R-HSA-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition). DR Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation. DR Reactome; R-HSA-5668599; RHO GTPases Activate NADPH Oxidases. DR Reactome; R-HSA-9634635; Estrogen-stimulated signaling through PRKCZ. DR SignaLink; Q05513; -. DR SIGNOR; Q05513; -. DR Agora; ENSG00000067606; -. DR BioGRID-ORCS; 5590; 23 hits in 1195 CRISPR screens. DR ChiTaRS; PRKCZ; human. DR GeneWiki; Protein_kinase_M_zeta/Protein_kinase_C_zeta; -. DR GenomeRNAi; 5590; -. DR Pharos; Q05513; Tchem. DR PRO; PR:Q05513; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q05513; protein. DR Bgee; ENSG00000067606; Expressed in right hemisphere of cerebellum and 168 other cell types or tissues. DR ExpressionAtlas; Q05513; baseline and differential. DR GO; GO:0045179; C:apical cortex; IEA:Ensembl. DR GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl. DR GO; GO:0043203; C:axon hillock; IEA:Ensembl. DR GO; GO:0005923; C:bicellular tight junction; IEA:Ensembl. DR GO; GO:0030054; C:cell junction; TAS:Reactome. DR GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB. DR GO; GO:0005814; C:centriole; IDA:HPA. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; TAS:ProtInc. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0016020; C:membrane; TAS:ProtInc. DR GO; GO:0035748; C:myelin sheath abaxonal region; IEA:Ensembl. DR GO; GO:0005635; C:nuclear envelope; IEA:Ensembl. DR GO; GO:0016363; C:nuclear matrix; IEA:Ensembl. DR GO; GO:0120157; C:PAR polarity complex; ISS:ComplexPortal. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0070160; C:tight junction; NAS:ComplexPortal. DR GO; GO:0031982; C:vesicle; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; EXP:Reactome. DR GO; GO:0043560; F:insulin receptor substrate binding; IDA:BHF-UCL. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:BHF-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0032869; P:cellular response to insulin stimulus; IBA:GO_Central. DR GO; GO:0030010; P:establishment of cell polarity; ISS:UniProtKB. DR GO; GO:0045197; P:establishment or maintenance of epithelial cell apical/basal polarity; ISS:ComplexPortal. DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0060291; P:long-term synaptic potentiation; ISS:UniProtKB. DR GO; GO:0000226; P:microtubule cytoskeleton organization; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; TAS:ProtInc. DR GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IMP:BHF-UCL. DR GO; GO:0031333; P:negative regulation of protein-containing complex assembly; IMP:BHF-UCL. DR GO; GO:1990138; P:neuron projection extension; IEA:Ensembl. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:UniProtKB. DR GO; GO:0046628; P:positive regulation of insulin receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0032733; P:positive regulation of interleukin-10 production; ISS:UniProtKB. DR GO; GO:0032736; P:positive regulation of interleukin-13 production; ISS:UniProtKB. DR GO; GO:0032753; P:positive regulation of interleukin-4 production; ISS:UniProtKB. DR GO; GO:0032754; P:positive regulation of interleukin-5 production; ISS:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISS:UniProtKB. DR GO; GO:2000553; P:positive regulation of T-helper 2 cell cytokine production; ISS:UniProtKB. DR GO; GO:0045630; P:positive regulation of T-helper 2 cell differentiation; ISS:UniProtKB. DR GO; GO:0072659; P:protein localization to plasma membrane; IBA:GO_Central. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd21095; C1_aPKC_zeta; 1. DR CDD; cd06404; PB1_aPKC; 1. DR CDD; cd05617; STKc_aPKC_zeta; 1. DR FunFam; 1.10.510.10:FF:000048; Protein kinase C; 1. DR FunFam; 3.10.20.90:FF:000071; Protein kinase C; 1. DR FunFam; 3.30.200.20:FF:000070; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000012; Protein kinase C; 1. DR Gene3D; 3.30.60.20; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR034662; aPKC_zeta. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR047314; C1_aPKC_zeta. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR053793; PB1-like. DR InterPro; IPR034877; PB1_aPKC. DR InterPro; IPR000270; PB1_dom. DR InterPro; IPR012233; PKC. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00130; C1_1; 1. DR Pfam; PF00564; PB1; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000554; PKC_zeta; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 1. DR SMART; SM00666; PB1; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF54277; CAD & PB1 domains; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS51745; PB1; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 1. DR PROSITE; PS50081; ZF_DAG_PE_2; 1. PE 1: Evidence at protein level; KW Alternative promoter usage; Alternative splicing; ATP-binding; KW Cell junction; Cytoplasm; Endosome; Inflammatory response; Kinase; KW Membrane; Metal-binding; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..592 FT /note="Protein kinase C zeta type" FT /id="PRO_0000055701" FT DOMAIN 15..98 FT /note="PB1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01081" FT DOMAIN 252..518 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 519..590 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT ZN_FING 130..180 FT /note="Phorbol-ester/DAG-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 79..145 FT /note="Interaction with SQSTM1" FT /evidence="ECO:0000250" FT ACT_SITE 376 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 258..266 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 281 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 410 FT /note="Phosphothreonine; by PDPK1 and PI3K" FT /evidence="ECO:0000269|PubMed:15314172, FT ECO:0000269|PubMed:20332120, ECO:0000269|PubMed:9768361" FT MOD_RES 560 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:24275569" FT MOD_RES 591 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P09217" FT VAR_SEQ 1..183 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_041904" FT VAR_SEQ 1..112 FT /note="MPSRTGPKMEGSGGRVRLKAHYGGDIFITSVDAATTFEELCEEVRDMCRLHQ FT QHPLTLKWVDSEGDPCTVSSQMELEEAFRLARQCRDEGLIIHVFPSTPEQPGLPCPGED FT K -> MLTPRTDE (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_046347" FT VARIANT 49 FT /note="R -> H (in dbSNP:rs35271800)" FT /id="VAR_050560" FT VARIANT 84 FT /note="R -> H (in dbSNP:rs56017162)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042310" FT VARIANT 514 FT /note="S -> F (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035467" FT VARIANT 519 FT /note="R -> C (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs376894109)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042311" FT MUTAGEN 19 FT /note="K->A: No effect on interaction with SQSTM1 and FT PARD6B." FT /evidence="ECO:0000269|PubMed:12887891" FT MUTAGEN 62 FT /note="D->A: Loss of interaction with SQSTM1 and PARD6B." FT /evidence="ECO:0000269|PubMed:12887891" FT MUTAGEN 66 FT /note="D->A: Loss of interaction with SQSTM1 and PARD6B." FT /evidence="ECO:0000269|PubMed:12887891" FT CONFLICT 6 FT /note="G -> D (in Ref. 1; AAA36488)" FT /evidence="ECO:0000305" FT CONFLICT 198 FT /note="K -> R (in Ref. 3; BAF83684)" FT /evidence="ECO:0000305" FT CONFLICT 262 FT /note="S -> T (in Ref. 1; AAA36488)" FT /evidence="ECO:0000305" FT CONFLICT 281 FT /note="K -> R (in Ref. 3; BAH11883)" FT /evidence="ECO:0000305" FT CONFLICT 366 FT /note="F -> L (in Ref. 3; BAF83684)" FT /evidence="ECO:0000305" FT CONFLICT 500 FT /note="R -> G (in Ref. 3; BAF83684)" FT /evidence="ECO:0000305" FT CONFLICT 522 FT /note="D -> G (in Ref. 3; BAF83684)" FT /evidence="ECO:0000305" SQ SEQUENCE 592 AA; 67660 MW; 88CCD0577E6A596C CRC64; MPSRTGPKME GSGGRVRLKA HYGGDIFITS VDAATTFEEL CEEVRDMCRL HQQHPLTLKW VDSEGDPCTV SSQMELEEAF RLARQCRDEG LIIHVFPSTP EQPGLPCPGE DKSIYRRGAR RWRKLYRANG HLFQAKRFNR RAYCGQCSER IWGLARQGYR CINCKLLVHK RCHGLVPLTC RKHMDSVMPS QEPPVDDKNE DADLPSEETD GIAYISSSRK HDSIKDDSED LKPVIDGMDG IKISQGLGLQ DFDLIRVIGR GSYAKVLLVR LKKNDQIYAM KVVKKELVHD DEDIDWVQTE KHVFEQASSN PFLVGLHSCF QTTSRLFLVI EYVNGGDLMF HMQRQRKLPE EHARFYAAEI CIALNFLHER GIIYRDLKLD NVLLDADGHI KLTDYGMCKE GLGPGDTTST FCGTPNYIAP EILRGEEYGF SVDWWALGVL MFEMMAGRSP FDIITDNPDM NTEDYLFQVI LEKPIRIPRF LSVKASHVLK GFLNKDPKER LGCRPQTGFS DIKSHAFFRS IDWDLLEKKQ ALPPFQPQIT DDYGLDNFDT QFTSEPVQLT PDDEDAIKRI DQSEFEGFEY INPLLLSTEE SV // ID LOX12_HUMAN Reviewed; 663 AA. AC P18054; O95569; Q6ISF8; Q9UQM4; DT 01-NOV-1990, integrated into UniProtKB/Swiss-Prot. DT 06-FEB-2007, sequence version 4. DT 28-JAN-2026, entry version 234. DE RecName: Full=Polyunsaturated fatty acid lipoxygenase ALOX12 {ECO:0000305}; DE EC=1.13.11.- {ECO:0000269|PubMed:17493578}; DE AltName: Full=Arachidonate (12S)-lipoxygenase {ECO:0000305|PubMed:17493578}; DE Short=12S-LOX; DE Short=12S-lipoxygenase {ECO:0000303|PubMed:23578768}; DE EC=1.13.11.31 {ECO:0000269|PubMed:17493578, ECO:0000269|PubMed:22984144, ECO:0000269|PubMed:24282679, ECO:0000269|PubMed:8500694}; DE AltName: Full=Arachidonate (15S)-lipoxygenase {ECO:0000305|PubMed:17493578}; DE EC=1.13.11.33 {ECO:0000269|PubMed:17493578}; DE AltName: Full=Linoleate (13S)-lipoxygenase {ECO:0000250|UniProtKB:P39655}; DE AltName: Full=Lipoxin synthase 12-LO; DE EC=3.3.2.-; DE AltName: Full=Platelet-type lipoxygenase 12; GN Name=ALOX12 {ECO:0000312|HGNC:HGNC:429}; Synonyms=12LO, LOG12; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-322. RX PubMed=2244907; DOI=10.1016/0006-291x(90)91580-l; RA Yoshimoto T., Yamamoto Y., Arakawa T., Suzuki H., Yamamoto S., Yokoyama C., RA Tanabe T., Toh H.; RT "Molecular cloning and expression of human arachidonate 12-lipoxygenase."; RL Biochem. Biophys. Res. Commun. 172:1230-1235(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-322. RX PubMed=2377602; DOI=10.1073/pnas.87.15.5638; RA Funk C.D., Furci L., Fitzgerald G.A.; RT "Molecular cloning, primary structure, and expression of the human RT platelet/erythroleukemia cell 12-lipoxygenase."; RL Proc. Natl. Acad. Sci. U.S.A. 87:5638-5642(1990). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ARG-261. RX PubMed=2217179; DOI=10.1073/pnas.87.19.7477; RA Izumi T., Hoshiko S., Raadmark O., Samuelsson B.; RT "Cloning of the cDNA for human 12-lipoxygenase."; RL Proc. Natl. Acad. Sci. U.S.A. 87:7477-7481(1990). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-261; SER-322 AND RP HIS-430. RG SeattleSNPs variation discovery resource; RL Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ARG-261. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-112. RX PubMed=1447217; DOI=10.1016/s0021-9258(18)35835-6; RA Yoshimoto T., Arakawa T., Hada T., Yamamoto S., Takahashi E.; RT "Structure and chromosomal localization of human arachidonate 12- RT lipoxygenase gene."; RL J. Biol. Chem. 267:24805-24809(1992). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-45. RX PubMed=1570320; DOI=10.1073/pnas.89.9.3962; RA Funk C.D., Funk L.B., Fitzgerald G.A., Samuelsson B.; RT "Characterization of human 12-lipoxygenase genes."; RL Proc. Natl. Acad. Sci. U.S.A. 89:3962-3966(1992). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 340-427. RC TISSUE=Skin; RX PubMed=8304420; DOI=10.1152/ajpcell.1994.266.1.c243; RA Hussain H., Shornick L.P., Shannon V.R., Wilson J.D., Funk C.D., RA Pentland A.P., Holtzman M.J.; RT "Epidermis contains platelet-type 12-lipoxygenase that is overexpressed in RT germinal layer keratinocytes in psoriasis."; RL Am. J. Physiol. 266:C243-C253(1994). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 531-663. RA Persson A.E., Lundeberg J., Uhlen M.; RT "EU-IMAGE: full-insert length sequencing of human cDNA clones."; RL Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases. RN [11] RP CATALYTIC ACTIVITY, PATHWAY, SUBSTRATE SPECIFICITY, BIOPHYSICOCHEMICAL RP PROPERTIES, AND FUNCTION. RX PubMed=1851637; DOI=10.1016/0005-2760(91)90128-5; RA Hada T., Ueda N., Takahashi Y., Yamamoto S.; RT "Catalytic properties of human platelet 12-lipoxygenase as compared with RT the enzymes of other origins."; RL Biochim. Biophys. Acta 1083:89-93(1991). RN [12] RP FUNCTION IN LIPOXIN SYNTHESIS, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL RP PROPERTIES, AND REACTION MECHANISM. RX PubMed=8250832; DOI=10.1042/bj2960127; RA Romano M., Chen X.S., Takahashi Y., Yamamoto S., Funk C.D., Serhan C.N.; RT "Lipoxin synthase activity of human platelet 12-lipoxygenase."; RL Biochem. J. 296:127-133(1993). RN [13] RP CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, RP AND FUNCTION. RX PubMed=8319693; DOI=10.1111/j.1432-1033.1993.tb17988.x; RA Chen X.S., Brash A.R., Funk C.D.; RT "Purification and characterization of recombinant histidine-tagged human RT platelet 12-lipoxygenase expressed in a baculovirus/insect cell system."; RL Eur. J. Biochem. 214:845-852(1993). RN [14] RP CATALYTIC ACTIVITY, MUTAGENESIS OF HIS-355; HIS-360; HIS-365; HIS-383; RP HIS-392; LYS-416; ALA-417; VAL-418 AND HIS-540, AND FUNCTION. RX PubMed=8500694; DOI=10.1096/fasebj.7.8.8500694; RA Chen X.S., Funk C.D.; RT "Structure-function properties of human platelet 12-lipoxygenase: chimeric RT enzyme and in vitro mutagenesis studies."; RL FASEB J. 7:694-701(1993). RN [15] RP SUBCELLULAR LOCATION, ACTIVITY REGULATION, AND INDUCTION. RX PubMed=8912711; DOI=10.1006/excr.1996.0317; RA Hagmann W., Gao X., Timar J., Chen Y.Q., Strohmaier A.R., Fahrenkopf C., RA Kagawa D., Lee M., Zacharek A., Honn K.V.; RT "12-Lipoxygenase in A431 cells: genetic identity, modulation of expression, RT and intracellular localization."; RL Exp. Cell Res. 228:197-205(1996). RN [16] RP FUNCTION IN ANGIOGENESIS. RX PubMed=9751607; RA Nie D., Hillman G.G., Geddes T., Tang K., Pierson C., Grignon D.J., RA Honn K.V.; RT "Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates RT angiogenesis and tumor growth."; RL Cancer Res. 58:4047-4051(1998). RN [17] RP FUNCTION IN ANGIOGENESIS. RX PubMed=16638750; DOI=10.1074/jbc.m601887200; RA Nie D., Krishnamoorthy S., Jin R., Tang K., Chen Y., Qiao Y., Zacharek A., RA Guo Y., Milanini J., Pages G., Honn K.V.; RT "Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate RT cancer cells."; RL J. Biol. Chem. 281:18601-18609(2006). RN [18] RP CATALYTIC ACTIVITY, FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=17493578; DOI=10.1016/j.abb.2007.04.007; RA Prusakiewicz J.J., Turman M.V., Vila A., Ball H.L., Al-Mestarihi A.H., RA Di Marzo V., Marnett L.J.; RT "Oxidative metabolism of lipoamino acids and vanilloids by lipoxygenases RT and cyclooxygenases."; RL Arch. Biochem. Biophys. 464:260-268(2007). RN [19] RP CATALYTIC ACTIVITY, AND FUNCTION. RX PubMed=18311922; DOI=10.1021/bi702530z; RA Turman M.V., Kingsley P.J., Rouzer C.A., Cravatt B.F., Marnett L.J.; RT "Oxidative metabolism of a fatty acid amide hydrolase-regulated lipid, RT arachidonoyltaurine."; RL Biochemistry 47:3917-3925(2008). RN [20] RP INDUCTION BY UV. RX PubMed=18755188; DOI=10.1016/j.febslet.2008.08.017; RA Yoo H., Jeon B., Jeon M.S., Lee H., Kim T.Y.; RT "Reciprocal regulation of 12- and 15-lipoxygenases by UV-irradiation in RT human keratinocytes."; RL FEBS Lett. 582:3249-3253(2008). RN [21] RP FUNCTION IN CELL MIGRATION. RX PubMed=22237009; DOI=10.1016/j.yexcr.2011.12.017; RA Klampfl T., Bogner E., Bednar W., Mager L., Massudom D., Kalny I., RA Heinzle C., Berger W., Staettner S., Karner J., Klimpfinger M., RA Fuerstenberger G., Krieg P., Marian B.; RT "Up-regulation of 12(S)-lipoxygenase induces a migratory phenotype in RT colorectal cancer cells."; RL Exp. Cell Res. 318:768-778(2012). RN [22] RP FUNCTION IN APOPTOTIC PROCESS, AND TISSUE SPECIFICITY. RX PubMed=23578768; DOI=10.1016/j.yexcr.2013.04.001; RA Weisinger G., Grafi-Cohen M., Hirsh M., Knoll E., Sharon O., Many A., RA Limor R., Stern N.; RT "12S-Lipoxygenase is necessary for human vascular smooth muscle cell RT survival."; RL Exp. Cell Res. 319:1586-1593(2013). RN [23] RP CATALYTIC ACTIVITY, AND FUNCTION. RX PubMed=22984144; DOI=10.1194/jlr.m026385; RA Ikei K.N., Yeung J., Apopa P.L., Ceja J., Vesci J., Holman T.R., RA Holinstat M.; RT "Investigations of human platelet-type 12-lipoxygenase: role of RT lipoxygenase products in platelet activation."; RL J. Lipid Res. 53:2546-2559(2012). RN [24] RP CATALYTIC ACTIVITY, FUNCTION, AND ACTIVITY REGULATION. RX PubMed=23504711; DOI=10.1096/fj.13-227728; RA Dalli J., Zhu M., Vlasenko N.A., Deng B., Haeggstroem J.Z., Petasis N.A., RA Serhan C.N.; RT "The novel 13S,14S-epoxy-maresin is converted by human macrophages to RT maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts RT macrophage phenotype."; RL FASEB J. 27:2573-2583(2013). RN [25] RP CATALYTIC ACTIVITY, FUNCTION, VARIANTS HIS-134; LYS-259; ARG-261 AND RP SER-322, AND CHARACTERIZATION OF VARIANTS HIS-134; LYS-259; ARG-261 AND RP SER-322. RX PubMed=24282679; DOI=10.1016/j.redox.2013.11.001; RA Horn T., Reddy Kakularam K., Anton M., Richter C., Reddanna P., Kuhn H.; RT "Functional characterization of genetic enzyme variations in human RT lipoxygenases."; RL Redox Biol. 1:566-577(2013). RN [26] RP CATALYTIC ACTIVITY, FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=25036362; DOI=10.1371/journal.pone.0102362; RA Deng B., Wang C.W., Arnardottir H.H., Li Y., Cheng C.Y., Dalli J., RA Serhan C.N.; RT "Maresin biosynthesis and identification of maresin 2, a new anti- RT inflammatory and pro-resolving mediator from human macrophages."; RL PLoS ONE 9:E102362-E102362(2014). RN [27] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=32404334; DOI=10.1194/jlr.ra120000777; RA Perry S.C., Kalyanaraman C., Tourdot B.E., Conrad W.S., Akinkugbe O., RA Freedman J.C., Holinstat M., Jacobson M.P., Holman T.R.; RT "15-Lipoxygenase-1 biosynthesis of 7S,14S-diHDHA implicates 15- RT lipoxygenase-2 in biosynthesis of resolvin D5."; RL J. Lipid Res. 61:1087-1103(2020). RN [28] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 172-662 IN COMPLEX WITH IRON IONS. RG Structural genomics consortium (SGC); RT "Crystal structure of the lipoxygenase domain of human arachidonate 12- RT lipoxygenase, 12s-type."; RL Submitted (FEB-2009) to the PDB data bank. RN [29] RP VARIANT ARG-261. RX PubMed=15308583; DOI=10.1093/carcin/bgh260; RA Goodman J.E., Bowman E.D., Chanock S.J., Alberg A.J., Harris C.C.; RT "Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms RT and colon cancer risk."; RL Carcinogenesis 25:2467-2472(2004). RN [30] RP VARIANT ARG-261, AND INVOLVEMENT IN COLORECTAL CANCER. RX PubMed=17151091; DOI=10.1093/carcin/bgl242; RA Tan W., Wu J., Zhang X., Guo Y., Liu J., Sun T., Zhang B., Zhao D., RA Yang M., Yu D., Lin D.; RT "Associations of functional polymorphisms in cyclooxygenase-2 and platelet RT 12-lipoxygenase with risk of occurrence and advanced disease status of RT colorectal cancer."; RL Carcinogenesis 28:1197-1201(2007). RN [31] RP VARIANT ARG-261, AND INVOLVEMENT IN ESOPHAGEAL CANCER. RX PubMed=17460548; DOI=10.1097/fpc.0b013e328010bda1; RA Guo Y., Zhang X., Tan W., Miao X., Sun T., Zhao D., Lin D.; RT "Platelet 12-lipoxygenase Arg261Gln polymorphism: functional RT characterization and association with risk of esophageal squamous cell RT carcinoma in combination with COX-2 polymorphisms."; RL Pharmacogenet. Genomics 17:197-205(2007). CC -!- FUNCTION: Catalyzes the regio and stereo-specific incorporation of CC molecular oxygen into free and esterified polyunsaturated fatty acids CC generating lipid hydroperoxides that can be further reduced to the CC corresponding hydroxy species (PubMed:17493578, PubMed:18311922, CC PubMed:1851637, PubMed:32404334, PubMed:8319693, PubMed:8500694). CC Mainly converts arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate) to the CC specific bioactive lipid (12S)-hydroperoxyeicosatetraenoate/(12S)-HPETE CC (PubMed:17493578, PubMed:22984144, PubMed:24282679, PubMed:8319693, CC PubMed:8500694). Through the production of bioactive lipids like (12S)- CC HPETE it regulates different biological processes including platelet CC activation (PubMed:8319693, PubMed:8500694). It can also catalyze the CC epoxidation of double bonds of polyunsaturated fatty acids such as CC (14S)-hydroperoxy-docosahexaenoate/(14S)-HPDHA resulting in the CC formation of (13S,14S)-epoxy-DHA (PubMed:23504711). Furthermore, it may CC participate in the sequential oxidations of DHA CC ((4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate) to generate specialized pro- CC resolving mediators (SPMs) like resolvin D5 ((7S,17S)-diHPDHA) and CC (7S,14S)-diHPDHA, that actively down-regulate the immune response and CC have anti-aggregation properties with platelets (PubMed:32404334). An CC additional function involves a multistep process by which it transforms CC leukotriene A4/LTA4 into the bioactive lipids lipoxin A4/LXA4 and CC lipoxin B4/LXB4, both are vasoactive and LXA4 may regulate neutrophil CC function via occupancy of specific recognition sites (PubMed:8250832). CC Can also peroxidize linoleate ((9Z,12Z)-octadecadienoate) to (13S)- CC hydroperoxyoctadecadienoate/ (13S-HPODE) (By similarity). Due to its CC role in regulating both the expression of the vascular endothelial CC growth factor (VEGF, an angiogenic factor involved in the survival and CC metastasis of solid tumors) and the expression of integrin beta-1 CC (known to affect tumor cell migration and proliferation), it can be CC regarded as protumorigenic (PubMed:16638750, PubMed:22237009, CC PubMed:9751607). Important for cell survival, as it may play a role not CC only in proliferation but also in the prevention of apoptosis in CC vascular smooth muscle cells (PubMed:23578768). CC {ECO:0000250|UniProtKB:P39655, ECO:0000269|PubMed:16638750, CC ECO:0000269|PubMed:17493578, ECO:0000269|PubMed:18311922, CC ECO:0000269|PubMed:1851637, ECO:0000269|PubMed:22237009, CC ECO:0000269|PubMed:22984144, ECO:0000269|PubMed:23504711, CC ECO:0000269|PubMed:23578768, ECO:0000269|PubMed:24282679, CC ECO:0000269|PubMed:32404334, ECO:0000269|PubMed:8250832, CC ECO:0000269|PubMed:8319693, ECO:0000269|PubMed:8500694, CC ECO:0000269|PubMed:9751607}. CC -!- CATALYTIC ACTIVITY: CC Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 = (12S)-hydroperoxy- CC (5Z,8Z,10E,14Z)-eicosatetraenoate; Xref=Rhea:RHEA:10428, CC ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57444; CC EC=1.13.11.31; Evidence={ECO:0000269|PubMed:17493578, CC ECO:0000269|PubMed:22984144, ECO:0000269|PubMed:24282679, CC ECO:0000269|PubMed:8319693, ECO:0000269|PubMed:8500694}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10429; CC Evidence={ECO:0000305|PubMed:17493578, ECO:0000305|PubMed:22984144}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 = (15S)-hydroperoxy- CC (5Z,8Z,11Z,13E)-eicosatetraenoate; Xref=Rhea:RHEA:16869, CC ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57446; CC EC=1.13.11.33; Evidence={ECO:0000269|PubMed:17493578}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:16870; CC Evidence={ECO:0000305|PubMed:17493578}; CC -!- CATALYTIC ACTIVITY: CC Reaction=2 leukotriene A4 + O2 + 2 H2O = 2 lipoxin A4; CC Xref=Rhea:RHEA:48584, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:57463, ChEBI:CHEBI:67026; CC Evidence={ECO:0000269|PubMed:1851637, ECO:0000269|PubMed:8250832}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48585; CC Evidence={ECO:0000305|PubMed:8250832}; CC -!- CATALYTIC ACTIVITY: CC Reaction=2 leukotriene A4 + O2 + 2 H2O = 2 lipoxin B4; CC Xref=Rhea:RHEA:48588, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:57463, ChEBI:CHEBI:67031; CC Evidence={ECO:0000269|PubMed:8250832}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48589; CC Evidence={ECO:0000305|PubMed:8250832}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(14S)-hydroperoxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate = CC (13S,14S)-epoxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoate + H2O; CC Xref=Rhea:RHEA:53532, ChEBI:CHEBI:15377, ChEBI:CHEBI:78048, CC ChEBI:CHEBI:131958; Evidence={ECO:0000269|PubMed:23504711}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53533; CC Evidence={ECO:0000305|PubMed:23504711}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-L-alanine + O2 = N-(15S)- CC hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoyl-alanine; CC Xref=Rhea:RHEA:50184, ChEBI:CHEBI:15379, ChEBI:CHEBI:132071, CC ChEBI:CHEBI:132077; Evidence={ECO:0000269|PubMed:17493578}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50185; CC Evidence={ECO:0000305|PubMed:17493578}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-L-alanine + O2 = N-(12S)- CC hydroperoxy-(5Z,8Z,10E,14Z)-eicosatetraenoyl-alanine; CC Xref=Rhea:RHEA:50172, ChEBI:CHEBI:15379, ChEBI:CHEBI:132071, CC ChEBI:CHEBI:132074; Evidence={ECO:0000269|PubMed:17493578}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50173; CC Evidence={ECO:0000305|PubMed:17493578}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-gamma-aminobutanoate + O2 = CC N-(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoyl-gamma- CC aminobutanoate; Xref=Rhea:RHEA:50180, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:132072, ChEBI:CHEBI:132078; CC Evidence={ECO:0000269|PubMed:17493578}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50181; CC Evidence={ECO:0000305|PubMed:17493578}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-gamma-aminobutanoate + O2 = CC N-(12S)-hydroperoxy-(5Z,8Z,10E,14Z)-eicosatetraenoyl-gamma- CC aminobutanoate; Xref=Rhea:RHEA:50176, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:132072, ChEBI:CHEBI:132075; CC Evidence={ECO:0000269|PubMed:17493578}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50177; CC Evidence={ECO:0000305|PubMed:17493578}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-glycine + O2 = N-(15S)- CC hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoyl-glycine; CC Xref=Rhea:RHEA:50188, ChEBI:CHEBI:15379, ChEBI:CHEBI:59002, CC ChEBI:CHEBI:132076; Evidence={ECO:0000269|PubMed:17493578}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50189; CC Evidence={ECO:0000305|PubMed:17493578}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-glycine + O2 = N-(12S)- CC hydroperoxy-(5Z,8Z,10E,14Z)-eicosatetraenoyl-glycine; CC Xref=Rhea:RHEA:50168, ChEBI:CHEBI:15379, ChEBI:CHEBI:59002, CC ChEBI:CHEBI:132073; Evidence={ECO:0000269|PubMed:17493578}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50169; CC Evidence={ECO:0000305|PubMed:17493578}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-taurine + O2 = N-(12S)- CC hydroperoxy-(5Z,8Z,10E,14Z)-eicosatetraenoyl-taurine; CC Xref=Rhea:RHEA:50160, ChEBI:CHEBI:15379, ChEBI:CHEBI:132060, CC ChEBI:CHEBI:132061; Evidence={ECO:0000269|PubMed:18311922}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50161; CC Evidence={ECO:0000305|PubMed:18311922}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-taurine + O2 = N-(15S)- CC hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoyl-taurine; CC Xref=Rhea:RHEA:50156, ChEBI:CHEBI:15379, ChEBI:CHEBI:132060, CC ChEBI:CHEBI:132062; Evidence={ECO:0000269|PubMed:18311922}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50157; CC Evidence={ECO:0000305|PubMed:18311922}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + O2 = (14S)- CC hydroperoxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate; CC Xref=Rhea:RHEA:41332, ChEBI:CHEBI:15379, ChEBI:CHEBI:77016, CC ChEBI:CHEBI:78048; Evidence={ECO:0000269|PubMed:25036362, CC ECO:0000269|PubMed:32404334}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41333; CC Evidence={ECO:0000305|PubMed:25036362, ECO:0000305|PubMed:32404334}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(7S)-hydroperoxy-(4Z,8E,10Z,13Z,16Z,19Z)-docosahexaenoate + O2 CC = (7S,14S)-dihydroperoxy-(4Z,8E,10Z,12E,16Z,19Z)-docosahexaenoate; CC Xref=Rhea:RHEA:64724, ChEBI:CHEBI:15379, ChEBI:CHEBI:156049, CC ChEBI:CHEBI:156082; Evidence={ECO:0000269|PubMed:32404334}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:64725; CC Evidence={ECO:0000305|PubMed:32404334}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(7S)-hydroperoxy-(4Z,8E,10Z,13Z,16Z,19Z)-docosahexaenoate + O2 CC = (7S,17S)-dihydroperoxy-(4Z,8E,10Z,13Z,15E,19Z)-docosahexaenoate; CC Xref=Rhea:RHEA:64728, ChEBI:CHEBI:15379, ChEBI:CHEBI:140349, CC ChEBI:CHEBI:156049; Evidence={ECO:0000269|PubMed:32404334}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:64729; CC Evidence={ECO:0000305|PubMed:32404334}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + O2 = (12S)- CC hydroperoxy-(5Z,8Z,10E,14Z,17Z)-eicosapentaenoate; CC Xref=Rhea:RHEA:48704, ChEBI:CHEBI:15379, ChEBI:CHEBI:58562, CC ChEBI:CHEBI:90772; Evidence={ECO:0000269|PubMed:22984144}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48705; CC Evidence={ECO:0000305|PubMed:22984144}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(8Z,11Z,14Z)-eicosatrienoate + O2 = (12S)-hydroperoxy- CC (8Z,10E,14Z)-eicosatrienoate; Xref=Rhea:RHEA:41328, CC ChEBI:CHEBI:15379, ChEBI:CHEBI:71589, ChEBI:CHEBI:78047; CC Evidence={ECO:0000269|PubMed:22984144}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41329; CC Evidence={ECO:0000305|PubMed:22984144}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(9Z,12Z)-octadecadienoate + O2 = (13S)-hydroperoxy-(9Z,11E)- CC octadecadienoate; Xref=Rhea:RHEA:22780, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:30245, ChEBI:CHEBI:57466; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:22781; CC Evidence={ECO:0000250|UniProtKB:P39655}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(5Z,8Z,11Z)-eicosatrienoate + O2 = (12S)-hydroperoxy- CC (5Z,8Z,10E)-eicosatrienoate; Xref=Rhea:RHEA:41324, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:78043, ChEBI:CHEBI:78046; CC Evidence={ECO:0000250|UniProtKB:P39655}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41325; CC Evidence={ECO:0000250|UniProtKB:P39655}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(14R,15S)-epoxy-(5Z,8Z,11Z)-eicosatrienoate + O2 = (12S)- CC hydroperoxy-(14R,15S)-epoxy-(5Z,8Z,10E)-eicosatrienoate; CC Xref=Rhea:RHEA:50276, ChEBI:CHEBI:15379, ChEBI:CHEBI:131965, CC ChEBI:CHEBI:132063; Evidence={ECO:0000250|UniProtKB:P39655}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50277; CC Evidence={ECO:0000250|UniProtKB:P39655}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(14S,15R)-epoxy-(5Z,8Z,11Z)-eicosatrienoate + O2 = (12S)- CC hydroperoxy-(14S,15R)-epoxy-(5Z,8Z,10E)-eicosatrienoate; CC Xref=Rhea:RHEA:50284, ChEBI:CHEBI:15379, ChEBI:CHEBI:131964, CC ChEBI:CHEBI:132065; Evidence={ECO:0000250|UniProtKB:P39655}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50285; CC Evidence={ECO:0000250|UniProtKB:P39655}; CC -!- COFACTOR: CC Name=Fe cation; Xref=ChEBI:CHEBI:24875; CC Note=Binds 1 Fe cation per subunit.; CC -!- ACTIVITY REGULATION: Activated by EGF (PubMed:8912711). Arachidonic CC acid conversion is inhibited by (13S,14S)-epoxy-(4Z,7Z,9E,11E,16Z,19Z)- CC docosahexaenoate (13S,14S-epoxy-DHA) (PubMed:23504711). Arachidonate CC 12-lipoxygenase activity is decreased when PH decreases from 7.4 to 6 CC (By similarity). {ECO:0000250|UniProtKB:P39655, CC ECO:0000269|PubMed:23504711, ECO:0000269|PubMed:8912711}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=8 uM for arachidonate (at pH 7.0 and 37 degrees Celsius) CC {ECO:0000269|PubMed:1851637}; CC KM=10 uM for arachidonate (at pH 8.0 and 25 degrees Celsius) CC {ECO:0000269|PubMed:8319693}; CC KM=6.2 uM for arachidonate (at pH 7.4) {ECO:0000269|PubMed:8250832}; CC KM=9 uM for linoleate (at pH 8.0 and 25 degrees Celsius) CC {ECO:0000269|PubMed:8319693}; CC KM=7.9 uM for leukotriene A4 (at pH 7.4) CC {ECO:0000269|PubMed:8250832}; CC KM=3 uM for eicosa-5,8,11,14,17-pentaenoate (at pH 7.0 and 37 degrees CC Celsius) {ECO:0000269|PubMed:1851637}; CC KM=35 uM for eicosa-8,11,14-trienoate (at pH 7.0 and 37 degrees CC Celsius) {ECO:0000269|PubMed:1851637}; CC KM=14.3 uM for 5,6-epoxy-8,11,14-eicosatrienoate (at pH 7.4) CC {ECO:0000269|PubMed:8250832}; CC KM=9.5 uM for arachidonic acid {ECO:0000269|PubMed:17493578}; CC KM=10.1 uM for N-arachidonoylglycine {ECO:0000269|PubMed:17493578}; CC KM=15.7 uM for N-arachidonoyl-L-alanine CC {ECO:0000269|PubMed:17493578}; CC KM=10.9 uM for N-arachidonoyl-gamma-aminobutyric acid CC {ECO:0000269|PubMed:17493578}; CC KM=9.7 uM for arachidonic acid {ECO:0000269|PubMed:25036362}; CC KM=5.1 uM for docosahexaenoate {ECO:0000269|PubMed:25036362}; CC KM=12.6 uM for arachidonic acid (in presence of calcium dichloride) CC {ECO:0000269|PubMed:25036362}; CC KM=7.1 uM for docosahexaenoate (in presence of calcium dichloride) CC {ECO:0000269|PubMed:25036362}; CC Vmax=3 umol/min/mg enzyme with arachidonate as substrate (at pH 8.0 CC and 25 degrees Celsius) {ECO:0000269|PubMed:8319693}; CC Vmax=1.057 umol/min/mg enzyme with arachidonate as substrate (at pH CC 7.4) {ECO:0000269|PubMed:8250832}; CC Vmax=0.0375 umol/min/mg enzyme with linoleate as substrate (at pH 8.0 CC and 25 degrees Celsius) {ECO:0000269|PubMed:8319693}; CC Vmax=0.025 umol/min/mg enzyme with leukotriene A4 as substrate (at pH CC 7.4) {ECO:0000269|PubMed:8250832}; CC Vmax=0.985 umol/min/mg enzyme with 5,6-epoxy-8,11,14-eicosatrienoate CC as substrate (at pH 7.4) {ECO:0000269|PubMed:8250832}; CC pH dependence: CC Optimum pH is 7.5-8.0 (for arachidonate 12-lipoxygenase activity). CC {ECO:0000269|PubMed:8250832, ECO:0000269|PubMed:8319693}; CC -!- PATHWAY: Lipid metabolism; hydroperoxy eicosatetraenoic acid CC biosynthesis. {ECO:0000269|PubMed:1851637}. CC -!- INTERACTION: CC P18054; P13647: KRT5; NbExp=7; IntAct=EBI-1633210, EBI-702187; CC P18054; P02545: LMNA; NbExp=4; IntAct=EBI-1633210, EBI-351935; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Membrane. Note=Membrane CC association is stimulated by EGF. CC -!- TISSUE SPECIFICITY: Expressed in vascular smooth muscle cells. CC {ECO:0000269|PubMed:23578768}. CC -!- INDUCTION: Down-regulated upon starvation, by UV-irradiation and 15- CC lipoxygenase metabolites. {ECO:0000269|PubMed:18755188, CC ECO:0000269|PubMed:8912711}. CC -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the CC esophagus. The most common types are esophageal squamous cell carcinoma CC and adenocarcinoma. Cancer of the esophagus remains a devastating CC disease because it is usually not detected until it has progressed to CC an advanced incurable stage. {ECO:0000269|PubMed:17460548}. CC Note=Disease susceptibility may be associated with variants affecting CC the gene represented in this entry. Gln at position 261 may confer CC interindividual susceptibility to esophageal cancer (PubMed:17460548). CC {ECO:0000269|PubMed:17460548}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:17151091}. Note=Disease CC susceptibility may be associated with variants affecting the gene CC represented in this entry. Gln at position 261 may confer CC interindividual susceptibility to colorectal cancer (PubMed:17460548). CC {ECO:0000269|PubMed:17460548}. CC -!- SIMILARITY: Belongs to the lipoxygenase family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/620/ALOX12"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M62982; AAA51533.1; -; mRNA. DR EMBL; M35418; AAA60056.1; -; mRNA. DR EMBL; M58704; AAA59523.1; -; mRNA. DR EMBL; AY527817; AAS00094.1; -; Genomic_DNA. DR EMBL; AC040977; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC069557; AAH69557.1; -; mRNA. DR EMBL; D12638; BAA02162.1; -; Genomic_DNA. DR EMBL; M87004; AAA51587.1; -; Genomic_DNA. DR EMBL; S68587; AAD14020.1; -; mRNA. DR EMBL; AF143883; AAD32700.1; -; mRNA. DR CCDS; CCDS11084.1; -. DR PIR; A38283; A38283. DR RefSeq; NP_000688.2; NM_000697.3. DR PDB; 3D3L; X-ray; 2.60 A; A/B=172-663. DR PDB; 8GHB; EM; 2.76 A; A=2-663. DR PDB; 8GHC; EM; 2.30 A; A/B=2-663. DR PDB; 8GHD; EM; 2.20 A; A/B/C/D/E/F=2-663. DR PDB; 8GHE; EM; 2.05 A; A/B/C/D=2-663. DR PDBsum; 3D3L; -. DR PDBsum; 8GHB; -. DR PDBsum; 8GHC; -. DR PDBsum; 8GHD; -. DR PDBsum; 8GHE; -. DR AlphaFoldDB; P18054; -. DR EMDB; EMD-40039; -. DR EMDB; EMD-40040; -. DR EMDB; EMD-40041; -. DR EMDB; EMD-40042; -. DR SMR; P18054; -. DR BioGRID; 106740; 12. DR FunCoup; P18054; 201. DR IntAct; P18054; 5. DR MINT; P18054; -. DR STRING; 9606.ENSP00000251535; -. DR BindingDB; P18054; -. DR ChEMBL; CHEMBL3687; -. DR DrugCentral; P18054; -. DR GuidetoPHARMACOLOGY; 1387; -. DR SwissLipids; SLP:000000670; -. DR GlyGen; P18054; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P18054; -. DR PhosphoSitePlus; P18054; -. DR BioMuta; ALOX12; -. DR DMDM; 125987838; -. DR MassIVE; P18054; -. DR PaxDb; 9606-ENSP00000251535; -. DR PeptideAtlas; P18054; -. DR ProteomicsDB; 53540; -. DR ABCD; P18054; 3 sequenced antibodies. DR Antibodypedia; 2760; 241 antibodies from 29 providers. DR DNASU; 239; -. DR Ensembl; ENST00000251535.11; ENSP00000251535.6; ENSG00000108839.13. DR GeneID; 239; -. DR KEGG; hsa:239; -. DR MANE-Select; ENST00000251535.11; ENSP00000251535.6; NM_000697.3; NP_000688.2. DR UCSC; uc002gdx.4; human. DR AGR; HGNC:429; -. DR ClinPGx; PA45; -. DR CTD; 239; -. DR DisGeNET; 239; -. DR GeneCards; ALOX12; -. DR HGNC; HGNC:429; ALOX12. DR HPA; ENSG00000108839; Tissue enhanced (cervix, esophagus, vagina). DR MIM; 114500; phenotype. DR MIM; 133239; phenotype. DR MIM; 152391; gene. DR OpenTargets; ENSG00000108839; -. DR VEuPathDB; HostDB:ENSG00000108839; -. DR eggNOG; ENOG502QQSP; Eukaryota. DR GeneTree; ENSGT00940000155191; -. DR HOGENOM; CLU_004282_3_3_1; -. DR InParanoid; P18054; -. DR OMA; NNGQYDW; -. DR OrthoDB; 407298at2759; -. DR PAN-GO; P18054; 10 GO annotations based on evolutionary models. DR PhylomeDB; P18054; -. DR BioCyc; MetaCyc:HS03167-MONOMER; -. DR BRENDA; 1.13.11.31; 2681. DR PathwayCommons; P18054; -. DR Reactome; R-HSA-2142696; Synthesis of Hepoxilins (HX) and Trioxilins (TrX). DR Reactome; R-HSA-2142700; Biosynthesis of Lipoxins (LX). DR Reactome; R-HSA-2142712; Synthesis of 12-eicosatetraenoic acid derivatives. DR Reactome; R-HSA-9018677; Biosynthesis of DHA-derived SPMs. DR Reactome; R-HSA-9025106; Biosynthesis of DPAn-6 SPMs. DR Reactome; R-HSA-9026290; Biosynthesis of DPAn-3-derived maresins. DR SABIO-RK; P18054; -. DR SignaLink; P18054; -. DR UniPathway; UPA00881; -. DR Agora; ENSG00000108839; -. DR BioGRID-ORCS; 239; 9 hits in 1152 CRISPR screens. DR ChiTaRS; ALOX12; human. DR EvolutionaryTrace; P18054; -. DR GeneWiki; ALOX12; -. DR GenomeRNAi; 239; -. DR Pharos; P18054; Tchem. DR PRO; PR:P18054; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P18054; protein. DR Bgee; ENSG00000108839; Expressed in lower esophagus mucosa and 116 other cell types or tissues. DR ExpressionAtlas; P18054; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0042383; C:sarcolemma; IDA:UniProtKB. DR GO; GO:0004052; F:arachidonate 12(S)-lipoxygenase activity; IDA:UniProtKB. DR GO; GO:0050473; F:arachidonate 15-lipoxygenase activity; IDA:UniProtKB. DR GO; GO:0047977; F:hepoxilin-epoxide hydrolase activity; ISS:UniProtKB. DR GO; GO:0005506; F:iron ion binding; IEA:InterPro. DR GO; GO:0016165; F:linoleate 13S-lipoxygenase activity; IDA:UniProtKB. DR GO; GO:0019369; P:arachidonate metabolic process; IDA:UniProtKB. DR GO; GO:0061436; P:establishment of skin barrier; ISS:UniProtKB. DR GO; GO:0019395; P:fatty acid oxidation; IDA:UniProtKB. DR GO; GO:0051122; P:hepoxilin biosynthetic process; ISS:UniProtKB. DR GO; GO:1901751; P:leukotriene A4 metabolic process; IDA:UniProtKB. DR GO; GO:0043651; P:linoleic acid metabolic process; IDA:UniProtKB. DR GO; GO:0006629; P:lipid metabolic process; IDA:UniProtKB. DR GO; GO:0034440; P:lipid oxidation; IBA:GO_Central. DR GO; GO:2001303; P:lipoxin A4 biosynthetic process; IDA:UniProtKB. DR GO; GO:2001306; P:lipoxin B4 biosynthetic process; IDA:UniProtKB. DR GO; GO:0019372; P:lipoxygenase pathway; IDA:UniProtKB. DR GO; GO:0010656; P:negative regulation of muscle cell apoptotic process; IMP:UniProtKB. DR GO; GO:0090331; P:negative regulation of platelet aggregation; ISS:UniProtKB. DR GO; GO:0042554; P:superoxide anion generation; NAS:UniProtKB. DR GO; GO:0033559; P:unsaturated fatty acid metabolic process; IDA:UniProtKB. DR CDD; cd01753; PLAT_LOX; 1. DR FunFam; 3.10.450.60:FF:000004; Arachidonate 12-lipoxygenase, 12S-type; 1. DR FunFam; 1.20.245.10:FF:000001; Arachidonate 5-lipoxygenase a; 1. DR FunFam; 2.60.60.20:FF:000002; Arachidonate 5-lipoxygenase a; 1. DR Gene3D; 3.10.450.60; -; 1. DR Gene3D; 1.20.245.10; Lipoxygenase-1, Domain 5; 1. DR Gene3D; 2.60.60.20; PLAT/LH2 domain; 1. DR InterPro; IPR000907; LipOase. DR InterPro; IPR013819; LipOase_C. DR InterPro; IPR036226; LipOase_C_sf. DR InterPro; IPR020834; LipOase_CS. DR InterPro; IPR020833; LipOase_Fe_BS. DR InterPro; IPR001885; LipOase_mml. DR InterPro; IPR001024; PLAT/LH2_dom. DR InterPro; IPR036392; PLAT/LH2_dom_sf. DR InterPro; IPR042062; PLAT_LOX_verte. DR PANTHER; PTHR11771; LIPOXYGENASE; 1. DR Pfam; PF00305; Lipoxygenase; 1. DR Pfam; PF01477; PLAT; 1. DR PRINTS; PR00087; LIPOXYGENASE. DR PRINTS; PR00467; MAMLPOXGNASE. DR SMART; SM00308; LH2; 1. DR SUPFAM; SSF49723; Lipase/lipooxygenase domain (PLAT/LH2 domain); 1. DR SUPFAM; SSF48484; Lipoxigenase; 1. DR PROSITE; PS00711; LIPOXYGENASE_1; 1. DR PROSITE; PS00081; LIPOXYGENASE_2; 1. DR PROSITE; PS51393; LIPOXYGENASE_3; 1. DR PROSITE; PS50095; PLAT; 1. PE 1: Evidence at protein level; KW 3D-structure; Cytoplasm; Dioxygenase; Fatty acid metabolism; Hydrolase; KW Iron; Lipid metabolism; Membrane; Metal-binding; Oxidoreductase; KW Phosphoprotein; Proteomics identification; Reference proteome. FT CHAIN 1..663 FT /note="Polyunsaturated fatty acid lipoxygenase ALOX12" FT /id="PRO_0000220682" FT DOMAIN 2..114 FT /note="PLAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00152" FT DOMAIN 115..663 FT /note="Lipoxygenase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00726" FT BINDING 360 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_note="catalytic" FT BINDING 365 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_note="catalytic" FT BINDING 540 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_note="catalytic" FT BINDING 544 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_note="catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00726" FT BINDING 663 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_note="catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00726" FT MOD_RES 246 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:F1LQ70" FT VARIANT 134 FT /note="D -> H (does not affect lipoxygenase activity; FT dbSNP:rs114985038)" FT /evidence="ECO:0000269|PubMed:24282679" FT /id="VAR_082032" FT VARIANT 259 FT /note="E -> K (does not affect lipoxygenase activity; FT dbSNP:rs4987104)" FT /evidence="ECO:0000269|PubMed:24282679" FT /id="VAR_030471" FT VARIANT 261 FT /note="Q -> R (does not affect lipoxygenase activity; FT dbSNP:rs1126667)" FT /evidence="ECO:0000269|PubMed:15308583, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17151091, FT ECO:0000269|PubMed:17460548, ECO:0000269|PubMed:2217179, FT ECO:0000269|PubMed:24282679, ECO:0000269|Ref.4" FT /id="VAR_018743" FT VARIANT 298 FT /note="A -> T" FT /id="VAR_004279" FT VARIANT 322 FT /note="N -> S (does not affect lipoxygenase activity; FT dbSNP:rs434473)" FT /evidence="ECO:0000269|PubMed:2244907, FT ECO:0000269|PubMed:2377602, ECO:0000269|PubMed:24282679, FT ECO:0000269|Ref.4" FT /id="VAR_018744" FT VARIANT 430 FT /note="R -> H (in dbSNP:rs11571342)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018745" FT MUTAGEN 355 FT /note="H->Q: No effect on arachidonate 12(S)-lipoxygenase FT activity." FT /evidence="ECO:0000269|PubMed:8500694" FT MUTAGEN 360 FT /note="H->Q,Y: Complete loss of arachidonate 12(S)- FT lipoxygenase activity." FT /evidence="ECO:0000269|PubMed:8500694" FT MUTAGEN 365 FT /note="H->Q: Complete loss of arachidonate 12(S)- FT lipoxygenase activity." FT /evidence="ECO:0000269|PubMed:8500694" FT MUTAGEN 383 FT /note="H->Q: Alteredarachidonate 12(S)-lipoxygenase FT activity and protein expression." FT /evidence="ECO:0000269|PubMed:8500694" FT MUTAGEN 392 FT /note="H->Q: No effect on arachidonate 12(S)-lipoxygenase FT activity." FT /evidence="ECO:0000269|PubMed:8500694" FT MUTAGEN 416 FT /note="K->Q: Reduced arachidonate 12(S)-lipoxygenase FT activity. No effect on the stereoselectivity of the FT oxygenation reaction." FT /evidence="ECO:0000269|PubMed:8500694" FT MUTAGEN 417 FT /note="A->I: Reduced arachidonate 12(S)-lipoxygenase FT activity. Alters the stereoselectivity of the oxygenation FT reaction." FT /evidence="ECO:0000269|PubMed:8500694" FT MUTAGEN 418 FT /note="V->M: No effect onarachidonate 12(S)-lipoxygenase FT activity. No effect on the stereoselectivity of the FT oxygenation reaction." FT /evidence="ECO:0000269|PubMed:8500694" FT MUTAGEN 540 FT /note="H->Q: Complete loss of arachidonate 12(S)- FT lipoxygenase activity." FT /evidence="ECO:0000269|PubMed:8500694" FT CONFLICT 189..192 FT /note="RVYT -> PCLH (in Ref. 1; AAA51533)" FT /evidence="ECO:0000305" FT CONFLICT 345 FT /note="S -> C (in Ref. 1; AAA51533)" FT /evidence="ECO:0000305" FT CONFLICT 389 FT /note="L -> P (in Ref. 2; AAA60056)" FT /evidence="ECO:0000305" FT STRAND 3..14 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 16..18 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 20..30 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 32..39 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 47..52 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 59..69 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 75..84 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 86..88 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 92..99 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 102..104 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 106..109 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 123..138 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 151..153 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 157..159 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 162..164 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 168..191 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 193..195 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 200..205 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 208..210 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 213..221 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 225..234 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 258..269 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 273..277 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 279..281 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 300..305 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 311..317 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 325..327 FT /evidence="ECO:0007829|PDB:3D3L" FT STRAND 333..335 FT /evidence="ECO:0007829|PDB:8GHC" FT HELIX 337..357 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 358..364 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 365..378 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 384..389 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 390..393 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 396..406 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 414..417 FT /evidence="ECO:0007829|PDB:8GHE" FT TURN 419..423 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 424..434 FT /evidence="ECO:0007829|PDB:8GHE" FT TURN 438..441 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 443..449 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 459..482 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 486..490 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 493..503 FT /evidence="ECO:0007829|PDB:8GHE" FT TURN 504..508 FT /evidence="ECO:0007829|PDB:8GHE" FT TURN 510..514 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 522..536 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 538..544 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 547..551 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 554..556 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 561..563 FT /evidence="ECO:0007829|PDB:8GHB" FT STRAND 567..571 FT /evidence="ECO:0007829|PDB:3D3L" FT HELIX 574..580 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 584..598 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 618..642 FT /evidence="ECO:0007829|PDB:8GHE" FT TURN 654..656 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 657..660 FT /evidence="ECO:0007829|PDB:8GHE" SQ SEQUENCE 663 AA; 75694 MW; C4D6D5B320666A77 CRC64; MGRYRIRVAT GAWLFSGSYN RVQLWLVGTR GEAELELQLR PARGEEEEFD HDVAEDLGLL QFVRLRKHHW LVDDAWFCDR ITVQGPGACA EVAFPCYRWV QGEDILSLPE GTARLPGDNA LDMFQKHREK ELKDRQQIYC WATWKEGLPL TIAADRKDDL PPNMRFHEEK RLDFEWTLKA GALEMALKRV YTLLSSWNCL EDFDQIFWGQ KSALAEKVRQ CWQDDELFSY QFLNGANPML LRRSTSLPSR LVLPSGMEEL QAQLEKELQN GSLFEADFIL LDGIPANVIR GEKQYLAAPL VMLKMEPNGK LQPMVIQIQP PNPSSPTPTL FLPSDPPLAW LLAKSWVRNS DFQLHEIQYH LLNTHLVAEV IAVATMRCLP GLHPIFKFLI PHIRYTMEIN TRARTQLISD GGIFDKAVST GGGGHVQLLR RAAAQLTYCS LCPPDDLADR GLLGLPGALY AHDALRLWEI IARYVEGIVH LFYQRDDIVK GDPELQAWCR EITEVGLCQA QDRGFPVSFQ SQSQLCHFLT MCVFTCTAQH AAINQGQLDW YAWVPNAPCT MRMPPPTTKE DVTMATVMGS LPDVRQACLQ MAISWHLSRR QPDMVPLGHH KEKYFSGPKP KAVLNQFRTD LEKLEKEITA RNEQLDWPYE YLKPSCIENS VTI // ID MLKL_HUMAN Reviewed; 471 AA. AC Q8NB16; A6NCE4; Q8N6V0; DT 05-SEP-2006, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2002, sequence version 1. DT 28-JAN-2026, entry version 185. DE RecName: Full=Mixed lineage kinase domain-like protein {ECO:0000305}; DE Short=hMLKL {ECO:0000303|PubMed:12471243}; GN Name=MLKL {ECO:0000303|PubMed:22265413, ECO:0000312|HGNC:HGNC:26617}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND NOMENCLATURE. RX PubMed=12471243; DOI=10.1126/science.1075762; RA Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S.; RT "The protein kinase complement of the human genome."; RL Science 298:1912-1934(2002). RN [2] {ECO:0000305, ECO:0000312|EMBL:BAC03728.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Chondrocyte {ECO:0000312|EMBL:BAC03728.1}; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15616553; DOI=10.1038/nature03187; RA Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G., RA Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E., RA Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M., RA Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C., RA Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M., RA Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M., RA Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D., RA Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., RA Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., RA Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., RA Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., RA Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J., RA Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D., RA Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S., RA Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A., RA Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M., RA Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H., RA Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A., RA Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J., RA DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J., RA Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., RA Myers R.M., Rubin E.M., Pennacchio L.A.; RT "The sequence and analysis of duplication-rich human chromosome 16."; RL Nature 432:988-994(2004). RN [4] {ECO:0000305, ECO:0000312|EMBL:AAH28141.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Leukocyte {ECO:0000312|EMBL:AAH28141.1}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-125, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [6] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-125, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [7] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [8] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [10] RP FUNCTION, INTERACTION WITH RIPK3, ACTIVITY REGULATION, PHOSPHORYLATION AT RP THR-357 AND SER-358, AND MUTAGENESIS OF CYS-86; THR-357 AND SER-358. RX PubMed=22265413; DOI=10.1016/j.cell.2011.11.031; RA Sun L., Wang H., Wang Z., He S., Chen S., Liao D., Wang L., Yan J., Liu W., RA Lei X., Wang X.; RT "Mixed lineage kinase domain-like protein mediates necrosis signaling RT downstream of RIP3 kinase."; RL Cell 148:213-227(2012). RN [11] RP FUNCTION, AND IDENTIFICATION IN COMPLEX WITH PGAM5; RIPK1 AND RIPK3. RX PubMed=22265414; DOI=10.1016/j.cell.2011.11.030; RA Wang Z., Jiang H., Chen S., Du F., Wang X.; RT "The mitochondrial phosphatase PGAM5 functions at the convergence point of RT multiple necrotic death pathways."; RL Cell 148:228-243(2012). RN [12] RP FUNCTION, AND INTERACTION WITH RIPK3. RX PubMed=22421439; DOI=10.1073/pnas.1200012109; RA Zhao J., Jitkaew S., Cai Z., Choksi S., Li Q., Luo J., Liu Z.G.; RT "Mixed lineage kinase domain-like is a key receptor interacting protein 3 RT downstream component of TNF-induced necrosis."; RL Proc. Natl. Acad. Sci. U.S.A. 109:5322-5327(2012). RN [13] RP FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, AND MUTAGENESIS OF LEU-58; ILE-76; RP LEU-162 AND LEU-165. RX PubMed=24316671; DOI=10.1038/ncb2883; RA Cai Z., Jitkaew S., Zhao J., Chiang H.C., Choksi S., Liu J., Ward Y., RA Wu L.G., Liu Z.G.; RT "Plasma membrane translocation of trimerized MLKL protein is required for RT TNF-induced necroptosis."; RL Nat. Cell Biol. 16:55-65(2014). RN [14] RP INTERACTION WITH RIPK3. RX PubMed=29883609; DOI=10.1016/j.molcel.2018.05.016; RA Choi S.W., Park H.H., Kim S., Chung J.M., Noh H.J., Kim S.K., Song H.K., RA Lee C.W., Morgan M.J., Kang H.C., Kim Y.S.; RT "PELI1 selectively targets kinase-active RIP3 for ubiquitylation-dependent RT proteasomal degradation."; RL Mol. Cell 70:920-935(2018). RN [15] RP FUNCTION, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-358, SUBUNIT, REGION RP NBB, AND SUBCELLULAR LOCATION. RX PubMed=29883610; DOI=10.1016/j.molcel.2018.05.010; RA Dovey C.M., Diep J., Clarke B.P., Hale A.T., McNamara D.E., Guo H., RA Brown N.W. Jr., Cao J.Y., Grace C.R., Gough P.J., Bertin J., Dixon S.J., RA Fiedler D., Mocarski E.S., Kaiser W.J., Moldoveanu T., York J.D., RA Carette J.E.; RT "MLKL requires the inositol phosphate code to execute necroptosis."; RL Mol. Cell 70:936-948(2018). RN [16] RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 189-471, ATP-BINDING, AND RP MUTAGENESIS OF LYS-230; LYS-331 AND GLU-351. RX PubMed=24219132; DOI=10.1042/bj20131270; RA Murphy J.M., Lucet I.S., Hildebrand J.M., Tanzer M.C., Young S.N., RA Sharma P., Lessene G., Alexander W.S., Babon J.J., Silke J., Czabotar P.E.; RT "Insights into the evolution of divergent nucleotide-binding mechanisms RT among pseudokinases revealed by crystal structures of human and mouse RT MLKL."; RL Biochem. J. 457:369-377(2014). RN [17] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 179-471. RX PubMed=24095729; DOI=10.1016/j.celrep.2013.08.044; RA Xie T., Peng W., Yan C., Wu J., Gong X., Shi Y.; RT "Structural insights into RIP3-mediated necroptotic signaling."; RL Cell Rep. 5:70-78(2013). RN [18] RP VARIANTS [LARGE SCALE ANALYSIS] THR-52; GLU-100; PRO-132; GLN-146; LEU-169; RP PRO-291; MET-364; ILE-398 AND HIS-421. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Pseudokinase that plays a key role in TNF-induced CC necroptosis, a programmed cell death process (PubMed:22265413, CC PubMed:22265414, PubMed:22421439, PubMed:24316671). Does not have CC protein kinase activity (PubMed:22265413, PubMed:22265414, CC PubMed:22421439, PubMed:24316671). Activated following phosphorylation CC by RIPK3, leading to homotrimerization, localization to the plasma CC membrane and execution of programmed necrosis characterized by calcium CC influx and plasma membrane damage (PubMed:22265413, PubMed:22265414, CC PubMed:22421439, PubMed:24316671). In addition to TNF-induced CC necroptosis, necroptosis can also take place in the nucleus in response CC to orthomyxoviruses infection: following activation by ZBP1, MLKL is CC phosphorylated by RIPK3 in the nucleus, triggering disruption of the CC nuclear envelope and leakage of cellular DNA into the cytosol.following CC ZBP1 activation, which senses double-stranded Z-RNA structures, nuclear CC RIPK3 catalyzes phosphorylation and activation of MLKL, promoting CC disruption of the nuclear envelope and leakage of cellular DNA into the CC cytosol (By similarity). Binds to highly phosphorylated inositol CC phosphates such as inositolhexakisphosphate (InsP6) which is essential CC for its necroptotic function (PubMed:29883610). CC {ECO:0000250|UniProtKB:Q9D2Y4, ECO:0000269|PubMed:22265413, CC ECO:0000269|PubMed:22265414, ECO:0000269|PubMed:22421439, CC ECO:0000269|PubMed:24316671, ECO:0000269|PubMed:29883610}. CC -!- ACTIVITY REGULATION: Activated via binding to highly phosphorylated CC inositol phosphates such as inositolhexakisphosphate (InsP6) which CC mediates the release of an N-terminal auto-inhibitory region CC (PubMed:29883610). Activation requires not only RIPK3-dependent CC phosphorylation but also binding to highly phosphorylated inositol CC phosphates (PubMed:29883610). Inhibited by necrosulfonamide, a specific CC inhibitor of necroptosis that targets Cys-86 (PubMed:22265413). CC {ECO:0000269|PubMed:22265413, ECO:0000269|PubMed:29883610}. CC -!- SUBUNIT: Homooligomer (PubMed:29883610). Homotrimer; forms homotrimers CC on necroptosis induction (PubMed:24316671). Upon TNF-induced necrosis, CC forms in complex with PGAM5, RIPK1 and RIPK3 (PubMed:22265414). Within CC this complex, may play a role in the proper targeting of RIPK1-RIPK3 to CC its downstream effector PGAM5 (PubMed:22265414). Interacts with RIPK3; CC the interaction is direct and promotes its phosphorylation and CC subsequent activation (PubMed:22265413, PubMed:22421439, CC PubMed:29883609). {ECO:0000269|PubMed:22265413, CC ECO:0000269|PubMed:22265414, ECO:0000269|PubMed:22421439, CC ECO:0000269|PubMed:24316671, ECO:0000269|PubMed:29883609, CC ECO:0000269|PubMed:29883610}. CC -!- INTERACTION: CC Q8NB16; Q9Y572: RIPK3; NbExp=10; IntAct=EBI-1055040, EBI-298250; CC Q8NB16-1; Q8NB16-1: MLKL; NbExp=2; IntAct=EBI-16084674, EBI-16084674; CC Q8NB16-2; P20618: PSMB1; NbExp=3; IntAct=EBI-19046912, EBI-372273; CC Q8NB16-2; P60903: S100A10; NbExp=3; IntAct=EBI-19046912, EBI-717048; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:24316671}. Cell CC membrane {ECO:0000269|PubMed:24316671, ECO:0000269|PubMed:29883610}. CC Nucleus {ECO:0000250|UniProtKB:Q9D2Y4}. Note=Localizes to the cytoplasm CC and translocates to the plasma membrane on necroptosis induction CC (PubMed:24316671). Localizes to the nucleus in response to CC orthomyxoviruses infection (By similarity). CC {ECO:0000250|UniProtKB:Q9D2Y4, ECO:0000269|PubMed:24316671}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1 {ECO:0000303|PubMed:12471243, ECO:0000303|PubMed:14702039}; CC IsoId=Q8NB16-1; Sequence=Displayed; CC Name=2 {ECO:0000303|PubMed:15489334}; CC IsoId=Q8NB16-2; Sequence=VSP_052133, VSP_052134; CC -!- DOMAIN: The protein kinase domain is catalytically inactive but CC contains an unusual pseudoactive site with an interaction between Lys- CC 230 and Gln-356 residues (By similarity). Upon phosphorylation by CC RIPK3, undergoes an active conformation (By similarity). CC {ECO:0000250|UniProtKB:Q9D2Y4}. CC -!- DOMAIN: The coiled coil region 2 is responsible for homotrimerization. CC {ECO:0000269|PubMed:24316671}. CC -!- PTM: Phosphorylation by RIPK3 induces a conformational switch that is CC required for necroptosis (PubMed:22265413). It also induces CC homotrimerization and localization to the plasma membrane CC (PubMed:22265413). {ECO:0000269|PubMed:22265413}. CC -!- MISCELLANEOUS: Interaction with RIPK3 is species specific: human MLKL CC only interacts with human RIPK3 and not mouse RIPK3. CC {ECO:0000305|PubMed:22265413}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK091708; BAC03728.1; -; mRNA. DR EMBL; AC109599; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC028141; AAH28141.1; -; mRNA. DR CCDS; CCDS32487.1; -. [Q8NB16-1] DR CCDS; CCDS45528.1; -. [Q8NB16-2] DR RefSeq; NP_001135969.1; NM_001142497.3. [Q8NB16-2] DR RefSeq; NP_689862.1; NM_152649.4. [Q8NB16-1] DR RefSeq; XP_005255891.1; XM_005255834.5. [Q8NB16-1] DR RefSeq; XP_054235719.1; XM_054379744.1. [Q8NB16-1] DR PDB; 2MSV; NMR; -; A=1-154. DR PDB; 4M67; X-ray; 1.90 A; A=179-471. DR PDB; 4MWI; X-ray; 1.70 A; A=183-471. DR PDB; 5KNJ; X-ray; 2.88 A; A/B=191-471. DR PDB; 5KO1; X-ray; 2.16 A; A=191-471. DR PDB; 6BWK; X-ray; 2.79 A; A=190-471. DR PDB; 6D74; NMR; -; A=1-156. DR PDB; 6LK5; X-ray; 2.50 A; A=1-471. DR PDB; 6LK6; X-ray; 2.41 A; A=179-471. DR PDB; 6O5Z; X-ray; 2.29 A; A/B=190-471. DR PDB; 6UX8; X-ray; 2.50 A; A=5-154. DR PDB; 6ZLE; NMR; -; A=2-154. DR PDB; 6ZPR; NMR; -; A=2-154. DR PDB; 6ZVO; X-ray; 1.37 A; A/B/C=2-150. DR PDB; 6ZZ1; X-ray; 1.64 A; A/B=2-150. DR PDB; 7JW7; X-ray; 2.63 A; A=190-471. DR PDB; 7JXU; X-ray; 2.44 A; A/B=190-471. DR PDB; 7MON; X-ray; 2.23 A; A=190-471. DR PDB; 7NM2; NMR; -; A=2-154. DR PDB; 7NM4; NMR; -; A=2-154. DR PDB; 7NM5; NMR; -; A=2-154. DR PDB; 8SLZ; X-ray; 2.30 A; A=190-471. DR PDBsum; 2MSV; -. DR PDBsum; 4M67; -. DR PDBsum; 4MWI; -. DR PDBsum; 5KNJ; -. DR PDBsum; 5KO1; -. DR PDBsum; 6BWK; -. DR PDBsum; 6D74; -. DR PDBsum; 6LK5; -. DR PDBsum; 6LK6; -. DR PDBsum; 6O5Z; -. DR PDBsum; 6UX8; -. DR PDBsum; 6ZLE; -. DR PDBsum; 6ZPR; -. DR PDBsum; 6ZVO; -. DR PDBsum; 6ZZ1; -. DR PDBsum; 7JW7; -. DR PDBsum; 7JXU; -. DR PDBsum; 7MON; -. DR PDBsum; 7NM2; -. DR PDBsum; 7NM4; -. DR PDBsum; 7NM5; -. DR PDBsum; 8SLZ; -. DR AlphaFoldDB; Q8NB16; -. DR BMRB; Q8NB16; -. DR SMR; Q8NB16; -. DR BioGRID; 128244; 57. DR CORUM; Q8NB16; -. DR DIP; DIP-41782N; -. DR FunCoup; Q8NB16; 497. DR IntAct; Q8NB16; 25. DR MINT; Q8NB16; -. DR STRING; 9606.ENSP00000308351; -. DR BindingDB; Q8NB16; -. DR ChEMBL; CHEMBL1938217; -. DR DrugCentral; Q8NB16; -. DR GuidetoPHARMACOLOGY; 2106; -. DR TCDB; 1.A.105.1.1; the mixed lineage kinase domain-like (mlkl) family. DR GlyCosmos; Q8NB16; 4 sites, 1 glycan. DR GlyGen; Q8NB16; 4 sites, 1 O-linked glycan (4 sites). DR iPTMnet; Q8NB16; -. DR PhosphoSitePlus; Q8NB16; -. DR SwissPalm; Q8NB16; -. DR BioMuta; MLKL; -. DR DMDM; 74762545; -. DR CPTAC; CPTAC-895; -. DR CPTAC; CPTAC-896; -. DR jPOST; Q8NB16; -. DR MassIVE; Q8NB16; -. DR PaxDb; 9606-ENSP00000308351; -. DR PeptideAtlas; Q8NB16; -. DR ProteomicsDB; 72718; -. [Q8NB16-1] DR ProteomicsDB; 72719; -. [Q8NB16-2] DR Pumba; Q8NB16; -. DR ABCD; Q8NB16; 4 sequenced antibodies. DR Antibodypedia; 2097; 400 antibodies from 40 providers. DR DNASU; 197259; -. DR Ensembl; ENST00000306247.11; ENSP00000303118.7; ENSG00000168404.14. [Q8NB16-2] DR Ensembl; ENST00000308807.12; ENSP00000308351.7; ENSG00000168404.14. [Q8NB16-1] DR GeneID; 197259; -. DR KEGG; hsa:197259; -. DR MANE-Select; ENST00000308807.12; ENSP00000308351.7; NM_152649.4; NP_689862.1. DR UCSC; uc002fdb.3; human. [Q8NB16-1] DR AGR; HGNC:26617; -. DR ClinPGx; PA142671349; -. DR CTD; 197259; -. DR DisGeNET; 197259; -. DR GeneCards; MLKL; -. DR HGNC; HGNC:26617; MLKL. DR HPA; ENSG00000168404; Low tissue specificity. DR MalaCards; MLKL; -. DR MIM; 615153; gene. DR OpenTargets; ENSG00000168404; -. DR VEuPathDB; HostDB:ENSG00000168404; -. DR eggNOG; KOG0192; Eukaryota. DR GeneTree; ENSGT00390000016453; -. DR HOGENOM; CLU_044216_0_0_1; -. DR InParanoid; Q8NB16; -. DR OMA; ESKVDWM; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q8NB16; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q8NB16; -. DR PathwayCommons; Q8NB16; -. DR Reactome; R-HSA-3295583; TRP channels. DR Reactome; R-HSA-5213460; RIPK1-mediated regulated necrosis. DR Reactome; R-HSA-5675482; Regulation of necroptotic cell death. DR Reactome; R-HSA-9686347; Microbial modulation of RIPK1-mediated regulated necrosis. DR SignaLink; Q8NB16; -. DR SIGNOR; Q8NB16; -. DR Agora; ENSG00000168404; -. DR BioGRID-ORCS; 197259; 17 hits in 1193 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; MLKL; human. DR EvolutionaryTrace; Q8NB16; -. DR GenomeRNAi; 197259; -. DR Pharos; Q8NB16; Tchem. DR PRO; PR:Q8NB16; -. DR Proteomes; UP000005640; Chromosome 16. DR RNAct; Q8NB16; protein. DR Bgee; ENSG00000168404; Expressed in granulocyte and 164 other cell types or tissues. DR ExpressionAtlas; Q8NB16; baseline and differential. DR GO; GO:0030054; C:cell junction; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0019901; F:protein kinase binding; IEA:Ensembl. DR GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB. DR GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro. DR GO; GO:0051607; P:defense response to virus; ISS:UniProtKB. DR GO; GO:0097528; P:execution phase of necroptosis; IDA:UniProt. DR GO; GO:0070266; P:necroptotic process; IMP:UniProtKB. DR GO; GO:0097527; P:necroptotic signaling pathway; IMP:UniProtKB. DR GO; GO:0070207; P:protein homotrimerization; IDA:UniProtKB. DR CDD; cd21037; MLKL_NTD; 1. DR FunFam; 1.10.510.10:FF:000663; Mixed lineage kinase domain-like pseudokinase; 1. DR FunFam; 1.20.930.20:FF:000005; Mixed lineage kinase domain-like pseudokinase; 1. DR FunFam; 3.30.200.20:FF:000437; Mixed lineage kinase domain-like pseudokinase; 1. DR Gene3D; 1.20.930.20; Adaptor protein Cbl, N-terminal domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR036537; Adaptor_Cbl_N_dom_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR059179; MLKL-like_MCAfunc. DR InterPro; IPR054000; MLKL_N. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR PANTHER; PTHR44329:SF298; MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN; 1. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR Pfam; PF22215; MLKL_N; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Coiled coil; Cytoplasm; Membrane; Necrosis; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome. FT CHAIN 1..471 FT /note="Mixed lineage kinase domain-like protein" FT /id="PRO_0000248239" FT DOMAIN 194..469 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..149 FT /note="N-terminal bundle and brace (NBB); mediates INSP6 FT binding" FT /evidence="ECO:0000269|PubMed:29883610" FT COILED 55..84 FT /evidence="ECO:0000255" FT COILED 139..180 FT /evidence="ECO:0000255" FT BINDING 209..217 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 230 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT SITE 86 FT /note="Target of necrosulfonamide inhibitor" FT /evidence="ECO:0000269|PubMed:22265413" FT MOD_RES 125 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976" FT MOD_RES 357 FT /note="Phosphothreonine; by RIPK3" FT /evidence="ECO:0000269|PubMed:22265413" FT MOD_RES 358 FT /note="Phosphoserine; by RIPK3" FT /evidence="ECO:0000269|PubMed:22265413, FT ECO:0000269|PubMed:29883610" FT MOD_RES 360 FT /note="Phosphoserine; by RIPK3" FT /evidence="ECO:0000250|UniProtKB:Q9D2Y4" FT VAR_SEQ 179..205 FT /note="YLPPKCMQEIPQEQIKEIKKEQLSGSP -> SLESSSGKSPLEISRFKVKNV FT KTGSAS (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_052133" FT VAR_SEQ 206..413 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_052134" FT VARIANT 52 FT /note="S -> T (in dbSNP:rs34251827)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041350" FT VARIANT 100 FT /note="D -> E (in dbSNP:rs33987771)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041351" FT VARIANT 132 FT /note="S -> P (in dbSNP:rs35589326)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041352" FT VARIANT 146 FT /note="R -> Q (in dbSNP:rs34515646)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041353" FT VARIANT 169 FT /note="M -> L (in dbSNP:rs55929310)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041354" FT VARIANT 291 FT /note="L -> P (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1313508921)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041355" FT VARIANT 364 FT /note="T -> M (in dbSNP:rs34389205)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041356" FT VARIANT 398 FT /note="F -> I (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041357" FT VARIANT 421 FT /note="R -> H (in dbSNP:rs55987292)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041358" FT MUTAGEN 58 FT /note="L->G: Does not affect formation of homotrimers, FT while translocation to the plasma membrane on necroptosis FT induction is impaired; when associated with G-76." FT /evidence="ECO:0000269|PubMed:24316671" FT MUTAGEN 76 FT /note="I->G: Does not affect formation of homotrimers, FT while translocation to the plasma membrane on necroptosis FT induction is impaired; when associated with G-58." FT /evidence="ECO:0000269|PubMed:24316671" FT MUTAGEN 86 FT /note="C->S: Abolishes binding to necrosulfonamide FT inhibitor." FT /evidence="ECO:0000269|PubMed:22265413" FT MUTAGEN 162 FT /note="L->G: Impairs formation of homotrimers and FT translocation to the plasma membrane on necroptosis FT induction; when associated with G-165." FT /evidence="ECO:0000269|PubMed:24316671" FT MUTAGEN 165 FT /note="L->G: Impairs formation of homotrimers and FT translocation to the plasma membrane on necroptosis FT induction; when associated with G-162." FT /evidence="ECO:0000269|PubMed:24316671" FT MUTAGEN 230 FT /note="K->M: Abolishes ATP-binding." FT /evidence="ECO:0000269|PubMed:24219132" FT MUTAGEN 331 FT /note="K->N: Impairs ATP-binding." FT /evidence="ECO:0000269|PubMed:24219132" FT MUTAGEN 351 FT /note="E->K: Binds ATP with an enhanced affinity." FT /evidence="ECO:0000269|PubMed:24219132" FT MUTAGEN 357..358 FT /note="TS->ED: Mimics phosphorylation state; acts as a FT dominant-negative mutant that impairs necroptosis." FT MUTAGEN 357 FT /note="T->A: No effect. Abolishes ability to mediate FT necroptosis; when associated with A-358." FT /evidence="ECO:0000269|PubMed:22265413" FT MUTAGEN 358 FT /note="S->A: No effect. Abolishes ability to mediate FT necroptosis; when associated with A-357." FT /evidence="ECO:0000269|PubMed:22265413" FT HELIX 2..20 FT /evidence="ECO:0007829|PDB:6ZVO" FT STRAND 22..24 FT /evidence="ECO:0007829|PDB:6ZZ1" FT HELIX 25..46 FT /evidence="ECO:0007829|PDB:6ZVO" FT HELIX 56..79 FT /evidence="ECO:0007829|PDB:6ZVO" FT HELIX 82..90 FT /evidence="ECO:0007829|PDB:6ZVO" FT STRAND 93..96 FT /evidence="ECO:0007829|PDB:2MSV" FT HELIX 99..120 FT /evidence="ECO:0007829|PDB:6ZVO" FT TURN 128..132 FT /evidence="ECO:0007829|PDB:2MSV" FT HELIX 133..148 FT /evidence="ECO:0007829|PDB:6ZVO" FT HELIX 198..201 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 202..204 FT /evidence="ECO:0007829|PDB:6O5Z" FT STRAND 207..211 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 213..222 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 225..232 FT /evidence="ECO:0007829|PDB:4MWI" FT HELIX 240..256 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 265..271 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 274..276 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 278..284 FT /evidence="ECO:0007829|PDB:4MWI" FT HELIX 291..297 FT /evidence="ECO:0007829|PDB:4MWI" FT HELIX 303..322 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 323..325 FT /evidence="ECO:0007829|PDB:4MWI" FT HELIX 334..336 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 337..339 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 345..347 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 349..352 FT /evidence="ECO:0007829|PDB:7MON" FT HELIX 353..359 FT /evidence="ECO:0007829|PDB:7MON" FT TURN 360..362 FT /evidence="ECO:0007829|PDB:7JXU" FT HELIX 373..376 FT /evidence="ECO:0007829|PDB:4MWI" FT HELIX 379..383 FT /evidence="ECO:0007829|PDB:4MWI" FT HELIX 391..407 FT /evidence="ECO:0007829|PDB:4MWI" FT TURN 411..414 FT /evidence="ECO:0007829|PDB:4MWI" FT HELIX 417..425 FT /evidence="ECO:0007829|PDB:4MWI" FT STRAND 435..437 FT /evidence="ECO:0007829|PDB:6O5Z" FT HELIX 439..448 FT /evidence="ECO:0007829|PDB:4MWI" FT HELIX 453..455 FT /evidence="ECO:0007829|PDB:4MWI" FT HELIX 459..467 FT /evidence="ECO:0007829|PDB:4MWI" SQ SEQUENCE 471 AA; 54479 MW; 005E7F7AB6D20649 CRC64; MENLKHIITL GQVIHKRCEE MKYCKKQCRR LGHRVLGLIK PLEMLQDQGK RSVPSEKLTT AMNRFKAALE EANGEIEKFS NRSNICRFLT ASQDKILFKD VNRKLSDVWK ELSLLLQVEQ RMPVSPISQG ASWAQEDQQD ADEDRRAFQM LRRDNEKIEA SLRRLEINMK EIKETLRQYL PPKCMQEIPQ EQIKEIKKEQ LSGSPWILLR ENEVSTLYKG EYHRAPVAIK VFKKLQAGSI AIVRQTFNKE IKTMKKFESP NILRIFGICI DETVTPPQFS IVMEYCELGT LRELLDREKD LTLGKRMVLV LGAARGLYRL HHSEAPELHG KIRSSNFLVT QGYQVKLAGF ELRKTQTSMS LGTTREKTDR VKSTAYLSPQ ELEDVFYQYD VKSEIYSFGI VLWEIATGDI PFQGCNSEKI RKLVAVKRQQ EPLGEDCPSE LREIIDECRA HDPSVRPSVD EILKKLSTFS K // ID NDRG1_HUMAN Reviewed; 394 AA. AC Q92597; B3KR80; B7Z446; O15207; Q6IBG2; Q9NYR6; Q9UK29; DT 15-JUL-1999, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1997, sequence version 1. DT 28-JAN-2026, entry version 219. DE RecName: Full=Protein NDRG1; DE AltName: Full=Differentiation-related gene 1 protein; DE Short=DRG-1; DE AltName: Full=N-myc downstream-regulated gene 1 protein; DE AltName: Full=Nickel-specific induction protein Cap43; DE AltName: Full=Reducing agents and tunicamycin-responsive protein; DE Short=RTP; DE AltName: Full=Rit42; GN Name=NDRG1; Synonyms=CAP43, DRG1, RTP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INDUCTION, AND TISSUE SPECIFICITY. RC TISSUE=Umbilical vein endothelial cell; RX PubMed=8939898; DOI=10.1074/jbc.271.47.29659; RA Kokame K., Kato H., Miyata T.; RT "Homocysteine-respondent genes in vascular endothelial cells identified by RT differential display analysis. GRP78/BiP and novel genes."; RL J. Biol. Chem. 271:29659-29665(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INDUCTION, SUBCELLULAR LOCATION, RP AND TISSUE SPECIFICITY. RX PubMed=9251681; RA van Belzen N., Dinjens W.N.M., Diesveld M.P.G., Groen N.A., RA van der Made A.C.J., Nozawa Y., Vlietstra R., Trapman J., Bosman F.T.; RT "A novel gene which is up-regulated during colon epithelial cell RT differentiation and down-regulated in colorectal neoplasms."; RL Lab. Invest. 77:85-92(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND INDUCTION. RC TISSUE=Lung; RX PubMed=9605764; RA Zhou D., Salnikow K., Costa M.; RT "Cap43, a novel gene specifically induced by Ni2+ compounds."; RL Cancer Res. 58:2182-2189(1998). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INDUCTION. RX PubMed=10395947; DOI=10.1016/s0167-4889(99)00056-7; RA Piquemal D., Joulia D., Balaguer P., Basset A., Marti J., Commes T.; RT "Differential expression of the RTP/Drg1/Ndr1 gene product in proliferating RT and growth arrested cells."; RL Biochim. Biophys. Acta 1450:364-373(1999). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3). RC TISSUE=Brain, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Kidney; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-21 (ISOFORM 1). RC TISSUE=Brain; RA Angelicheva D., Kalaydjieva L.; RL Submitted (FEB-2000) to the EMBL/GenBank/DDBJ databases. RN [11] RP PROTEIN SEQUENCE OF 4-19; 54-70; 133-148; 199-212; 286-300; 307-322; RP 328-341 AND 364-388, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Fetal brain cortex; RA Lubec G., Chen W.-Q., Sun Y.; RL Submitted (DEC-2008) to UniProtKB. RN [12] RP FUNCTION, AND INDUCTION. RX PubMed=9766676; RA Kurdistani S.K., Arizti P., Reimer C.L., Sugrue M.M., Aaronson S.A., RA Lee S.W.; RT "Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 RT and DNA damage."; RL Cancer Res. 58:4439-4444(1998). RN [13] RP INVOLVEMENT IN CMT4D. RX PubMed=10831399; DOI=10.1086/302978; RA Kalaydjieva L., Gresham D., Gooding R., Heather L., Baas F., de Jonge R., RA Blechschmidt K., Angelicheva D., Chandler D., Worsley P., Rosenthal A., RA King R.H.M., Thomas P.K.; RT "N-myc downstream-regulated gene 1 is mutated in hereditary motor and RT sensory neuropathy-Lom."; RL Am. J. Hum. Genet. 67:47-58(2000). RN [14] RP PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=10860807; DOI=10.1006/bbrc.2000.2833; RA Agarwala K.L., Kokame K., Kato H., Miyata T.; RT "Phosphorylation of RTP, an ER stress-responsive cytoplasmic protein."; RL Biochem. Biophys. Res. Commun. 272:641-647(2000). RN [15] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=12432451; DOI=10.1007/s00418-002-0460-9; RA Lachat P., Shaw P., Gebhard S., van Belzen N., Chaubert P., Bosman F.T.; RT "Expression of NDRG1, a differentiation-related gene, in human tissues."; RL Histochem. Cell Biol. 118:399-408(2002). RN [16] RP PHOSPHORYLATION AT THR-328; SER-330; THR-346; THR-356 AND THR-366. RX PubMed=15461589; DOI=10.1042/bj20041057; RA Murray J.T., Campbell D.G., Morrice N., Auld G.C., Shpiro N., Marquez R., RA Peggie M., Bain J., Bloomberg G.B., Grahammer F., Lang F., Wulff P., RA Kuhl D., Cohen P.; RT "Exploitation of KESTREL to identify NDRG family members as physiological RT substrates for SGK1 and GSK3."; RL Biochem. J. 384:477-488(2004). RN [17] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=15247272; DOI=10.1074/jbc.m400781200; RA Kim K.T., Ongusaha P.P., Hong Y.K., Kurdistani S.K., Nakamura M., Lu K.P., RA Lee S.W.; RT "Function of Drg1/Rit42 in p53-dependent mitotic spindle checkpoint."; RL J. Biol. Chem. 279:38597-38602(2004). RN [18] RP FUNCTION. RX PubMed=15377670; DOI=10.1074/jbc.m400386200; RA Stein S., Thomas E.K., Herzog B., Westfall M.D., Rocheleau J.V., RA Jackson R.S. II, Wang M., Liang P.; RT "NDRG1 is necessary for p53-dependent apoptosis."; RL J. Biol. Chem. 279:48930-48940(2004). RN [19] RP INTERACTION WITH APOA1; APOA2; PRA1 AND RTN1, AND POSSIBLE FUNCTION. RX PubMed=15922294; DOI=10.1016/j.bbrc.2005.05.050; RA Hunter M., Angelicheva D., Tournev I., Ingley E., Chan D.C., Watts G.F., RA Kremensky I., Kalaydjieva L.; RT "NDRG1 interacts with APO A-I and A-II and is a functional candidate for RT the HDL-C QTL on 8q24."; RL Biochem. Biophys. Res. Commun. 332:982-992(2005). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-330 AND SER-333, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [22] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Prostate cancer; RX PubMed=17487921; DOI=10.1002/elps.200600782; RA Giorgianni F., Zhao Y., Desiderio D.M., Beranova-Giorgianni S.; RT "Toward a global characterization of the phosphoproteome in prostate cancer RT cells: identification of phosphoproteins in the LNCaP cell line."; RL Electrophoresis 28:2027-2034(2007). RN [23] RP SUBCELLULAR LOCATION, AND INDUCTION. RX PubMed=17316623; DOI=10.1016/j.febslet.2007.01.080; RA Sibold S., Roh V., Keogh A., Studer P., Tiffon C., Angst E., RA Vorburger S.A., Weimann R., Candinas D., Stroka D.; RT "Hypoxia increases cytoplasmic expression of NDRG1, but is insufficient for RT its membrane localization in human hepatocellular carcinoma."; RL FEBS Lett. 581:989-994(2007). RN [24] RP INTERACTION WITH RAB4A, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=17786215; DOI=10.1371/journal.pone.0000844; RA Kachhap S.K., Faith D., Qian D.Z., Shabbeer S., Galloway N.L., Pili R., RA Denmeade S.R., DeMarzo A.M., Carducci M.A.; RT "The N-Myc down regulated Gene1 (NDRG1) is a Rab4a effector involved in RT vesicular recycling of E-cadherin."; RL PLoS ONE 2:E844-E844(2007). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-326; SER-330; SER-333; RP SER-336; SER-364 AND THR-375, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [26] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [27] RP PHOSPHORYLATION AT THR-346; THR-356 AND THR-366. RX PubMed=18787837; DOI=10.1007/s00424-008-0587-1; RA Inglis S.K., Gallacher M., Brown S.G., McTavish N., Getty J., Husband E.M., RA Murray J.T., Wilson S.M.; RT "SGK1 activity in Na+ absorbing airway epithelial cells monitored by RT assaying NDRG1-Thr346/356/366 phosphorylation."; RL Pflugers Arch. 457:1287-1301(2009). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-328 AND SER-330, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-333, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [30] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [31] RP PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=21708134; DOI=10.1016/j.bbrc.2011.06.092; RA McCaig C., Potter L., Abramczyk O., Murray J.T.; RT "Phosphorylation of NDRG1 is temporally and spatially controlled during the RT cell cycle."; RL Biochem. Biophys. Res. Commun. 411:227-234(2011). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; THR-328; SER-330; SER-333; RP SER-336; SER-364; THR-366 AND THR-375, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-328; SER-332 AND SER-333, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). CC -!- FUNCTION: Stress-responsive protein involved in hormone responses, cell CC growth, and differentiation. Acts as a tumor suppressor in many cell CC types. Necessary but not sufficient for p53/TP53-mediated caspase CC activation and apoptosis. Has a role in cell trafficking, notably of CC the Schwann cell, and is necessary for the maintenance and development CC of the peripheral nerve myelin sheath. Required for vesicular recycling CC of CDH1 and TF. May also function in lipid trafficking. Protects cells CC from spindle disruption damage. Functions in p53/TP53-dependent mitotic CC spindle checkpoint. Regulates microtubule dynamics and maintains CC euploidy. {ECO:0000269|PubMed:15247272, ECO:0000269|PubMed:15377670, CC ECO:0000269|PubMed:17786215, ECO:0000269|PubMed:9766676}. CC -!- SUBUNIT: Interacts with RAB4A (membrane-bound form); the interaction CC involves NDRG1 in vesicular recycling of CDH1. CC {ECO:0000269|PubMed:15922294, ECO:0000269|PubMed:17786215}. CC -!- INTERACTION: CC Q92597; P05023: ATP1A1; NbExp=2; IntAct=EBI-716486, EBI-358778; CC Q92597; P27824: CANX; NbExp=2; IntAct=EBI-716486, EBI-355947; CC Q92597; Q9H6J7-2: CSTPP1; NbExp=3; IntAct=EBI-716486, EBI-13328871; CC Q92597; P35222: CTNNB1; NbExp=3; IntAct=EBI-716486, EBI-491549; CC Q92597; Q9H816: DCLRE1B; NbExp=3; IntAct=EBI-716486, EBI-3508943; CC Q92597; Q3SYB3: FOXD4L6; NbExp=3; IntAct=EBI-716486, EBI-6425864; CC Q92597; Q9BYZ2: LDHAL6B; NbExp=3; IntAct=EBI-716486, EBI-1108377; CC Q92597; Q9H204: MED28; NbExp=3; IntAct=EBI-716486, EBI-514199; CC Q92597; Q9Y3D2: MSRB2; NbExp=3; IntAct=EBI-716486, EBI-9092052; CC Q92597; Q6ZNA4-2: RNF111; NbExp=3; IntAct=EBI-716486, EBI-21535400; CC Q92597; Q8N488: RYBP; NbExp=3; IntAct=EBI-716486, EBI-752324; CC Q92597; O75446: SAP30; NbExp=3; IntAct=EBI-716486, EBI-632609; CC Q92597; Q99932-2: SPAG8; NbExp=3; IntAct=EBI-716486, EBI-11959123; CC Q92597; Q8IUW3: SPATA2L; NbExp=3; IntAct=EBI-716486, EBI-2510414; CC Q92597; Q6PID6: TTC33; NbExp=3; IntAct=EBI-716486, EBI-2555404; CC Q92597; P12956: XRCC6; NbExp=2; IntAct=EBI-716486, EBI-353208; CC Q92597; P61981: YWHAG; NbExp=3; IntAct=EBI-716486, EBI-359832; CC Q92597; Q96NC0: ZMAT2; NbExp=3; IntAct=EBI-716486, EBI-2682299; CC Q92597-3; Q9Y3D8: AK6; NbExp=3; IntAct=EBI-10278703, EBI-2896123; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cytoplasm, cytoskeleton, CC microtubule organizing center, centrosome. Nucleus. Cell membrane. CC Note=Mainly cytoplasmic but differentially localized to other regions. CC Associates with the plasma membrane in intestinal epithelia and CC lactating mammary gland. Translocated to the nucleus in a p53/TP53- CC dependent manner. In prostate epithelium and placental chorion, located CC in both the cytoplasm and in the nucleus. No nuclear localization in CC colon epithelium cells. In intestinal mucosa, prostate and renal CC cortex, located predominantly adjacent to adherens junctions. CC Cytoplasmic with granular staining in proximal tubular cells of the CC kidney and salivary gland ducts. Recruits to the membrane of CC recycling/sorting and late endosomes via binding to CC phosphatidylinositol 4-phosphate. Associates with microtubules. CC Colocalizes with TUBG1 in the centrosome. Cytoplasmic location CC increased with hypoxia. Phosphorylated form found associated with CC centromeres during S-phase of mitosis and with the plasma membrane. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q92597-1; Sequence=Displayed; CC Name=2; CC IsoId=Q92597-2; Sequence=VSP_045038; CC Name=3; CC IsoId=Q92597-3; Sequence=VSP_045037; CC -!- TISSUE SPECIFICITY: Ubiquitous; expressed most prominently in placental CC membranes and prostate, kidney, small intestine, and ovary tissues. CC Also expressed in heart, brain, skeletal muscle, lung, liver and CC pancreas. Low levels in peripheral blood leukocytes and in tissues of CC the immune system. Expressed mainly in epithelial cells. Also found in CC Schwann cells of peripheral neurons. Reduced expression in CC adenocarcinomas compared to normal tissues. In colon, prostate and CC placental membranes, the cells that border the lumen show the highest CC expression. {ECO:0000269|PubMed:12432451, ECO:0000269|PubMed:8939898, CC ECO:0000269|PubMed:9251681, ECO:0000269|PubMed:9605764}. CC -!- INDUCTION: By homocysteine, 2-mercaptoethanol, tunicamycin in CC endothelial cells. Induced approximately 20-fold during in vitro CC differentiation of the colon carcinoma cell lines HT-29-D4 and Caco-2. CC Induced by oxidative stress in colon cancers. Decreased expression in CC colon adenomas and adenocarcinomas. Induced by nickel compounds in all CC tested cell lines. The primary signal for its induction is an elevation CC of free intracellular calcium ion caused by nickel ion exposure. CC Okadaic acid, a serine/threonine phosphatase inhibitor, induced its CC expression more rapidly and more efficiently than nickel. CC {ECO:0000269|PubMed:10395947, ECO:0000269|PubMed:17316623, CC ECO:0000269|PubMed:8939898, ECO:0000269|PubMed:9251681, CC ECO:0000269|PubMed:9605764, ECO:0000269|PubMed:9766676}. CC -!- PTM: Under stress conditions, phosphorylated in the C-terminal on many CC serine and threonine residues. Phosphorylated in vitro by PKA. CC Phosphorylation enhanced by increased intracellular cAMP levels. CC Homocysteine induces dephosphorylation. Phosphorylation by SGK1 is cell CC cycle dependent. {ECO:0000269|PubMed:10860807, CC ECO:0000269|PubMed:15461589, ECO:0000269|PubMed:18787837, CC ECO:0000269|PubMed:21708134}. CC -!- DISEASE: Charcot-Marie-Tooth disease, demyelinating, type 4D (CMT4D) CC [MIM:601455]: A recessive demyelinating form of Charcot-Marie-Tooth CC disease, a disorder of the peripheral nervous system, characterized by CC progressive weakness and atrophy, initially of the peroneal muscles and CC later of the distal muscles of the arms. Charcot-Marie-Tooth disease is CC classified in two main groups on the basis of electrophysiologic CC properties and histopathology: primary peripheral demyelinating CC neuropathies (designated CMT1 when they are dominantly inherited) and CC primary peripheral axonal neuropathies (CMT2). Demyelinating CC neuropathies are characterized by severely reduced nerve conduction CC velocities (less than 38 m/sec), segmental demyelination and CC remyelination with onion bulb formations on nerve biopsy, slowly CC progressive distal muscle atrophy and weakness, absent deep tendon CC reflexes, and hollow feet. By convention autosomal recessive forms of CC demyelinating Charcot-Marie-Tooth disease are designated CMT4. CC {ECO:0000269|PubMed:10831399}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the NDRG family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41512/NDRG1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D87953; BAA13505.1; -; mRNA. DR EMBL; X92845; CAA63430.1; -; mRNA. DR EMBL; AF004162; AAC13419.1; -; mRNA. DR EMBL; AF186190; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CR456842; CAG33123.1; -; mRNA. DR EMBL; AK091147; BAG52292.1; -; mRNA. DR EMBL; AK126924; BAG54400.1; -; mRNA. DR EMBL; AK296794; BAH12432.1; -; mRNA. DR EMBL; AF192304; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471060; EAW92164.1; -; Genomic_DNA. DR EMBL; BC003175; AAH03175.1; -; mRNA. DR EMBL; AF230380; AAF71305.1; -; mRNA. DR CCDS; CCDS34945.1; -. [Q92597-1] DR CCDS; CCDS59113.1; -. [Q92597-2] DR RefSeq; NP_001128714.1; NM_001135242.2. [Q92597-1] DR RefSeq; NP_001245361.1; NM_001258432.2. [Q92597-2] DR RefSeq; NP_001245362.1; NM_001258433.2. [Q92597-3] DR RefSeq; NP_001361774.1; NM_001374845.1. [Q92597-1] DR RefSeq; NP_001361775.1; NM_001374846.1. [Q92597-1] DR RefSeq; NP_001361776.1; NM_001374847.1. [Q92597-2] DR RefSeq; NP_006087.2; NM_006096.3. [Q92597-1] DR PDB; 6ZMM; X-ray; 2.96 A; A/B=31-319. DR PDBsum; 6ZMM; -. DR AlphaFoldDB; Q92597; -. DR SMR; Q92597; -. DR BioGRID; 115669; 247. DR FunCoup; Q92597; 1492. DR IntAct; Q92597; 165. DR MINT; Q92597; -. DR STRING; 9606.ENSP00000404854; -. DR ChEMBL; CHEMBL4295916; -. DR ESTHER; human-NDRG1; Ndr_family. DR MEROPS; S33.988; -. DR GlyGen; Q92597; 3 sites, 2 O-linked glycans (3 sites). DR iPTMnet; Q92597; -. DR MetOSite; Q92597; -. DR PhosphoSitePlus; Q92597; -. DR SwissPalm; Q92597; -. DR BioMuta; NDRG1; -. DR DMDM; 6166568; -. DR jPOST; Q92597; -. DR MassIVE; Q92597; -. DR PaxDb; 9606-ENSP00000404854; -. DR PeptideAtlas; Q92597; -. DR ProteomicsDB; 3585; -. DR ProteomicsDB; 6569; -. DR ProteomicsDB; 75343; -. [Q92597-1] DR Pumba; Q92597; -. DR TopDownProteomics; Q92597-1; -. [Q92597-1] DR Antibodypedia; 1521; 643 antibodies from 43 providers. DR DNASU; 10397; -. DR Ensembl; ENST00000323851.13; ENSP00000319977.8; ENSG00000104419.17. [Q92597-1] DR Ensembl; ENST00000414097.6; ENSP00000404854.2; ENSG00000104419.17. [Q92597-1] DR Ensembl; ENST00000522476.5; ENSP00000427894.1; ENSG00000104419.17. [Q92597-2] DR GeneID; 10397; -. DR KEGG; hsa:10397; -. DR MANE-Select; ENST00000323851.13; ENSP00000319977.8; NM_006096.4; NP_006087.2. DR UCSC; uc003yug.3; human. [Q92597-1] DR AGR; HGNC:7679; -. DR ClinPGx; PA31482; -. DR CTD; 10397; -. DR DisGeNET; 10397; -. DR GeneCards; NDRG1; -. DR GeneReviews; NDRG1; -. DR HGNC; HGNC:7679; NDRG1. DR HPA; ENSG00000104419; Low tissue specificity. DR MalaCards; NDRG1; -. DR MIM; 601455; phenotype. DR MIM; 605262; gene. DR OpenTargets; ENSG00000104419; -. DR Orphanet; 99950; Charcot-Marie-Tooth disease type 4D. DR VEuPathDB; HostDB:ENSG00000104419; -. DR eggNOG; KOG2931; Eukaryota. DR GeneTree; ENSGT00950000182872; -. DR HOGENOM; CLU_035361_1_0_1; -. DR InParanoid; Q92597; -. DR OMA; LVEKGEX; -. DR OrthoDB; 741027at2759; -. DR PAN-GO; Q92597; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q92597; -. DR PathwayCommons; Q92597; -. DR Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain. DR SignaLink; Q92597; -. DR SIGNOR; Q92597; -. DR Agora; ENSG00000104419; -. DR BioGRID-ORCS; 10397; 11 hits in 1163 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; NDRG1; human. DR GeneWiki; NDRG1; -. DR GenomeRNAi; 10397; -. DR Pharos; Q92597; Tbio. DR PRO; PR:Q92597; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; Q92597; protein. DR Bgee; ENSG00000104419; Expressed in olfactory bulb and 205 other cell types or tissues. DR ExpressionAtlas; Q92597; baseline and differential. DR GO; GO:0005912; C:adherens junction; IDA:UniProtKB. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005874; C:microtubule; IDA:UniProtKB. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0055038; C:recycling endosome membrane; IDA:UniProtKB. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0120238; C:sperm glycocalyx; IDA:HPA. DR GO; GO:0120212; C:sperm head-tail coupling apparatus; IDA:HPA. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0045296; F:cadherin binding; IDA:UniProtKB. DR GO; GO:0043015; F:gamma-tubulin binding; IDA:UniProtKB. DR GO; GO:0008017; F:microtubule binding; IDA:UniProtKB. DR GO; GO:0016151; F:nickel cation binding; IPI:DisProt. DR GO; GO:0031267; F:small GTPase binding; IDA:UniProtKB. DR GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IEP:UniProtKB. DR GO; GO:0045576; P:mast cell activation; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl. DR GO; GO:0032287; P:peripheral nervous system myelin maintenance; IEA:Ensembl. DR GO; GO:0010038; P:response to metal ion; TAS:ProtInc. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR DisProt; DP03990; -. DR FunFam; 3.40.50.1820:FF:000006; NDRG family member 3; 1. DR Gene3D; 3.40.50.1820; alpha/beta hydrolase; 1. DR InterPro; IPR029058; AB_hydrolase_fold. DR InterPro; IPR004142; NDRG. DR PANTHER; PTHR11034; N-MYC DOWNSTREAM REGULATED; 1. DR Pfam; PF03096; Ndr; 1. DR SUPFAM; SSF53474; alpha/beta-Hydrolases; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cell membrane; KW Charcot-Marie-Tooth disease; Cytoplasm; Cytoskeleton; KW Direct protein sequencing; Membrane; Microtubule; Neurodegeneration; KW Neuropathy; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330" FT CHAIN 2..394 FT /note="Protein NDRG1" FT /id="PRO_0000159573" FT REPEAT 339..348 FT /note="1" FT REPEAT 349..358 FT /note="2" FT REPEAT 359..368 FT /note="3" FT REGION 325..394 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 339..368 FT /note="3 X 10 AA tandem repeats of G-T-R-S-R-S-H-T-S-E" FT COMPBIAS 327..339 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 345..371 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:19413330" FT MOD_RES 2 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 319 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62433" FT MOD_RES 326 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 328 FT /note="Phosphothreonine; by SGK1" FT /evidence="ECO:0000269|PubMed:15461589, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 330 FT /note="Phosphoserine; by SGK1" FT /evidence="ECO:0000269|PubMed:15461589, FT ECO:0007744|PubMed:16964243, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 332 FT /note="Phosphoserine; by SGK1" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 333 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 335 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62433" FT MOD_RES 336 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 340 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62433" FT MOD_RES 342 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62433" FT MOD_RES 346 FT /note="Phosphothreonine; by SGK1" FT /evidence="ECO:0000269|PubMed:15461589, FT ECO:0000269|PubMed:18787837" FT MOD_RES 352 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q6JE36" FT MOD_RES 356 FT /note="Phosphothreonine; by SGK1" FT /evidence="ECO:0000269|PubMed:15461589, FT ECO:0000269|PubMed:18787837" FT MOD_RES 362 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q6JE36" FT MOD_RES 364 FT /note="Phosphoserine; by SGK1" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 366 FT /note="Phosphothreonine; by SGK1" FT /evidence="ECO:0000269|PubMed:15461589, FT ECO:0000269|PubMed:18787837, ECO:0007744|PubMed:23186163" FT MOD_RES 375 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..81 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045037" FT VAR_SEQ 1..66 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045038" FT VARIANT 67 FT /note="M -> V (in dbSNP:rs2233319)" FT /id="VAR_050234" FT VARIANT 111 FT /note="M -> L (in dbSNP:rs2233328)" FT /id="VAR_050235" FT CONFLICT 145 FT /note="I -> T (in Ref. 2; CAA63430)" FT /evidence="ECO:0000305" FT STRAND 33..39 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 42..48 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 58..62 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 69..72 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 74..77 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 80..82 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 83..88 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 90..95 FT /evidence="ECO:0007829|PDB:6ZMM" FT TURN 97..99 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 115..120 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 122..128 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 134..139 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 141..152 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 154..156 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 157..164 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 187..195 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 209..217 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 221..232 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 255..260 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 266..274 FT /evidence="ECO:0007829|PDB:6ZMM" FT TURN 278..280 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 281..286 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 293..296 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 298..311 FT /evidence="ECO:0007829|PDB:6ZMM" SQ SEQUENCE 394 AA; 42835 MW; 4C816B9C85E3756F CRC64; MSREMQDVDL AEVKPLVEKG ETITGLLQEF DVQEQDIETL HGSVHVTLCG TPKGNRPVIL TYHDIGMNHK TCYNPLFNYE DMQEITQHFA VCHVDAPGQQ DGAASFPAGY MYPSMDQLAE MLPGVLQQFG LKSIIGMGTG AGAYILTRFA LNNPEMVEGL VLINVNPCAE GWMDWAASKI SGWTQALPDM VVSHLFGKEE MQSNVEVVHT YRQHIVNDMN PGNLHLFINA YNSRRDLEIE RPMPGTHTVT LQCPALLVVG DSSPAVDAVV ECNSKLDPTK TTLLKMADCG GLPQISQPAK LAEAFKYFVQ GMGYMPSASM TRLMRSRTAS GSSVTSLDGT RSRSHTSEGT RSRSHTSEGT RSRSHTSEGA HLDITPNSGA AGNSAGPKSM EVSC // ID NOX5_HUMAN Reviewed; 765 AA. AC Q96PH1; B2RBJ4; Q08AN2; Q08AN3; Q8TEQ1; Q8TER4; Q96PH2; Q96PJ8; Q96PJ9; AC Q9H6E0; Q9HAM8; DT 07-MAR-2006, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2001, sequence version 1. DT 28-JAN-2026, entry version 181. DE RecName: Full=NADPH oxidase 5; DE EC=1.-.-.- {ECO:0000269|PubMed:34784249}; DE EC=1.6.3.- {ECO:0000269|PubMed:12686516}; GN Name=NOX5 {ECO:0000312|HGNC:HGNC:14874}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS V1; V2; V3 AND V4), FUNCTION (ISOFORM RP V2), TISSUE SPECIFICITY, AND CATALYTIC ACTIVITY (ISOFORM V2). RC TISSUE=Spleen, and Testis; RX PubMed=11483596; DOI=10.1074/jbc.m103034200; RA Banfi B., Molnar G., Maturana A., Steger K., Hegedus B., Demaurex N., RA Krause K.-H.; RT "A Ca(2+)-activated NADPH oxidase in testis, spleen, and lymph nodes."; RL J. Biol. Chem. 276:37594-37601(2001). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM V5), AND NUCLEOTIDE RP SEQUENCE [LARGE SCALE MRNA] OF 98-765 (ISOFORMS V3/V4). RC TISSUE=Spleen; RA Jikuya H., Takano J., Nomura N., Kikuno R., Nagase T., Ohara O.; RT "The nucleotide sequence of a long cDNA clone isolated from human spleen."; RL Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM V4), AND NUCLEOTIDE RP SEQUENCE [LARGE SCALE MRNA] OF 159-765 (ISOFORMS V1/V2/V3/V4/V6). RC TISSUE=Kidney epithelium, and Spleen; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM V5). RG NHLBI resequencing and genotyping service (RS&G); RL Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16572171; DOI=10.1038/nature04601; RA Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K., RA Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K., RA FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N., RA Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S., RA Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K., RA DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J., RA Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E., RA Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B., RA Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R., RA O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B., RA Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S., RA Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.; RT "Analysis of the DNA sequence and duplication history of human chromosome RT 15."; RL Nature 440:671-675(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS V2 AND V6). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 177-765 (ISOFORMS V1/V2/V3/V4/V6). RC TISSUE=Spleen; RX PubMed=15994299; DOI=10.1074/jbc.m501882200; RA Kawahara T., Ritsick D., Cheng G., Lambeth J.D.; RT "Point mutations in the proline-rich region of p22phox are dominant RT inhibitors of Nox1- and Nox2-dependent reactive oxygen generation."; RL J. Biol. Chem. 280:31859-31869(2005). RN [9] RP TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE. RX PubMed=11376945; DOI=10.1016/s0378-1119(01)00449-8; RA Cheng G., Cao Z., Xu X., van Meir E.G., Lambeth J.D.; RT "Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and RT Nox5."; RL Gene 269:131-140(2001). RN [10] RP FUNCTION, TISSUE SPECIFICITY, AND CATALYTIC ACTIVITY. RX PubMed=12686516; DOI=10.1152/ajpcell.00525.2002; RA Brar S.S., Corbin Z., Kennedy T.P., Hemendinger R., Thornton L., RA Bommarius B., Arnold R.S., Whorton A.R., Sturrock A.B., Huecksteadt T.P., RA Quinn M.T., Krenitsky K., Ardie K.G., Lambeth J.D., Hoidal J.R.; RT "NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate RT cancer cells."; RL Am. J. Physiol. 285:C353-C369(2003). RN [11] RP ACTIVITY REGULATION (ISOFORM V2), COFACTOR (ISOFORM V2), MUTAGENESIS OF RP GLU-31 (ISOFORM V2), BIOPHYSICOCHEMICAL PROPERTIES (ISOFORM V2), FUNCTION RP (ISOFORM V2), CATALYTIC ACTIVITY (ISOFORM V2), AND N-TERMINAL REGULATORY EF RP DOMAIN (ISOFORM V2). RX PubMed=14982937; DOI=10.1074/jbc.m310268200; RA Banfi B., Tirone F., Durussel I., Knisz J., Moskwa P., Molnar G.Z., RA Krause K.-H., Cox J.A.; RT "Mechanism of Ca2+ activation of the NADPH oxidase 5 (NOX5)."; RL J. Biol. Chem. 279:18583-18591(2004). RN [12] RP TISSUE SPECIFICITY, AND INDUCTION. RX PubMed=16179589; DOI=10.1161/01.res.0000187457.24338.3d; RA Cucoranu I., Clempus R., Dikalova A., Phelan P.J., Ariyan S., Dikalov S., RA Sorescu D.; RT "NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced RT differentiation of cardiac fibroblasts into myofibroblasts."; RL Circ. Res. 97:900-907(2005). RN [13] RP TISSUE SPECIFICITY. RX PubMed=16339585; DOI=10.4049/jimmunol.175.12.8424; RA Kamiguti A.S., Serrander L., Lin K., Harris R.J., Cawley J.C., Allsup D.J., RA Slupsky J.R., Krause K.-H., Zuzel M.; RT "Expression and activity of NOX5 in the circulating malignant B cells of RT hairy cell leukemia."; RL J. Immunol. 175:8424-8430(2005). RN [14] RP FUNCTION (ISOFORM V2), CATALYTIC ACTIVITY (ISOFORM V2), SUBCELLULAR RP LOCATION (ISOFORM V2), AND ACTIVITY REGULATION (ISOFORM V2). RX PubMed=17587483; DOI=10.1016/j.biochi.2007.05.004; RA Serrander L., Jaquet V., Bedard K., Plastre O., Hartley O., Arnaudeau S., RA Demaurex N., Schlegel W., Krause K.H.; RT "NOX5 is expressed at the plasma membrane and generates superoxide in RT response to protein kinase C activation."; RL Biochimie 89:1159-1167(2007). RN [15] RP FUNCTION (ISOFORMS V2 AND V5), TISSUE SPECIFICITY (ISOFORMS V1; V2; V3; V4 RP AND V5), SUBCELLULAR LOCATION (ISOFORMS V2 AND V5), AND CATALYTIC ACTIVITY RP (ISOFORMS V2 AND V5). RX PubMed=17275676; DOI=10.1016/j.freeradbiomed.2006.10.054; RA BelAiba R.S., Djordjevic T., Petry A., Diemer K., Bonello S., Banfi B., RA Hess J., Pogrebniak A., Bickel C., Gorlach A.; RT "NOX5 variants are functionally active in endothelial cells."; RL Free Radic. Biol. Med. 42:446-459(2007). RN [16] RP FUNCTION (ISOFORM V1), CATALYTIC ACTIVITY (ISOFORM V1), SUBUNIT (ISOFORM RP V1), AND MUTAGENESIS OF LEU-277; PRO-567 AND ASP-656 (ISOFORM V1). RX PubMed=21319793; DOI=10.1021/bi1020088; RA Kawahara T., Jackson H.M., Smith S.M., Simpson P.D., Lambeth J.D.; RT "Nox5 forms a functional oligomer mediated by self-association of its RT dehydrogenase domain."; RL Biochemistry 50:2013-2025(2011). RN [17] RP FUNCTION (ISOFORM V2), CATALYTIC ACTIVITY (ISOFORM V2), PHOSPHORYLATION AT RP SER-475; THR-494; SER-498; SER-502 AND SER-659 (ISOFORM V2), AND RP MUTAGENESIS OF SER-475; THR-494; SER-498; SER-502 AND SER-659 (ISOFORM V2). RX PubMed=21642394; DOI=10.1124/mol.110.070193; RA Pandey D., Gratton J.P., Rafikov R., Black S.M., Fulton D.J.; RT "Calcium/calmodulin-dependent kinase II mediates the phosphorylation and RT activation of NADPH oxidase 5."; RL Mol. Pharmacol. 80:407-415(2011). RN [18] RP FUNCTION (ISOFORMS V1 AND V2), CATALYTIC ACTIVITY (ISOFORMS V1 AND V2), RP ABSENCE OF CATALYTIC ACTIVITY (ISOFORMS V3; V4 AND V5), TISSUE SPECIFICITY RP (ISOFORMS V1 AND V2), AND DOMAIN. RX PubMed=22427510; DOI=10.1152/ajpheart.00910.2011; RA Pandey D., Patel A., Patel V., Chen F., Qian J., Wang Y., Barman S.A., RA Venema R.C., Stepp D.W., Rudic R.D., Fulton D.J.; RT "Expression and functional significance of NADPH oxidase 5 (Nox5) and its RT splice variants in human blood vessels."; RL Am. J. Physiol. 302:H1919-H1928(2012). RN [19] RP FUNCTION (ISOFORM V2), CATALYTIC ACTIVITY (ISOFORM V2), S-NITROSYLATION AT RP CYS-107; CYS-246; CYS-519 AND CYS-694 (ISOFORM V2), PHOSPHORYLATION AT RP SER-490; THR-494 AND SER-498 (ISOFORM V2), AND MUTAGENESIS OF CYS-107; RP CYS-519 AND CYS-694 (ISOFORM V2). RX PubMed=22387196; DOI=10.1016/j.freeradbiomed.2012.02.029; RA Qian J., Chen F., Kovalenkov Y., Pandey D., Moseley M.A., Foster M.W., RA Black S.M., Venema R.C., Stepp D.W., Fulton D.J.; RT "Nitric oxide reduces NADPH oxidase 5 (Nox5) activity by reversible S- RT nitrosylation."; RL Free Radic. Biol. Med. 52:1806-1819(2012). RN [20] RP FUNCTION (ISOFORM V2), CATALYTIC ACTIVITY (ISOFORM V2), PHOSPHORYLATION AT RP SER-490; THR-494 AND SER-498 (ISOFORM V2), AND MUTAGENESIS OF SER-490; RP THR-494 AND SER-498 (ISOFORM V2). RX PubMed=24505490; DOI=10.1371/journal.pone.0088405; RA Chen F., Yu Y., Haigh S., Johnson J., Lucas R., Stepp D.W., Fulton D.J.; RT "Regulation of NADPH oxidase 5 by protein kinase C isoforms."; RL PLoS ONE 9:e88405-e88405(2014). RN [21] RP FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=34784249; DOI=10.1126/scisignal.abe3800; RA Gu F., Krueger A., Roggenkamp H.G., Alpers R., Lodygin D., Jaquet V., RA Moeckl F., Hernandez L.C., Winterberg K., Bauche A., Rosche A., RA Grasberger H., Kao J.Y., Schetelig D., Werner R., Schroeder K., Carty M., RA Bowie A.G., Huber S., Meier C., Mittruecker H.W., Heeren J., Krause K.H., RA Fluegel A., Diercks B.P., Guse A.H.; RT "Dual NADPH oxidases DUOX1 and DUOX2 synthesize NAADP and are necessary for RT Ca2+ signaling during T cell activation."; RL Sci. Signal. 14:eabe3800-eabe3800(2021). RN [22] RP FUNCTION (ISOFORMS V2 AND V5), CATALYTIC ACTIVITY (ISOFORMS V2 AND V5), RP ACTIVITY REGULATION (ISOFORM V2), SUBCELLULAR LOCATION (ISOFORM V2), AND RP MUTAGENESIS OF GLU-110; SER-111; ALA-112; ILE-113; SER-114; LEU-115 AND RP PRO-116 (ISOFORM V2). RX PubMed=36653838; DOI=10.1002/1873-3468.14577; RA Miyano K., Kajikawa M.; RT "Ca2+ -binding-region-dependent cell surface localization of NADPH oxidase RT Nox5."; RL FEBS Lett. 597:702-713(2023). RN [23] {ECO:0007744|PDB:6SZ5} RP X-RAY CRYSTALLOGRAPHY (2.23 ANGSTROMS) OF 674-684 (ISOFORM V2) IN COMPLEX RP WITH CALMODULIN, AND N-TERMINAL REGULATORY EF DOMAIN (ISOFORM V2) AND RP C-TERMINAL CATALYTIC DEHYDROGENASE DOMAIN (ISOFORM V2). RX PubMed=31785178; DOI=10.1111/febs.15160; RA Millana Fananas E., Todesca S., Sicorello A., Masino L., Pompach P., RA Magnani F., Pastore A., Mattevi A.; RT "On the mechanism of calcium-dependent activation of NADPH oxidase 5 RT (NOX5)."; RL FEBS J. 287:2486-2503(2020). CC -!- FUNCTION: Calcium-dependent NADPH oxidase that catalyzes the generation CC of superoxide from molecular oxygen utilizing NADPH as an electron CC donor (PubMed:12686516). Also synthesizes NAADP from its reduced NAADPH CC form which promotes Ca(2+) signaling during T cell activation CC (PubMed:34784249). May play a role in cell growth and apoptosis CC (PubMed:12686516). {ECO:0000269|PubMed:12686516, CC ECO:0000269|PubMed:34784249}. CC -!- FUNCTION: [Isoform v2]: Calcium-dependent NADPH oxidase that catalyzes CC the generation of superoxide from molecular oxygen utilizing NADPH as CC an electron donor (PubMed:11483596, PubMed:14982937, PubMed:17275676, CC PubMed:17587483, PubMed:21642394, PubMed:22387196, PubMed:22427510, CC PubMed:24505490, PubMed:36653838). Involved in endothelial generation CC of reactive oxygen species (ROS), proliferation and angiogenesis and CC contributes to endothelial response to thrombin (PubMed:17275676). CC Regulates redox-dependent processes in lymphocytes and spermatozoa CC (PubMed:11483596). {ECO:0000269|PubMed:11483596, CC ECO:0000269|PubMed:14982937, ECO:0000269|PubMed:17275676, CC ECO:0000269|PubMed:17587483, ECO:0000269|PubMed:21642394, CC ECO:0000269|PubMed:22387196, ECO:0000269|PubMed:22427510, CC ECO:0000269|PubMed:24505490, ECO:0000269|PubMed:36653838}. CC -!- FUNCTION: [Isoform v1]: Calcium-dependent NADPH oxidase that catalyzes CC the generation of superoxide from molecular oxygen utilizing NADPH as CC an electron donor. {ECO:0000269|PubMed:21319793, CC ECO:0000269|PubMed:22427510}. CC -!- FUNCTION: [Isoform v5]: This isoform lacks calcium-binding domains and CC was showed to present a NADPH oxidase activity in a calcium-independent CC manner (PubMed:17275676, PubMed:36653838). May be involved in CC endothelial generation of reactive oxygen species (ROS), proliferation CC and angiogenesis and contribute to endothelial response to thrombin CC (PubMed:17275676). However another study showed an absence of oxidase CC activity (PubMed:22427510). Subject to rapid degradation CC (PubMed:36653838). {ECO:0000269|PubMed:17275676, CC ECO:0000269|PubMed:22427510, ECO:0000269|PubMed:36653838}. CC -!- FUNCTION: [Isoform v3]: Lacks calcium-dependent NADPH oxidase activity. CC {ECO:0000269|PubMed:22427510}. CC -!- FUNCTION: [Isoform v4]: Lacks calcium-dependent NADPH oxidase activity. CC {ECO:0000269|PubMed:22427510}. CC -!- CATALYTIC ACTIVITY: CC Reaction=NADPH + 2 O2 = 2 superoxide + NADP(+) + H(+); CC Xref=Rhea:RHEA:63180, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:18421, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; CC Evidence={ECO:0000269|PubMed:12686516}; CC -!- CATALYTIC ACTIVITY: [Isoform v2]: CC Reaction=NADPH + 2 O2 = 2 superoxide + NADP(+) + H(+); CC Xref=Rhea:RHEA:63180, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:18421, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; CC Evidence={ECO:0000269|PubMed:11483596, ECO:0000269|PubMed:14982937, CC ECO:0000269|PubMed:17275676, ECO:0000269|PubMed:17587483, CC ECO:0000269|PubMed:21642394, ECO:0000269|PubMed:22387196, CC ECO:0000269|PubMed:22427510, ECO:0000269|PubMed:24505490, CC ECO:0000269|PubMed:36653838}; CC -!- CATALYTIC ACTIVITY: [Isoform v1]: CC Reaction=NADPH + 2 O2 = 2 superoxide + NADP(+) + H(+); CC Xref=Rhea:RHEA:63180, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:18421, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; CC Evidence={ECO:0000269|PubMed:21319793, ECO:0000269|PubMed:22427510}; CC -!- CATALYTIC ACTIVITY: [Isoform v5]: CC Reaction=NADPH + 2 O2 = 2 superoxide + NADP(+) + H(+); CC Xref=Rhea:RHEA:63180, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:18421, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; CC Evidence={ECO:0000269|PubMed:17275676, ECO:0000269|PubMed:36653838}; CC -!- CATALYTIC ACTIVITY: CC Reaction=NAADPH + 2 O2 = NAADP(+) + 2 superoxide + H(+); CC Xref=Rhea:RHEA:86239, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:18421, ChEBI:CHEBI:75967, ChEBI:CHEBI:235461; CC Evidence={ECO:0000269|PubMed:34784249}; CC -!- COFACTOR: [Isoform v2]: CC Name=FAD; Xref=ChEBI:CHEBI:57692; CC Evidence={ECO:0000269|PubMed:14982937}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:14982937}; CC -!- ACTIVITY REGULATION: [Isoform v2]: Activated by calcium which induces CC conformational changes and interaction between the N-terminal CC regulatory region and the C-terminal catalytic region. Inhibited by CC diphenylene iodonium. {ECO:0000269|PubMed:14982937, CC ECO:0000269|PubMed:17587483, ECO:0000269|PubMed:36653838}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: [Isoform v2]: CC Kinetic parameters: CC KM=1.06 uM for calcium {ECO:0000269|PubMed:14982937}; CC pH dependence: CC Optimum pH is 7.5 with NAADPH as substrate (PubMed:34784249). Optimum CC pH is between 8 and 9 with NADPH as substrate (PubMed:34784249). CC {ECO:0000269|PubMed:34784249}; CC -!- SUBUNIT: [Isoform v1]: Homooligomer. {ECO:0000269|PubMed:21319793}. CC -!- INTERACTION: CC Q96PH1-4; P62157: CALM; Xeno; NbExp=3; IntAct=EBI-7305642, EBI-397403; CC -!- SUBCELLULAR LOCATION: [Isoform v2]: Endoplasmic reticulum CC {ECO:0000269|PubMed:17275676, ECO:0000269|PubMed:17587483}. Cell CC membrane {ECO:0000269|PubMed:17587483, ECO:0000269|PubMed:36653838}; CC Multi-pass membrane protein {ECO:0000255}. Note=Calcium-sensitive CC association and dissociation between the N- and C-terminal domains CC appears to facilitate its localization to the cell membrane. CC {ECO:0000269|PubMed:36653838}. CC -!- SUBCELLULAR LOCATION: [Isoform v5]: Endoplasmic reticulum CC {ECO:0000269|PubMed:17275676}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Name=v3; Synonyms=NOX5gamma; CC IsoId=Q96PH1-1; Sequence=Displayed; CC Name=v1; Synonyms=NOX5alpha; CC IsoId=Q96PH1-3; Sequence=VSP_017328; CC Name=v2; Synonyms=NOX5beta; CC IsoId=Q96PH1-4; Sequence=VSP_017327, VSP_017328; CC Name=v4; Synonyms=NOX5delta; CC IsoId=Q96PH1-2; Sequence=VSP_017327; CC Name=v5; Synonyms=NOX5epsilon, NOX5S; CC IsoId=Q96PH1-5; Sequence=VSP_017326; CC Name=v6; Synonyms=NOX5zeta; CC IsoId=Q96PH1-6; Sequence=VSP_041619, VSP_017328; CC -!- TISSUE SPECIFICITY: Mainly expressed in pachytene spermatocytes of CC testis and in lymphocyte-rich areas of spleen and lymph nodes. Also CC detected in ovary, placenta, pancreas, cardiac fibroblasts. Expressed CC in B-cells and prostate malignant cells. {ECO:0000269|PubMed:11376945, CC ECO:0000269|PubMed:11483596, ECO:0000269|PubMed:12686516, CC ECO:0000269|PubMed:16179589, ECO:0000269|PubMed:16339585}. CC -!- TISSUE SPECIFICITY: [Isoform v1]: Expressed in spleen CC (PubMed:11483596). Expressed in endothelial cells, pulmonary artery CC smooth muscle cells and epithelial colorectal adenocarcinoma cells CC (PubMed:17275676, PubMed:22427510). {ECO:0000269|PubMed:11483596, CC ECO:0000269|PubMed:17275676, ECO:0000269|PubMed:22427510}. CC -!- TISSUE SPECIFICITY: [Isoform v2]: Expressed in microvascular CC endothelial cells (at protein level) (PubMed:17275676). Expressed in CC testis (PubMed:11483596). Expressed in endothelial cells and pulmonary CC artery smooth muscle cells (PubMed:17275676, PubMed:22427510). CC {ECO:0000269|PubMed:11483596, ECO:0000269|PubMed:17275676, CC ECO:0000269|PubMed:22427510}. CC -!- TISSUE SPECIFICITY: [Isoform v3]: Expressed in pulmonary artery smooth CC muscle cells and epithelial colorectal adenocarcinoma cells. CC {ECO:0000269|PubMed:17275676}. CC -!- TISSUE SPECIFICITY: [Isoform v4]: Expressed in endothelial cells and CC pulmonary artery smooth muscle cells. {ECO:0000269|PubMed:17275676}. CC -!- TISSUE SPECIFICITY: [Isoform v5]: Expressed in microvascular CC endothelial cells (at protein level). {ECO:0000269|PubMed:17275676}. CC -!- DEVELOPMENTAL STAGE: Expressed in fetal tissues. CC {ECO:0000269|PubMed:11376945}. CC -!- INDUCTION: Down-regulated by TGFB1. {ECO:0000269|PubMed:16179589}. CC -!- DOMAIN: [Isoform v2]: The C-lobe of the N-terminal calmodulin-like CC regulatory EF-domain acquires a folded and ordered structure upon CC calcium binding, and as a consequence, it is able to bind the C- CC terminal catalytic dehydrogenase domain, triggering enzyme activation. CC {ECO:0000269|PubMed:31785178}. CC -!- DOMAIN: [Isoform v1]: The C-terminal catalytic dehydrogenase domain CC mediates its homooligomerization. {ECO:0000269|PubMed:21319793}. CC -!- DOMAIN: [Isoform v3]: Absence of enzyme activity may be because the CC third EF-hand domain is interrupted by an insert. CC {ECO:0000305|PubMed:22427510}. CC -!- DOMAIN: [Isoform v4]: Absence of enzyme activity may be because the CC third EF-hand domain is interrupted by an insert. CC {ECO:0000305|PubMed:22427510}. CC -!- DOMAIN: [Isoform v5]: Absence of enzyme activity may be due to absence CC of EF-hand domains. {ECO:0000305|PubMed:22427510}. CC -!- PTM: [Isoform v2]: Phosphorylation at Ser-475 by CaMK2 and at Ser-490, CC Thr-494 and Ser-498 by PKC/PRKCA positively regulates its catalytic CC activity. {ECO:0000269|PubMed:21642394, ECO:0000269|PubMed:24505490}. CC -!- PTM: [Isoform v2]: S-nitrosylation in response to nitric oxide inhibits CC its catalytic activity. {ECO:0000269|PubMed:22387196}. CC -!- CAUTION: [Isoform v2]: This isoform was proposed to act as a calcium- CC dependent proton channel to compensate charge and pH alterations due to CC electron export; however the channel activity seems to lack strong CC experimental evidences. {ECO:0000305|PubMed:11483596}. CC -!- SEQUENCE CAUTION: CC Sequence=AAG33638.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB15319.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB84897.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF325189; AAK57193.1; -; mRNA. DR EMBL; AF325190; AAK57194.1; -; mRNA. DR EMBL; AF353088; AAK57338.1; -; mRNA. DR EMBL; AF353089; AAK57339.1; -; mRNA. DR EMBL; AK074058; BAB84884.1; -; mRNA. DR EMBL; AK074071; BAB84897.1; ALT_INIT; mRNA. DR EMBL; AK026011; BAB15319.1; ALT_INIT; mRNA. DR EMBL; AK314689; BAG37241.1; -; mRNA. DR EMBL; DQ314884; ABC40743.1; -; Genomic_DNA. DR EMBL; AC027088; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC087639; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471082; EAW77830.1; -; Genomic_DNA. DR EMBL; BC125097; AAI25098.1; -; mRNA. DR EMBL; BC125098; AAI25099.1; -; mRNA. DR EMBL; AF317889; AAG33638.1; ALT_INIT; mRNA. DR CCDS; CCDS32276.2; -. [Q96PH1-1] DR CCDS; CCDS53954.1; -. [Q96PH1-3] DR RefSeq; NP_001171708.1; NM_001184779.2. [Q96PH1-3] DR RefSeq; NP_001171709.1; NM_001184780.1. [Q96PH1-6] DR RefSeq; NP_078781.3; NM_024505.3. [Q96PH1-1] DR PDB; 6SZ5; X-ray; 2.23 A; B/C=19-765. DR PDB; 8U7Y; EM; 4.06 A; A/B=19-765. DR PDB; 8U85; EM; 3.20 A; A/C=19-765. DR PDB; 8U86; EM; 3.30 A; A/C=19-765. DR PDB; 8U87; EM; 3.86 A; A/C=19-765. DR PDBsum; 6SZ5; -. DR PDBsum; 8U7Y; -. DR PDBsum; 8U85; -. DR PDBsum; 8U86; -. DR PDBsum; 8U87; -. DR AlphaFoldDB; Q96PH1; -. DR EMDB; EMD-42013; -. DR EMDB; EMD-42014; -. DR EMDB; EMD-42015; -. DR EMDB; EMD-42016; -. DR EMDB; EMD-42345; -. DR EMDB; EMD-42348; -. DR SMR; Q96PH1; -. DR BioGRID; 122660; 47. DR FunCoup; Q96PH1; 206. DR IntAct; Q96PH1; 10. DR MINT; Q96PH1; -. DR STRING; 9606.ENSP00000373518; -. DR BindingDB; Q96PH1; -. DR ChEMBL; CHEMBL1926497; -. DR GuidetoPHARMACOLOGY; 3005; -. DR PeroxiBase; 6024; HsNOx05. DR TCDB; 5.B.1.1.5; the phagocyte (gp91(phox)) nadph oxidase family. DR iPTMnet; Q96PH1; -. DR PhosphoSitePlus; Q96PH1; -. DR BioMuta; NOX5; -. DR DMDM; 74717091; -. DR jPOST; Q96PH1; -. DR MassIVE; Q96PH1; -. DR PaxDb; 9606-ENSP00000373518; -. DR PeptideAtlas; Q96PH1; -. DR ProteomicsDB; 77694; -. [Q96PH1-1] DR ProteomicsDB; 77695; -. [Q96PH1-2] DR ProteomicsDB; 77696; -. [Q96PH1-3] DR ProteomicsDB; 77697; -. [Q96PH1-4] DR ProteomicsDB; 77698; -. [Q96PH1-5] DR ProteomicsDB; 77699; -. [Q96PH1-6] DR Antibodypedia; 57978; 240 antibodies from 30 providers. DR DNASU; 79400; -. DR Ensembl; ENST00000388866.8; ENSP00000373518.3; ENSG00000255346.11. [Q96PH1-1] DR Ensembl; ENST00000530406.7; ENSP00000432440.2; ENSG00000255346.11. [Q96PH1-3] DR GeneID; 79400; -. DR KEGG; hsa:134826889; -. DR KEGG; hsa:79400; -. DR MANE-Select; ENST00000388866.8; ENSP00000373518.3; NM_024505.4; NP_078781.3. DR UCSC; uc002arp.3; human. [Q96PH1-1] DR AGR; HGNC:14874; -. DR ClinPGx; PA31693; -. DR CTD; 79400; -. DR DisGeNET; 79400; -. DR GeneCards; NOX5; -. DR HGNC; HGNC:14874; NOX5. DR HPA; ENSG00000255346; Tissue enriched (lymphoid). DR HPA; ENSG00000290203; Not detected. DR MIM; 606572; gene. DR OpenTargets; ENSG00000255346; -. DR VEuPathDB; HostDB:ENSG00000255346; -. DR eggNOG; KOG0039; Eukaryota. DR GeneTree; ENSGT00940000162591; -. DR HOGENOM; CLU_009773_0_0_1; -. DR InParanoid; Q96PH1; -. DR OMA; WFVVPGC; -. DR OrthoDB; 167398at2759; -. DR PAN-GO; Q96PH1; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q96PH1; -. DR PathwayCommons; Q96PH1; -. DR Reactome; R-HSA-3299685; Detoxification of Reactive Oxygen Species. DR SABIO-RK; Q96PH1; -. DR SignaLink; Q96PH1; -. DR SIGNOR; Q96PH1; -. DR Agora; ENSG00000255346; -. DR BioGRID-ORCS; 79400; 14 hits in 1148 CRISPR screens. DR ChiTaRS; NOX5; human. DR GeneWiki; NOX5; -. DR GenomeRNAi; 79400; -. DR Pharos; Q96PH1; Tchem. DR PRO; PR:Q96PH1; -. DR Proteomes; UP000005640; Chromosome 15. DR RNAct; Q96PH1; protein. DR Bgee; ENSG00000255346; Expressed in oocyte and 141 other cell types or tissues. DR ExpressionAtlas; Q96PH1; baseline and differential. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome. DR GO; GO:0043020; C:NADPH oxidase complex; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0005509; F:calcium ion binding; IEA:InterPro. DR GO; GO:0050660; F:flavin adenine dinucleotide binding; NAS:UniProtKB. DR GO; GO:0020037; F:heme binding; NAS:UniProtKB. DR GO; GO:0050661; F:NADP binding; NAS:UniProtKB. DR GO; GO:0015252; F:proton channel activity; IDA:UniProtKB. DR GO; GO:0016175; F:superoxide-generating NAD(P)H oxidase activity; IDA:UniProtKB. DR GO; GO:0106292; F:superoxide-generating NADPH oxidase activity; IDA:FlyBase. DR GO; GO:0001525; P:angiogenesis; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; NAS:UniProtKB. DR GO; GO:0061640; P:cytoskeleton-dependent cytokinesis; NAS:UniProtKB. DR GO; GO:0006952; P:defense response; IBA:GO_Central. DR GO; GO:0001935; P:endothelial cell proliferation; IDA:UniProtKB. DR GO; GO:0001819; P:positive regulation of cytokine production; NAS:UniProtKB. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IDA:UniProtKB. DR GO; GO:1902600; P:proton transmembrane transport; IDA:UniProtKB. DR GO; GO:0043012; P:regulation of fusion of sperm to egg plasma membrane; NAS:UniProtKB. DR GO; GO:0042554; P:superoxide anion generation; IDA:UniProtKB. DR CDD; cd00051; EFh; 2. DR CDD; cd06186; NOX_Duox_like_FAD_NADP; 1. DR FunFam; 2.40.30.10:FF:000056; NADPH oxidase 5; 1. DR FunFam; 1.10.238.10:FF:000210; NADPH oxidase 5 isoform X2; 1. DR FunFam; 3.40.50.80:FF:000012; NADPH oxidase, isoform B; 1. DR Gene3D; 1.10.238.10; EF-hand; 1. DR Gene3D; 3.40.50.80; Nucleotide-binding domain of ferredoxin-NADP reductase (FNR) module; 1. DR Gene3D; 2.40.30.10; Translation factors; 1. DR InterPro; IPR011992; EF-hand-dom_pair. DR InterPro; IPR018247; EF_Hand_1_Ca_BS. DR InterPro; IPR002048; EF_hand_dom. DR InterPro; IPR013112; FAD-bd_8. DR InterPro; IPR017927; FAD-bd_FR_type. DR InterPro; IPR013130; Fe3_Rdtase_TM_dom. DR InterPro; IPR013121; Fe_red_NAD-bd_6. DR InterPro; IPR039261; FNR_nucleotide-bd. DR InterPro; IPR050369; RBOH/FRE. DR InterPro; IPR017938; Riboflavin_synthase-like_b-brl. DR PANTHER; PTHR11972; NADPH OXIDASE; 1. DR PANTHER; PTHR11972:SF58; NADPH OXIDASE 5; 1. DR Pfam; PF13202; EF-hand_5; 1. DR Pfam; PF13405; EF-hand_6; 1. DR Pfam; PF08022; FAD_binding_8; 1. DR Pfam; PF01794; Ferric_reduct; 1. DR Pfam; PF08030; NAD_binding_6; 1. DR SFLD; SFLDS00052; Ferric_Reductase_Domain; 1. DR SFLD; SFLDG01168; Ferric_reductase_subgroup_(FRE; 1. DR SFLD; SFLDG01169; NADPH_oxidase_subgroup_(NOX); 1. DR SMART; SM00054; EFh; 2. DR SUPFAM; SSF47473; EF-hand; 1. DR SUPFAM; SSF52343; Ferredoxin reductase-like, C-terminal NADP-linked domain; 1. DR SUPFAM; SSF63380; Riboflavin synthase domain-like; 1. DR PROSITE; PS00018; EF_HAND_1; 2. DR PROSITE; PS50222; EF_HAND_2; 3. DR PROSITE; PS51384; FAD_FR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Angiogenesis; Calcium; Cell membrane; KW Electron transport; Endoplasmic reticulum; FAD; Flavoprotein; Ion channel; KW Ion transport; Membrane; Metal-binding; NADP; Oxidoreductase; KW Proteomics identification; Reference proteome; Repeat; Transmembrane; KW Transmembrane helix; Transport. FT CHAIN 1..765 FT /note="NADPH oxidase 5" FT /id="PRO_0000224995" FT TOPO_DOM 1..238 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 239..259 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 260..266 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 267..289 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 290..317 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 318..338 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 339..362 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 363..383 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 384..394 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 395..417 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 418..434 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 435..455 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 456..583 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 584..604 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 605..765 FT /note="Extracellular" FT /evidence="ECO:0000255" FT DOMAIN 26..56 FT /note="EF-hand 1" FT /evidence="ECO:0000305" FT DOMAIN 57..92 FT /note="EF-hand 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT DOMAIN 93..156 FT /note="EF-hand 3; atypical; contains an insert of 28 FT residues" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT DOMAIN 165..200 FT /note="EF-hand 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT DOMAIN 293..440 FT /note="Ferric oxidoreductase" FT DOMAIN 441..577 FT /note="FAD-binding FR-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00716" FT REGION 122..141 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 42 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000305" FT BINDING 44 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000305" FT BINDING 49 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000305" FT BINDING 70 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 72 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 74 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 76 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 81 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 106 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000305" FT BINDING 108 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000305" FT BINDING 138 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000305" FT BINDING 140 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000305" FT BINDING 145 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000305" FT BINDING 178 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 180 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 182 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 189 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT VAR_SEQ 1..200 FT /note="Missing (in isoform v5)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017326" FT VAR_SEQ 1..18 FT /note="Missing (in isoform v2 and isoform v4)" FT /evidence="ECO:0000303|PubMed:11483596, FT ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334" FT /id="VSP_017327" FT VAR_SEQ 1..17 FT /note="MNTSGDPAQTGPEGCRG -> MAFVCAGLSD (in isoform v6)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_041619" FT VAR_SEQ 109..136 FT /note="Missing (in isoform v1, isoform v2 and isoform v6)" FT /evidence="ECO:0000303|PubMed:11483596, FT ECO:0000303|PubMed:15489334" FT /id="VSP_017328" FT VARIANT 576 FT /note="R -> H (in dbSNP:rs2277552)" FT /id="VAR_055820" FT VARIANT 759 FT /note="R -> G (in dbSNP:rs7168025)" FT /id="VAR_055821" FT CONFLICT 208 FT /note="A -> T (in Ref. 8; AAG33638)" FT /evidence="ECO:0000305" FT CONFLICT 272 FT /note="G -> S (in Ref. 7; AAI25099)" FT /evidence="ECO:0000305" FT CONFLICT 375 FT /note="L -> P (in Ref. 3; BAG37241)" FT /evidence="ECO:0000305" FT CONFLICT 380 FT /note="L -> F (in Ref. 2; BAB84884/BAB84897, 3; BAB15319/ FT BAG37241, 6; EAW77830 and 7; AAI25098/AAI25099)" FT /evidence="ECO:0000305" FT HELIX 23..35 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 47..53 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 60..69 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 79..90 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 94..105 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 143..152 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 157..159 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 163..177 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 187..196 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 200..203 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 229..259 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 267..286 FT /evidence="ECO:0007829|PDB:8U85" FT TURN 290..292 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 293..296 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 301..304 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 307..309 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 310..340 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 366..368 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 369..383 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 387..391 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 397..402 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 405..413 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 419..436 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 441..444 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 447..454 FT /evidence="ECO:0007829|PDB:8U85" FT TURN 455..457 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 458..464 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 476..479 FT /evidence="ECO:0007829|PDB:8U85" FT TURN 482..484 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 490..494 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 502..509 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 513..524 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 567..571 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 576..579 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 580..589 FT /evidence="ECO:0007829|PDB:8U85" FT TURN 590..593 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 594..609 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 611..613 FT /evidence="ECO:0007829|PDB:8U86" FT TURN 615..617 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 620..622 FT /evidence="ECO:0007829|PDB:8U86" FT STRAND 634..639 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 647..659 FT /evidence="ECO:0007829|PDB:8U85" FT TURN 664..666 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 670..675 FT /evidence="ECO:0007829|PDB:8U85" FT TURN 682..685 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 686..695 FT /evidence="ECO:0007829|PDB:8U85" FT TURN 696..700 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 703..705 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 707..710 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 711..714 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 721..728 FT /evidence="ECO:0007829|PDB:6SZ5" FT STRAND 736..741 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 743..756 FT /evidence="ECO:0007829|PDB:8U85" FT REGION Q96PH1-3:416..737 FT /note="C-terminal catalytic dehydrogenase domain" FT /evidence="ECO:0000305|PubMed:21319793" FT MUTAGEN Q96PH1-3:277 FT /note="L->R: Loss of activity but no effect on protein FT levels." FT /evidence="ECO:0000269|PubMed:21319793" FT MUTAGEN Q96PH1-3:567 FT /note="P->H: Loss of activity but no effect on protein FT levels." FT /evidence="ECO:0000269|PubMed:21319793" FT MUTAGEN Q96PH1-3:656 FT /note="D->A: Loss of activity but no effect on protein FT levels." FT /evidence="ECO:0000269|PubMed:21319793" FT REGION Q96PH1-4:1..161 FT /note="N-terminal regulatory EF domain" FT /evidence="ECO:0000269|PubMed:14982937, FT ECO:0000305|PubMed:31785178" FT REGION Q96PH1-4:1..77 FT /note="N-terminal lobe of N-terminal regulatory EF domain" FT /evidence="ECO:0000305|PubMed:31785178" FT REGION Q96PH1-4:78..161 FT /note="C-terminal lobe of N-terminal regulatory EF domain" FT /evidence="ECO:0000305|PubMed:31785178" FT REGION Q96PH1-4:398..719 FT /note="C-terminal catalytic dehydrogenase domain" FT /evidence="ECO:0000305|PubMed:31785178" FT MOD_RES Q96PH1-4:107 FT /note="S-nitrosocysteine" FT /evidence="ECO:0000269|PubMed:22387196" FT MOD_RES Q96PH1-4:246 FT /note="S-nitrosocysteine" FT /evidence="ECO:0000269|PubMed:22387196" FT MOD_RES Q96PH1-4:475 FT /note="Phosphoserine; by CaMK2" FT /evidence="ECO:0000269|PubMed:21642394" FT MOD_RES Q96PH1-4:490 FT /note="Phosphothreonine; by PKC/PRKCA" FT /evidence="ECO:0000269|PubMed:22387196, FT ECO:0000269|PubMed:24505490" FT MOD_RES Q96PH1-4:494 FT /note="Phosphothreonine; by CaMK2 and PKC/PRKCA" FT /evidence="ECO:0000269|PubMed:21642394, FT ECO:0000269|PubMed:22387196, ECO:0000269|PubMed:24505490" FT MOD_RES Q96PH1-4:498 FT /note="Phosphoserine; by CaMK2 and PKC/PRKCA" FT /evidence="ECO:0000269|PubMed:21642394, FT ECO:0000269|PubMed:22387196, ECO:0000269|PubMed:24505490" FT MOD_RES Q96PH1-4:502 FT /note="Phosphoserine; by CaMK2" FT /evidence="ECO:0000269|PubMed:21642394" FT MOD_RES Q96PH1-4:519 FT /note="S-nitrosocysteine" FT /evidence="ECO:0000269|PubMed:22387196" FT MOD_RES Q96PH1-4:659 FT /note="Phosphoserine; by CaMK2" FT /evidence="ECO:0000269|PubMed:21642394" FT MOD_RES Q96PH1-4:694 FT /note="S-nitrosocysteine" FT /evidence="ECO:0000269|PubMed:22387196" FT MUTAGEN Q96PH1-4:31 FT /note="E->Q: Loss of binding of 1 calcium molecule. No FT effect on catalytic activity." FT /evidence="ECO:0000269|PubMed:14982937" FT MUTAGEN Q96PH1-4:107 FT /note="C->S: Substantial loss of catalytic activity." FT /evidence="ECO:0000269|PubMed:22387196" FT MUTAGEN Q96PH1-4:110 FT /note="E->A: No effect on cell membrane localization and FT catalytic activity." FT /evidence="ECO:0000269|PubMed:36653838" FT MUTAGEN Q96PH1-4:111 FT /note="S->A: No effect on cell membrane localization and FT catalytic activity." FT /evidence="ECO:0000269|PubMed:36653838" FT MUTAGEN Q96PH1-4:112 FT /note="A->N: No effect on cell membrane localization and FT catalytic activity." FT /evidence="ECO:0000269|PubMed:36653838" FT MUTAGEN Q96PH1-4:113 FT /note="I->N: Significant reduction in cell membrane FT localization and catalytic activity. Reduced calcium- FT dependent interaction between the N-terminal regulatory FT region and the C-terminal catalytic region." FT /evidence="ECO:0000269|PubMed:36653838" FT MUTAGEN Q96PH1-4:114 FT /note="S->A: No effect on cell membrane localization and FT catalytic activity." FT /evidence="ECO:0000269|PubMed:36653838" FT MUTAGEN Q96PH1-4:115 FT /note="L->A: Significant reduction in cell membrane FT localization and catalytic activity. No effect on calcium- FT dependent interaction between the N-terminal regulatory FT region and the C-terminal catalytic region." FT /evidence="ECO:0000269|PubMed:36653838" FT MUTAGEN Q96PH1-4:116 FT /note="P->A: No effect on cell membrane localization and FT catalytic activity." FT /evidence="ECO:0000269|PubMed:36653838" FT MUTAGEN Q96PH1-4:475 FT /note="S->A: Loss of CaMK2-mediated activation of its FT activity." FT /evidence="ECO:0000269|PubMed:21642394" FT MUTAGEN Q96PH1-4:490 FT /note="S->A: Loss of PKC/PRKCA-mediated activation of its FT activity; when associated with A-494 and A-498." FT /evidence="ECO:0000269|PubMed:24505490" FT MUTAGEN Q96PH1-4:494 FT /note="T->A: No effect on CaMK2-mediated activation of its FT activity. Loss of PKC/PRKCA-mediated activation of its FT activity; when associated with A-490 and A-498." FT /evidence="ECO:0000269|PubMed:21642394, FT ECO:0000269|PubMed:24505490" FT MUTAGEN Q96PH1-4:498 FT /note="S->A: No effect on CaMK2-mediated activation of its FT activity. Loss of PKC/PRKCA-mediated activation of its FT activity; when associated with A-490 and A-494." FT /evidence="ECO:0000269|PubMed:21642394, FT ECO:0000269|PubMed:24505490" FT MUTAGEN Q96PH1-4:502 FT /note="S->A: No effect on CaMK2-mediated activation of its FT activity." FT /evidence="ECO:0000269|PubMed:21642394" FT MUTAGEN Q96PH1-4:519 FT /note="C->S: Very significant loss of catalytic activity." FT /evidence="ECO:0000269|PubMed:22387196" FT MUTAGEN Q96PH1-4:549 FT /note="P->H: No effect on cell membrane localization but FT loss of catalytic activity." FT /evidence="ECO:0000269|PubMed:36653838" FT MUTAGEN Q96PH1-4:659 FT /note="S->A: No effect on CaMK2-mediated activation of its FT activity." FT /evidence="ECO:0000269|PubMed:21642394" FT MUTAGEN Q96PH1-4:694 FT /note="C->S: Reduced nitrosylation. Very significant loss FT of catalytic activity." FT /evidence="ECO:0000269|PubMed:22387196" SQ SEQUENCE 765 AA; 86439 MW; 96B57225BF919682 CRC64; MNTSGDPAQT GPEGCRGTMS AEEDARWLRW VTQQFKTIAG EDGEISLQEF KAALHVKESF FAERFFALFD SDRSGTITLQ ELQEALTLLI HGSPMDKLKF LFQVYDIDVC ARQGASAGTE WGAGAGPHWA SSPLGTGSGS IDPDELRTVL QSCLRESAIS LPDEKLDQLT LALFESADAD GNGAITFEEL RDELQRFPGV MENLTISAAH WLTAPAPRPR PRRPRQLTRA YWHNHRSQLF CLATYAGLHV LLFGLAASAH RDLGASVMVA KGCGQCLNFD CSFIAVLMLR RCLTWLRATW LAQVLPLDQN IQFHQLMGYV VVGLSLVHTV AHTVNFVLQA QAEASPFQFW ELLLTTRPGI GWVHGSASPT GVALLLLLLL MFICSSSCIR RSGHFEVFYW THLSYLLVWL LLIFHGPNFW KWLLVPGILF FLEKAIGLAV SRMAAVCIME VNLLPSKVTH LLIKRPPFFH YRPGDYLYLN IPTIARYEWH PFTISSAPEQ KDTIWLHIRS QGQWTNRLYE SFKASDPLGR GSKRLSRSVT MRKSQRSSKG SEILLEKHKF CNIKCYIDGP YGTPTRRIFA SEHAVLIGAG IGITPFASIL QSIMYRHQKR KHTCPSCQHS WIEGVQDNMK LHKVDFIWIN RDQRSFEWFV SLLTKLEMDQ AEEAQYGRFL ELHMYMTSAL GKNDMKAIGL QMALDLLANK EKKDSITGLQ TRTQPGRPDW SKVFQKVAAE KKGKVQVFFC GSPALAKVLK GHCEKFGFRF FQENF // ID NTRK2_HUMAN Reviewed; 822 AA. AC Q16620; B1ANZ4; B4DFV9; Q16675; Q59GJ1; Q8WXJ5; Q8WXJ6; Q8WXJ7; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 249. DE RecName: Full=BDNF/NT-3 growth factors receptor; DE EC=2.7.10.1 {ECO:0000269|PubMed:15494731}; DE AltName: Full=GP145-TrkB; DE Short=Trk-B; DE AltName: Full=Neurotrophic tyrosine kinase receptor type 2; DE AltName: Full=TrkB tyrosine kinase; DE AltName: Full=Tropomyosin-related kinase B; DE Flags: Precursor; GN Name=NTRK2; Synonyms=TRKB; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB). RC TISSUE=Hippocampus; RX PubMed=7789988; DOI=10.1016/0888-7543(95)80055-q; RA Nakagawara A., Liu X.-G., Ikegaki N., White P.S., Yamashiro D.J., RA Nycum L.M., Biegel J.A., Brodeur G.M.; RT "Cloning and chromosomal localization of the human TRK-B tyrosine kinase RT receptor gene (NTRK2)."; RL Genomics 25:538-546(1995). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TRKB AND TRKB-T1). RC TISSUE=Brain; RX PubMed=7823156; DOI=10.1523/jneurosci.15-01-00477.1995; RA Shelton D.L., Sutherland J., Gripp J., Camerato T., Armanini M.P., RA Phillips H.S., Carroll K., Spencer S.D., Levinson A.D.; RT "Human trks: molecular cloning, tissue distribution, and expression of RT extracellular domain immunoadhesins."; RL J. Neurosci. 15:477-491(1995). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB-T1), TISSUE SPECIFICITY, AND RP DEVELOPMENTAL STAGE. RC TISSUE=Hippocampus; RX PubMed=7936202; DOI=10.1016/0306-4522(94)90507-x; RA Allen S.J., Dawbarn D., Eckford S.D., Wilcock G.K., Ashcroft M., RA Colebrook S.M., Feeney R., Macgowan S.H.; RT "Cloning of a non-catalytic form of human trkB and distribution of RT messenger RNA for trkB in human brain."; RL Neuroscience 60:825-834(1994). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TRKB; TRKB-T1; TRKB-T-SHC; 4 AND 5), RP ALTERNATIVE SPLICING, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=11798182; DOI=10.1006/bbrc.2001.6301; RA Stoilov P., Castren E., Stamm S.; RT "Analysis of the human TrkB gene genomic organization reveals novel TrkB RT isoforms, unusual gene length, and splicing mechanism."; RL Biochem. Biophys. Res. Commun. 290:1054-1065(2002). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB-T1), AND VARIANT ARG-309. RA Steinbeck J.A., Thomsen S., Wessig J., Leypoldt F., Lewerenz J., RA Methner A.; RT "Full length truncated TrkB sequence identified in a screen for genes RT regulated by ischemic preconditioning."; RL Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-N-T1). RC TISSUE=Amygdala; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-T-TK). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RT "Homo sapiens protein coding cDNA."; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-T1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP FUNCTION, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-67; ASN-95; ASN-121; RP ASN-178; ASN-205; ASN-241; ASN-254; ASN-280; ASN-338 AND ASN-412. RX PubMed=7574684; DOI=10.1006/abbi.1995.1460; RA Haniu M., Talvenheimo J., Le J., Katta V., Welcher A., Rohde M.F.; RT "Extracellular domain of neurotrophin receptor trkB: disulfide structure, RT N-glycosylation sites, and ligand binding."; RL Arch. Biochem. Biophys. 322:256-264(1995). RN [12] RP INTERACTION WITH FRS2. RX PubMed=10092678; DOI=10.1074/jbc.274.14.9861; RA Meakin S.O., MacDonald J.I.S., Gryz E.A., Kubu C.J., Verdi J.M.; RT "The signaling adapter FRS-2 competes with Shc for binding to the nerve RT growth factor receptor TrkA. A model for discriminating proliferation and RT differentiation."; RL J. Biol. Chem. 274:9861-9870(1999). RN [13] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-67; ASN-121 AND ASN-254. RC TISSUE=Plasma; RX PubMed=16335952; DOI=10.1021/pr0502065; RA Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J., RA Smith R.D.; RT "Human plasma N-glycoproteome analysis by immunoaffinity subtraction, RT hydrazide chemistry, and mass spectrometry."; RL J. Proteome Res. 4:2070-2080(2005). RN [14] RP ALTERNATIVE SPLICING (ISOFORMS TRKB-T-TK AND TRKB-N-T1). RX PubMed=20193039; DOI=10.1111/j.1471-4159.2010.06662.x; RA Luberg K., Wong J., Weickert C.S., Timmusk T.; RT "Human TrkB gene: novel alternative transcripts, protein isoforms and RT expression pattern in the prefrontal cerebral cortex during postnatal RT development."; RL J. Neurochem. 113:952-964(2010). RN [15] {ECO:0007744|PDB:1WWB} RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 283-385, AND DISULFIDE BONDS. RX PubMed=10388563; DOI=10.1006/jmbi.1999.2816; RA Ultsch M.H., Wiesmann C., Simmons L.C., Henrich J., Yang M., Reilly D., RA Bass S.H., de Vos A.M.; RT "Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and RT TrkC."; RL J. Mol. Biol. 290:149-159(1999). RN [16] {ECO:0007744|PDB:1HCF} RP X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 284-383 IN COMPLEX WITH NTF4, AND RP DISULFIDE BONDS. RX PubMed=11738045; DOI=10.1016/s0969-2126(01)00681-5; RA Banfield M.J., Naylor R.L., Robertson A.G., Allen S.J., Dawbarn D., RA Brady R.L.; RT "Specificity in Trk receptor:neurotrophin interactions: the crystal RT structure of TrkB-d5 in complex with neurotrophin-4/5."; RL Structure 9:1191-1199(2001). RN [17] RP INTERACTION WITH SLITRK2. RX PubMed=35840571; DOI=10.1038/s41467-022-31566-z; RA El Chehadeh S., Han K.A., Kim D., Jang G., Bakhtiari S., Lim D., Kim H.Y., RA Kim J., Kim H., Wynn J., Chung W.K., Vitiello G., Cutcutache I., Page M., RA Gecz J., Harper K., Han A.R., Kim H.M., Wessels M., Bayat A., Jaen A.F., RA Selicorni A., Maitz S., de Brouwer A.P.M., Silfhout A.V., Armstrong M., RA Symonds J., Kuery S., Isidor B., Cogne B., Nizon M., Feger C., Muller J., RA Torti E., Grange D.K., Willems M., Kruer M.C., Ko J., Piton A., Um J.W.; RT "SLITRK2 variants associated with neurodevelopmental disorders impair RT excitatory synaptic function and cognition in mice."; RL Nat. Commun. 13:4112-4112(2022). RN [18] RP VARIANT OBHD CYS-706, CHARACTERIZATION OF VARIANT OBHD CYS-706, FUNCTION AS RP A BDNF-ACTIVATED RECEPTOR, CATALYTIC ACTIVITY, PHOSPHORYLATION, AND RP SUBCELLULAR LOCATION. RX PubMed=15494731; DOI=10.1038/nn1336; RA Yeo G.S., Connie Hung C.C., Rochford J., Keogh J., Gray J., RA Sivaramakrishnan S., O'Rahilly S., Farooqi I.S.; RT "A de novo mutation affecting human TrkB associated with severe obesity and RT developmental delay."; RL Nat. Neurosci. 7:1187-1189(2004). RN [19] RP VARIANT [LARGE SCALE ANALYSIS] PHE-138. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [20] RP VARIANTS ILE-697; GLY-699 AND CYS-718. RX PubMed=18293376; DOI=10.1002/humu.20707; RA Marchetti A., Felicioni L., Pelosi G., Del Grammastro M., Fumagalli C., RA Sciarrotta M., Malatesta S., Chella A., Barassi F., Mucilli F., RA Camplese P., D'Antuono T., Sacco R., Buttitta F.; RT "Frequent mutations in the neurotrophic tyrosine receptor kinase gene RT family in large cell neuroendocrine carcinoma of the lung."; RL Hum. Mutat. 29:609-616(2008). RN [21] RP VARIANT OBHD 444-GLY--GLY-822 DEL. RX PubMed=27884935; DOI=10.1136/jmedgenet-2016-104215; RA Miller K.A., Twigg S.R., McGowan S.J., Phipps J.M., Fenwick A.L., RA Johnson D., Wall S.A., Noons P., Rees K.E., Tidey E.A., Craft J., RA Taylor J., Taylor J.C., Goos J.A., Swagemakers S.M., Mathijssen I.M., RA van der Spek P.J., Lord H., Lester T., Abid N., Cilliers D., Hurst J.A., RA Morton J.E., Sweeney E., Weber A., Wilson L.C., Wilkie A.O.; RT "Diagnostic value of exome and whole genome sequencing in RT craniosynostosis."; RL J. Med. Genet. 54:260-268(2017). RN [22] RP VARIANT DEE58 CYS-434, VARIANT OBHD ILE-704, AND INVOLVEMENT IN DEE58. RX PubMed=29100083; DOI=10.1016/j.ajhg.2017.09.008; RG Deciphering Developmental Disorders Study; RA Hamdan F.F., Myers C.T., Cossette P., Lemay P., Spiegelman D., RA Laporte A.D., Nassif C., Diallo O., Monlong J., Cadieux-Dion M., RA Dobrzeniecka S., Meloche C., Retterer K., Cho M.T., Rosenfeld J.A., Bi W., RA Massicotte C., Miguet M., Brunga L., Regan B.M., Mo K., Tam C., RA Schneider A., Hollingsworth G., FitzPatrick D.R., Donaldson A., Canham N., RA Blair E., Kerr B., Fry A.E., Thomas R.H., Shelagh J., Hurst J.A., RA Brittain H., Blyth M., Lebel R.R., Gerkes E.H., Davis-Keppen L., Stein Q., RA Chung W.K., Dorison S.J., Benke P.J., Fassi E., Corsten-Janssen N., RA Kamsteeg E.J., Mau-Them F.T., Bruel A.L., Verloes A., Ounap K., RA Wojcik M.H., Albert D.V.F., Venkateswaran S., Ware T., Jones D., Liu Y.C., RA Mohammad S.S., Bizargity P., Bacino C.A., Leuzzi V., Martinelli S., RA Dallapiccola B., Tartaglia M., Blumkin L., Wierenga K.J., Purcarin G., RA O'Byrne J.J., Stockler S., Lehman A., Keren B., Nougues M.C., Mignot C., RA Auvin S., Nava C., Hiatt S.M., Bebin M., Shao Y., Scaglia F., Lalani S.R., RA Frye R.E., Jarjour I.T., Jacques S., Boucher R.M., Riou E., Srour M., RA Carmant L., Lortie A., Major P., Diadori P., Dubeau F., D'Anjou G., RA Bourque G., Berkovic S.F., Sadleir L.G., Campeau P.M., Kibar Z., RA Lafreniere R.G., Girard S.L., Mercimek-Mahmutoglu S., Boelman C., RA Rouleau G.A., Scheffer I.E., Mefford H.C., Andrade D.M., Rossignol E., RA Minassian B.A., Michaud J.L.; RT "High rate of recurrent de novo mutations in developmental and epileptic RT encephalopathies."; RL Am. J. Hum. Genet. 101:664-685(2017). CC -!- FUNCTION: Receptor tyrosine kinase involved in the development and the CC maturation of the central and the peripheral nervous systems through CC regulation of neuron survival, proliferation, migration, CC differentiation, and synapse formation and plasticity (By similarity). CC Receptor for BDNF/brain-derived neurotrophic factor and CC NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3 CC which is less efficient in activating the receptor but regulates neuron CC survival through NTRK2 (PubMed:15494731, PubMed:7574684). Upon ligand- CC binding, undergoes homodimerization, autophosphorylation and activation CC (PubMed:15494731). Recruits, phosphorylates and/or activates several CC downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that CC regulate distinct overlapping signaling cascades. Through SHC1, FRS2, CC SH2B1, SH2B2 activates the GRB2-Ras-MAPK cascade that regulates for CC instance neuronal differentiation including neurite outgrowth. Through CC the same effectors controls the Ras-PI3 kinase-AKT1 signaling cascade CC that mainly regulates growth and survival. Through PLCG1 and the CC downstream protein kinase C-regulated pathways controls synaptic CC plasticity. Thereby, plays a role in learning and memory by regulating CC both short term synaptic function and long-term potentiation. PLCG1 CC also leads to NF-Kappa-B activation and the transcription of genes CC involved in cell survival. Hence, it is able to suppress anoikis, the CC apoptosis resulting from loss of cell-matrix interactions. May also CC play a role in neutrophin-dependent calcium signaling in glial cells CC and mediate communication between neurons and glia. CC {ECO:0000250|UniProtKB:P15209, ECO:0000269|PubMed:15494731, CC ECO:0000269|PubMed:7574684}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:15494731}; CC -!- ACTIVITY REGULATION: The neuronal activity and the influx of calcium CC positively regulate the kinase activity and the internalization of the CC receptor which are both important for active signaling. Regulated by CC NGFR that may control the internalization of the receptor. NGFR may CC also stimulate the activation by BDNF compared to NTF3 and NTF4. SH2D1A CC inhibits the autophosphorylation of the receptor, and alters the CC recruitment and activation of downstream effectors and signaling CC cascades. The formation of active receptors dimers able to fully CC transduce the ligand-mediated signal, may be negatively regulated by CC the formation of inactive heterodimers with the non-catalytic isoforms CC (By similarity). {ECO:0000250|UniProtKB:P15209, CC ECO:0000250|UniProtKB:Q63604}. CC -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low CC affinity) and dimeric (high affinity) structures. Interacts CC (phosphorylated upon activation by BDNF) with SHC1; mediates SHC1 CC phosphorylation and activation. Interacts (phosphorylated upon CC activation by BDNF) with PLCG1 and/or PLCG2; mediates PLCG1 CC phosphorylation and activation. Interacts with SH2B1 and SH2B2. CC Interacts with NGFR; may regulate the ligand specificity of the CC receptor (By similarity). Interacts with SORCS2; this interaction is CC important for normal targeting to post-synaptic densities in response CC to high-frequency stimulation (By similarity). Interacts CC (phosphorylated upon ligand-binding) with SH2D1A; regulates NTRK2. CC Interacts with SQSTM1 and KIDINS220 (By similarity). Interacts CC (phosphorylated upon ligand-binding) with FRS2; activates the MAPK CC signaling pathway (PubMed:10092678). Interacts with APPL1 (By CC similarity). Interacts with MAPK8IP3/JIP3 and KLC1; interaction with CC KLC1 is mediated by MAPK8IP3/JIP3 (By similarity). Interacts with CC SORL1; this interaction facilitates NTRK2 trafficking between synaptic CC plasma membranes, postsynaptic densities and cell soma, hence CC positively regulates BDNF signaling (By similarity). Interacts with CC SLITRK2 (PubMed:35840571). {ECO:0000250|UniProtKB:P04629, CC ECO:0000250|UniProtKB:P15209, ECO:0000250|UniProtKB:Q63604, CC ECO:0000269|PubMed:10092678, ECO:0000269|PubMed:11738045, CC ECO:0000269|PubMed:35840571}. CC -!- INTERACTION: CC Q16620; P00533: EGFR; NbExp=3; IntAct=EBI-3904881, EBI-297353; CC Q16620; Q16288: NTRK3; NbExp=3; IntAct=EBI-3904881, EBI-3936704; CC Q16620; Q13485: SMAD4; NbExp=4; IntAct=EBI-3904881, EBI-347263; CC Q16620; Q03114: Cdk5; Xeno; NbExp=3; IntAct=EBI-3904881, EBI-2008531; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15494731}; CC Single-pass type I membrane protein {ECO:0000305}. Endosome membrane CC {ECO:0000250|UniProtKB:P15209}; Single-pass type I membrane protein CC {ECO:0000250|UniProtKB:P15209}. Early endosome membrane CC {ECO:0000250|UniProtKB:P15209}. Cell projection, axon CC {ECO:0000250|UniProtKB:Q63604}. Cell projection, dendrite CC {ECO:0000250|UniProtKB:Q63604}. Cytoplasm, perinuclear region CC {ECO:0000250|UniProtKB:Q63604}. Postsynaptic density CC {ECO:0000250|UniProtKB:P15209}. Note=Internalized to endosomes upon CC ligand-binding. {ECO:0000250|UniProtKB:P15209}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Comment=Additional isoforms seem to exist.; CC Name=TrkB; Synonyms=gp145-TrkB; CC IsoId=Q16620-1; Sequence=Displayed; CC Name=TrkB-T1; CC IsoId=Q16620-2; Sequence=VSP_002901, VSP_002902; CC Name=TrkB-T-Shc; CC IsoId=Q16620-3; Sequence=VSP_002903, VSP_002904; CC Name=4; CC IsoId=Q16620-4; Sequence=VSP_041942; CC Name=5; CC IsoId=Q16620-5; Sequence=VSP_041942, VSP_002903, VSP_002904; CC Name=TrkB-T-TK; CC IsoId=Q16620-6; Sequence=VSP_042178, VSP_042179; CC Name=TrkB-N-T1; CC IsoId=Q16620-7; Sequence=VSP_042177, VSP_002901, VSP_002902; CC -!- TISSUE SPECIFICITY: Isoform TrkB is expressed in the central and CC peripheral nervous system. In the central nervous system (CNS), CC expression is observed in the cerebral cortex, hippocampus, thalamus, CC choroid plexus, granular layer of the cerebellum, brain stem, and CC spinal cord. In the peripheral nervous system, it is expressed in many CC cranial ganglia, the ophthalmic nerve, the vestibular system, multiple CC facial structures, the submaxillary glands, and dorsal root ganglia. CC Isoform TrkB-T1 is mainly expressed in the brain but also detected in CC other tissues including pancreas, kidney and heart. Isoform TrkB-T-Shc CC is predominantly expressed in the brain. {ECO:0000269|PubMed:11798182, CC ECO:0000269|PubMed:7936202}. CC -!- DEVELOPMENTAL STAGE: Widely expressed in fetal brain. CC {ECO:0000269|PubMed:7936202}. CC -!- PTM: Phosphorylated. Undergoes ligand-mediated autophosphorylation that CC is required for interaction with SHC1 and PLCG1 and other downstream CC effectors. Isoform TrkB-T-Shc is not phosphorylated. CC {ECO:0000269|PubMed:15494731}. CC -!- PTM: Ubiquitinated. Undergoes polyubiquitination upon activation; CC regulated by NGFR. Ubiquitination regulates the internalization of the CC receptor (By similarity). {ECO:0000250}. CC -!- DISEASE: Developmental and epileptic encephalopathy 58 (DEE58) CC [MIM:617830]: A form of epileptic encephalopathy, a heterogeneous group CC of severe early-onset epilepsies characterized by refractory seizures, CC neurodevelopmental impairment, and poor prognosis. Development is CC normal prior to seizure onset, after which cognitive and motor delays CC become apparent. DEE58 is an autosomal dominant condition characterized CC by onset of refractory seizures in the first days or months of life. CC {ECO:0000269|PubMed:29100083}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Obesity, hyperphagia, and developmental delay (OBHD) CC [MIM:613886]: A disorder characterized by early-onset obesity, CC hyperphagia, and severe developmental delay in motor function, speech, CC and language. {ECO:0000269|PubMed:15494731, CC ECO:0000269|PubMed:27884935, ECO:0000269|PubMed:29100083}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- MISCELLANEOUS: Trk also stands for tropomyosin-related kinase since the CC first Trk was isolated as an oncogenic protein which was the result of CC a fusion between the tropomyosin gene TPM3 and NTRK1. CC -!- MISCELLANEOUS: [Isoform TrkB-T1]: Non-catalytic isoform. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41589/NTRK2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U12140; AAC51371.1; -; mRNA. DR EMBL; S76473; AAB33109.1; -; mRNA. DR EMBL; S76474; AAB33110.1; -; mRNA. DR EMBL; X75958; CAA53571.1; -; mRNA. DR EMBL; AF410899; AAL67965.1; -; mRNA. DR EMBL; AF410900; AAL67966.1; -; mRNA. DR EMBL; AF410901; AAL67967.1; -; mRNA. DR EMBL; AF508964; AAM77876.1; -; mRNA. DR EMBL; AB209118; BAD92355.1; -; mRNA. DR EMBL; AK294285; BAG57570.1; -; mRNA. DR EMBL; AL390777; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL445532; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL596132; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471089; EAW62688.1; -; Genomic_DNA. DR EMBL; BC031835; AAH31835.1; -; mRNA. DR CCDS; CCDS35050.1; -. [Q16620-1] DR CCDS; CCDS35051.1; -. [Q16620-5] DR CCDS; CCDS35052.1; -. [Q16620-3] DR CCDS; CCDS35053.1; -. [Q16620-2] DR CCDS; CCDS6671.1; -. [Q16620-4] DR CCDS; CCDS94429.1; -. [Q16620-7] DR PIR; A56853; A56853. DR PIR; I73631; I73631. DR RefSeq; NP_001007098.1; NM_001007097.3. [Q16620-2] DR RefSeq; NP_001018074.1; NM_001018064.3. [Q16620-1] DR RefSeq; NP_001018075.1; NM_001018065.2. [Q16620-5] DR RefSeq; NP_001018076.1; NM_001018066.3. [Q16620-3] DR RefSeq; NP_001356461.1; NM_001369532.1. [Q16620-1] DR RefSeq; NP_001356462.1; NM_001369533.1. [Q16620-1] DR RefSeq; NP_001356466.1; NM_001369537.1. [Q16620-5] DR RefSeq; NP_001356467.1; NM_001369538.1. [Q16620-3] DR RefSeq; NP_001356468.1; NM_001369539.1. [Q16620-2] DR RefSeq; NP_001356469.1; NM_001369540.1. [Q16620-2] DR RefSeq; NP_001356470.1; NM_001369541.1. [Q16620-2] DR RefSeq; NP_001356471.1; NM_001369542.1. [Q16620-2] DR RefSeq; NP_001356472.1; NM_001369543.1. [Q16620-2] DR RefSeq; NP_001356473.1; NM_001369544.1. [Q16620-2] DR RefSeq; NP_001356474.1; NM_001369545.1. [Q16620-2] DR RefSeq; NP_001356477.1; NM_001369548.1. [Q16620-2] DR RefSeq; NP_001356478.1; NM_001369549.1. [Q16620-2] DR RefSeq; NP_001356479.1; NM_001369550.1. [Q16620-7] DR RefSeq; NP_001356480.1; NM_001369551.1. [Q16620-7] DR RefSeq; NP_001356481.1; NM_001369552.1. [Q16620-7] DR RefSeq; NP_006171.2; NM_006180.4. [Q16620-4] DR RefSeq; XP_005252058.1; XM_005252001.4. [Q16620-4] DR RefSeq; XP_005252060.1; XM_005252003.4. [Q16620-4] DR RefSeq; XP_005252061.1; XM_005252004.3. [Q16620-4] DR RefSeq; XP_011517020.1; XM_011518718.4. [Q16620-1] DR RefSeq; XP_016870240.1; XM_017014751.3. [Q16620-4] DR RefSeq; XP_016870241.1; XM_017014752.2. [Q16620-1] DR RefSeq; XP_016870242.1; XM_017014753.3. [Q16620-1] DR RefSeq; XP_016870244.1; XM_017014755.1. [Q16620-5] DR RefSeq; XP_016870249.1; XM_017014760.3. [Q16620-2] DR RefSeq; XP_047279388.1; XM_047423432.1. [Q16620-4] DR RefSeq; XP_047279389.1; XM_047423433.1. [Q16620-4] DR RefSeq; XP_054218993.1; XM_054363018.1. [Q16620-4] DR RefSeq; XP_054218994.1; XM_054363019.1. [Q16620-4] DR RefSeq; XP_054218995.1; XM_054363020.1. [Q16620-4] DR RefSeq; XP_054218996.1; XM_054363021.1. [Q16620-4] DR RefSeq; XP_054218997.1; XM_054363022.1. [Q16620-4] DR RefSeq; XP_054218998.1; XM_054363023.1. [Q16620-4] DR RefSeq; XP_054218999.1; XM_054363024.1. [Q16620-1] DR RefSeq; XP_054219000.1; XM_054363025.1. [Q16620-1] DR RefSeq; XP_054219001.1; XM_054363026.1. [Q16620-1] DR RefSeq; XP_054219002.1; XM_054363027.1. [Q16620-5] DR RefSeq; XP_054219003.1; XM_054363028.1. [Q16620-2] DR PDB; 1HCF; X-ray; 2.70 A; X/Y=286-383. DR PDB; 1WWB; X-ray; 2.10 A; X=283-385. DR PDB; 2MFQ; NMR; -; B=497-519. DR PDB; 4ASZ; X-ray; 1.70 A; A=527-822. DR PDB; 4AT3; X-ray; 1.77 A; A=527-822. DR PDB; 4AT4; X-ray; 2.36 A; A=527-822. DR PDB; 4AT5; X-ray; 1.71 A; A=527-822. DR PDB; 5MO9; X-ray; 2.59 A; X=278-426. DR PDB; 8OYD; NMR; -; A/B=422-466. DR PDBsum; 1HCF; -. DR PDBsum; 1WWB; -. DR PDBsum; 2MFQ; -. DR PDBsum; 4ASZ; -. DR PDBsum; 4AT3; -. DR PDBsum; 4AT4; -. DR PDBsum; 4AT5; -. DR PDBsum; 5MO9; -. DR PDBsum; 8OYD; -. DR AlphaFoldDB; Q16620; -. DR SMR; Q16620; -. DR BioGRID; 110970; 137. DR DIP; DIP-5720N; -. DR FunCoup; Q16620; 1218. DR IntAct; Q16620; 116. DR MINT; Q16620; -. DR STRING; 9606.ENSP00000277120; -. DR BindingDB; Q16620; -. DR ChEMBL; CHEMBL4898; -. DR DrugBank; DB00321; Amitriptyline. DR DrugBank; DB11986; Entrectinib. DR DrugBank; DB11823; Esketamine. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB16056; GZ-389988. DR DrugBank; DB14723; Larotrectinib. DR DrugBank; DB16826; Repotrectinib. DR DrugCentral; Q16620; -. DR GuidetoPHARMACOLOGY; 1818; -. DR TCDB; 8.A.23.1.38; the basigin (basigin) family. DR GlyConnect; 1029; 12 N-Linked glycans (7 sites). DR GlyCosmos; Q16620; 13 sites, 14 glycans. DR GlyGen; Q16620; 13 sites, 21 N-linked glycans (8 sites), 1 O-linked glycan (1 site). DR iPTMnet; Q16620; -. DR PhosphoSitePlus; Q16620; -. DR SwissPalm; Q16620; -. DR BioMuta; NTRK2; -. DR DMDM; 2497560; -. DR jPOST; Q16620; -. DR MassIVE; Q16620; -. DR PaxDb; 9606-ENSP00000277120; -. DR PeptideAtlas; Q16620; -. DR ProteomicsDB; 60955; -. [Q16620-1] DR ProteomicsDB; 60956; -. [Q16620-2] DR ProteomicsDB; 60957; -. [Q16620-3] DR ProteomicsDB; 60958; -. [Q16620-4] DR ProteomicsDB; 60959; -. [Q16620-5] DR ProteomicsDB; 60960; -. [Q16620-6] DR ProteomicsDB; 60961; -. [Q16620-7] DR ABCD; Q16620; 146 sequenced antibodies. DR Antibodypedia; 2081; 1498 antibodies from 49 providers. DR DNASU; 4915; -. DR Ensembl; ENST00000277120.8; ENSP00000277120.3; ENSG00000148053.19. [Q16620-4] DR Ensembl; ENST00000304053.11; ENSP00000306167.7; ENSG00000148053.19. [Q16620-3] DR Ensembl; ENST00000359847.4; ENSP00000352906.3; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000376208.6; ENSP00000365381.1; ENSG00000148053.19. [Q16620-3] DR Ensembl; ENST00000376213.6; ENSP00000365386.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000395882.6; ENSP00000379221.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000685720.1; ENSP00000509031.1; ENSG00000148053.19. [Q16620-5] DR Ensembl; ENST00000686259.1; ENSP00000509743.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000686322.1; ENSP00000510032.1; ENSG00000148053.19. [Q16620-7] DR Ensembl; ENST00000686324.1; ENSP00000510134.1; ENSG00000148053.19. [Q16620-4] DR Ensembl; ENST00000686443.1; ENSP00000509093.1; ENSG00000148053.19. [Q16620-3] DR Ensembl; ENST00000686496.1; ENSP00000510060.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000687148.1; ENSP00000510717.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000687596.1; ENSP00000509999.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000687636.1; ENSP00000508829.1; ENSG00000148053.19. [Q16620-5] DR Ensembl; ENST00000688013.1; ENSP00000508443.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000689685.1; ENSP00000509169.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000689815.1; ENSP00000510451.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000690281.1; ENSP00000510757.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000691415.1; ENSP00000509058.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000691788.1; ENSP00000509401.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000692181.1; ENSP00000510619.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000692389.1; ENSP00000508497.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000692506.1; ENSP00000508622.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000692762.1; ENSP00000510071.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000693109.1; ENSP00000509456.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000693539.1; ENSP00000510640.1; ENSG00000148053.19. [Q16620-5] DR GeneID; 4915; -. DR KEGG; hsa:4915; -. DR MANE-Select; ENST00000277120.8; ENSP00000277120.3; NM_006180.6; NP_006171.2. [Q16620-4] DR UCSC; uc004anz.1; human. [Q16620-1] DR AGR; HGNC:8032; -. DR CIViC; 4915; 5 evidence items across 2 molecular profiles. DR ClinPGx; PA31818; -. DR CTD; 4915; -. DR DisGeNET; 4915; -. DR GeneCards; NTRK2; -. DR HGNC; HGNC:8032; NTRK2. DR HPA; ENSG00000148053; Tissue enhanced (brain, thyroid gland). DR MalaCards; NTRK2; -. DR MIM; 600456; gene. DR MIM; 613886; phenotype. DR MIM; 617830; phenotype. DR OpenTargets; ENSG00000148053; -. DR Orphanet; 99704; Early-onset obesity-hyperphagia-severe developmental delay syndrome. DR Orphanet; 697160; Infantile epileptic spasms syndrome. DR Orphanet; 442835; Non-specific early-onset epileptic encephalopathy. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR VEuPathDB; HostDB:ENSG00000148053; -. DR eggNOG; KOG1026; Eukaryota. DR GeneTree; ENSGT00940000155181; -. DR HOGENOM; CLU_000288_74_1_1; -. DR InParanoid; Q16620; -. DR OMA; HIAMQIA; -. DR OrthoDB; 10005095at2759; -. DR PAN-GO; Q16620; 16 GO annotations based on evolutionary models. DR PhylomeDB; Q16620; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q16620; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-187024; NGF-independant TRKA activation. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-9024909; BDNF activates NTRK2 (TRKB) signaling. DR Reactome; R-HSA-9025046; NTF3 activates NTRK2 (TRKB) signaling. DR Reactome; R-HSA-9026357; NTF4 activates NTRK2 (TRKB) signaling. DR Reactome; R-HSA-9026519; Activated NTRK2 signals through RAS. DR Reactome; R-HSA-9026527; Activated NTRK2 signals through PLCG1. DR Reactome; R-HSA-9028335; Activated NTRK2 signals through PI3K. DR Reactome; R-HSA-9028731; Activated NTRK2 signals through FRS2 and FRS3. DR Reactome; R-HSA-9032500; Activated NTRK2 signals through FYN. DR Reactome; R-HSA-9032759; NTRK2 activates RAC1. DR Reactome; R-HSA-9032845; Activated NTRK2 signals through CDK5. DR SignaLink; Q16620; -. DR SIGNOR; Q16620; -. DR Agora; ENSG00000148053; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 4915; 10 hits in 1188 CRISPR screens. DR ChiTaRS; NTRK2; human. DR EvolutionaryTrace; Q16620; -. DR GeneWiki; TrkB_receptor; -. DR GenomeRNAi; 4915; -. DR Pharos; Q16620; Tclin. DR PRO; PR:Q16620; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q16620; protein. DR Bgee; ENSG00000148053; Expressed in cranial nerve II and 196 other cell types or tissues. DR ExpressionAtlas; Q16620; baseline and differential. DR GO; GO:0030424; C:axon; ISS:UniProtKB. DR GO; GO:0043679; C:axon terminus; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IEA:Ensembl. DR GO; GO:0030425; C:dendrite; ISS:UniProtKB. DR GO; GO:0043197; C:dendritic spine; IBA:GO_Central. DR GO; GO:0005769; C:early endosome; ISS:UniProtKB. DR GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell. DR GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0014069; C:postsynaptic density; ISS:ARUK-UCL. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0043195; C:terminal bouton; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0048403; F:brain-derived neurotrophic factor binding; ISS:UniProtKB. DR GO; GO:0060175; F:brain-derived neurotrophic factor receptor activity; IMP:UniProtKB. DR GO; GO:0043121; F:neurotrophin binding; IDA:UniProtKB. DR GO; GO:0002020; F:protease binding; IPI:ARUK-UCL. DR GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB. DR GO; GO:0031547; P:brain-derived neurotrophic factor receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl. DR GO; GO:1990416; P:cellular response to brain-derived neurotrophic factor stimulus; IBA:GO_Central. DR GO; GO:0021954; P:central nervous system neuron development; ISS:UniProtKB. DR GO; GO:0021987; P:cerebral cortex development; ISS:UniProtKB. DR GO; GO:0007623; P:circadian rhythm; IEA:Ensembl. DR GO; GO:0007631; P:feeding behavior; IEA:Ensembl. DR GO; GO:0014047; P:glutamate secretion; IEA:Ensembl. DR GO; GO:0007612; P:learning; ISS:UniProtKB. DR GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl. DR GO; GO:0042490; P:mechanoreceptor differentiation; IEA:Ensembl. DR GO; GO:0022011; P:myelination in peripheral nervous system; IEA:Ensembl. DR GO; GO:1902430; P:negative regulation of amyloid-beta formation; IGI:ARUK-UCL. DR GO; GO:2000811; P:negative regulation of anoikis; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:UniProtKB. DR GO; GO:0030182; P:neuron differentiation; ISS:UniProtKB. DR GO; GO:0001764; P:neuron migration; ISS:UniProtKB. DR GO; GO:0019227; P:neuronal action potential propagation; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0048935; P:peripheral nervous system neuron development; IEA:Ensembl. DR GO; GO:0050772; P:positive regulation of axonogenesis; ISS:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB. DR GO; GO:0010976; P:positive regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISS:UniProtKB. DR GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB. DR GO; GO:0043087; P:regulation of GTPase activity; ISS:UniProtKB. DR GO; GO:0046548; P:retinal rod cell development; IEA:Ensembl. DR GO; GO:0099183; P:trans-synaptic signaling by BDNF, modulating synaptic transmission; IEA:Ensembl. DR GO; GO:0001570; P:vasculogenesis; IEA:Ensembl. DR CDD; cd05855; IgI_TrkB_d5; 1. DR CDD; cd05093; PTKc_TrkB; 1. DR DisProt; DP03945; -. DR FunFam; 2.60.40.10:FF:000239; BDNF/NT-3 growth factors receptor; 1. DR FunFam; 3.80.10.10:FF:000048; BDNF/NT-3 growth factors receptor; 1. DR FunFam; 1.10.510.10:FF:000034; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000486; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.30.200.20:FF:000033; Tyrosine-protein kinase receptor; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00672; -. DR InterPro; IPR000483; Cys-rich_flank_reg_C. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR001611; Leu-rich_rpt. DR InterPro; IPR032675; LRR_dom_sf. DR InterPro; IPR000372; LRRNT. DR InterPro; IPR020777; NTRK. DR InterPro; IPR020455; NTRK2. DR InterPro; IPR031635; NTRK_LRRCT. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR002011; Tyr_kinase_rcpt_2_CS. DR PANTHER; PTHR24416:SF136; BDNF_NT-3 GROWTH FACTORS RECEPTOR; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF07679; I-set; 2. DR Pfam; PF13855; LRR_8; 1. DR Pfam; PF16920; LRRCT_2; 1. DR Pfam; PF01462; LRRNT; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR01939; NTKRECEPTOR. DR PRINTS; PR01941; NTKRECEPTOR2. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 1. DR SMART; SM00408; IGc2; 1. DR SMART; SM00082; LRRCT; 1. DR SMART; SM00013; LRRNT; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 2. DR SUPFAM; SSF52058; L domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Cell projection; Cytoplasm; Developmental protein; Differentiation; KW Disease variant; Disulfide bond; Endosome; Epilepsy; Glycoprotein; KW Immunoglobulin domain; Kinase; Leucine-rich repeat; Membrane; Neurogenesis; KW Nucleotide-binding; Obesity; Phosphoprotein; Proteomics identification; KW Receptor; Reference proteome; Repeat; Signal; Synapse; Transferase; KW Transmembrane; Transmembrane helix; Tyrosine-protein kinase; KW Ubl conjugation. FT SIGNAL 1..31 FT CHAIN 32..822 FT /note="BDNF/NT-3 growth factors receptor" FT /id="PRO_0000016727" FT TOPO_DOM 32..430 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 431..454 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 455..822 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 32..61 FT /note="LRRNT" FT REPEAT 92..113 FT /note="LRR 1" FT REPEAT 116..137 FT /note="LRR 2" FT DOMAIN 148..196 FT /note="LRRCT" FT DOMAIN 197..282 FT /note="Ig-like C2-type 1" FT DOMAIN 295..365 FT /note="Ig-like C2-type 2" FT DOMAIN 538..807 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 455..466 FT /note="Interaction with MAPK8IP3/JIP3" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT REGION 475..498 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 485..495 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 676 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 544..552 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 572 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 516 FT /note="Interaction with SHC1" FT /evidence="ECO:0000250" FT SITE 706 FT /note="Interaction with SH2D1A" FT /evidence="ECO:0000250" FT SITE 817 FT /note="Interaction with PLCG1" FT /evidence="ECO:0000250" FT MOD_RES 516 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:P15209" FT MOD_RES 702 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT MOD_RES 706 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT MOD_RES 707 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT MOD_RES 817 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT CARBOHYD 67 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:7574684" FT CARBOHYD 95 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 121 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:7574684" FT CARBOHYD 178 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 205 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 241 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 254 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:7574684" FT CARBOHYD 280 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 325 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 338 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 412 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT DISULFID 32..38 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 36..45 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 152..176 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 154..194 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 218..266 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 302..345 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:10388563, ECO:0000269|PubMed:11738045, FT ECO:0000269|PubMed:7574684, ECO:0007744|PDB:1HCF, FT ECO:0007744|PDB:1WWB, ECO:0007744|PDB:5MO9" FT VAR_SEQ 1..156 FT /note="Missing (in isoform TrkB-N-T1)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_042177" FT VAR_SEQ 465 FT /note="K -> KDFSWFGFGKVKSRQGV (in isoform 4 and isoform 5)" FT /evidence="ECO:0000303|PubMed:11798182" FT /id="VSP_041942" FT VAR_SEQ 467..477 FT /note="PASVISNDDDS -> FVLFHKIPLDG (in isoform TrkB-T1 and FT isoform TrkB-N-T1)" FT /evidence="ECO:0000303|PubMed:11798182, FT ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7823156, ECO:0000303|PubMed:7936202, FT ECO:0000303|Ref.5" FT /id="VSP_002901" FT VAR_SEQ 478..822 FT /note="Missing (in isoform TrkB-T1 and isoform TrkB-N-T1)" FT /evidence="ECO:0000303|PubMed:11798182, FT ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7823156, ECO:0000303|PubMed:7936202, FT ECO:0000303|Ref.5" FT /id="VSP_002902" FT VAR_SEQ 529..537 FT /note="FVQHIKRHN -> WPRGSPKTA (in isoform TrkB-T-Shc and FT isoform 5)" FT /evidence="ECO:0000303|PubMed:11798182" FT /id="VSP_002903" FT VAR_SEQ 538..822 FT /note="Missing (in isoform TrkB-T-Shc and isoform 5)" FT /evidence="ECO:0000303|PubMed:11798182" FT /id="VSP_002904" FT VAR_SEQ 710..735 FT /note="GGHTMLPIRWMPPESIMYRKFTTESD -> SSCADQRPQGPLSLRDPCCICL FT LRLS (in isoform TrkB-T-TK)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_042178" FT VAR_SEQ 736..822 FT /note="Missing (in isoform TrkB-T-TK)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_042179" FT VARIANT 138 FT /note="L -> F (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041470" FT VARIANT 309 FT /note="G -> R" FT /evidence="ECO:0000269|Ref.5" FT /id="VAR_016320" FT VARIANT 338 FT /note="N -> Y (in dbSNP:rs1047856)" FT /id="VAR_011973" FT VARIANT 434 FT /note="Y -> C (in DEE58; uncertain significance; FT dbSNP:rs886041091)" FT /evidence="ECO:0000269|PubMed:29100083" FT /id="VAR_080659" FT VARIANT 444..822 FT /note="Missing (in OBHD)" FT /evidence="ECO:0000269|PubMed:27884935" FT /id="VAR_080660" FT VARIANT 545 FT /note="G -> V (in dbSNP:rs1075108)" FT /id="VAR_049715" FT VARIANT 697 FT /note="M -> I (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046518" FT VARIANT 699 FT /note="R -> G (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046519" FT VARIANT 704 FT /note="T -> I (in OBHD; uncertain significance; FT dbSNP:rs1554774973)" FT /evidence="ECO:0000269|PubMed:29100083" FT /id="VAR_080661" FT VARIANT 706 FT /note="Y -> C (in OBHD; expressed normally on the cell FT surface; results in markedly impaired ligand-induced FT phosphorylation as well as impaired downstream MAPK1 FT phosphorylation; dbSNP:rs121434633)" FT /evidence="ECO:0000269|PubMed:15494731" FT /id="VAR_065890" FT VARIANT 718 FT /note="R -> C (in a lung carcinoma sample; somatic FT mutation; dbSNP:rs1324578301)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046520" FT STRAND 285..292 FT /evidence="ECO:0007829|PDB:5MO9" FT STRAND 300..308 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 314..319 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 322..324 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 328..337 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 339..350 FT /evidence="ECO:0007829|PDB:1WWB" FT HELIX 353..355 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 357..364 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 369..376 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 380..382 FT /evidence="ECO:0007829|PDB:5MO9" FT HELIX 428..460 FT /evidence="ECO:0007829|PDB:8OYD" FT STRAND 462..464 FT /evidence="ECO:0007829|PDB:8OYD" FT STRAND 500..503 FT /evidence="ECO:0007829|PDB:2MFQ" FT STRAND 506..512 FT /evidence="ECO:0007829|PDB:2MFQ" FT TURN 515..517 FT /evidence="ECO:0007829|PDB:2MFQ" FT HELIX 535..537 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 538..545 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 552..557 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 567..574 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 579..592 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 603..607 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 609..618 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 625..631 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 634..638 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 641..643 FT /evidence="ECO:0007829|PDB:4AT5" FT HELIX 650..669 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 679..681 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 682..684 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 686..688 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 690..692 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 698..701 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 703..705 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 707..709 FT /evidence="ECO:0007829|PDB:4ASZ" FT TURN 710..712 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 713..715 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 717..719 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 722..727 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 732..747 FT /evidence="ECO:0007829|PDB:4ASZ" FT TURN 748..750 FT /evidence="ECO:0007829|PDB:4ASZ" FT TURN 753..756 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 759..768 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 780..789 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 794..796 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 800..813 FT /evidence="ECO:0007829|PDB:4ASZ" SQ SEQUENCE 822 AA; 91999 MW; 2FEB9159948F0D13 CRC64; MSSWIRWHGP AMARLWGFCW LVVGFWRAAF ACPTSCKCSA SRIWCSDPSP GIVAFPRLEP NSVDPENITE IFIANQKRLE IINEDDVEAY VGLRNLTIVD SGLKFVAHKA FLKNSNLQHI NFTRNKLTSL SRKHFRHLDL SELILVGNPF TCSCDIMWIK TLQEAKSSPD TQDLYCLNES SKNIPLANLQ IPNCGLPSAN LAAPNLTVEE GKSITLSCSV AGDPVPNMYW DVGNLVSKHM NETSHTQGSL RITNISSDDS GKQISCVAEN LVGEDQDSVN LTVHFAPTIT FLESPTSDHH WCIPFTVKGN PKPALQWFYN GAILNESKYI CTKIHVTNHT EYHGCLQLDN PTHMNNGDYT LIAKNEYGKD EKQISAHFMG WPGIDDGANP NYPDVIYEDY GTAANDIGDT TNRSNEIPST DVTDKTGREH LSVYAVVVIA SVVGFCLLVM LFLLKLARHS KFGMKGPASV ISNDDDSASP LHHISNGSNT PSSSEGGPDA VIIGMTKIPV IENPQYFGIT NSQLKPDTFV QHIKRHNIVL KRELGEGAFG KVFLAECYNL CPEQDKILVA VKTLKDASDN ARKDFHREAE LLTNLQHEHI VKFYGVCVEG DPLIMVFEYM KHGDLNKFLR AHGPDAVLMA EGNPPTELTQ SQMLHIAQQI AAGMVYLASQ HFVHRDLATR NCLVGENLLV KIGDFGMSRD VYSTDYYRVG GHTMLPIRWM PPESIMYRKF TTESDVWSLG VVLWEIFTYG KQPWYQLSNN EVIECITQGR VLQRPRTCPQ EVYELMLGCW QREPHMRKNI KGIHTLLQNL AKASPVYLDI LG // ID PAK3_HUMAN Reviewed; 559 AA. AC O75914; A8K389; B1GX77; B1GX78; B1GX79; Q5JWX1; Q5JWX2; Q7Z2D6; Q7Z2E4; AC Q7Z3Z8; Q8WWK5; Q8WX23; Q9P0J8; DT 15-DEC-1998, integrated into UniProtKB/Swiss-Prot. DT 10-MAY-2004, sequence version 2. DT 28-JAN-2026, entry version 229. DE RecName: Full=Serine/threonine-protein kinase PAK 3; DE EC=2.7.11.1; DE AltName: Full=Beta-PAK; DE AltName: Full=Oligophrenin-3; DE AltName: Full=p21-activated kinase 3; DE Short=PAK-3; GN Name=PAK3; Synonyms=OPHN3; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND INVOLVEMENT IN XLID30. RX PubMed=9731525; DOI=10.1038/1675; RA Allen K.M., Gleeson J.G., Bagrodia S., Partington M.W., Macmillan J.C., RA Cerione R.A., Mulley J.C., Walsh C.A.; RT "PAK3 mutation in nonsyndromic X-linked mental retardation."; RL Nat. Genet. 20:25-30(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Adrenal gland; RA Jiang C., Gu J., Fu S., Ren S., Gu Y., Huang Q., Dong H., Yu Y., Fu G., RA Wang Y., Chen Z., Han Z.; RT "A novel gene expressed in the human adrenal gland."; RL Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=12777533; DOI=10.1093/molbev/msg134; RA Kitano T., Schwarz C., Nickel B., Paeaebo S.; RT "Gene diversity patterns at 10 X-chromosomal loci in humans and RT chimpanzees."; RL Mol. Biol. Evol. 20:1281-1289(2003). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 3 AND 4). RC TISSUE=Brain; RX PubMed=18507705; DOI=10.1111/j.1471-4159.2008.05474.x; RA Kreis P., Rousseau V., Thevenot E., Combeau G., Barnier J.V.; RT "The four mammalian splice variants encoded by the p21-activated kinase 3 RT gene have different biological properties."; RL J. Neurochem. 106:1184-1197(2008). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP INTERACTION WITH GIT1 AND GIT2. RX PubMed=10896954; DOI=10.1074/jbc.275.29.22373; RA Premont R.T., Claing A., Vitale N., Perry S.J., Lefkowitz R.J.; RT "The GIT family of ADP-ribosylation factor GTPase-activating proteins. RT Functional diversity of GIT2 through alternative splicing."; RL J. Biol. Chem. 275:22373-22380(2000). RN [9] RP AUTOPHOSPHORYLATION. RX PubMed=11278486; DOI=10.1074/jbc.m009316200; RA Chong C., Tan L., Lim L., Manser E.; RT "The mechanism of PAK activation. Autophosphorylation events in both RT regulatory and kinase domains control activity."; RL J. Biol. Chem. 276:17347-17353(2001). RN [10] RP INTERACTION WITH ARHGEF6 AND ARHGEF7. RX PubMed=11741931; DOI=10.1074/jbc.m107704200; RA Feng Q., Albeck J.G., Cerione R.A., Yang W.; RT "Regulation of the Cool/Pix proteins: key binding partners of the Cdc42/Rac RT targets, the p21-activated kinases."; RL J. Biol. Chem. 277:5644-5650(2002). RN [11] RP TISSUE SPECIFICITY. RX PubMed=12890786; DOI=10.1523/jneurosci.23-17-06914.2003; RA McPhie D.L., Coopersmith R., Hines-Peralta A., Chen Y., Ivins K.J., RA Manly S.P., Kozlowski M.R., Neve K.A., Neve R.L.; RT "DNA synthesis and neuronal apoptosis caused by familial Alzheimer disease RT mutants of the amyloid precursor protein are mediated by the p21 activated RT kinase PAK3."; RL J. Neurosci. 23:6914-6927(2003). RN [12] RP NEDDYLATION. RX PubMed=20596523; DOI=10.1371/journal.pone.0011332; RA Del Rincon S.V., Rogers J., Widschwendter M., Sun D., Sieburg H.B., RA Spruck C.; RT "Development and validation of a method for profiling post-translational RT modification activities using protein microarrays."; RL PLoS ONE 5:E11332-E11332(2010). RN [13] RP FUNCTION IN PHOSPHORYLATION OF MAPK4 AND MAPK6. RX PubMed=21177870; DOI=10.1074/jbc.m110.181529; RA Deleris P., Trost M., Topisirovic I., Tanguay P.L., Borden K.L., RA Thibault P., Meloche S.; RT "Activation loop phosphorylation of ERK3/ERK4 by group I p21-activated RT kinases (PAKs) defines a novel PAK-ERK3/4-MAPK-activated protein kinase 5 RT signaling pathway."; RL J. Biol. Chem. 286:6470-6478(2011). RN [14] RP REVIEW ON FUNCTION. RX PubMed=19036346; DOI=10.1016/j.cellsig.2008.11.001; RA Kreis P., Barnier J.V.; RT "PAK signalling in neuronal physiology."; RL Cell. Signal. 21:384-393(2009). RN [15] RP VARIANT XLID30 CYS-67. RX PubMed=10946356; RX DOI=10.1002/1096-8628(20000814)93:4<294::aid-ajmg8>3.0.co;2-f; RA Bienvenu T., des Portes V., McDonell N., Carrie A., Zemni R., Couvert P., RA Ropers H.-H., Moraine C., van Bokhoven H., Fryns J.-P., Allen K., RA Walsh C.A., Boue J., Kahn A., Chelly J., Beldjord C.; RT "Missense mutation in PAK3, R67C, causes X-linked nonspecific mental RT retardation."; RL Am. J. Med. Genet. 93:294-298(2000). RN [16] RP VARIANT XLID30 GLU-380. RX PubMed=12884430; DOI=10.1002/ajmg.a.20131; RA Gedeon A.K., Nelson J., Gecz J., Mulley J.C.; RT "X-linked mild non-syndromic mental retardation with neuropsychiatric RT problems and the missense mutation A365E in PAK3."; RL Am. J. Med. Genet. A 120:509-517(2003). RN [17] RP VARIANT [LARGE SCALE ANALYSIS] SER-440. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine protein kinase that plays a role in a CC variety of different signaling pathways including cytoskeleton CC regulation, cell migration, or cell cycle regulation. Plays a role in CC dendrite spine morphogenesis as well as synapse formation and CC plasticity. Acts as a downstream effector of the small GTPases CDC42 CC and RAC1. Activation by the binding of active CDC42 and RAC1 results in CC a conformational change and a subsequent autophosphorylation on several CC serine and/or threonine residues. Phosphorylates MAPK4 and MAPK6 and CC activates the downstream target MAPKAPK5, a regulator of F-actin CC polymerization and cell migration. Additionally, phosphorylates CC TNNI3/troponin I to modulate calcium sensitivity and relaxation CC kinetics of thin myofilaments. May also be involved in early neuronal CC development. In hippocampal neurons, necessary for the formation of CC dendritic spines and excitatory synapses; this function is dependent on CC kinase activity and may be exerted by the regulation of actomyosin CC contractility through the phosphorylation of myosin II regulatory light CC chain (MLC) (By similarity). {ECO:0000250|UniProtKB:Q61036, CC ECO:0000269|PubMed:21177870}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC -!- ACTIVITY REGULATION: Activated by binding small G proteins. Binding of CC GTP-bound CDC42 or RAC1 to the autoregulatory region releases monomers CC from the autoinhibited dimer, enables phosphorylation of Thr-436 and CC allows the kinase domain to adopt an active structure (By similarity). CC {ECO:0000250}. CC -!- SUBUNIT: Interacts tightly with GTP-bound but not GDP-bound CDC42/p21 CC and RAC1. Shows highly specific binding to the SH3 domains of CC phospholipase C-gamma and of adapter protein NCK. Interacts with the C- CC terminal of APP (By similarity). Interacts with ARHGEF6 and ARHGEF7. CC Interacts with GIT1 and GIT2 (PubMed:10896954). {ECO:0000250, CC ECO:0000269|PubMed:10896954, ECO:0000269|PubMed:11741931}. CC -!- INTERACTION: CC O75914; P60953-2: CDC42; NbExp=2; IntAct=EBI-3389553, EBI-287394; CC O75914-2; Q9H4E5: RHOJ; NbExp=3; IntAct=EBI-17483970, EBI-6285694; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; Synonyms=PAK3b; CC IsoId=O75914-1; Sequence=Displayed; CC Name=2; CC IsoId=O75914-2; Sequence=VSP_010242; CC Name=3; Synonyms=PAK3cb; CC IsoId=O75914-3; Sequence=VSP_041839; CC Name=4; Synonyms=PAK3c; CC IsoId=O75914-4; Sequence=VSP_041840; CC -!- TISSUE SPECIFICITY: Restricted to the nervous system. Highly expressed CC in postmitotic neurons of the developing and postnatal cerebral cortex CC and hippocampus. {ECO:0000269|PubMed:12890786}. CC -!- PTM: Autophosphorylated when activated by CDC42/p21. CC -!- PTM: Neddylated. {ECO:0000269|PubMed:20596523}. CC -!- DISEASE: Intellectual developmental disorder, X-linked 30 (XLID30) CC [MIM:300558]: A disorder characterized by significantly below average CC general intellectual functioning associated with impairments in CC adaptive behavior and manifested during the developmental period. CC Intellectual deficiency is the only primary symptom of non-syndromic X- CC linked forms, while syndromic intellectual disability presents with CC associated physical, neurological and/or psychiatric manifestations. CC {ECO:0000269|PubMed:10946356, ECO:0000269|PubMed:12884430, CC ECO:0000269|PubMed:9731525}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. STE20 subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF068864; AAC36097.1; -; mRNA. DR EMBL; AF155651; AAF67008.1; -; mRNA. DR EMBL; AB102659; BAC81128.1; -; mRNA. DR EMBL; AB102251; BAC80750.1; -; Genomic_DNA. DR EMBL; AB102252; BAC80751.1; -; Genomic_DNA. DR EMBL; AB102253; BAC80752.1; -; Genomic_DNA. DR EMBL; AB102254; BAC80753.1; -; Genomic_DNA. DR EMBL; AB102255; BAC80754.1; -; Genomic_DNA. DR EMBL; AB102256; BAC80755.1; -; Genomic_DNA. DR EMBL; AB102257; BAC80756.1; -; Genomic_DNA. DR EMBL; AB102258; BAC80757.1; -; Genomic_DNA. DR EMBL; AB102259; BAC80758.1; -; Genomic_DNA. DR EMBL; AB102260; BAC80759.1; -; Genomic_DNA. DR EMBL; AB102261; BAC80760.1; -; Genomic_DNA. DR EMBL; AB102262; BAC80761.1; -; Genomic_DNA. DR EMBL; AB102263; BAC80762.1; -; Genomic_DNA. DR EMBL; AB102264; BAC80763.1; -; Genomic_DNA. DR EMBL; AB102265; BAC80764.1; -; Genomic_DNA. DR EMBL; AB102266; BAC80765.1; -; Genomic_DNA. DR EMBL; AB102267; BAC80766.1; -; Genomic_DNA. DR EMBL; AB102268; BAC80767.1; -; Genomic_DNA. DR EMBL; AB102269; BAC80768.1; -; Genomic_DNA. DR EMBL; AB102270; BAC80769.1; -; Genomic_DNA. DR EMBL; AB102281; BAC80780.1; -; Genomic_DNA. DR EMBL; AB102282; BAC80781.1; -; Genomic_DNA. DR EMBL; AB102283; BAC80782.1; -; Genomic_DNA. DR EMBL; AB102284; BAC80783.1; -; Genomic_DNA. DR EMBL; AB102285; BAC80784.1; -; Genomic_DNA. DR EMBL; AB102286; BAC80785.1; -; Genomic_DNA. DR EMBL; AB102287; BAC80786.1; -; Genomic_DNA. DR EMBL; AB102288; BAC80787.1; -; Genomic_DNA. DR EMBL; AB102289; BAC80788.1; -; Genomic_DNA. DR EMBL; AB102290; BAC80789.1; -; Genomic_DNA. DR EMBL; AB102291; BAC80790.1; -; Genomic_DNA. DR EMBL; AB102292; BAC80791.1; -; Genomic_DNA. DR EMBL; AB102293; BAC80792.1; -; Genomic_DNA. DR EMBL; AB102294; BAC80793.1; -; Genomic_DNA. DR EMBL; AB102295; BAC80794.1; -; Genomic_DNA. DR EMBL; AB102296; BAC80795.1; -; Genomic_DNA. DR EMBL; AB102297; BAC80796.1; -; Genomic_DNA. DR EMBL; AB102298; BAC80797.1; -; Genomic_DNA. DR EMBL; AB102299; BAC80798.1; -; Genomic_DNA. DR EMBL; AB102300; BAC80799.1; -; Genomic_DNA. DR EMBL; AM943850; CAQ16016.1; -; mRNA. DR EMBL; AM943851; CAQ16017.1; -; mRNA. DR EMBL; AM943852; CAQ16018.1; -; mRNA. DR EMBL; AK290504; BAF83193.1; -; mRNA. DR EMBL; AL356578; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL357774; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL031117; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL117326; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471120; EAX02654.1; -; Genomic_DNA. DR CCDS; CCDS14554.1; -. [O75914-2] DR CCDS; CCDS48151.1; -. [O75914-3] DR CCDS; CCDS48152.1; -. [O75914-4] DR CCDS; CCDS48153.1; -. [O75914-1] DR RefSeq; NP_001121638.1; NM_001128166.3. [O75914-2] DR RefSeq; NP_001121639.1; NM_001128167.3. [O75914-2] DR RefSeq; NP_001121640.1; NM_001128168.3. [O75914-3] DR RefSeq; NP_001121644.1; NM_001128172.2. [O75914-4] DR RefSeq; NP_001121645.1; NM_001128173.3. [O75914-1] DR RefSeq; NP_001311254.1; NM_001324325.2. [O75914-2] DR RefSeq; NP_001311255.1; NM_001324326.2. [O75914-2] DR RefSeq; NP_001311256.1; NM_001324327.2. [O75914-1] DR RefSeq; NP_001311257.1; NM_001324328.2. [O75914-1] DR RefSeq; NP_001311258.1; NM_001324329.2. [O75914-1] DR RefSeq; NP_001311259.1; NM_001324330.2. [O75914-2] DR RefSeq; NP_001311260.1; NM_001324331.2. [O75914-2] DR RefSeq; NP_001311261.1; NM_001324332.2. [O75914-2] DR RefSeq; NP_001311262.1; NM_001324333.2. [O75914-1] DR RefSeq; NP_001311263.1; NM_001324334.2. [O75914-2] DR RefSeq; NP_002569.1; NM_002578.5. [O75914-2] DR RefSeq; XP_016885046.1; XM_017029557.2. [O75914-1] DR RefSeq; XP_016885052.1; XM_017029563.2. [O75914-3] DR RefSeq; XP_047298104.1; XM_047442148.1. [O75914-2] DR RefSeq; XP_047298105.1; XM_047442149.1. [O75914-2] DR RefSeq; XP_054183127.1; XM_054327152.1. [O75914-1] DR RefSeq; XP_054183134.1; XM_054327159.1. [O75914-2] DR RefSeq; XP_054183135.1; XM_054327160.1. [O75914-2] DR RefSeq; XP_054183137.1; XM_054327162.1. [O75914-3] DR PDB; 6FD3; X-ray; 1.52 A; A=261-559. DR PDBsum; 6FD3; -. DR AlphaFoldDB; O75914; -. DR SMR; O75914; -. DR BioGRID; 111099; 36. DR FunCoup; O75914; 1542. DR IntAct; O75914; 32. DR MINT; O75914; -. DR STRING; 9606.ENSP00000353864; -. DR BindingDB; O75914; -. DR ChEMBL; CHEMBL2999; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; O75914; -. DR GuidetoPHARMACOLOGY; 2135; -. DR GlyGen; O75914; 2 sites. DR iPTMnet; O75914; -. DR MetOSite; O75914; -. DR PhosphoSitePlus; O75914; -. DR BioMuta; PAK3; -. DR jPOST; O75914; -. DR MassIVE; O75914; -. DR PaxDb; 9606-ENSP00000353864; -. DR PeptideAtlas; O75914; -. DR ProteomicsDB; 50266; -. [O75914-1] DR ProteomicsDB; 50267; -. [O75914-2] DR ProteomicsDB; 50268; -. [O75914-3] DR ProteomicsDB; 50269; -. [O75914-4] DR Antibodypedia; 29512; 521 antibodies from 38 providers. DR DNASU; 5063; -. DR Ensembl; ENST00000262836.6; ENSP00000262836.4; ENSG00000077264.18. [O75914-1] DR Ensembl; ENST00000360648.8; ENSP00000353864.4; ENSG00000077264.18. [O75914-3] DR Ensembl; ENST00000372007.10; ENSP00000361077.4; ENSG00000077264.18. [O75914-2] DR Ensembl; ENST00000372010.5; ENSP00000361080.1; ENSG00000077264.18. [O75914-1] DR Ensembl; ENST00000417227.5; ENSP00000389172.1; ENSG00000077264.18. [O75914-4] DR Ensembl; ENST00000425146.5; ENSP00000401982.1; ENSG00000077264.18. [O75914-2] DR Ensembl; ENST00000446737.5; ENSP00000410853.1; ENSG00000077264.18. [O75914-2] DR Ensembl; ENST00000518291.6; ENSP00000428921.1; ENSG00000077264.18. [O75914-3] DR Ensembl; ENST00000519681.5; ENSP00000429113.1; ENSG00000077264.18. [O75914-4] DR GeneID; 5063; -. DR KEGG; hsa:5063; -. DR MANE-Select; ENST00000372007.10; ENSP00000361077.4; NM_002578.5; NP_002569.1. [O75914-2] DR UCSC; uc004eoz.3; human. [O75914-1] DR AGR; HGNC:8592; -. DR ClinPGx; PA32919; -. DR CTD; 5063; -. DR DisGeNET; 5063; -. DR GeneCards; PAK3; -. DR HGNC; HGNC:8592; PAK3. DR HPA; ENSG00000077264; Tissue enhanced (brain, pancreas, pituitary gland). DR MalaCards; PAK3; -. DR MIM; 300142; gene. DR MIM; 300558; phenotype. DR OpenTargets; ENSG00000077264; -. DR Orphanet; 528084; Non-specific syndromic intellectual disability. DR VEuPathDB; HostDB:ENSG00000077264; -. DR eggNOG; KOG0578; Eukaryota. DR GeneTree; ENSGT00950000182988; -. DR HOGENOM; CLU_000288_26_6_1; -. DR InParanoid; O75914; -. DR OMA; KKGMFTF; -. DR OrthoDB; 1022360at2759; -. DR PAN-GO; O75914; 7 GO annotations based on evolutionary models. DR PhylomeDB; O75914; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; O75914; -. DR Reactome; R-HSA-202433; Generation of second messenger molecules. DR Reactome; R-HSA-389359; CD28 dependent Vav1 pathway. DR Reactome; R-HSA-3928664; Ephrin signaling. DR Reactome; R-HSA-399954; Sema3A PAK dependent Axon repulsion. DR Reactome; R-HSA-428540; Activation of RAC1. DR Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability. DR Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling. DR Reactome; R-HSA-5627123; RHO GTPases activate PAKs. DR Reactome; R-HSA-5687128; MAPK6/MAPK4 signaling. DR Reactome; R-HSA-9013148; CDC42 GTPase cycle. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR Reactome; R-HSA-9013409; RHOJ GTPase cycle. DR Reactome; R-HSA-9013420; RHOU GTPase cycle. DR SignaLink; O75914; -. DR SIGNOR; O75914; -. DR Agora; ENSG00000077264; -. DR BioGRID-ORCS; 5063; 13 hits in 809 CRISPR screens. DR ChiTaRS; PAK3; human. DR GeneWiki; PAK3; -. DR GenomeRNAi; 5063; -. DR Pharos; O75914; Tchem. DR PRO; PR:O75914; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; O75914; protein. DR Bgee; ENSG00000077264; Expressed in middle temporal gyrus and 157 other cell types or tissues. DR ExpressionAtlas; O75914; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; TAS:Reactome. DR GO; GO:0014069; C:postsynaptic density; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004708; F:MAP kinase kinase activity; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; EXP:Reactome. DR GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW. DR GO; GO:0031267; F:small GTPase binding; IEA:Ensembl. DR GO; GO:0007409; P:axonogenesis; ISS:UniProtKB. DR GO; GO:0016477; P:cell migration; IBA:GO_Central. DR GO; GO:0009267; P:cellular response to starvation; IBA:GO_Central. DR GO; GO:0016358; P:dendrite development; ISS:UniProtKB. DR GO; GO:0060997; P:dendritic spine morphogenesis; ISS:UniProtKB. DR GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; IBA:GO_Central. DR GO; GO:0030833; P:regulation of actin filament polymerization; IDA:UniProtKB. DR GO; GO:0050770; P:regulation of axonogenesis; IBA:GO_Central. DR GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central. DR GO; GO:0099175; P:regulation of postsynapse organization; IEA:Ensembl. DR GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome. DR GO; GO:0050808; P:synapse organization; TAS:UniProtKB. DR CDD; cd01093; CRIB_PAK_like; 1. DR CDD; cd06656; STKc_PAK3; 1. DR FunFam; 1.10.510.10:FF:000011; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:000069; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.90.810.10:FF:000001; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 3.90.810.10; CRIB domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000095; CRIB_dom. DR InterPro; IPR036936; CRIB_dom_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR051931; PAK3-like. DR InterPro; IPR033923; PAK_BD. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR035063; STK_PAK3. DR PANTHER; PTHR45832; SERINE/THREONINE-PROTEIN KINASE SAMKA-RELATED-RELATED; 1. DR PANTHER; PTHR45832:SF11; SERINE_THREONINE-PROTEIN KINASE PAK 3; 1. DR Pfam; PF00786; PBD; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00285; PBD; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50108; CRIB; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Allosteric enzyme; Alternative splicing; ATP-binding; KW Cytoplasm; Developmental protein; Disease variant; Intellectual disability; KW Kinase; Magnesium; Metal-binding; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; SH3-binding; Transferase; Ubl conjugation. FT CHAIN 1..559 FT /note="Serine/threonine-protein kinase PAK 3" FT /id="PRO_0000086469" FT DOMAIN 70..83 FT /note="CRIB" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00057" FT DOMAIN 283..534 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..72 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 65..150 FT /note="Autoregulatory region" FT /evidence="ECO:0000250" FT REGION 65..123 FT /note="GTPase-binding" FT /evidence="ECO:0000250" FT REGION 84..282 FT /note="Linker" FT REGION 164..212 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 228..262 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 18..32 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 63..72 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 186..201 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 239..250 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 402 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 289..297 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 312 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 2 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62829" FT MOD_RES 50 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q62829" FT MOD_RES 154 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q62829" FT MOD_RES 186 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61036" FT MOD_RES 436 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q62829" FT VAR_SEQ 92..107 FT /note="TPDLYGSQMCPGKLPE -> TNSPFQTSRPVTVASSQSEGKM (in FT isoform 4)" FT /evidence="ECO:0000303|PubMed:18507705" FT /id="VSP_041840" FT VAR_SEQ 92 FT /note="T -> TNSPFQTSRPVTVASSQSEGKM (in isoform 3)" FT /evidence="ECO:0000303|PubMed:18507705" FT /id="VSP_041839" FT VAR_SEQ 93..107 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:9731525, ECO:0000303|Ref.2" FT /id="VSP_010242" FT VARIANT 67 FT /note="R -> C (in XLID30; dbSNP:rs121434612)" FT /evidence="ECO:0000269|PubMed:10946356" FT /id="VAR_023825" FT VARIANT 380 FT /note="A -> E (in XLID30; dbSNP:rs121434613)" FT /evidence="ECO:0000269|PubMed:12884430" FT /id="VAR_023826" FT VARIANT 440 FT /note="T -> S (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046764" FT CONFLICT 32 FT /note="S -> F (in Ref. 2; AAF67008)" FT /evidence="ECO:0000305" FT CONFLICT 36 FT /note="P -> S (in Ref. 2; AAF67008)" FT /evidence="ECO:0000305" FT CONFLICT 73 FT /note="P -> S (in Ref. 2; AAF67008)" FT /evidence="ECO:0000305" FT CONFLICT 106..107 FT /note="PE -> SL (in Ref. 2; AAF67008)" FT /evidence="ECO:0000305" FT CONFLICT 123 FT /note="T -> P (in Ref. 2; AAF67008)" FT /evidence="ECO:0000305" FT CONFLICT 127..130 FT /note="QKKN -> PEEE (in Ref. 2; AAF67008)" FT /evidence="ECO:0000305" FT CONFLICT 134..137 FT /note="VLDV -> CSRC (in Ref. 2; AAF67008)" FT /evidence="ECO:0000305" FT CONFLICT 146..148 FT /note="TVN -> PVT (in Ref. 2; AAF67008)" FT /evidence="ECO:0000305" FT CONFLICT 175 FT /note="T -> P (in Ref. 2; AAF67008)" FT /evidence="ECO:0000305" FT HELIX 263..273 FT /evidence="ECO:0007829|PDB:6FD3" FT STRAND 274..277 FT /evidence="ECO:0007829|PDB:6FD3" FT HELIX 279..281 FT /evidence="ECO:0007829|PDB:6FD3" FT STRAND 283..291 FT /evidence="ECO:0007829|PDB:6FD3" FT STRAND 293..302 FT /evidence="ECO:0007829|PDB:6FD3" FT TURN 303..305 FT /evidence="ECO:0007829|PDB:6FD3" FT STRAND 308..315 FT /evidence="ECO:0007829|PDB:6FD3" FT HELIX 316..318 FT /evidence="ECO:0007829|PDB:6FD3" FT HELIX 324..334 FT /evidence="ECO:0007829|PDB:6FD3" FT STRAND 343..349 FT /evidence="ECO:0007829|PDB:6FD3" FT STRAND 352..358 FT /evidence="ECO:0007829|PDB:6FD3" FT HELIX 365..371 FT /evidence="ECO:0007829|PDB:6FD3" FT HELIX 376..395 FT /evidence="ECO:0007829|PDB:6FD3" FT HELIX 405..407 FT /evidence="ECO:0007829|PDB:6FD3" FT STRAND 408..410 FT /evidence="ECO:0007829|PDB:6FD3" FT STRAND 416..418 FT /evidence="ECO:0007829|PDB:6FD3" FT HELIX 441..443 FT /evidence="ECO:0007829|PDB:6FD3" FT HELIX 446..449 FT /evidence="ECO:0007829|PDB:6FD3" FT HELIX 458..472 FT /evidence="ECO:0007829|PDB:6FD3" FT TURN 476..479 FT /evidence="ECO:0007829|PDB:6FD3" FT HELIX 482..492 FT /evidence="ECO:0007829|PDB:6FD3" FT HELIX 500..502 FT /evidence="ECO:0007829|PDB:6FD3" FT HELIX 505..514 FT /evidence="ECO:0007829|PDB:6FD3" FT TURN 519..521 FT /evidence="ECO:0007829|PDB:6FD3" FT HELIX 525..528 FT /evidence="ECO:0007829|PDB:6FD3" FT HELIX 532..536 FT /evidence="ECO:0007829|PDB:6FD3" FT HELIX 540..543 FT /evidence="ECO:0007829|PDB:6FD3" FT HELIX 544..555 FT /evidence="ECO:0007829|PDB:6FD3" SQ SEQUENCE 559 AA; 62310 MW; BC39AEC6F0A5478B CRC64; MSDGLDNEEK PPAPPLRMNS NNRDSSALNH SSKPLPMAPE EKNKKARLRS IFPGGGDKTN KKKEKERPEI SLPSDFEHTI HVGFDAVTGE FTPDLYGSQM CPGKLPEGIP EQWARLLQTS NITKLEQKKN PQAVLDVLKF YDSKETVNNQ KYMSFTSGDK SAHGYIAAHP SSTKTASEPP LAPPVSEEED EEEEEEEDEN EPPPVIAPRP EHTKSIYTRS VVESIASPAV PNKEVTPPSA ENANSSTLYR NTDRQRKKSK MTDEEILEKL RSIVSVGDPK KKYTRFEKIG QGASGTVYTA LDIATGQEVA IKQMNLQQQP KKELIINEIL VMRENKNPNI VNYLDSYLVG DELWVVMEYL AGGSLTDVVT ETCMDEGQIA AVCRECLQAL DFLHSNQVIH RDIKSDNILL GMDGSVKLTD FGFCAQITPE QSKRSTMVGT PYWMAPEVVT RKAYGPKVDI WSLGIMAIEM VEGEPPYLNE NPLRALYLIA TNGTPELQNP ERLSAVFRDF LNRCLEMDVD RRGSAKELLQ HPFLKLAKPL SSLTPLIIAA KEAIKNSSR // ID PGFRB_HUMAN Reviewed; 1106 AA. AC P09619; B5A957; Q8N5L4; DT 01-JUL-1989, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-1989, sequence version 1. DT 28-JAN-2026, entry version 269. DE RecName: Full=Platelet-derived growth factor receptor beta; DE Short=PDGF-R-beta; DE Short=PDGFR-beta; DE EC=2.7.10.1; DE AltName: Full=Beta platelet-derived growth factor receptor; DE AltName: Full=Beta-type platelet-derived growth factor receptor; DE AltName: Full=CD140 antigen-like family member B; DE AltName: Full=Platelet-derived growth factor receptor 1; DE Short=PDGFR-1; DE AltName: CD_antigen=CD140b; DE Flags: Precursor; GN Name=PDGFRB; Synonyms=PDGFR, PDGFR1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION AS PDGFB RECEPTOR, RP SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND INTERACTION WITH PDGFB. RX PubMed=2835772; DOI=10.1073/pnas.85.10.3435; RA Gronwald R.G.K., Grant F.J., Haldeman B.A., Hart C.E., O'Hara P.J., RA Hagen F.S., Ross R., Bowen-Pope D.F., Murray M.J.; RT "Cloning and expression of a cDNA coding for the human platelet-derived RT growth factor receptor: evidence for more than one receptor class."; RL Proc. Natl. Acad. Sci. U.S.A. 85:3435-3439(1988). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION AS PDGFB RECEPTOR, RP SUBCELLULAR LOCATION, GLYCOSYLATION, AUTOPHOSPHORYLATION, AND INTERACTION RP WITH PDGFA AND PDGFB. RX PubMed=2850496; DOI=10.1128/mcb.8.8.3476-3486.1988; RA Claesson-Welsh L., Eriksson A., Moren A., Severinsson L., Ek B., RA Oestman A., Betsholtz C., Heldin C.-H.; RT "cDNA cloning and expression of a human platelet-derived growth factor RT (PDGF) receptor specific for B-chain-containing PDGF molecules."; RL Mol. Cell. Biol. 8:3476-3486(1988). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING. RX PubMed=18593464; DOI=10.1186/ar2447; RA Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., RA Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.; RT "Novel splice variants derived from the receptor tyrosine kinase RT superfamily are potential therapeutics for rheumatoid arthritis."; RL Arthritis Res. Ther. 10:R73-R73(2008). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT PHE-180. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 548-569. RX PubMed=9285559; DOI=10.1038/sj.onc.1201267; RA Chi K.D., McPhee R.A., Wagner A.S., Dietz J.J., Pantazis P., Goustin A.S.; RT "Integration of proviral DNA into the PDGF beta-receptor gene in HTLV-I- RT infected T-cells results in a novel tyrosine kinase product with RT transforming activity."; RL Oncogene 15:1051-1057(1997). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 559-1106 (ISOFORM 1), AND CHROMOSOMAL RP TRANSLOCATION WITH CEP85L. RX PubMed=21938754; DOI=10.1002/gcc.20930; RA Chmielecki J., Peifer M., Viale A., Hutchinson K., Giltnane J., Socci N.D., RA Hollis C.J., Dean R.S., Yenamandra A., Jagasia M., Kim A.S., Dave U.P., RA Thomas R.K., Pao W.; RT "Systematic screen for tyrosine kinase rearrangements identifies a novel RT C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated RT myeloproliferative neoplasm."; RL Genes Chromosomes Cancer 51:54-65(2012). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1046-1106. RX PubMed=2846185; DOI=10.1016/0092-8674(88)90224-3; RA Roberts W.M., Look A.T., Roussel M.F., Sherr C.J.; RT "Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor genes."; RL Cell 55:655-661(1988). RN [9] RP PROTEIN SEQUENCE OF 33-47. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [10] RP PHOSPHORYLATION AT TYR-751 AND TYR-857. RX PubMed=2550144; DOI=10.1016/0092-8674(89)90510-2; RA Kazlauskas A., Cooper J.A.; RT "Autophosphorylation of the PDGF receptor in the kinase insert region RT regulates interactions with cell proteins."; RL Cell 58:1121-1133(1989). RN [11] RP FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION AND CHEMOTAXIS, AND RP SUBCELLULAR LOCATION. RX PubMed=2554309; DOI=10.1073/pnas.86.21.8314; RA Matsui T., Pierce J.H., Fleming T.P., Greenberger J.S., LaRochelle W.J., RA Ruggiero M., Aaronson S.A.; RT "Independent expression of human alpha or beta platelet-derived growth RT factor receptor cDNAs in a naive hematopoietic cell leads to functional RT coupling with mitogenic and chemotactic signaling pathways."; RL Proc. Natl. Acad. Sci. U.S.A. 86:8314-8318(1989). RN [12] RP FUNCTION IN CELL PROLIFERATION; ACTIVATION OF PLCG1 AND IN PHOSPHORYLATION RP OF PLCG1 AND RASA1/GAP, AND MUTAGENESIS OF TYR-751 AND TYR-857. RX PubMed=1653029; DOI=10.1091/mbc.2.6.413; RA Kazlauskas A., Durden D.L., Cooper J.A.; RT "Functions of the major tyrosine phosphorylation site of the PDGF receptor RT beta subunit."; RL Cell Regul. 2:413-425(1991). RN [13] RP INTERACTION WITH PDGFRA; PDGFA AND PDGFB, FUNCTION AS RECEPTOR FOR PDGFA RP AND PDGFB, AND PHOSPHORYLATION AT TYR-857 AND TYR-751. RX PubMed=1709159; DOI=10.1016/s0021-9258(18)31541-2; RA Kelly J.D., Haldeman B.A., Grant F.J., Murray M.J., Seifert R.A., RA Bowen-Pope D.F., Cooper J.A., Kazlauskas A.; RT "Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit RT dimerization and intersubunit trans-phosphorylation."; RL J. Biol. Chem. 266:8987-8992(1991). RN [14] RP FUNCTION AS RECEPTOR FOR PDGFA AND PDGFB, SUBCELLULAR LOCATION, CATALYTIC RP ACTIVITY, AND MUTAGENESIS OF LYS-634. RX PubMed=1846866; DOI=10.1083/jcb.112.3.469; RA Sorkin A., Westermark B., Heldin C.H., Claesson-Welsh L.; RT "Effect of receptor kinase inactivation on the rate of internalization and RT degradation of PDGF and the PDGF beta-receptor."; RL J. Cell Biol. 112:469-478(1991). RN [15] RP FUNCTION IN ACTIVATION OF PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY, RP INTERACTION WITH PIK3R1 AND RASA1, PHOSPHORYLATION AT TYR-740; TYR-751; RP TYR-771 AND TYR-857, AND MUTAGENESIS OF LYS-634; TYR-716; TYR-740; TYR-751; RP TYR-763; TYR-771; TYR-775; TYR-778 AND TYR-857. RX PubMed=1314164; DOI=10.1002/j.1460-2075.1992.tb05182.x; RA Kashishian A., Kazlauskas A., Cooper J.A.; RT "Phosphorylation sites in the PDGF receptor with different specificities RT for binding GAP and PI3 kinase in vivo."; RL EMBO J. 11:1373-1382(1992). RN [16] RP FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION AND PHOSPHORYLATION OF RP PLCG1, INTERACTION WITH PLCG1, PHOSPHORYLATION AT TYR-1009 AND TYR-1021, RP AND MUTAGENESIS OF TYR-1009 AND TYR-1021. RX PubMed=1396585; DOI=10.1002/j.1460-2075.1992.tb05484.x; RA Ronnstrand L., Mori S., Arridsson A.K., Eriksson A., Wernstedt C., RA Hellman U., Claesson-Welsh L., Heldin C.H.; RT "Identification of two C-terminal autophosphorylation sites in the PDGF RT beta-receptor: involvement in the interaction with phospholipase C-gamma."; RL EMBO J. 11:3911-3919(1992). RN [17] RP UBIQUITINATION, AND DEGRADATION. RX PubMed=1313434; DOI=10.1016/s0021-9258(18)42714-7; RA Mori S., Heldin C.H., Claesson-Welsh L.; RT "Ligand-induced polyubiquitination of the platelet-derived growth factor RT beta-receptor."; RL J. Biol. Chem. 267:6429-6434(1992). RN [18] RP INTERACTION WITH PIK3R1 AND RASA1, AND MUTAGENESIS OF TYR-740; TYR-751 AND RP TYR-771. RX PubMed=1375321; DOI=10.1128/mcb.12.6.2534-2544.1992; RA Kazlauskas A., Kashishian A., Cooper J.A., Valius M.; RT "GTPase-activating protein and phosphatidylinositol 3-kinase bind to RT distinct regions of the platelet-derived growth factor receptor beta RT subunit."; RL Mol. Cell. Biol. 12:2534-2544(1992). RN [19] RP FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION, PHOSPHORYLATION AT RP TYR-579 AND TYR-581; INTERACTION WITH SRC, CATALYTIC ACTIVITY, AND RP MUTAGENESIS OF TYR-579 AND TYR-581. RX PubMed=7685273; DOI=10.1002/j.1460-2075.1993.tb05879.x; RA Mori S., Ronnstrand L., Yokote K., Engstrom A., Courtneidge S.A., RA Claesson-Welsh L., Heldin C.H.; RT "Identification of two juxtamembrane autophosphorylation sites in the PDGF RT beta-receptor; involvement in the interaction with Src family tyrosine RT kinases."; RL EMBO J. 12:2257-2264(1993). RN [20] RP INTERACTION WITH DGFA AND PDGFB. RX PubMed=7679113; DOI=10.1016/s0021-9258(18)53739-x; RA Fretto L.J., Snape A.J., Tomlinson J.E., Seroogy J.J., Wolf D.L., RA LaRochelle W.J., Giese N.A.; RT "Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB binding RT to alpha and beta PDGF receptor."; RL J. Biol. Chem. 268:3625-3631(1993). RN [21] RP FUNCTION IN PHOSPHORYLATION AND ACTIVATION OF PTPN11, INTERACTION WITH RP PTPN11; PIK3R1; PLCG1 AND RASA1, AND MUTAGENESIS OF TYR-1009. RX PubMed=7691811; DOI=10.1016/s0021-9258(20)80562-6; RA Lechleider R.J., Sugimoto S., Bennett A.M., Kashishian A.S., Cooper J.A., RA Shoelson S.E., Walsh C.T., Neel B.G.; RT "Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by RT its binding site, phosphotyrosine 1009, on the human platelet-derived RT growth factor receptor."; RL J. Biol. Chem. 268:21478-21481(1993). RN [22] RP INTERACTION WITH NCK1 AND PIK3R1, FUNCTION IN PHOSPHORYLATION OF NCK1, AND RP MUTAGENESIS OF TYR-751. RX PubMed=7692233; DOI=10.1128/mcb.13.11.6889-6896.1993; RA Nishimura R., Li W., Kashishian A., Mondino A., Zhou M., Cooper J., RA Schlessinger J.; RT "Two signaling molecules share a phosphotyrosine-containing binding site in RT the platelet-derived growth factor receptor."; RL Mol. Cell. Biol. 13:6889-6896(1993). RN [23] RP INTERACTION WITH SHB. RX PubMed=8302579; RA Welsh M., Mares J., Karlsson T., Lavergne C., Breant B., Claesson-Welsh L.; RT "Shb is a ubiquitously expressed Src homology 2 protein."; RL Oncogene 9:19-27(1994). RN [24] RP INTERACTION WITH GRB7. RX PubMed=8940081; DOI=10.1074/jbc.271.48.30942; RA Yokote K., Margolis B., Heldin C.H., Claesson-Welsh L.; RT "Grb7 is a downstream signaling component of platelet-derived growth factor RT alpha- and beta-receptors."; RL J. Biol. Chem. 271:30942-30949(1996). RN [25] RP CHROMOSOMAL TRANSLOCATION WITH TRIP11. RX PubMed=9373237; RA Abe A., Emi N., Tanimoto M., Terasaki H., Marunouchi T., Saito H.; RT "Fusion of the platelet-derived growth factor receptor beta to a novel gene RT CEV14 in acute myelogenous leukemia after clonal evolution."; RL Blood 90:4271-4277(1997). RN [26] RP INTERACTION WITH GRB10, AND MUTAGENESIS OF TYR-579; TYR-581; TYR-716; RP TYR-740; TYR-751; TYR-771; TYR-857; TYR-1009 AND TYR-1021. RX PubMed=10454568; DOI=10.1128/mcb.19.9.6217; RA Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A., RA Swamy O.R., Leone M.E., Riedel H.; RT "Grb10, a positive, stimulatory signaling adapter in platelet-derived RT growth factor BB-, insulin-like growth factor I-, and insulin-mediated RT mitogenesis."; RL Mol. Cell. Biol. 19:6217-6228(1999). RN [27] RP INTERACTION WITH SH2B2/APS. RX PubMed=9989826; DOI=10.1038/sj.onc.1202326; RA Yokouchi M., Wakioka T., Sakamoto H., Yasukawa H., Ohtsuka S., Sasaki A., RA Ohtsubo M., Valius M., Inoue A., Komiya S., Yoshimura A.; RT "APS, an adaptor protein containing PH and SH2 domains, is associated with RT the PDGF receptor and c-Cbl and inhibits PDGF-induced mitogenesis."; RL Oncogene 18:759-767(1999). RN [28] RP PHOSPHORYLATION AT TYR-562; TYR-751; TYR-763; TYR-771; TYR-775; TYR-778; RP TYR-857; TYR-1009 AND TYR-1021, AND DEPHOSPHORYLATION AT TYR-751; TYR-857; RP TYR-1009 AND TYR-1021 BY PTPRJ. RX PubMed=10821867; DOI=10.1074/jbc.275.21.16219; RA Kovalenko M., Denner K., Sandstrom J., Persson C., Gross S., Jandt E., RA Vilella R., Bohmer F., Ostman A.; RT "Site-selective dephosphorylation of the platelet-derived growth factor RT beta-receptor by the receptor-like protein-tyrosine phosphatase DEP-1."; RL J. Biol. Chem. 275:16219-16226(2000). RN [29] RP INTERACTION WITH PIK3C2B. RX PubMed=10805725; DOI=10.1128/mcb.20.11.3817-3830.2000; RA Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D., RA Domin J.; RT "Class II phosphoinositide 3-kinases are downstream targets of activated RT polypeptide growth factor receptors."; RL Mol. Cell. Biol. 20:3817-3830(2000). RN [30] RP FUNCTION AS A RECEPTOR FOR PDGFC, AND INTERACTION WITH PDGFC. RX PubMed=11297552; DOI=10.1074/jbc.m101056200; RA Gilbertson D.G., Duff M.E., West J.W., Kelly J.D., Sheppard P.O., RA Hofstrand P.D., Gao Z., Shoemaker K., Bukowski T.R., Moore M., RA Feldhaus A.L., Humes J.M., Palmer T.E., Hart C.E.; RT "Platelet-derived growth factor C (PDGF-C), a novel growth factor that RT binds to PDGF alpha and beta receptor."; RL J. Biol. Chem. 276:27406-27414(2001). RN [31] RP FUNCTION AS A RECEPTOR FOR PDGFD. RX PubMed=11331881; DOI=10.1038/35074588; RA Bergsten E., Uutela M., Li X., Pietras K., Oestman A., Heldin C.-H., RA Alitalo K., Eriksson U.; RT "PDGF-D is a specific, protease-activated ligand for the PDGF beta- RT receptor."; RL Nat. Cell Biol. 3:512-516(2001). RN [32] RP CHROMOSOMAL TRANSLOCATION WITH ETV6. RX PubMed=12181402; DOI=10.1056/nejmoa020150; RA Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., RA Baxter E.J., Chase A., Chessells J.M., Colombat M., Dearden C.E., RA Dimitrijevic S., Mahon F.-X., Marin D., Nikolova Z., Olavarria E., RA Silberman S., Schultheis B., Cross N.C.P., Goldman J.M.; RT "Response to imatinib mesylate in patients with chronic myeloproliferative RT diseases with rearrangements of the platelet-derived growth factor receptor RT beta."; RL N. Engl. J. Med. 347:481-487(2002). RN [33] RP CHROMOSOMAL TRANSLOCATION WITH PDE4DIP. RX PubMed=12907457; DOI=10.1182/blood-2003-04-1150; RA Wilkinson K., Velloso E.R.P., Lopes L.F., Lee C., Aster J.C., Shipp M.A., RA Aguiar R.C.T.; RT "Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated RT with eosinophilia: involvement of PDGFRB and response to imatinib."; RL Blood 102:4187-4190(2003). RN [34] RP CHROMOSOMAL TRANSLOCATION WITH SPECC1. RX PubMed=15087372; DOI=10.1158/0008-5472.can-03-4026; RA Morerio C., Acquila M., Rosanda C., Rapella A., Dufour C., Locatelli F., RA Maserati E., Pasquali F., Panarello C.; RT "HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic RT leukemia with t(5;17)(q33;p11.2)."; RL Cancer Res. 64:2649-2651(2004). RN [35] RP CHROMOSOMAL TRANSLOCATION WITH TP53BP1, AND ACTIVITY REGULATION. RX PubMed=15492236; DOI=10.1158/0008-5472.can-04-2005; RA Grand F.H., Burgstaller S., Kuhr T., Baxter E.J., Webersinke G., Thaler J., RA Chase A.J., Cross N.C.; RT "p53-Binding protein 1 is fused to the platelet-derived growth factor RT receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib- RT responsive eosinophilic myeloproliferative disorder."; RL Cancer Res. 64:7216-7219(2004). RN [36] RP PHOSPHORYLATION AT TYR-579; TYR-751; TYR-771 AND TYR-1021, AND RP DEPHOSPHORYLATION AT TYR-579 AND TYR-1021 BY PTPN2. RX PubMed=14966296; DOI=10.1128/mcb.24.5.2190-2201.2004; RA Persson C., Saevenhed C., Bourdeau A., Tremblay M.L., Markova B., RA Boehmer F.D., Haj F.G., Neel B.G., Elson A., Heldin C.H., Roennstrand L., RA Ostman A., Hellberg C.; RT "Site-selective regulation of platelet-derived growth factor beta receptor RT tyrosine phosphorylation by T-cell protein tyrosine phosphatase."; RL Mol. Cell. Biol. 24:2190-2201(2004). RN [37] RP PHOSPHORYLATION AT TYR-579; TYR-581; TYR-716; TYR-740; TYR-771; TYR-857; RP TYR-1009 AND TYR-1021. RX PubMed=15902258; DOI=10.1038/nature03587; RA Choi M.H., Lee I.K., Kim G.W., Kim B.U., Han Y.H., Yu D.Y., Park H.S., RA Kim K.Y., Lee J.S., Choi C., Bae Y.S., Lee B.I., Rhee S.G., Kang S.W.; RT "Regulation of PDGF signalling and vascular remodelling by peroxiredoxin RT II."; RL Nature 435:347-353(2005). RN [38] RP INTERACTION WITH CBL, SUBCELLULAR LOCATION, MUTAGENESIS OF TYR-1021, AND RP UBIQUITINATION. RX PubMed=17620338; DOI=10.1074/jbc.m701797200; RA Reddi A.L., Ying G., Duan L., Chen G., Dimri M., Douillard P., Druker B.J., RA Naramura M., Band V., Band H.; RT "Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived RT growth factor receptor beta provides a dual mechanism of negative RT regulation."; RL J. Biol. Chem. 282:29336-29347(2007). RN [39] RP FUNCTION AS PDGFD RECEPTOR. RX PubMed=21098708; DOI=10.1158/0008-5472.can-10-0511; RA Ustach C.V., Huang W., Conley-LaComb M.K., Lin C.Y., Che M., Abrams J., RA Kim H.R.; RT "A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human prostate RT cancer."; RL Cancer Res. 70:9631-9640(2010). RN [40] RP FUNCTION IN PHOSPHORYLATION OF CBL; STAM; PDCD6IP/ALIX; PLCG1 AND PTPN11, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF LYS-634 AND TYR-857. RX PubMed=20494825; DOI=10.1016/j.cellsig.2010.05.004; RA Wardega P., Heldin C.H., Lennartsson J.; RT "Mutation of tyrosine residue 857 in the PDGF beta-receptor affects cell RT proliferation but not migration."; RL Cell. Signal. 22:1363-1368(2010). RN [41] RP FUNCTION. RX PubMed=20529858; DOI=10.1074/jbc.m110.102566; RA Mendelson K., Swendeman S., Saftig P., Blobel C.P.; RT "Stimulation of platelet-derived growth factor receptor beta (PDGFRbeta) RT activates ADAM17 and promotes metalloproteinase-dependent cross-talk RT between the PDGFRbeta and epidermal growth factor receptor (EGFR) signaling RT pathways."; RL J. Biol. Chem. 285:25024-25032(2010). RN [42] RP FUNCTION IN SMOOTH MUSCLE CELL PROLIFERATION AND MIGRATION. RX PubMed=21733313; DOI=10.1017/s0007114511002571; RA Kim H.J., Cha B.Y., Choi B., Lim J.S., Woo J.T., Kim J.S.; RT "Glyceollins inhibit platelet-derived growth factor-mediated human arterial RT smooth muscle cell proliferation and migration."; RL Br. J. Nutr. 107:24-35(2012). RN [43] RP INTERACTION WITH SHC1 AND GRB2, AND FUNCTION IN PHOSPHORYLATION OF SHC1. RX PubMed=8195171; DOI=10.1016/s0021-9258(17)36611-5; RA Yokote K., Mori S., Hansen K., McGlade J., Pawson T., Heldin C.H., RA Claesson-Welsh L.; RT "Direct interaction between Shc and the platelet-derived growth factor RT beta-receptor."; RL J. Biol. Chem. 269:15337-15343(1994). RN [44] RP FUNCTION IN SMOOTH MUSCLE CELL MIGRATION AND NEOINTIMA FORMATION AFTER RP BLOOD VESSEL INJURY, AND MUTAGENESIS OF TYR-740; TYR-751 AND TYR-1021. RX PubMed=21679854; DOI=10.1016/j.jacc.2011.02.037; RA Caglayan E., Vantler M., Leppanen O., Gerhardt F., Mustafov L., RA Ten Freyhaus H., Kappert K., Odenthal M., Zimmermann W.H., Tallquist M.D., RA Rosenkranz S.; RT "Disruption of platelet-derived growth factor-dependent RT phosphatidylinositol 3-kinase and phospholipase Cgamma 1 activity abolishes RT vascular smooth muscle cell proliferation and migration and attenuates RT neointima formation in vivo."; RL J. Am. Coll. Cardiol. 57:2527-2538(2011). RN [45] RP INVOLVEMENT IN PENTT, VARIANT PENTT ALA-665, AND CHARACTERIZATION OF RP VARIANT PENTT ALA-665. RX PubMed=26279204; DOI=10.1016/j.ajhg.2015.07.009; RA Johnston J.J., Sanchez-Contreras M.Y., Keppler-Noreuil K.M., Sapp J., RA Crenshaw M., Finch N.A., Cormier-Daire V., Rademakers R., Sybert V.P., RA Biesecker L.G.; RT "A point mutation in PDGFRB causes autosomal-dominant Penttinen syndrome."; RL Am. J. Hum. Genet. 97:465-474(2015). RN [46] RP INVOLVEMENT IN KOGS, AND VARIANT KOGS ARG-584. RX PubMed=25454926; DOI=10.1016/j.jpeds.2014.10.015; RA Takenouchi T., Yamaguchi Y., Tanikawa A., Kosaki R., Okano H., Kosaki K.; RT "Novel overgrowth syndrome phenotype due to recurrent de novo PDGFRB RT mutation."; RL J. Pediatr. 166:483-486(2015). RN [47] RP CHARACTERIZATION OF VARIANTS IBGC4 PRO-658; TRP-987 AND VAL-1071, AND RP FUNCTION. RX PubMed=26599395; DOI=10.1371/journal.pone.0143407; RA Vanlandewijck M., Lebouvier T., Andaloussi Maee M., Nahar K., Hornemann S., RA Kenkel D., Cunha S.I., Lennartsson J., Boss A., Heldin C.H., Keller A., RA Betsholtz C.; RT "Functional characterization of germline mutations in PDGFB and PDGFRB in RT primary familial brain calcification."; RL PLoS ONE 10:E0143407-E0143407(2015). RN [48] RP REVIEW ON SIGNALING AND AUTOPHOSPHORYLATION. RX PubMed=9739761; DOI=10.1016/s0304-419x(98)00015-8; RA Heldin C.H., Ostman A., Ronnstrand L.; RT "Signal transduction via platelet-derived growth factor receptors."; RL Biochim. Biophys. Acta 1378:F79-113(1998). RN [49] RP REVIEW. RX PubMed=15207817; DOI=10.1016/j.cytogfr.2004.03.002; RA Ostman A.; RT "PDGF receptors-mediators of autocrine tumor growth and regulators of tumor RT vasculature and stroma."; RL Cytokine Growth Factor Rev. 15:275-286(2004). RN [50] RP REVIEW. RX PubMed=17419949; DOI=10.1016/s0065-230x(06)97011-0; RA Ostman A., Heldin C.H.; RT "PDGF receptors as targets in tumor treatment."; RL Adv. Cancer Res. 97:247-274(2007). RN [51] RP REVIEW ON FUNCTION; LIGANDS; ROLE IN DEVELOPMENT AND DISEASE AND ACTIVATION RP OF SIGNALING PATHWAYS. RX PubMed=18483217; DOI=10.1101/gad.1653708; RA Andrae J., Gallini R., Betsholtz C.; RT "Role of platelet-derived growth factors in physiology and medicine."; RL Genes Dev. 22:1276-1312(2008). RN [52] RP X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 751-755 IN COMPLEX WITH PIK3R1, RP AND COMPARISON WITH NMR ANALYSIS. RX PubMed=11567151; DOI=10.1107/s0907444901012434; RA Pauptit R.A., Dennis C.A., Derbyshire D.J., Breeze A.L., Weston S.A., RA Rowsell S., Murshudov G.N.; RT "NMR trial models: experiences with the colicin immunity protein Im7 and RT the p85alpha C-terminal SH2-peptide complex."; RL Acta Crystallogr. D 57:1397-1404(2001). RN [53] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1102-1106 IN COMPLEX WITH NHERF1, RP AND INTERACTION WITH NHERF1. RX PubMed=11882663; DOI=10.1074/jbc.m201507200; RA Karthikeyan S., Leung T., Ladias J.A.A.; RT "Structural determinants of the Na+/H+ exchanger regulatory factor RT interaction with the beta 2 adrenergic and platelet-derived growth factor RT receptors."; RL J. Biol. Chem. 277:18973-18978(2002). RN [54] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 33-314 IN COMPLEX WITH PDGFB, RP SUBUNIT, GLYCOSYLATION AT ASN-45; ASN-89; ASN-103; ASN-215; ASN-230; RP ASN-292 AND ASN-307, AND DISULFIDE BONDS. RX PubMed=20534510; DOI=10.1073/pnas.1000806107; RA Shim A.H., Liu H., Focia P.J., Chen X., Lin P.C., He X.; RT "Structures of a platelet-derived growth factor/propeptide complex and a RT platelet-derived growth factor/receptor complex."; RL Proc. Natl. Acad. Sci. U.S.A. 107:11307-11312(2010). RN [55] RP VARIANTS [LARGE SCALE ANALYSIS] PHE-29; LYS-282; LYS-485; HIS-589; TYR-718 RP AND ILE-882. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [56] RP VARIANT IMF1 THR-660, AND INVOLVEMENT IN IMF1. RX PubMed=23731542; DOI=10.1016/j.ajhg.2013.04.024; RA Martignetti J.A., Tian L., Li D., Ramirez M.C., Camacho-Vanegas O., RA Camacho S.C., Guo Y., Zand D.J., Bernstein A.M., Masur S.K., Kim C.E., RA Otieno F.G., Hou C., Abdel-Magid N., Tweddale B., Metry D., Fournet J.C., RA Papp E., McPherson E.W., Zabel C., Vaksmann G., Morisot C., Keating B., RA Sleiman P.M., Cleveland J.A., Everman D.B., Zackai E., Hakonarson H.; RT "Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis."; RL Am. J. Hum. Genet. 92:1001-1007(2013). RN [57] RP VARIANT IMF1 CYS-561, AND INVOLVEMENT IN IMF1. RX PubMed=23731537; DOI=10.1016/j.ajhg.2013.04.026; RA Cheung Y.H., Gayden T., Campeau P.M., Leduc C.A., Russo D., Nguyen V.H., RA Guo J., Qi M., Guan Y., Albrecht S., Moroz B., Eldin K.W., Lu J.T., RA Schwartzentruber J., Malkin D., Berghuis A.M., Emil S., Gibbs R.A., RA Burk D.L., Vanstone M., Lee B.H., Orchard D., Boycott K.M., Chung W.K., RA Jabado N.; RT "A recurrent PDGFRB mutation causes familial infantile myofibromatosis."; RL Am. J. Hum. Genet. 92:996-1000(2013). RN [58] RP VARIANTS IBGC4 PRO-658; TRP-987 AND VAL-1071, AND INVOLVEMENT IN IBGC4. RX PubMed=24065723; DOI=10.1093/brain/awt255; RG French IBGC Study Group; RA Nicolas G., Pottier C., Charbonnier C., Guyant-Marechal L., Le Ber I., RA Pariente J., Labauge P., Ayrignac X., Defebvre L., Maltete D., RA Martinaud O., Lefaucheur R., Guillin O., Wallon D., Chaumette B., RA Rondepierre P., Derache N., Fromager G., Schaeffer S., Krystkowiak P., RA Verny C., Jurici S., Sauvee M., Verin M., Lebouvier T., Rouaud O., RA Thauvin-Robinet C., Rousseau S., Rovelet-Lecrux A., Frebourg T., RA Campion D., Hannequin D.; RT "Phenotypic spectrum of probable and genetically-confirmed idiopathic basal RT ganglia calcification."; RL Brain 136:3395-3407(2013). RN [59] RP VARIANTS IBGC4 PRO-658 AND TRP-987, AND INVOLVEMENT IN IBGC4. RX PubMed=23255827; DOI=10.1212/wnl.0b013e31827ccf34; RA Nicolas G., Pottier C., Maltete D., Coutant S., Rovelet-Lecrux A., RA Legallic S., Rousseau S., Vaschalde Y., Guyant-Marechal L., Augustin J., RA Martinaud O., Defebvre L., Krystkowiak P., Pariente J., Clanet M., RA Labauge P., Ayrignac X., Lefaucheur R., Le Ber I., Frebourg T., RA Hannequin D., Campion D.; RT "Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia RT calcification."; RL Neurology 80:181-187(2013). RN [60] RP VARIANT PENTT SER-666, CHARACTERIZATION OF VARIANT PENTT SER-666, AND RP INVOLVEMENT IN PENTT. RX PubMed=30573803; DOI=10.1038/s41431-018-0323-z; RA Bredrup C., Stokowy T., McGaughran J., Lee S., Sapkota D., Cristea I., RA Xu L., Tveit K.S., Hoevding G., Steen V.M., Roedahl E., Bruland O., RA Houge G.; RT "A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a RT progeria-like condition in the severe end of Penttinen syndrome."; RL Eur. J. Hum. Genet. 27:574-581(2019). RN [61] RP VARIANT OPDKD TYR-666, CHARACTERIZATION OF VARIANT OPDKD TYR-666, AND RP INVOLVEMENT IN OPDKD. RX PubMed=33450762; DOI=10.1093/hmg/ddab014; RA Bredrup C., Cristea I., Safieh L.A., Di Maria E., Gjertsen B.T., RA Tveit K.S., Thu F., Bull N., Edward D.P., Hennekam R.C.M., Hoevding G., RA Haugen O.H., Houge G., Roedahl E., Bruland O.; RT "Temperature-dependent autoactivation associated with clinical variability RT of PDGFRB Asn666 substitutions."; RL Hum. Mol. Genet. 30:72-77(2021). CC -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor CC for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA CC and PDGFB, and plays an essential role in the regulation of embryonic CC development, cell proliferation, survival, differentiation, chemotaxis CC and migration. Plays an essential role in blood vessel development by CC promoting proliferation, migration and recruitment of pericytes and CC smooth muscle cells to endothelial cells. Plays a role in the migration CC of vascular smooth muscle cells and the formation of neointima at CC vascular injury sites. Required for normal development of the CC cardiovascular system. Required for normal recruitment of pericytes CC (mesangial cells) in the kidney glomerulus, and for normal formation of CC a branched network of capillaries in kidney glomeruli. Promotes CC rearrangement of the actin cytoskeleton and the formation of membrane CC ruffles. Binding of its cognate ligands - homodimeric PDGFB, CC heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD -leads to CC the activation of several signaling cascades; the response depends on CC the nature of the bound ligand and is modulated by the formation of CC heterodimers between PDGFRA and PDGFRB. Phosphorylates PLCG1, PIK3R1, CC PTPN11, RASA1/GAP, CBL, SHC1 and NCK1. Activation of PLCG1 leads to the CC production of the cellular signaling molecules diacylglycerol and CC inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the CC activation of protein kinase C. Phosphorylation of PIK3R1, the CC regulatory subunit of phosphatidylinositol 3-kinase, leads to the CC activation of the AKT1 signaling pathway. Phosphorylation of SHC1, or CC of the C-terminus of PTPN11, creates a binding site for GRB2, resulting CC in the activation of HRAS, RAF1 and down-stream MAP kinases, including CC MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation and activation CC of SRC family kinases. Promotes phosphorylation of PDCD6IP/ALIX and CC STAM. Receptor signaling is down-regulated by protein phosphatases that CC dephosphorylate the receptor and its down-stream effectors, and by CC rapid internalization of the activated receptor. CC {ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:11331881, CC ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1396585, CC ECO:0000269|PubMed:1653029, ECO:0000269|PubMed:1709159, CC ECO:0000269|PubMed:1846866, ECO:0000269|PubMed:20494825, CC ECO:0000269|PubMed:20529858, ECO:0000269|PubMed:21098708, CC ECO:0000269|PubMed:21679854, ECO:0000269|PubMed:21733313, CC ECO:0000269|PubMed:2554309, ECO:0000269|PubMed:26599395, CC ECO:0000269|PubMed:2835772, ECO:0000269|PubMed:2850496, CC ECO:0000269|PubMed:7685273, ECO:0000269|PubMed:7691811, CC ECO:0000269|PubMed:7692233, ECO:0000269|PubMed:8195171}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:1846866, ECO:0000269|PubMed:20494825, CC ECO:0000269|PubMed:7685273}; CC -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence CC of bound ligand. Binding of PDGFB and/or PDGFD leads to dimerization CC and activation by autophosphorylation on tyrosine residues. Inhibited CC by imatinib. {ECO:0000269|PubMed:15492236}. CC -!- SUBUNIT: Interacts with homodimeric PDGFB and PDGFD, and with CC heterodimers formed by PDGFA and PDGFB. May also interact with CC homodimeric PDGFC. Monomer in the absence of bound ligand. Interaction CC with homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or CC homodimeric PDGFD, leads to receptor dimerization, where both PDGFRA CC homodimers and heterodimers with PDGFRB are observed. Interacts with CC SH2B2/APS. Interacts directly (tyrosine phosphorylated) with SHB. CC Interacts (tyrosine phosphorylated) with PIK3R1 and RASA1. Interacts CC (tyrosine phosphorylated) with CBL. Interacts (tyrosine phosphorylated) CC with SRC and SRC family kinases. Interacts (tyrosine phosphorylated) CC with PIK3C2B, maybe indirectly. Interacts (tyrosine phosphorylated) CC with SHC1, GRB7, GRB10 and NCK1. Interaction with GRB2 is mediated by CC SHC1. Interacts (via C-terminus) with NHERF1. CC {ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:10805725, CC ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:11567151, CC ECO:0000269|PubMed:11882663, ECO:0000269|PubMed:1314164, CC ECO:0000269|PubMed:1375321, ECO:0000269|PubMed:1396585, CC ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:17620338, CC ECO:0000269|PubMed:20534510, ECO:0000269|PubMed:2835772, CC ECO:0000269|PubMed:2850496, ECO:0000269|PubMed:7679113, CC ECO:0000269|PubMed:7691811, ECO:0000269|PubMed:7692233, CC ECO:0000269|PubMed:8195171, ECO:0000269|PubMed:8302579, CC ECO:0000269|PubMed:8940081, ECO:0000269|PubMed:9989826}. CC -!- INTERACTION: CC P09619; P05067: APP; NbExp=3; IntAct=EBI-641237, EBI-77613; CC P09619; Q8TAP6: CEP76; NbExp=3; IntAct=EBI-641237, EBI-742887; CC P09619; P06241: FYN; NbExp=3; IntAct=EBI-641237, EBI-515315; CC P09619; Q14451: GRB7; NbExp=4; IntAct=EBI-641237, EBI-970191; CC P09619; P14778: IL1R1; NbExp=2; IntAct=EBI-641237, EBI-525905; CC P09619; P35968: KDR; NbExp=2; IntAct=EBI-641237, EBI-1005487; CC P09619; Q53G59: KLHL12; NbExp=6; IntAct=EBI-641237, EBI-740929; CC P09619; Q5T749: KPRP; NbExp=3; IntAct=EBI-641237, EBI-10981970; CC P09619; Q15323: KRT31; NbExp=3; IntAct=EBI-641237, EBI-948001; CC P09619; O76011: KRT34; NbExp=3; IntAct=EBI-641237, EBI-1047093; CC P09619; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-641237, EBI-10172052; CC P09619; P60328: KRTAP12-3; NbExp=3; IntAct=EBI-641237, EBI-11953334; CC P09619; O94898: LRIG2; NbExp=3; IntAct=EBI-641237, EBI-2830372; CC P09619; O75581: LRP6; NbExp=3; IntAct=EBI-641237, EBI-910915; CC P09619; O14745: NHERF1; NbExp=5; IntAct=EBI-641237, EBI-349787; CC P09619; Q15599: NHERF2; NbExp=2; IntAct=EBI-641237, EBI-1149760; CC P09619; P01127: PDGFB; NbExp=16; IntAct=EBI-641237, EBI-1554925; CC P09619; P27986: PIK3R1; NbExp=21; IntAct=EBI-641237, EBI-79464; CC P09619; O00459: PIK3R2; NbExp=3; IntAct=EBI-641237, EBI-346930; CC P09619; P19174: PLCG1; NbExp=7; IntAct=EBI-641237, EBI-79387; CC P09619; P60484: PTEN; NbExp=3; IntAct=EBI-641237, EBI-696162; CC P09619; P18031: PTPN1; NbExp=3; IntAct=EBI-641237, EBI-968788; CC P09619; Q06124: PTPN11; NbExp=8; IntAct=EBI-641237, EBI-297779; CC P09619; Q05209: PTPN12; NbExp=3; IntAct=EBI-641237, EBI-2266035; CC P09619; P23470: PTPRG; NbExp=2; IntAct=EBI-641237, EBI-2258115; CC P09619; Q12913: PTPRJ; NbExp=4; IntAct=EBI-641237, EBI-2264500; CC P09619; P20936: RASA1; NbExp=3; IntAct=EBI-641237, EBI-1026476; CC P09619; Q13239: SLA; NbExp=4; IntAct=EBI-641237, EBI-726214; CC P09619; Q15654: TRIP6; NbExp=3; IntAct=EBI-641237, EBI-742327; CC P09619; P07947: YES1; NbExp=3; IntAct=EBI-641237, EBI-515331; CC P09619; P0CK45: E5; Xeno; NbExp=2; IntAct=EBI-641237, EBI-7015490; CC P09619; P35918: Kdr; Xeno; NbExp=4; IntAct=EBI-641237, EBI-1555005; CC P09619; Q28619: NHERF1; Xeno; NbExp=3; IntAct=EBI-641237, EBI-7073613; CC P09619; P23727: PIK3R1; Xeno; NbExp=6; IntAct=EBI-641237, EBI-520244; CC P09619; P08487: PLCG1; Xeno; NbExp=3; IntAct=EBI-641237, EBI-8013886; CC P09619; P41499: Ptpn11; Xeno; NbExp=4; IntAct=EBI-641237, EBI-7180604; CC P09619; P25020: V-SRC; Xeno; NbExp=4; IntAct=EBI-641237, EBI-8636140; CC -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane CC protein. Cytoplasmic vesicle. Lysosome lumen. Note=After ligand CC binding, the autophosphorylated receptor is ubiquitinated and CC internalized, leading to its degradation. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P09619-1; Sequence=Displayed; CC Name=2; CC IsoId=P09619-2; Sequence=VSP_056008, VSP_056009; CC -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding. CC Autophosphorylation occurs in trans, i.e. one subunit of the dimeric CC receptor phosphorylates tyrosine residues on the other subunit. CC Phosphorylation at Tyr-579, and to a lesser degree, at Tyr-581, is CC important for interaction with SRC family kinases. Phosphorylation at CC Tyr-740 and Tyr-751 is important for interaction with PIK3R1. CC Phosphorylation at Tyr-751 is important for interaction with NCK1. CC Phosphorylation at Tyr-771 and Tyr-857 is important for interaction CC with RASA1/GAP. Phosphorylation at Tyr-857 is important for efficient CC phosphorylation of PLCG1 and PTPN11, resulting in increased CC phosphorylation of AKT1, MAPK1/ERK2 and/or MAPK3/ERK1, PDCD6IP/ALIX and CC STAM, and in increased cell proliferation. Phosphorylation at Tyr-1009 CC is important for interaction with PTPN11. Phosphorylation at Tyr-1009 CC and Tyr-1021 is important for interaction with PLCG1. Phosphorylation CC at Tyr-1021 is important for interaction with CBL; PLCG1 and CBL CC compete for the same binding site. Dephosphorylated by PTPRJ at Tyr- CC 751, Tyr-857, Tyr-1009 and Tyr-1021. Dephosphorylated by PTPN2 at Tyr- CC 579 and Tyr-1021. {ECO:0000269|PubMed:10821867, CC ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1396585, CC ECO:0000269|PubMed:14966296, ECO:0000269|PubMed:15902258, CC ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:2550144, CC ECO:0000269|PubMed:7685273}. CC -!- PTM: N-glycosylated. {ECO:0000269|PubMed:20534510, CC ECO:0000269|PubMed:2850496}. CC -!- PTM: Ubiquitinated. After autophosphorylation, the receptor is CC polyubiquitinated, leading to its degradation. CC {ECO:0000269|PubMed:1313434, ECO:0000269|PubMed:17620338}. CC -!- DISEASE: Note=A chromosomal aberration involving PDGFRB is found in a CC form of chronic myelomonocytic leukemia (CMML). Translocation CC t(5;12)(q33;p13) with EVT6/TEL. It is characterized by abnormal clonal CC myeloid proliferation and by progression to acute myelogenous leukemia CC (AML). CC -!- DISEASE: Myeloproliferative disorder chronic with eosinophilia (MPE) CC [MIM:131440]: A hematologic disorder characterized by malignant CC eosinophils proliferation. Note=The gene represented in this entry may CC be involved in disease pathogenesis. Chromosomal aberrations involving CC PDGFRB have been found in many instances of chronic myeloproliferative CC disorder with eosinophilia. Translocation t(5;12) with ETV6 on CC chromosome 12 creating an PDGFRB-ETV6 fusion protein (PubMed:12181402). CC Translocation t(5;15)(q33;q22) with TP53BP1 creating a PDGFRB-TP53BP1 CC fusion protein (PubMed:15492236). Translocation t(1;5)(q23;q33) that CC forms a PDE4DIP-PDGFRB fusion protein (PubMed:12907457). Translocation CC t(5;6)(q33-34;q23) with CEP85L that fuses the 5'-end of CEP85L (isoform CC 4) to the 3'-end of PDGFRB (PubMed:21938754). CC {ECO:0000269|PubMed:12181402, ECO:0000269|PubMed:12907457, CC ECO:0000269|PubMed:15492236, ECO:0000269|PubMed:21938754}. CC -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of CC acute leukemia, a cancer of the white blood cells. AML is a malignant CC disease of bone marrow characterized by maturational arrest of CC hematopoietic precursors at an early stage of development. Clonal CC expansion of myeloid blasts occurs in bone marrow, blood, and other CC tissue. Myelogenous leukemias develop from changes in cells that CC normally produce neutrophils, basophils, eosinophils and monocytes. CC Note=The gene represented in this entry may be involved in disease CC pathogenesis. A chromosomal aberration involving PDGFRB has been found CC in a patient with AML. Translocation t(5;14)(q33;q32) with TRIP11 CC (PubMed:9373237). {ECO:0000269|PubMed:9373237}. CC -!- DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An CC aggressive pediatric myelodysplastic syndrome/myeloproliferative CC disorder characterized by malignant transformation in the hematopoietic CC stem cell compartment with proliferation of differentiated progeny. CC Patients have splenomegaly, enlarged lymph nodes, rashes, and CC hemorrhages. Note=The gene represented in this entry may be involved in CC disease pathogenesis. A chromosomal aberration involving PDGFRB has CC been found in a patient with JMML. Translocation t(5;17)(q33;p11.2) CC with SPECC1 (PubMed:15087372). {ECO:0000269|PubMed:15087372}. CC -!- DISEASE: Basal ganglia calcification, idiopathic, 4 (IBGC4) CC [MIM:615007]: A form of basal ganglia calcification, an autosomal CC dominant condition characterized by symmetric calcification in the CC basal ganglia and other brain regions. Affected individuals can either CC be asymptomatic or show a wide spectrum of neuropsychiatric symptoms, CC including parkinsonism, dystonia, tremor, ataxia, dementia, psychosis, CC seizures, and chronic headache. Serum levels of calcium, phosphate, CC alkaline phosphatase and parathyroid hormone are normal. The CC neuropathological hallmark of the disease is vascular and pericapillary CC calcification, mainly of calcium phosphate, in the affected brain CC areas. {ECO:0000269|PubMed:23255827, ECO:0000269|PubMed:24065723, CC ECO:0000269|PubMed:26599395}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Myofibromatosis, infantile 1 (IMF1) [MIM:228550]: A rare CC mesenchymal disorder characterized by the development of benign tumors CC in the skin, striated muscles, bones, and, more rarely, visceral CC organs. Subcutaneous or soft tissue nodules commonly involve the skin CC of the head, neck, and trunk. Skeletal and muscular lesions occur in CC about half of the patients. Lesions may be solitary or multicentric, CC and they may be present at birth or become apparent in early infancy or CC occasionally in adult life. Visceral lesions are associated with high CC morbidity and mortality. {ECO:0000269|PubMed:23731537, CC ECO:0000269|PubMed:23731542}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Kosaki overgrowth syndrome (KOGS) [MIM:616592]: A syndrome CC characterized by somatic overgrowth, distinctive facial features, CC hyperelastic and fragile skin, and progressive neurologic deterioration CC with white matter lesions on brain imaging. CC {ECO:0000269|PubMed:25454926}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Premature aging syndrome, Penttinen type (PENTT) [MIM:601812]: CC An autosomal dominant syndrome characterized by a prematurely aged CC appearance with lipoatrophy, epidermal and dermal atrophy along with CC hypertrophic lesions that resemble scars, thin hair, proptosis, CC underdeveloped cheekbones, and marked acro-osteolysis. CC {ECO:0000269|PubMed:26279204, ECO:0000269|PubMed:30573803}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Ocular pterygium-digital keloid dysplasia syndrome (OPDKD) CC [MIM:621091]: An autosomal dominant disorder that presents in childhood CC with aggressive ingrowth of vascularized connective tissue on the CC cornea, ultimately leading to loss of vision. Later, affected CC individuals develop keloids on digits after minor trauma, but are CC otherwise healthy. {ECO:0000269|PubMed:33450762}. Note=The disease may CC be caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. CSF-1/PDGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/21/PDGFRB"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; J03278; AAA60049.1; -; mRNA. DR EMBL; M21616; AAA36427.1; -; mRNA. DR EMBL; EU826595; ACF47631.1; -; mRNA. DR EMBL; AC005895; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC011382; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC032224; AAH32224.1; -; mRNA. DR EMBL; U33172; AAC51675.1; -; Genomic_DNA. DR CCDS; CCDS4303.1; -. [P09619-1] DR PIR; A28206; PFHUGB. DR RefSeq; NP_002600.1; NM_002609.4. [P09619-1] DR PDB; 1GQ5; X-ray; 2.20 A; A=1102-1106. DR PDB; 1H9O; X-ray; 1.79 A; B=751-755. DR PDB; 1SHA; X-ray; 1.50 A; B=751-755. DR PDB; 2IUI; X-ray; 2.40 A; C/D=748-758. DR PDB; 2L6W; NMR; -; A/B=526-563. DR PDB; 2PLD; NMR; -; B=1018-1029. DR PDB; 2PLE; NMR; -; B=1018-1029. DR PDB; 3MJG; X-ray; 2.30 A; X/Y=33-314. DR PDBsum; 1GQ5; -. DR PDBsum; 1H9O; -. DR PDBsum; 1SHA; -. DR PDBsum; 2IUI; -. DR PDBsum; 2L6W; -. DR PDBsum; 2PLD; -. DR PDBsum; 2PLE; -. DR PDBsum; 3MJG; -. DR AlphaFoldDB; P09619; -. DR BMRB; P09619; -. DR EMDB; EMD-6426; -. DR SMR; P09619; -. DR BioGRID; 111185; 211. DR ComplexPortal; CPX-2882; PDGF receptor beta - PDGF-BB complex. DR ComplexPortal; CPX-2883; PDGF receptor alpha-beta - PDGF-BB complex. DR ComplexPortal; CPX-2886; PDGF receptor beta - PDGF-AB complex. DR ComplexPortal; CPX-2888; PDGF receptor alpha-beta - PDGF-CC complex. DR ComplexPortal; CPX-2889; PDGF receptor beta - PDGF-DD complex. DR ComplexPortal; CPX-2890; PDGF receptor alpha-beta - PDGF-DD complex. DR ComplexPortal; CPX-2891; PDGF receptor beta - PDGF-CC complex. DR ComplexPortal; CPX-2892; PDGF receptor alpha-beta - PDGF-AB complex. DR CORUM; P09619; -. DR DIP; DIP-558N; -. DR FunCoup; P09619; 1764. DR IntAct; P09619; 390. DR MINT; P09619; -. DR STRING; 9606.ENSP00000261799; -. DR BindingDB; P09619; -. DR ChEMBL; CHEMBL1913; -. DR DrugBank; DB00102; Becaplermin. DR DrugBank; DB01254; Dasatinib. DR DrugBank; DB12147; Erdafitinib. DR DrugBank; DB11741; Famitinib. DR DrugBank; DB10770; Foreskin fibroblast (neonatal). DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB00619; Imatinib. DR DrugBank; DB11845; Lucitanib. DR DrugBank; DB06595; Midostaurin. DR DrugBank; DB09079; Nintedanib. DR DrugBank; DB06589; Pazopanib. DR DrugBank; DB08339; PD-166326. DR DrugBank; DB17041; PD-173952. DR DrugBank; DB02567; PD173955. DR DrugBank; DB12978; Pexidartinib. DR DrugBank; DB09221; Polaprezinc. DR DrugBank; DB15822; Pralsetinib. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB14840; Ripretinib. DR DrugBank; DB06436; Semaxanib. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB08009; SU-11652. DR DrugBank; DB01268; Sunitinib. DR DrugBank; DB13093; TAK-593. DR DrugBank; DB11800; Tivozanib. DR DrugBank; DB09283; Trapidil. DR DrugBank; DB05146; XL820. DR DrugBank; DB05014; XL999. DR DrugCentral; P09619; -. DR GuidetoPHARMACOLOGY; 1804; -. DR TCDB; 8.A.23.1.37; the basigin (basigin) family. DR GlyConnect; 1967; 4 N-Linked glycans (3 sites). DR GlyCosmos; P09619; 11 sites, 4 glycans. DR GlyGen; P09619; 13 sites, 4 N-linked glycans (3 sites), 1 O-linked glycan (1 site). DR iPTMnet; P09619; -. DR PhosphoSitePlus; P09619; -. DR BioMuta; PDGFRB; -. DR DMDM; 129890; -. DR CPTAC; CPTAC-1630; -. DR CPTAC; CPTAC-3063; -. DR jPOST; P09619; -. DR MassIVE; P09619; -. DR PaxDb; 9606-ENSP00000261799; -. DR PeptideAtlas; P09619; -. DR ProteomicsDB; 52253; -. [P09619-1] DR Pumba; P09619; -. DR ABCD; P09619; 7 sequenced antibodies. DR Antibodypedia; 3424; 2244 antibodies from 49 providers. DR DNASU; 5159; -. DR Ensembl; ENST00000261799.9; ENSP00000261799.4; ENSG00000113721.15. [P09619-1] DR GeneID; 5159; -. DR KEGG; hsa:5159; -. DR MANE-Select; ENST00000261799.9; ENSP00000261799.4; NM_002609.4; NP_002600.1. DR UCSC; uc003lro.4; human. [P09619-1] DR AGR; HGNC:8804; -. DR CIViC; 5159; 2 evidence items across 3 molecular profiles. DR ClinPGx; PA33148; -. DR CTD; 5159; -. DR DisGeNET; 5159; -. DR GeneCards; PDGFRB; -. DR GeneReviews; PDGFRB; -. DR HGNC; HGNC:8804; PDGFRB. DR HPA; ENSG00000113721; Low tissue specificity. DR MalaCards; PDGFRB; -. DR MIM; 131440; phenotype. DR MIM; 173410; gene. DR MIM; 228550; phenotype. DR MIM; 601626; phenotype. DR MIM; 601812; phenotype. DR MIM; 607785; phenotype. DR MIM; 615007; phenotype. DR MIM; 616592; phenotype. DR MIM; 621091; phenotype. DR OpenTargets; ENSG00000113721; -. DR Orphanet; 363665; Acroosteolysis-keloid-like lesions-premature aging syndrome. DR Orphanet; 1980; Bilateral striopallidodentate calcinosis. DR Orphanet; 86830; Chronic myeloproliferative disease, unclassifiable. DR Orphanet; 2591; Infantile myofibromatosis. DR Orphanet; 477831; Kosaki overgrowth syndrome. DR Orphanet; 168950; Myeloid/lymphoid neoplasm associated with PDGFRB rearrangement. DR Orphanet; 314950; Primary hypereosinophilic syndrome. DR VEuPathDB; HostDB:ENSG00000113721; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000157138; -. DR HOGENOM; CLU_000288_49_0_1; -. DR InParanoid; P09619; -. DR OMA; WPEDQEF; -. DR OrthoDB; 9936425at2759; -. DR PAN-GO; P09619; 10 GO annotations based on evolutionary models. DR PhylomeDB; P09619; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P09619; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-186763; Downstream signal transduction. DR Reactome; R-HSA-186797; Signaling by PDGF. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR SignaLink; P09619; -. DR SIGNOR; P09619; -. DR Agora; ENSG00000113721; -. DR BioGRID-ORCS; 5159; 18 hits in 1194 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; PDGFRB; human. DR EvolutionaryTrace; P09619; -. DR GeneWiki; PDGFRB; -. DR GenomeRNAi; 5159; -. DR Pharos; P09619; Tclin. DR PRO; PR:P09619; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P09619; protein. DR Bgee; ENSG00000113721; Expressed in stromal cell of endometrium and 182 other cell types or tissues. DR ExpressionAtlas; P09619; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-SubCell. DR GO; GO:0005925; C:focal adhesion; HDA:UniProtKB. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0043202; C:lysosomal lumen; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; IDA:BHF-UCL. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0005096; F:GTPase activator activity; IMP:UniProtKB. DR GO; GO:0160185; F:phospholipase C activator activity; IMP:UniProtKB. DR GO; GO:0004992; F:platelet activating factor receptor activity; TAS:ProtInc. DR GO; GO:0005019; F:platelet-derived growth factor beta-receptor activity; IDA:UniProtKB. DR GO; GO:0048407; F:platelet-derived growth factor binding; IDA:UniProtKB. DR GO; GO:0005017; F:platelet-derived growth factor receptor activity; TAS:ProtInc. DR GO; GO:0005161; F:platelet-derived growth factor receptor binding; IPI:BHF-UCL. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0005102; F:signaling receptor binding; IPI:UniProtKB. DR GO; GO:0038085; F:vascular endothelial growth factor binding; IPI:BHF-UCL. DR GO; GO:0001525; P:angiogenesis; IBA:GO_Central. DR GO; GO:0035909; P:aorta morphogenesis; ISS:BHF-UCL. DR GO; GO:0055003; P:cardiac myofibril assembly; ISS:UniProtKB. DR GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB. DR GO; GO:0060981; P:cell migration involved in coronary angiogenesis; ISS:UniProtKB. DR GO; GO:0035441; P:cell migration involved in vasculogenesis; ISS:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0072277; P:metanephric glomerular capillary formation; ISS:UniProtKB. DR GO; GO:0072262; P:metanephric glomerular mesangial cell proliferation involved in metanephros development; ISS:UniProtKB. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0035791; P:platelet-derived growth factor receptor-beta signaling pathway; IMP:UniProtKB. DR GO; GO:0090280; P:positive regulation of calcium ion import; ISS:UniProtKB. DR GO; GO:0050850; P:positive regulation of calcium-mediated signaling; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0038091; P:positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0050921; P:positive regulation of chemotaxis; ISS:UniProtKB. DR GO; GO:2000573; P:positive regulation of DNA biosynthetic process; ISS:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0043406; P:positive regulation of MAP kinase activity; ISS:UniProtKB. DR GO; GO:0035793; P:positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway; ISS:UniProtKB. DR GO; GO:0045840; P:positive regulation of mitotic nuclear division; ISS:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProtKB. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; ISS:UniProtKB. DR GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IMP:UniProtKB. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; ISS:BHF-UCL. DR GO; GO:0061298; P:retina vasculature development in camera-type eye; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0014805; P:smooth muscle adaptation; NAS:BHF-UCL. DR GO; GO:0071670; P:smooth muscle cell chemotaxis; ISS:BHF-UCL. DR CDD; cd00096; Ig; 1. DR CDD; cd05859; Ig4_PDGFR; 1. DR CDD; cd05861; IgI_PDGFR-alphabeta; 1. DR CDD; cd05107; PTKc_PDGFR_beta; 1. DR FunFam; 3.30.200.20:FF:000025; Platelet-derived growth factor receptor alpha; 1. DR FunFam; 1.10.510.10:FF:000140; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000223; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000572; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000715; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000814; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000982; Platelet-derived growth factor receptor beta; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 5. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR013151; Immunoglobulin_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR027288; PGFRB. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR001824; Tyr_kinase_rcpt_3_CS. DR PANTHER; PTHR24416:SF53; PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00047; ig; 1. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF25305; Ig_PDGFR_d4; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF500948; Beta-PDGF_receptor; 1. DR PIRSF; PIRSF000615; TyrPK_CSF1-R; 1. DR PRINTS; PR01832; VEGFRECEPTOR. DR SMART; SM00409; IG; 3. DR SMART; SM00408; IGc2; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; Chemotaxis; KW Chromosomal rearrangement; Cytoplasmic vesicle; Developmental protein; KW Direct protein sequencing; Disease variant; Disulfide bond; Glycoprotein; KW Immunoglobulin domain; Kinase; Lysosome; Membrane; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Proto-oncogene; Receptor; KW Reference proteome; Repeat; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..32 FT /evidence="ECO:0000269|PubMed:15340161" FT CHAIN 33..1106 FT /note="Platelet-derived growth factor receptor beta" FT /id="PRO_0000016757" FT TOPO_DOM 33..532 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 533..553 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 554..1106 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 33..120 FT /note="Ig-like C2-type 1" FT DOMAIN 129..210 FT /note="Ig-like C2-type 2" FT DOMAIN 214..309 FT /note="Ig-like C2-type 3" FT DOMAIN 331..403 FT /note="Ig-like C2-type 4" FT DOMAIN 416..524 FT /note="Ig-like C2-type 5" FT DOMAIN 600..962 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1019..1106 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1043..1060 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1066..1088 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 826 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 606..614 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 634 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT SITE 527..528 FT /note="Breakpoint for insertion to form PDE4DIP-PDGFRB FT fusion protein" FT SITE 527..528 FT /note="Breakpoint for translocation to form TRIP11-PDGFRB" FT SITE 558..559 FT /note="Breakpoint for translocation to form the CEP85L- FT PDGFRB fusion protein" FT MOD_RES 562 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867" FT MOD_RES 579 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14966296, FT ECO:0000269|PubMed:15902258, ECO:0000269|PubMed:7685273" FT MOD_RES 581 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15902258, FT ECO:0000269|PubMed:7685273" FT MOD_RES 686 FT /note="Phosphotyrosine; by ABL1 and ABL2" FT /evidence="ECO:0000250|UniProtKB:P05622" FT MOD_RES 716 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15902258" FT MOD_RES 740 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:1314164, FT ECO:0000269|PubMed:15902258" FT MOD_RES 751 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:14966296, FT ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:2550144" FT MOD_RES 763 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867" FT MOD_RES 771 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:14966296, FT ECO:0000269|PubMed:15902258" FT MOD_RES 775 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867" FT MOD_RES 778 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867" FT MOD_RES 857 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:15902258, FT ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:2550144" FT MOD_RES 934 FT /note="Phosphotyrosine; by ABL1 and ABL2" FT /evidence="ECO:0000250|UniProtKB:P05622" FT MOD_RES 970 FT /note="Phosphotyrosine; by ABL1 and ABL2" FT /evidence="ECO:0000250|UniProtKB:P05622" FT MOD_RES 1009 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:15902258" FT MOD_RES 1021 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:14966296, FT ECO:0000269|PubMed:15902258" FT CARBOHYD 45 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 89 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 103 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 215 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 230 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 292 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 307 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 354 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 371 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 468 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 479 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 54..100 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:20534510" FT DISULFID 149..190 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:20534510" FT DISULFID 235..291 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:20534510" FT DISULFID 436..508 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 311..336 FT /note="VESGYVRLLGEVGTLQFAELHRSRTL -> RAATCGSWERWAHYNLLSCIGA FT GHCR (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056008" FT VAR_SEQ 337..1106 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056009" FT VARIANT 29 FT /note="I -> F (in dbSNP:rs17110944)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_034377" FT VARIANT 180 FT /note="S -> F (in dbSNP:rs17853027)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_035125" FT VARIANT 282 FT /note="E -> K (in dbSNP:rs34586048)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042027" FT VARIANT 345 FT /note="P -> S (in dbSNP:rs2229558)" FT /id="VAR_049717" FT VARIANT 485 FT /note="E -> K (in dbSNP:rs41287110)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042028" FT VARIANT 561 FT /note="R -> C (in IMF1; dbSNP:rs367543286)" FT /evidence="ECO:0000269|PubMed:23731537" FT /id="VAR_069925" FT VARIANT 584 FT /note="P -> R (in KOGS; dbSNP:rs863224946)" FT /evidence="ECO:0000269|PubMed:25454926" FT /id="VAR_075865" FT VARIANT 589 FT /note="Y -> H (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042029" FT VARIANT 658 FT /note="L -> P (in IBGC4; no effect on protein abundance; FT loss of PDGF beta receptor activity; dbSNP:rs397509381)" FT /evidence="ECO:0000269|PubMed:23255827, FT ECO:0000269|PubMed:24065723, ECO:0000269|PubMed:26599395" FT /id="VAR_069320" FT VARIANT 660 FT /note="P -> T (in IMF1; dbSNP:rs144050370)" FT /evidence="ECO:0000269|PubMed:23731542" FT /id="VAR_069926" FT VARIANT 665 FT /note="V -> A (in PENTT; gain of function in protein FT tyrosine kinase activity; shows ligand-independent FT constitutive signaling; dbSNP:rs1554108211)" FT /evidence="ECO:0000269|PubMed:26279204" FT /id="VAR_075866" FT VARIANT 666 FT /note="N -> S (in PENTT; likely pathogenic; gain-of- FT function variant resulting in constitutive FT autophosphorylation and increased phosphorylation of FT downstream signaling proteins; levels of protein FT phosphorylation are similar at 32 and 37 degrees Celsius; FT dbSNP:rs2113894766)" FT /evidence="ECO:0000269|PubMed:30573803" FT /id="VAR_090402" FT VARIANT 666 FT /note="N -> Y (in OPDKD; likely pathogenic; gain-of- FT function variant resulting in temperature-dependent FT constitutive autophosphorylation and increased FT phosphorylation of downstream signaling proteins; levels of FT protein phosphorylation at 32 degrees Celsius are higher FT than at 37 degrees; dbSNP:rs797044887)" FT /evidence="ECO:0000269|PubMed:33450762" FT /id="VAR_090403" FT VARIANT 718 FT /note="N -> Y (in dbSNP:rs35322465)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042030" FT VARIANT 882 FT /note="T -> I (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042031" FT VARIANT 987 FT /note="R -> W (in IBGC4; decreased protein abundance; no FT effect on receptor activity; decreased PDGF signaling FT pathway; dbSNP:rs397509382)" FT /evidence="ECO:0000269|PubMed:23255827, FT ECO:0000269|PubMed:24065723, ECO:0000269|PubMed:26599395" FT /id="VAR_069321" FT VARIANT 1071 FT /note="E -> V (in IBGC4; no effect on protein abundance; no FT effect on receptor activity; decreased PDGF signaling FT pathway)" FT /evidence="ECO:0000269|PubMed:24065723, FT ECO:0000269|PubMed:26599395" FT /id="VAR_075395" FT MUTAGEN 579 FT /note="Y->F: Loss of kinase activity; when associated with FT F-581. Strongly reduces interaction with SRC family FT kinases. No effect on interaction with GRB10." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:7685273" FT MUTAGEN 581 FT /note="Y->F: Loss of kinase activity; when associated with FT F-579. No effect on interaction with GRB10." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:7685273" FT MUTAGEN 634 FT /note="K->A,R: Loss of kinase activity. Abolishes FT interaction with RASA1. No effect on phosphatidylinositol FT 3-kinase activity." FT /evidence="ECO:0000269|PubMed:1314164, FT ECO:0000269|PubMed:1846866, ECO:0000269|PubMed:20494825" FT MUTAGEN 716 FT /note="Y->F: No effect neither on interaction with GRB10 FT and RASA1 nor on phosphatidylinositol 3-kinase activity." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164" FT MUTAGEN 740 FT /note="Y->F: Strongly reduces up-regulation of cell FT proliferation; when associated with F-751. Strongly FT decreases phosphatidylinositol 3-kinase activity. No effect FT on interaction with GRB10 and RASA1." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321, FT ECO:0000269|PubMed:21679854" FT MUTAGEN 751 FT /note="Y->F: Strongly reduces up-regulation of cell FT proliferation; when associated with F-740. Abolishes FT phosphatidylinositol 3-kinase activity and interaction with FT NCK1, and slightly reduces interaction with RASA1. No FT effect on interaction with GRB10." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321, FT ECO:0000269|PubMed:1653029, ECO:0000269|PubMed:21679854, FT ECO:0000269|PubMed:7692233" FT MUTAGEN 763 FT /note="Y->F: No effect on interaction with RASA1 and on FT phosphatidylinositol 3-kinase activity." FT /evidence="ECO:0000269|PubMed:1314164" FT MUTAGEN 771 FT /note="Y->F: Loss of interaction with GRB10. Abolishes FT interaction with RASA1. No effect on phosphatidylinositol FT 3-kinase activity." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321" FT MUTAGEN 775 FT /note="Y->F: No effect on interaction with RASA1 and on FT phosphatidylinositol 3-kinase activity." FT /evidence="ECO:0000269|PubMed:1314164" FT MUTAGEN 778 FT /note="Y->F: Strongly reduces expression levels." FT /evidence="ECO:0000269|PubMed:1314164" FT MUTAGEN 857 FT /note="Y->F: Reduces kinase activity. No effect on FT interaction with GRB10. Abolishes interaction with RASA1. FT No effect on phosphatidylinositol 3-kinase activity." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1653029, FT ECO:0000269|PubMed:20494825" FT MUTAGEN 1009 FT /note="Y->F: No effect on interaction with GRB10. Abolishes FT interaction with PLCG1; when associated with F-1021." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:7691811" FT MUTAGEN 1021 FT /note="Y->F: Strongly reduces up-regulation of cell FT proliferation. Abolishes interaction with PLCG1; when FT associated with F-1009. No effect on interaction with FT GRB10." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:17620338, FT ECO:0000269|PubMed:21679854" FT CONFLICT 241 FT /note="E -> D (in Ref. 2; AAA36427)" FT /evidence="ECO:0000305" FT STRAND 40..43 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 50..58 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 61..64 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 70..75 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 81..87 FT /evidence="ECO:0007829|PDB:3MJG" FT HELIX 92..94 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 96..101 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 114..119 FT /evidence="ECO:0007829|PDB:3MJG" FT HELIX 132..135 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 136..141 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 145..147 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 158..164 FT /evidence="ECO:0007829|PDB:3MJG" FT TURN 175..177 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 178..181 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 185..194 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 197..200 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 204..208 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 217..221 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 223..226 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 231..239 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 241..248 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 252..255 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 261..265 FT /evidence="ECO:0007829|PDB:3MJG" FT TURN 267..270 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 271..280 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 287..295 FT /evidence="ECO:0007829|PDB:3MJG" FT TURN 296..299 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 300..311 FT /evidence="ECO:0007829|PDB:3MJG" FT HELIX 530..556 FT /evidence="ECO:0007829|PDB:2L6W" SQ SEQUENCE 1106 AA; 123968 MW; 038C15E531D6E89D CRC64; MRLPGAMPAL ALKGELLLLS LLLLLEPQIS QGLVVTPPGP ELVLNVSSTF VLTCSGSAPV VWERMSQEPP QEMAKAQDGT FSSVLTLTNL TGLDTGEYFC THNDSRGLET DERKRLYIFV PDPTVGFLPN DAEELFIFLT EITEITIPCR VTDPQLVVTL HEKKGDVALP VPYDHQRGFS GIFEDRSYIC KTTIGDREVD SDAYYVYRLQ VSSINVSVNA VQTVVRQGEN ITLMCIVIGN EVVNFEWTYP RKESGRLVEP VTDFLLDMPY HIRSILHIPS AELEDSGTYT CNVTESVNDH QDEKAINITV VESGYVRLLG EVGTLQFAEL HRSRTLQVVF EAYPPPTVLW FKDNRTLGDS SAGEIALSTR NVSETRYVSE LTLVRVKVAE AGHYTMRAFH EDAEVQLSFQ LQINVPVRVL ELSESHPDSG EQTVRCRGRG MPQPNIIWSA CRDLKRCPRE LPPTLLGNSS EEESQLETNV TYWEEEQEFE VVSTLRLQHV DRPLSVRCTL RNAVGQDTQE VIVVPHSLPF KVVVISAILA LVVLTIISLI ILIMLWQKKP RYEIRWKVIE SVSSDGHEYI YVDPMQLPYD STWELPRDQL VLGRTLGSGA FGQVVEATAH GLSHSQATMK VAVKMLKSTA RSSEKQALMS ELKIMSHLGP HLNVVNLLGA CTKGGPIYII TEYCRYGDLV DYLHRNKHTF LQHHSDKRRP PSAELYSNAL PVGLPLPSHV SLTGESDGGY MDMSKDESVD YVPMLDMKGD VKYADIESSN YMAPYDNYVP SAPERTCRAT LINESPVLSY MDLVGFSYQV ANGMEFLASK NCVHRDLAAR NVLICEGKLV KICDFGLARD IMRDSNYISK GSTFLPLKWM APESIFNSLY TTLSDVWSFG ILLWEIFTLG GTPYPELPMN EQFYNAIKRG YRMAQPAHAS DEIYEIMQKC WEEKFEIRPP FSQLVLLLER LLGEGYKKKY QQVDEEFLRS DHPAILRSQA RLPGFHGLRS PLDTSSVLYT AVQPNEGDND YIIPLPDPKP EVADEGPLEG SPSLASSTLN EVNTSSTISC DSPLEPQDEP EPEPQLELQV EPEPELEQLP DSGCPAPRAE AEDSFL // ID PKP3_HUMAN Reviewed; 797 AA. AC Q9Y446; F8J390; Q53EX8; DT 23-JAN-2002, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1999, sequence version 1. DT 28-JAN-2026, entry version 191. DE RecName: Full=Plakophilin-3; GN Name=PKP3; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PKP3A), SUBCELLULAR LOCATION, AND RP TISSUE SPECIFICITY. RC TISSUE=Colon carcinoma; RX PubMed=10374265; DOI=10.1046/j.1432-0436.1999.6450291.x; RA Schmidt A., Langbein L., Praetzel S., Rode M., Rackwitz H.-R., Franke W.W.; RT "Plakophilin 3 -- a novel cell-type-specific desmosomal plaque protein."; RL Differentiation 64:291-306(1999). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PKP3A). RX PubMed=10381383; DOI=10.1242/jcs.112.14.2265; RA Bonne S., van Hengel J., Nollet F., Kools P., van Roy F.; RT "Plakophilin-3, a novel armadillo-like protein present in nuclei and RT desmosomes of epithelial cells."; RL J. Cell Sci. 112:2265-2276(1999). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PKP3B), ALTERNATIVE PROMOTER USAGE, RP SUBCELLULAR LOCATION (ISOFORMS PKP3A AND PKP3B), AND TISSUE SPECIFICITY RP (ISOFORMS PKP3A AND PKP3B). RX PubMed=24178805; DOI=10.1007/s00441-013-1736-1; RA Muhmer M., Ditthardt D., Jakel J., Wischmann V., Moll R., Schmidt A.; RT "An alternative promoter of the human plakophilin-3 gene controls the RT expression of the new isoform PKP3b."; RL Cell Tissue Res. 355:143-162(2014). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM PKP3A). RC TISSUE=Colon; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.; RL Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM PKP3A). RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-178 (ISOFORM PKP3B). RC TISSUE=Tongue; RX PubMed=16344560; DOI=10.1101/gr.4039406; RA Kimura K., Wakamatsu A., Suzuki Y., Ota T., Nishikawa T., Yamashita R., RA Yamamoto J., Sekine M., Tsuritani K., Wakaguri H., Ishii S., Sugiyama T., RA Saito K., Isono Y., Irie R., Kushida N., Yoneyama T., Otsuka R., Kanda K., RA Yokoi T., Kondo H., Wagatsuma M., Murakawa K., Ishida S., Ishibashi T., RA Takahashi-Fujii A., Tanase T., Nagai K., Kikuchi H., Nakai K., Isogai T., RA Sugano S.; RT "Diversification of transcriptional modulation: large-scale identification RT and characterization of putative alternative promoters of human genes."; RL Genome Res. 16:55-65(2006). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-238, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [8] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-180; SER-238; SER-240; RP SER-313 AND SER-314, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [11] RP SUBCELLULAR LOCATION. RX PubMed=20613778; DOI=10.1038/jid.2010.191; RA Sobolik-Delmaire T., Reddy R., Pashaj A., Roberts B.J., Wahl J.K. III; RT "Plakophilin-1 localizes to the nucleus and interacts with single-stranded RT DNA."; RL J. Invest. Dermatol. 130:2638-2646(2010). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-238; SER-313 AND SER-314, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [14] RP FUNCTION, INTERACTION WITH JUP, AND SUBCELLULAR LOCATION. RX PubMed=20859650; DOI=10.1007/s00018-010-0531-3; RA Gosavi P., Kundu S.T., Khapare N., Sehgal L., Karkhanis M.S., Dalal S.N.; RT "E-cadherin and plakoglobin recruit plakophilin3 to the cell border to RT initiate desmosome assembly."; RL Cell. Mol. Life Sci. 68:1439-1454(2011). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-314, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-180; SER-183; SER-238; RP THR-250; SER-313; SER-314 AND SER-331, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [17] RP FUNCTION, INTERACTION WITH SFN, SUBCELLULAR LOCATION, PHOSPHORYLATION AT RP SER-285, AND MUTAGENESIS OF SER-285. RX PubMed=24124604; DOI=10.1371/journal.pone.0077012; RA Roberts B.J., Reddy R., Wahl J.K. III; RT "Stratifin (14-3-3 sigma) limits plakophilin-3 exchange with the desmosomal RT plaque."; RL PLoS ONE 8:e77012-e77012(2013). RN [18] RP FUNCTION, IDENTIFICATION IN A COMPLEX WITH RAP1A AND CDH1, AND INTERACTION RP WITH CDH1 AND RAP1A. RX PubMed=25208567; DOI=10.1091/mbc.e14-05-0968; RA Todorovic V., Koetsier J.L., Godsel L.M., Green K.J.; RT "Plakophilin 3 mediates Rap1-dependent desmosome assembly and adherens RT junction maturation."; RL Mol. Biol. Cell 25:3749-3764(2014). RN [19] RP FUNCTION, AND INTERACTION WITH FXR1. RX PubMed=25225333; DOI=10.1128/mcb.00766-14; RA Fischer-Keso R., Breuninger S., Hofmann S., Henn M., Roehrig T., RA Stroebel P., Stoecklin G., Hofmann I.; RT "Plakophilins 1 and 3 bind to FXR1 and thereby influence the mRNA stability RT of desmosomal proteins."; RL Mol. Cell. Biol. 34:4244-4256(2014). RN [20] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-81 AND ARG-261, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [21] RP SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT TYR-195. RX PubMed=25501895; DOI=10.1007/s00441-014-2063-x; RA Neuber S., Jaeger S., Meyer M., Wischmann V., Koch P.J., Moll R., RA Schmidt A.; RT "c-Src mediated tyrosine phosphorylation of plakophilin 3 as a new RT mechanism to control desmosome composition in cells exposed to oxidative RT stress."; RL Cell Tissue Res. 359:799-816(2015). RN [22] RP INTERACTION WITH SFN, AND MUTAGENESIS OF SER-285. RX PubMed=29678907; DOI=10.1242/jcs.212191; RA Rietscher K., Keil R., Jordan A., Hatzfeld M.; RT "14-3-3 proteins regulate desmosomal adhesion via plakophilins."; RL J. Cell Sci. 131:0-0(2018). RN [23] RP SUBCELLULAR LOCATION. RX PubMed=30949721; DOI=10.1007/s00018-019-03083-8; RA Fuchs M., Foresti M., Radeva M.Y., Kugelmann D., Keil R., Hatzfeld M., RA Spindler V., Waschke J., Vielmuth F.; RT "Plakophilin 1 but not plakophilin 3 regulates desmoglein clustering."; RL Cell. Mol. Life Sci. 76:3465-3476(2019). RN [24] RP FUNCTION, INTERACTION WITH GSK3B, AND SUBCELLULAR LOCATION. RX PubMed=34058472; DOI=10.1016/j.bbrc.2021.05.043; RA Hong J.Y., Zapata J., Blackburn A., Baumert R., Bae S.M., Ji H., Nam H.J., RA Miller R.K., McCrea P.D.; RT "A catenin of the plakophilin-subfamily, Pkp3, responds to canonical-Wnt RT pathway components and signals."; RL Biochem. Biophys. Res. Commun. 563:31-39(2021). CC -!- FUNCTION: A component of desmosome cell-cell junctions which are CC required for positive regulation of cellular adhesion CC (PubMed:24124604). Required for the localization of DSG2, DSP and PKP2 CC to mature desmosome junctions (PubMed:20859650). May also play a role CC in the maintenance of DSG3 protein abundance in keratinocytes (By CC similarity). Required for the formation of DSP-containing desmosome CC precursors in the cytoplasm during desmosome assembly CC (PubMed:25208567). Also regulates the accumulation of CDH1 to mature CC desmosome junctions, via cAMP-dependent signaling and its interaction CC with activated RAP1A (PubMed:25208567). Positively regulates the CC stabilization of PKP2 mRNA and therefore protein abundance, via its CC interaction with FXR1, may also regulate the protein abundance of DSP CC via the same mechanism (PubMed:25225333). May also regulate the protein CC abundance of the desmosome component PKP1 (By similarity). Required for CC the organization of desmosome junctions at intercellular borders CC between basal keratinocytes of the epidermis, as a result plays a role CC in maintenance of the dermal barrier and regulation of the dermal CC inflammatory response (By similarity). Required during epidermal CC keratinocyte differentiation for cell adherence at tricellular cell- CC cell contacts, via regulation of the timely formation of adherens CC junctions and desmosomes in a calcium-dependent manner, and may also CC play a role in the organization of the intracellular actin fiber belt CC (By similarity). Acts as a negative regulator of the inflammatory CC response in hematopoietic cells of the skin and intestine, via CC modulation of proinflammatory cytokine production (By similarity). CC Important for epithelial barrier maintenance in the intestine to reduce CC intestinal permeability, thereby plays a role in protection from CC intestinal-derived endotoxemia (By similarity). Required for the CC development of hair follicles, via a role in the regulation of inner CC root sheaf length, correct alignment and anterior-posterior polarity of CC hair follicles (By similarity). Promotes proliferation and cell-cycle CC G1/S phase transition of keratinocytes (By similarity). Promotes E2F1- CC driven transcription of G1/S phase promoting genes by acting to release CC E2F1 from its inhibitory interaction with RB1, via sequestering RB1 and CC CDKN1A to the cytoplasm and thereby increasing CDK4- and CDK6-driven CC phosphorylation of RB1 (By similarity). May act as a scaffold protein CC to facilitate MAPK phosphorylation of RPS6KA protein family members and CC subsequently promote downstream EGFR signaling (By similarity). May CC play a role in the positive regulation of transcription of Wnt-mediated CC TCF-responsive target genes (PubMed:34058472). CC {ECO:0000250|UniProtKB:Q9QY23, ECO:0000269|PubMed:20859650, CC ECO:0000269|PubMed:24124604, ECO:0000269|PubMed:25208567, CC ECO:0000269|PubMed:25225333, ECO:0000269|PubMed:34058472}. CC -!- SUBUNIT: Found in a complex composed of CDH1, RAP1A and PKP3; PKP3 acts CC as a scaffold protein within the complex, the complex is required for CC CDH1 localization to mature desmosome cell junctions (PubMed:25208567). CC Interacts with FXR1; the interaction facilitates the binding of PKP3 to CC PKP2 mRNA (PubMed:25225333). Interacts (via ARM repeats) with GSK3B; CC the interaction may be involved in PKP3 protein degradation CC (PubMed:34058472). Interacts with hyperphosphorylated and CC hypophosphorylated RB1; the interaction inhibits RB1 interaction with CC and repression of the transcription factor E2F1, potentially via CC sequestering RB1 to the cytoplasm (By similarity). Interacts with CC CDKN1A; the interaction sequesters CDKN1A to the cytoplasm thereby CC repressing its role as an inhibitor of CDK4- and CDK6-driven RB1 CC phosphorylation (By similarity). Interacts (via N-terminus) with SFN; CC the interaction maintains the cytoplasmic pool of PKP3, facilitates CC PKP3 exchange at desmosomes and restricts PKP3 localization to existing CC desmosome cell junctions (PubMed:24124604, PubMed:29678907). Interacts CC (via N-terminus) with JUP; the interaction is required for PKP3 CC localization to desmosome cell-cell junctions (PubMed:20859650). CC {ECO:0000250|UniProtKB:Q9QY23, ECO:0000269|PubMed:20859650, CC ECO:0000269|PubMed:24124604, ECO:0000269|PubMed:25208567, CC ECO:0000269|PubMed:25225333, ECO:0000269|PubMed:29678907, CC ECO:0000269|PubMed:34058472}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:24124604, CC ECO:0000269|PubMed:34058472}. Cell junction, desmosome CC {ECO:0000269|PubMed:10374265, ECO:0000269|PubMed:20613778, CC ECO:0000269|PubMed:20859650, ECO:0000269|PubMed:24124604, CC ECO:0000269|PubMed:25501895}. Cytoplasm {ECO:0000269|PubMed:24124604, CC ECO:0000269|PubMed:25501895, ECO:0000269|PubMed:34058472}. Cell CC membrane {ECO:0000269|PubMed:25501895, ECO:0000269|PubMed:30949721}; CC Peripheral membrane protein {ECO:0000305}. Cell junction, adherens CC junction {ECO:0000250|UniProtKB:Q9QY23}. Note=Translocates to the CC nucleus following canonical WNT signaling activation by WNT3A CC (PubMed:34058472). Maintains a cytoplasmic pool which can then be CC translocated to the desmosome, the cytoplasmic pool is maintained CC through PKP3 interaction with SFN (PubMed:24124604). Aberrant increases CC in translocation to the desmosome result in cell junction instability CC and therefore decreased cell adhesion (PubMed:24124604). Partially CC colocalizes at cell junctions in a zipper-like pattern with DSP, CDH1, CC CTNNB1 and CTNND1 in the early stages of keratinocyte differentiation CC (By similarity). Moves to cell junctions at tricellular contacts as CC differentiation progresses and as epithelial sheet formation completes CC (By similarity). {ECO:0000250|UniProtKB:Q9QY23, CC ECO:0000269|PubMed:24124604, ECO:0000269|PubMed:34058472}. CC -!- SUBCELLULAR LOCATION: [Isoform PKP3a]: Cell junction, desmosome CC {ECO:0000269|PubMed:24178805}. Cytoplasm {ECO:0000269|PubMed:24178805}. CC -!- SUBCELLULAR LOCATION: [Isoform PKP3b]: Cell junction, desmosome CC {ECO:0000269|PubMed:24178805}. Cytoplasm {ECO:0000269|PubMed:24178805}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage; Named isoforms=2; CC Name=PKP3a; CC IsoId=Q9Y446-1; Sequence=Displayed; CC Name=PKP3b; CC IsoId=Q9Y446-2; Sequence=VSP_053646; CC -!- TISSUE SPECIFICITY: Expressed in the epidermis of the skin, in squamous CC non-cornifying epithelial cells in the vagina, single layer epithelia CC of the duodenum and pancreas acini and non-epithelial dendritic CC reticulum cells of lymph node follicles (at protein level). CC {ECO:0000269|PubMed:10374265}. CC -!- TISSUE SPECIFICITY: [Isoform PKP3a]: Expressed in the oral cavity CC mucosa, epidermis and small intestine epithelium (at protein level). CC {ECO:0000269|PubMed:24178805}. CC -!- TISSUE SPECIFICITY: [Isoform PKP3b]: Expressed in the oral cavity CC mucosa and epithelial cells of the crypts and villi in the small CC intestine (at protein level) (PubMed:24178805). Expressed in the CC epidermis with more abundant expression found in the basal and low CC spinous cells (at protein level) (PubMed:24178805). CC {ECO:0000269|PubMed:24178805}. CC -!- PTM: Phosphorylated at Ser-285 when localized to the cytoplasm, PKP3 at CC desmosome cell junctions is not phosphorylated (PubMed:24124604). CC Phosphorylation at Try-195 by SRC is induced by reactive oxygen species CC and potentially acts as a release mechanism from desmosome cell-cell CC junctions (PubMed:25501895). {ECO:0000269|PubMed:24124604, CC ECO:0000269|PubMed:25501895}. CC -!- MISCELLANEOUS: Poorly differentiated, high Gleason grade prostate CC adenocarcinomas show an increase in phosphorylation at Tyr-195, CC potentially indicating a role for SRC-driven phosphorylation of PKP3 in CC the dedifferentiation of prostate tumor cells. CC {ECO:0000269|PubMed:25501895}. CC -!- SIMILARITY: Belongs to the beta-catenin family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Z98265; CAB44310.1; -; mRNA. DR EMBL; AF053719; AAF23050.1; -; mRNA. DR EMBL; FN421477; CAZ65731.1; -; mRNA. DR EMBL; AK223511; BAD97231.1; -; mRNA. DR EMBL; BC000081; AAH00081.1; -; mRNA. DR EMBL; DA439471; -; NOT_ANNOTATED_CDS; mRNA. DR CCDS; CCDS7695.1; -. [Q9Y446-1] DR RefSeq; NP_001289958.1; NM_001303029.2. [Q9Y446-2] DR RefSeq; NP_009114.1; NM_007183.4. [Q9Y446-1] DR AlphaFoldDB; Q9Y446; -. DR EMDB; EMD-40675; -. DR SMR; Q9Y446; -. DR BioGRID; 116357; 164. DR FunCoup; Q9Y446; 720. DR MINT; Q9Y446; -. DR STRING; 9606.ENSP00000331678; -. DR GlyGen; Q9Y446; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q9Y446; -. DR PhosphoSitePlus; Q9Y446; -. DR SwissPalm; Q9Y446; -. DR BioMuta; PKP3; -. DR DMDM; 20139301; -. DR CPTAC; CPTAC-990; -. DR jPOST; Q9Y446; -. DR MassIVE; Q9Y446; -. DR PaxDb; 9606-ENSP00000331678; -. DR PeptideAtlas; Q9Y446; -. DR PRIDE; Q9Y446; -. DR ProteomicsDB; 86098; -. [Q9Y446-1] DR Antibodypedia; 4571; 291 antibodies from 34 providers. DR DNASU; 11187; -. DR Ensembl; ENST00000331563.7; ENSP00000331678.2; ENSG00000184363.11. [Q9Y446-1] DR Ensembl; ENST00000534401.6; ENSP00000434517.3; ENSG00000184363.11. [Q9Y446-2] DR GeneID; 11187; -. DR KEGG; hsa:11187; -. DR MANE-Select; ENST00000331563.7; ENSP00000331678.2; NM_007183.4; NP_009114.1. DR UCSC; uc001lpc.3; human. [Q9Y446-1] DR AGR; HGNC:9025; -. DR ClinPGx; PA33358; -. DR CTD; 11187; -. DR DisGeNET; 11187; -. DR GeneCards; PKP3; -. DR HGNC; HGNC:9025; PKP3. DR HPA; ENSG00000184363; Tissue enhanced (esophagus, skin). DR MIM; 605561; gene. DR OpenTargets; ENSG00000184363; -. DR VEuPathDB; HostDB:ENSG00000184363; -. DR eggNOG; KOG1048; Eukaryota. DR GeneTree; ENSGT00940000159515; -. DR HOGENOM; CLU_009111_2_0_1; -. DR InParanoid; Q9Y446; -. DR OMA; YAFERQM; -. DR PAN-GO; Q9Y446; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q9Y446; -. DR PathwayCommons; Q9Y446; -. DR Reactome; R-HSA-6805567; Keratinization. DR Reactome; R-HSA-6809371; Formation of the cornified envelope. DR SignaLink; Q9Y446; -. DR SIGNOR; Q9Y446; -. DR Agora; ENSG00000184363; -. DR BioGRID-ORCS; 11187; 9 hits in 1157 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; PKP3; human. DR GeneWiki; PKP3; -. DR GenomeRNAi; 11187; -. DR Pharos; Q9Y446; Tbio. DR PRO; PR:Q9Y446; -. DR Proteomes; UP000005640; Chromosome 11. DR RNAct; Q9Y446; protein. DR Bgee; ENSG00000184363; Expressed in lower esophagus mucosa and 157 other cell types or tissues. DR ExpressionAtlas; Q9Y446; baseline and differential. DR GO; GO:0005912; C:adherens junction; HDA:BHF-UCL. DR GO; GO:0030054; C:cell junction; IDA:HPA. DR GO; GO:0005911; C:cell-cell junction; TAS:ProtInc. DR GO; GO:0001533; C:cornified envelope; TAS:Reactome. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0030057; C:desmosome; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0045294; F:alpha-catenin binding; IPI:BHF-UCL. DR GO; GO:0045296; F:cadherin binding; IBA:GO_Central. DR GO; GO:0098641; F:cadherin binding involved in cell-cell adhesion; HDA:BHF-UCL. DR GO; GO:0050839; F:cell adhesion molecule binding; IPI:UniProtKB. DR GO; GO:0019899; F:enzyme binding; IPI:CAFA. DR GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW. DR GO; GO:0030036; P:actin cytoskeleton organization; ISS:UniProtKB. DR GO; GO:0098609; P:cell-cell adhesion; IBA:GO_Central. DR GO; GO:0002159; P:desmosome assembly; IMP:UniProtKB. DR GO; GO:0002934; P:desmosome organization; ISS:UniProtKB. DR GO; GO:0090136; P:epithelial cell-cell adhesion; ISS:UniProtKB. DR GO; GO:0010669; P:epithelial structure maintenance; ISS:UniProtKB. DR GO; GO:1902373; P:negative regulation of mRNA catabolic process; IMP:CAFA. DR GO; GO:0045785; P:positive regulation of cell adhesion; IMP:UniProtKB. DR GO; GO:1902808; P:positive regulation of cell cycle G1/S phase transition; ISS:UniProtKB. DR GO; GO:0022409; P:positive regulation of cell-cell adhesion; IMP:UniProtKB. DR GO; GO:1903829; P:positive regulation of protein localization; ISS:UniProtKB. DR GO; GO:0072659; P:protein localization to plasma membrane; IMP:UniProtKB. DR GO; GO:0002718; P:regulation of cytokine production involved in immune response; ISS:UniProtKB. DR GO; GO:0051797; P:regulation of hair follicle development; ISS:UniProtKB. DR FunFam; 1.25.10.10:FF:000199; plakophilin-3; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR000225; Armadillo. DR InterPro; IPR028435; Plakophilin/d_Catenin. DR PANTHER; PTHR10372:SF1; PLAKOPHILIN-3; 1. DR PANTHER; PTHR10372; PLAKOPHILLIN-RELATED; 1. DR Pfam; PF00514; Arm; 2. DR SMART; SM00185; ARM; 4. DR SUPFAM; SSF48371; ARM repeat; 1. DR PROSITE; PS50176; ARM_REPEAT; 1. PE 1: Evidence at protein level; KW Alternative promoter usage; Cell adhesion; Cell junction; Cell membrane; KW Cytoplasm; Membrane; Methylation; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; RNA-binding. FT CHAIN 1..797 FT /note="Plakophilin-3" FT /id="PRO_0000064287" FT REPEAT 305..348 FT /note="ARM 1" FT REPEAT 351..390 FT /note="ARM 2" FT REPEAT 393..432 FT /note="ARM 3" FT REPEAT 449..487 FT /note="ARM 4" FT REPEAT 491..536 FT /note="ARM 5" FT REPEAT 596..637 FT /note="ARM 6" FT REPEAT 645..684 FT /note="ARM 7" FT REPEAT 689..730 FT /note="ARM 8" FT REGION 56..82 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 283..288 FT /note="Required for interaction with SFN" FT /evidence="ECO:0000269|PubMed:24124604" FT REGION 294..724 FT /note="Required for interaction with GSK3B" FT /evidence="ECO:0000269|PubMed:34058472" FT REGION 516..797 FT /note="Required for binding to PKP2 mRNA" FT /evidence="ECO:0000269|PubMed:25225333" FT SITE 285 FT /note="Interacts with SFN" FT /evidence="ECO:0000269|PubMed:29678907" FT MOD_RES 81 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 123 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9QY23" FT MOD_RES 180 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 183 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 195 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:25501895" FT MOD_RES 238 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 240 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 250 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 261 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 285 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:24124604" FT MOD_RES 313 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 314 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 331 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..12 FT /note="MQDGNFLLSALQ -> MESWTPRPSAVASGMSWEAGGIRTTSR (in FT isoform PKP3b)" FT /evidence="ECO:0000303|PubMed:16344560, FT ECO:0000303|PubMed:24178805" FT /id="VSP_053646" FT MUTAGEN 285 FT /note="S->A: Abolishes interaction with SFN." FT /evidence="ECO:0000269|PubMed:24124604, FT ECO:0000269|PubMed:29678907" FT CONFLICT 719 FT /note="V -> A (in Ref. 4; BAD97231)" FT /evidence="ECO:0000305" FT CONFLICT 730 FT /note="V -> G (in Ref. 4; BAD97231)" FT /evidence="ECO:0000305" SQ SEQUENCE 797 AA; 87082 MW; D43C7E77FA805E7E CRC64; MQDGNFLLSA LQPEAGVCSL ALPSDLQLDR RGAEGPEAER LRAARVQEQV RARLLQLGQQ PRHNGAAEPE PEAETARGTS RGQYHTLQAG FSSRSQGLSG DKTSGFRPIA KPAYSPASWS SRSAVDLSCS RRLSSAHNGG SAFGAAGYGG AQPTPPMPTR PVSFHERGGV GSRADYDTLS LRSLRLGPGG LDDRYSLVSE QLEPAATSTY RAFAYERQAS SSSSRAGGLD WPEATEVSPS RTIRAPAVRT LQRFQSSHRS RGVGGAVPGA VLEPVARAPS VRSLSLSLAD SGHLPDVHGF NSYGSHRTLQ RLSSGFDDID LPSAVKYLMA SDPNLQVLGA AYIQHKCYSD AAAKKQARSL QAVPRLVKLF NHANQEVQRH ATGAMRNLIY DNADNKLALV EENGIFELLR TLREQDDELR KNVTGILWNL SSSDHLKDRL ARDTLEQLTD LVLSPLSGAG GPPLIQQNAS EAEIFYNATG FLRNLSSASQ ATRQKMRECH GLVDALVTSI NHALDAGKCE DKSVENAVCV LRNLSYRLYD EMPPSALQRL EGRGRRDLAG APPGEVVGCF TPQSRRLREL PLAADALTFA EVSKDPKGLE WLWSPQIVGL YNRLLQRCEL NRHTTEAAAG ALQNITAGDR RWAGVLSRLA LEQERILNPL LDRVRTADHH QLRSLTGLIR NLSRNARNKD EMSTKVVSHL IEKLPGSVGE KSPPAEVLVN IIAVLNNLVV ASPIAARDLL YFDGLRKLIF IKKKRDSPDS EKSSRAASSL LANLWQYNKL HRDFRAKGYR KEDFLGP // ID RB_HUMAN Reviewed; 928 AA. AC P06400; A8K5E3; P78499; Q5VW46; Q8IZL4; DT 01-JAN-1988, integrated into UniProtKB/Swiss-Prot. DT 01-JAN-1990, sequence version 2. DT 28-JAN-2026, entry version 286. DE RecName: Full=Retinoblastoma-associated protein; DE AltName: Full=p105-Rb; DE AltName: Full=p110-RB1 {ECO:0000303|PubMed:8336704}; DE AltName: Full=pRb; DE Short=Rb; DE AltName: Full=pp110; GN Name=RB1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=3657987; DOI=10.1038/329642a0; RA Lee W.-H., Shew J.-Y., Hong F.D., Sery T.W., Donoso L.A., Young L.-J.S., RA Bookstein R., Lee E.Y.-H.P.; RT "The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein RT associated with DNA binding activity."; RL Nature 329:642-645(1987). RN [2] RP SEQUENCE REVISION. RX PubMed=3823889; DOI=10.1126/science.3823889; RA Lee W.-H., Bookstein R., Hong F.D., Young L.-J., Shew J.-Y., Lee E.Y.-H.P.; RT "Human retinoblastoma susceptibility gene: cloning, identification, and RT sequence."; RL Science 235:1394-1399(1987). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=3480530; DOI=10.1073/pnas.84.24.9059; RA Friend S.H., Horowitz J.M., Gerber M.R., Wang X.-F., Bogenmann E., Li F.P., RA Weinberg R.A.; RT "Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: RT organization of the sequence and its encoded protein."; RL Proc. Natl. Acad. Sci. U.S.A. 84:9059-9063(1987). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=2701949; DOI=10.1016/0378-1119(89)90256-4; RA McGee T.L., Yandell D.W., Dryja T.P.; RT "Structure and partial genomic sequence of the human retinoblastoma RT susceptibility gene."; RL Gene 80:119-128(1989). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC TISSUE=Carcinoma; RX PubMed=1352398; RA Hogg A., Onadim Z., Baird P.N., Cowell J.K.; RT "Detection of heterozygous mutations in the RB1 gene in retinoblastoma RT patients using single-strand conformation polymorphism analysis and RT polymerase chain reaction sequencing."; RL Oncogene 7:1445-1451(1992). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=7902321; DOI=10.1006/geno.1993.1368; RA Toguchida J., McGee T.L., Paterson J.C., Eagle J.R., Tucker S., RA Yandell D.W., Dryja T.P.; RT "Complete genomic sequence of the human retinoblastoma susceptibility RT gene."; RL Genomics 17:535-543(1993). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LYS-436 AND GLY-525. RG NIEHS SNPs program; RL Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057823; DOI=10.1038/nature02379; RA Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L., RA Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S., RA Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P., RA Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L., RA Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P., RA Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P., RA Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C., RA Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P., RA Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L., RA Frankish A.G., Frankland J., French L., Garner P., Garnett J., RA Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M., RA Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D., RA Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D., RA Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., RA Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S., RA Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S., RA Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R., RA Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W., RA Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P., RA Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L., RA Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R., RA Rogers J., Ross M.T.; RT "The DNA sequence and analysis of human chromosome 13."; RL Nature 428:522-528(2004). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Cervix, and Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-45. RX PubMed=2717184; RA T'Ang A., Wu K.J., Hashimoto T., Liu W.Y., Takahashi R., Shi X.H., RA Mihara K., Zhang F.H., Chen Y.Y., Du C., Qian J., Lin Y.G., Murphree A.L., RA Qiu W.R., Thompson T., Benedict W.F., Fung Y.K.T.; RT "Genomic organization of the human retinoblastoma gene."; RL Oncogene 4:401-407(1989). RN [13] RP PROTEIN SEQUENCE OF 47-65, AND INVOLVEMENT IN RETINOBLASTOMA. RX PubMed=7881418; DOI=10.1093/hmg/3.12.2187; RA Lohmann D.R., Brandt B., Hopping W., Passarge E., Horsthemke B.; RT "Spectrum of small length germline mutations in the RB1 gene."; RL Hum. Mol. Genet. 3:2187-2193(1994). RN [14] RP INTERACTION WITH SV40 LARGE T ANTIGEN AND HPV E7 PROTEIN (MICROBIAL RP INFECTION). RX PubMed=1316611; DOI=10.1073/pnas.89.10.4549; RA Chellappan S., Kraus V.B., Kroger B., Munger K., Howley P.M., Phelps W.C., RA Nevins J.R.; RT "Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 RT protein share the capacity to disrupt the interaction between transcription RT factor E2F and the retinoblastoma gene product."; RL Proc. Natl. Acad. Sci. U.S.A. 89:4549-4553(1992). RN [15] RP INTERACTION WITH E2F1. RX PubMed=8336704; DOI=10.1128/mcb.13.8.4588-4599.1993; RA Zacksenhaus E., Bremner R., Phillips R.A., Gallie B.L.; RT "A bipartite nuclear localization signal in the retinoblastoma gene product RT and its importance for biological activity."; RL Mol. Cell. Biol. 13:4588-4599(1993). RN [16] RP PHOSPHORYLATION BY CDK6. RX PubMed=8114739; DOI=10.1128/mcb.14.3.2077-2086.1994; RA Meyerson M., Harlow E.; RT "Identification of G1 kinase activity for cdk6, a novel cyclin D partner."; RL Mol. Cell. Biol. 14:2077-2086(1994). RN [17] RP INTERACTION WITH SV40 LARGE T ANTIGEN (MICROBIAL INFECTION). RX PubMed=2839300; DOI=10.1016/0092-8674(88)90559-4; RA Decaprio J.A., Ludlow J.W., Figge J., Shew J.-Y., Huang C.-M., Lee W.-H., RA Marsilio E., Paucha E., Livingston D.M.; RT "SV40 large tumor antigen forms a specific complex with the product of the RT retinoblastoma susceptibility gene."; RL Cell 54:275-283(1988). RN [18] RP INVOLVEMENT IN RETINOBLASTOMA. RX PubMed=3413073; DOI=10.1073/pnas.85.16.6017; RA Lee E.Y.-H.P., Bookstein R., Young L.-J., Lin C.-J., Rosenfeld M.G., RA Lee W.-H.; RT "Molecular mechanism of retinoblastoma gene inactivation in retinoblastoma RT cell line Y79."; RL Proc. Natl. Acad. Sci. U.S.A. 85:6017-6021(1988). RN [19] RP PHOSPHORYLATION AT SER-249; THR-252; THR-373; SER-807 AND SER-811. RX PubMed=1756735; DOI=10.1002/j.1460-2075.1991.tb05006.x; RA Lees J.A., Buchkovich K.J., Marshak D.R., Anderson C.W., Harlow E.; RT "The retinoblastoma protein is phosphorylated on multiple sites by human RT cdc2."; RL EMBO J. 10:4279-4290(1991). RN [20] RP INTERACTION WITH KDM5A AND ARID4A. RX PubMed=8414517; RA Fattaey A.R., Helin K., Dembski M.S., Dyson N., Harlow E., Vuocolo G.A., RA Hanobik M.G., Haskell K.M., Oliff A., Defeo-Jones D., Jones R.E.; RT "Characterization of the retinoblastoma binding proteins RBP1 and RBP2."; RL Oncogene 8:3149-3156(1993). RN [21] RP INTERACTION WITH THOC1. RX PubMed=7525595; DOI=10.1083/jcb.127.3.609; RA Durfee T., Mancini M.A., Jones D., Elledge S.J., Lee W.H.; RT "The amino-terminal region of the retinoblastoma gene product binds a novel RT nuclear matrix protein that co-localizes to centers for RNA processing."; RL J. Cell Biol. 127:609-622(1994). RN [22] RP INTERACTION WITH KDM5A. RX PubMed=7935440; DOI=10.1128/mcb.14.11.7256-7264.1994; RA Kim Y.W., Otterson G.A., Kratzke R.A., Coxon A.B., Kaye F.J.; RT "Differential specificity for binding of retinoblastoma binding protein 2 RT to RB, p107, and TATA-binding protein."; RL Mol. Cell. Biol. 14:7256-7264(1994). RN [23] RP INTERACTION WITH HHV-5 PROTEIN UL123 (MICROBIAL INFECTION). RX PubMed=8892909; DOI=10.1128/jvi.70.11.7867-7877.1996; RA Poma E.E., Kowalik T.F., Zhu L., Sinclair J.H., Huang E.S.; RT "The human cytomegalovirus IE1-72 protein interacts with the cellular p107 RT protein and relieves p107-mediated transcriptional repression of an E2F- RT responsive promoter."; RL J. Virol. 70:7867-7877(1996). RN [24] RP INTERACTION WITH ARID3B. RX PubMed=10446990; RA Numata S., Claudio P.P., Dean C., Giordano A., Croce C.M.; RT "Bdp, a new member of a family of DNA-binding proteins, associates with the RT retinoblastoma gene product."; RL Cancer Res. 59:3741-3747(1999). RN [25] RP FUNCTION, PHOSPHORYLATION AT SER-567 BY CDK2, AND PHOSPHORYLATION BY CDK4 RP AND CDK6. RX PubMed=10499802; DOI=10.1016/s0092-8674(00)81519-6; RA Harbour J.W., Luo R.X., Dei Santi A., Postigo A.A., Dean D.C.; RT "Cdk phosphorylation triggers sequential intramolecular interactions that RT progressively block Rb functions as cells move through G1."; RL Cell 98:859-869(1999). RN [26] RP INTERACTION WITH NDC80. RX PubMed=10409732; DOI=10.1128/mcb.19.8.5417; RA Zheng L., Chen Y., Lee W.-H.; RT "Hec1p, an evolutionarily conserved coiled-coil protein, modulates RT chromosome segregation through interaction with SMC proteins."; RL Mol. Cell. Biol. 19:5417-5428(1999). RN [27] RP INTERACTION WITH NDC80. RX PubMed=10779342; DOI=10.1128/mcb.20.10.3529-3537.2000; RA Zheng L., Chen Y., Riley D.J., Chen P.-L., Lee W.-H.; RT "Retinoblastoma protein enhances the fidelity of chromosome segregation RT mediated by hsHec1p."; RL Mol. Cell. Biol. 20:3529-3537(2000). RN [28] RP INTERACTION WITH TAF1. RX PubMed=9858607; DOI=10.1128/mcb.19.1.846; RA Siegert J.L., Robbins P.D.; RT "Rb inhibits the intrinsic kinase activity of TATA-binding protein- RT associated factor TAFII250."; RL Mol. Cell. Biol. 19:846-854(1999). RN [29] RP INTERACTION WITH PAX5. RX PubMed=10197586; RA Eberhard D., Busslinger M.; RT "The partial homeodomain of the transcription factor Pax-5 (BSAP) is an RT interaction motif for the retinoblastoma and TATA-binding proteins."; RL Cancer Res. 59:1716-1724(1999). RN [30] RP INTERACTION WITH E4F1. RX PubMed=10869426; DOI=10.1073/pnas.130198397; RA Fajas L., Paul C., Zugasti O., Le Cam L., Polanowska J., Fabbrizio E., RA Medema R., Vignais M.-L., Sardet C.; RT "pRB binds to and modulates the transrepressing activity of the E1A- RT regulated transcription factor p120E4F."; RL Proc. Natl. Acad. Sci. U.S.A. 97:7738-7743(2000). RN [31] RP INTERACTION WITH EID1. RX PubMed=11223246; DOI=10.1016/s0378-1119(00)00585-0; RA Wen H., Ao S.; RT "Identification and characterization of a novel human cDNA encoding a 21 RT kDa pRb-associated protein."; RL Gene 263:85-92(2001). RN [32] RP INTERACTION WITH DNMT1. RX PubMed=10888886; DOI=10.1038/77124; RA Robertson K.D., Ait-Si-Ali S., Yokochi T., Wade P.A., Jones P.L., RA Wolffe A.P.; RT "DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription RT from E2F-responsive promoters."; RL Nat. Genet. 25:338-342(2000). RN [33] RP INTERACTION WITH SUV39H1. RX PubMed=11484059; DOI=10.1038/35087620; RA Nielsen S.J., Schneider R., Bauer U.-M., Bannister A.J., Morrison A., RA O'Carroll D., Firestein R., Cleary M.L., Jenuwein T., Herrera R.E., RA Kouzarides T.; RT "Rb targets histone H3 methylation and HP1 to promoters."; RL Nature 412:561-565(2001). RN [34] RP INTERACTION WITH USP4. RX PubMed=11571652; DOI=10.1038/sj.onc.1204824; RA DeSalle L.M., Latres E., Lin D., Graner E., Montagnoli A., Baker R.T., RA Pagano M., Loda M.; RT "The de-ubiquitinating enzyme Unp interacts with the retinoblastoma RT protein."; RL Oncogene 20:5538-5542(2001). RN [35] RP INTERACTION WITH AATF. RX PubMed=12450794; DOI=10.1016/s1535-6108(02)00182-4; RA Bruno T., De Angelis R., De Nicola F., Barbato C., Di Padova M., Corbi N., RA Libri V., Benassi B., Mattei E., Chersi A., Soddu S., Floridi A., RA Passananti C., Fanciulli M.; RT "Che-1 affects cell growth by interfering with the recruitment of HDAC1 by RT Rb."; RL Cancer Cell 2:387-399(2002). RN [36] RP INTERACTION WITH TMPO-ALPHA AND LMNA. RX PubMed=12475961; DOI=10.1091/mbc.e02-07-0450; RA Markiewicz E., Dechat T., Foisner R., Quinlan R.A., Hutchison C.J.; RT "Lamin A/C binding protein LAP2alpha is required for nuclear anchorage of RT retinoblastoma protein."; RL Mol. Biol. Cell 13:4401-4413(2002). RN [37] RP INTERACTION WITH SNW1. RX PubMed=12466551; DOI=10.1093/nar/gkf658; RA Prathapam T., Kuhne C., Banks L.; RT "Skip interacts with the retinoblastoma tumor suppressor and inhibits its RT transcriptional repression activity."; RL Nucleic Acids Res. 30:5261-5268(2002). RN [38] RP INTERACTION WITH P-TEFB COMPLEX. RX PubMed=12037672; DOI=10.1038/sj.onc.1205511; RA Simone C., Bagella L., Bellan C., Giordano A.; RT "Physical interaction between pRb and cdk9/cyclinT2 complex."; RL Oncogene 21:4158-4165(2002). RN [39] RP INTERACTION WITH PELP1. RX PubMed=12682072; DOI=10.1074/jbc.m212822200; RA Balasenthil S., Vadlamudi R.K.; RT "Functional interactions between the estrogen receptor coactivator RT PELP1/MNAR and retinoblastoma protein."; RL J. Biol. Chem. 278:22119-22127(2003). RN [40] RP INTERACTION WITH HUMAN CYTOMEGALOVIRUS PROTEIN UL82 (MICROBIAL INFECTION). RX PubMed=12626766; DOI=10.1073/pnas.0538058100; RA Kalejta R.F., Shenk T.; RT "Proteasome-dependent, ubiquitin-independent degradation of the Rb family RT of tumor suppressors by the human cytomegalovirus pp71 protein."; RL Proc. Natl. Acad. Sci. U.S.A. 100:3263-3268(2003). RN [41] RP FUNCTION IN G0-G1 TRANSITION, AND PHOSPHORYLATION AT SER-807 AND SER-811 BY RP CDK3. RX PubMed=15084261; DOI=10.1016/s0092-8674(04)00300-9; RA Ren S., Rollins B.J.; RT "Cyclin C/cdk3 promotes Rb-dependent G0 exit."; RL Cell 117:239-251(2004). RN [42] RP INTERACTION WITH LIN9. RX PubMed=15538385; DOI=10.1038/sj.emboj.7600470; RA Gagrica S., Hauser S., Kolfschoten I., Osterloh L., Agami R., Gaubatz S.; RT "Inhibition of oncogenic transformation by mammalian Lin-9, a pRB- RT associated protein."; RL EMBO J. 23:4627-4638(2004). RN [43] RP INTERACTION WITH CEBPA. RX PubMed=15107404; DOI=10.1101/gad.1183304; RA Wang G.L., Iakova P., Wilde M., Awad S., Timchenko N.A.; RT "Liver tumors escape negative control of proliferation via PI3K/Akt- RT mediated block of C/EBP alpha growth inhibitory activity."; RL Genes Dev. 18:912-925(2004). RN [44] RP INTERACTION WITH LIMD1. RX PubMed=15542589; DOI=10.1073/pnas.0407123101; RA Sharp T.V., Munoz F., Bourboulia D., Presneau N., Darai E., Wang H.-W., RA Cannon M., Butcher D.N., Nicholson A.G., Klein G., Imreh S., Boshoff C.; RT "LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded at RT chromosome 3p21.3, binds pRB and represses E2F-driven transcription."; RL Proc. Natl. Acad. Sci. U.S.A. 101:16531-16536(2004). RN [45] RP PHOSPHORYLATION AT THR-821 AND THR-826. RX PubMed=15809340; DOI=10.1093/jb/mvi050; RA Takaki T., Fukasawa K., Suzuki-Takahashi I., Semba K., Kitagawa M., RA Taya Y., Hirai H.; RT "Preferences for phosphorylation sites in the retinoblastoma protein of D- RT type cyclin-dependent kinases, Cdk4 and Cdk6, in vitro."; RL J. Biochem. 137:381-386(2005). RN [46] RP INTERACTION WITH KDM4A. RX PubMed=15927959; DOI=10.1074/jbc.m413687200; RA Gray S.G., Iglesias A.H., Lizcano F., Villanueva R., Camelo S., Jingu H., RA Teh B.T., Koibuchi N., Chin W.W., Kokkotou E., Dangond F.; RT "Functional characterization of JMJD2A, a histone deacetylase- and RT retinoblastoma-binding protein."; RL J. Biol. Chem. 280:28507-28518(2005). RN [47] RP INTERACTION WITH KDM5B. RX PubMed=15803180; DOI=10.1038/modpathol.3800413; RA Roesch A., Becker B., Meyer S., Wild P., Hafner C., Landthaler M., Vogt T.; RT "Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding RT protein downregulated in malignant melanomas."; RL Mod. Pathol. 18:1249-1257(2005). RN [48] RP INTERACTION WITH KDM5A. RX PubMed=15949438; DOI=10.1016/j.molcel.2005.05.012; RA Benevolenskaya E.V., Murray H.L., Branton P., Young R.A., Kaelin W.G. Jr.; RT "Binding of pRB to the PHD protein RBP2 promotes cellular RT differentiation."; RL Mol. Cell 18:623-635(2005). RN [49] RP INTERACTION WITH PSMA3. RX PubMed=16337594; DOI=10.1016/j.molcel.2005.10.017; RA Sdek P., Ying H., Chang D.L., Qiu W., Zheng H., Touitou R., Allday M.J., RA Xiao Z.X.; RT "MDM2 promotes proteasome-dependent ubiquitin-independent degradation of RT retinoblastoma protein."; RL Mol. Cell 20:699-708(2005). RN [50] RP INTERACTION WITH ZUBR1. RX PubMed=16214886; DOI=10.1073/pnas.0507458102; RA Nakatani Y., Konishi H., Vassilev A., Kurooka H., Ishiguro K., Sawada J., RA Ikura T., Korsmeyer S.J., Qin J., Herlitz A.M.; RT "p600, a unique protein required for membrane morphogenesis and cell RT survival."; RL Proc. Natl. Acad. Sci. U.S.A. 102:15093-15098(2005). RN [51] RP INTERACTION WITH KDM5B. RX PubMed=16645588; DOI=10.1038/sj.jid.5700324; RA Roesch A., Becker B., Schneider-Brachert W., Hagen I., Landthaler M., RA Vogt T.; RT "Re-expression of the retinoblastoma-binding protein 2-homolog 1 reveals RT tumor-suppressive functions in highly metastatic melanoma cells."; RL J. Invest. Dermatol. 126:1850-1859(2006). RN [52] RP PHOSPHORYLATION AT SER-612 BY CHEK2, AND INTERACTION WITH CHEK2. RX PubMed=17380128; DOI=10.1038/sj.emboj.7601652; RA Inoue Y., Kitagawa M., Taya Y.; RT "Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB RT and E2F-1 after DNA damage."; RL EMBO J. 26:2083-2093(2007). RN [53] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-249; THR-252 AND THR-356, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [54] RP INTERACTION WITH MOLLUSCUM CONTAGIOSUM VIRUS PROTEIN MC007 (MICROBIAL RP FUNCTION). RX PubMed=18701596; DOI=10.1128/jvi.01187-08; RA Mohr S., Grandemange S., Massimi P., Darai G., Banks L., Martinou J.C., RA Zeier M., Muranyi W.; RT "Targeting the retinoblastoma protein by MC007L, gene product of the RT molluscum contagiosum virus: detection of a novel virus-cell interaction by RT a member of the poxviruses."; RL J. Virol. 82:10625-10633(2008). RN [55] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37; SER-249; THR-252; RP SER-612; SER-807; SER-811; THR-823 AND THR-826, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [56] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [57] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37; SER-249; THR-373; SER-807 RP AND THR-841, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [58] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [59] RP METHYLATION AT LYS-860, INTERACTION WITH L3MBTL1, AND MUTAGENESIS OF RP LYS-860; LYS-870 AND 873-LYS-LYS-874. RX PubMed=20870719; DOI=10.1074/jbc.m110.137612; RA Saddic L.A., West L.E., Aslanian A., Yates J.R. III, Rubin S.M., Gozani O., RA Sage J.; RT "Methylation of the retinoblastoma tumor suppressor by SMYD2."; RL J. Biol. Chem. 285:37733-37740(2010). RN [60] RP SUBCELLULAR LOCATION, TISSUE SPECIFICITY, ACETYLATION AT LYS-873 AND RP LYS-874, AND MUTAGENESIS OF 873-LYS--LYS-874. RX PubMed=20940255; DOI=10.1242/jcs.068924; RA Pickard A., Wong P.P., McCance D.J.; RT "Acetylation of Rb by PCAF is required for nuclear localization and RT keratinocyte differentiation."; RL J. Cell Sci. 123:3718-3726(2010). RN [61] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-821 AND THR-826, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [62] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [63] RP INTERACTION WITH UHRF2. RX PubMed=21952639; DOI=10.4161/cc.10.19.17176; RA Mori T., Ikeda D.D., Fukushima T., Takenoshita S., Kochi H.; RT "NIRF constitutes a nodal point in the cell cycle network and is a RT candidate tumor suppressor."; RL Cell Cycle 10:3284-3299(2011). RN [64] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-249, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [65] RP METHYLATION AT LYS-810 BY SMYD2. RX PubMed=22787429; DOI=10.1593/neo.12656; RA Cho H.S., Hayami S., Toyokawa G., Maejima K., Yamane Y., Suzuki T., RA Dohmae N., Kogure M., Kang D., Neal D.E., Ponder B.A., Yamaue H., RA Nakamura Y., Hamamoto R.; RT "RB1 methylation by SMYD2 enhances cell cycle progression through an RT increase of RB1 phosphorylation."; RL Neoplasia 14:476-486(2012). RN [66] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-249; THR-252; THR-356; RP THR-373; SER-624; SER-780; SER-788; SER-795; SER-807; SER-811; THR-821; RP THR-823; THR-826 AND SER-855, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [67] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [68] RP INTERACTION WITH BLCAP. RX PubMed=26986503; DOI=10.3892/or.2016.4686; RA Zhao M., Zhang L., Qiu X., Zeng F., Chen W., An Y., Hu B., Wu X., Wu X.; RT "BLCAP arrests G(1)/S checkpoint and induces apoptosis through RT downregulation of pRb1 in HeLa cells."; RL Oncol. Rep. 35:3050-3058(2016). RN [69] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 378-562. RX PubMed=9145110; DOI=10.1038/nsb0597-390; RA Kim H.Y., Cho Y.; RT "Structural similarity between the pocket region of retinoblastoma tumour RT suppressor and the cyclin-box."; RL Nat. Struct. Biol. 4:390-395(1997). RN [70] RP X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 380-785. RX PubMed=9495340; DOI=10.1038/36038; RA Lee J.O., Russo A.A., Pavletich N.P.; RT "Structure of the retinoblastoma tumour-suppressor pocket domain bound to a RT peptide from HPV E7."; RL Nature 391:859-865(1998). RN [71] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 860-876 IN COMPLEX WITH KPNA2. RX PubMed=12695505; DOI=10.1074/jbc.m303275200; RA Fontes M.R.M., Teh T., Jans D., Brinkworth R.I., Kobe B.; RT "Structural basis for the specificity of bipartite nuclear localization RT sequence binding by importin-alpha."; RL J. Biol. Chem. 278:27981-27987(2003). RN [72] RP X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 829-874 IN COMPLEX WITH E2F1 AND RP TFDP1, INTERACTION WITH HETERODIMERIC COMPLEXES CONTAINING TFDP1 AND EITHER RP E2F1; E2F3; E2F4 OR E2F5, MUTAGENESIS OF THR-821 AND THR-826, AND RP PHOSPHORYLATION AT THR-821 AND THR-826. RX PubMed=16360038; DOI=10.1016/j.cell.2005.09.044; RA Rubin S.M., Gall A.-L., Zheng N., Pavletich N.P.; RT "Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for RT phosphorylation-induced E2F release."; RL Cell 123:1093-1106(2005). RN [73] RP X-RAY CRYSTALLOGRAPHY (1.67 ANGSTROMS) OF 380-787 IN COMPLEX WITH HUMAN RP ADENOVIRUS E1A PROTEIN (MICROBIAL INFECTION). RX PubMed=17974914; DOI=10.1101/gad.1590607; RA Liu X., Marmorstein R.; RT "Structure of the retinoblastoma protein bound to adenovirus E1A reveals RT the molecular basis for viral oncoprotein inactivation of a tumor RT suppressor."; RL Genes Dev. 21:2711-2716(2007). RN [74] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 52-355, PARTIAL PROTEIN SEQUENCE, RP IDENTIFICATION BY MASS SPECTROMETRY, INTERACTION WITH THOC1 AND GRIP1, AND RP INTERACTION OF THE UNPHOSPHORYLATED PROTEIN WITH EID1. RX PubMed=17996702; DOI=10.1016/j.molcel.2007.08.023; RA Hassler M., Singh S., Yue W.W., Luczynski M., Lakbir R., RA Sanchez-Sanchez F., Bader T., Pearl L.H., Mittnacht S.; RT "Crystal structure of the retinoblastoma protein N domain provides insight RT into tumor suppression, ligand interaction, and holoprotein architecture."; RL Mol. Cell 28:371-385(2007). RN [75] RP VARIANT RB LEU-567. RX PubMed=2594029; DOI=10.1056/nejm198912213212501; RA Yandell D.W., Campbell T.A., Dayton S.H., Petersen R., Walton D., RA Little J.B., McConkie-Rosell A., Buckley E., Dryja T.P.; RT "Oncogenic point mutations in the human retinoblastoma gene: their RT application to genetic counseling."; RL N. Engl. J. Med. 321:1689-1695(1989). RN [76] RP VARIANT RB TRP-661. RX PubMed=1352883; DOI=10.1073/pnas.89.13.6177; RA Onadim Z., Hogg A., Baird P.N., Cowell J.K.; RT "Oncogenic point mutations in exon 20 of the RB1 gene in families showing RT incomplete penetrance and mild expression of the retinoblastoma RT phenotype."; RL Proc. Natl. Acad. Sci. U.S.A. 89:6177-6181(1992). RN [77] RP VARIANT RB ARG-457. RX PubMed=8346255; DOI=10.1073/pnas.90.15.7351; RA Hogg A., Bia B., Onadim Z., Cowell J.K.; RT "Molecular mechanisms of oncogenic mutations in tumors from patients with RT bilateral and unilateral retinoblastoma."; RL Proc. Natl. Acad. Sci. U.S.A. 90:7351-7355(1993). RN [78] RP VARIANT RB ARG-530. RX PubMed=7704558; DOI=10.1159/000472372; RA Cowell J.K., Smith T., Bia B.; RT "Frequent constitutional C to T mutations in CGA-arginine codons in the RB1 RT gene produce premature stop codons in patients with bilateral (hereditary) RT retinoblastoma."; RL Eur. J. Hum. Genet. 2:281-290(1994). RN [79] RP VARIANTS RB ASN-480 DEL AND TRP-661. RX PubMed=7927327; DOI=10.1007/bf00201591; RA Lohmann D.R., Brandt B., Hoepping W., Passarge E., Horsthemke B.; RT "Distinct RB1 gene mutations with low penetrance in hereditary RT retinoblastoma."; RL Hum. Genet. 94:349-354(1994). RN [80] RP VARIANT RB TYR-706. RX PubMed=8118465; DOI=10.1002/humu.1380030108; RA Kato M.V., Ishizaki K., Toguchida J., Kaneko A., Takayama J., Tanooka H., RA Kato T., Shimizu T., Sasaki M.S.; RT "Mutations in the retinoblastoma gene and their expression in somatic and RT tumor cells of patients with hereditary retinoblastoma."; RL Hum. Mutat. 3:44-51(1994). RN [81] RP VARIANTS RB GLN-72; TYR-549 AND LYS-803. RX PubMed=8605116; DOI=10.1002/gcc.2870140406; RA Liu Z., Song Y., Bia B., Cowell J.K.; RT "Germline mutations in the RB1 gene in patients with hereditary RT retinoblastoma."; RL Genes Chromosomes Cancer 14:277-284(1995). RN [82] RP VARIANTS RB THR-185; PRO-635; GLU-654 AND PRO-685. RX PubMed=7795591; DOI=10.1093/hmg/4.3.383; RA Blanquet V., Turleau C., Gross-Morand M.S., Senamaud-Beaufort C., Doz F., RA Besmond C.; RT "Spectrum of germline mutations in the RB1 gene: a study of 232 patients RT with hereditary and non hereditary retinoblastoma."; RL Hum. Mol. Genet. 4:383-388(1995). RN [83] RP VARIANTS RB GLY-358; PRO-657 AND TRP-661. RX PubMed=8776589; DOI=10.1093/hmg/5.6.755; RA Van Orsouw N.J., Li D., van der Vlies P., Scheffer H., Eng C., RA Buys C.H.C.M., Li F.P., Vijg J.; RT "Mutational scanning of large genes by extensive PCR multiplexing and two- RT dimensional electrophoresis: application to the RB1 gene."; RL Hum. Mol. Genet. 5:755-761(1996). RN [84] RP VARIANTS RB ASP-137 AND TRP-661. RX PubMed=9311732; DOI=10.1086/514845; RA Lohmann D.R., Gerick M., Brandt B., Oelschlaeger U., Lorenz B., RA Passarge E., Horsthemke B.; RT "Constitutional RB1-gene mutations in patients with isolated unilateral RT retinoblastoma."; RL Am. J. Hum. Genet. 61:282-294(1997). RN [85] RP VARIANT RB GLN-447. RX PubMed=9140452; DOI=10.1016/s0165-4608(96)00387-1; RA Mateu E., Sanchez F., Najera C., Beneyto M., Castell V., Hernandez M., RA Serra I., Prieto F.; RT "Genetics of retinoblastoma: a study."; RL Cancer Genet. Cytogenet. 95:40-50(1997). RN [86] RP VARIANTS RB LEU-567; PRO-662 AND ARG-712. RX PubMed=10671068; RX DOI=10.1002/(sici)1098-1004(1998)12:6<434::aid-humu16>3.0.co;2-7; RA Yilmaz S., Horsthemke B., Lohmann D.R.; RT "Twelve novel RB1 gene mutations in patients with hereditary RT retinoblastoma."; RL Hum. Mutat. 12:434-434(1998). RN [87] RP VARIANT RB GLU-310. RX PubMed=9973307; DOI=10.1086/302254; RA Klutz M., Horsthemke B., Lohmann D.R.; RT "RB1 gene mutations in peripheral blood DNA of patients with isolated RT unilateral retinoblastoma."; RL Am. J. Hum. Genet. 64:667-668(1999). RN [88] RP VARIANTS RB GLY-500 AND GLU-616. RX PubMed=11524739; DOI=10.1002/humu.1184; RA Yu Y.S., Kim I.-J., Ku J.-L., Park J.-G.; RT "Identification of four novel RB1 germline mutations in Korean RT retinoblastoma patients."; RL Hum. Mutat. 18:252-252(2001). RN [89] RP VARIANT HIS-173. RX PubMed=23033978; DOI=10.1056/nejmoa1206524; RA de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G., RA Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C., RA del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G., RA Veltman J.A., Vissers L.E.; RT "Diagnostic exome sequencing in persons with severe intellectual RT disability."; RL N. Engl. J. Med. 367:1921-1929(2012). CC -!- FUNCTION: Tumor suppressor that is a key regulator of the G1/S CC transition of the cell cycle (PubMed:10499802). The hypophosphorylated CC form binds transcription regulators of the E2F family, preventing CC transcription of E2F-responsive genes (PubMed:10499802). Both CC physically blocks E2Fs transactivating domain and recruits chromatin- CC modifying enzymes that actively repress transcription CC (PubMed:10499802). Cyclin and CDK-dependent phosphorylation of RB1 CC induces its dissociation from E2Fs, thereby activating transcription of CC E2F responsive genes and triggering entry into S phase CC (PubMed:10499802). RB1 also promotes the G0-G1 transition upon CC phosphorylation and activation by CDK3/cyclin-C (PubMed:15084261). CC Directly involved in heterochromatin formation by maintaining overall CC chromatin structure and, in particular, that of constitutive CC heterochromatin by stabilizing histone methylation. Recruits and CC targets histone methyltransferases SUV39H1, KMT5B and KMT5C, leading to CC epigenetic transcriptional repression. Controls histone H4 'Lys-20' CC trimethylation. Inhibits the intrinsic kinase activity of TAF1. CC Mediates transcriptional repression by SMARCA4/BRG1 by recruiting a CC histone deacetylase (HDAC) complex to the c-FOS promoter. In resting CC neurons, transcription of the c-FOS promoter is inhibited by BRG1- CC dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon CC calcium influx, RB1 is dephosphorylated by calcineurin, which leads to CC release of the repressor complex (By similarity). CC {ECO:0000250|UniProtKB:P13405, ECO:0000250|UniProtKB:P33568, CC ECO:0000269|PubMed:10499802, ECO:0000269|PubMed:15084261}. CC -!- FUNCTION: (Microbial infection) In case of viral infections, CC interactions with SV40 large T antigen, HPV E7 protein or adenovirus CC E1A protein induce the disassembly of RB1-E2F1 complex thereby CC disrupting RB1's activity. {ECO:0000269|PubMed:1316611, CC ECO:0000269|PubMed:17974914, ECO:0000269|PubMed:18701596, CC ECO:0000269|PubMed:2839300, ECO:0000269|PubMed:8892909}. CC -!- SUBUNIT: The hypophosphorylated form interacts with and sequesters the CC E2F1 transcription factor, thereby inhibiting E2F1 transcription CC (PubMed:20940255, PubMed:8336704). Interacts with heterodimeric E2F/DP CC transcription factor complexes containing TFDP1 and either E2F1, E2F3, CC E2F4 or E2F5, or TFDP2 and E2F4. Interacts (when hyperphosphorylated CC and hypophosphorylated) with PKP3; the interaction inhibits RB1 CC interaction with and repression of the transcription factor E2F1, CC potentially via sequestering RB1 to the cytoplasm (By similarity). The CC unphosphorylated form interacts with EID1, ARID3B, KDM5A, SUV39H1, CC MJD2A/JHDM3A and THOC1. Interacts with the N-terminal domain of TAF1. CC Interacts with SNW1, ATAD5, AATF, DNMT1, LIN9, LMNA, KMT5B, KMT5C, CC PELP1, UHRF2 and TMPO-alpha. Interacts with GRIP1 and UBR4. Interacts CC with ARID4A and KDM5B. Interacts with E4F1 and LIMD1. Interacts with CC SMARCA4/BRG1 and HDAC1 (By similarity). Interacts with PSMA3 and USP4. CC Interacts (when methylated at Lys-860) with L3MBTL1. Interacts with CC CHEK2; phosphorylates RB1. Interacts with CDK1 and CDK2 (By CC similarity). Interacts with PRMT2. Interacts with CEBPA CC (PubMed:15107404). P-TEFB complex interacts with RB1; promotes CC phosphorylation of RB1 (PubMed:12037672). Interacts with RBBP9; the CC interaction disrupts RB1 binding to E2F1 (By similarity). Interacts CC with KAT2B/PCAF and EP300/P300 (By similarity). Interacts with PAX5 CC (PubMed:10197586). Interacts (phosphorylated and unphosphorylated) with CC BLCAP (PubMed:26986503). May interact with NDC80. CC {ECO:0000250|UniProtKB:P13405, ECO:0000250|UniProtKB:P33568, CC ECO:0000269|PubMed:10197586, ECO:0000269|PubMed:10409732, CC ECO:0000269|PubMed:10446990, ECO:0000269|PubMed:10779342, CC ECO:0000269|PubMed:10869426, ECO:0000269|PubMed:10888886, CC ECO:0000269|PubMed:11223246, ECO:0000269|PubMed:11484059, CC ECO:0000269|PubMed:11571652, ECO:0000269|PubMed:12037672, CC ECO:0000269|PubMed:12450794, ECO:0000269|PubMed:12466551, CC ECO:0000269|PubMed:12475961, ECO:0000269|PubMed:12682072, CC ECO:0000269|PubMed:12695505, ECO:0000269|PubMed:15107404, CC ECO:0000269|PubMed:15538385, ECO:0000269|PubMed:15542589, CC ECO:0000269|PubMed:15803180, ECO:0000269|PubMed:15927959, CC ECO:0000269|PubMed:15949438, ECO:0000269|PubMed:16214886, CC ECO:0000269|PubMed:16337594, ECO:0000269|PubMed:16360038, CC ECO:0000269|PubMed:16645588, ECO:0000269|PubMed:17380128, CC ECO:0000269|PubMed:17996702, ECO:0000269|PubMed:20870719, CC ECO:0000269|PubMed:20940255, ECO:0000269|PubMed:21952639, CC ECO:0000269|PubMed:26986503, ECO:0000269|PubMed:7525595, CC ECO:0000269|PubMed:7935440, ECO:0000269|PubMed:8336704, CC ECO:0000269|PubMed:8414517, ECO:0000269|PubMed:9858607}. CC -!- SUBUNIT: (Microbial infection) Interacts with adenovirus E1A protein. CC {ECO:0000269|PubMed:17974914}. CC -!- SUBUNIT: (Microbial infection) Interacts with HPV E7 protein. CC {ECO:0000269|PubMed:1316611}. CC -!- SUBUNIT: (Microbial infection) Interacts with SV40 large T antigen. CC {ECO:0000269|PubMed:1316611, ECO:0000269|PubMed:2839300}. CC -!- SUBUNIT: (Microbial infection) Interacts with human CC cytomegalovirus/HHV-5 proteins UL82 and UL123. CC {ECO:0000269|PubMed:12626766, ECO:0000269|PubMed:8892909}. CC -!- SUBUNIT: (Microbial infection) Interacts with molluscum contagiosum CC virus protein MC007. {ECO:0000269|PubMed:18701596}. CC -!- INTERACTION: CC P06400; Q9UKV8: AGO2; NbExp=3; IntAct=EBI-491274, EBI-528269; CC P06400; P24863: CCNC; NbExp=4; IntAct=EBI-491274, EBI-395261; CC P06400; P24941: CDK2; NbExp=3; IntAct=EBI-491274, EBI-375096; CC P06400; O14757: CHEK1; NbExp=3; IntAct=EBI-491274, EBI-974488; CC P06400; O96017: CHEK2; NbExp=3; IntAct=EBI-491274, EBI-1180783; CC P06400; P39880: CUX1; NbExp=4; IntAct=EBI-491274, EBI-719064; CC P06400; Q13574-2: DGKZ; NbExp=6; IntAct=EBI-491274, EBI-715527; CC P06400; Q13627: DYRK1A; NbExp=4; IntAct=EBI-491274, EBI-1053596; CC P06400; Q9Y463: DYRK1B; NbExp=4; IntAct=EBI-491274, EBI-634187; CC P06400; Q01094: E2F1; NbExp=32; IntAct=EBI-491274, EBI-448924; CC P06400; Q14209: E2F2; NbExp=5; IntAct=EBI-491274, EBI-718476; CC P06400; O00716: E2F3; NbExp=5; IntAct=EBI-491274, EBI-765551; CC P06400; Q16254: E2F4; NbExp=6; IntAct=EBI-491274, EBI-448943; CC P06400; Q15329: E2F5; NbExp=2; IntAct=EBI-491274, EBI-1389773; CC P06400; O43524: FOXO3; NbExp=2; IntAct=EBI-491274, EBI-1644164; CC P06400; P42685: FRK; NbExp=3; IntAct=EBI-491274, EBI-1383583; CC P06400; P15976: GATA1; NbExp=2; IntAct=EBI-491274, EBI-3909284; CC P06400; P62993: GRB2; NbExp=4; IntAct=EBI-491274, EBI-401755; CC P06400; O60381: HBP1; NbExp=2; IntAct=EBI-491274, EBI-954175; CC P06400; Q13547: HDAC1; NbExp=19; IntAct=EBI-491274, EBI-301834; CC P06400; Q14653: IRF3; NbExp=2; IntAct=EBI-491274, EBI-2650369; CC P06400; P29375: KDM5A; NbExp=2; IntAct=EBI-491274, EBI-1560836; CC P06400; Q16539: MAPK14; NbExp=4; IntAct=EBI-491274, EBI-73946; CC P06400; Q00987: MDM2; NbExp=5; IntAct=EBI-491274, EBI-389668; CC P06400; O15151: MDM4; NbExp=4; IntAct=EBI-491274, EBI-398437; CC P06400; Q9Y676: MRPS18B; NbExp=2; IntAct=EBI-491274, EBI-750085; CC P06400; Q14686: NCOA6; NbExp=3; IntAct=EBI-491274, EBI-78670; CC P06400; P07197: NEFM; NbExp=2; IntAct=EBI-491274, EBI-1105035; CC P06400; Q9UQ80: PA2G4; NbExp=4; IntAct=EBI-491274, EBI-924893; CC P06400; P62136: PPP1CA; NbExp=5; IntAct=EBI-491274, EBI-357253; CC P06400; P55345: PRMT2; NbExp=3; IntAct=EBI-491274, EBI-78458; CC P06400; Q00577: PURA; NbExp=6; IntAct=EBI-491274, EBI-1045860; CC P06400; P04049: RAF1; NbExp=3; IntAct=EBI-491274, EBI-365996; CC P06400; P06400: RB1; NbExp=3; IntAct=EBI-491274, EBI-491274; CC P06400; Q99708: RBBP8; NbExp=2; IntAct=EBI-491274, EBI-745715; CC P06400; O75150: RNF40; NbExp=3; IntAct=EBI-491274, EBI-744408; CC P06400; Q8WTS6: SETD7; NbExp=4; IntAct=EBI-491274, EBI-1268586; CC P06400; Q96PU4: UHRF2; NbExp=4; IntAct=EBI-491274, EBI-625304; CC P06400; Q93009: USP7; NbExp=8; IntAct=EBI-491274, EBI-302474; CC P06400; P30285: Cdk4; Xeno; NbExp=2; IntAct=EBI-491274, EBI-847225; CC P06400; Q155P7: Cenpf; Xeno; NbExp=4; IntAct=EBI-491274, EBI-2211248; CC P06400; A0MPS7: E7; Xeno; NbExp=2; IntAct=EBI-491274, EBI-7014709; CC P06400; P03129: E7; Xeno; NbExp=30; IntAct=EBI-491274, EBI-866453; CC P06400; P04020: E7; Xeno; NbExp=3; IntAct=EBI-491274, EBI-7005254; CC P06400; P06464: E7; Xeno; NbExp=3; IntAct=EBI-491274, EBI-6944797; CC P06400; P06465: E7; Xeno; NbExp=3; IntAct=EBI-491274, EBI-963841; CC P06400; P06788: E7; Xeno; NbExp=4; IntAct=EBI-491274, EBI-1776887; CC P06400; P52927: Hmga2; Xeno; NbExp=5; IntAct=EBI-491274, EBI-912574; CC P06400; Q9R002: Ifi202; Xeno; NbExp=5; IntAct=EBI-491274, EBI-3043899; CC P06400; Q8VSP9: ospF; Xeno; NbExp=2; IntAct=EBI-491274, EBI-6506625; CC P06400; Q9Z2X2: Psmd10; Xeno; NbExp=3; IntAct=EBI-491274, EBI-8377084; CC P06400; PRO_0000037321 [P0C6X7]: rep; Xeno; NbExp=3; IntAct=EBI-491274, EBI-25487301; CC P06400; Q923E4: Sirt1; Xeno; NbExp=4; IntAct=EBI-491274, EBI-1802585; CC P06400; Q3TKT4: Smarca4; Xeno; NbExp=4; IntAct=EBI-491274, EBI-1210244; CC P06400; P03070; Xeno; NbExp=9; IntAct=EBI-491274, EBI-617698; CC P06400; P03254; Xeno; NbExp=3; IntAct=EBI-491274, EBI-8599077; CC P06400; P03255; Xeno; NbExp=10; IntAct=EBI-491274, EBI-2603114; CC P06400; P03255-1; Xeno; NbExp=2; IntAct=EBI-491274, EBI-6692439; CC P06400; P03255-2; Xeno; NbExp=3; IntAct=EBI-491274, EBI-6859460; CC P06400; PRO_0000041225 [Q86500]; Xeno; NbExp=3; IntAct=EBI-491274, EBI-2568719; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20940255}. Cytoplasm CC {ECO:0000250|UniProtKB:P13405}. Note=During keratinocyte CC differentiation, acetylation by KAT2B/PCAF is required for nuclear CC localization (PubMed:20940255). Localizes to the cytoplasm when CC hyperphosphorylated (By similarity). {ECO:0000250|UniProtKB:P13405, CC ECO:0000269|PubMed:20940255}. CC -!- TISSUE SPECIFICITY: Expressed in the retina. Expressed in foreskin CC keratinocytes (at protein level) (PubMed:20940255). CC {ECO:0000269|PubMed:20940255}. CC -!- DOMAIN: The Pocket domain binds to the threonine-phosphorylated domain CC C, thereby preventing interaction with heterodimeric E2F/DP CC transcription factor complexes. CC -!- PTM: Phosphorylated by CDK6 and CDK4, and subsequently by CDK2 at Ser- CC 567 in G1, thereby releasing E2F1 which is then able to activate cell CC growth. Dephosphorylated at the late M phase. SV40 large T antigen, HPV CC E7 and adenovirus E1A bind to the underphosphorylated, active form of CC pRb. Phosphorylation at Thr-821 and Thr-826 promotes interaction CC between the C-terminal domain C and the Pocket domain, and thereby CC inhibits interactions with heterodimeric E2F/DP transcription factor CC complexes. Dephosphorylated at Ser-795 by calcineruin upon calcium CC stimulation. CDK3/cyclin-C-mediated phosphorylation at Ser-807 and Ser- CC 811 is required for G0-G1 transition. Phosphorylated by CDK1 and CDK2 CC upon TGFB1-mediated apoptosis. {ECO:0000269|PubMed:10499802, CC ECO:0000269|PubMed:8114739}. CC -!- PTM: N-terminus is methylated by METTL11A/NTM1 (By similarity). CC Monomethylation at Lys-810 by SMYD2 enhances phosphorylation at Ser-807 CC and Ser-811, and promotes cell cycle progression. Monomethylation at CC Lys-860 by SMYD2 promotes interaction with L3MBTL1. {ECO:0000250, CC ECO:0000269|PubMed:15084261, ECO:0000269|PubMed:15809340, CC ECO:0000269|PubMed:16360038, ECO:0000269|PubMed:17380128, CC ECO:0000269|PubMed:1756735, ECO:0000269|PubMed:20870719, CC ECO:0000269|PubMed:22787429}. CC -!- PTM: Acetylated during keratinocyte differentiation. Acetylation at CC Lys-873 and Lys-874 regulates subcellular localization. Can be CC deacetylated by SIRT1. {ECO:0000269|PubMed:20940255}. CC -!- DISEASE: Childhood cancer retinoblastoma (RB) [MIM:180200]: Congenital CC malignant tumor that arises from the nuclear layers of the retina. It CC occurs in about 1:20'000 live births and represents about 2% of CC childhood malignancies. It is bilateral in about 30% of cases. Although CC most RB appear sporadically, about 20% are transmitted as an autosomal CC dominant trait with incomplete penetrance. The diagnosis is usually CC made before the age of 2 years when strabismus or a gray to yellow CC reflex from pupil ('cat eye') is investigated. CC {ECO:0000269|PubMed:10671068, ECO:0000269|PubMed:11524739, CC ECO:0000269|PubMed:1352883, ECO:0000269|PubMed:2594029, CC ECO:0000269|PubMed:7704558, ECO:0000269|PubMed:7795591, CC ECO:0000269|PubMed:7927327, ECO:0000269|PubMed:8118465, CC ECO:0000269|PubMed:8346255, ECO:0000269|PubMed:8605116, CC ECO:0000269|PubMed:8776589, ECO:0000269|PubMed:9140452, CC ECO:0000269|PubMed:9311732, ECO:0000269|PubMed:9973307}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in CC tissues of the urinary bladder. It often presents with multiple tumors CC appearing at different times and at different sites in the bladder. CC Most bladder cancers are transitional cell carcinomas that begin in CC cells that normally make up the inner lining of the bladder. Other CC types of bladder cancer include squamous cell carcinoma (cancer that CC begins in thin, flat cells) and adenocarcinoma (cancer that begins in CC cells that make and release mucus and other fluids). Bladder cancer is CC a complex disorder with both genetic and environmental influences. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- DISEASE: Osteogenic sarcoma (OSRC) [MIM:259500]: A sarcoma originating CC in bone-forming cells, affecting the ends of long bones. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the retinoblastoma protein (RB) family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=RB1base; Note=RB1 mutation db; CC URL="http://rb1-lsdb.d-lohmann.de/"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/90/RB1"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Retinoblastoma protein entry; CC URL="https://en.wikipedia.org/wiki/Retinoblastoma_protein"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M15400; AAA69807.1; ALT_SEQ; mRNA. DR EMBL; M28419; AAA69808.1; -; mRNA. DR EMBL; M33647; AAA69806.1; -; mRNA. DR EMBL; L41870; AAB59465.1; -; mRNA. DR EMBL; M27866; AAA53484.1; -; Genomic_DNA. DR EMBL; M27845; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27846; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27847; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27849; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27850; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27851; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; L35146; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27852; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27853; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27854; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27855; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27856; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27857; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27858; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27859; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27860; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; L35147; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27862; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27863; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27864; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27865; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; L41889; AAB59467.1; -; Genomic_DNA. DR EMBL; L41890; AAA65735.1; -; Genomic_DNA. DR EMBL; L41891; AAA65736.1; -; Genomic_DNA. DR EMBL; L41893; AAA65737.1; -; Genomic_DNA. DR EMBL; L41894; AAA65738.1; -; Genomic_DNA. DR EMBL; L41895; AAA65739.1; -; Genomic_DNA. DR EMBL; L41896; AAA65740.1; -; Genomic_DNA. DR EMBL; L41897; AAA65741.1; -; Genomic_DNA. DR EMBL; L41898; AAB59471.1; -; Genomic_DNA. DR EMBL; L41899; AAB59473.1; -; Genomic_DNA. DR EMBL; L41997; AAB59482.1; -; Genomic_DNA. DR EMBL; X16439; CAA34462.1; -; Genomic_DNA. DR EMBL; AF551763; AAN64133.1; -; Genomic_DNA. DR EMBL; AK291258; BAF83947.1; -; mRNA. DR EMBL; AL136960; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL392048; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471075; EAX08793.1; -; Genomic_DNA. DR EMBL; BC039060; AAH39060.1; -; mRNA. DR EMBL; BC040540; AAH40540.1; -; mRNA. DR EMBL; L11910; AAA53483.1; -; Genomic_DNA. DR CCDS; CCDS31973.1; -. DR PIR; JS0276; RBHU. DR RefSeq; NP_000312.2; NM_000321.3. DR PDB; 1AD6; X-ray; 2.30 A; A=378-562. DR PDB; 1GH6; X-ray; 3.20 A; B=379-577, B=645-772. DR PDB; 1GUX; X-ray; 1.85 A; A=372-589, B=636-787. DR PDB; 1H25; X-ray; 2.50 A; E=868-878. DR PDB; 1N4M; X-ray; 2.20 A; A/B=380-785. DR PDB; 1O9K; X-ray; 2.60 A; A/C/E/G=372-589, B/D/F/H=636-787. DR PDB; 1PJM; X-ray; 2.50 A; A=858-881. DR PDB; 2AZE; X-ray; 2.55 A; C=829-874. DR PDB; 2QDJ; X-ray; 2.00 A; A=52-355. DR PDB; 2R7G; X-ray; 1.67 A; A/C=380-787. DR PDB; 3N5U; X-ray; 3.20 A; C=870-882. DR PDB; 3POM; X-ray; 2.50 A; A/B=380-577, A/B=643-783. DR PDB; 4CRI; X-ray; 2.35 A; C/D=802-817. DR PDB; 4ELJ; X-ray; 2.70 A; A=53-787. DR PDB; 4ELL; X-ray; 1.98 A; A/B=380-787. DR PDB; 9DGK; X-ray; 2.38 A; A/B=380-793. DR PDB; 9DHC; X-ray; 2.32 A; A/B=380-793. DR PDB; 9DHF; X-ray; 2.26 A; A/B=380-793. DR PDB; 9DHU; X-ray; 2.16 A; A/B=380-786. DR PDBsum; 1AD6; -. DR PDBsum; 1GH6; -. DR PDBsum; 1GUX; -. DR PDBsum; 1H25; -. DR PDBsum; 1N4M; -. DR PDBsum; 1O9K; -. DR PDBsum; 1PJM; -. DR PDBsum; 2AZE; -. DR PDBsum; 2QDJ; -. DR PDBsum; 2R7G; -. DR PDBsum; 3N5U; -. DR PDBsum; 3POM; -. DR PDBsum; 4CRI; -. DR PDBsum; 4ELJ; -. DR PDBsum; 4ELL; -. DR PDBsum; 9DGK; -. DR PDBsum; 9DHC; -. DR PDBsum; 9DHF; -. DR PDBsum; 9DHU; -. DR AlphaFoldDB; P06400; -. DR SMR; P06400; -. DR BioGRID; 111860; 389. DR ComplexPortal; CPX-155; RB1-E2F1-DP1 transcriptional repressor complex. DR ComplexPortal; CPX-175; RB1-E2F2-DP1 transcriptional repressor complex. DR ComplexPortal; CPX-469; L3MBTL1 complex. DR ComplexPortal; CPX-7728; RB1-E2F3-DP1 transcriptional repressor complex. DR CORUM; P06400; -. DR DIP; DIP-582N; -. DR FunCoup; P06400; 3043. DR IntAct; P06400; 229. DR MINT; P06400; -. DR STRING; 9606.ENSP00000267163; -. DR BindingDB; P06400; -. DR ChEMBL; CHEMBL5288; -. DR GlyGen; P06400; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P06400; -. DR PhosphoSitePlus; P06400; -. DR BioMuta; RB1; -. DR DMDM; 132164; -. DR CPTAC; CPTAC-1328; -. DR CPTAC; CPTAC-3251; -. DR CPTAC; CPTAC-3288; -. DR CPTAC; CPTAC-898; -. DR CPTAC; CPTAC-941; -. DR CPTAC; CPTAC-942; -. DR jPOST; P06400; -. DR MassIVE; P06400; -. DR PaxDb; 9606-ENSP00000267163; -. DR PeptideAtlas; P06400; -. DR ProteomicsDB; 51900; -. DR Pumba; P06400; -. DR Antibodypedia; 3758; 3580 antibodies from 52 providers. DR CPTC; P06400; 6 antibodies. DR DNASU; 5925; -. DR Ensembl; ENST00000267163.6; ENSP00000267163.4; ENSG00000139687.18. DR GeneID; 5925; -. DR KEGG; hsa:5925; -. DR MANE-Select; ENST00000267163.6; ENSP00000267163.4; NM_000321.3; NP_000312.2. DR UCSC; uc001vcb.4; human. DR AGR; HGNC:9884; -. DR CIViC; 5925; 17 evidence items across 13 molecular profiles. DR ClinPGx; PA295; -. DR CTD; 5925; -. DR DisGeNET; 5925; -. DR GeneCards; RB1; -. DR GeneReviews; RB1; -. DR HGNC; HGNC:9884; RB1. DR HPA; ENSG00000139687; Low tissue specificity. DR MalaCards; RB1; -. DR MIM; 109800; phenotype. DR MIM; 180200; phenotype. DR MIM; 259500; phenotype. DR MIM; 614041; gene. DR OpenTargets; ENSG00000139687; -. DR Orphanet; 357027; Hereditary retinoblastoma. DR Orphanet; 1587; Monosomy 13q14 syndrome. DR Orphanet; 357034; Non-hereditary retinoblastoma. DR Orphanet; 668; Osteosarcoma. DR Orphanet; 70573; Small cell lung cancer. DR VEuPathDB; HostDB:ENSG00000139687; -. DR eggNOG; KOG1010; Eukaryota. DR GeneTree; ENSGT00950000183202; -. DR HOGENOM; CLU_015754_0_0_1; -. DR InParanoid; P06400; -. DR OMA; VKDIGCI; -. DR OrthoDB; 844594at2759; -. DR PAN-GO; P06400; 7 GO annotations based on evolutionary models. DR PhylomeDB; P06400; -. DR PathwayCommons; P06400; -. DR Reactome; R-HSA-113501; Inhibition of replication initiation of damaged DNA by RB1/E2F1. DR Reactome; R-HSA-174178; APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1. DR Reactome; R-HSA-2299718; Condensation of Prophase Chromosomes. DR Reactome; R-HSA-2559584; Formation of Senescence-Associated Heterochromatin Foci (SAHF). DR Reactome; R-HSA-2559585; Oncogene Induced Senescence. DR Reactome; R-HSA-69200; Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes. DR Reactome; R-HSA-69202; Cyclin E associated events during G1/S transition. DR Reactome; R-HSA-69231; Cyclin D associated events in G1. DR Reactome; R-HSA-69656; Cyclin A:Cdk2-associated events at S phase entry. DR Reactome; R-HSA-8940973; RUNX2 regulates osteoblast differentiation. DR Reactome; R-HSA-9661069; Defective binding of RB1 mutants to E2F1,(E2F2, E2F3). DR Reactome; R-HSA-9661070; Defective translocation of RB1 mutants to the nucleus. DR Reactome; R-HSA-9682706; Replication of the SARS-CoV-1 genome. DR Reactome; R-HSA-9687136; Aberrant regulation of mitotic exit in cancer due to RB1 defects. DR Reactome; R-HSA-9694686; Replication of the SARS-CoV-2 genome. DR Reactome; R-HSA-9725371; Nuclear events stimulated by ALK signaling in cancer. DR Reactome; R-HSA-9764790; Positive Regulation of CDH1 Gene Transcription. DR Reactome; R-HSA-9841922; MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis. DR SignaLink; P06400; -. DR SIGNOR; P06400; -. DR Agora; ENSG00000139687; -. DR BioGRID-ORCS; 5925; 32 hits in 1194 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; RB1; human. DR EvolutionaryTrace; P06400; -. DR GeneWiki; Retinoblastoma_protein; -. DR GenomeRNAi; 5925; -. DR Pharos; P06400; Tchem. DR PRO; PR:P06400; -. DR Proteomes; UP000005640; Chromosome 13. DR RNAct; P06400; protein. DR Bgee; ENSG00000139687; Expressed in epithelium of nasopharynx and 200 other cell types or tissues. DR ExpressionAtlas; P06400; baseline and differential. DR GO; GO:0000785; C:chromatin; IBA:GO_Central. DR GO; GO:0061793; C:chromatin lock complex; IPI:ComplexPortal. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005654; C:nucleoplasm; IDA:CAFA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IDA:UniProtKB. DR GO; GO:0035189; C:Rb-E2F complex; IDA:CAFA. DR GO; GO:0005819; C:spindle; IEA:Ensembl. DR GO; GO:0016514; C:SWI/SNF complex; TAS:BHF-UCL. DR GO; GO:0097718; F:disordered domain specific binding; IPI:CAFA. DR GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0061676; F:importin-alpha family protein binding; IPI:CAFA. DR GO; GO:0019900; F:kinase binding; IDA:UniProtKB. DR GO; GO:0060090; F:molecular adaptor activity; EXP:DisProt. DR GO; GO:0051219; F:phosphoprotein binding; IPI:UniProtKB. DR GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IBA:GO_Central. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IEA:Ensembl. DR GO; GO:0003714; F:transcription corepressor activity; TAS:ARUK-UCL. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0003180; P:aortic valve morphogenesis; ISS:BHF-UCL. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0051301; P:cell division; IEA:Ensembl. DR GO; GO:0048667; P:cell morphogenesis involved in neuron differentiation; IBA:GO_Central. DR GO; GO:0032869; P:cellular response to insulin stimulus; IEA:Ensembl. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0002062; P:chondrocyte differentiation; IEA:Ensembl. DR GO; GO:0006338; P:chromatin remodeling; TAS:BHF-UCL. DR GO; GO:0051276; P:chromosome organization; IMP:BHF-UCL. DR GO; GO:0048565; P:digestive tract development; IEA:Ensembl. DR GO; GO:0043353; P:enucleate erythrocyte differentiation; IEA:Ensembl. DR GO; GO:0050673; P:epithelial cell proliferation; IEA:Ensembl. DR GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IEA:Ensembl. DR GO; GO:0034349; P:glial cell apoptotic process; IEA:Ensembl. DR GO; GO:0014009; P:glial cell proliferation; IEA:Ensembl. DR GO; GO:0097284; P:hepatocyte apoptotic process; IEA:Ensembl. DR GO; GO:0031507; P:heterochromatin formation; IDA:ComplexPortal. DR GO; GO:0034088; P:maintenance of mitotic sister chromatid cohesion; IMP:BHF-UCL. DR GO; GO:0045445; P:myoblast differentiation; IMP:UniProtKB. DR GO; GO:2001234; P:negative regulation of apoptotic signaling pathway; ISS:ARUK-UCL. DR GO; GO:0045786; P:negative regulation of cell cycle; ISS:ARUK-UCL. DR GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB. DR GO; GO:0120163; P:negative regulation of cold-induced thermogenesis; ISS:YuBioLab. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IEA:Ensembl. DR GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IBA:GO_Central. DR GO; GO:0010629; P:negative regulation of gene expression; IMP:MGI. DR GO; GO:0060253; P:negative regulation of glial cell proliferation; IEA:Ensembl. DR GO; GO:1903944; P:negative regulation of hepatocyte apoptotic process; IEA:Ensembl. DR GO; GO:0050728; P:negative regulation of inflammatory response; ISS:BHF-UCL. DR GO; GO:1904761; P:negative regulation of myofibroblast differentiation; ISS:BHF-UCL. DR GO; GO:0006469; P:negative regulation of protein kinase activity; IPI:UniProtKB. DR GO; GO:0045879; P:negative regulation of smoothened signaling pathway; IEA:Ensembl. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; TAS:BHF-UCL. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0042551; P:neuron maturation; IEA:Ensembl. DR GO; GO:0031175; P:neuron projection development; IBA:GO_Central. DR GO; GO:1904028; P:positive regulation of collagen fibril organization; ISS:BHF-UCL. DR GO; GO:1903055; P:positive regulation of extracellular matrix organization; ISS:BHF-UCL. DR GO; GO:0045651; P:positive regulation of macrophage differentiation; IEA:Ensembl. DR GO; GO:0045842; P:positive regulation of mitotic metaphase/anaphase transition; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:2000679; P:positive regulation of transcription regulatory region DNA binding; IDA:MGI. DR GO; GO:0071459; P:protein localization to chromosome, centromeric region; IMP:BHF-UCL. DR GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL. DR GO; GO:0051726; P:regulation of cell cycle; TAS:BHF-UCL. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:ComplexPortal. DR GO; GO:0043550; P:regulation of lipid kinase activity; IDA:UniProtKB. DR GO; GO:0007346; P:regulation of mitotic cell cycle; IMP:BHF-UCL. DR GO; GO:0031134; P:sister chromatid biorientation; IMP:BHF-UCL. DR GO; GO:0035914; P:skeletal muscle cell differentiation; IEA:Ensembl. DR GO; GO:0007224; P:smoothened signaling pathway; IEA:Ensembl. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl. DR GO; GO:0001894; P:tissue homeostasis; IEA:Ensembl. DR GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl. DR CDD; cd20599; CYCLIN_RB; 1. DR DisProt; DP01426; -. DR FunFam; 1.10.472.10:FF:000039; RB transcriptional corepressor 1; 1. DR FunFam; 1.10.472.140:FF:000002; RB transcriptional corepressor 1; 1. DR FunFam; 1.10.472.10:FF:000033; retinoblastoma-associated protein isoform X1; 1. DR Gene3D; 1.10.472.140; -; 1. DR Gene3D; 6.10.140.1380; -; 1. DR Gene3D; 6.10.250.530; -; 1. DR Gene3D; 1.10.472.10; Cyclin-like; 2. DR IDEAL; IID00017; -. DR InterPro; IPR013763; Cyclin-like_dom. DR InterPro; IPR036915; Cyclin-like_sf. DR InterPro; IPR002720; RB_A. DR InterPro; IPR002719; RB_B. DR InterPro; IPR015030; RB_C. DR InterPro; IPR028309; RB_fam. DR InterPro; IPR024599; RB_N. DR PANTHER; PTHR13742:SF36; RETINOBLASTOMA-ASSOCIATED PROTEIN; 1. DR PANTHER; PTHR13742; RETINOBLASTOMA-ASSOCIATED PROTEIN RB -RELATED; 1. DR Pfam; PF11934; DUF3452; 1. DR Pfam; PF01858; RB_A; 1. DR Pfam; PF01857; RB_B; 1. DR Pfam; PF08934; Rb_C; 1. DR SMART; SM00385; CYCLIN; 1. DR SMART; SM01367; DUF3452; 1. DR SMART; SM01368; RB_A; 1. DR SMART; SM01369; Rb_C; 1. DR SUPFAM; SSF47954; Cyclin-like; 2. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Cell cycle; Chromatin regulator; Cytoplasm; KW Direct protein sequencing; Disease variant; DNA-binding; KW Host-virus interaction; Methylation; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repressor; Transcription; KW Transcription regulation; Tumor suppressor. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000250|UniProtKB:P13405" FT CHAIN 2..928 FT /note="Retinoblastoma-associated protein" FT /id="PRO_0000167836" FT REGION 1..42 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 373..771 FT /note="Pocket; binds T and E1A" FT REGION 373..579 FT /note="Domain A" FT REGION 580..639 FT /note="Spacer" FT REGION 610..632 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 640..771 FT /note="Domain B" FT REGION 763..928 FT /note="Interaction with LIMD1" FT /evidence="ECO:0000269|PubMed:15542589" FT REGION 771..928 FT /note="Domain C; mediates interaction with E4F1" FT /evidence="ECO:0000269|PubMed:10869426" FT REGION 860..928 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 860..876 FT /note="Bipartite nuclear localization signal" FT /evidence="ECO:0000250|UniProtKB:P13405" FT COMPBIAS 8..19 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 29..39 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 619..632 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 915..928 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N,N-dimethylproline" FT /evidence="ECO:0000250|UniProtKB:P13405" FT MOD_RES 37 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:24275569" FT MOD_RES 249 FT /note="Phosphoserine; by CDK1" FT /evidence="ECO:0000269|PubMed:1756735, FT ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 252 FT /note="Phosphothreonine; by CDK1" FT /evidence="ECO:0000269|PubMed:1756735, FT ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 356 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18220336, FT ECO:0007744|PubMed:23186163" FT MOD_RES 373 FT /note="Phosphothreonine; by CDK1" FT /evidence="ECO:0000269|PubMed:1756735, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 567 FT /note="Phosphoserine; by CDK2" FT /evidence="ECO:0000269|PubMed:10499802" FT MOD_RES 608 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P13405" FT MOD_RES 612 FT /note="Phosphoserine; by CHEK2 and CHEK1" FT /evidence="ECO:0000269|PubMed:17380128, FT ECO:0007744|PubMed:18669648" FT MOD_RES 624 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 780 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 788 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 795 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 807 FT /note="Phosphoserine; by CDK1 and CDK3" FT /evidence="ECO:0000269|PubMed:15084261, FT ECO:0000269|PubMed:1756735, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 810 FT /note="N6-methyllysine; by SMYD2" FT /evidence="ECO:0000269|PubMed:22787429" FT MOD_RES 811 FT /note="Phosphoserine; by CDK1 and CDK3" FT /evidence="ECO:0000269|PubMed:15084261, FT ECO:0000269|PubMed:1756735, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 821 FT /note="Phosphothreonine; by CDK6" FT /evidence="ECO:0000269|PubMed:15809340, FT ECO:0000269|PubMed:16360038, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 823 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 826 FT /note="Phosphothreonine; by CDK4" FT /evidence="ECO:0000269|PubMed:15809340, FT ECO:0000269|PubMed:16360038, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 841 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 855 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 860 FT /note="N6-methyllysine; by SMYD2" FT /evidence="ECO:0000269|PubMed:20870719" FT MOD_RES 873 FT /note="N6-acetyllysine; by PCAF" FT /evidence="ECO:0000269|PubMed:20940255" FT MOD_RES 874 FT /note="N6-acetyllysine; by PCAF" FT /evidence="ECO:0000269|PubMed:20940255" FT VARIANT 72 FT /note="E -> Q (in RB; dbSNP:rs369833913)" FT /evidence="ECO:0000269|PubMed:8605116" FT /id="VAR_005572" FT VARIANT 133 FT /note="N -> H (in dbSNP:rs3092900)" FT /id="VAR_051909" FT VARIANT 137 FT /note="E -> D (in RB; unilateral form; dbSNP:rs3092902)" FT /evidence="ECO:0000269|PubMed:9311732" FT /id="VAR_005573" FT VARIANT 173 FT /note="Y -> H" FT /evidence="ECO:0000269|PubMed:23033978" FT /id="VAR_069376" FT VARIANT 185 FT /note="I -> T (in RB)" FT /evidence="ECO:0000269|PubMed:7795591" FT /id="VAR_005574" FT VARIANT 310 FT /note="G -> E (in RB; uncertain significance; FT dbSNP:rs200844292)" FT /evidence="ECO:0000269|PubMed:9973307" FT /id="VAR_010045" FT VARIANT 358 FT /note="R -> G (in RB; dbSNP:rs121913301)" FT /evidence="ECO:0000269|PubMed:8776589" FT /id="VAR_010046" FT VARIANT 358 FT /note="R -> Q (in RB; dbSNP:rs767011440)" FT /id="VAR_005575" FT VARIANT 436 FT /note="Q -> K (in dbSNP:rs4151534)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_019379" FT VARIANT 447 FT /note="K -> Q (in RB)" FT /evidence="ECO:0000269|PubMed:9140452" FT /id="VAR_010048" FT VARIANT 457 FT /note="M -> R (in RB)" FT /evidence="ECO:0000269|PubMed:8346255" FT /id="VAR_005576" FT VARIANT 480 FT /note="Missing (in RB; mild form)" FT /evidence="ECO:0000269|PubMed:7927327" FT /id="VAR_005577" FT VARIANT 500 FT /note="R -> G (in RB)" FT /evidence="ECO:0000269|PubMed:11524739" FT /id="VAR_011580" FT VARIANT 525 FT /note="A -> G (in dbSNP:rs4151539)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_019380" FT VARIANT 530 FT /note="K -> R (in RB; dbSNP:rs1948534047)" FT /evidence="ECO:0000269|PubMed:7704558" FT /id="VAR_010049" FT VARIANT 549 FT /note="H -> Y (in RB; dbSNP:rs1050717570)" FT /evidence="ECO:0000269|PubMed:8605116" FT /id="VAR_005578" FT VARIANT 567 FT /note="S -> L (in RB; dbSNP:rs137853292)" FT /evidence="ECO:0000269|PubMed:10671068, FT ECO:0000269|PubMed:2594029" FT /id="VAR_005579" FT VARIANT 569 FT /note="L -> F (in dbSNP:rs3092895)" FT /id="VAR_051910" FT VARIANT 616 FT /note="K -> E (in RB)" FT /evidence="ECO:0000269|PubMed:11524739" FT /id="VAR_011581" FT VARIANT 635 FT /note="A -> P (in RB; dbSNP:rs1949359622)" FT /evidence="ECO:0000269|PubMed:7795591" FT /id="VAR_005580" FT VARIANT 654 FT /note="V -> E (in RB; dbSNP:rs769113950)" FT /evidence="ECO:0000269|PubMed:7795591" FT /id="VAR_005581" FT VARIANT 657 FT /note="L -> P (in RB)" FT /evidence="ECO:0000269|PubMed:8776589" FT /id="VAR_010050" FT VARIANT 661 FT /note="R -> W (in RB; mild form; dbSNP:rs137853294)" FT /evidence="ECO:0000269|PubMed:1352883, FT ECO:0000269|PubMed:7927327, ECO:0000269|PubMed:8776589, FT ECO:0000269|PubMed:9311732" FT /id="VAR_005582" FT VARIANT 662 FT /note="L -> P (in RB)" FT /evidence="ECO:0000269|PubMed:10671068" FT /id="VAR_005583" FT VARIANT 673 FT /note="H -> P (in RB; dbSNP:rs2138336107)" FT /id="VAR_005584" FT VARIANT 685 FT /note="Q -> P (in RB)" FT /evidence="ECO:0000269|PubMed:7795591" FT /id="VAR_005585" FT VARIANT 697 FT /note="D -> E (in dbSNP:rs3092903)" FT /id="VAR_051911" FT VARIANT 706 FT /note="C -> Y (in RB; dbSNP:rs121913295)" FT /evidence="ECO:0000269|PubMed:8118465" FT /id="VAR_005586" FT VARIANT 712 FT /note="C -> R (in RB; dbSNP:rs137853296)" FT /evidence="ECO:0000269|PubMed:10671068" FT /id="VAR_005587" FT VARIANT 746 FT /note="E -> G (in dbSNP:rs3092905)" FT /id="VAR_034442" FT VARIANT 803 FT /note="N -> K (in RB; dbSNP:rs1379479714)" FT /evidence="ECO:0000269|PubMed:8605116" FT /id="VAR_005588" FT MUTAGEN 821 FT /note="T->A: Abolishes interaction with Pocket domain; when FT associated with A-826." FT /evidence="ECO:0000269|PubMed:16360038" FT MUTAGEN 826 FT /note="T->A: Abolishes interaction with Pocket domain; when FT associated with A-821." FT /evidence="ECO:0000269|PubMed:16360038" FT MUTAGEN 860 FT /note="K->R: Abolishes monomethylation by SMYD2 and FT subsequent interaction with L3MBTL1." FT /evidence="ECO:0000269|PubMed:20870719" FT MUTAGEN 870 FT /note="K->R: Does not affect the ability to be methylated FT by SMYD2; when associated with 873-R-R-874." FT /evidence="ECO:0000269|PubMed:20870719" FT MUTAGEN 873..874 FT /note="KK->R: Does not affect the ability to be methylated FT by SMYD2; when associated with 873-R-R-874." FT /evidence="ECO:0000269|PubMed:20870719, FT ECO:0000269|PubMed:20940255" FT MUTAGEN 873..874 FT /note="KK->RR: Does not alter Rb localization in cycling FT cells, but mislocalizes to the cytoplasm during FT keratinocyte differentiation. Does not affect the ability FT to arrest cell growth. Probable loss of acetylation by FT PCAF." FT /evidence="ECO:0000269|PubMed:20870719, FT ECO:0000269|PubMed:20940255" FT CONFLICT 500..501 FT /note="RS -> SN (in Ref. 7; AAN64133)" FT /evidence="ECO:0000305" FT HELIX 55..63 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 68..82 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 95..110 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 117..124 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 128..135 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 142..172 FT /evidence="ECO:0007829|PDB:2QDJ" FT STRAND 180..182 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 188..204 FT /evidence="ECO:0007829|PDB:2QDJ" FT STRAND 207..209 FT /evidence="ECO:0007829|PDB:4ELJ" FT HELIX 212..228 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 232..234 FT /evidence="ECO:0007829|PDB:2QDJ" FT TURN 237..240 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 241..243 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 272..281 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 285..294 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 296..299 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 302..306 FT /evidence="ECO:0007829|PDB:4ELJ" FT HELIX 314..328 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 333..338 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 341..343 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 347..353 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 382..391 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 398..405 FT /evidence="ECO:0007829|PDB:2R7G" FT STRAND 407..409 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 412..434 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 436..438 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 439..468 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 474..477 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 480..501 FT /evidence="ECO:0007829|PDB:2R7G" FT TURN 504..506 FT /evidence="ECO:0007829|PDB:1N4M" FT STRAND 511..513 FT /evidence="ECO:0007829|PDB:4ELJ" FT HELIX 516..521 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 525..529 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 532..538 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 544..559 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 561..563 FT /evidence="ECO:0007829|PDB:2R7G" FT STRAND 564..566 FT /evidence="ECO:0007829|PDB:4ELJ" FT HELIX 569..577 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 582..586 FT /evidence="ECO:0007829|PDB:4ELL" FT HELIX 602..607 FT /evidence="ECO:0007829|PDB:4ELL" FT HELIX 645..669 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 676..690 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 692..695 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 700..714 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 721..728 FT /evidence="ECO:0007829|PDB:2R7G" FT STRAND 731..733 FT /evidence="ECO:0007829|PDB:1N4M" FT HELIX 737..740 FT /evidence="ECO:0007829|PDB:2R7G" FT STRAND 741..743 FT /evidence="ECO:0007829|PDB:2R7G" FT STRAND 745..747 FT /evidence="ECO:0007829|PDB:2R7G" FT STRAND 748..750 FT /evidence="ECO:0007829|PDB:9DHU" FT HELIX 752..758 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 760..770 FT /evidence="ECO:0007829|PDB:2R7G" FT STRAND 773..775 FT /evidence="ECO:0007829|PDB:2R7G" FT STRAND 830..836 FT /evidence="ECO:0007829|PDB:2AZE" FT TURN 838..840 FT /evidence="ECO:0007829|PDB:2AZE" FT HELIX 841..853 FT /evidence="ECO:0007829|PDB:2AZE" SQ SEQUENCE 928 AA; 106159 MW; C8E746111E19CC32 CRC64; MPPKTPRKTA ATAAAAAAEP PAPPPPPPPE EDPEQDSGPE DLPLVRLEFE ETEEPDFTAL CQKLKIPDHV RERAWLTWEK VSSVDGVLGG YIQKKKELWG ICIFIAAVDL DEMSFTFTEL QKNIEISVHK FFNLLKEIDT STKVDNAMSR LLKKYDVLFA LFSKLERTCE LIYLTQPSSS ISTEINSALV LKVSWITFLL AKGEVLQMED DLVISFQLML CVLDYFIKLS PPMLLKEPYK TAVIPINGSP RTPRRGQNRS ARIAKQLEND TRIIEVLCKE HECNIDEVKN VYFKNFIPFM NSLGLVTSNG LPEVENLSKR YEEIYLKNKD LDARLFLDHD KTLQTDSIDS FETQRTPRKS NLDEEVNVIP PHTPVRTVMN TIQQLMMILN SASDQPSENL ISYFNNCTVN PKESILKRVK DIGYIFKEKF AKAVGQGCVE IGSQRYKLGV RLYYRVMESM LKSEEERLSI QNFSKLLNDN IFHMSLLACA LEVVMATYSR STSQNLDSGT DLSFPWILNV LNLKAFDFYK VIESFIKAEG NLTREMIKHL ERCEHRIMES LAWLSDSPLF DLIKQSKDRE GPTDHLESAC PLNLPLQNNH TAADMYLSPV RSPKKKGSTT RVNSTANAET QATSAFQTQK PLKSTSLSLF YKKVYRLAYL RLNTLCERLL SEHPELEHII WTLFQHTLQN EYELMRDRHL DQIMMCSMYG ICKVKNIDLK FKIIVTAYKD LPHAVQETFK RVLIKEEEYD SIIVFYNSVF MQRLKTNILQ YASTRPPTLS PIPHIPRSPY KFPSSPLRIP GGNIYISPLK SPYKISEGLP TPTKMTPRSR ILVSIGESFG TSEKFQKINQ MVCNSDRVLK RSAEGSNPPK PLKKLRFDIE GSDEADGSKH LPGESKFQQK LAEMTSTRTR MQKQKMNDSM DTSNKEEK // ID S100P_HUMAN Reviewed; 95 AA. AC P25815; Q5J7W2; DT 01-MAY-1992, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-1992, sequence version 2. DT 28-JAN-2026, entry version 206. DE RecName: Full=Protein S100-P; DE AltName: Full=Migration-inducing gene 9 protein; DE Short=MIG9; DE AltName: Full=Protein S100-E; DE AltName: Full=S100 calcium-binding protein P; GN Name=S100P; Synonyms=S100E; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Placenta; RX PubMed=1633809; DOI=10.1111/j.1432-1033.1992.tb17080.x; RA Becker T., Gerke V., Kube E., Weber K.; RT "S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, RT recombinant protein expression and Ca2+ binding properties."; RL Eur. J. Biochem. 207:541-547(1992). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RA Jin G., Wang S., Chen J.; RT "Cloning, expression and characterization of a novel human calcium-binding RT S100 gene."; RL Submitted (AUG-2002) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Kim J.W.; RT "Identification of a human migration-inducing gene 9 (MIG9)."; RL Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP PROTEIN SEQUENCE OF 1-91. RC TISSUE=Placenta; RX PubMed=1540168; DOI=10.1016/0006-291x(92)91865-n; RA Emoto Y., Kobayashi R., Akatsuka H., Hidaka H.; RT "Purification and characterization of a new member of the S-100 protein RT family from human placenta."; RL Biochem. Biophys. Res. Commun. 182:1246-1253(1992). RN [7] RP INTERACTION WITH EZR. RX PubMed=12808036; DOI=10.1091/mbc.e02-09-0553; RA Koltzscher M., Neumann C., Konig S., Gerke V.; RT "Ca2+-dependent binding and activation of dormant ezrin by dimeric S100P."; RL Mol. Biol. Cell 14:2372-2384(2003). RN [8] RP TISSUE SPECIFICITY. RX PubMed=14672411; DOI=10.1023/a:1026311423326; RA Jin G., Wang S., Hu X., Jing Z., Chen J., Ying K., Xie Y., Mao Y.; RT "Characterization of the tissue-specific expression of the s100P gene which RT encodes an EF-hand Ca2+-binding protein."; RL Mol. Biol. Rep. 30:243-248(2003). RN [9] RP SUBUNIT, AND INTERACTION WITH S100A1. RX PubMed=15171681; DOI=10.1042/bj20040142; RA Wang G., Zhang S., Fernig D.G., Spiller D., Martin-Fernandez M., Zhang H., RA Ding Y., Rao Z., Rudland P.S., Barraclough R.; RT "Heterodimeric interaction and interfaces of S100A1 and S100P."; RL Biochem. J. 382:375-383(2004). RN [10] RP FUNCTION. RX PubMed=14617629; DOI=10.1074/jbc.m310124200; RA Arumugam T., Simeone D.M., Schmidt A.M., Logsdon C.D.; RT "S100P stimulates cell proliferation and survival via receptor for RT activated glycation end products (RAGE)."; RL J. Biol. Chem. 279:5059-5065(2004). RN [11] RP INTERACTION WITH S100PBP, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=15632002; DOI=10.1016/s0002-9440(10)62234-1; RA Dowen S.E., Crnogorac-Jurcevic T., Gangeswaran R., Hansen M., RA Eloranta J.J., Bhakta V., Brentnall T.A., Luettges J., Kloeppel G., RA Lemoine N.R.; RT "Expression of S100P and its novel binding partner S100PBPR in early RT pancreatic cancer."; RL Am. J. Pathol. 166:81-92(2005). RN [12] RP FUNCTION, INTERACTION WITH EZR, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP 21-SER--GLY-23; ASN-64; GLN-68 AND GLU-73. RX PubMed=19111582; DOI=10.1016/j.bbamcr.2008.11.012; RA Austermann J., Nazmi A.R., Heil A., Fritz G., Kolinski M., Filipek S., RA Gerke V.; RT "Generation and characterization of a novel, permanently active S100P RT mutant."; RL Biochim. Biophys. Acta 1793:1078-1085(2009). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [14] RP FUNCTION, INTERACTION WITH PPP5C, AND MUTAGENESIS OF 21-SER--GLY-23; RP ASN-64; GLN-68 AND GLU-73. RX PubMed=22399290; DOI=10.1074/jbc.m111.329771; RA Yamaguchi F., Umeda Y., Shimamoto S., Tsuchiya M., Tokumitsu H., Tokuda M., RA Kobayashi R.; RT "S100 proteins modulate protein phosphatase 5 function: a link between CA2+ RT signal transduction and protein dephosphorylation."; RL J. Biol. Chem. 287:13787-13798(2012). RN [15] RP INTERACTION WITH P.FALCIPARUM MSP1 (MICROBIAL INFECTION). RX PubMed=22431641; DOI=10.1073/pnas.1202689109; RA Waisberg M., Cerqueira G.C., Yager S.B., Francischetti I.M., Lu J., RA Gera N., Srinivasan P., Miura K., Rada B., Lukszo J., Barbian K.D., RA Leto T.L., Porcella S.F., Narum D.L., El-Sayed N., Miller L.H., RA Pierce S.K.; RT "Plasmodium falciparum merozoite surface protein 1 blocks the RT proinflammatory protein S100P."; RL Proc. Natl. Acad. Sci. U.S.A. 109:5429-5434(2012). RN [16] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS). RX PubMed=12507480; DOI=10.1016/s0022-2836(02)01278-0; RA Zhang H., Wang G., Ding Y., Wang Z., Barraclough R., Rudland P.S., RA Fernig D.G., Rao Z.; RT "The crystal structure at 2A resolution of the Ca2+ -binding protein RT S100P."; RL J. Mol. Biol. 325:785-794(2003). RN [17] RP STRUCTURE BY NMR. RX PubMed=15213440; DOI=10.1023/b:jnmr.0000032617.88899.4b; RA Lee Y.C., Volk D.E., Thiviyanathan V., Kleerekoper Q., Gribenko A.V., RA Zhang S., Gorenstein D.G., Makhatadze G.I., Luxon B.A.; RT "NMR structure of the Apo-S100P protein."; RL J. Biomol. NMR 29:399-402(2004). CC -!- FUNCTION: May function as calcium sensor and contribute to cellular CC calcium signaling. In a calcium-dependent manner, functions by CC interacting with other proteins, such as EZR and PPP5C, and indirectly CC plays a role in physiological processes like the formation of CC microvilli in epithelial cells. May stimulate cell proliferation in an CC autocrine manner via activation of the receptor for activated glycation CC end products (RAGE). {ECO:0000269|PubMed:14617629, CC ECO:0000269|PubMed:19111582, ECO:0000269|PubMed:22399290}. CC -!- SUBUNIT: Homodimer and heterodimer with S100A1. Interacts with S100PBP CC and S100Z. Interacts with CACYBP in a calcium-dependent manner. Dimeric CC form binds to and activates EZR/Ezrin by unmasking its F-actin binding CC sites. Interacts with PPP5C (via TPR repeats); the interaction is CC calcium-dependent and modulates PPP5C activity. CC {ECO:0000269|PubMed:12808036, ECO:0000269|PubMed:15171681, CC ECO:0000269|PubMed:15632002, ECO:0000269|PubMed:19111582, CC ECO:0000269|PubMed:22399290}. CC -!- SUBUNIT: (Microbial infection) Interacts with P.falciparum (strains 3D7 CC and FVO) MSP1 subunit p33; the interaction blocks S100P inflammatory CC and chemotactic activities. {ECO:0000269|PubMed:22431641}. CC -!- INTERACTION: CC P25815; Q15109: AGER; NbExp=2; IntAct=EBI-743700, EBI-1646426; CC P25815; Q7LC44: ARC; NbExp=3; IntAct=EBI-743700, EBI-750550; CC P25815; P52907: CAPZA1; NbExp=2; IntAct=EBI-743700, EBI-355586; CC P25815; P42858: HTT; NbExp=9; IntAct=EBI-743700, EBI-466029; CC P25815; P20809: IL11; NbExp=2; IntAct=EBI-743700, EBI-751694; CC P25815; P35579: MYH9; NbExp=3; IntAct=EBI-743700, EBI-350338; CC P25815; P07196: NEFL; NbExp=4; IntAct=EBI-743700, EBI-475646; CC P25815; P23297: S100A1; NbExp=11; IntAct=EBI-743700, EBI-743686; CC P25815; Q5T7Y6: S100A1; NbExp=4; IntAct=EBI-743700, EBI-11746600; CC P25815; P04271: S100B; NbExp=7; IntAct=EBI-743700, EBI-458391; CC P25815; Q8WXG8: S100Z; NbExp=3; IntAct=EBI-743700, EBI-12198403; CC P25815; Q9NYB0: TERF2IP; NbExp=2; IntAct=EBI-743700, EBI-750109; CC P25815; Q9UBB9: TFIP11; NbExp=3; IntAct=EBI-743700, EBI-1105213; CC P25815; Q15582: TGFBI; NbExp=3; IntAct=EBI-743700, EBI-10236573; CC P25815; P04637: TP53; NbExp=2; IntAct=EBI-743700, EBI-366083; CC P25815; P11441: UBL4A; NbExp=3; IntAct=EBI-743700, EBI-356983; CC P25815; O76024: WFS1; NbExp=3; IntAct=EBI-743700, EBI-720609; CC P25815; Q9CXW3: Cacybp; Xeno; NbExp=2; IntAct=EBI-743700, EBI-767146; CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Cell projection, microvillus CC membrane. Note=Colocalizes with S100PBP in the nucleus. Colocalizes CC with EZR in the microvilli in a calcium-dependent manner. CC -!- TISSUE SPECIFICITY: Detected in all of the tissues except brain, testis CC and small intestine, expression level is higher in placenta, heart, CC lung, skeletal muscle, spleen and leukocyte. Up-regulated in various CC pancreatic ductal adenocarcinomas and pancreatic intraepithelial CC neoplasias. {ECO:0000269|PubMed:14672411, ECO:0000269|PubMed:15632002}. CC -!- MISCELLANEOUS: This protein binds two calcium ions. CC -!- SIMILARITY: Belongs to the S-100 family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAS00487.1; Type=Miscellaneous discrepancy; Note=Sequencing error in Met-1 codon.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/42196/S100P"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X65614; CAA46566.1; -; mRNA. DR EMBL; AF539739; AAO41114.1; -; mRNA. DR EMBL; BT007289; AAP35953.1; -; mRNA. DR EMBL; AY423724; AAS00487.1; ALT_SEQ; mRNA. DR EMBL; BC006819; AAH06819.1; -; mRNA. DR CCDS; CCDS3391.1; -. DR PIR; S24146; S24146. DR RefSeq; NP_005971.1; NM_005980.3. DR PDB; 1J55; X-ray; 2.00 A; A=1-95. DR PDB; 1OZO; NMR; -; A/B=1-95. DR PDB; 2MJW; NMR; -; B/D=1-94. DR PDB; 7NMI; X-ray; 2.10 A; B=1-95. DR PDBsum; 1J55; -. DR PDBsum; 1OZO; -. DR PDBsum; 2MJW; -. DR PDBsum; 7NMI; -. DR AlphaFoldDB; P25815; -. DR BMRB; P25815; -. DR SMR; P25815; -. DR BioGRID; 112194; 307. DR FunCoup; P25815; 233. DR IntAct; P25815; 241. DR MINT; P25815; -. DR STRING; 9606.ENSP00000296370; -. DR DrugBank; DB01003; Cromoglicic acid. DR DrugCentral; P25815; -. DR GlyGen; P25815; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P25815; -. DR PhosphoSitePlus; P25815; -. DR BioMuta; S100P; -. DR DMDM; 134142; -. DR jPOST; P25815; -. DR MassIVE; P25815; -. DR PaxDb; 9606-ENSP00000296370; -. DR PeptideAtlas; P25815; -. DR ProteomicsDB; 54298; -. DR Pumba; P25815; -. DR TopDownProteomics; P25815; -. DR Antibodypedia; 4560; 460 antibodies from 34 providers. DR DNASU; 6286; -. DR Ensembl; ENST00000296370.4; ENSP00000296370.3; ENSG00000163993.7. DR GeneID; 6286; -. DR KEGG; hsa:6286; -. DR MANE-Select; ENST00000296370.4; ENSP00000296370.3; NM_005980.3; NP_005971.1. DR UCSC; uc003gjl.4; human. DR AGR; HGNC:10504; -. DR ClinPGx; PA34913; -. DR CTD; 6286; -. DR DisGeNET; 6286; -. DR GeneCards; S100P; -. DR HGNC; HGNC:10504; S100P. DR HPA; ENSG00000163993; Tissue enhanced (bone marrow, stomach, urinary bladder). DR MIM; 600614; gene. DR OpenTargets; ENSG00000163993; -. DR VEuPathDB; HostDB:ENSG00000163993; -. DR eggNOG; ENOG502S6E1; Eukaryota. DR GeneTree; ENSGT00940000162871; -. DR HOGENOM; CLU_138624_6_1_1; -. DR InParanoid; P25815; -. DR OMA; TCACHNR; -. DR OrthoDB; 26525at2759; -. DR PAN-GO; P25815; 4 GO annotations based on evolutionary models. DR PhylomeDB; P25815; -. DR PathwayCommons; P25815; -. DR Reactome; R-HSA-6798695; Neutrophil degranulation. DR SignaLink; P25815; -. DR SIGNOR; P25815; -. DR Agora; ENSG00000163993; -. DR BioGRID-ORCS; 6286; 17 hits in 1160 CRISPR screens. DR ChiTaRS; S100P; human. DR EvolutionaryTrace; P25815; -. DR GeneWiki; S100P; -. DR GenomeRNAi; 6286; -. DR Pharos; P25815; Tbio. DR PRO; PR:P25815; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; P25815; protein. DR Bgee; ENSG00000163993; Expressed in nasal cavity epithelium and 149 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0031528; C:microvillus membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:HGNC-UCL. DR GO; GO:0034774; C:secretory granule lumen; TAS:Reactome. DR GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL. DR GO; GO:0005509; F:calcium ion binding; IBA:GO_Central. DR GO; GO:0048306; F:calcium-dependent protein binding; IPI:HGNC-UCL. DR GO; GO:0000287; F:magnesium ion binding; TAS:HGNC-UCL. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0046914; F:transition metal ion binding; IEA:InterPro. DR GO; GO:0043542; P:endothelial cell migration; IMP:UniProtKB. DR CDD; cd00213; S-100; 1. DR FunFam; 1.10.238.10:FF:000044; Protein S100; 1. DR Gene3D; 1.10.238.10; EF-hand; 1. DR InterPro; IPR011992; EF-hand-dom_pair. DR InterPro; IPR002048; EF_hand_dom. DR InterPro; IPR034325; S-100_dom. DR InterPro; IPR001751; S100/CaBP7/8-like_CS. DR InterPro; IPR013787; S100_Ca-bd_sub. DR PANTHER; PTHR11639:SF139; PROTEIN S100-P; 1. DR PANTHER; PTHR11639; S100 CALCIUM-BINDING PROTEIN; 1. DR Pfam; PF01023; S_100; 1. DR SMART; SM00054; EFh; 1. DR SMART; SM01394; S_100; 1. DR SUPFAM; SSF47473; EF-hand; 1. DR PROSITE; PS50222; EF_HAND_2; 1. DR PROSITE; PS00303; S100_CABP; 1. PE 1: Evidence at protein level; KW 3D-structure; Calcium; Cell membrane; Cell projection; Cytoplasm; KW Direct protein sequencing; Membrane; Metal-binding; Nucleus; KW Proteomics identification; Reference proteome; Repeat. FT CHAIN 1..95 FT /note="Protein S100-P" FT /id="PRO_0000144032" FT DOMAIN 12..47 FT /note="EF-hand 1" FT /evidence="ECO:0000305" FT DOMAIN 49..84 FT /note="EF-hand 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 25 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /ligand_note="low affinity" FT /evidence="ECO:0000305" FT BINDING 27 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /ligand_note="low affinity" FT /evidence="ECO:0000305" FT BINDING 32 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /ligand_note="low affinity" FT /evidence="ECO:0000305" FT BINDING 62 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /ligand_note="high affinity" FT /evidence="ECO:0000305" FT BINDING 64 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /ligand_note="high affinity" FT /evidence="ECO:0000305" FT BINDING 66 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /ligand_note="high affinity" FT /evidence="ECO:0000305" FT BINDING 68 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /ligand_note="high affinity" FT /evidence="ECO:0000305" FT BINDING 73 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /ligand_note="high affinity" FT /evidence="ECO:0000305" FT MUTAGEN 21..23 FT /note="Missing: In S100Ppa; permanently active, interacts FT with EZR and PPP5C in absence of calcium; when associated FT with C-64, K-68 and S-73." FT /evidence="ECO:0000269|PubMed:19111582, FT ECO:0000269|PubMed:22399290" FT MUTAGEN 64 FT /note="N->C: In S100Ppa; permanently active, interacts with FT EZR and PPP5C in absence of calcium; when associated with FT 21-S--G-23, K-68 and S-73." FT /evidence="ECO:0000269|PubMed:19111582, FT ECO:0000269|PubMed:22399290" FT MUTAGEN 68 FT /note="Q->K: In S100Ppa; permanently active, interacts with FT EZR and PPP5C in absence of calcium; when associated with FT 21-S--G-23, C-64 and S-73." FT /evidence="ECO:0000269|PubMed:19111582, FT ECO:0000269|PubMed:22399290" FT MUTAGEN 73 FT /note="E->S: In S100Ppa; permanently active, interacts with FT EZR and PPP5C in absence of calcium; when associated with FT 21-S--G-23, C-64 and K-68." FT /evidence="ECO:0000269|PubMed:19111582, FT ECO:0000269|PubMed:22399290" FT CONFLICT 12 FT /note="I -> M (in Ref. 4; AAS00487)" FT /evidence="ECO:0000305" FT CONFLICT 32 FT /note="E -> T (in Ref. 6; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 44 FT /note="F -> E (in Ref. 6; AA sequence)" FT /evidence="ECO:0000305" FT HELIX 3..18 FT /evidence="ECO:0007829|PDB:1J55" FT STRAND 21..23 FT /evidence="ECO:0007829|PDB:1J55" FT STRAND 25..28 FT /evidence="ECO:0007829|PDB:7NMI" FT HELIX 30..40 FT /evidence="ECO:0007829|PDB:1J55" FT HELIX 44..46 FT /evidence="ECO:0007829|PDB:1OZO" FT HELIX 53..61 FT /evidence="ECO:0007829|PDB:1J55" FT STRAND 63..70 FT /evidence="ECO:0007829|PDB:1J55" FT HELIX 71..92 FT /evidence="ECO:0007829|PDB:1J55" SQ SEQUENCE 95 AA; 10400 MW; 786E6E3F3EACC6C1 CRC64; MTELETAMGM IIDVFSRYSG SEGSTQTLTK GELKVLMEKE LPGFLQSGKD KDAVDKLLKD LDANGDAQVD FSEFIVFVAA ITSACHKYFE KAGLK // ID TRPM7_HUMAN Reviewed; 1865 AA. AC Q96QT4; Q6ZMF5; Q86VJ4; Q8NBW2; Q9BXB2; Q9NXQ2; DT 07-DEC-2004, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2001, sequence version 1. DT 28-JAN-2026, entry version 188. DE RecName: Full=Transient receptor potential cation channel subfamily M member 7; DE EC=2.7.11.1 {ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, ECO:0000269|PubMed:18394644}; DE AltName: Full=Channel-kinase 1; DE AltName: Full=Long transient receptor potential channel 7 {ECO:0000303|PubMed:11385574}; DE Short=LTrpC-7; DE Short=LTrpC7; DE Contains: DE RecName: Full=TRPM7 kinase, cleaved form {ECO:0000250|UniProtKB:Q923J1}; DE Short=M7CK; DE Contains: DE RecName: Full=TRPM7 channel, cleaved form {ECO:0000250|UniProtKB:Q923J1}; GN Name=TRPM7; Synonyms=CHAK1, LTRPC7 {ECO:0000303|PubMed:11385574}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TRANSPORTER ACTIVITY, AND ACTIVITY RP REGULATION. RX PubMed=11385574; DOI=10.1038/35079092; RA Nadler M.J.S., Hermosura M.C., Inabe K., Perraud A.-L., Zhu Q., RA Stokes A.J., Kurosaki T., Kinet J.-P., Penner R., Scharenberg A.M., RA Fleig A.; RT "LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell RT viability."; RL Nature 411:590-595(2001). RN [2] RP ERRATUM OF PUBMED:11385574. RA Nadler M.J.S., Hermosura M.C., Inabe K., Perraud A.-L., Zhu Q., RA Stokes A.J., Kurosaki T., Kinet J.-P., Penner R., Scharenberg A.M., RA Fleig A.; RL Nature 412:660-660(2001). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION. RX PubMed=14594813; DOI=10.1074/jbc.m308820200; RA Ryazanova L.V., Dorovkov M.V., Ansari A., Ryazanov A.G.; RT "Characterization of the protein kinase activity of TRPM7/ChaK1, a protein RT kinase fused to the transient receptor potential ion channel."; RL J. Biol. Chem. 279:3708-3716(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-575 AND 1096-1865, AND VARIANT RP ILE-1482. RC TISSUE=Colon, and Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 464-998. RC TISSUE=Liver; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP FUNCTION, TRANSPORTER ACTIVITY, AND MUTAGENESIS OF LYS-1648 AND GLY-1799. RX PubMed=12887921; DOI=10.1016/s0092-8674(03)00556-7; RA Schmitz C., Perraud A.-L., Johnson C.O., Inabe K., Smith M.K., Penner R., RA Kurosaki T., Fleig A., Scharenberg A.M.; RT "Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7."; RL Cell 114:191-200(2003). RN [7] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15485879; DOI=10.1074/jbc.c400441200; RA Dorovkov M.V., Ryazanov A.G.; RT "Phosphorylation of annexin I by TRPM7 channel-kinase."; RL J. Biol. Chem. 279:50643-50646(2004). RN [8] RP INTERACTION WITH TRPM6. RX PubMed=14976260; DOI=10.1073/pnas.0305252101; RA Chubanov V., Waldegger S., Mederos y Schnitzler M., Vitzthum H., RA Sassen M.C., Seyberth H.W., Konrad M., Gudermann T.; RT "Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 RT gene causes hypomagnesemia with secondary hypocalcemia."; RL Proc. Natl. Acad. Sci. U.S.A. 101:2894-2899(2004). RN [9] RP INTERACTION WITH TRPM6. RX PubMed=16636202; DOI=10.1085/jgp.200609502; RA Li M., Jiang J., Yue L.; RT "Functional characterization of homo- and heteromeric channel kinases TRPM6 RT and TRPM7."; RL J. Gen. Physiol. 127:525-537(2006). RN [10] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=18394644; DOI=10.1016/j.jmb.2008.02.057; RA Clark K., Middelbeek J., Lasonder E., Dulyaninova N.G., Morrice N.A., RA Ryazanov A.G., Bresnick A.R., Figdor C.G., van Leeuwen F.N.; RT "TRPM7 regulates myosin IIA filament stability and protein localization by RT heavy chain phosphorylation."; RL J. Mol. Biol. 378:790-803(2008). RN [11] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND PHOSPHORYLATION AT RP THR-1163; SER-1191; SER-1193; SER-1255; SER-1258; THR-1265; SER-1287; RP SER-1358; SER-1361; SER-1387; SER-1390; SER-1396; SER-1404; THR-1405; RP SER-1407; THR-1435; SER-1446; THR-1455; SER-1456; SER-1463; SER-1468; RP THR-1471; SER-1476; SER-1477; THR-1482; SER-1493; SER-1504; THR-1508; RP SER-1513; SER-1527; SER-1533; THR-1537; THR-1542; SER-1543; THR-1551; RP SER-1567; SER-1569; THR-1583; SER-1598; SER-1615; SER-1660; THR-1685; RP SER-1779; THR-1830 AND SER-1860. RX PubMed=18365021; DOI=10.1371/journal.pone.0001876; RA Clark K., Middelbeek J., Morrice N.A., Figdor C.G., Lasonder E., RA van Leeuwen F.N.; RT "Massive autophosphorylation of the Ser/Thr-rich domain controls protein RT kinase activity of TRPM6 and TRPM7."; RL PLoS ONE 3:e1876-e1876(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [14] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-101; SER-1387; SER-1390; RP SER-1395; SER-1404; SER-1477; SER-1527 AND SER-1569, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [16] RP FUNCTION. RX PubMed=24316671; DOI=10.1038/ncb2883; RA Cai Z., Jitkaew S., Zhao J., Chiang H.C., Choksi S., Liu J., Ward Y., RA Wu L.G., Liu Z.G.; RT "Plasma membrane translocation of trimerized MLKL protein is required for RT TNF-induced necroptosis."; RL Nat. Cell Biol. 16:55-65(2014). RN [17] RP PALMITOYLATION AT CYS-1143; CYS-1144 AND CYS-1146, FUNCTION, AND RP TRANSPORTER ACTIVITY. RX PubMed=36027648; DOI=10.1016/j.ceca.2022.102639; RA Gao X., Kuo C.W., Main A., Brown E., Rios F.J., Camargo L.L., Mary S., RA Wypijewski K., Goek C., Touyz R.M., Fuller W.; RT "Palmitoylation regulates cellular distribution of and transmembrane Ca RT flux through TrpM7."; RL Cell Calcium 106:102639-102639(2022). RN [18] RP VARIANT ILE-1482, CHARACTERIZATION OF VARIANT ILE-1482, AND ACTIVITY RP REGULATION. RX PubMed=16051700; DOI=10.1073/pnas.0505149102; RA Hermosura M.C., Nayakanti H., Dorovkov M.V., Calderon F.R., Ryazanov A.G., RA Haymer D.S., Garruto R.M.; RT "A TRPM7 variant shows altered sensitivity to magnesium that may contribute RT to the pathogenesis of two Guamanian neurodegenerative disorders."; RL Proc. Natl. Acad. Sci. U.S.A. 102:11510-11515(2005). RN [19] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-68; CYS-406; THR-459; ASN-574; SER-720; RP VAL-830; TYR-949; ARG-1064; THR-1211; VAL-1254; GLU-1306; LYS-1444 AND RP ILE-1482. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [20] RP FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, VARIANT ASP-1046, RP CHARACTERIZATION OF VARIANT ASP-1046, AND INVOLVEMENT IN HYPOMAGNESEMIA RP WITH SECONDARY HYPOCALCEMIA. RX PubMed=35561741; DOI=10.1093/ndt/gfac182; RA Vargas-Poussou R., Claverie-Martin F., Prot-Bertoye C., Carotti V., RA van der Wijst J., Perdomo-Ramirez A., Fraga-Rodriguez G.M., Hureaux M., RA Bos C., Latta F., Houillier P., Hoenderop J., de Baaij J.; RT "Possible role for rare TRPM7 variants in patients with hypomagnesemia with RT secondary hypocalcemia."; RL Nephrol. Dial. Transplant. 0:0-0(2022). CC -!- FUNCTION: Bifunctional protein that combines an ion channel with an CC intrinsic kinase domain, enabling it to modulate cellular functions CC either by conducting ions through the pore or by phosphorylating CC downstream proteins via its kinase domain. The channel is highly CC permeable to divalent cations, specifically calcium (Ca2+), magnesium CC (Mg2+) and zinc (Zn2+) and mediates their influx (PubMed:11385574, CC PubMed:12887921, PubMed:15485879, PubMed:24316671, PubMed:35561741, CC PubMed:36027648). Controls a wide range of biological processes such as CC Ca2(+), Mg(2+) and Zn(2+) homeostasis, vesicular Zn(2+) release channel CC and intracellular Ca(2+) signaling, embryonic development, immune CC responses, cell motility, proliferation and differentiation (By CC similarity). The C-terminal alpha-kinase domain autophosphorylates CC cytoplasmic residues of TRPM7 (PubMed:18365021). In vivo, TRPM7 CC phosphorylates SMAD2, suggesting that TRPM7 kinase may play a role in CC activating SMAD signaling pathways. In vitro, TRPM7 kinase CC phosphorylates ANXA1 (annexin A1), myosin II isoforms and a variety of CC proteins with diverse cellular functions (PubMed:15485879, CC PubMed:18394644). {ECO:0000250|UniProtKB:Q923J1, CC ECO:0000269|PubMed:11385574, ECO:0000269|PubMed:12887921, CC ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, CC ECO:0000269|PubMed:18394644, ECO:0000269|PubMed:24316671, CC ECO:0000269|PubMed:35561741, ECO:0000269|PubMed:36027648}. CC -!- FUNCTION: [TRPM7 channel, cleaved form]: The cleaved channel exhibits CC substantially higher current and potentiates Fas receptor signaling. CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- FUNCTION: [TRPM7 kinase, cleaved form]: The C-terminal kinase domain CC can be cleaved from the channel segment in a cell-type-specific CC fashion. In immune cells, the TRPM7 kinase domain is clipped from the CC channel domain by caspases in response to Fas-receptor stimulation. The CC cleaved kinase fragments can translocate to the nucleus, and bind CC chromatin-remodeling complex proteins in a Zn(2+)-dependent manner to CC ultimately phosphorylate specific Ser/Thr residues of histones known to CC be functionally important for cell differentiation and embryonic CC development. {ECO:0000250|UniProtKB:Q923J1}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, CC ECO:0000269|PubMed:18394644}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:18365021, ECO:0000269|PubMed:18394644}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Mg(2+)(in) = Mg(2+)(out); Xref=Rhea:RHEA:29827, CC ChEBI:CHEBI:18420; Evidence={ECO:0000269|PubMed:11385574, CC ECO:0000269|PubMed:12887921, ECO:0000269|PubMed:35561741}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:11385574, CC ECO:0000269|PubMed:36027648}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Zn(2+)(in) = Zn(2+)(out); Xref=Rhea:RHEA:29351, CC ChEBI:CHEBI:29105; Evidence={ECO:0000250|UniProtKB:Q923J1}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Evidence={ECO:0000250|UniProtKB:Q923J1}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000250|UniProtKB:Q923J1}; CC -!- ACTIVITY REGULATION: Channel displays constitutive activity. Channel CC activity is negatively regulated by cytosolic Mg(2+) and Mg-ATP CC (PubMed:11385574, PubMed:16051700). Channel activity is negatively CC regulated by low intracellular pH (By similarity). Resting free CC cytosolic Mg(2+) and Mg-ATP concentrations seem to be sufficient to CC block native TRPM7 channel activity (By similarity). TRPM7 channel CC activity is highly dependent on membrane levels of phosphatidylinositol CC 4,5 bisphosphate (PIP2). PIP2 hydrolysis negatively regulates TRPM7 CC channel activity (By similarity). TRPM7 kinase activity does not affect CC channel activity (By similarity). The kinase activity is controlled CC through the autophosphorylation of a serine/threonine-rich region CC located N-terminal to the catalytic domain (PubMed:18365021). CC {ECO:0000250|UniProtKB:Q923J1, ECO:0000250|UniProtKB:Q925B3, CC ECO:0000269|PubMed:11385574, ECO:0000269|PubMed:16051700, CC ECO:0000269|PubMed:18365021}. CC -!- SUBUNIT: Homotetramer (By similarity). Interacts with PLCB1 (By CC similarity). Forms heteromers with TRPM6; heteromeric channels are CC functionally different from the homomeric channels (PubMed:14976260, CC PubMed:16636202). {ECO:0000250|UniProtKB:Q923J1, CC ECO:0000250|UniProtKB:Q925B3, ECO:0000269|PubMed:14976260, CC ECO:0000269|PubMed:16636202}. CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:24316671, CC ECO:0000269|PubMed:35561741}; Multi-pass membrane protein CC {ECO:0000250|UniProtKB:Q923J1}. Cytoplasmic vesicle membrane CC {ECO:0000250|UniProtKB:Q923J1}; Multi-pass membrane protein CC {ECO:0000250|UniProtKB:Q923J1}. Note=Localized largely in intracellular CC Zn(2+)-storage vesicles. {ECO:0000250|UniProtKB:Q923J1}. CC -!- SUBCELLULAR LOCATION: [TRPM7 kinase, cleaved form]: Nucleus CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- PTM: Palmitoylated; palmitoylation at Cys-1143, Cys-1144 and Cys-1146 CC promotes TRPM7 trafficking from the Golgi to the surface membrane. CC {ECO:0000269|PubMed:36027648}. CC -!- PTM: Autophosphorylated; autophosphorylation of C-terminus regulates CC TRPM7 kinase activity towards its substrates. CC {ECO:0000269|PubMed:18365021}. CC -!- PTM: The C-terminal kinase domain can be cleaved from the channel CC segment in a cell-type-specific fashion. TRPM7 is cleaved by caspase-8, CC dissociating the kinase from the ion-conducting pore. The cleaved CC kinase fragments (M7CKs) can translocate to the cell nucleus and binds CC chromatin-remodeling complex proteins in a Zn(2+)-dependent manner to CC ultimately phosphorylate specific Ser/Thr residues of histones. CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- DISEASE: Amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 CC (ALS-PDC1) [MIM:105500]: A neurodegenerative disorder characterized by CC chronic, progressive and uniformly fatal amyotrophic lateral sclerosis CC and parkinsonism-dementia. Both diseases are known to occur in the same CC kindred, the same sibship and even the same individual. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Note=TRPM7 variants have been identified as a potential cause CC of disease in patients suffering from seizures and muscle cramps due to CC magnesium deficiency and episodes of hypocalcemia. CC {ECO:0000269|PubMed:35561741}. CC -!- SIMILARITY: In the C-terminal section; belongs to the protein kinase CC superfamily. Alpha-type protein kinase family. ALPK subfamily. CC {ECO:0000305}. CC -!- SIMILARITY: In the N-terminal section; belongs to the transient CC receptor (TC 1.A.4) family. LTrpC subfamily. TRPM7 sub-subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAC11462.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=BAD18773.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY032950; AAK44211.1; -; mRNA. DR EMBL; AF346629; AAK19738.2; -; mRNA. DR EMBL; AK000124; BAA90958.1; -; mRNA. DR EMBL; AK172800; BAD18773.1; ALT_INIT; mRNA. DR EMBL; AK075193; BAC11462.1; ALT_INIT; mRNA. DR EMBL; BC051024; AAH51024.1; -; mRNA. DR CCDS; CCDS42035.1; -. DR RefSeq; NP_001288141.1; NM_001301212.1. DR RefSeq; NP_060142.3; NM_017672.5. DR AlphaFoldDB; Q96QT4; -. DR SMR; Q96QT4; -. DR BioGRID; 120177; 153. DR CORUM; Q96QT4; -. DR FunCoup; Q96QT4; 1775. DR IntAct; Q96QT4; 44. DR MINT; Q96QT4; -. DR STRING; 9606.ENSP00000495860; -. DR BindingDB; Q96QT4; -. DR ChEMBL; CHEMBL1250412; -. DR DrugBank; DB04447; 1,4-Dithiothreitol. DR DrugBank; DB14513; Magnesium. DR DrugBank; DB09481; Magnesium carbonate. DR DrugBank; DB06757; Manganese cation. DR DrugBank; DB00179; Masoprocol. DR DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester. DR GuidetoPHARMACOLOGY; 499; -. DR TCDB; 1.A.4.5.1; the transient receptor potential ca2+/cation channel (trp-cc) family. DR CarbonylDB; Q96QT4; -. DR iPTMnet; Q96QT4; -. DR PhosphoSitePlus; Q96QT4; -. DR SwissPalm; Q96QT4; -. DR BioMuta; TRPM7; -. DR DMDM; 56404941; -. DR jPOST; Q96QT4; -. DR MassIVE; Q96QT4; -. DR PaxDb; 9606-ENSP00000320239; -. DR PeptideAtlas; Q96QT4; -. DR ProteomicsDB; 77898; -. DR Pumba; Q96QT4; -. DR Antibodypedia; 24755; 465 antibodies from 40 providers. DR DNASU; 54822; -. DR Ensembl; ENST00000646667.1; ENSP00000495860.1; ENSG00000092439.16. DR GeneID; 54822; -. DR KEGG; hsa:54822; -. DR MANE-Select; ENST00000646667.1; ENSP00000495860.1; NM_017672.6; NP_060142.3. DR UCSC; uc001zyt.5; human. DR AGR; HGNC:17994; -. DR ClinPGx; PA38273; -. DR CTD; 54822; -. DR DisGeNET; 54822; -. DR GeneCards; TRPM7; -. DR HGNC; HGNC:17994; TRPM7. DR HPA; ENSG00000092439; Tissue enriched (parathyroid). DR MalaCards; TRPM7; -. DR MIM; 105500; phenotype. DR MIM; 605692; gene. DR OpenTargets; ENSG00000092439; -. DR Orphanet; 140957; Autosomal dominant macrothrombocytopenia. DR Orphanet; 90020; Parkinson-dementia complex of Guam. DR VEuPathDB; HostDB:ENSG00000092439; -. DR eggNOG; KOG3614; Eukaryota. DR GeneTree; ENSGT00940000157091; -. DR InParanoid; Q96QT4; -. DR OMA; SSKDPHX; -. DR OrthoDB; 301415at2759; -. DR PAN-GO; Q96QT4; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q96QT4; -. DR PathwayCommons; Q96QT4; -. DR Reactome; R-HSA-3295583; TRP channels. DR SignaLink; Q96QT4; -. DR SIGNOR; Q96QT4; -. DR Agora; ENSG00000092439; -. DR BioGRID-ORCS; 54822; 406 hits in 1198 CRISPR screens. DR ChiTaRS; TRPM7; human. DR GeneWiki; TRPM7; -. DR GenomeRNAi; 54822; -. DR Pharos; Q96QT4; Tchem. DR PRO; PR:Q96QT4; -. DR Proteomes; UP000005640; Chromosome 15. DR RNAct; Q96QT4; protein. DR Bgee; ENSG00000092439; Expressed in left ventricle myocardium and 179 other cell types or tissues. DR ExpressionAtlas; Q96QT4; baseline and differential. DR GO; GO:0031410; C:cytoplasmic vesicle; ISS:UniProtKB. DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0001726; C:ruffle; IEA:Ensembl. DR GO; GO:0003779; F:actin binding; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005262; F:calcium channel activity; IDA:UniProtKB. DR GO; GO:0015095; F:magnesium ion transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0017022; F:myosin binding; IEA:Ensembl. DR GO; GO:0004672; F:protein kinase activity; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0005385; F:zinc ion transmembrane transporter activity; IEA:Ensembl. DR GO; GO:0031032; P:actomyosin structure organization; IEA:Ensembl. DR GO; GO:0070588; P:calcium ion transmembrane transport; IDA:UniProtKB. DR GO; GO:0006816; P:calcium ion transport; IBA:GO_Central. DR GO; GO:0016340; P:calcium-dependent cell-matrix adhesion; IEA:Ensembl. DR GO; GO:0010961; P:intracellular magnesium ion homeostasis; ISS:UniProtKB. DR GO; GO:0010960; P:magnesium ion homeostasis; IDA:UniProtKB. DR GO; GO:0015693; P:magnesium ion transport; IDA:UniProtKB. DR GO; GO:0098655; P:monoatomic cation transmembrane transport; IBA:GO_Central. DR GO; GO:0070266; P:necroptotic process; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0051289; P:protein homotetramerization; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0006829; P:zinc ion transport; ISS:UniProtKB. DR CDD; cd16971; Alpha_kinase_ChaK1_TRMP7; 1. DR FunFam; 1.20.5.1010:FF:000002; Transient receptor potential cation channel subfamily M member 7; 1. DR FunFam; 3.20.200.10:FF:000001; Transient receptor potential cation channel, subfamily M, member 7; 1. DR FunFam; 3.30.200.20:FF:000129; Transient receptor potential cation channel, subfamily M, member 7; 1. DR Gene3D; 3.20.200.10; MHCK/EF2 kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.20.5.1010; TRPM, tetramerisation domain; 1. DR InterPro; IPR004166; a-kinase_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050927; TRPM. DR InterPro; IPR057366; TRPM-like. DR InterPro; IPR029601; TRPM7_a-kinase_dom. DR InterPro; IPR041491; TRPM_SLOG. DR InterPro; IPR032415; TRPM_tetra. DR InterPro; IPR037162; TRPM_tetra_sf. DR PANTHER; PTHR13800:SF8; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY M MEMBER 7; 1. DR PANTHER; PTHR13800; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 6; 1. DR Pfam; PF02816; Alpha_kinase; 1. DR Pfam; PF18139; LSDAT_euk; 1. DR Pfam; PF25508; TRPM2; 2. DR Pfam; PF16519; TRPM_tetra; 1. DR SMART; SM00811; Alpha_kinase; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51158; ALPHA_KINASE; 1. PE 1: Evidence at protein level; KW Acetylation; Amyotrophic lateral sclerosis; ATP-binding; Calcium; KW Calcium channel; Calcium transport; Cell membrane; Coiled coil; KW Cytoplasmic vesicle; Disease variant; Ion channel; Ion transport; Kinase; KW Lipoprotein; Membrane; Metal-binding; Necrosis; Neurodegeneration; KW Nucleotide-binding; Nucleus; Palmitate; Parkinsonism; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Transmembrane; KW Transmembrane helix; Transport; Zinc. FT CHAIN 1..1865 FT /note="Transient receptor potential cation channel FT subfamily M member 7" FT /id="PRO_0000215331" FT CHAIN 1..? FT /note="TRPM7 channel, cleaved form" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT /id="PRO_0000461294" FT CHAIN ?..1865 FT /note="TRPM7 kinase, cleaved form" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT /id="PRO_0000461295" FT TOPO_DOM 1..850 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 851..876 FT /note="Helical; Name=1" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 877..882 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 883..904 FT /note="Helical; Name=2" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 905..923 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 924..943 FT /note="Helical; Name=3" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 944..956 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 957..980 FT /note="Helical; Name=4" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 981..999 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 1000..1023 FT /note="Helical; Name=5" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1024..1025 FT /note="Extracellular" FT /evidence="ECO:0000305" FT INTRAMEM 1026..1066 FT /note="Pore-forming" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1067..1069 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 1070..1098 FT /note="Helical; Name=6" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1099..1865 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT DOMAIN 1594..1824 FT /note="Alpha-type protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00501" FT REGION 544..575 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1386..1407 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1492..1511 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1524..1543 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1836..1865 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 1198..1250 FT /evidence="ECO:0000250" FT COMPBIAS 544..555 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 560..573 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1386..1398 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1494..1511 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1844..1865 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 1767 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 1621 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1622 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1623 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1624 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1648 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1720 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1721 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1723 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1753 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1777 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1810 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1812 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1816 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 101 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1163 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1191 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1193 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1224 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1255 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1258 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1265 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1287 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1301 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1358 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1361 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1386 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1387 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1390 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1395 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1396 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1404 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1405 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1407 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1435 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1446 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1455 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1456 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1463 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1467 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1468 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1471 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1476 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1477 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 1482 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1493 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1500 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1504 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1508 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1513 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1527 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1533 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1537 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1542 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1543 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1551 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1567 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1569 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1583 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1598 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1615 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1660 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1685 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1779 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1830 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1851 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1860 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT LIPID 1143 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT LIPID 1144 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT LIPID 1146 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT VARIANT 68 FT /note="G -> V (in dbSNP:rs56064201)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042395" FT VARIANT 406 FT /note="S -> C (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042396" FT VARIANT 459 FT /note="I -> T (in dbSNP:rs55924090)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042397" FT VARIANT 574 FT /note="K -> N (in dbSNP:rs56040619)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042398" FT VARIANT 720 FT /note="T -> S (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs1040254222)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042399" FT VARIANT 830 FT /note="M -> V (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042400" FT VARIANT 949 FT /note="F -> Y (in dbSNP:rs55681028)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042401" FT VARIANT 1033 FT /note="A -> G (in dbSNP:rs34530969)" FT /id="VAR_052381" FT VARIANT 1046 FT /note="G -> D (found in a patient with hypomagnesemia and FT secondary hypocalcemia; likely pathogenic; de novo variant; FT causes severely reduced Mg(2+) uptake in transfected cells; FT dbSNP:rs2059709974)" FT /evidence="ECO:0000269|PubMed:35561741" FT /id="VAR_086707" FT VARIANT 1064 FT /note="Q -> R (in dbSNP:rs56298128)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042402" FT VARIANT 1145 FT /note="I -> V (in dbSNP:rs34711809)" FT /id="VAR_052382" FT VARIANT 1211 FT /note="I -> T (in dbSNP:rs56090496)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042403" FT VARIANT 1254 FT /note="A -> V (in dbSNP:rs56288221)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042404" FT VARIANT 1306 FT /note="D -> E (in dbSNP:rs55970334)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042405" FT VARIANT 1444 FT /note="R -> K (in dbSNP:rs55840070)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042406" FT VARIANT 1482 FT /note="T -> I (mutant channels are functional but show FT increased susceptibility to inhibition by intracellular FT Mg(2+) concentrations compared to wild-type channels; FT dbSNP:rs8042919)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:16051700, ECO:0000269|PubMed:17344846" FT /id="VAR_019967" FT MUTAGEN 1648 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:12887921" FT MUTAGEN 1799 FT /note="G->D: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:12887921" FT CONFLICT 573..575 FT /note="EKM -> KKK (in Ref. 4; BAD18773)" FT /evidence="ECO:0000305" FT CONFLICT 998 FT /note="A -> S (in Ref. 5)" FT /evidence="ECO:0000305" FT CONFLICT 1496 FT /note="Missing (in Ref. 3; AAK19738)" FT /evidence="ECO:0000305" FT CONFLICT 1520 FT /note="D -> V (in Ref. 3; AAK19738)" FT /evidence="ECO:0000305" SQ SEQUENCE 1865 AA; 212697 MW; BE732674D52D7485 CRC64; MSQKSWIEST LTKRECVYII PSSKDPHRCL PGCQICQQLV RCFCGRLVKQ HACFTASLAM KYSDVKLGDH FNQAIEEWSV EKHTEQSPTD AYGVINFQGG SHSYRAKYVR LSYDTKPEVI LQLLLKEWQM ELPKLVISVH GGMQKFELHP RIKQLLGKGL IKAAVTTGAW ILTGGVNTGV AKHVGDALKE HASRSSRKIC TIGIAPWGVI ENRNDLVGRD VVAPYQTLLN PLSKLNVLNN LHSHFILVDD GTVGKYGAEV RLRRELEKTI NQQRIHARIG QGVPVVALIF EGGPNVILTV LEYLQESPPV PVVVCEGTGR AADLLAYIHK QTEEGGNLPD AAEPDIISTI KKTFNFGQNE ALHLFQTLME CMKRKELITV FHIGSDEHQD IDVAILTALL KGTNASAFDQ LILTLAWDRV DIAKNHVFVY GQQWLVGSLE QAMLDALVMD RVAFVKLLIE NGVSMHKFLT IPRLEELYNT KQGPTNPMLF HLVRDVKQGN LPPGYKITLI DIGLVIEYLM GGTYRCTYTR KRFRLIYNSL GGNNRRSGRN TSSSTPQLRK SHESFGNRAD KKEKMRHNHF IKTAQPYRPK IDTVMEEGKK KRTKDEIVDI DDPETKRFPY PLNELLIWAC LMKRQVMARF LWQHGEESMA KALVACKIYR SMAYEAKQSD LVDDTSEELK QYSNDFGQLA VELLEQSFRQ DETMAMKLLT YELKNWSNST CLKLAVSSRL RPFVAHTCTQ MLLSDMWMGR LNMRKNSWYK VILSILVPPA ILLLEYKTKA EMSHIPQSQD AHQMTMDDSE NNFQNITEEI PMEVFKEVRI LDSNEGKNEM EIQMKSKKLP ITRKFYAFYH APIVKFWFNT LAYLGFLMLY TFVVLVQMEQ LPSVQEWIVI AYIFTYAIEK VREIFMSEAG KVNQKIKVWF SDYFNISDTI AIISFFIGFG LRFGAKWNFA NAYDNHVFVA GRLIYCLNII FWYVRLLDFL AVNQQAGPYV MMIGKMVANM FYIVVIMALV LLSFGVPRKA ILYPHEAPSW TLAKDIVFHP YWMIFGEVYA YEIDVCANDS VIPQICGPGT WLTPFLQAVY LFVQYIIMVN LLIAFFNNVY LQVKAISNIV WKYQRYHFIM AYHEKPVLPP PLIILSHIVS LFCCICKRRK KDKTSDGPKL FLTEEDQKKL HDFEEQCVEM YFNEKDDKFH SGSEERIRVT FERVEQMCIQ IKEVGDRVNY IKRSLQSLDS QIGHLQDLSA LTVDTLKTLT AQKASEASKV HNEITRELSI SKHLAQNLID DGPVRPSVWK KHGVVNTLSS SLPQGDLESN NPFHCNILMK DDKDPQCNIF GQDLPAVPQR KEFNFPEAGS SSGALFPSAV SPPELRQRLH GVELLKIFNK NQKLGSSSTS IPHLSSPPTK FFVSTPSQPS CKSHLETGTK DQETVCSKAT EGDNTEFGAF VGHRDSMDLQ RFKETSNKIK ILSNNNTSEN TLKRVSSLAG FTDCHRTSIP VHSKQAEKIS RRPSTEDTHE VDSKAALIPD WLQDRPSNRE MPSEEGTLNG LTSPFKPAMD TNYYYSAVER NNLMRLSQSI PFTPVPPRGE PVTVYRLEES SPNILNNSMS SWSQLGLCAK IEFLSKEEMG GGLRRAVKVQ CTWSEHDILK SGHLYIIKSF LPEVVNTWSS IYKEDTVLHL CLREIQQQRA AQKLTFAFNQ MKPKSIPYSP RFLEVFLLYC HSAGQWFAVE ECMTGEFRKY NNNNGDEIIP TNTLEEIMLA FSHWTYEYTR GELLVLDLQG VGENLTDPSV IKAEEKRSCD MVFGPANLGE DAIKNFRAKH HCNSCCRKLK LPDLKRNDYT PDKIIFPQDE PSDLNLQPGN STKESESTNS VRLML // ID WNK1_HUMAN Reviewed; 2382 AA. AC Q9H4A3; A1L4B0; C5HTZ5; C5HTZ6; C5HTZ7; H6WZW3; O15052; P54963; Q4VBX9; AC Q6IFS5; Q86WL5; Q8N673; Q96CZ6; Q9P1S9; DT 02-FEB-2004, integrated into UniProtKB/Swiss-Prot. DT 18-MAY-2010, sequence version 2. DT 28-JAN-2026, entry version 231. DE RecName: Full=Serine/threonine-protein kinase WNK1 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:15883153, ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:16832045, ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:31656913}; DE AltName: Full=Erythrocyte 65 kDa protein; DE Short=p65; DE AltName: Full=Kinase deficient protein; DE AltName: Full=Protein kinase lysine-deficient 1 {ECO:0000312|HGNC:HGNC:14540}; DE AltName: Full=Protein kinase with no lysine 1 {ECO:0000303|PubMed:11571656}; DE Short=hWNK1; GN Name=WNK1 {ECO:0000303|PubMed:11571656, ECO:0000312|HGNC:HGNC:14540}; GN Synonyms=HSN2 {ECO:0000303|PubMed:15060842}, KDP, GN KIAA0344 {ECO:0000312|EMBL:BAA20802.2}, GN PRKWNK1 {ECO:0000312|HGNC:HGNC:14540}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606 {ECO:0000312|EMBL:CAC15059.1}; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, CHROMOSOMAL RP LOCATION, AND VARIANTS PRO-1056; SER-1506 AND ILE-1808. RC TISSUE=Heart {ECO:0000312|EMBL:CAC15059.1}; RX PubMed=11571656; DOI=10.1038/sj.onc.1204726; RA Verissimo F., Jordan P.; RT "WNK kinases, a novel protein kinase subfamily in multi-cellular RT organisms."; RL Oncogene 20:5562-5569(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6), ALTERNATIVE SPLICING, AND TISSUE RP SPECIFICITY. RC TISSUE=Neuron; RX PubMed=22701532; DOI=10.1371/journal.pone.0037751; RA Vidal-Petiot E., Cheval L., Faugeroux J., Malard T., Doucet A., RA Jeunemaitre X., Hadchouel J.; RT "A new methodology for quantification of alternatively spliced exons RT reveals a highly tissue-specific expression pattern of WNK1 isoforms."; RL PLoS ONE 7:E37751-E37751(2012). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-1056; SER-1506 AND RP ILE-1808. RG NHLBI resequencing and genotyping service (RS&G); RL Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16541075; DOI=10.1038/nature04569; RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y., RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C., RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K., RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D., RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R., RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E., RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N., RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N., RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R., RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S., RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H., RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P., RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G., RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E., RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S., RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J., RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A., RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M., RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I., RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A., RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y., RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A., RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F., RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L., RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G., RA Gibbs R.A.; RT "The finished DNA sequence of human chromosome 12."; RL Nature 440:346-351(2006). RN [5] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-668 (ISOFORMS 1/2), FUNCTION, CATALYTIC RP ACTIVITY, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RC TISSUE=Mammary carcinoma; RX PubMed=10660600; DOI=10.1074/jbc.275.6.4311; RA Moore T.M., Garg R., Johnson C., Coptcoat M.J., Ridley A.J., Morris J.D.H.; RT "PSK, a novel STE20-like kinase derived from prostatic carcinoma that RT activates the JNK MAPK pathway and regulates actin cytoskeletal RT organisation."; RL J. Biol. Chem. 275:4311-4322(2000). RN [6] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 69-2382 (ISOFORM 2), AND VARIANTS RP PRO-1056 AND SER-1506. RC TISSUE=Brain {ECO:0000312|EMBL:BAA20802.2}; RX PubMed=9205841; DOI=10.1093/dnares/4.2.141; RA Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N., RA Tanaka A., Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. VII. The RT complete sequences of 100 new cDNA clones from brain which can code for RT large proteins in vitro."; RL DNA Res. 4:141-150(1997). RN [7] {ECO:0000305} RP SEQUENCE REVISION TO N-TERMINUS. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [8] RP PROTEIN SEQUENCE OF 163-175, AND GLYCOSYLATION. RX PubMed=2507249; DOI=10.1002/9780470513828.ch7; RA Hart G.W., Haltiwanger R.S., Holt G.D., Kelly W.G.; RT "Nucleoplasmic and cytoplasmic glycoproteins."; RL Ciba Found. Symp. 145:102-118(1989). RN [9] {ECO:0000305} RP PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (N-TERMINUS OF ISOFORM 3), ALTERNATIVE RP PROMOTER USAGE, ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY. RC TISSUE=Kidney {ECO:0000269|PubMed:14645531}; RX PubMed=14645531; DOI=10.1128/mcb.23.24.9208-9221.2003; RA Delaloy C., Lu J., Houot A.-M., Disse-Nicodeme S., Gasc J.-M., Corvol P., RA Jeunemaitre X.; RT "Multiple promoters in the WNK1 gene: one controls expression of a kidney- RT specific kinase-defective isoform."; RL Mol. Cell. Biol. 23:9208-9221(2003). RN [10] {ECO:0000305} RP PARTIAL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1/4/5). RC TISSUE=Placenta {ECO:0000269|PubMed:15489334}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP IDENTIFICATION (ISOFORMS 4/5), AND INVOLVEMENT IN HSAN2A. RX PubMed=15060842; DOI=10.1086/420795; RA Lafreniere R.G., MacDonald M.L.E., Dube M.-P., MacFarlane J., RA O'Driscoll M., Brais B., Meilleur S., Brinkman R.R., Dadivas O., Pape T., RA Platon C., Radomski C., Risler J., Thompson J., Guerra-Escobio A.-M., RA Davar G., Breakefield X.O., Pimstone S.N., Green R., Pryse-Phillips W., RA Goldberg Y.P., Younghusband H.B., Hayden M.R., Sherrington R., RA Rouleau G.A., Samuels M.E.; RT "Identification of a novel gene (HSN2) causing hereditary sensory and RT autonomic neuropathy type II through the study of Canadian genetic RT isolates."; RL Am. J. Hum. Genet. 74:1064-1073(2004). RN [12] {ECO:0000305} RP INVOLVEMENT IN PHA2C. RX PubMed=11498583; DOI=10.1126/science.1062844; RA Wilson F.H., Disse-Nicodeme S., Choate K.A., Ishikawa K., RA Nelson-Williams C., Desitter I., Gunel M., Milford D.V., Lipkin G.W., RA Achard J.-M., Feely M.P., Dussol B., Berland Y., Unwin R.J., Mayan H., RA Simon D.B., Farfel Z., Jeunemaitre X., Lifton R.P.; RT "Human hypertension caused by mutations in WNK kinases."; RL Science 293:1107-1112(2001). RN [13] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND PHOSPHORYLATION AT RP SER-382. RX PubMed=15883153; DOI=10.1074/jbc.m502598200; RA Lenertz L.Y., Lee B.H., Min X., Xu B.E., Wedin K., Earnest S., RA Goldsmith E.J., Cobb M.H.; RT "Properties of WNK1 and implications for other family members."; RL J. Biol. Chem. 280:26653-26658(2005). RN [14] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVE SITE, ACTIVITY REGULATION, DOMAIN, RP PHOSPHORYLATION AT SER-382, AND MUTAGENESIS OF LYS-233; ASP-368; SER-382; RP PHE-1258; PHE-1860; PHE-1946 AND PHE-1958. RX PubMed=16263722; DOI=10.1074/jbc.m510042200; RA Moriguchi T., Urushiyama S., Hisamoto N., Iemura S., Uchida S., Natsume T., RA Matsumoto K., Shibuya H.; RT "WNK1 regulates phosphorylation of cation-chloride-coupled cotransporters RT via the STE20-related kinases, SPAK and OSR1."; RL J. Biol. Chem. 280:42685-42693(2005). RN [15] RP INVOLVEMENT IN HSAN2A. RX PubMed=15911806; DOI=10.1212/01.wnl.0000161849.29944.43; RA Roddier K., Thomas T., Marleau G., Gagnon A.M., Dicaire M.J., St Denis A., RA Gosselin I., Sarrazin A.M., Larbrisseau A., Lambert M., Vanasse M., RA Gaudet D., Rouleau G.A., Brais B.; RT "Two mutations in the HSN2 gene explain the high prevalence of HSAN2 in RT French Canadians."; RL Neurology 64:1762-1767(2005). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2002 AND SER-2032, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1261, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [18] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, PHOSPHORYLATION AT RP SER-382, AND MUTAGENESIS OF SER-382. RX PubMed=16832045; DOI=10.1073/pnas.0604607103; RA Anselmo A.N., Earnest S., Chen W., Juang Y.C., Kim S.C., Zhao Y., RA Cobb M.H.; RT "WNK1 and OSR1 regulate the Na+, K+, 2Cl- cotransporter in HeLa cells."; RL Proc. Natl. Acad. Sci. U.S.A. 103:10883-10888(2006). RN [19] RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, ACTIVITY REGULATION, RP PHOSPHORYLATION AT SER-15; SER-167; SER-382; THR-1848; SER-1261; SER-2012; RP SER-2029; SER-2032 AND SER-2372, AND MUTAGENESIS OF ASP-368 AND SER-382. RX PubMed=17190791; DOI=10.1083/jcb.200605093; RA Zagorska A., Pozo-Guisado E., Boudeau J., Vitari A.C., Rafiqi F.H., RA Thastrup J., Deak M., Campbell D.G., Morrice N.A., Prescott A.R., RA Alessi D.R.; RT "Regulation of activity and localization of the WNK1 protein kinase by RT hyperosmotic stress."; RL J. Cell Biol. 176:89-100(2007). RN [20] RP ALTERNATIVE SPLICING (ISOFORMS 4 AND 5), AND INVOLVEMENT IN HSAN2A. RX PubMed=18521183; DOI=10.1172/jci34088; RA Shekarabi M., Girard N., Riviere J.B., Dion P., Houle M., Toulouse A., RA Lafreniere R.G., Vercauteren F., Hince P., Laganiere J., Rochefort D., RA Faivre L., Samuels M., Rouleau G.A.; RT "Mutations in the nervous system--specific HSN2 exon of WNK1 cause RT hereditary sensory neuropathy type II."; RL J. Clin. Invest. 118:2496-2505(2008). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-1261; SER-2011; RP SER-2012; SER-2027; SER-2029 AND SER-2032, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [24] RP FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND ACTIVITY RP REGULATION. RX PubMed=19739668; DOI=10.1021/bi900666n; RA Yagi Y.I., Abe K., Ikebukuro K., Sode K.; RT "Kinetic mechanism and inhibitor characterization of WNK1 kinase."; RL Biochemistry 48:10255-10266(2009). RN [25] RP FUNCTION. RX PubMed=19665974; DOI=10.1016/j.cell.2009.05.031; RA Rinehart J., Maksimova Y.D., Tanis J.E., Stone K.L., Hodson C.A., Zhang J., RA Risinger M., Pan W., Wu D., Colangelo C.M., Forbush B., Joiner C.H., RA Gulcicek E.E., Gallagher P.G., Lifton R.P.; RT "Sites of regulated phosphorylation that control K-Cl cotransporter RT activity."; RL Cell 138:525-536(2009). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1978, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-1261; SER-1978; RP SER-2032 AND SER-2121, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [28] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [29] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=21321328; DOI=10.1242/jcs.077230; RA Richardson C., Sakamoto K., de los Heros P., Deak M., Campbell D.G., RA Prescott A.R., Alessi D.R.; RT "Regulation of the NKCC2 ion cotransporter by SPAK-OSR1-dependent and RT -independent pathways."; RL J. Cell Sci. 124:789-800(2011). RN [30] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=21220314; DOI=10.1073/pnas.1018567108; RA Tu S.W., Bugde A., Luby-Phelps K., Cobb M.H.; RT "WNK1 is required for mitosis and abscission."; RL Proc. Natl. Acad. Sci. U.S.A. 108:1385-1390(2011). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2027; SER-2029 AND SER-2032, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [32] RP FUNCTION, SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF VAL-318. RX PubMed=22989884; DOI=10.1074/jbc.m112.398750; RA Sengupta S., Tu S.W., Wedin K., Earnest S., Stippec S., Luby-Phelps K., RA Cobb M.H.; RT "Interactions with WNK (with no lysine) family members regulate oxidative RT stress response 1 and ion co-transporter activity."; RL J. Biol. Chem. 287:37868-37879(2012). RN [33] RP UBIQUITINATION BY KLHL2. RX PubMed=23838290; DOI=10.1016/j.bbrc.2013.06.104; RA Takahashi D., Mori T., Wakabayashi M., Mori Y., Susa K., Zeniya M., RA Sohara E., Rai T., Sasaki S., Uchida S.; RT "KLHL2 interacts with and ubiquitinates WNK kinases."; RL Biochem. Biophys. Res. Commun. 437:457-462(2013). RN [34] RP UBIQUITINATION. RX PubMed=23387299; DOI=10.1042/bj20121903; RA Ohta A., Schumacher F.R., Mehellou Y., Johnson C., Knebel A., RA Macartney T.J., Wood N.T., Alessi D.R., Kurz T.; RT "The CUL3-KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome RT interacts with and ubiquitylates WNK isoforms: disease-causing mutations in RT KLHL3 and WNK4 disrupt interaction."; RL Biochem. J. 451:111-122(2013). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-167; SER-174; RP SER-1261; SER-2029; SER-2032; SER-2370 AND SER-2372, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [36] RP UBIQUITINATION. RX PubMed=23576762; DOI=10.1073/pnas.1304592110; RA Shibata S., Zhang J., Puthumana J., Stone K.L., Lifton R.P.; RT "Kelch-like 3 and Cullin 3 regulate electrolyte homeostasis via RT ubiquitination and degradation of WNK4."; RL Proc. Natl. Acad. Sci. U.S.A. 110:7838-7843(2013). RN [37] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-167; SER-174; SER-1978 AND RP SER-2027, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [38] RP FUNCTION. RX PubMed=25362046; DOI=10.1073/pnas.1419057111; RA Dbouk H.A., Weil L.M., Perera G.K., Dellinger M.T., Pearson G., RA Brekken R.A., Cobb M.H.; RT "Actions of the protein kinase WNK1 on endothelial cells are differentially RT mediated by its substrate kinases OSR1 and SPAK."; RL Proc. Natl. Acad. Sci. U.S.A. 111:15999-16004(2014). RN [39] RP FUNCTION. RX PubMed=25477473; DOI=10.1152/ajprenal.00612.2014; RA Roy A., Goodman J.H., Begum G., Donnelly B.F., Pittman G., Weinman E.J., RA Sun D., Subramanya A.R.; RT "Generation of WNK1 knockout cell lines by CRISPR/Cas-mediated genome RT editing."; RL Am. J. Physiol. 308:F366-F376(2015). RN [40] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH UVRAG. RX PubMed=27911840; DOI=10.1073/pnas.1617649113; RA Gallolu Kankanamalage S., Lee A.Y., Wichaidit C., Lorente-Rodriguez A., RA Shah A.M., Stippec S., Whitehurst A.W., Cobb M.H.; RT "Multistep regulation of autophagy by WNK1."; RL Proc. Natl. Acad. Sci. U.S.A. 113:14342-14347(2016). RN [41] RP FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION. RX PubMed=29196535; DOI=10.1101/gad.303677.117; RA Volanakis A., Kamieniarz-Gdula K., Schlackow M., Proudfoot N.J.; RT "WNK1 kinase and the termination factor PCF11 connect nuclear mRNA export RT with transcription."; RL Genes Dev. 31:2175-2185(2017). RN [42] RP MUTAGENESIS OF GLY-1255 AND ARG-1257. RX PubMed=29581290; DOI=10.1073/pnas.1802339115; RA Taylor C.A. IV, An S.W., Kankanamalage S.G., Stippec S., Earnest S., RA Trivedi A.T., Yang J.Z., Mirzaei H., Huang C.L., Cobb M.H.; RT "OSR1 regulates a subset of inward rectifier potassium channels via a RT binding motif variant."; RL Proc. Natl. Acad. Sci. U.S.A. 115:3840-3845(2018). RN [43] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND PHOSPHORYLATION AT RP SER-378 AND SER-382. RX PubMed=31656913; DOI=10.1021/acsomega.9b02187; RA Jonniya N.A., Sk M.F., Kar P.; RT "Investigating phosphorylation-induced conformational changes in WNK1 RT kinase by molecular dynamics simulations."; RL ACS Omega 4:17404-17416(2019). RN [44] RP FUNCTION, ACTIVITY REGULATION, AND PHOSPHORYLATION AT SER-382. RX PubMed=34289367; DOI=10.1016/j.celrep.2021.109416; RA Schiapparelli P., Pirman N.L., Mohler K., Miranda-Herrera P.A., Zarco N., RA Kilic O., Miller C., Shah S.R., Rogulina S., Hungerford W., Abriola L., RA Hoyer D., Turk B.E., Guerrero-Cazares H., Isaacs F.J., RA Quinones-Hinojosa A., Levchenko A., Rinehart J.; RT "Phosphorylated WNK kinase networks in recoded bacteria recapitulate RT physiological function."; RL Cell Rep. 36:109416-109416(2021). RN [45] RP FUNCTION, INTERACTION WITH EMC2, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP PHE-2246; ASP-2248; ASP-2249; LEU-2250; HIS-2251; LEU-2253; TRP-2257 AND RP ASP-2260. RX PubMed=33964204; DOI=10.1016/j.molcel.2021.04.013; RA Pleiner T., Hazu M., Tomaleri G.P., Januszyk K., Oania R.S., RA Sweredoski M.J., Moradian A., Guna A., Voorhees R.M.; RT "WNK1 is an assembly factor for the human ER membrane protein complex."; RL Mol. Cell 81:2693-2704(2021). RN [46] RP FUNCTION, ACTIVITY REGULATION, SUBCELLULAR LOCATION, AND DOMAIN. RX PubMed=36318922; DOI=10.1016/j.cell.2022.09.042; RA Boyd-Shiwarski C.R., Shiwarski D.J., Griffiths S.E., Beacham R.T., RA Norrell L., Morrison D.E., Wang J., Mann J., Tennant W., Anderson E.N., RA Franks J., Calderon M., Connolly K.A., Cheema M.U., Weaver C.J., RA Nkashama L.J., Weckerly C.C., Querry K.E., Pandey U.B., Donnelly C.J., RA Sun D., Rodan A.R., Subramanya A.R.; RT "WNK kinases sense molecular crowding and rescue cell volume via phase RT separation."; RL Cell 185:4488-4506(2022). RN [47] RP FUNCTION, INTERACTION WITH SGK1, INTERACTION WITH THE MTORC2 COMPLEX, AND RP MUTAGENESIS OF LYS-233. RX PubMed=36373794; DOI=10.1242/jcs.260313; RA Saha B., Leite-Dellova D.C.A., Demko J., Soerensen M.V., Takagi E., RA Gleason C.E., Shabbir W., Pearce D.; RT "WNK1 is a chloride-stimulated scaffold that regulates mTORC2 activity and RT ion transport."; RL J. Cell Sci. 135:0-0(2022). RN [48] {ECO:0007744|PDB:4PWN} RP X-RAY CRYSTALLOGRAPHY (1.84 ANGSTROMS) OF 210-482. RX PubMed=24803536; DOI=10.1126/scisignal.2005050; RA Piala A.T., Moon T.M., Akella R., He H., Cobb M.H., Goldsmith E.J.; RT "Chloride sensing by WNK1 involves inhibition of autophosphorylation."; RL Sci. Signal. 7:RA41-RA41(2014). RN [49] {ECO:0007744|PDB:5TF9} RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 206-483 IN COMPLEX WITH ATP AND RP ALLOSTERIC INHIBITOR. RX PubMed=27712055; DOI=10.1021/acschembio.6b00511; RA Yamada K., Zhang J.H., Xie X., Reinhardt J., Xie A.Q., LaSala D., Kohls D., RA Yowe D., Burdick D., Yoshisue H., Wakai H., Schmidt I., Gunawan J., RA Yasoshima K., Yue Q.K., Kato M., Mogi M., Idamakanti N., Kreder N., RA Drueckes P., Pandey P., Kawanami T., Huang W., Yagi Y.I., Deng Z., RA Park H.M.; RT "Discovery and characterization of allosteric WNK kinase inhibitors."; RL ACS Chem. Biol. 11:3338-3346(2016). RN [50] {ECO:0007744|PDB:5WDY, ECO:0007744|PDB:5WE8} RP X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 206-483 IN COMPLEX WITH ATP RP ANALOG AND ALLOSTERIC INHIBITOR. RX PubMed=28771350; DOI=10.1021/acs.jmedchem.7b00708; RA Yamada K., Levell J., Yoon T., Kohls D., Yowe D., Rigel D.F., Imase H., RA Yuan J., Yasoshima K., DiPetrillo K., Monovich L., Xu L., Zhu M., Kato M., RA Jain M., Idamakanti N., Taslimi P., Kawanami T., Argikar U.A., RA Kunjathoor V., Xie X., Yagi Y.I., Iwaki Y., Robinson Z., Park H.M.; RT "Optimization of allosteric With-No-Lysine (WNK) kinase inhibitors and RT efficacy in rodent hypertension models."; RL J. Med. Chem. 60:7099-7107(2017). RN [51] RP VARIANTS [LARGE SCALE ANALYSIS] GLY-1199 AND GLU-1799. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [52] RP VARIANTS [LARGE SCALE ANALYSIS] THR-141; VAL-149; GLN-419; THR-509; RP GLY-527; ILE-665; ALA-674; ARG-823; VAL-1546; GLU-1799; ILE-1808; LEU-1823; RP HIS-1957; CYS-2190; LEU-2362 AND TRP-2380. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase component of the WNK1- CC SPAK/OSR1 kinase cascade, which acts as a key regulator of blood CC pressure and regulatory volume increase by promoting ion influx CC (PubMed:15883153, PubMed:17190791, PubMed:31656913, PubMed:34289367, CC PubMed:36318922). WNK1 mediates regulatory volume increase in response CC to hyperosmotic stress by acting as a molecular crowding sensor, which CC senses cell shrinkage and mediates formation of a membraneless CC compartment by undergoing liquid-liquid phase separation CC (PubMed:36318922). The membraneless compartment concentrates WNK1 with CC its substrates, OXSR1/OSR1 and STK39/SPAK, promoting WNK1-dependent CC phosphorylation and activation of downstream kinases OXSR1/OSR1 and CC STK39/SPAK (PubMed:15883153, PubMed:16263722, PubMed:17190791, CC PubMed:19739668, PubMed:21321328, PubMed:22989884, PubMed:25477473, CC PubMed:34289367, PubMed:36318922). Following activation, OXSR1/OSR1 and CC STK39/SPAK catalyze phosphorylation of ion cotransporters CC SLC12A1/NKCC2, SLC12A2/NKCC1, SLC12A5/KCC2 and SLC12A6/KCC3, regulating CC their activity (PubMed:16263722, PubMed:21321328). Phosphorylation of CC Na-K-Cl cotransporters SLC12A2/NKCC1 and SLC12A2/NKCC1 promote their CC activation and ion influx; simultaneously, phosphorylation of K-Cl CC cotransporters SLC12A5/KCC2 and SLC12A6/KCC3 inhibit their activity, CC blocking ion efflux (PubMed:19665974, PubMed:21321328). Also acts as a CC regulator of angiogenesis in endothelial cells via activation of CC OXSR1/OSR1 and STK39/SPAK: activation of OXSR1/OSR1 regulates CC chemotaxis and invasion, while STK39/SPAK regulates endothelial cell CC proliferation (PubMed:25362046). Also acts independently of the WNK1- CC SPAK/OSR1 kinase cascade by catalyzing phosphorylation of other CC substrates, such as SYT2, PCF11 and NEDD4L (PubMed:29196535). Mediates CC phosphorylation of SYT2, regulating SYT2 association with phospholipids CC and membrane-binding (By similarity). Regulates mRNA export in the CC nucleus by mediating phosphorylation of PCF11, thereby decreasing the CC association between PCF11 and POLR2A/RNA polymerase II and promoting CC mRNA export to the cytoplasm (PubMed:29196535). Acts as a negative CC regulator of autophagy (PubMed:27911840). Required for the abscission CC step during mitosis, independently of the WNK1-SPAK/OSR1 kinase cascade CC (PubMed:21220314). May also play a role in actin cytoskeletal CC reorganization (PubMed:10660600). Also acts as a scaffold protein CC independently of its protein kinase activity: negatively regulates cell CC membrane localization of various transporters and channels, such as CC SLC4A4, SLC26A6, SLC26A9, TRPV4 and CFTR (By similarity). Involved in CC the regulation of epithelial Na(+) channel (ENaC) by promoting CC activation of SGK1 in a kinase-independent manner: probably acts as a CC scaffold protein that promotes the recruitment of SGK1 to the mTORC2 CC complex in response to chloride, leading to mTORC2-dependent CC phosphorylation and activation of SGK1 (PubMed:36373794). Acts as an CC assembly factor for the ER membrane protein complex independently of CC its protein kinase activity: associates with EMC2 in the cytoplasm via CC its amphipathic alpha-helix, and prevents EMC2 ubiquitination and CC subsequent degradation, thereby promoting EMC2 stabilization CC (PubMed:33964204). {ECO:0000250|UniProtKB:P83741, CC ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:10660600, CC ECO:0000269|PubMed:15883153, ECO:0000269|PubMed:16263722, CC ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:19665974, CC ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:21220314, CC ECO:0000269|PubMed:21321328, ECO:0000269|PubMed:22989884, CC ECO:0000269|PubMed:25362046, ECO:0000269|PubMed:25477473, CC ECO:0000269|PubMed:27911840, ECO:0000269|PubMed:29196535, CC ECO:0000269|PubMed:31656913, ECO:0000269|PubMed:33964204, CC ECO:0000269|PubMed:34289367, ECO:0000269|PubMed:36318922, CC ECO:0000269|PubMed:36373794}. CC -!- FUNCTION: [Isoform 3]: Kinase-defective isoform specifically expressed CC in kidney, which acts as a dominant-negative regulator of the longer CC isoform 1 (PubMed:14645531). Does not directly inhibit WNK4 and has no CC direct effect on sodium and chloride ion transport (By similarity). CC Down-regulates sodium-chloride cotransporter activity indirectly by CC inhibiting isoform 1, it associates with isoform 1 and attenuates its CC kinase activity (By similarity). In kidney, may play an important role CC regulating sodium and potassium balance (By similarity). CC {ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:14645531}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:15883153, CC ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:17190791, CC ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:29196535, CC ECO:0000269|PubMed:31656913}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:16263722, CC ECO:0000269|PubMed:16832045, ECO:0000269|PubMed:19739668, CC ECO:0000269|PubMed:21321328, ECO:0000269|PubMed:29196535}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:10660600}; CC -!- ACTIVITY REGULATION: Activated in response to hyperosmotic stress: cell CC shrinkage promotes formation of a membraneless compartment that CC concentrates WNK1 with its substrates, OXSR1/OSR1 and STK39/SPAK CC (PubMed:36318922). Activation requires autophosphorylation of Ser-382 CC and, to a lower extent, Ser-378 (PubMed:15883153, PubMed:16263722, CC PubMed:16832045, PubMed:17190791, PubMed:31656913, PubMed:34289367). CC Autophosphorylation and subsequent activation is inhibited by increases CC in intracellular ionic strength: Cl(-) potently inhibits WNK1 kinase CC activity via direct binding (By similarity). Also inhibited by K(+) CC ions (By similarity). Inhibited by small compounds staurosporine, CC tyrphostin 47, as well as Src tyrosine kinase inhibitors PP1 and PP2 CC (PubMed:19739668). {ECO:0000250|UniProtKB:Q9JIH7, CC ECO:0000269|PubMed:15883153, ECO:0000269|PubMed:16263722, CC ECO:0000269|PubMed:16832045, ECO:0000269|PubMed:17190791, CC ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:31656913, CC ECO:0000269|PubMed:34289367, ECO:0000269|PubMed:36318922}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=52.0 uM for ATP {ECO:0000269|PubMed:19739668}; CC KM=68.4 uM for a OXSR1/OSR1 peptide {ECO:0000269|PubMed:19739668}; CC -!- SUBUNIT: Interacts with WNK3 (By similarity). Interacts with WNK4; CC inhibiting the activity of WNK4 (By similarity). Interacts with SGK1; CC promoting its activation (PubMed:36373794). Associates with the mTORC2 CC complex (PubMed:36373794). Interacts with UVRAG (PubMed:27911840). CC Interacts (via amphipathic alpha-helix region) with EMC2; promoting the CC ER membrane protein complex assembly (PubMed:33964204). CC {ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:27911840, CC ECO:0000269|PubMed:33964204, ECO:0000269|PubMed:36373794}. CC -!- SUBUNIT: [Isoform 3]: Interacts with isoform 1; inhibiting isoform 1 CC activity. {ECO:0000250|UniProtKB:Q9JIH7}. CC -!- INTERACTION: CC Q9H4A3; O95747: OXSR1; NbExp=9; IntAct=EBI-457907, EBI-620853; CC Q9H4A3; P62136: PPP1CA; NbExp=2; IntAct=EBI-457907, EBI-357253; CC Q9H4A3; P31947: SFN; NbExp=4; IntAct=EBI-457907, EBI-476295; CC Q9H4A3; P62258: YWHAE; NbExp=7; IntAct=EBI-457907, EBI-356498; CC Q9H4A3; P61981: YWHAG; NbExp=7; IntAct=EBI-457907, EBI-359832; CC Q9H4A3; P63104: YWHAZ; NbExp=3; IntAct=EBI-457907, EBI-347088; CC Q9H4A3; P29101: Syt2; Xeno; NbExp=2; IntAct=EBI-457907, EBI-458017; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10660600, CC ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:21220314, CC ECO:0000269|PubMed:22989884, ECO:0000269|PubMed:27911840, CC ECO:0000269|PubMed:33964204, ECO:0000269|PubMed:36318922}. Nucleus CC {ECO:0000269|PubMed:29196535}. Cytoplasm, cytoskeleton, spindle CC {ECO:0000269|PubMed:21220314}. Note=Mediates formation and localizes to CC cytoplasmic membraneless compartment in response to hyperosmotic stress CC (PubMed:36318922). Also localizes to the nucleus (PubMed:29196535). CC Localizes to the mitotic spindle during mitosis (PubMed:21220314). CC {ECO:0000269|PubMed:21220314, ECO:0000269|PubMed:29196535, CC ECO:0000269|PubMed:36318922}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=6; CC Comment=WNK1 is a complex 33-exons gene, in total 9 WNK1 exons are CC alternatively spliced, some expressed in a tissue-specific manner. CC Additional isoforms seems to exist.; CC Name=1; Synonyms=L-WNK1 {ECO:0000303|PubMed:22701532}; CC IsoId=Q9H4A3-1; Sequence=Displayed; CC Name=2 {ECO:0000303|PubMed:9205841}; CC IsoId=Q9H4A3-2; Sequence=VSP_040269, VSP_050638; CC Name=3; Synonyms=KS-WNK1, Kidney-Specific; CC IsoId=Q9H4A3-4; Sequence=VSP_050634, VSP_050637; CC Name=4; Synonyms=Brain and spinal cord variant; CC IsoId=Q9H4A3-5; Sequence=VSP_040268; CC Name=5; Synonyms=Dorsal root ganglia and sciatic nerve variant, DRG and CC sciatic nerve variant; CC IsoId=Q9H4A3-6; Sequence=VSP_040267, VSP_040270; CC Name=6; CC IsoId=Q9H4A3-7; Sequence=VSP_040267, VSP_053767; CC -!- TISSUE SPECIFICITY: Widely expressed, with highest levels observed in CC the testis, heart, kidney and skeletal muscle. CC {ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:11571656, CC ECO:0000269|PubMed:22701532}. CC -!- TISSUE SPECIFICITY: [Isoform 1]: Strong expression in dorsal root CC ganglia and spinal cord. {ECO:0000269|PubMed:22701532}. CC -!- TISSUE SPECIFICITY: [Isoform 3]: This isoform is kidney-specific and CC specifically expressed in the distal convoluted tubule (DCT) and CC connecting tubule (CNT) of the nephron. {ECO:0000269|PubMed:14645531}. CC -!- DOMAIN: Disordered regions undergo liquid-liquid phase separation CC (LLPS) for the formation of a cytoplasmic membraneless compartment that CC concentrates WNK1 with its substrates, OXSR1/OSR1 and STK39/SPAK. CC {ECO:0000269|PubMed:36318922}. CC -!- DOMAIN: The RFXV motifs mediate recognition with downstream kinases CC OXSR1/OSR1 and STK39/SPAK. {ECO:0000269|PubMed:16263722, CC ECO:0000269|PubMed:22989884}. CC -!- PTM: Autophosphorylated at Ser-378 and Ser-382, promoting its activity CC (PubMed:15883153, PubMed:16263722, PubMed:16832045, PubMed:17190791, CC PubMed:31656913, PubMed:34289367). Autophosphorylation at Ser-382 is CC inhibited by intracellular calcium (By similarity). Phosphorylation at CC Thr-60 increases ability to activate SGK1 (By similarity). CC {ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:15883153, CC ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:16832045, CC ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:31656913, CC ECO:0000269|PubMed:34289367}. CC -!- PTM: Ubiquitinated by the BCR(KLHL3) complex, leading to its CC degradation (PubMed:23387299, PubMed:23576762). Also ubiquitinated by CC the BCR(KLHL2) complex (PubMed:23838290). {ECO:0000269|PubMed:23387299, CC ECO:0000269|PubMed:23576762, ECO:0000269|PubMed:23838290}. CC -!- PTM: May be O-glycosylated. {ECO:0000269|PubMed:2507249}. CC -!- DISEASE: Pseudohypoaldosteronism 2C (PHA2C) [MIM:614492]: An autosomal CC dominant disorder characterized by severe hypertension, hyperkalemia, CC hyperchloremia, mild hyperchloremic metabolic acidosis in some cases, CC and correction of physiologic abnormalities by thiazide diuretics. CC {ECO:0000269|PubMed:11498583}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Neuropathy, hereditary sensory and autonomic, 2A (HSAN2A) CC [MIM:201300]: A form of hereditary sensory and autonomic neuropathy, a CC genetically and clinically heterogeneous group of disorders CC characterized by degeneration of dorsal root and autonomic ganglion CC cells, and by sensory and/or autonomic abnormalities. HSAN2A is an CC autosomal recessive disorder characterized by impairment of pain, CC temperature and touch sensation, onset of symptoms in infancy or early CC childhood, occurrence of distal extremity pathologies (paronychia, CC whitlows, ulcers, and Charcot joints), frequent amputations, sensory CC loss that affects all modalities of sensation (lower and upper limbs CC and perhaps the trunk as well), absence or diminution of tendon CC reflexes (usually in all limbs), minimal autonomic dysfunction, absence CC of sensory nerve action potentials, and virtual absence of myelinated CC fibers with decreased numbers of unmyelinated fibers in sural nerves. CC {ECO:0000269|PubMed:15060842, ECO:0000269|PubMed:15911806, CC ECO:0000269|PubMed:18521183}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 4]: Contains the nervous system-specific exon CC HSN2. Produced by alternative splicing. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 5]: Contains the nervous system-specific exon CC HSN2. Produced by alternative splicing. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 6]: Contains the nervous system-specific exon CC HSN2. Produced by alternative splicing. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. WNK subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- CAUTION: Was named WNK/'with no lysine(K)' because key residues for CC catalysis, including the lysine involved in ATP binding, are either not CC conserved or differ compared to the residues described in other kinase CC family proteins. {ECO:0000305|PubMed:27712055}. CC -!- CAUTION: HSN2 was originally thought to be an intronless gene lying CC within a WNK1 gene intron. It has been shown to be a nervous system- CC specific exon of WNK1 included in isoform 4 and isoform 5 CC (PubMed:18521183). {ECO:0000305|PubMed:18521183}. CC -!- CAUTION: It is uncertain whether Met-1 or Met-214 is the initiator in CC isoform 4 and isoform 5. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAF31483.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the C-terminal part.; Evidence={ECO:0000305}; CC Sequence=AAI30468.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=AAI30470.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=DAA04494.1; Type=Erroneous gene model prediction; Note=Includes 3' and 3' intronic sequences.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AJ296290; CAC15059.1; -; mRNA. DR EMBL; JQ358908; AEY99342.1; -; mRNA. DR EMBL; FJ515833; ACS13726.1; -; Genomic_DNA. DR EMBL; FJ515833; ACS13727.1; -; Genomic_DNA. DR EMBL; FJ515833; ACS13728.1; -; Genomic_DNA. DR EMBL; AC004765; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC004803; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AF061944; AAF31483.1; ALT_SEQ; mRNA. DR EMBL; AB002342; BAA20802.2; -; mRNA. DR EMBL; AY231477; AAO46160.1; -; mRNA. DR EMBL; BC013629; AAH13629.2; -; mRNA. DR EMBL; BC130467; AAI30468.1; ALT_SEQ; mRNA. DR EMBL; BC130469; AAI30470.1; ALT_SEQ; mRNA. DR EMBL; BK004108; DAA04494.1; ALT_SEQ; Genomic_DNA. DR CCDS; CCDS73419.1; -. [Q9H4A3-5] DR CCDS; CCDS8506.1; -. [Q9H4A3-1] DR RefSeq; NP_001171914.1; NM_001184985.2. [Q9H4A3-6] DR RefSeq; NP_055638.2; NM_014823.2. DR RefSeq; NP_061852.3; NM_018979.4. [Q9H4A3-1] DR RefSeq; NP_998820.3; NM_213655.5. [Q9H4A3-5] DR RefSeq; XP_016875326.1; XM_017019837.1. DR RefSeq; XP_016875327.1; XM_017019838.2. [Q9H4A3-2] DR PDB; 4PWN; X-ray; 1.84 A; A=210-482. DR PDB; 5TF9; X-ray; 2.50 A; A/B=206-483. DR PDB; 5WDY; X-ray; 2.46 A; A/B=206-483. DR PDB; 5WE8; X-ray; 2.01 A; A/B=206-483. DR PDB; 6FBK; X-ray; 1.74 A; P=1247-1269. DR PDBsum; 4PWN; -. DR PDBsum; 5TF9; -. DR PDBsum; 5WDY; -. DR PDBsum; 5WE8; -. DR PDBsum; 6FBK; -. DR AlphaFoldDB; Q9H4A3; -. DR BMRB; Q9H4A3; -. DR SMR; Q9H4A3; -. DR BioGRID; 122403; 141. DR CORUM; Q9H4A3; -. DR DIP; DIP-32648N; -. DR ELM; Q9H4A3; -. DR FunCoup; Q9H4A3; 2655. DR IntAct; Q9H4A3; 121. DR MINT; Q9H4A3; -. DR STRING; 9606.ENSP00000341292; -. DR BindingDB; Q9H4A3; -. DR ChEMBL; CHEMBL1075173; -. DR GuidetoPHARMACOLOGY; 2280; -. DR MoonDB; Q9H4A3; Predicted. DR TCDB; 8.A.23.1.69; the basigin (basigin) family. DR GlyConnect; 484; 1 O-GlcNAc glycan. DR GlyCosmos; Q9H4A3; 38 sites, 2 glycans. DR GlyGen; Q9H4A3; 67 sites, 2 O-linked glycans (64 sites). DR iPTMnet; Q9H4A3; -. DR MetOSite; Q9H4A3; -. DR PhosphoSitePlus; Q9H4A3; -. DR BioMuta; WNK1; -. DR DMDM; 296453029; -. DR jPOST; Q9H4A3; -. DR MassIVE; Q9H4A3; -. DR PeptideAtlas; Q9H4A3; -. DR ProteomicsDB; 80804; -. [Q9H4A3-1] DR ProteomicsDB; 80805; -. [Q9H4A3-2] DR ProteomicsDB; 80806; -. [Q9H4A3-4] DR ProteomicsDB; 80807; -. [Q9H4A3-5] DR ProteomicsDB; 80808; -. [Q9H4A3-6] DR Pumba; Q9H4A3; -. DR Antibodypedia; 22083; 602 antibodies from 42 providers. DR DNASU; 65125; -. DR Ensembl; ENST00000315939.11; ENSP00000313059.6; ENSG00000060237.20. [Q9H4A3-1] DR Ensembl; ENST00000340908.9; ENSP00000341292.5; ENSG00000060237.20. [Q9H4A3-5] DR Ensembl; ENST00000530271.6; ENSP00000433548.3; ENSG00000060237.20. [Q9H4A3-7] DR Ensembl; ENST00000537687.5; ENSP00000444465.1; ENSG00000060237.20. [Q9H4A3-6] DR Ensembl; ENST00000675631.1; ENSP00000502415.1; ENSG00000060237.20. [Q9H4A3-4] DR GeneID; 65125; -. DR KEGG; hsa:65125; -. DR MANE-Select; ENST00000315939.11; ENSP00000313059.6; NM_018979.4; NP_061852.3. DR UCSC; uc001qio.4; human. [Q9H4A3-1] DR AGR; HGNC:14540; -. DR CIViC; 65125; 1 evidence item across 1 molecular profile. DR ClinPGx; PA33782; -. DR CTD; 65125; -. DR DisGeNET; 65125; -. DR GeneCards; WNK1; -. DR GeneReviews; WNK1; -. DR HGNC; HGNC:14540; WNK1. DR HPA; ENSG00000060237; Low tissue specificity. DR MalaCards; WNK1; -. DR MIM; 201300; phenotype. DR MIM; 605232; gene. DR MIM; 614492; phenotype. DR OpenTargets; ENSG00000060237; -. DR Orphanet; 970; Hereditary sensory and autonomic neuropathy type 2. DR Orphanet; 88940; Pseudohypoaldosteronism type 2C. DR VEuPathDB; HostDB:ENSG00000060237; -. DR eggNOG; KOG0584; Eukaryota. DR GeneTree; ENSGT00940000155474; -. DR InParanoid; Q9H4A3; -. DR OMA; PEPNGMT; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q9H4A3; 11 GO annotations based on evolutionary models. DR PhylomeDB; Q9H4A3; -. DR PathwayCommons; Q9H4A3; -. DR Reactome; R-HSA-2672351; Stimuli-sensing channels. DR SignaLink; Q9H4A3; -. DR SIGNOR; Q9H4A3; -. DR Agora; ENSG00000060237; -. DR BioGRID-ORCS; 65125; 582 hits in 1210 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; WNK1; human. DR EvolutionaryTrace; Q9H4A3; -. DR GeneWiki; WNK1; -. DR GenomeRNAi; 65125; -. DR Pharos; Q9H4A3; Tchem. DR PRO; PR:Q9H4A3; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q9H4A3; protein. DR Bgee; ENSG00000060237; Expressed in medial globus pallidus and 204 other cell types or tissues. DR ExpressionAtlas; Q9H4A3; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0043232; C:intracellular membraneless organelle; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; ISS:ParkinsonsUK-UCL. DR GO; GO:0072686; C:mitotic spindle; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0140693; F:molecular condensate scaffold activity; IDA:UniProtKB. DR GO; GO:0019902; F:phosphatase binding; IDA:UniProtKB. DR GO; GO:0030295; F:protein kinase activator activity; IMP:ParkinsonsUK-UCL. DR GO; GO:0004672; F:protein kinase activity; IMP:ParkinsonsUK-UCL. DR GO; GO:0019901; F:protein kinase binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0006884; P:cell volume homeostasis; IDA:UniProtKB. DR GO; GO:0071474; P:cellular hyperosmotic response; IDA:UniProtKB. DR GO; GO:1990869; P:cellular response to chemokine; IMP:BHF-UCL. DR GO; GO:0038116; P:chemokine (C-C motif) ligand 21 signaling pathway; ISS:BHF-UCL. DR GO; GO:0006974; P:DNA damage response; IBA:GO_Central. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0030644; P:intracellular chloride ion homeostasis; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0097022; P:lymphocyte migration into lymph node; ISS:BHF-UCL. DR GO; GO:0140694; P:membraneless organelle assembly; IDA:UniProtKB. DR GO; GO:0055080; P:monoatomic cation homeostasis; ISS:UniProtKB. DR GO; GO:0006811; P:monoatomic ion transport; ISS:UniProtKB. DR GO; GO:0010507; P:negative regulation of autophagy; IMP:UniProtKB. DR GO; GO:0033633; P:negative regulation of cell-cell adhesion mediated by integrin; IMP:BHF-UCL. DR GO; GO:0034115; P:negative regulation of heterotypic cell-cell adhesion; IMP:BHF-UCL. DR GO; GO:1903038; P:negative regulation of leukocyte cell-cell adhesion; IMP:BHF-UCL. DR GO; GO:0090188; P:negative regulation of pancreatic juice secretion; IEA:Ensembl. DR GO; GO:1903077; P:negative regulation of protein localization to plasma membrane; ISS:UniProtKB. DR GO; GO:0031397; P:negative regulation of protein ubiquitination; IDA:UniProtKB. DR GO; GO:0051058; P:negative regulation of small GTPase mediated signal transduction; IMP:BHF-UCL. DR GO; GO:0010766; P:negative regulation of sodium ion transport; ISS:UniProtKB. DR GO; GO:0048666; P:neuron development; NAS:UniProtKB. DR GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:FlyBase. DR GO; GO:1903490; P:positive regulation of mitotic cytokinesis; IDA:UniProtKB. DR GO; GO:0003084; P:positive regulation of systemic arterial blood pressure; IEA:Ensembl. DR GO; GO:0010820; P:positive regulation of T cell chemotaxis; IMP:BHF-UCL. DR GO; GO:1904595; P:positive regulation of termination of RNA polymerase II transcription; IDA:UniProtKB. DR GO; GO:0055075; P:potassium ion homeostasis; IEA:Ensembl. DR GO; GO:0045050; P:protein insertion into ER membrane by stop-transfer membrane-anchor sequence; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:1904062; P:regulation of monoatomic cation transmembrane transport; IMP:ARUK-UCL. DR GO; GO:0010793; P:regulation of mRNA export from nucleus; IDA:UniProtKB. DR GO; GO:1902305; P:regulation of sodium ion transmembrane transport; IEA:Ensembl. DR GO; GO:0002028; P:regulation of sodium ion transport; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IDA:ParkinsonsUK-UCL. DR GO; GO:0035725; P:sodium ion transmembrane transport; IEA:Ensembl. DR GO; GO:0050852; P:T cell receptor signaling pathway; ISS:BHF-UCL. DR CDD; cd14030; STKc_WNK1; 1. DR FunFam; 3.10.20.90:FF:000007; Serine/threonine-protein kinase WNK1 isoform 1; 1. DR FunFam; 1.10.510.10:FF:000006; Serine/threonine-protein kinase WNK1 isoform 2; 1. DR FunFam; 3.10.20.90:FF:000012; Serine/threonine-protein kinase WNK1 isoform 2; 1. DR FunFam; 3.30.200.20:FF:000494; serine/threonine-protein kinase WNK2 isoform X2; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR056865; CCTL2_WNK. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR024678; Kinase_OSR1/WNK_CCT. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR050588; WNK_Ser-Thr_kinase. DR PANTHER; PTHR13902; SERINE/THREONINE-PROTEIN KINASE WNK WITH NO LYSINE -RELATED; 1. DR Pfam; PF24889; CCTL2_WNK; 1. DR Pfam; PF12202; OSR1_C; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative promoter usage; Alternative splicing; KW ATP-binding; Chloride; Cytoplasm; Cytoskeleton; Direct protein sequencing; KW Glycoprotein; Kinase; Neurodegeneration; Neuropathy; Nucleotide-binding; KW Nucleus; Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation. FT CHAIN 1..2382 FT /note="Serine/threonine-protein kinase WNK1" FT /id="PRO_0000086819" FT DOMAIN 221..479 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..81 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 95..203 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 488..555 FT /note="Autoinhibitory domain" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT REGION 573..779 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 628..638 FT /note="Interaction with KLHL3" FT /evidence="ECO:0000250|UniProtKB:Q96J92" FT REGION 1018..1041 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1053..1119 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1457..1476 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1733..1790 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1866..1948 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1994..2069 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2101..2196 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2241..2261 FT /note="Amphipathic alpha-helix" FT /evidence="ECO:0000269|PubMed:33964204" FT REGION 2332..2352 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 1257..1260 FT /note="RFXV motif 1" FT /evidence="ECO:0000269|PubMed:16263722" FT MOTIF 1859..1862 FT /note="RFXV motif 2" FT /evidence="ECO:0000269|PubMed:16263722" FT MOTIF 1945..1948 FT /note="RFXV motif 3" FT /evidence="ECO:0000269|PubMed:16263722" FT MOTIF 1957..1960 FT /note="RFXV motif 4" FT /evidence="ECO:0000269|PubMed:16263722" FT COMPBIAS 50..66 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 95..108 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 125..153 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 573..588 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 598..614 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 615..625 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 637..689 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 709..779 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1025..1041 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1053..1077 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1080..1090 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1098..1119 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1457..1467 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1733..1745 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1869..1884 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1887..1905 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1927..1940 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1994..2003 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2035..2062 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2122..2134 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2135..2145 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2146..2167 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2175..2196 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 368 FT /note="Proton acceptor" FT /evidence="ECO:0000305|PubMed:16263722" FT BINDING 231 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27712055, FT ECO:0000305|PubMed:28771350, ECO:0007744|PDB:5TF9, FT ECO:0007744|PDB:5WDY, ECO:0007744|PDB:5WE8" FT BINDING 283 FT /ligand="chloride" FT /ligand_id="ChEBI:CHEBI:17996" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT BINDING 299 FT /ligand="chloride" FT /ligand_id="ChEBI:CHEBI:17996" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT BINDING 301..304 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27712055, FT ECO:0000305|PubMed:28771350, ECO:0007744|PDB:5TF9, FT ECO:0007744|PDB:5WDY, ECO:0007744|PDB:5WE8" FT BINDING 351 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27712055, FT ECO:0000305|PubMed:28771350, ECO:0007744|PDB:5TF9, FT ECO:0007744|PDB:5WDY, ECO:0007744|PDB:5WE8" FT BINDING 369 FT /ligand="chloride" FT /ligand_id="ChEBI:CHEBI:17996" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT BINDING 371 FT /ligand="chloride" FT /ligand_id="ChEBI:CHEBI:17996" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT MOD_RES 15 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791" FT MOD_RES 19 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 60 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT MOD_RES 167 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 174 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 378 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:31656913" FT MOD_RES 382 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15883153, FT ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:16832045, FT ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:31656913, FT ECO:0000269|PubMed:34289367" FT MOD_RES 1261 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:16964243, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 1848 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:17190791" FT MOD_RES 1978 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:24275569" FT MOD_RES 2002 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983" FT MOD_RES 2011 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2012 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:18669648" FT MOD_RES 2027 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569" FT MOD_RES 2029 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2032 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2121 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 2270 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P83741" FT MOD_RES 2286 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P83741" FT MOD_RES 2370 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2372 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..407 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_050634" FT VAR_SEQ 408..437 FT /note="FGMCMLEMATSEYPYSECQNAAQIYRRVTS -> MDIKKKDFCSVFVIINSH FT CCCCPQKDCINE (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_050637" FT VAR_SEQ 713 FT /note="V -> VPQSMAHPCGGTPTYPESQIFFPTIHERPVSFSPPPTCPPKVAISQR FT RKSTSFLEAQTHHFQPLLRTVGQSLLPPGGSPTNWTPEAVVMLGTTASRVTGESCEIQV FT HPMFEPSQVYSDYRPGLVLPEEAHYFIPQEAVYVAGVHYQARVAEQYEGIPYNSSVLSS FT PMKQIPEQKPVQGGPTSSSVFEFPSGQAFLVGHLQNLRLDSGLGPGSPLSSISAPISTD FT ATRLKFHPVFVPHSAPAVLTHNNESRSNCVFEFHVHTPSSSSGEGGGILPQRVYRNRQV FT AVDLNQEELPPQSVGLHGYLQPVTEEKHNYHAPELTVSVVEPIGQNWPIGSPEYSSDSS FT QITSSDPSDFQSPPPTGGAAAPFGSDVSMPFIHLPQTVLQESPLFFCFPQGTTSQQVLT FT ASFSSGGSALHPQ (in isoform 5 and isoform 6)" FT /evidence="ECO:0000303|PubMed:22701532" FT /id="VSP_040267" FT VAR_SEQ 714..1037 FT /note="AQGQSQGQPSSSSLTGVSSSQPIQHPQQQQGIQQTAPPQQTVQYSLSQTSTS FT SEATTAQPVSQPQAPQVLPQVSAGKQLPVSQPVPTIQGEPQIPVATQPSVVPVHSGAHF FT LPVGQPLPTPLLPQYPVSQIPISTPHVSTAQTGFSSLPITMAAGITQPLLTLASSATTA FT AIPGVSTVVPSQLPTLLQPVTQLPSQVHPQLLQPAVQSMGIPANLGQAAEVPLSSGDVL FT YQGFPPRLPPQYPGDSNIAPSSNVASVCIHSTVLSPPMPTEVLATPGYFPTVVQPYVES FT NLLVPMGGVGGQVQVSQPGGSLAQAPTTSSQQAVLE -> PRRGRSMSVCVPIFLLLPL FT CPASLPVLFHPTASTVCTSFSFPPPDCPEETFAEKLSKALESVLPMHSASQRKHRRSSL FT PSLFVSTPQSMAHPCGGTPTYPESQIFFPTIHERPVSFSPPPTCPPKVAISQRRKSTSF FT LEAQTHHFQPLLRTVGQSLLPPGGSPTNWTPEAVVMLGTTASRVTGESCEIQVHPMFEP FT SQVYSDYRPGLVLPEEAHYFIPQEAVYVAGVHYQARVAEQYEGIPYNSSVLSSPMKQIP FT EQKPVQGGPTSSSVFEFPSGQAFLVGHLQNLRLDSGLGPGSPLSSISAPISTDATRLKF FT HPVFVPHSAPAVLTHNNESRSNCVFEFHVHTPSSSSGEGGGILPQRVYRNRQVAVDLNQ FT EELPPQSVGLHGYLQPVTEEKHNYHAPELTVSVVEPIGQNWPIGSPEYSSDSSQITSSD FT PSDFQSPPPTGGAAAPFGSDVSMPFIHLPQTVLQESPLFFCFPQGTTSQQVLTASFSSG FT GSALHPQAQGQSQGQPSSSSLTGVSSSQPIQHPQQQQGIQQTAPPQQTVQYSLSQTSTS FT SEATTAQPVSQPQAPQVLPQVSAGKQ (in isoform 4)" FT /evidence="ECO:0000305" FT /id="VSP_040268" FT VAR_SEQ 740 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9205841" FT /id="VSP_040269" FT VAR_SEQ 792..1037 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9205841" FT /id="VSP_050638" FT VAR_SEQ 792..944 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000305" FT /id="VSP_040270" FT VAR_SEQ 2215 FT /note="G -> GCAKFNCASEQVTFKPGGRRTRFLRKMVKKVCPCNQLCR (in FT isoform 6)" FT /evidence="ECO:0000303|PubMed:22701532" FT /id="VSP_053767" FT VARIANT 141 FT /note="A -> T (in dbSNP:rs11554421)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041309" FT VARIANT 149 FT /note="A -> V (in dbSNP:rs34880640)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041310" FT VARIANT 419 FT /note="E -> Q (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041311" FT VARIANT 509 FT /note="I -> T (in dbSNP:rs34728563)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041312" FT VARIANT 527 FT /note="D -> G (in dbSNP:rs34408667)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041313" FT VARIANT 665 FT /note="T -> I (in dbSNP:rs2286007)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_019992" FT VARIANT 674 FT /note="T -> A (in dbSNP:rs11833299)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041314" FT VARIANT 823 FT /note="H -> R (in dbSNP:rs56015776)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041315" FT VARIANT 1056 FT /note="T -> P (in dbSNP:rs956868)" FT /evidence="ECO:0000269|PubMed:11571656, FT ECO:0000269|PubMed:9205841, ECO:0000269|Ref.3" FT /id="VAR_059033" FT VARIANT 1199 FT /note="E -> G (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035640" FT VARIANT 1506 FT /note="C -> S (in dbSNP:rs7955371)" FT /evidence="ECO:0000269|PubMed:11571656, FT ECO:0000269|PubMed:9205841, ECO:0000269|Ref.3" FT /id="VAR_059034" FT VARIANT 1546 FT /note="A -> V (in dbSNP:rs56351358)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041316" FT VARIANT 1799 FT /note="Q -> E (in breast cancer samples; infiltrating FT ductal carcinoma; somatic mutation)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17344846" FT /id="VAR_035641" FT VARIANT 1808 FT /note="M -> I (in dbSNP:rs12828016)" FT /evidence="ECO:0000269|PubMed:11571656, FT ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_041317" FT VARIANT 1823 FT /note="P -> L (in dbSNP:rs17755373)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041318" FT VARIANT 1957 FT /note="R -> H (in dbSNP:rs36083875)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041319" FT VARIANT 2190 FT /note="S -> C (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041320" FT VARIANT 2362 FT /note="F -> L (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041321" FT VARIANT 2380 FT /note="R -> W (in dbSNP:rs56262445)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041322" FT MUTAGEN 233 FT /note="K->M: Abolished serine/threonine-protein kinase FT activity. Does not affect ability to activate SGK1." FT /evidence="ECO:0000269|PubMed:16263722, FT ECO:0000269|PubMed:36373794" FT MUTAGEN 318 FT /note="V->E: Does not affect ability to phosphorylate FT OXSR1/OSR1." FT /evidence="ECO:0000269|PubMed:22989884" FT MUTAGEN 368 FT /note="D->A: Abolished serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:16263722, FT ECO:0000269|PubMed:17190791" FT MUTAGEN 382 FT /note="S->A: Decreased autophosphorylation, preventing FT activation of the serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:16263722, FT ECO:0000269|PubMed:16832045, ECO:0000269|PubMed:17190791" FT MUTAGEN 1255 FT /note="G->R,N,D,C,Q,H,I,L,K,M,F,P,S,T,W,Y,V: Does not FT affect binding to OXSR1/OSR1." FT /evidence="ECO:0000269|PubMed:29581290" FT MUTAGEN 1257 FT /note="R->A,N,C,E,Q,H,I,L,K,M,F,S,T,W,Y,V: Does not affect FT binding to OXSR1/OSR1." FT /evidence="ECO:0000269|PubMed:29581290" FT MUTAGEN 1258 FT /note="F->A: Slightly decreased binding to OXSR1/OSR1 and FT STK39/SPAK; when associated with A-1860. Abolished binding FT to OXSR1/OSR1 and STK39/SPAK; when associated with A-1860, FT A-1946 and A-1958." FT /evidence="ECO:0000269|PubMed:16263722" FT MUTAGEN 1860 FT /note="F->A: Slightly decreased binding to OXSR1/OSR1 and FT STK39/SPAK; when associated with A-1258. Abolished binding FT to OXSR1/OSR1 and STK39/SPAK; when associated with A-1258, FT A-1946 and A-1958." FT /evidence="ECO:0000269|PubMed:16263722" FT MUTAGEN 1946 FT /note="F->A: Slightly decreased binding to OXSR1/OSR1 and FT STK39/SPAK; when associated with A-1958. Abolished binding FT to OXSR1/OSR1 and STK39/SPAK; when associated with A-1257, FT A-1860 and A-1958." FT /evidence="ECO:0000269|PubMed:16263722" FT MUTAGEN 1958 FT /note="F->A: Slightly decreased binding to OXSR1/OSR1 and FT STK39/SPAK; when associated with A-1946. Abolished binding FT to OXSR1/OSR1 and STK39/SPAK; when associated with A-1258, FT A-1860 and A-1946." FT /evidence="ECO:0000269|PubMed:16263722" FT MUTAGEN 2246 FT /note="F->K: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2248 FT /note="D->K: Does not affect interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2249 FT /note="D->A,K: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2250 FT /note="Missing: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2251 FT /note="H->K: Does not affect interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2253 FT /note="L->K: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2257 FT /note="W->K,L,A: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2260 FT /note="D->A,K: Does not affect interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT CONFLICT 164 FT /note="R -> S (in Ref. 8; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 1836 FT /note="Missing (in Ref. 6; BAA20802)" FT /evidence="ECO:0000305" FT STRAND 211..214 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 216..218 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 220..228 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 231..240 FT /evidence="ECO:0007829|PDB:4PWN" FT TURN 241..244 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 245..252 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 266..273 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 283..288 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 291..295 FT /evidence="ECO:0007829|PDB:5WDY" FT STRAND 297..302 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 309..316 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 321..340 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 341..343 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 352..354 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 355..358 FT /evidence="ECO:0007829|PDB:4PWN" FT TURN 359..362 FT /evidence="ECO:0007829|PDB:5WE8" FT STRAND 364..366 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 369..371 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 377..380 FT /evidence="ECO:0007829|PDB:5WE8" FT HELIX 392..396 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 402..417 FT /evidence="ECO:0007829|PDB:4PWN" FT TURN 421..424 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 428..435 FT /evidence="ECO:0007829|PDB:4PWN" FT TURN 436..438 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 442..446 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 450..459 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 464..466 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 470..474 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 477..481 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 1248..1251 FT /evidence="ECO:0007829|PDB:6FBK" FT STRAND 1257..1261 FT /evidence="ECO:0007829|PDB:6FBK" SQ SEQUENCE 2382 AA; 250794 MW; 426785F98A452A0A CRC64; MSGGAAEKQS STPGSLFLSP PAPAPKNGSS SDSSVGEKLG AAAADAVTGR TEEYRRRRHT MDKDSRGAAA TTTTTEHRFF RRSVICDSNA TALELPGLPL SLPQPSIPAA VPQSAPPEPH REETVTATAT SQVAQQPPAA AAPGEQAVAG PAPSTVPSST SKDRPVSQPS LVGSKEEPPP ARSGSGGGSA KEPQEERSQQ QDDIEELETK AVGMSNDGRF LKFDIEIGRG SFKTVYKGLD TETTVEVAWC ELQDRKLTKS ERQRFKEEAE MLKGLQHPNI VRFYDSWEST VKGKKCIVLV TELMTSGTLK TYLKRFKVMK IKVLRSWCRQ ILKGLQFLHT RTPPIIHRDL KCDNIFITGP TGSVKIGDLG LATLKRASFA KSVIGTPEFM APEMYEEKYD ESVDVYAFGM CMLEMATSEY PYSECQNAAQ IYRRVTSGVK PASFDKVAIP EVKEIIEGCI RQNKDERYSI KDLLNHAFFQ EETGVRVELA EEDDGEKIAI KLWLRIEDIK KLKGKYKDNE AIEFSFDLER DVPEDVAQEM VESGYVCEGD HKTMAKAIKD RVSLIKRKRE QRQLVREEQE KKKQEESSLK QQVEQSSASQ TGIKQLPSAS TGIPTASTTS ASVSTQVEPE EPEADQHQQL QYQQPSISVL SDGTVDSGQG SSVFTESRVS SQQTVSYGSQ HEQAHSTGTV PGHIPSTVQA QSQPHGVYPP SSVAQGQSQG QPSSSSLTGV SSSQPIQHPQ QQQGIQQTAP PQQTVQYSLS QTSTSSEATT AQPVSQPQAP QVLPQVSAGK QLPVSQPVPT IQGEPQIPVA TQPSVVPVHS GAHFLPVGQP LPTPLLPQYP VSQIPISTPH VSTAQTGFSS LPITMAAGIT QPLLTLASSA TTAAIPGVST VVPSQLPTLL QPVTQLPSQV HPQLLQPAVQ SMGIPANLGQ AAEVPLSSGD VLYQGFPPRL PPQYPGDSNI APSSNVASVC IHSTVLSPPM PTEVLATPGY FPTVVQPYVE SNLLVPMGGV GGQVQVSQPG GSLAQAPTTS SQQAVLESTQ GVSQVAPAEP VAVAQTQATQ PTTLASSVDS AHSDVASGMS DGNENVPSSS GRHEGRTTKR HYRKSVRSRS RHEKTSRPKL RILNVSNKGD RVVECQLETH NRKMVTFKFD LDGDNPEEIA TIMVNNDFIL AIERESFVDQ VREIIEKADE MLSEDVSVEP EGDQGLESLQ GKDDYGFSGS QKLEGEFKQP IPASSMPQQI GIPTSSLTQV VHSAGRRFIV SPVPESRLRE SKVFPSEITD TVAASTAQSP GMNLSHSASS LSLQQAFSEL RRAQMTEGPN TAPPNFSHTG PTFPVVPPFL SSIAGVPTTA AATAPVPATS SPPNDISTSV IQSEVTVPTE EGIAGVATST GVVTSGGLPI PPVSESPVLS SVVSSITIPA VVSISTTSPS LQVPTSTSEI VVSSTALYPS VTVSATSASA GGSTATPGPK PPAVVSQQAA GSTTVGATLT SVSTTTSFPS TASQLCIQLS SSTSTPTLAE TVVVSAHSLD KTSHSSTTGL AFSLSAPSSS SSPGAGVSSY ISQPGGLHPL VIPSVIASTP ILPQAAGPTS TPLLPQVPSI PPLVQPVANV PAVQQTLIHS QPQPALLPNQ PHTHCPEVDS DTQPKAPGID DIKTLEEKLR SLFSEHSSSG AQHASVSLET SLVIESTVTP GIPTTAVAPS KLLTSTTSTC LPPTNLPLGT VALPVTPVVT PGQVSTPVST TTSGVKPGTA PSKPPLTKAP VLPVGTELPA GTLPSEQLPP FPGPSLTQSQ QPLEDLDAQL RRTLSPEMIT VTSAVGPVSM AAPTAITEAG TQPQKGVSQV KEGPVLATSS GAGVFKMGRF QVSVAADGAQ KEGKNKSEDA KSVHFESSTS ESSVLSSSSP ESTLVKPEPN GITIPGISSD VPESAHKTTA SEAKSDTGQP TKVGRFQVTT TANKVGRFSV SKTEDKITDT KKEGPVASPP FMDLEQAVLP AVIPKKEKPE LSEPSHLNGP SSDPEAAFLS RDVDDGSGSP HSPHQLSSKS LPSQNLSQSL SNSFNSSYMS SDNESDIEDE DLKLELRRLR DKHLKEIQDL QSRQKHEIES LYTKLGKVPP AVIIPPAAPL SGRRRRPTKS KGSKSSRSSS LGNKSPQLSG NLSGQSAASV LHPQQTLHPP GNIPESGQNQ LLQPLKPSPS SDNLYSAFTS DGAISVPSLS APGQGTSSTN TVGATVNSQA AQAQPPAMTS SRKGTFTDDL HKLVDNWARD AMNLSGRRGS KGHMNYEGPG MARKFSAPGQ LCISMTSNLG GSAPISAASA TSLGHFTKSM CPPQQYGFPA TPFGAQWSGT GGPAPQPLGQ FQPVGTASLQ NFNISNLQKS ISNPPGSNLR TT //